PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HOHENEGGER, M; NANOFF, C; AHORN, H; FREISSMUTH, M				HOHENEGGER, M; NANOFF, C; AHORN, H; FREISSMUTH, M			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE INTERACTION BETWEEN 2',3'-DIALDEHYDE GUANINE-NUCLEOTIDE ANALOGS AND THE STIMULATORY G-PROTEIN ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; H-RAS P21; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING-SITE; TRIPHOSPHATE CONFORMATION; SARCOPLASMIC-RETICULUM; ACTIVE-SITE; GTP-BINDING; 2 FORMS	We have searched for irreversible ligands which target the guanine nucleotide binding pocket of G protein alpha-subunits by testing the ability of periodate-oxidized 2',3'-dialdehyde guanine nucleotide analogues of GTP (oGTP) and GTP gamma S (oGTP gamma S) to bind to the recombinant cy-subunit of the stimulatory G protein, rG(s alpha-s). oGTP and oGTP gamma S bind to rG(s alpha-s) in a quasi-irreversible manner via formation of a Schiff's base, which can be reduced with borhydrid resulting in covalent incorporation of [alpha-P-32]oGTP and [S-35]oGTP gamma S into rG(s alpha-s). When bound to rG(s alpha), oGTP is hydrolyzed and traps the protein in the inactive conformation, while oGTP gamma S persistently activates rG(s alpha). Thus, oGTP and oGTP gamma S act as irreversible G protein antagonist and agonist, respectively, and represent a pair of nucleotide analogues suitable as functional and structural tools, Cleavage of covalently Iabeled rG(s alpha-s) with cyanogen bromide generates several labeled fragments. Labeled fragments were assigned to the G(1) and G(4) region of the guanine nucleotide binding pocket using sequence-specific antisera. An additional, labeled fragment was identified by amino-terminal sequencing and corresponded to the helix alpha A in the recently determined crystal structure of the transducin alpha-subunit (Noel, J. P., Hamm, H. E., and Sigler, P. B. (1993) Nature 366, 654-663), In the oGDP-liganded conformation, incorporation occurs predominantly into the G(1)-fragment, while [S-35]oGTP gamma S labels the additional fragments to a similar extent indicating tight packing around the guanine nucleotide binding pocket in the active conformation, Furthermore, rG(s alpha-s) contains a single acid cleavable bond (Asp(317)-pro(318)), such that formic acid releases a carboxyl-terminal fragment from [alpha(32)PGTP- and [S-35]oGTP gamma S-liganded rG(s alpha-s). This fragment contains a single lysine residue (Lys(324)) which is only labeled by [S-35]oGTP gamma S. Lys(324) is unique to G(s alpha) and lies within its effector binding region, Hence, during the switch from the inactive to the active state, this region undergoes a major conformational change that moves it closer to the nucleotide binding pocket.	UNIV VIENNA, INST PHARMACOL, A-1090 VIENNA, AUSTRIA; ERNST BOEHRINGER INST ARZNEIMITTELFORSCH, DEPT PROT CHEM, A-1120 VIENNA, AUSTRIA	University of Vienna			Hohenegger, Martin/AAF-6479-2020	Hohenegger, Martin/0000-0001-6537-9574; nanoff, christian/0000-0002-8857-2470; Freissmuth, Michael/0000-0001-9398-1765				BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIDWAI AP, 1989, J BIOL CHEM, V264, P11790; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOHENEGGER M, 1992, EUR J BIOCHEM, V205, P173, DOI 10.1111/j.1432-1033.1992.tb16765.x; ITOH H, 1991, J BIOL CHEM, V266, P16226; JOCKERS R, 1994, IN PRESS J BIOL CHEM; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LACOUR TFM, 1985, EMBO J, V4, P191; LINDEN J, 1984, MOL PHARMACOL, V26, P414; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOW A, 1993, EUR J BIOCHEM, V215, P473, DOI 10.1111/j.1432-1033.1993.tb18056.x; LOW A, 1992, FEBS LETT, V303, P64, DOI 10.1016/0014-5793(92)80478-Y; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MIGNACO J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P305, DOI 10.1016/0167-4838(90)90263-F; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MIZIORKO HM, 1990, J BIOL CHEM, V265, P3642; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NANOFF C, 1994, J BIOL CHEM, V269, P31999; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETER ME, 1988, BIOCHEMISTRY-US, V27, P9132, DOI 10.1021/bi00426a010; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRMER NK, 1991, EUR J BIOCHEM, V200, P295, DOI 10.1111/j.1432-1033.1991.tb16185.x; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					32008	32015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989377				2022-12-27	WOS:A1994PX30300102
J	HOBERT, O; JALLAL, B; SCHLESSINGER, J; ULLRICH, A				HOBERT, O; JALLAL, B; SCHLESSINGER, J; ULLRICH, A			NOVEL SIGNALING PATHWAY SUGGESTED BY SH3 DOMAIN-MEDIATED P95(VAV)/HETEROGENEOUS RIBONUCLEOPROTEIN-K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VAV PROTOONCOGENE PRODUCT; RNA-BINDING PROTEINS; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; NUCLEIC-ACID; GENE; HOMOLOGY; GAP	The role of the protooncogene product p95(vav) in signal transduction was investigated by characterizing its interactions with proteins that may represent components of a novel signaling pathway. We demonstrate here stable association of p95(vav) with the heterogeneous ribonucleoprotein K (hnRNP-K), a protein that not only was found to be part of hnRNP particles but has also been implicated in transcriptional regulation of the c-myc gene. Through the PLPPPPPPRG sequence, hnRNP-K specifically interacts with the SH3 domain of p95(vav) and thus represents a novel SH3 binding protein that may be capable of translating cell surface receptor signals through p95(vav) activation into regulatory events on the level of gene expression.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University				Hobert, Oliver/0000-0002-7634-2854				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1993; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	32	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20225	20228						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051112				2022-12-27	WOS:A1994PB31700005
J	HAWN, TR; STRAND, M				HAWN, TR; STRAND, M			DEVELOPMENTALLY-REGULATED LOCALIZATION AND PHOSPHORYLATION OF SMIRV1, A SCHISTOSOMA-MANSONI ANTIGEN WITH SIMILARITY TO CALNEXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-ATTENUATED CERCARIAE; PARASITE SURFACE-ANTIGEN; CALCIUM-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; IRRADIATED CERCARIAE; PROTECTIVE IMMUNITY; TRANSMEMBRANE PROTEINS; RECOMBINANT FRAGMENT; MICE; IDENTIFICATION	Potential molecular targets of a protective humoral immune response against schistosomiasis have previously been identified based on their enhanced immunogenicity in mice vaccinated with irradiated cercaria as compared to chronically infected mice, One of these antigens, IrV1, has been molecularly cloned and its sequence shown to be similar to the molecular chaperone calnexin. In this investigation, we partially characterized IrV1 from different developmental stages of the schistosome. Immunoprecipitation studies with antibodies raised against a portion of recombinant IrV1 demonstrated its presence in cercaria, schistosomula, and adult worms with an apparent molecular mass on SDS-polyacrylamide gel electrophoresis of 90 kDa. There was an approximate 6-fold increase in protein expression level during the cercaria to schistosomula transformation. Consistent with a potential role as a molecular chaperone, IrV1 was associated with several metabolically labeled proteins in co-immunoprecipitation studies with the adult worm tegumental fraction. Similar to calnexin, IrV1 was metabolically labeled with P-32 in adult worms on serine and threonine residues and was one of the major phosphoproteins of this stage. This phosphorylation was developmentally regulated and coincided with the transformation of cercaria into schistosomula. The localization was also stage-specific as IrV1 was transported from internal regions of cercaria to the outer tegumental layer of schistosomula. The presence of IrV1 on the surface of schistosomula, an unprecedented localization for this family of endoplasmic reticulum proteins, supports additional studies of the immunoprophylactic potential of this molecule.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019217, R37AI019217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007039] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19217] Funding Source: Medline; NIGMS NIH HHS [5T32GM07039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BICKLE QD, 1982, J IMMUNOL, V128, P2101; BUTTERWORTH AE, 1987, PARASITOL TODAY, V3, P11, DOI 10.1016/0169-4758(87)90091-3; CALA SE, 1993, J BIOL CHEM, V268, P2969; CIANFRIGLIA M, 1983, HYBRIDOMA, V2, P451, DOI 10.1089/hyb.1983.2.451; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DALTON JP, 1986, J IMMUNOL, V136, P4689; DALTON JP, 1987, J IMMUNOL, V139, P2474; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEAN DA, 1992, AM J TROP MED HYG, V47, P238, DOI 10.4269/ajtmh.1992.47.238; GERSTEN DM, 1991, BIOCHIM BIOPHYS ACTA, V1096, P20; GOUDOTCROZEL V, 1989, J EXP MED, V170, P2065, DOI 10.1084/jem.170.6.2065; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARN DA, 1992, J IMMUNOL, V148, P562; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; Hockley D.J., 1973, Advances Parasit, V11, P233, DOI 10.1016/S0065-308X(08)60188-8; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES SL, 1992, IMMUNOL INVEST, V21, P477, DOI 10.3109/08820139209069385; KALOPOTHAKIS E, 1987, MOL BIOCHEM PARASIT, V26, P39, DOI 10.1016/0166-6851(87)90128-9; KASSIM OO, 1992, AM J TROP MED HYG, V47, P231, DOI 10.4269/ajtmh.1992.47.231; KHALIFE J, 1993, MOL BIOCHEM PARASIT, V57, P193, DOI 10.1016/0166-6851(93)90195-4; KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; MANGOLD BL, 1986, J IMMUNOL, V136, P2644; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; OAKS JA, 1983, J PARASITOL, V69, P519, DOI 10.2307/3281366; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SOISSON LA, 1993, J IMMUNOL, V151, P4782; SOISSON LA, 1993, EXP PARASITOL, V77, P492, DOI 10.1006/expr.1993.1111; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7; STRAND M, 1982, EXP PARASITOL, V54, P145, DOI 10.1016/0014-4894(82)90121-7; UNNASCH TR, 1988, J CLIN INVEST, V82, P262, DOI 10.1172/JCI113581; VANDERLINDEN PWG, 1984, EXP PARASITOL, V57, P125, DOI 10.1016/0014-4894(84)90071-7; WADA I, 1991, J BIOL CHEM, V266, P19599; WIEST PM, 1991, EXP PARASITOL, V73, P214, DOI 10.1016/0014-4894(91)90024-Q	44	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20083	20089						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051095				2022-12-27	WOS:A1994PA12600064
J	QUEST, AFG; BELL, RM				QUEST, AFG; BELL, RM			THE REGULATORY REGION OF PROTEIN-KINASE C-GAMMA - STUDIES OF PHORBOL ESTER BINDING TO INDIVIDUAL, AND COMBINED FUNCTIONAL SEGMENTS EXPRESSED AS GLUTATHIONE-S-TRANSFERASE FUSION PROTEINS INDICATE A COMPLEX MECHANISM OF REGULATION BY PHOSPHOLIPIDS, PHORBOL ESTERS, AND DIVALENT-CATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-100 MIXED MICELLES; DILUTE-SOLUTION; ACIDIC LIPIDS; ACTIVATION; DIACYLGLYCEROL; PHOSPHATIDYLSERINE; CONTAINS; CALCIUM; DOMAIN; PURIFICATION	The regulatory domain of protein kinase C gamma (PKC gamma) contains the following functional elements which can interact with lipids: the pseudosubstrate motif within the first variable region (V1), cysteine rich domains, Cys1 and Cys2 which contain zinc and bind phorbol dibutyrate (PDBu)/diacylglycero1, and the calcium dependent lipid binding domain (CaLB). The function of individual or combined segments of the regulatory domain was investigated, using glutathione S-transferase (GST) fusion proteins and mixed micellar or liposomal assays. GST-Cys1 and GST-Cys2 bound PDBu with comparable affinity (K-d = 14-17 nM). GST-Cys1Cys2 yielded a protein with a PDBu binding affinity of 3.4 nM, in the presence of calcium, similar to that of intact PKC gamma (K-d = 2.6 nM). The phosphatidylserine (PS) dependence of PDBu binding was highly cooperative for all fusion proteins tested with Hill numbers (n) lying in the range of 3.5-4.8, similar to values obtained for intact PKC gamma. While Hill numbers were similar under all conditions, the PS concentration necessary for half-maximal PDBu binding was dependent upon the nature and presence of divalent cations. The PS requirement was lowest in the presence of calcium for GST-Cys1, GST-Cys2, and GST-Cys1Cys2 (K-m for PS = 11, 14, and 12 mol %, respectively) but still significantly above the value for intact PKC gamma (5.4 mol %). The data establish Cys1 and Cys2 as independent PDBu binding domains that are modulated by divalent cations. While PDBu binding affinity to a GST-V1Cys1 fusion protein (K-d = 36 nM) was comparable to that of GST-Cys1, the CaLB domain dramatically reduced PDBu binding affinity of GST-Cys2CaLB (K-d = 912 nM). This effect of the CaLB domain on PDBu binding to Cys2 suggests that PDBu/diacylglycerol binding to native PKC gamma may occur at Cys1 and that the Cys2 domain may serve another regulatory function.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; EBLING JG, 1985, P NATL ACAD SCI USA, V82, P815; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONIG B, 1985, J CELL BIOCHEM, V29, P37, DOI 10.1002/jcb.240290105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LUO JH, 1993, J BIOL CHEM, V268, P3715; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; MOSIOR M, 1992, PROTEIN KINASE C CUR, P157; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1993, METH NEUROSCI, V18, P138; QUEST AFG, 1994, PROTEIN KINASE C, P64; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARKEY NA, 1985, BIOCHEM BIOPH RES CO, V133, P1051, DOI 10.1016/0006-291X(85)91242-2; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	40	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20000	20012						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051084				2022-12-27	WOS:A1994PA12600053
J	XIAO, R; PENEFSKY, HS				XIAO, R; PENEFSKY, HS			UNISITE CATALYSIS AND THE DELTA-SUBUNIT OF F1-ATPASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; CARBOXYL-TERMINAL REGION; ATP-SYNTHASE; BEEF-HEART; H+-ATPASE; BETA-SUBUNIT; SINGLE-SITE; PROTON-ATPASE; BACTERIUM PS3; MECHANISM	The 5-subunit form of the Escherichia coli F-1-ATPase, characterized by the subunit composition alpha(3) beta(3) gamma delta epsilon failed to exhibit a rate acceleration when samples of the enzyme hydrolyzing substoichiometric concentrations of [gamma-P-32]ATP were switched from unisite to multisite hydrolysis by the addition of a cold chase. A 4-subunit form of the enzyme lacking in the delta subunit (alpha(3) beta(3) gamma epsilon) did exhibit cold chase-promoted accelerations in the hydrolysis of ATP. Reconstitution of a 5-subunit enzyme by incubating the 4-subunit form of the enzyme with a purified preparation of subunit delta was accompanied by a disappearance in the response to a cold chase. The rate constants and equilibrium constants for unisite catalysis by the 4-subunit enzyme did not differ significantly from previously reported values that may have been based on a mixture of 4- and 5-subunit forms of the enzyme. The vesicular form of Escherichia coli F,F,-ATPase exhibited a response to a cold chase only if the vesicles were first extracted with KCl. [gamma-P-32]ATP bound in the high affinity catalytic sites of KCl-extracted membranes partially dissociated in an energy-dependent manner when the vesicles oxidized NADH.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIGMS NIH HHS [GM21737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1973, ARCH BIOCHEM BIOPHYS, V159, P664, DOI 10.1016/0003-9861(73)90505-5; BRAGG PD, 1975, ARCH BIOCHEM BIOPHYS, V167, P311, DOI 10.1016/0003-9861(75)90467-1; COX GB, 1973, BIOCHEM J, V134, P1015, DOI 10.1042/bj1341015; COX GB, 1970, BIOCHEM J, V117, P551, DOI 10.1042/bj1170551; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HAZARD AL, 1994, J BIOL CHEM, V269, P427; HISABORI T, 1992, J BIOL CHEM, V267, P4551; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JOSHI S, 1992, J BIOL CHEM, V267, P12860; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, V4, P383; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NELSON N, 1974, P NATL ACAD SCI USA, V71, P2720, DOI 10.1073/pnas.71.7.2720; NOUMI T, 1986, J BIOL CHEM, V261, P9196; Penefsky H S, 1979, Methods Enzymol, V56, P527; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TURINA P, 1993, J BIOL CHEM, V268, P6978; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19232	19237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034684				2022-12-27	WOS:A1994NY33200008
J	HOLST, JJ; BERSANI, M; JOHNSEN, AH; KOFOD, H; HARTMANN, B; ORSKOV, C				HOLST, JJ; BERSANI, M; JOHNSEN, AH; KOFOD, H; HARTMANN, B; ORSKOV, C			PROGLUCAGON PROCESSING IN PORCINE AND HUMAN PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; HUMAN SMALL-INTESTINE; PIG SMALL-INTESTINE; PREPROGLUCAGON GENE; GLICENTIN; CONTAINS; SEQUENCE; PRODUCTS; GLP-1; FRAGMENT	In the pancreas proglucagon (PG), a peptide precursor of 160 amino acids is cleaved to produce glucagon and a 30-amino acid N-terminal flanking peptide, but the fate of the C-terminal flanking peptide (99 amino acids) is incompletely known. We subjected acid ethanol extracts of human and porcine pancreases to gel filtration and analyzed the fractions with specific radioimmunoassays for the following regions of proglucagon: PG 62-69, PG 72-81, PG 78-87, PG 98-107 amide, PG 126-134, and PG 149-158. Based on these assays and successive purifications by high performance liquid chromatography we isolated and purified to homogeneity three porcine peptides which were subjected to mass spectrometry and sequencing. One peptide was PG 64-69. The second was PG 72-108, as determined by mass spectrometry, N-terminal amino acid sequencing, and specific radioimmunoassays. The third had a molecular size of approximately 10,000, an N-terminal sequence corresponding to PG 72-81, and a C terminal sequence terminating at PG 158 (specific radioimmunoassay). A similar peptide with an identical N-terminal sequence, a C-terminal sequence corresponding to PG 146-158, and a molecular mass of 9969 (theoretical mass for human PG 72-158 = 9971) was isolated from human pancreas together with small amounts of a peptide corresponding to PG 72-107 amide. Thus, the pancreatic processing of the C-terminal flanking peptide in proglucagon includes the formation of equimolar (to glucagon) amounts of PG 64-69 and PG 72-158 (major proglucagon fragment) and smaller amounts of N-terminally extended glucagon-like peptide-1 (GLP-1) (PG 72-108 in pigs and PG 72-107 amide in humans).	NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN,DENMARK	Novo Nordisk; Rigshospitalet; University of Copenhagen	HOLST, JJ (corresponding author), UNIV COPENHAGEN,PANUM INST,DEPT MED PHYSIOL,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN N,DENMARK.		Holst, Jens/AAA-8022-2022	Hartmann, Bolette/0000-0001-8509-2036; Orskov, Cathrine/0000-0002-7762-2372; Holst, Jens Juul/0000-0001-6853-3805				BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038/304368a0; BUHL T, 1988, J BIOL CHEM, V263, P8621; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOLST JJ, 1982, BIOCHEM J, V207, P381, DOI 10.1042/bj2070381; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HOLST JJ, 1983, DIABETOLOGIA, V24, P359; HOLST JJ, 1991, METHODS NEUROSCIENCE, V5, P3, DOI DOI 10.1016/B978-0-12-185259-7.50006-5; HVIDBERG A, 1994, METABOLISM, V43, P104, DOI 10.1016/0026-0495(94)90164-3; MIHOLIC J, 1991, DIGEST DIS SCI, V36, P1361, DOI 10.1007/BF01296800; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOODY AJ, 1981, NATURE, V289, P514, DOI 10.1038/289514a0; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, FEBS LETT, V247, P193, DOI 10.1016/0014-5793(89)81332-8; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1987, SCAND J CLIN LAB INV, V47, P165; ORSKOV C, 1992, DIABETOLOGIA, V35, pA109; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012; PATZELT C, 1986, EMBO J, V5, P2103, DOI 10.1002/j.1460-2075.1986.tb04472.x; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; SCHJOLDAGER BGT, 1989, DIGEST DIS SCI, V35, P703; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007/BF00291980; THAM JP, 1983, J AM CHEM SOC, V105, P6442; THIM L, 1981, REGUL PEPTIDES, V2, P139, DOI 10.1016/0167-0115(81)90007-0; YANAIHARA C, 1985, FEBS LETT, V187, P307, DOI 10.1016/0014-5793(85)81265-5; YANAIHARA C, 1985, FEBS LETT, V189, P50, DOI 10.1016/0014-5793(85)80840-1	31	139	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18827	18833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034635				2022-12-27	WOS:A1994NX32700022
J	BROOKS, W; JACKSON, V				BROOKS, W; JACKSON, V			THE RAPID TRANSFER AND SELECTIVE ASSOCIATION OF HISTONES H2A AND H2B ONTO NEGATIVELY COILED DNA AT PHYSIOLOGICAL IONIC-STRENGTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; NUCLEOSOME CORE PARTICLES; CLOSED CIRCULAR DNA; REPLICATION INVITRO; TRANSCRIPTION; CHROMATIN; OCTAMER; PROTEIN; PURIFICATION; INITIATION	The interaction of histones H2A and H2B with closed circular DNA maintained in either a positive or negatively coiled state has been studied. The methods involved separation of complexes by sucrose gradients and by agarose gel electrophoresis. Histones H2A and H2B have a 10-fold preference for DNA that contains preformed negative coils as compared to DNA that is positively coiled or topologically unrestrained. It was also observed that histones H2A and H2B, when initially reconstituted onto positively coiled DNA, transfer very efficiently to negatively coiled DNA at 100 mM NaCl. Transfer is virtually complete within 5 s at 4 degrees C. By utilizing a cross linking agent (disuccinimidyl suberate), it was found that histones H2A and H2B could be crosslinked into a tetrameric structure when on negatively coiled DNA but not on positively coiled DNA. It is concluded that protein-protein interactions facilitate the transfer. The importance of these protein-protein interactions is further demonstrated in experiments in which H3,H4 were included, and, in this instance, the strong interaction of H2A,H2B with H3,H4 negates the preference of H2A,H2B for negatively coiled DNA. These observations are discussed with regard to the mobility of histones during the transcription process during which transcription-induced stresses may be produced.			BROOKS, W (corresponding author), MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; ARAGAY AM, 1991, BIOCHEMISTRY-US, V30, P5022, DOI 10.1021/bi00234a026; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; BENEDICT RC, 1984, BIOCHEMISTRY-US, V23, P1214, DOI 10.1021/bi00301a029; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BROOKS TL, 1977, NUCLEIC ACIDS RES, V4, P4261, DOI 10.1093/nar/4.12.4261; BUSTIN M, 1978, NUCLEIC ACIDS RES, V5, P925, DOI 10.1093/nar/5.3.925; BUTLER AP, 1982, BIOCHIM BIOPHYS ACTA, V698, P199, DOI 10.1016/0167-4781(82)90135-X; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; COX RF, 1976, CELL, V7, P455, DOI 10.1016/0092-8674(76)90176-8; DABAN JR, 1982, J MOL BIOL, V156, P749, DOI 10.1016/0022-2836(82)90140-1; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; ELIA MC, 1988, J BIOL CHEM, V263, P9958; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; FENG HP, 1993, BIOCHEMISTRY-US, V32, P7824, DOI 10.1021/bi00081a030; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GERMOND JE, 1976, NUCLEIC ACIDS RES, V3, P3173, DOI 10.1093/nar/3.11.3173; GODFREY JE, 1980, BIOCHEMISTRY-US, V19, P1339, DOI 10.1021/bi00548a012; HEGGELERBORDIER B, 1992, EMBO J, V11, P667; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JACKSON S, 1994, BIOCHEMISTRY-US, V33, P5392, DOI 10.1021/bi00184a006; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JACKSON V, 1993, BIOCHEMISTRY-US, V32, P5901, DOI 10.1021/bi00073a024; JORCANO JL, 1979, BIOCHEMISTRY-US, V18, P108; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; Maniatis T., 1982, MOL CLONING; MENEGUZZI G, 1979, NUCLEIC ACIDS RES, V6, P2947, DOI 10.1093/nar/6.8.2947; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS GENET, V7, P175; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STEIN A, 1980, J BIOL CHEM, V255, P3629; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1977, J MOL BIOL, V116, P769, DOI 10.1016/0022-2836(77)90270-4; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1989, CHROMATIN, P146; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	65	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18155	18166						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027077				2022-12-27	WOS:A1994NV42200061
J	HEINONEN, TYK; PEARLMAN, RE				HEINONEN, TYK; PEARLMAN, RE			A GERM LINE-SPECIFIC SEQUENCE ELEMENT IN AN INTRON IN TETRAHYMENA-THERMOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN OXYTRICHA-NOVA; MACRONUCLEAR DEVELOPMENT; EUPLOTES-CRASSUS; SOMATIC NUCLEUS; DNA-SEQUENCES; CILIATE TETRAHYMENA; MICRONUCLEAR DNA; BINDING PROTEIN; GENE; FAMILY	In the ciliated protozoa, the germ line micronucleus carries DNA sequences that are eliminated during the developmental program that produces the somatic macronucleus. We have identified such a micronuclear element in an intron of a gene in the holotrichous ciliate, Tetrahymena thermophila, The macronuclear version of this gene, numbered from the transcription initiation site to the polyadenylation site, is 1569 nucleotides long and contains two introns: intron 1 from nucleotides 206 to 382 and intron 2 from nucleotides 665 to 898. The gene is transcribed into a stable polyadenylated mRNA which is predicted to encode a polypeptide with a highly repetitive structure and an unknown function. The micronuclear version of the gene contains a 2.9-kb sequence element, mse2.9, in intron 2. This element was characterized by sequencing two micronuclear genomic clones that contain 909 and 764 base pairs of micronucleus-specific sequence from its left and right ends, respectively. This sequence has an (A + T) content of 81% and is present as a single copy. The termini of mse2.9 are located within a 4-nucleotide direct repeat, TTAT, one copy of which is retained in the macronuclear gene, be tween positions 755 and 759. Other features near the termini of mse2.9 include a GC-rich sequence motif, CCAACCCGTTG, 31 nucleotides outside the left terminus and a 20-nucleotide palindrome 6 nucleotides outside the right terminus.	YORK UNIV, DEPT BIOL, TORONTO M3J 1P3, ON, CANADA	York University - Canada								ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALLITTO BA, 1986, NUCLEIC ACIDS RES, V14, P8007, DOI 10.1093/nar/14.20.8007; AUSTERBERRY CF, 1988, MOL CELL BIOL, V8, P3947, DOI 10.1128/MCB.8.9.3947; AUSTERBERRY CF, 1987, MOL CELL BIOL, V7, P435, DOI 10.1128/MCB.7.1.435; AUSTERBERRY CF, 1989, NUCLEIC ACIDS RES, V17, P7263, DOI 10.1093/nar/17.18.7263; BAIRD SE, 1989, MOL CELL BIOL, V9, P3793, DOI 10.1128/MCB.9.9.3793; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BRUNK CF, 1982, CAN J BIOCHEM CELL B, V60, P847, DOI 10.1139/o82-107; CALLAHAN RC, 1984, CELL, V36, P441, DOI 10.1016/0092-8674(84)90237-X; CASSIDYHANLEY D, 1994, GENETICS, V137, P95; CHERRY JM, 1985, CELL, V43, P747, DOI 10.1016/0092-8674(85)90248-X; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; CSANK C, 1991, THESIS MCGILL U; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALL JG, 1974, P NATL ACAD SCI USA, V71, P3078, DOI 10.1073/pnas.71.8.3078; GANZ PR, 1980, EUR J BIOCHEM, V113, P159; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GRESLIN AF, 1989, P NATL ACAD SCI USA, V86, P6264, DOI 10.1073/pnas.86.16.6264; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HOWARD EA, 1985, MOL CELL BIOL, V5, P2039, DOI 10.1128/MCB.5.8.2039; HUNTER DJ, 1989, GENE DEV, V3, P2101, DOI 10.1101/gad.3.12b.2101; JAHN CL, 1989, CELL, V59, P1009, DOI 10.1016/0092-8674(89)90757-5; KARRER KM, 1983, MOL CELL BIOL, V3, P1909, DOI 10.1128/MCB.3.11.1909; KATOH M, 1993, NUCLEIC ACIDS RES, V21, P2409, DOI 10.1093/nar/21.10.2409; KILE JP, 1988, MOL CELL BIOL, V8, P5043, DOI 10.1128/MCB.8.11.5043; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; Klobutcher LA, 1991, CURR OPIN GENET DEV, V1, P397, DOI 10.1016/S0959-437X(05)80306-5; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MITCHAM JL, 1992, GENE DEV, V6, P788, DOI 10.1101/gad.6.5.788; Orias E., 1986, P45; PRESCOTT DM, 1992, TRENDS GENET, V8, P439, DOI 10.1016/0168-9525(92)90177-6; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RIBASAPARICIO RM, 1987, GENE DEV, V1, P323, DOI 10.1101/gad.1.4.323; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKEMASA T, 1990, J BIOL CHEM, V265, P2514; TAUSTA SL, 1989, CELL, V59, P1019, DOI 10.1016/0092-8674(89)90758-7; TAUSTA SL, 1991, NUCLEIC ACIDS RES, V19, P3229, DOI 10.1093/nar/19.12.3229; TSAO NNG, 1992, DEV GENET, V13, P75, DOI 10.1002/dvg.1020130112; WHITE TC, 1986, J PROTOZOOL, V33, P30, DOI 10.1111/j.1550-7408.1986.tb05551.x; WYMAN C, 1991, GENETICS, V129, P57; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO M, 1974, CHROMOSOMA, V48, P1; YAO MC, 1982, J CELL BIOL, V92, P783, DOI 10.1083/jcb.92.3.783; YAO MC, 1979, J PROTOZOOL, V26, P10, DOI 10.1111/j.1550-7408.1979.tb02723.x; YAO MC, 1984, CELL, V36, P433, DOI 10.1016/0092-8674(84)90236-8; Yao MC, 1989, MOBILE DNA, P715; YOKOYAMA R, 1984, NUCLEIC ACIDS RES, V12, P6103, DOI 10.1093/nar/12.15.6103	54	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17428	17433						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021245				2022-12-27	WOS:A1994NU12800016
J	BRODBECK, RM; BROWN, JL				BRODBECK, RM; BROWN, JL			STUDY OF THE ROLES OF PROLINE-391 AND A HIGHLY CONSERVED SEQUENCE IN THE CARBOXYL-TERMINAL REGION OF MEMBERS OF THE SERPIN FAMILY IN THE SECRETION OF ALPHA-1-PROTEINASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; MYXOMA VIRUS; SALT BRIDGE; PROTEINS; VARIANT; ALPHA-1-ANTITRYPSIN; DEGRADATION; MUTATIONS; ELASTASE; CALNEXIN	Truncation of alpha 1-proteinase inhibitor prior to Pro(391) prevents its secretion. This residue is the carboxyl terminus of a highly conserved sequence in serpins, suggesting that either Pro(391) or the conserved sequence may serve as at least a part of a signal recognized by components of the secretory pathway. To evaluate these possibilities, we have determined the effects of replacement of Pro(391) On the secretion of alpha 1-proteinase inhibitor and have examined the ability of the 9-residue conserved sequence to mediate secretion. We find that replacement of Pro(391) with hydrophobic residues yields variants that are well secreted, but replacement with other classes of amino acids severely restricts secretion. These results show that while alpha 1-proteinase inhibitor is secreted most efficiently when proline occupies position 391, Pro(391) is not an absolute requirement for its secretion. Our results show that the 9-amino acid conserved sequence found near the carboxyl termini of proteins of the serpin family is not sufficient to direct the secretion of alpha 1-proteinase inhibitor. We conclude that mutations affecting residue 391 and other positions in the conserved region lead to structural changes, possibly very minor, that influence the secretion of alpha 1-proteinase inhibitor.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NHLBI NIH HHS [HL37128] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; BRODBECK RM, 1993, J BIOL CHEM, V268, P6771; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; DUBIN A, 1992, J BIOL CHEM, V267, P6576; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1994, J BIOL CHEM, V269, P7514; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LOMAS DA, 1993, J BIOL CHEM, V268, P516; MCCRACKEN AA, 1991, J BIOL CHEM, V266, P7578; MCCRACKEN AA, 1989, MOL CELL BIOL, V9, P1406, DOI 10.1128/MCB.9.4.1406; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; SAMANDARI T, 1993, PROTEIN SCI, V2, P1400, DOI 10.1002/pro.5560020905; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; WADA I, 1991, J BIOL CHEM, V266, P19599	28	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17252	17256						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006033				2022-12-27	WOS:A1994NT84600042
J	GE, H; ROEDER, RG				GE, H; ROEDER, RG			THE HIGH-MOBILITY GROUP PROTEIN HMG1 CAN REVERSIBLY INHIBIT CLASS-II GENE-TRANSCRIPTION BY INTERACTION WITH THE TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; IMMEDIATE EARLY PROTEIN; NEGATIVE REGULATOR; ACTIVATION DOMAIN; PREINITIATION COMPLEX; INITIATION-FACTORS; BASIC REPEAT; FACTOR-TFIIB; INVITRO; PROMOTER	Regulation of transcription by RNA polymerase II in eukaryotic cells requires both basal and accessory factors, which interact through specific protein-DNA or protein-protein interactions. The high mobility group 1 protein (HMG1) was previously demonstrated to be a nonhistone chromatin-associated protein, which selectively recognizes cruciform DNA rather than a specific primary sequence element. During our investigations of proteins that interact with TFIID, we found that purified mammalian HMG1, as well as recombinant human HMG1, can interact with TATA-binding protein (TBP) in the presence of a TATA box-containing oligonucleotide to form a specific HMG1.TBP.promoter complex. This complex prevents TFIIB binding to TBP and consequently blocks formation of the preinitiation complex. In contrast, TFIIA can compete with HMG1 for binding to TBP. In an in vitro transcription assay reconstituted with highly purified or recombinant general factors, HMG1 is able to inhibit transcription by RNA polymerase II over 30-fold. As expected, addition of TFIIA can partially reverse this repression in a concentration-dependent manner. These results demonstrate that HMG1, a chromatin-associated protein, has the potential to act as a TBP-dependent negative transcription factor and may provide an important link between chromatin structure and the modulation of class II gene transcription.			GE, H (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IGOKEMENES T, 1982, ANNU REV BIOCHEM, V51, P89, DOI 10.1146/annurev.bi.51.070182.000513; INOSTROZA JA, 1992, CELL, V70, P477; KIM WY, 1988, J BIOL CHEM, V263, P18880; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROEDER GS, 1985, MOL CELL BIOL, V5, P1543, DOI 10.1128/MCB.5.7.1543; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	165	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17136	17140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006019				2022-12-27	WOS:A1994NT84600026
J	FAY, PJ; BEATTIE, T; HUGGINS, CF; REGAN, LM				FAY, PJ; BEATTIE, T; HUGGINS, CF; REGAN, LM			FACTOR-VIIIA A2-SUBUNIT RESIDUES-558-565 REPRESENT A FACTOR-IXA INTERACTIVE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; ACTIVATED PROTEIN-C; A1/A3-C1-C2 DIMER; HEMOPHILIA-A; PROCOAGULANT ACTIVITY; FACTOR-XA; FACTOR-VA; THROMBIN; BINDING; INACTIVATION	Factor VIIIa is a non-covalent heterotrimer of A1, A2, and A3-C1-C2 subunits. Previously, we speculated that the central portion of the A2 subunit, in and around the activated protein C-sensitive bond at Arg(562)-Gly (Fay, P. J., Smudzin, T. M., and Walker, F J. (1991) J. Biol. Chem. 266, 20139-20145), is important for macromolecular interactions within the factor Xase enzyme complex. A peptide corresponding to factor VIII residues 558-565, SVDQRGNQ and designated FVIII558-565, was chemically synthesized and inhibited factor Xa generation in a purified system with an apparent K-I of 105 mu M. Tryptic cleavage of FVIII558-565 eliminated its inhibitory activity, whereas a scrambled sequence version of the peptide possessed <30% the inhibitory activity of the native version. Overlapping peptides FVIII556-564 and FVIII561-569 were also inhibitory and confirmed the importance of residues in and around the scissile bond for functional factor Xase. Kinetic analysis revealed that peptide-mediated inhibition was non-competitive with respect to factor X. However, increasing factor IXa concentration overcame the observed inhibition. Furthermore, the peptide inhibited the factor IXa-dependent enhancement of factor VIIIa reconstituted from isolated A1/A3-C1-C2 dimer plus A2 subunit. Isolated factor VIII heavy chain (contiguous A1-A2 domains) was cleaved at Arg(336) by an equimolar concentration of factor IXa in a reaction that was phospholipid-independent. No proteolysis of the isolated A1 subunit was observed in a similar reaction. These results indicate that the A2 subunit sequence delineated by residues 558-565 contributes to the interaction of cofactor with protease and that this interaction is essential for intrinsic factor Xase activity. Furthermore, that this peptide blocks both factor Xase activity and the capacity of factor IXa to stabilize the labile factor VIIIa heterotrimer suggest that this latter property is of physiologic significance.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	FAY, PJ (corresponding author), UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,HEMATOL UNIT,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.			Huggins, Christine/0000-0002-5873-1194	NHLBI NIH HHS [HL-30616, HL-38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALY AM, 1992, P NATL ACAD SCI USA, V89, P4933, DOI 10.1073/pnas.89.11.4933; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FOSTER PA, 1990, BLOOD, V75, P1999; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P8307, DOI 10.1073/pnas.88.19.8307; KANE WH, 1988, BLOOD, V71, P539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LENTING PJ, 1993, THROMB HAEMOSTASIS, V69, P959; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MCGINNISS MJ, 1993, GENOMICS, V15, P392, DOI 10.1006/geno.1993.1073; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PITTMAN DD, 1992, BLOOD, V79, P389; REGAN LM, 1994, J BIOL CHEM, V269, P9445; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	34	137	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20522	20527						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051150				2022-12-27	WOS:A1994PB31700050
J	HRESKO, RC; KRUSE, M; STRUBE, M; MUECKLER, M				HRESKO, RC; KRUSE, M; STRUBE, M; MUECKLER, M			TOPOLOGY OF THE GLUT-1 GLUCOSE-TRANSPORTER DEDUCED FROM GLYCOSYLATION SCANNING MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; CYTOPLASMIC MEMBRANE-PROTEINS; HUMAN-ERYTHROCYTE; XENOPUS-OOCYTES; ESCHERICHIA-COLI; STRUCTURAL BASIS; ORIENTATION; ANTIBODIES; SEQUENCE; IDENTIFICATION	The erythrocyte glucose transporter (Glut 1) is predicted to contain 12 membrane-spanning domains based on the hydropathy plot of its deduced amino acid sequence, The membrane topology of Glut 1 was analyzed by a scanning mutagenesis procedure in which the glycosylated exofacial domain of Glut 4 was inserted independently into each of the putative hydrophilic soluble domains of an aglyco-Glut 1 construct. The transporter mutants were expressed both in vitro using a rabbit reticulocyte lysate translation system and in vivo in Xenopus oocytes. The cytoplasmic or exofacial orientation of each soluble domain was inferred from the glycosylation state of the corresponding insertion mutant. The results from the cell-free system were aberrant in that two topological orientations were observed when the epitope was inserted into any of the short cytoplasmic loops or the NH2 terminus. The in vivo data, however, were in complete agreement with the proposed 12-helix model. Therefore, the multiple topologies observed in vitro probably resulted from the inability of the cell-free system to facilitate the proper folding of the insertion mutants into the membrane. 2-Deoxyglucose uptake data on the glycosylation mutants indicated that epitope insertion into the NH2 terminus, the large central loop, or the second, third, or fifth exofacial loop had no dramatic effect on the activity of the transporter. However, insertion into the other soluble domains either completely abolished or significantly reduced transport activity.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; BALDWIN SA, 1982, BIOCHEMISTRY-US, V21, P3836, DOI 10.1021/bi00259a018; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHIN JJ, 1986, J BIOL CHEM, V261, P7101; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; DAVIES A, 1990, BIOCHEM J, V266, P799; DAVIES A, 1987, J BIOL CHEM, V262, P9347; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASPEL HC, 1988, J BIOL CHEM, V263, P398; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER K, 1989, J BIOL CHEM, V264, P18884; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MAY JM, 1990, BIOCHEMISTRY-US, V29, P10393, DOI 10.1021/bi00497a014; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PRESTON RAJ, 1993, BIOCHEM SOC T, V21, P309, DOI 10.1042/bst0210309; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YAMANE K, 1990, J BIOL CHEM, V265, P21166	37	134	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20482	20488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051147				2022-12-27	WOS:A1994PB31700044
J	KASSNER, PD; KAWAGUCHI, S; HEMLER, ME				KASSNER, PD; KAWAGUCHI, S; HEMLER, ME			MINIMUM ALPHA-CHAIN CYTOPLASMIC TAIL SEQUENCE NEEDED TO SUPPORT INTEGRIN-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; MONOCLONAL-ANTIBODY; BETA-SUBUNIT; BINDING-SITE; FIBRONECTIN RECEPTOR; GPIIB-IIIA; T-CELLS; TERMINAL DIFFERENTIATION; LIGAND AVIDITY; DOMAIN	Previously, we found that deletion of the integrin alpha(4) and alpha(2) subunit cytoplasmic domains, just after the conserved GFFKR motif, causes a loss of adhesive activity mediated by VLA-4 or VLA-2, respectively (Kassner, P. D., and Hemler, M. E. (1993) J. Exp. Med. 178, 649-60; Kawaguchi, S., and Hemler, M. E. (1993) J. Biol. Chem. 268, 16279-12685). Here, we show for alpha(4) and alpha(2) chains (expressed in MIP101 and Chinese hamster ovary cells) that adding only 3-4 amino acids after the GFFKR motif restores substantial adhesive activity and that 5-7 amino acids confers maximal adhesive activity (to VCAM-1, CS1 peptide, or collagen, respectively), Point mutations within the most critical 5 alpha(4) residues had no effect on alpha(4) adhesive activity, nor did exchange of the alpha(4) tail with that of alpha(2). Thus, only a short and relatively nonspecific stretch of alpha chain cytoplasmic domain amino acids may be required to achieve maximal integrin adhesive activity. Also, comprehensive divalent cation titration assays revealed (i) that deletion of alpha chain cytoplasmic domains caused a marked decrease in the efficiency of divalent cation utilization during cell adhesion assays and (ii) that cytoplasmic domain deletion effects could be either suppressed or accentuated depending on the type and amount of divalent cation and the cellular environment utilized. Notably, integrin cu chain tail deletions did not appear to alter the intrinsic ability to interact with ligand because deletion effects were minimal in the presence of metabolic energy inhibitors and were absent during cell-free ligand binding assays.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Kassner, Paul/0000-0002-1471-1191	NIGMS NIH HHS [GM46526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P109; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KENNEL SJ, 1981, CANCER RES, V41, P3465; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PISCHEL KD, 1987, J IMMUNOL, V138, P226; RABB H, 1993, J IMMUNOL, V151, P990; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMITH JW, 1990, J BIOL CHEM, V265, P2168; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	68	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19859	19867						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051067				2022-12-27	WOS:A1994PA12600033
J	MATSUSHIMA, M; ICHINOSE, M; YAHAGI, N; KAKEI, N; TSUKADA, S; MIKI, K; KUROKAWA, K; TASHIRO, K; SHIOKAWA, K; SHINOMIYA, K; UMEYAMA, H; INOUE, H; TAKAHASHI, T; TAKAHASHI, K				MATSUSHIMA, M; ICHINOSE, M; YAHAGI, N; KAKEI, N; TSUKADA, S; MIKI, K; KUROKAWA, K; TASHIRO, K; SHIOKAWA, K; SHINOMIYA, K; UMEYAMA, H; INOUE, H; TAKAHASHI, T; TAKAHASHI, K			STRUCTURAL CHARACTERIZATION OF PORCINE ENTEROPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; INTERNAL SIGNAL SEQUENCE; BLOOD-COAGULATION FACTOR; COMPLEMENT PROTEIN C8; 4 TANDEM REPEATS; BOVINE ENTEROKINASE; LDL-RECEPTOR; SERINE PROTEASE; PLASMA PREKALLIKREIN; LIPOPROTEIN RECEPTOR	Enteropeptidase (EC 3.4.21.9) is a key enzyme in the intestinal digestion cascade responsible for the conversion of trypsinogen to trypsin, which then activates various pancreatic zymogens. In order to structurally characterize the enzyme, we purified the enzyme from porcine duodenal mucosa and showed that it consists of three polypeptide chains, which we named ''mini'' chain (M chain), light chain (L chain), and heavy chain (H chain) in order of increasing molecular size. Based on their NH2-terminal sequences, a cDNA clone for porcine enteropeptidase was isolated and analyzed. The clone was 3597 base pairs long, which encoded 1034 amino acid residues of a single-chain precursor form of enteropeptidase. The precursor contained an additional NH2-terminal 51-residue sequence including a putative internal signal sequence, followed by the M chain (66 residues), the H chain (682 residues), and the L chain (235 residues) in that order. The H chain had regions partially homologous in sequence with low density lipoprotein receptor and complement components. On the other hand, the L chain was highly homologous with the catalytic domains of trypsin-like serine proteinases. The structural model of the L chain suggests that the sequence, Arg(885)-Arg-Arg-Lys(888), is probably involved in the unique substrate specificity of the enzyme, preferring acidic amino acid residues at the P-2-P-5 sites.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT ZOOL,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,TOKYO 113,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Kitasato University								BARATTI J, 1976, BIOCHIM BIOPHYS ACTA, V452, P488, DOI 10.1016/0005-2744(76)90199-6; BARATTI J, 1973, BIOCHIM BIOPHYS ACTA, V315, P147, DOI 10.1016/0005-2744(73)90138-1; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; FONSECA P, 1983, J BIOL CHEM, V258, P4516; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GHISHAN FK, 1983, GASTROENTEROLOGY, V85, P727; GRANT DAW, 1975, BIOCHEM J, V147, P363, DOI 10.1042/bj1470363; GRANT DAW, 1976, BIOCHEM J, V155, P243, DOI 10.1042/bj1550243; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMILTON KK, 1993, J BIOL CHEM, V268, P3632; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HARTLEY BS, 1966, BIOCHEM J, V101, P229, DOI 10.1042/bj1010229; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HERMONTAYLOR J, 1977, GUT, V18, P259, DOI 10.1136/gut.18.4.259; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KAJIHARA A, 1993, PROTEIN ENG, V6, P615, DOI 10.1093/protein/6.6.615; KAWASHIMA I, 1987, DNA-J MOLEC CELL BIO, V6, P163, DOI 10.1089/dna.1987.6.163; KOMOOKA H, 1991, 14TH S CHEM INF COMP, P71; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LeGendre N., 1989, PRACTICAL GUIDE PROT, P52; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIEPNIEKS JJ, 1979, J BIOL CHEM, V254, P1677; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LIGHT A, 1980, ANAL BIOCHEM, V106, P199, DOI 10.1016/0003-2697(80)90138-4; LIGHT A, 1984, J BIOL CHEM, V259, P3195; LOJDA Z, 1983, HISTOCHEMISTRY, V78, P251, DOI 10.1007/BF00489503; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MAGEE AI, 1981, CLIN CHIM ACTA, V115, P241, DOI 10.1016/0009-8981(81)90238-2; MAROUX S, 1971, J BIOL CHEM, V246, P5031; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MELOUN B, 1966, BIOCHIM BIOPHYS ACTA, V130, P543, DOI 10.1016/0304-4165(66)90258-3; MIKES O, 1966, BIOCHEM BIOPH RES CO, V24, P346, DOI 10.1016/0006-291X(66)90162-8; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SOUTAR AK, 1990, BRIT MED BULL, V46, P891, DOI 10.1093/oxfordjournals.bmb.a072445; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; TOYODA S, 1985, DIGEST DIS SCI, V30, P1174, DOI 10.1007/BF01314053; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WATT VM, 1989, J BIOL CHEM, V264, P5480; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	62	58	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19976	19982						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051081				2022-12-27	WOS:A1994PA12600050
J	SHEAFF, RJ; KUCHTA, RD				SHEAFF, RJ; KUCHTA, RD			MISINCORPORATION OF NUCLEOTIDES BY CALF THYMUS DNA PRIMASE AND ELONGATION OF PRIMERS CONTAINING MULTIPLE NONCOGNATE NUCLEOTIDES BY DNA-POLYMERASE-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; I KLENOW; DROSOPHILA-MELANOGASTER; KINETIC MECHANISM; FIDELITY; INITIATION; COMPLEX; TRIPHOSPHATES; TEMPLATE; ACCURACY	Misincorporation of nucleotides by calf thymus DNA primase was examined using synthetic DNA templates of defined sequence. Primase seldom misincorporated NTPs during initiation of a new primer (i.e. polymerization of two NTPs to generate the dinucleotide). Following dinucleotide formation, however, primase readily misincorporated NTPs. Although the rate of misincorporation varied according to both the identity of the mismatch and the template sequence, primase is by far the least accurate nucleotide-polymerizing enzyme known. In some eases primase discriminated against incorrect NTPs by less than a factor of 100. After primase incorporated a noncognate nucleotide into the primer, the next correct NTP was readily added. Remarkably, primase could also polymerize consecutive noncognate nucleotides and generate primers containing multiple mismatches. Generation of a correctly base-paired primer-template negatively regulated further primer synthesis; however, generation of a primer-template containing multiple mismatches did not. After primase synthesized a primer containing multiple mismatches, the primer was transferred to the polymerase cu active site via an intramolecular mechanism. Importantly, polymerase cu readily elongated this primer if dNTPs were present. These data are discussed with respect to the question of why primase is required for DNA replication.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder								BIALEK G, 1992, J BIOL CHEM, V267, P2915; CHANG LMS, 1984, J BIOL CHEM, V259, P4679; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; FRY M, 1986, ANIMAL CELL DNA POLY, P13; Hauschka P V, 1973, Methods Cell Biol, V7, P361; HAY RT, 1984, J MOL BIOL, V175, P131, DOI 10.1016/0022-2836(84)90471-6; HU SZ, 1984, J BIOL CHEM, V259, P2602; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KITANI T, 1984, MOL CELL BIOL, V4, P1591, DOI 10.1128/MCB.4.8.1591; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SHEAFF RJ, 1994, BIOCHEMISTRY-US, V33, P2247, DOI 10.1021/bi00174a035; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; SINGH H, 1986, J BIOL CHEM, V261, P8564; TSENG BY, 1980, J BIOL CHEM, V255, P2062; VISHWANATHA JK, 1986, NUCLEIC ACIDS RES, V14, P7305, DOI 10.1093/nar/14.18.7305; WEISS SJ, 1992, J BIOL CHEM, V267, P18520; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P6254; ZHANG SS, 1990, J MOL BIOL, V216, P475, DOI 10.1016/0022-2836(90)90370-2	27	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19225	19231						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034683				2022-12-27	WOS:A1994NY33200007
J	SWAIM, WD; MINOGUCHI, K; OLIVER, C; HAMAWY, MM; KIHARA, H; STEPHAN, V; BERENSTEIN, EH; SIRAGANIAN, RP				SWAIM, WD; MINOGUCHI, K; OLIVER, C; HAMAWY, MM; KIHARA, H; STEPHAN, V; BERENSTEIN, EH; SIRAGANIAN, RP			THE ANTIGANGLIOSIDE MONOCLONAL-ANTIBODY AA4 INDUCES PROTEIN-TYROSINE PHOSPHORYLATIONS, BUT NOT DEGRANULATION, IN RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; AFFINITY IGE RECEPTOR; FC-EPSILON-RI; IMMUNOGLOBULIN-E RECEPTORS; MAST-CELLS; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; PHOSPHOLIPASE C-GAMMA-1; MEDIATED MODULATION; KINASE-ACTIVITY	The monoclonal antibody AA4 (mAb AA4) recognizes novel alpha-galactosyl derivatives of G(D1b) on rat basophilic leukemia (RBL-2H3) cells. The binding of mAb AA4 induced protein tyrosine phosphorylations without histamine release. Several of the same proteins including Fc epsilon RI beta, Fc epsilon RI gamma, p72(syk), and phospholipase C-gamma 1 were tyrosine-phosphorylated by mAb AA4 binding and by the activation of the high affinity IgE receptor, Fc epsilon RI. There was also activation of the p53/56(lym) and p72(syk) protein-tyrosine kinases, but compared to direct Fc epsilon RI activation, mAb AA4 did not result in increased tyrosine phosphorylation of pp105-115 or pp125(FAK), and the receptor subunits (Fc epsilon RI beta and Fc epsilon RI gamma) were more heavily phosphorylated. Furthermore, the time course of the phosphorylations with mAb AA4 was slower than that induced by Fc epsilon RI aggregation. By immunofluorescence, the tyrosine-phosphorylated proteins after mAb AA4 stimulation were localized in patches at the cell membrane and in areas of cell-cell contact, whereas after Fc epsilon RI activation, there was a reticular cytoplasmic pattern. There were no protein tyrosine phosphorylations either when Fc epsilon RI was saturated with IgE or when F(ab')(2) fragments of mAb AA4 were used, although the F(ab')(2) fragments still induced morphological changes. There was also coprecipitation of the beta and gamma subunits of Fc epsilon RI with the anti-ganglioside antibody. These data strongly suggest the involvement of Fc epsilon RI in the antiganglioside-induced protein tyrosine phosphorylations. Moreover, phosphorylations of these proteins including the beta and gamma chains of Fc epsilon RI and activation of p53/56(lyn) and p72(syk) did not result in histamine release.			SWAIM, WD (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; BALAKRISHNAN K, 1982, J BIOL CHEM, V257, P6427; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CHABAY R, 1980, J BIOL CHEM, V255, P4628; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DELISI C, 1979, J IMMUNOL, V122, P2286; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; EISEMAN E, 1992, NATURE, V355, P78; ESTES KAS, 1988, THESIS CORNELL U; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GUO N, 1989, J BIOL CHEM, V264, P13267; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1992, J IMMUNOL, V148, P524; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANAI N, 1988, J BIOL CHEM, V263, P10915; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KANE P, 1986, MOL IMMUNOL, V23, P783, DOI 10.1016/0161-5890(86)90090-8; KATZ HR, 1988, J IMMUNOL, V140, P3090; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KITANI S, 1991, J BIOL CHEM, V266, P1903; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVER C, 1992, J CELL BIOL, V116, P635, DOI 10.1083/jcb.116.3.635; OLIVER JM, 1988, PROG ALLERGY, V42, P185; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; SAHARA N, 1990, J HISTOCHEM CYTOCHEM, V38, P975, DOI 10.1177/38.7.1693935; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; SONG WX, 1991, J BIOL CHEM, V266, P10174; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STEPHAN V, 1991, J IMMUNOL, V146, P4271; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YU KT, 1991, J BIOL CHEM, V266, P22564; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	65	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19466	19473						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034715				2022-12-27	WOS:A1994NY33200043
J	AOYAMA, T; UENO, I; KAMIJO, T; HASHIMOTO, T				AOYAMA, T; UENO, I; KAMIJO, T; HASHIMOTO, T			RAT VERY-LONG-CHAIN ACYL-COA DEHYDROGENASE, A NOVEL MITOCHONDRIAL ACYL-COA DEHYDROGENASE GENE-PRODUCT, IS A RATE-LIMITING ENZYME IN LONG-CHAIN FATTY-ACID BETA-OXIDATION SYSTEM - CDNA AND DEDUCED AMINO AMINO-ACID-SEQUENCE AND DISTINCT SPECIFICITIES OF THE CDNA-EXPRESSED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; LIVER MITOCHONDRIA; VACCINIA VIRUS; CULTURED FIBROBLASTS; CARNITINE DEFICIENCY; PREVALENT MUTATION; CATALYTIC ACTIVITY; PURIFICATION	cDNA encoding the precursor of rat very-long-chain acyl-CoA dehydrogenase (VLCAD) was cloned and sequenced. The longest cDNA insert had 2117 bases. This cDNA encodes the entire protein of 655 amino acids, including a 40-amino acid leader peptide and a 615-amino acid mature polypeptide. The identity of the VLCAD clone was confirmed by matching the amino acid sequence predicted from the cDNA to the NH2 terminus and seven internal proteolytic peptide sequences from purified rat liver VLCAD. The calculated molecular masses of the precursor protein, the mature protein, and the leader peptide are 70,961, 66,508, and 4,470 daltons, respectively. At the amino acid level, the significant homology to the other acyl-CoA dehydrogenases was found at the range from the 94th to the 473rd amino acid residue of the amino-terminal side. The catalytic residue and the residue lying near the dimethylbenzene side (si-side) of the flavin ring were speculated to be Glu-462 and Trp-249, respectively. The VLCAD cDNA was expressed in four kinds of hepatoma cells using a vaccinia virus expression system and was shown to encode the catalytically active enzyme. The cDNA expression in both rat heptoma H4IIEC3 and McA-RH7777 enhanced about 3 fold mitochondrial beta-oxidation activity of long-chain fatty acids such as palmitic acid and stearic acid; hence, VLCAD is probably a rate-limiting enzyme in the long-chain fatty acid beta-oxidation system in these cell lines.	SHINSHU UNIV, SCH MED, DEPT BIOCHEM, MATSUMOTO, NAGANO 390, JAPAN; SHINSHU UNIV HOSP, CENT CLIN LABS, MATSUMOTO, NAGANO 390, JAPAN; SHINSHU UNIV, SCH MED, DEPT PEDIAT, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University; Shinshu University; Shinshu University								AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; AOYAMA T, 1989, EUR J BIOCHEM, V181, P331, DOI 10.1111/j.1432-1033.1989.tb14728.x; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; AOYAMA T, 1989, J BIOL CHEM, V264, P21327; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COATES PM, 1992, J LIPID RES, V33, P1099; COATES PM, 1988, J CLIN INVEST, V81, P171, DOI 10.1172/JCI113290; COATES PM, 1992, NEW DEV FATTY ACID O; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; Engel P. C., 1992, CHEM BIOCH FLAVOENZY, P597; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; HALE DE, 1985, PEDIATR RES, V19, P666, DOI 10.1203/00006450-198507000-00006; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INDO Y, 1991, PEDIATR RES, V30, P211, DOI 10.1203/00006450-199109000-00001; INDO Y, 1991, GENOMICS, V11, P609, DOI 10.1016/0888-7543(91)90068-P; IZAI K, 1992, J BIOL CHEM, V267, P1027; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1992, PROG CLIN BIOL RES, V375, P111; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NAITO E, 1989, J CLIN INVEST, V84, P1671, DOI 10.1172/JCI114346; RHEAD WJ, 1983, SCIENCE, V221, P73, DOI 10.1126/science.6857268; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUZUKI Y, 1991, BIOCHEM PHARMACOL, V41, P453, DOI 10.1016/0006-2952(91)90544-F; TANAKA K, 1990, FATTY ACID OXIDATION; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNBULL DM, 1984, NEW ENGL J MED, V311, P1232, DOI 10.1056/NEJM198411083111906; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VOCKLEY J, 1992, J BIOL CHEM, V267, P2494; YOKOTA I, 1991, AM J HUM GENET, V49, P1280; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	44	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19088	19094						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034667				2022-12-27	WOS:A1994NX32700059
J	YANG, HQ; MA, H; TAKANO, E; HATANAKA, M; MAKI, M				YANG, HQ; MA, H; TAKANO, E; HATANAKA, M; MAKI, M			ANALYSIS OF CALCIUM-DEPENDENT INTERACTION BETWEEN AMINO-TERMINAL CONSERVED REGION OF CALPASTATIN FUNCTIONAL DOMAIN AND CALMODULIN-LIKE DOMAIN OF MU-CALPAIN LARGE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; 4 REPEATING DOMAINS; ENDOGENOUS INHIBITOR; COMPLEX-FORMATION; ESCHERICHIA-COLI; PIG CALPASTATIN; PEPTIDE COMPLEX; EXPRESSION; BINDING; IDENTIFICATION	Calpain requires Ca2+ both for proteolysis of its substrates and for interaction with its endogenous inhibitor, calpastatin. Although calmodulin-like domains (CaMLDs) of large and small subunits of calpain have been suggested to be the sites for Ca2+-dependent interaction with calpastatin, specificity and molecular basis of the interaction have remained unclear. We investigated the interaction between the CaMLD of human mu-calpain large subunit expressed in Escherichia coli and a 19-residue synthetic oligopeptide corresponding to the region A (the amino-terminal conserved acidic region) of one of the four repetitive functional domains of calpastatin. The recombinant CaMLD bound to the oligopeptide immobilized on Sepharose beads in a Ca2+-dependent manner. The CaMLD failed in binding to a mutant oligopeptide with one amino acid substitution. Enhancement of fluorescence intensity of a hydrophobic probe, 2-(p-toluidino)naphthalene-6-sulfonate, was observed upon incubating with the CaMLD and further increased by Ca2+. The Ca2+-dependent enhancement of fluorescence intensity was strongly suppressed by the wild type oligopeptide, but not by the mutant one. Kinetic experiments were performed with BIAcore(TM) where binding of the CaMLD to the oligopeptide immobilized on a biosensor chip was detected as real time signals of surface plasmon resonance. The determined dissociation constant (K-D) was 3.1 x 10(-9) M. These results suggest that the region A of calpastatin binds to the CaMLD in a specific manner similar to interactions between calmodulin-binding peptides and calmodulin where hydrophobic properties are known to be important.	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; EMORI Y, 1988, J BIOL CHEM, V263, P2364; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; GOPALAKRISHNA R, 1985, FEBS LETT, V186, P246, DOI 10.1016/0014-5793(85)80717-1; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; KRETSINGER RH, 1992, SCIENCE, V258, P50, DOI 10.1126/science.1439768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MELLGREN RL, 1990, INTRACELLULAR CALCIU; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROSS E, 1973, ANAL BIOCHEM, V54, P304, DOI 10.1016/0003-2697(73)90280-7; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SHIGETA K, 1984, BIOCHEM INT, V9, P327; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TSUJI S, 1981, J BIOCHEM-TOKYO, V90, P1405, DOI 10.1093/oxfordjournals.jbchem.a133606; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q	37	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18977	18984						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034655				2022-12-27	WOS:A1994NX32700043
J	WEBER, T; PAESOLD, G; GALLI, C; MISCHLER, R; SEMENZA, G; BRUNNER, J				WEBER, T; PAESOLD, G; GALLI, C; MISCHLER, R; SEMENZA, G; BRUNNER, J			EVIDENCE FOR H+-INDUCED INSERTION OF INFLUENZA HEMAGGLUTININ HA2 N-TERMINAL SEGMENT INTO VIRAL MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HEMAGGLUTININ; LOW PH; FUSION ACTIVITY; CONFORMATIONAL CHANGE; MECHANISM; PROTEINS; INACTIVATION; MICROSCOPY; SUBUNIT; ACID	Fusion of influenza virus with target membranes is induced by acid and involves complex changes in the viral fusion protein hemagglutinin. At 0 degrees C, in a first kinetically resolvable step, the hemagglutinin polypeptide 2 (HA2) N-terminal segment (fusion peptide) is exposed and inserts into the target membrane (Tsurudome, M., Gluck, R., Graf, R., Falchetto, R., Schaller, U., and Brunner, J. (1992) J. Biol. Chem. 267, 20225-20232). We now report studies of the changes taking place at pH 5.0 and 37 degrees C, conditions that result in fusion or, in the absence of a target membrane, in inactivation of the virus' fusion capacity. To this end, we synthesized the new photosensitive phospholipid, 1-palmitoyl-2-[decanedioyl mono-[2-(I-125)iodo-4-(3-trifluoromethyl-3H- diazirin-3-yl)-benzyl]ester]-sn-glycero-3-phosphocholine (specific radioactivity, >2000 Ci/mmol), and worked out a protocol to incorporate this lipid into the viral membrane. Subsequent photoactivation of the reagent resulted in selective labeling of the C-terminal portion of the HA2 polypeptide chain, in agreement with the membrane topology of hemagglutinin. When, however, prior to reagent activation, the viruses were exposed at pH 5.0, 37 degrees C, both the HA2 C-terminal and the N-terminal regions were labeled, suggesting that the HA2 N-terminal segment (fusion peptide) inserted into the viral membrane. Possible implications for fusion and virus inactivation are discussed.	ETH ZENTRUM,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND; SWISS SERUM & VACCINE INST,CH-3021 BERN,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Paesold, Günther/K-1768-2013; Weber, Thomas/GLS-9125-2022; Weber, Thomas/A-2363-2008	Weber, Thomas/0000-0002-0494-0484; Weber, Thomas/0000-0002-0494-0484; Paesold, Gunther/0000-0002-8597-356X				BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; BENTZ J, 1993, VIRAL FUSION MECHANI, P453; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BRUNNER J, 1993, VIRAL FUSION MECHANI, P67; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; CLAGUE MJ, 1993, VIRAL FUSION MECHANI, P113; GERHARD W, 1976, J EXP MED, V144, P985, DOI 10.1084/jem.144.4.985; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HELM CA, 1989, SCIENCE, V246, P919, DOI 10.1126/science.2814514; KAMP HH, 1974, METHOD ENZYMOL, V22, P140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; MOERLEIN SM, 1988, J CHEM SOC PERK T 1, P779, DOI 10.1039/p19880000779; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; RUIGROK RWH, 1992, J GEN VIROL, V73, P995, DOI 10.1099/0022-1317-73-4-995; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHROIT AJ, 1987, BIOCHEMISTRY-US, V26, P1812, DOI 10.1021/bi00381a004; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TSAO YH, 1993, SCIENCE, V262, P547, DOI 10.1126/science.8211182; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WARD CW, 1980, AUST J BIOL SCI, V33, P441; White J M, 1993, Trends Cell Biol, V3, P99, DOI 10.1016/0962-8924(93)90081-B; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	40	96	98	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18353	18358						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034580				2022-12-27	WOS:A1994NW79800021
J	ZHOU, Y; LINDBERG, I				ZHOU, Y; LINDBERG, I			ENZYMATIC-PROPERTIES OF CARBOXYL-TERMINALLY TRUNCATED PROHORMONE CONVERTASE-1 (PC1/SPC3) AND EVIDENCE FOR AUTOCATALYTIC CONVERSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; PROCESSING ENZYME; POSTTRANSLATIONAL MODIFICATIONS; CHROMAFFIN GRANULES; KEX2 PROTEASE; PC2; FURIN; ENDOPROTEASE; IDENTIFICATION	Previous studies have shown that the prohormone convertase 1 (PC1, or SPC3), a member of the new eukaryotic subtilisin-like proteinase family, undergoes a series of proteolytic processing events during its biosynthesis. The first cleavage, of the amino-terminal prosegment, is probably involved in enzyme activation, while the secondary cleavages at the carboxyl terminus are of unknown significance and occur mainly in cells possessing a regulated secretory pathway. In this work, we found that 87-kDa PC1, a homogeneous recombinant protein, could spontaneously convert to 74- and 66-kDa forms in vitro. Limited digestion of 87-kDa PC1 using chymotrypsin and trypsin could also generate 74- and 66-kDa-like PC1s, which were enzymatically active against the fluorogenic peptide carbobenzoxy-Arg-Tyr-Lys-Arg-aminomethylcoumarin. The 74/66 kDa PC1 generated by spontaneous conversion was purified away from the 87-kDa form and enzymatically characterized. Compared to the 87-kDa form, 74/66-kDa PC1 was more active but less stable. In addition, 74/66-kDa PC1 exhibited a narrower pH optimum (between 5.0 and 5.5) and was activated by higher concentrations of calcium. Carboxyl-terminally truncated PC1 also appeared to be more sensitive to certain protease inhibitors than 87-kDa PC1. Taken together, our results suggest that autocatalysis could be involved in carboxyl-terminal cleavages of PC1. These carboxyl-terminal cleavages of PC1 result in alterations in certain PC1 properties and may therefore possess potential significance with respect to prohormone processing.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA	Louisiana State University System			Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, NIDA 05084, R01 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHRISTIE DL, 1984, BIOCHEM BIOPH RES CO, V120, P650, DOI 10.1016/0006-291X(84)91305-6; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MILGRAM S, 1994, INPRESS J CELL SCI; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; YI Z, 1993, J BIOL CHEM, V268, P5615	35	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18408	18413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034588				2022-12-27	WOS:A1994NW79800030
J	BUBIEN, JK; JOPE, RS; WARNOCK, DG				BUBIEN, JK; JOPE, RS; WARNOCK, DG			G-PROTEINS MODULATE AMILORIDE-SENSITIVE SODIUM-CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPITHELIAL NA+ CHANNELS; COINCIDENT SIGNALS; ACTIVATION; CELLS; CAMP; CONDUCTANCE; VASOPRESSIN; A6	We examined the regulation of an amiloride-sensitive sodium conductance expressed in human B lymphoid cells. This conductance was activated by two independent pathways, one involving cyclic adenylyl monophosphate (cAMP)-dependent protein kinase and the other involving a pertussis toxin-sensitive G-protein. Cholera toxin, presumably by increasing cellular cAMP, and pertussis toxin, which ADP-ribosylates certain GTP-binding proteins, both independently increased the amiloride-sensitive sodium conductance. Simultaneous treatment with both toxins, however, failed to increase the sodium conductance, implying that a single set of sodium channels was being affected by both toxins. In cells preactivated with pertussis toxin, 8-chlorophenylthio-cAMP inhibited the activated sodium conductance back to the basal level. Thus, cyclic AMP-dependent pathways can either activate or inhibit amiloride-sensitive sodium channels, depending upon the activation state of a pertussis toxin-sensitive GTP-binding protein. These findings support a hypothesis for the regulation of amiloride sensitive sodium channels which incorporates the independent effects of cholera and pertussis toxins, and in which cyclic AMP can play a dual role in the regulation of channel activity.	UNIV ALABAMA,DEPT MED,DIV NEPHROL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; DEPT VET AFFAIRS MED CTR,BIRMINGHAM,AL; UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BUBIEN, JK (corresponding author), UNIV ALABAMA,CTR NEPHROL RES & TRAINING,961 SPARKS CTR,BIRMINGHAM,AL 35294, USA.							AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BENOS DJ, 1991, MEMEBRANE TRANSPORT, V5, P166; BOURNE HR, 1992, COLD SPRING HARB SYM, V57, P145, DOI 10.1101/SQB.1992.057.01.018; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; DARNELL J, 1990, MOL CELL BIOL, P1105; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; GARTY H, 1989, AM J PHYSIOL, V256, pF965, DOI 10.1152/ajprenal.1989.256.5.F965; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MCGILL JM, 1993, J MEMBRANE BIOL, V133, P253; NICHOLLS JG, 1992, NEURON BRAIN, P807; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; OHARA A, 1993, AM J PHYSIOL, V264, pC352, DOI 10.1152/ajpcell.1993.264.2.C352; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; SCHAFER JA, 1990, AM J PHYSIOL, V259, pF823, DOI 10.1152/ajprenal.1990.259.5.F823; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453	22	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17780	17783						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027031				2022-12-27	WOS:A1994NV42200007
J	CORRELL, CC; NG, L; EDWARDS, PA				CORRELL, CC; NG, L; EDWARDS, PA			IDENTIFICATION OF FARNESOL AS THE NONSTEROL DERIVATIVE OF MEVALONIC ACID REQUIRED FOR THE ACCELERATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							A REDUCTASE; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; REGULATED DEGRADATION; PERMEABILIZED CELLS; BETA-GALACTOSIDASE; MEMBRANE DOMAIN; MAMMALIAN-CELLS; PROTEIN; SYNTHASE	The degradation of the microsomal enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is highly regulated and is dependent on both a sterol and non-sterol derivative of mevalonic acid (MVA). We re cently proposed that the non-sterol component is derived from farnesyl diphosphate (FPP), presqualene pyrophosphate, or squalene (Correll, C. C. and Edwards, P.A. (1994) J. Biol. Chem. 269, 633-638). In the current study, we have used digitonin-permeabilized cells to further define this MVA-derived non-sterol component required for the regulated degradation of HMG-CoA reductase. The addition of either FPP or farnesol to digitonin-permeabilized cells resulted in a rapid and dose-dependent degradation of HMG-CoA reductase. The effect of FPP, but not farnesol, was blocked by the phosphatase inhibitor sodium fluoride. The enhanced degradation of HMG-CoA reductase in permeabilized cells specifically required farnesol, since the addition of any of the structurally related isoprenoids geraniol, geranyl diphosphate, geranylgeranyl diphosphate, nerolidol, or all-cis-farnesol, or of the non-sterol squalene to the permeabilized cells did not stimulate enzyme degradation. The present studies demonstrate for the first time that the accelerated degradation of HMG-CoA reductase can be initiated in vitro. Further, since farnesol is shown to be specifically required for the enhanced degradation of the enzyme in vitro, we propose that this isoprenoid alcohol is important in this process in intact cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P633; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; JOLY A, 1991, J BIOL CHEM, V266, P13495; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LISCUM L, 1985, J BIOL CHEM, V260, P522; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	28	133	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17390	17393						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021239				2022-12-27	WOS:A1994NU12800009
J	LI, Q; CATHCART, MK				LI, Q; CATHCART, MK			PROTEIN-KINASE-C ACTIVITY IS REQUIRED FOR LIPID OXIDATION OF LOW-DENSITY-LIPOPROTEIN BY ACTIVATED HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED MACROPHAGE DEGRADATION; PERITONEAL-MACROPHAGES; SELECTIVE INHIBITOR; CALPHOSTIN-C; CELLS; PHOSPHORYLATION; EXPRESSION; SUBSTRATE; POTENT; SUPEROXIDE	Our previous studies have shown that human monocytes can oxidize native low density lipoprotein (LDL) and transform it to a cytotoxin. We also found that intracellular Ca2+ levels are integrally involved in lipid oxidation of LDL by activated monocytes. In these studies, we investigated the protein kinase C (PKC) signaling pathway for its contribution to the process of monocyte oxidation of LDL lipids. We found substantial protein phosphorylation induced upon monocyte activation. Pharmacologic inhibition of PKC activity with the PKC inhibitors H-7 (1-100 mu M), calphostin C (1-10 mu M), and GF109203X (0.1-10 mu M) caused a dose-dependent inhibition of cellular protein phosphorylation, including that of several previously identified PKC substrates. These inhibitors of PKC activity also substantially inhibited LDL lipid oxidation by activated monocytes. This inhibition was correlated with a profound suppression of superoxide anion production by these cells. In contrast, inhibition of cAMP dependent protein kinase activity altered neither monocyte-mediated LDL lipid oxidation nor O-2(-) production by activated monocytes. Delaying the addition of PKC inhibitors until after the peak production of O-2(-) which occurs during the respiratory burst, still resulted in inhibition bf LDL lipid oxidation, suggesting roles for PKC in both early and late events. To corroborate these findings using other approaches, we used phorbol 12-myristate 13-acetate to down-regulate PKC activity and also used antisense oligonucleotides as specific PKC inhibitors. Results of both types of studies support the conclusion that PKC activity is required for activated monocytes to oxidize LDL lipids. Thus, PKC activation in this system is essential, one critical pathway regulated by PKC activity is the production of O-2(-) and continued PKC activity is required for optimal oxidation of LDL Lipids.	CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CATHCART MK, 1991, J LIPID RES, V32, P63; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1988, IN VITRO CELL DEV B, V24, P1001; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; ELSAADANI M, 1989, J LIPID RES, V30, P627; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FOLCIK VA, 1993, J LIPID RES, V34, P69; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INTRONA M, 1986, J IMMUNOL, V137, P2711; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; MARCUS AJ, 1993, J LIPID RES, V34, P2017; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; POSTERNAK T, 1971, ANN NY ACAD SCI, V185, P42; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RADZIOCH D, 1987, MOL CELL BIOL, V7, P595, DOI 10.1128/MCB.7.2.595; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; SMITH MR, 1992, J IMMUNOL, V149, P1304; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	40	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17508	17515						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021258				2022-12-27	WOS:A1994NU12800029
J	GONOI, T; MIZUNO, N; INAGAKI, N; KUROMI, H; SEINO, Y; MIYAZAKI, J; SEINO, S				GONOI, T; MIZUNO, N; INAGAKI, N; KUROMI, H; SEINO, Y; MIYAZAKI, J; SEINO, S			FUNCTIONAL NEURONAL IONOTROPIC GLUTAMATE RECEPTORS ARE EXPRESSED IN THE NONNEURONAL CELL-LINE MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; NMDA RECEPTOR; CURRENTS; CHANNELS; CALCIUM; CLONING; MODULATION; GLUCOSE; FAMILY	We report that a non-neuronal cell line, MIN6, derived from insulin-secreting pancreatic beta-cells, naturally expresses functional ionotropic glutamate receptors. Electrophysiological recordings show that kainate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and N-methyl-D-aspartate (NMDA) depolarize single MIN6 cells and evoke inward ionic currents. These agents also increase the intracellular calcium concentration in MIN6 cells. Furthermore, insulin secretion from MIN6 cells is stimulated by kainate, AMPA, and NMDA. The presence of AMPA/kainate and NMDA receptor subtypes is confirmed by reverse transcriptase-polymerase chain reaction. These results demonstrate that ionotropic glutamate receptors with properties similar to those in neuronal cells are expressed in a non-neuronal cell line, MIN6. Thus, MIN6 provides a useful and valuable model system for biochemical, pharmacological, and physiological studies of ionotropic glutamate receptors.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR,CHUO KU,CHIBA 260,JAPAN; KYOTO UNIV,SCH MED,DEPT METAB & CLIN NUTR,SAKYO KU,KYOTO 606,JAPAN; UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN	Chiba University; Chiba University; Kyoto University; Novartis; Sandoz; University of Tokyo			gonoi, tohru/AAC-5181-2021; , gonoi/GRS-0648-2022; Miyazaki, Jun-ichi/N-1976-2015	gonoi, tohru/0000-0003-3655-7911; , gonoi/0000-0003-3655-7911; Miyazaki, Jun-ichi/0000-0003-2475-589X; Inagaki, Nobuya/0000-0001-8261-2593				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; GIBBONS SJ, 1993, ANN NY ACAD SCI, V679, P22, DOI 10.1111/j.1749-6632.1993.tb18286.x; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MAYER ML, 1989, J PHYSIOL-LONDON, V415, P329, DOI 10.1113/jphysiol.1989.sp017724; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; TURETSKY DM, 1993, J NEUROBIOL, V24, P1157, DOI 10.1002/neu.480240904; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	26	101	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					16989	16992						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006003				2022-12-27	WOS:A1994NT84600002
J	IWAMOTO, M; JIKKO, A; MURAKAMI, H; SHIMAZU, A; NAKASHIMA, K; IWAMOTO, M; TAKIGAWA, M; BABA, H; SUZUKI, F; KATO, Y				IWAMOTO, M; JIKKO, A; MURAKAMI, H; SHIMAZU, A; NAKASHIMA, K; IWAMOTO, M; TAKIGAWA, M; BABA, H; SUZUKI, F; KATO, Y			CHANGES IN PARATHYROID-HORMONE RECEPTORS DURING CHONDROCYTE CYTODIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT COSTAL CHONDROCYTES; FIBROBLAST GROWTH-FACTOR; TERMINAL DIFFERENTIATION; CYCLIC-AMP; ORNITHINE DECARBOXYLASE; PROTEOGLYCAN SYNTHESIS; ALKALINE-PHOSPHATASE; EMBRYONIC CHICK; CARTILAGE; CULTURES	The purpose of this study was to investigate the relationship between changes in parathyroid hormone (PTH) receptor levels and chondrocyte maturation during endochondral ossification. Chondrocytes were isolated from the growth plate of rabbit ribs and maintained in the presence of 10% serum in mass cultures. Treatment with PTH-(1-84) and a PTH-(1-34) fragment suppressed the increases in alkaline phosphatase activity and in type X collagen and 1 alpha,25-dihydroxyvitamin D-3 receptor levels and abolished Ca-45 incorporation into mineral, all of which occurred in parallel untreated cultures in the hypertrophic (terminal) stage. These effects of PTH were observed at low concentrations (10(-10) to 10(-9) M) and within 24-48 h of treatment. PTH-(1-84) and PTH-(1-34) also increased [S-36]sulfate incorporation into newly synthesized proteoglycans. In contrast, the middle and carboxyl-terminal fragments of PTH tested had little effect on proteoglycan synthesis or terminal differentiation. The binding of I-125-PTH-(1-34) to cells in the growth plate was greater than that to cells in liver, skin, muscle, brain, or kidney. When the correlation between binding levels and stage of maturation was examined, we found that I-125-PTH-(134) binding to its 72-kDa receptor was low in resting and proliferating chondrocytes, increased 10 fold in matrix-forming chondrocytes, and thereafter decreased in hypertrophic chondrocytes both in vitro and in situ. Scatchard analysis revealed that the changes in PTH binding were due to changes in the number, and not in the affinity, of the receptor. The changes in PTH-(1-34) binding paralleled those in [S-35]sulfate incorporation into proteoglycans. These findings suggest that stage dependent increases in PTH/PTH-related peptide receptor levels localize the hormone stimulation of proteoglycan synthesis and inhibition of precocious hypertrophy in the matrix-forming zone of growth plates.	HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, MINAMI KU, HIROSHIMA 734, JAPAN; OSAKA UNIV, FAC DENT, DEPT RADIOL, OSAKA 565, JAPAN; OSAKA UNIV, FAC DENT, DEPT BIOCHEM, OSAKA 565, JAPAN; OSAKA CITY UNIV, SCH MED, DEPT PEDIAT, OSAKA 545, JAPAN; KOBE UNIV, SCH MED, DEPT MED, DIV 3, KOBE 650, JAPAN; KOBE UNIV, SCH MED, DEPT BIOSIGNAL PATHOPHYSIOL, KOBE 650, JAPAN	Hiroshima University; Osaka University; Osaka University; Osaka Metropolitan University; Kobe University; Kobe University				Nakashima, Kazuhisa/0000-0003-0491-2149				BESSEY OA, 1946, J BIOL CHEM, V164, P321; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BURCH WM, 1983, CALCIFIED TISSUE INT, V35, P526, DOI 10.1007/BF02405088; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; ENOMOTO M, 1989, BIOCHEM BIOPH RES CO, V162, P1222, DOI 10.1016/0006-291X(89)90804-8; HIRAKI Y, 1985, BIOCHIM BIOPHYS ACTA, V845, P445, DOI 10.1016/0167-4889(85)90210-1; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; IWAMOTO M, 1989, DEV BIOL, V136, P500, DOI 10.1016/0012-1606(89)90275-3; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JIKKO A, 1993, DEV BIOL, V156, P372, DOI 10.1006/dbio.1993.1084; JOHNSONWINT B, 1982, ANAL BIOCHEM, V122, P338, DOI 10.1016/0003-2697(82)90292-5; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KATO Y, 1990, P NATL ACAD SCI USA, V87, P6522, DOI 10.1073/pnas.87.17.6522; KATO Y, 1988, ENDOCRINOLOGY, V122, P1991, DOI 10.1210/endo-122-5-1991; KATO Y, 1990, ENDOCRINOLOGY, V127, P114, DOI 10.1210/endo-127-1-114; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; KAWASHIMA K, 1980, ENDOCRINOL JAPON, V27, P357; KAWASHIMA K, 1980, ENDOCRINOL JAPON, V27, P349; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAOR G, 1987, COLLAGEN REL RES, V7, P351; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MURRAY TM, 1989, ENDOCRINOLOGY, V117, P1632; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; RODDA CP, 1988, J ENDOCRINOL, V117, P261, DOI 10.1677/joe.0.1170261; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; SCHMID TM, 1982, J BIOL CHEM, V257, P2451; SHIGENO C, 1988, J BIOL CHEM, V263, P3864; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SILBERMANN M, 1991, CALCIFIED TISSUE INT, V48, P260, DOI 10.1007/BF02556377; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; SUZUKI F, 1976, FEBS LETT, V70, P155, DOI 10.1016/0014-5793(76)80747-8; TAKANO T, 1985, ENDOCRINOLOGY, V116, P2536, DOI 10.1210/endo-116-6-2536; TAKIGAWA M, 1981, J CELL PHYSIOL, V106, P259, DOI 10.1002/jcp.1041060212; VALLE PL, 1993, J CELL BIOL, V121, P1173, DOI 10.1083/jcb.121.5.1173	38	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17245	17251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006032				2022-12-27	WOS:A1994NT84600041
J	ZHANG, ZJ; ZHAO, SM; LONG, FX; ZHANG, LF; BAI, G; SHIMA, H; NAGAO, M; LEE, EYC				ZHANG, ZJ; ZHAO, SM; LONG, FX; ZHANG, LF; BAI, G; SHIMA, H; NAGAO, M; LEE, EYC			A MUTANT OF PROTEIN PHOSPHATASE-1 THAT EXHIBITS ALTERED TOXIN SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OKADAIC ACID; CATALYTIC SUBUNIT; POTENT INHIBITOR; TUMOR PROMOTER; MICROCYSTIN-LR; CALYCULIN-A; MOUSE SKIN; TYPE-1; NODULARIN; EXPRESSION	A chimeric mutant was constructed in which a 4-amino acid region (GEFD, residues 274-277) of rabbit muscle protein phosphatase-1 was replaced with the sequence YRCG corresponding to residues 267-270 of rabbit protein phosphatase-2A. This was based on the finding of a gene mutation in okadaic acid-resistant cells which results in a Cys --> Gly conversion in protein phosphatase-2A. The YRCG mutant of protein phosphatase-1 was expressed and purified. The properties of the mutant enzyme were investigated in terms of its sensitivity toward several toxin inhibitors (okadaic acid, microcystin, nodularin, calyculin A, and cantharidic acid), as well as inhibitor-2. The mutant enzyme exhibited a gain of function in the form of a 10-fold increased sensitivity toward okadaic acid that suggests this region is involved in toxin binding. Significant changes in sensitivity to inhibitor-2 and several of the other toxins were also observed, indicating that these may have a common binding region.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL R629, MIAMI, FL 33101 USA; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, TOKYO 104, JAPAN	University of Miami; National Cancer Center - Japan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18512] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAI GE, 1988, FASEB J, V2, P3010, DOI 10.1096/fasebj.2.14.2846396; BALLOU LM, 1986, ENZYMES, V17, P311; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HONKANEN RE, 1991, MOL PHARMACOL, V40, P577; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; NAGAO M, 1993, 52ND P JAP CANC ASS, P36; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIMA H, 1994, IN PRESS P NATL ACAD; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; YOSHIZAWA S, 1990, J CANCER RES CLIN, V116, P609, DOI 10.1007/BF01637082; ZHANG ZJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P37, DOI 10.1006/abbi.1994.1005; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762	27	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					16997	17000						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006004				2022-12-27	WOS:A1994NT84600004
J	GASPARINI, S; KIYATKIN, N; DREVET, P; BOULAIN, JC; TACNET, F; RIPOCHE, P; FOREST, E; GRISHIN, E; MENEZ, A				GASPARINI, S; KIYATKIN, N; DREVET, P; BOULAIN, JC; TACNET, F; RIPOCHE, P; FOREST, E; GRISHIN, E; MENEZ, A			THE LOW-MOLECULAR-WEIGHT PROTEIN WHICH COPURIFIES WITH ALPHA-LATROTOXIN IS STRUCTURALLY RELATED TO CRUSTACEAN HYPERGLYCEMIC HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE PREDICTION; TRANSMITTER RELEASE; BRAIN SYNAPTOSOMES; ESCHERICHIA-COLI; PLASMA-MEMBRANE; FUSION PROTEIN; SINUS GLAND; TOXIN	LMWP is the low molecular weight protein which co-purifies with alpha-latrotoxin, the main neurotoxin from the black widow venom. It contains 70 residues and three disulfides. We found that its primary structure, including its 6 half cystines, can be aligned with the amino acid sequences of crustacean hyperglycemic hormones (CHHs) which contain 72-73 residues and three disulfides. To further investigate this structural relationship, we produced a recombinant analog of LMWP in which the unique Met was changed in Leu (LMWP(M35L)). LMWP(M35L) was produced as a folded fusion protein in the periplasm of Escherichia coli and was generated in vitro by treating the fusion protein with cyanogen bromide. We showed that LMWP(M35L) and CHHs have an identical disulfide pairing pattern and possess some alpha-helical structure, as deduced from a comparison of their circular dichroism spectra. In addition, LMWP(M35L) and CHHs are consensually predicted to possess a helical structure within the region 13-17. Together, the data indicate that CHHs are structurally related to LMWP(M35L) and presumably also to LMWP. Finally, preliminary studies showed that LMWP(M35L) is not toxic to mice and does not form channels in lipid bilayers, two well-known properties of alpha-latrotoxin preparations.	CE SACLAY, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE; CE SACLAY, DEPT BIOL CELLULAIRE & MOLEC SBCE, F-91191 GIF SUR YVETTE, FRANCE; INST BIOL STRUCT, SPECTROMETRIE MASSE PROT LAB, F-38027 GRENOBLE, FRANCE; RUSSIAN ACAD SCI, SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM, MOSCOW, RUSSIA	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			TACNET, Frédérique/B-3074-2009; Forest, Eric/E-9042-2012; Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951				ARNOUX B, 1994, FEBS LETT, V342, P12, DOI 10.1016/0014-5793(94)80574-1; AUDSLEY N, 1992, J EXP BIOL, V173, P261; BENHAM CJ, 1993, PROTEIN SCI, V2, P41; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; DUFTON MJ, 1983, EUR J BIOCHEM, V137, P537, DOI 10.1111/j.1432-1033.1983.tb07859.x; Endo T., 1991, P165; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; GRASSO A, 1976, BIOCHIM BIOPHYS ACTA, V439, P406, DOI 10.1016/0005-2795(76)90077-5; GRISHIN EV, 1993, FEBS LETT, V336, P205, DOI 10.1016/0014-5793(93)80803-3; HODGSON D, 1993, EUR J BIOCHEM, V212, P441, DOI 10.1111/j.1432-1033.1993.tb17680.x; HUBERMAN A, 1993, PEPTIDES, V14, P7, DOI 10.1016/0196-9781(93)90004-Z; HUBERMAN A, 1989, PEPTIDES, V10, P1113, DOI 10.1016/0196-9781(89)90198-8; KEGEL G, 1991, PEPTIDES, V12, P909, DOI 10.1016/0196-9781(91)90036-O; KEGEL G, 1989, FEBS LETT, V255, P10, DOI 10.1016/0014-5793(89)81051-8; KIYATKIN N, 1992, TOXICON, V30, P771, DOI 10.1016/0041-0101(92)90012-T; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LISHKO VK, 1990, FEBS LETT, V266, P99, DOI 10.1016/0014-5793(90)81516-Q; MARTIN G, 1993, EUR J BIOCHEM, V211, P601, DOI 10.1111/j.1432-1033.1993.tb17587.x; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MENEZ A, 1993, SCIENCE, V190, P34; MEUNIER JC, 1972, BIOCHEMISTRY-US, V11, P1200, DOI 10.1021/bi00757a014; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PILLET L, 1993, J BIOL CHEM, V268, P909; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; TENSEN CP, 1991, EUR J BIOCHEM, V200, P103, DOI 10.1111/j.1432-1033.1991.tb21054.x; TZENG MC, 1978, BRAIN RES, V139, P190, DOI 10.1016/0006-8993(78)90073-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; Webster S.G., 1987, PEPTIDES AMINES INVE, P173, DOI [10.1017/cbo9780511752230.011, DOI 10.1017/CBO9780511752230.011]	41	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19803	19809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051061				2022-12-27	WOS:A1994PA12600025
J	GATTI, E; POPOLO, L; VAI, M; ROTA, N; ALBERGHINA, L				GATTI, E; POPOLO, L; VAI, M; ROTA, N; ALBERGHINA, L			O-LINKED OLIGOSACCHARIDES IN YEAST GLYCOSYL PHOSPHATIDYLINOSITOL-ANCHORED PROTEIN GP115 ARE CLUSTERED IN A SERINE-RICH REGION NOT ESSENTIAL FOR ITS FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CELL-SEPARATION; GLYCOPROTEIN; CHAIN; IDENTIFICATION; SEQUENCE; CLONING; MUTANTS	The protein gp115 is an exocellular yeast glycoprotein modified by O- and N-glycosylation and attached to the plasma membrane through a glycosylphosphatidylinositol. The more remarkable structural feature in gp115 is the presence of a 36 amino acid serine-rich region. Similar sequences have been found in mammalian glycoproteins, such as the low density lipoprotein receptor, the decay-accelerating factor, and the mucins, where they are targets of multiple sites of O-glycosylation. The modification of these regions greatly influences their conformation and gives rise to ''rodlike'' structures. In this work, we have deleted or duplicated the Ser-rich region of gp115. The analysis of the size and glycosylation state of both mutant proteins indicates that about 52% of the total contribution of the O-glycosylation to the mass of the protein is concentrated in this region. The phenotype of ggp1 null mutant expressing the mutant proteins was also analyzed to understand if this region is important for gp115 function. The defects of slow growth rate and resistance to zymolyase of the ggp1 cells are completely complemented by both mutant proteins, suggesting that this region could be dispensable for gp115 function. A tentative model of gp115 structure is presented on the basis of the obtained data.	UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,SEZ BIOCHIM COMPARATA,I-20133 MILAN,ITALY	University of Milan			Gatti, Evelina/B-7941-2012; Popolo, Laura/B-1173-2017	Gatti, Evelina/0000-0002-0667-0799; Alberghina, Lilia/0000-0003-1694-931X; Popolo, Laura/0000-0002-5590-0167				BALLOU CE, 1981, MOL BIOL YEAST SACCH, P335; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CAPPELLARO C, 1991, EMBO J, V10, P4081, DOI 10.1002/j.1460-2075.1991.tb04984.x; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DENOBEL JG, 1991, YEAST, V7, P313, DOI 10.1002/yea.320070402; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORLEAN P, 1991, METHOD ENZYMOL, V194, P670; POPOLO L, 1988, EUR J CELL BIOL, V47, P173; POPOLO L, 1984, P NATL ACAD SCI-BIOL, V81, P120, DOI 10.1073/pnas.81.1.120; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; REDDY P, 1989, J BIOL CHEM, V264, P17329; ROHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; VAI M, 1986, FEBS LETT, V206, P135, DOI 10.1016/0014-5793(86)81355-2; VAI M, 1991, J BIOL CHEM, V266, P12242; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983; VITALA J, 1985, TRENDS BIOCHEM SCI, V10, P392; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; ZLOTNIK H, 1984, J BACTERIOL, V159, P1018, DOI 10.1128/JB.159.3.1018-1026.1984	38	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19695	19700						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051047				2022-12-27	WOS:A1994PA12600010
J	GOWDA, DC; DAVIDSON, EA				GOWDA, DC; DAVIDSON, EA			ISOLATION AND CHARACTERIZATION OF NOVEL MUCIN-LIKE GLYCOPROTEINS FROM COBRA VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; GASTRIC MUCIN; STRUCTURAL CHARACTERIZATION; NEUTRAL OLIGOSACCHARIDES; CARBOHYDRATE MOIETIES; ENDOPLASMIC-RETICULUM; SCHISTOSOMA-MANSONI; MUCUS GLYCOPROTEIN; SWINE TRACHEA; SUGAR CHAINS	A high molecular weight, heavily glycosylated protein fraction was isolated from cobra venom. It consists of mucin-like glycoproteins (designated as cobra venom mucin) in noncovalent association with several lower molecular weight proteins and glycoproteins. The mucin was purified by CsBr density gradient centrifugation under dissociative conditions. The purified venom mucin comprised about 85% carbohydrate and 15% protein and was rich in Thr, Ser, Pro, Gly, Glu, Asp, and Ala. The mucin was resolved into two or more distinct classes of mucin-like glycoproteins which differ in their amino acid compositions and/or carbohydrate content. Unlike other mucins, cobra venom mucin does not form highly viscous solutions. It appears to keep several venom proteins and glycoproteins soluble by noncovalent interactions. Cobra venom mucin contains both O- and N-linked oligosaccharides; 1 N-linked chain for every 8-10 O-linked oligosaccharides. The O-linked chains are novel structures with high molar proportions of fucose, galactose, and N-acetylglucosamine relative to N-acetyl-galactosamine; they have a very low sialic acid content and lack sulfate esters. The majority of the O-linked oligosaccharides are unusually large and contain 15 to as many as 50 sugar residues. The O-linked oligosaccharides are poly-N-acetyllactosaminyl chains consisting of -3Gal beta 1-4GlcNAc beta 1- and -3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-repeats and thus they contain inner Le(X) antigenic determinants. These oligosaccharides terminate with novel alpha-galactosylated Le(X) and Le(a) epitopes. Due to the abundance of terminal alpha-galactosyl residues, cobra venom mucin reacts with anti-alpha-Gal antibodies that are normally present in human serum.			GOWDA, DC (corresponding author), GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3900 RESERVOIR RD, NW, WASHINGTON, DC 20007 USA.			Gowda, Channe/0000-0002-6860-5108	NCI NIH HHS [CA 61210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA061210, R55CA061210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIVA JL, 1989, J IMMUNOL, V142, P2828; ALLEN A, 1987, PHYSL GASTROINTESTIN, P617; AMANO J, 1991, J BIOL CHEM, V266, P11461; AMERONGEN AVN, 1987, CARBOHYD RES, V164, P43; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BHAVANANDAN VP, 1987, J BIOL CHEM, V262, P5913; CARLSON DM, 1966, J BIOL CHEM, V241, P2984; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHANDRASEKARAN EV, 1984, J BIOL CHEM, V259, P2908; CORFIELD T, 1992, GLYCOCONJUGATE J, V9, P217; DEKKER J, 1989, J BIOL CHEM, V264, P10431; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEIZI T, 1984, BIOCHEM SOC T, V12, P591, DOI 10.1042/bst0120591; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GIBBONS RA, 1972, GLYCOPROTEINS, P31; Gowda D. Channe, 1993, Glycobiology, V3, P533; GOWDA DC, 1992, MOL IMMUNOL, V29, P335, DOI 10.1016/0161-5890(92)90020-X; GOWDA DC, 1992, BIOCHEM BIOPH RES CO, V182, P294, DOI 10.1016/S0006-291X(05)80144-5; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILL HD, 1977, J BIOL CHEM, V252, P3791; HOROWITZ M, 1977, GLYCOCONJUGATES; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KIM YS, 1991, AM REV RESPIR DIS, V144, pS10, DOI 10.1164/ajrccm/144.3_pt_2.S10; KITAGAWA H, 1991, BIOCHEM BIOPH RES CO, V178, P1429, DOI 10.1016/0006-291X(91)91053-F; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KOBATA A, 1988, BIOCHIMIE, V70, P1575, DOI 10.1016/0300-9084(88)90293-3; KULINA MK, 1991, AM REV RESPIR DIS, V144, pS52; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; LOOMIS RE, 1987, ARCH BIOCHEM BIOPHYS, V258, P452, DOI 10.1016/0003-9861(87)90366-3; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; Murphy L A, 1978, Methods Enzymol, V50, P345; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; RANA SS, 1984, J BIOL CHEM, V259, P2899; REDDY MS, 1992, BIOCHEM J, V287, P639, DOI 10.1042/bj2870639; ROSE MC, 1992, AM PHYSL SOC, V7, P557; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SHEEHAN JK, 1991, AM REV RESPIR DIS, V144, pS5; SIEFTER S, 1950, ARCH BIOCH, V25, P191; SINGHAL AK, 1990, CANCER RES, V50, P1375; SLOMIANY A, 1984, J BIOL CHEM, V259, P4743; SLOMIANY BL, 1980, J BIOL CHEM, V255, P9719; SLOMIANY BL, 1984, J BIOL CHEM, V259, P2863; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; Stocker K., 1990, P1; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TU AT, 1991, REPTILE VENOMS TOXIN, V5, P1; VANDAM GJ, 1993, GLYCOCONJUGATE J, V10, P289, DOI 10.1007/BF01210015; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANHALBEEK H, 1984, BIOCHEM SOC T, V12, P601, DOI 10.1042/bst0120601; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WOODWARD HD, 1987, BIOCHEMISTRY-US, V26, P5315, DOI 10.1021/bi00391a015; YORK WS, 1986, METHOD ENZYMOL, V118, P3; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	74	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20031	20039						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051088				2022-12-27	WOS:A1994PA12600057
J	HOSAKA, H; SAKABE, I; SAKAMOTO, K; YOKOYAMA, S; TAKAKU, H				HOSAKA, H; SAKABE, I; SAKAMOTO, K; YOKOYAMA, S; TAKAKU, H			SEQUENCE-SPECIFIC CLEAVAGE OF OLIGORIBONUCLEOTIDE CAPABLE OF FORMING A STEM AND LOOP STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; INTERVENING SEQUENCE; SELF-CLEAVAGE; HAMMERHEAD RIBOZYMES; GUANOSINE RESIDUE; CATALYTIC RNA; PRECURSOR RNA; VIRUS-RNA; HYDROLYSIS	The precursor of an RNA molecule from T4-infected Escherichia coli cells (p2Sp1 RNA)(1) has the capacity to cleave itself at specific positions (UpA (137-138) and CpA (170-171)) within a possible loop and stem structure. This specific cleavage requires at least a monovalent cation and nonionic detergents. To confirm that the sequence-specific cleavage occurs autolytically, we studied the selective hydrolysis of RNA using a chemically synthesized 13-mer (GUUUCGUACAAAC) having sequences corresponding to G(131)-C-143 of P2Sp1 RNA. The cleavage occurred at two identical sites (UpA and CpA) of a hairpin loop under physiological conditions and was affected by monovalent or divalent metals, nonionic detergent, salt, pH, and temperature. The hairpin loop domain and specific sequences are necessary for the cleavage of RNA 13-mer (GUUUCGUACAAAC).	CHIBA INST TECHNOL,DEPT IND CHEM,NARASHINO,CHIBA 275,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Chiba Institute of Technology; University of Tokyo			Sakamoto, Kensaku/N-7496-2015; Marlétaz, Ferdinand/H-3018-2019; Yokoyama, Shigeyuki/N-6911-2015	Sakamoto, Kensaku/0000-0003-2866-5031; Marlétaz, Ferdinand/0000-0001-8124-4266; Yokoyama, Shigeyuki/0000-0003-3133-7338				BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BUZAYAN JM, 1986, P NATL ACAD SCI USA, V83, P8859, DOI 10.1073/pnas.83.23.8859; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; DOCKBREGEON AC, 1987, COLD SPRING HARB SYM, V52, P113, DOI 10.1101/SQB.1987.052.01.016; EPSTEIN LM, 1987, CELL, V48, P535, DOI 10.1016/0092-8674(87)90204-2; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FORSTER AC, 1988, NATURE, V334, P365; GANNISTRARO VJ, 1986, J MOL BIOL, V192, P257; GERLACH W, 1988, NATURE, V344, P585; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HOSAKA H, 1991, FEBS LETT, V293, P204, DOI 10.1016/0014-5793(91)81187-D; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P4403; JEFFRIES AC, 1989, NUCLEIC ACIDS RES, V17, P1371, DOI 10.1093/nar/17.4.1371; KAZAKOV S, 1992, P NATL ACAD SCI USA, V89, P7939, DOI 10.1073/pnas.89.17.7939; KOCHETKOV NK, 1972, ORGANIC CHEM NUCLE B, P477; KOIZUMI M, 1988, FEBS LETT, V239, P285, DOI 10.1016/0014-5793(88)80935-9; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCLENNAN BD, 1968, CAN J BIOCHEM CELL B, V46, P93, DOI 10.1139/o68-014; ODAI O, 1990, FEBS LETT, V267, P150, DOI 10.1016/0014-5793(90)80311-6; RICHARDS FM, 1971, ENZYMES, V4, P647; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; RUFFNER DE, 1989, GENE, V82, P31, DOI 10.1016/0378-1119(89)90027-9; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SCHEELE G, 1979, P NATL ACAD SCI USA, V76, P4898, DOI 10.1073/pnas.76.10.4898; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SHIDA ND, 1984, NUCLEIC ACIDS RES, V12, P4539; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WATSON N, 1981, BIOCHEM BIOPH RES CO, V103, P543, DOI 10.1016/0006-291X(81)90486-1; WATSON N, 1984, J MOL BIOL, V172, P301, DOI 10.1016/S0022-2836(84)80028-5; WU HN, 1992, J MOL BIOL, V223, P233, DOI 10.1016/0022-2836(92)90728-3; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; YAMAKAGE S, 1989, TETRAHEDRON LETT, V30, P6361, DOI 10.1016/S0040-4039(01)93894-8; ZAUG AJ, 1982, NUCLEIC ACIDS RES, V10, P2823, DOI 10.1093/nar/10.9.2823; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0	43	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20090	20094						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051096				2022-12-27	WOS:A1994PA12600065
J	KAMIBAYASHI, C; ESTES, R; LICKTEIG, RL; YANG, SI; CRAFT, C; MUMBY, MC				KAMIBAYASHI, C; ESTES, R; LICKTEIG, RL; YANG, SI; CRAFT, C; MUMBY, MC			COMPARISON OF HETEROTRIMERIC PROTEIN PHOSPHATASE-2A CONTAINING DIFFERENT B-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; RABBIT SKELETAL-MUSCLE; MEDIUM TUMOR-ANTIGEN; SMALL-T-ANTIGEN; CELLULAR-REGULATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; SIMIAN VIRUS-40; SACCHAROMYCES-CEREVISIAE; A-SUBUNIT	Protein phosphatase 2A (PP2A) is composed of structural (A), catalytic (C), and regulatory subunits (B). Immunological analyses identified B alpha/PR55 alpha as the major regulatory subunit of brain PP2A while a unique B' subunit was associated with the cardiac enzyme. Recombinant PP2A heterotrimers were purified from insect cells infected with baculoviruses expressing A and C, in combination with viruses expressing B alpha/PR55 alpha, B beta/PR55 beta, or SV40 small tumor antigen (st). Phosphatase activities of rAC-B alpha and rAC-B beta were similar to those for brain AC-B alpha, while rAC-st was 50-80% less active. Heparin had no effect on rAC-st myosin light chain phosphatase activity, while the B subunit-containing forms were stimulated 2-3-fold. Protamine caused a 3-4-fold increase in AC-B alpha and rAC-st activities and a marked activation of rAC-B beta (6-fold) and AC-B' (10.5-fold). When histone H1 was used as substrate, all of the heterotrimers were stimulated similar to 4-fold by heparin. The activity of AC-B' and rAC-B beta were increased a fold by Mn2+, while a 6-fold stimulation was observed with rAC-st. Chemical crosslinking of AC-B alpha and AC-B beta generated 200-kDa complexes, while AC-st was present as a 150-kDa complex. These results demonstrate that different regulatory pro- teins affect enzyme activity and the response to agents that modify PP2A activity in vitro. Different PP2A heterotrimers are likely to have distinct functions in vivo, and changes in subunit composition will have an important impact on signal transduction pathways.	UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KAMIBAYASHI, C (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107, P50HL017669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31107, HL17669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CSORTOS C, 1993, FASEB J, V7, pA1156; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HARLOW E, 1988, ANTIBODIES LABORATOR; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JOG P, 1990, J VIROL, V64, P2895, DOI 10.1128/JVI.64.6.2895-2900.1990; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PATO MD, 1986, J BIOL CHEM, V261, P3770; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; REED L. J., 1938, AMER JOUR HYG, V27, P493; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; UMI H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	49	160	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20139	20148						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051102				2022-12-27	WOS:A1994PA12600072
J	OTTO, JC; SMITH, WL				OTTO, JC; SMITH, WL			THE ORIENTATION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1 AND SYNTHASE-2 IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; H-SYNTHASE; INDUCIBLE CYCLOOXYGENASE; SUBCELLULAR-LOCALIZATION; THROMBOXANE SYNTHASE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; CDNA SEQUENCE; MESSENGER-RNA	Prostaglandin endoperoxide H synthases (PGHS)-1 and -2 are integral membrane proteins of the endoplasmic reticulum (ER). The luminal versus cytoplasmic orientations of several epitopes of PGHS-1 and PGHS-2 were determined by immunocytofluorescent staining of cells following treatment with membrane-selective permeants. With serum-stimulated, murine NIH/3T3 cells expressing PGHS-2, an anti-peptide antibody directed against a domain near the COOH terminus of this isozyme caused staining only after all membranes were permeabilized with 0.2% saponin; no staining occurred with 3T3 cells treated with digitonin to permeabilize only the plasma membrane. Similarly, cos-1 cells expressing ovine PGHS-1 were stained with anti-peptide antibodies directed against (a) the amino terminus (residues 25-35), (b) a domain containing the tryptic cleavage site at Arg(277) (residues 272-284), or (c) a region near the carboxyl terminus (residues 583-594) following permeabilization with saponin but not with digitonin or streptolysin O. The results obtained with the antibodies against the Arg(277)-containing domain of PGHS-1 were surprising because the enzyme is susceptible to tryptic cleavage at Arg(277) in microsomal preparations. However, enzymatic and immunochemical analyses of microsomes prepared from ovine vesicular glands and cos-1 cells indicated that these microsomes are not intact. Accordingly, our results indicate that the trypsin cleavage site (Arg(277)) as well as the NH2 and COOH termini of ovine PGHS-1 are on the luminal side of the ER. The NH2 terminus, the Arg(277) domain, and the N glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249). We conclude that PGHS-1 and, by analogy, the highly homologous PGHS-2 are luminal ER proteins. Assuming that the PGHS-1 and PGHS-2 present in the ER are functional in intact cells, our results indicate that PGH(2) synthesis from arachidonate occurs in the lumen of the ER.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042, R01DK042509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07404] Funding Source: Medline; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANION O, 1992, P NATL ACAD SCI USA, V89, P4888; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1981, J BIOL CHEM, V256, P375; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; LANEUVILLE O, 1994, IN PRESS J PHARM EXP; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEADE EA, 1993, J LIPID MEDIATOR, V6, P119; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; METASAKI M, 1992, J CELL SCI, V101, P315; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OHASHI K, 1992, J BIOL CHEM, V267, P789; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; RUAN KH, 1993, J BIOL CHEM, V268, P19483; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIRIOS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SMITH WL, 1983, J BIOL CHEM, V258, P5922; SMITH WL, 1994, CURR OPIN INVEST DR, V3, P1; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	55	123	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19868	19875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051068				2022-12-27	WOS:A1994PA12600034
J	YAGISAWA, H; HIRATA, M; KANEMATSU, T; WATANABE, Y; OZAKI, S; SAKUMA, K; TANAKA, H; YABUTA, N; KAMATA, H; HIRATA, H; NOJIMA, H				YAGISAWA, H; HIRATA, M; KANEMATSU, T; WATANABE, Y; OZAKI, S; SAKUMA, K; TANAKA, H; YABUTA, N; KAMATA, H; HIRATA, H; NOJIMA, H			EXPRESSION AND CHARACTERIZATION OF AN INOSITOL 1,4,5-TRISPHOSPHATE BINDING DOMAIN OF PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C-DELTA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONOSYLTRANSFERASE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE-BINDING; AFFINITY-CHROMATOGRAPHY; BRAIN CYTOSOL; C-GAMMA; PROTEINS; SEQUENCE; RAT; RECEPTOR	It was previously found that the 85-kDa protein purified from rat brain using an inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3)-immobilized matrix was the delta(1) isoform of phosphatidylinositol-specific phospholipase C (PLC). We expressed rat PLC-delta(1) in Escherichia coli as a fusion protein with glutathione S-transferase, and found that the bacterial lysate shows a significant amount of Ins(1,4,5)P-3 binding. The lysate was applied to Ins(1,4,5)P-3-immobilized column chromatography and the eluate with 2 M NaCl solution containing only a 100-kDa protein showed high Ins(1,4,5)P-3 binding. The lysate was also purified to near homogeneity using a glutathione- Sepharose 4B affinity system. Bacterially-expressed enzyme thus purified showed essentially the same inositol phosphate binding characteristics as the brain-derived enzyme. PLC-delta(1) consists of the amino-terminal nonconserved region and two well-conserved regions among isozymes, designated as X and Y, which are thought to constitute a catalytic core of the enzyme. Using a combination of deletion mutants and proteolytic products of the enzyme, we were able to locate an Ins(1,4,5)P-3 binding domain in the molecule. Deletion of 223 residues from the amino terminus completely abolished the binding activity, while deletion of X region only partially inhibited the binding and deletion of Y region did not affect the binding. A 76-kDa proteolytic product of the expressed PLC-delta(1) which lacked 60 amino acids at the amino terminus showed a minimal Ins(1,4,5)P-3 binding activity. A peptide consists of 14 amino acids corresponding to residues 30-43 of PLC-delta(1), which contains 6 basic amino acids, binds to an Ins(1,4,5)P-3-immobilized matrix. Moreover, Ins(1,4,5)P-3 binding was blocked by phospholipid vesicles containing phosphatidylinositol 4,5 bisphosphate. These results, taken together, indicate that the amino-terminal domain of PLC-delta(1) is important for the binding of both Ins(1,4,5)P-3 and phosphatidylinositol 4,5-bisphosphate.	KYUSHU UNIV, FAC DENT, DEPT BIOCHEM, FUKUOKA 812, JAPAN; EHIME UNIV, FAC ENGN, DEPT APPL CHEM, MATSUYAMA, EHIME 790, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT MOLEC GENET, OSAKA 565, JAPAN	Kyushu University; Ehime University; Osaka University	YAGISAWA, H (corresponding author), HIMEJI INST TECHNOL, FAC SCI, DEPT LIFE SCI, HIMEJI, HYOGO 67812, JAPAN.		Kamata, Hideaki/N-3907-2017					ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; EMORI Y, 1989, J BIOL CHEM, V264, P21885; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; IYANAGI T, 1991, J BIOL CHEM, V266, P24048; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRITZ R, 1990, CIBA F S, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OZAKI S, 1991, ACS SYM SER, V463, P43; OZAKI S, 1992, CARBOHYD RES, V234, P189, DOI 10.1016/0008-6215(92)85048-5; PARK DG, 1993, J BIOL CHEM, V268, P3710; RATH HM, 1990, J BIOL CHEM, V265, P3080; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; RHEE SG, 1992, ADV SEC MESS PHOSPH, V26, P565; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WEIGELE M, 1972, J AM CHEM SOC, V94, P5927, DOI 10.1021/ja00771a084; WU DQ, 1993, J BIOL CHEM, V268, P3704; XU CJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P49, DOI 10.1016/0167-4838(92)90423-B; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1992, J BIOL CHEM, V267, P14616	49	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20179	20188						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051106				2022-12-27	WOS:A1994PA12600077
J	ZHENG, CF; GUAN, KL				ZHENG, CF; GUAN, KL			CYTOPLASMIC LOCALIZATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATOR MEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; TYROSINE THREONINE KINASE; SIGNAL-REGULATED KINASES; MAP KINASE; NUCLEAR-LOCALIZATION; INTRACELLULAR-LOCALIZATION; GENE-PRODUCT; A431 CELLS; PHOSPHORYLATION	The mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase (ERK) is phosphorylated and activated by an upstream activator kinase, MEK (MAPK or ERK kinase), in response to mitogenic growth factors. ERKs translocate into the nucleus upon mitogen stimulation, suggesting that the subcellular redistribution of ERK may play a critical role in signal transfer from cytoplasm to the nucleus. We demonstrated in this report that MEK was exclusively localized in cytoplasm in several cell lines, including Swiss 3T3, HeLa, COS, and PC12. Immunofluorescence analysis of both native and transiently expressed MEK with a MEK-specific antibody revealed that both MEK1 and MEK2 were localized only in the cytoplasm. The cytoplasmic localization of MEK was further supported by subcellular fractionations as well as detergent permeabilization experiments. In contrast to ERK, mitogen stimulation did not cause any nuclear accumulation of MEK. These data suggest that ERK is phosphorylated and activated in the cytoplasm. The activated ERK could subsequently translocate into the nucleus and phosphorylate its nuclear substrates.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008808, P60AG008808] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NIA NIH HHS [AG-08808] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KREL W, 1992, J CELL BIOL, V116, P43; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2545; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Sambrook J, 1989, MOL CLONING LABORATO; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1991, J BIOL CHEM, V266, P23521; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	53	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19947	19952						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051079				2022-12-27	WOS:A1994PA12600046
J	WOLFF, RA; DOBROWSKY, RT; BIELAWSKA, A; OBEID, LM; HANNUN, YA				WOLFF, RA; DOBROWSKY, RT; BIELAWSKA, A; OBEID, LM; HANNUN, YA			ROLE OF CERAMIDE-ACTIVATED PROTEIN PHOSPHATASE IN CERAMIDE-MEDIATED SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; C-MYC EXPRESSION; FACTOR-KAPPA-B; HL-60 CELLS; SPHINGOMYELIN TURNOVER; TRANSCRIPTION; DIFFERENTIATION; RECEPTOR; ACID; SPHINGOSINE	Extracellular agonists such as tumor necrosis factor-alpha (TNF-alpha) activate the sphingomyelin cycle leading to the generation of ceramide. Ceramide has been suggested as an important mediator of the effects of TNF-alpha on growth inhibition, c-myc down-regulation, apoptosis, and the activation of the nuclear factor kappa B. Although there is no clearly defined intracellular target for ceramide activity, previous studies have demonstrated the existence of a ceramide-activated protein phosphatase (CAPP) in vitro. Since c myc is an early downstream cellular target for TNF-alpha, we examined the role of ceramide and CAPP in c-myc down-regulation. In intact HL-60 cells ceramide induced down-regulation of c-myc RNA levels. C-2-ceramide was active at 1-10 mu M and caused 40-80% inhibition of c-myc RNA levels at 30-120 min of treatment. In nuclear run-on studies, C-2-ceramide induced a block to transcription elongation of the c-myc transcript without affecting transcription through the first exon. Therefore, ceramide appeared to inhibit c myc expression via a mechanism identical with that of TNF-alpha. HL-60 cells contained CAPP which was inhibited by okadaic acid (0.1-10 nm). CAPP in HL-60 cells was activated by D-erythro-ceramide but not D-erythro-dihydroceramide. The specificity of activation of CAPP by ceramide in vitro was matched by a similar specificity of c myc downregulation in cells. Moreover, okadaic acid inhibited the effects of ceramide and TNF-alpha on c-myc down-regulation. On the other hand, okadaic acid did not inhibit the ability of phorbol 12-myristate 13-acetate to down-regulate c-myc, demonstrating the existence of at least two distinct pathways in the regulation of c myc expression. These results demonstrate that CAPP is important for ceramide induced down-regulation of c-myc in myeloid leukemia cells. The implications of these findings in further delineating a sphingomyelin signaling pathway with important anti-proliferative effects are discussed.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Duke University				obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BITTER GA, 1978, BIOCHEMISTRY-US, V17, P2198, DOI 10.1021/bi00604a028; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; KIM MY, 1991, J BIOL CHEM, V266, P484; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SALEHI Z, 1988, J BIOL CHEM, V263, P1898; SALEHI Z, 1990, J IMMUNOL, V145, P276; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TOBLER A, 1987, BLOOD, V70, P200; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YANG ZH, 1993, J BIOL CHEM, V268, P20520	26	268	272	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19605	19609						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034729				2022-12-27	WOS:A1994NY33200063
J	ZHANG, LJ; ESKO, JD				ZHANG, LJ; ESKO, JD			AMINO-ACID DETERMINANTS THAT DRIVE HEPARAN-SULFATE ASSEMBLY IN A PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN-ATTACHMENT SITE; GROWTH-FACTOR; DIRECTED MUTAGENESIS; CORE PROTEIN; EXPRESSION; RECEPTOR; CLONING; IDENTIFICATION; PURIFICATION; BIOSYNTHESIS	To study how cells regulate the composition of glycosaminoglycan chains on proteoglycans, we have examined the assembly of chains on chimeric proteoglycans containing segments of betaglycan (transforming growth factor-beta Type III receptors) fused to protein A. Transient expression of the chimeras in Chinese hamster ovary cells revealed that only two glycosaminoglycan attachment sites exist. One site at Ser(535) supported both chondroitin sulfate and heparan sulfate synthesis, whereas the site at Ser(546) supported only chondroitin sulfate. The compositions of the chimeras were the same in CHO-K1, CHOP-C4, BHK-21, and HeLa S3 cells and in chimeras containing polyhistidine fused to the C terminus, Deletion experiments showed that the assembly of heparan sulfate chains on the chimeras required a peptide segment of less than or equal to 16 amino acids (SPGDSS(535)-GWPDGYEDLE) and the first 5 amino acids were not essential, Truncation of the acidic cluster (EDLE), site-directed mutation of the acidic residues in the cluster or deletion of the sequence between the cluster and the Ser attachment site decreased heparan sulfate assembly. Mutation of Trp(537) adjacent to the site also decreased heparan sulfate assembly. More importantly, introducing tryptophan next to three different Ser-Gly dipeptides in betaglycan and syndecan-1 chimeras stimulated assembly of heparan sulfate. Thus, one type of heparan sulfate attachment site consists of a Ser-Gly dipeptide and a flanking cluster of acidic residues. An adjacent tryptophan residue can augment the proportion of heparan sulfate.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CASTLE AM, 1993, J BIOL CHEM, V268, P20490; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FASMAN GD, 1989, PREDICTION PROTEIN S, P208; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HUBER S, 1988, J BIOL CHEM, V263, P752; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P887; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANN DM, 1990, J BIOL CHEM, V265, P5317; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	30	122	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19295	19299						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034692				2022-12-27	WOS:A1994NY33200017
J	ZOLNIEROWICZ, S; CRON, P; SOLINASTOLDO, S; FRIES, R; LIN, HY; HEMMINGS, BA				ZOLNIEROWICZ, S; CRON, P; SOLINASTOLDO, S; FRIES, R; LIN, HY; HEMMINGS, BA			ISOLATION, CHARACTERIZATION, AND CHROMOSOMAL LOCALIZATION OF THE PORCINE CALCITONIN RECEPTOR GENE - IDENTIFICATION OF 2 VARIANTS OF THE RECEPTOR GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; EXPRESSION CLONING; CELL-LINE; ADENYLATE-CYCLASE; MESSENGER-RNA; TRANSCRIPTION FACTOR; RAT OSTEOCLASTS; BINDING-PROTEIN; POLYPEPTIDE; HORMONE	The gene encoding the calcitonin receptor (CTR) was isolated from a porcine kidney epithelial cell line (LLC-PK1) genomic library and found to span approximately 70 kilobases. Analysis of the gene sequence revealed that the CTR mRNA encompasses 14 exons with 12 exons encoding the protein. Two splicing acceptor sites separated by 48 nucleotides were found in intron 7. The ex pression of two mRNA species in LLC-PK1 cells was subsequently confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and DNA sequencing. In LLC-PK1 cells the mRNA encoding the shorter CTR (CTR-1a) is approximately 1,000 times more abundant than the longer variant (CTR-1b), as estimated by the competitive RT-PCR. The transcription initiation site of the CTR gene was mapped by primer extension, S1 nuclease, and RT-PCR analysis. The proximal promoter region of 500 base pair is GC-rich (66%) and CpG-rich (CpG/GpC ratio 0.71). Transient transfection of CTR gene promoter-luciferase chimeras in LLC-PK1, cells led to the expression of luciferase activity. The CTR gene was mapped to chromosome band 9q11-q12.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; ETH ZURICH, INST NUTZTIERWISSENSCH, CH-8092 ZURICH, SWITZERLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich; Massachusetts Institute of Technology (MIT); Whitehead Institute				Fries, Ruedi/0000-0002-4657-1787				ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; AUSIELLO DA, 1980, BIOCHEM J, V186, P773, DOI 10.1042/bj1860773; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem-57-4-819; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECHARD G, 1992, CYTOGENET CELL GENET, V61, P146, DOI 10.1159/000133394; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINDLAY DM, 1980, CANCER RES, V40, P1311; FOSTER GV, 1964, NATURE, V202, P1303, DOI 10.1038/2021303a0; FRIES R, 1991, GENE MAPPING STRATEG, P159; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GUSTAVSSON I, 1988, HEREDITAS, V109, P151, DOI 10.1111/j.1601-5223.1988.tb00351.x; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HEERSCHE JN, 1974, ENDOCRINOLOGY, V94, P241, DOI 10.1210/endo-94-1-241; HOSODA K, 1992, J BIOL CHEM, V267, P18797; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JANS DA, 1987, EUR J BIOCHEM, V162, P571, DOI 10.1111/j.1432-1033.1987.tb10677.x; JANS DA, 1986, EUR J BIOCHEM, V160, P407, DOI 10.1111/j.1432-1033.1986.tb09986.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANIS JA, 1974, BRIT MED J, V3, P727, DOI 10.1136/bmj.3.5933.727; LAMP SJ, 1981, J BIOL CHEM, V256, P2269; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv-8-4-377; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MURPHY E, 1986, AM J PHYSIOL, V251, pC491, DOI 10.1152/ajpcell.1986.251.4.C491; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; POTTS JT, 1968, P NATL ACAD SCI USA, V59, P1321, DOI 10.1073/pnas.59.4.1321; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REAGAN JD, 1994, J BIOL CHEM, V269, P9; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STROOP SD, 1993, J BIOL CHEM, V268, P19927; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	56	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19530	19538						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034723				2022-12-27	WOS:A1994NY33200052
J	BLUML, K; MUTSCHLER, E; WESS, J				BLUML, K; MUTSCHLER, E; WESS, J			FUNCTIONAL-ROLE IN LIGAND FINDING AND RECEPTOR ACTIVATION OF AN ASPARAGINE RESIDUE PRESENT IN THE 6TH TRANSMEMBRANE DOMAIN OF ALL MUSCARINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; ANTAGONIST BINDING; TYROSINE RESIDUES; MUTATION; M3-MUSCARINIC-RECEPTOR; IDENTIFICATION; HYDROLYSIS; THREONINE	The molecular mechanisms through which muscarinic receptors are activated upon binding of the neurotransmitter acetylcholine (ACh) are still poorly understood. Classical structure-function relationship studies have previously established that the ACh ester moiety plays a key role in muscarinic receptor recognition and activation. Consistent with this notion, all recently proposed three dimensional muscarinic receptor models predict that an asparagine residue present in transmembrane domain VI of all muscarinic receptors is critically involved in the binding of the ACh ester moiety by means of hydrogen bonding. To test the correctness of this hypothesis, we created several mutant m3 muscarinic receptors in which this residue (Asn(507)) was replaced with alanine, serine, or aspartic acid. Radioligand binding studies with transfected COS-7 cells showed that, in contrast to the predictions made based on molecular modeling studies, all three mutant receptors were able to bind ACh and the structurally related muscarinic agonist, carbachol, with high affinities which differed from the corresponding wild type values by less than 5-fold. However, all three mutations led to dramatic reductions (235-28,300-fold) in binding affinities for certain subclasses of muscarinic antagonists including atropine-like agents and pirenzepine. The m3(Asn(507) --> Ala) and m3(Asn(507) --> Asp) mutant receptors were able to mediate carbachol-induced phosphatidylinositol hydrolysis in a fashion similar to that of the wild type receptor. Interestingly, the m3(Asn(507) --> Ser) mutant receptor displayed about 2-fold increased basal inositol phosphate levels, raising the possibility that it is constitutively active. In conclusion, our data suggest that the asparagine residue present in transmembrane domain VI of all muscarinic receptors is not critical for ACh binding and agonist-induced receptor activation, but plays a key role in the binding of certain subclasses of muscarinic antagonists.	NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892; UNIV FRANKFURT,DEPT PHARMACOL,D-60053 FRANKFURT,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Goethe University Frankfurt								ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JG, 1981, BURGERS MED CHEM, P339; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEROUTKA SJ, 1994, HDB RECEPTORS CHANNE, V1; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WARD JS, 1992, J MED CHEM, V35, P4011, DOI 10.1021/jm00100a005; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1990, COMPREHENSIVE MED CH, V3, P423	37	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18870	18876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034642				2022-12-27	WOS:A1994NX32700029
J	SETTE, C; VICINI, E; CONTI, M				SETTE, C; VICINI, E; CONTI, M			THE RATPDE3/IVD PHOSPHODIESTERASE GENE CODES FOR MULTIPLE PROTEINS DIFFERENTIALLY ACTIVATED BY CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-AMP PHOSPHODIESTERASE; FOLLICLE-STIMULATING-HORMONE; LEYDIG TUMOR-CELLS; SERTOLI-CELL; DROSOPHILA-MELANOGASTER; CLONING; FAMILY; SEQUENCE; DUNCE; INHIBITORS	Several mRNAs coding for a cAMP-specific phosphodiesterase (ratPDE3/IVd) with divergent 5' regions have been detected in mammalian cells. To determine the physiological significance of these differences, the expression of these mRNAs and the properties of the corresponding proteins were investigated. At least three mRNA species derived from the ratPDE3/IVd gene (ratPDE3.1, ratPDE3.2, and ratPDE3.3 mRNAs) are present in Sertoli and thyroid cells and in brain. Expression of ratPDE3.1 and ratPDE3.2 but not ratPDE3.3 mRNAs was dependent on hormone stimulation. The ratPDE3.2 and ratPDE3.3 mRNA variants were translated into polypeptides with immunochemical and biochemical properties identical to the native cAMP phosphodiesterases (PDEs) found in the Sertoli cell and thyroid FRTL-5 cells. Incubation of the recombinant PDEs with the catalytic subunit of the cAMP-dependent protein kinase in a cell-free system caused the phosphorylation and activation of the ratPDE3.3 protein variant. Under the same experimental conditions, ratPDE3.1 and ratPDE3.2 protein variants were neither phosphorylated nor activated by the cAMP-dependent protein kinase. Similar results were obtained by stimulating cells expressing the three recombinant PDE variants with dibutyryl cAMP. These findings demonstrate that the ratPDE3/IVd gene codes for PDE forms subject to different regulations.	STANFORD UNIV, MED CTR, DEPT GYNECOL & OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA; UNIV ROME, INST HISTOL & GEN EMBRYOL, I-00161 ROME, ITALY	Stanford University; Sapienza University Rome				Sette, Claudio/0000-0003-2864-8266; Vicini, Elena/0000-0003-0399-0145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1992, ADV SEC MESS PHOSPH, V25, P87; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; CONTI M, 1983, ENDOCRINOLOGY, V113, P1845, DOI 10.1210/endo-113-5-1845; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DORRINGTON JH, 1975, MOL CELL ENDOCRINOL, V3, P57, DOI 10.1016/0303-7207(75)90031-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MONACO L, 1994, J BIOL CHEM, V269, P347; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETTE C, 1994, J BIOL CHEM, V269, P9245; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311	30	123	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18271	18274						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034568				2022-12-27	WOS:A1994NW79800004
J	ROBERTS, JR; NARASIMHAN, C; HRUZ, PW; MITCHELL, GA; MIZIORKO, HM				ROBERTS, JR; NARASIMHAN, C; HRUZ, PW; MITCHELL, GA; MIZIORKO, HM			3-HYDROXY-3-METHYLGLUTARYL-COA LYASE - EXPRESSION AND ISOLATION OF THE RECOMBINANT HUMAN ENZYME AND INVESTIGATION OF A MECHANISM FOR REGULATION OF ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; PSEUDOMONAS-MEVALONII; ESCHERICHIA-COLI; PROTEIN; DEFICIENCY; BINDING; CLONING; SITE; HL	cDNA encoding the mature form of human hydroxymethylglutaryl-CoA (HMG-CoA) lyase, a mitochondrial matrix protein, has been used to prepare expression plasmids appropriate for production of this protein in Escherichia coli. Using a T7 RNA polymerase-based pET system, HMG-CoA lyase was overexpressed but largely recovered in an insoluble, catalytically inactive form. In contrast, an expression plasmid (pTrcHL-1), derived from pTrc99a, supported production of soluble, active enzyme. A synthetic oligonucleotide cassette was employed to produce an enzyme variant in which cysteine was replaced by serine at position 323. Both wild-type and C323S HMG-CoA lyases were isolated in homogeneous form and characterized. The function of Cys-323 in influencing catalytic activity in vitro has been investigated by comparing the response of wild-type and C323S lyases to oxidation and reduction. Additionally, the con sequences of treatment of these enzymes with the sulfhydryl-directed bifunctional reagent, o-phenylenedimaleimide have been determined. The results support the hypothesis that a thiol/disulfide exchange mechanism affects enzyme activity in vitro and indicate that Cys-323 residues on adjacent subunits of the homodimeric native enzyme are suitably positioned to form an intersubunit cross-link upon oxidative inactivation and disulfide formation.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; HOP ST JUSTINE, MED GENET SECT, MONTREAL H3T 1C5, PQ, CANADA	Medical College of Wisconsin; Universite de Montreal				Hruz, Paul/0000-0002-1478-3355	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21491] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BACHHAWAT BK, 1955, J BIOL CHEM, V216, P727; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; GOLDFARB S, 1971, J LIPID RES, V12, P512; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; JENG J, 1991, ARCH BIOCHEM BIOPHYS, V289, P221; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISRA I, 1993, J BIOL CHEM, V268, P12129; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; MIZIORKO HM, 1979, BIOCHEMISTRY-US, V18, P399, DOI 10.1021/bi00570a001; NARASIMHAN C, 1992, BIOCHEMISTRY-US, V31, P11224, DOI 10.1021/bi00160a037; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHER DS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P321, DOI 10.1016/0005-2760(89)90239-7; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; WANDERS RJA, 1988, CLIN CHIM ACTA, V171, P95, DOI 10.1016/0009-8981(88)90294-X; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; WELLS JA, 1980, J BIOL CHEM, V255, P1135; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	26	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17841	17846						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027038				2022-12-27	WOS:A1994NV42200016
J	WADSWORTH, JDF; DOORTY, KB; STRONG, PN				WADSWORTH, JDF; DOORTY, KB; STRONG, PN			COMPARABLE 30-KDA APAMIN BINDING POLYPEPTIDES MAY FULFILL EQUIVALENT ROLES WITHIN PUTATIVE SUBTYPES OF SMALL-CONDUCTANCE CA2+-ACTIVATED K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; RAT-BRAIN; GUINEA-PIG; POTENT INHIBITOR; SCORPION TOXIN; ION CHANNELS; BOVINE BRAIN; RECEPTOR; HEPATOCYTES; AFFINITY	Apamin, a peptide neurotoxin from bee venom, blocks small conductance Ca2+-activated K+ channels in central synapses and peripheral tissues. Using I-125-apamin, single classes of high affinity binding sites (K-d 1-3 pM) were identified on plasma membranes from rat, rabbit, guinea pig, and bovine brain and from rabbit, guinea pig, and bovine liver. Binding was sensitive to scyllatoxin, dequalinium, gallamine, and d-tubocurarine but not to charybdotoxin, toxin I, or mast cell degranulating peptide. In contrast, saturable binding of I-125-apamin to rat liver plasma membranes was virtually undetectable, thereby providing a correlation with the ability to measure apamin-sensitive Ca2+-activated potassium currents in rabbit and guinea pig hepatocytes but not in rat hepatocytes. In agreement with membrane binding studies, homobifunctional cross-linkers identified apparently identical 33-kDa I-125-apamin binding polypeptides on brain plasma membranes from all species and analogous but distinct polypeptides on plasma membranes from rabbit, guinea pig, and bovine liver. None of these affinity-labeled polypeptides were detectable on plasma membranes from rat liver. Affinity labeling was abolished on both liver and brain membranes by apamin, scyllatoxin, dequalinium, gallamine, and d-tubocurarine. These results indicate that comparable similar to 30-kDa polypeptides may fulfill equivalent functional roles within putative subtypes of apamin-sensitive small conductance Ca2+-activated K+ channels.			WADSWORTH, JDF (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.			Wadsworth, Jonathan/0000-0002-4797-2259	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; AUGUSTE P, 1989, FEBS LETT, V248, P150, DOI 10.1016/0014-5793(89)80451-X; AUGUSTE P, 1990, J BIOL CHEM, V265, P4753; BREWSTER BS, 1992, POTASSIUM CHANNEL MO, P272; BURGESS GM, 1981, J PHYSIOL-LONDON, V317, P67, DOI 10.1113/jphysiol.1981.sp013814; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; CASTLE NA, 1993, EUR J PHARMACOL, V236, P201, DOI 10.1016/0014-2999(93)90590-E; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; DOLLY JO, 1992, HDB EXPT PHARM, P681; EVANS WH, 1980, BIOCHIM BIOPHYS ACTA, V604, P27, DOI 10.1016/0005-2736(80)90584-2; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; HUGUES M, 1982, J BIOL CHEM, V257, P2762; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; LEVEQUE C, 1990, FEBS LETT, V275, P185, DOI 10.1016/0014-5793(90)81468-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUEZE B, 1987, EUR J BIOCHEM, V169, P295, DOI 10.1111/j.1432-1033.1987.tb13611.x; MEUNIER S, 1993, BIOCHEMISTRY-US, V32, P11969, DOI 10.1021/bi00096a005; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SCHMIDANTOMARCHI H, 1984, EUR J BIOCHEM, V142, P1, DOI 10.1111/j.1432-1033.1984.tb08242.x; SCHMIDANTOMARCHI H, 1986, J BIOL CHEM, V261, P8633; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1987, J NEUROSCI, V7, P565; SEAGAR MJ, 1985, J BIOL CHEM, V260, P3895; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; SEAGAR MJ, 1987, BRAIN RES, V411, P226, DOI 10.1016/0006-8993(87)91073-0; Strong P. N., 1992, Methods in Neurosciences, V8, P15; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; TAKANASHI H, 1992, JPN J PHYSIOL, V42, P415, DOI 10.2170/jjphysiol.42.415; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604	36	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18053	18061						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027065				2022-12-27	WOS:A1994NV42200047
J	BLAHO, JA; MITCHELL, C; ROIZMAN, B				BLAHO, JA; MITCHELL, C; ROIZMAN, B			AN AMINO-ACID-SEQUENCE SHARED BY THE HERPES-SIMPLEX VIRUS-1-ALPHA REGULATORY PROTEIN-0, PROTEIN-4, PROTEIN-22, AND PROTEIN-27 PREDICTS THE NUCLEOTIDYLYLATION OF THE U(L)21, U(L)31, U(L)47, AND U(L)49 GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR-SYNTHESIS; INFECTED-CELLS; POSTTRANSLATIONAL MODIFICATION; MONOCLONAL-ANTIBODIES; VIRAL POLYPEPTIDES; DELETION MUTANTS; ADP-RIBOSYLATION; RNA-POLYMERASE; TYPE-1; DNA	Earlier reports showed that at least 3 herpes simplex virus 1 proteins were adenylylated and guanylylated in addition to the infected cell proteins (ICPs) 0, 4, 22, and 27. ICP22 and 27 share the amino acid sequence R/PRAP/SR which is also predicted to be in ICPs 4 and 0 and in the products of the HSV-1 genes U(L)21, U(L)31, U(L)47, and U,49. ICPs 0, 4, 22, and 27 are regulatory proteins, U(L)21 is dispensable for growth in cultured cells, U(L)31 co-fractionates with the nuclear matrix, and U(L)47 may interact stoichiometrically with the alpha trans-inducing factor (VP16, the product of the U(L)48 gene). To avoid bias, the genes encoding the additional nucleotidylylated proteins were mapped, initially by analyses of intertypic recombinant viruses, and subsequently by analyses of the products encoded by the mapped genome domains. We conclude that (i) the products of U(L)21, U(L)31, U(L)47, and U(L)49 are nucleotidylylated by [alpha-P-32]GTP or [alpha-P-32]ATP in isolated nuclei, (ii) this modification does not involve the viral protein kinases encoded by the U(L)13 and U(S)3 gene products and, (iii) U(L)49 is a virion protein which is labeled in cells with [P-32]orthophosphate and also is ADP-ribosylated.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, CHICAGO, IL 60637 USA	University of Chicago					NCI NIH HHS [CA47451] Funding Source: Medline; NIAID NIH HHS [AI124009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047451] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMANN M, 1984, J VIROL, V52, P108, DOI 10.1128/JVI.52.1.108-118.1984; BAINES JD, 1994, J VIROL, V68, P2929, DOI 10.1128/JVI.68.5.2929-2936.1994; BALL LA, 1982, TEX REP BIOL MED, V41, P487; BARKER DE, 1992, J VIROL, V66, P562, DOI 10.1128/JVI.66.1.562-566.1992; BARKER DE, 1990, VIROLOGY, V177, P684, DOI 10.1016/0042-6822(90)90534-X; BLAHO JA, 1993, J VIROL, V67, P3891, DOI 10.1128/JVI.67.7.3891-3900.1993; BLAHO JA, 1992, J VIROL, V66, P6398, DOI 10.1128/JVI.66.11.6398-6407.1992; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CHANG YE, 1993, J VIROL, V67, P6348, DOI 10.1128/JVI.67.11.6348-6356.1993; CONLEY AJ, 1981, J VIROL, V37, P191, DOI 10.1128/JVI.37.1.191-206.1981; COULTER LJ, 1993, J GEN VIROL, V74, P387, DOI 10.1099/0022-1317-74-3-387; DELUCA NA, 1985, MOL CELL BIOL, V5, P1997, DOI 10.1128/MCB.5.8.1997; DESAI P, 1993, J VIROL, V67, P1357, DOI 10.1128/JVI.67.3.1357-1364.1993; DESIDERIO SV, 1981, J MOL BIOL, V145, P319, DOI 10.1016/0022-2836(81)90208-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; GIBSON W, 1974, J VIROL, V13, P155, DOI 10.1128/JVI.13.1.155-165.1974; HEINE JW, 1974, J VIROL, V14, P640, DOI 10.1128/JVI.14.3.640-651.1974; HONESS RW, 1975, P NATL ACAD SCI USA, V72, P1276, DOI 10.1073/pnas.72.4.1276; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; JOSE ES, 1990, J BIOL CHEM, V265, P20653; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KNIPE DM, 1981, J VIROL, V38, P539, DOI 10.1128/JVI.38.2.539-547.1981; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCKNIGHT JLC, 1987, J VIROL, V61, P992, DOI 10.1128/JVI.61.4.992-1001.1987; MEREDITH DM, 1991, J GEN VIROL, V72, P2771, DOI 10.1099/0022-1317-72-11-2771; MORSE LS, 1978, J VIROL, V26, P389, DOI 10.1128/JVI.26.2.389-410.1978; PEREIRA L, 1977, VIROLOGY, V77, P733, DOI 10.1016/0042-6822(77)90495-0; POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; PRESTON CM, 1983, VIROLOGY, V131, P492, DOI 10.1016/0042-6822(83)90515-9; PURVES FC, 1991, J VIROL, V65, P5757, DOI 10.1128/JVI.65.11.5757-5764.1991; PURVES FC, 1992, P NATL ACAD SCI USA, V89, P7310, DOI 10.1073/pnas.89.16.7310; PURVES FC, 1987, J VIROL, V61, P2896, DOI 10.1128/JVI.61.9.2896-2901.1987; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; RICE SA, 1988, J VIROL, V62, P3814, DOI 10.1128/JVI.62.10.3814-3823.1988; ROIZMAN B, 1990, VIROLOGY 1990, P1795; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; SANJOSE E, 1993, BIOL CHEM H-S, V374, P133, DOI 10.1515/bchm3.1993.374.1-6.133; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; SPEAR PG, 1972, J VIROL, V9, P143, DOI 10.1128/JVI.9.1.143-159.1972; STADTMAN ER, 1990, METHOD ENZYMOL, V182, P793; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TACK LC, 1988, J VIROL, V62, P1028, DOI 10.1128/JVI.62.3.1028-1037.1988; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VENKATESAN S, 1982, P NATL ACAD SCI-BIOL, V79, P340, DOI 10.1073/pnas.79.2.340; WEISS B, 1967, P NATL ACAD SCI USA, V57, P1021, DOI 10.1073/pnas.57.4.1021; WILCOX KW, 1980, J VIROL, V33, P167, DOI 10.1128/JVI.33.1.167-182.1980; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	61	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17401	17410						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021242				2022-12-27	WOS:A1994NU12800012
J	DUESCHER, RJ; LAWTON, MP; PHILPOT, RM; ELFARRA, AA				DUESCHER, RJ; LAWTON, MP; PHILPOT, RM; ELFARRA, AA			FLAVIN-CONTAINING MONOOXYGENASE (FMO)-DEPENDENT METABOLISM OF METHIONINE AND EVIDENCE FOR FMO3 BEING THE MAJOR FMO INVOLVED IN METHIONINE SULFOXIDATION IN RABBIT LIVER AND KIDNEY MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN LIVER; MULTIPLE FORMS; RAT-LIVER; COVALENT STRUCTURE; ESCHERICHIA-COLI; S-OXIDASE; PURIFICATION; LUNG; EXPRESSION; PATHWAY	Methionine was a substrate for cDNA-expressed rabbit flavin containing monooxygenase (FMO) 1, FMO2, and FMO3, while incubations with membrane fractions containing cDNA-expressed FMO5 did not lead to the detection of methionine sulfoxide; K-m values with FMO1, FMO2, and FMO3 were about 48.0, 30.0, and 6.5 mM, respectively. With FMO3 methionine d-sulfoxide was formed in nearly 8-fold higher concentrations than the l-diastereomer, whereas with FMO1 and FMO2, the d:l diastereomeric ratios were approximately 1.5:1 and 0.7:1, respectively. These results provide evidence for methionine being the first identified endogenous compound metabolized to diastereomeric sulfoxides by flavin-containing monooxygenases. The K-m values for methionine sulfoxidation in rabbit liver and kidney microsomes (3.7 and 6.0 man, respectively) were more comparable to the K-m value obtained with FMO3 than with FMO1 or FMO2. This result provides evidence that FMO3 is the major FMO isoform involved in methionine sulfoxidation in rabbit liver and kidney microsomes. Further evidence for this hypothesis is provided by the finding that methionine d-sulfoxide was also the preferred product in rabbit liver and kidney microsomes by nearly 8:1 and 6:1 over the l-diastereomer, respectively.	UNIV WISCONSIN,SCH VET SCI,DEPT COMPARAT BIOSCI,MADISON,WI 53706; UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NIDDK NIH HHS [DK44295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; AYMARD C, 1979, AGR BIOL CHEM TOKYO, V43, P1869, DOI 10.1080/00021369.1979.10863724; BENEVENGA NJ, 1974, J AGR FOOD CHEM, V22, P2, DOI 10.1021/jf60191a036; BLOM HJ, 1989, METABOLISM, V38, P577, DOI 10.1016/0026-0495(89)90220-5; DANIEL RG, 1969, J NUTR, V99, P299, DOI 10.1093/jn/99.3.299; DENT CE, 1946, SCIENCE, V105, P335; ELFARRA AA, 1992, FASEB J, V6, pA1844; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; LAVINE TF, 1947, J BIOL CHEM, V169, P477; LAWRY OH, 1951, J BIOL CHEM, V193, P265; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LOMRI N, 1993, CHEM RES TOXICOL, V6, P800, DOI 10.1021/tx00036a008; MILLER SA, 1970, J NUTR, V100, P909, DOI 10.1093/jn/100.8.909; NAGATA T, 1990, CHEM RES TOXICOL, V3, P372, DOI 10.1021/tx00016a016; OZOLS J, 1990, J BIOL CHEM, V265, P10289; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; PERRY TL, 1965, PEDIATRICS, V36, P236; PERRY TL, 1967, CLIN CHIM ACTA, V15, P409, DOI 10.1016/0009-8981(67)90005-8; REGINA M, 1993, ARCH BIOCHEM BIOPHYS, V300, P598, DOI 10.1006/abbi.1993.1083; RETTIE AE, 1990, MOL PHARMACOL, V37, P674; SADEQUE AJM, 1993, BIOCHIM BIOPHYS ACTA, V1162, P127, DOI 10.1016/0167-4838(93)90138-H; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SAUSEN PJ, 1993, MOL PHARMACOL, V43, P388; STEIN WH, 1954, J BIOL CHEM, V211, P915; TYNES RE, 1987, MOL PHARMACOL, V31, P569; YAMADA H, 1990, ARCH BIOCHEM BIOPHYS, V280, P305, DOI 10.1016/0003-9861(90)90334-U; ZIEGLER DM, 1993, ANNU REV PHARMACOL, V33, P179, DOI 10.1146/annurev.pharmtox.33.1.179; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	31	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17525	17530						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021260				2022-12-27	WOS:A1994NU12800031
J	MULNERLORILLON, O; MINELLA, O; CORMIER, P; CAPONY, JP; CAVADORE, JC; MORALES, J; POULHE, R; BELLE, R				MULNERLORILLON, O; MINELLA, O; CORMIER, P; CAPONY, JP; CAVADORE, JC; MORALES, J; POULHE, R; BELLE, R			ELONGATION-FACTOR EF-1-DELTA, A NEW TARGET FOR MATURATION-PROMOTING FACTOR IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MOLECULAR-CLONING; M-PHASE; CDC2; SUBSTRATE; LAEVIS; IDENTIFICATION; PURIFICATION; MECHANISM; CONTAINS	A new physiological target for Cdc2 protein kinase has been identified. It corresponds to a protein EF-1 delta, a constituent of the nucleotide exchange factor EF-1 beta gamma delta, involved in the elongation step of protein synthesis. EF-1 delta is phosphorylated by Cdc2 kinase on threonine and serine residues. Threonine has been identified as Thr(122) in the sequence VQVTPAAK. During oocyte maturation, Thr(122) is phosphorylated at metaphase, when p34(cdc2) is ac- tive. Phosphorylation studies revealed the presence of two post-translational regulated forms of EF-1 delta protein. Identification of two isoforms of the delta protein, together with the presence of two guanine-nucleotide exchange proteins (beta and delta) and physiologically regulated phosphorylation sites by Cdc2 kinase on gamma and delta proteins, implicate that EF-1 beta gamma delta exists in the cell under a multitude of macromolecular forms which suggests that EF-1 beta gamma delta is a sophisticated regulatory factor rather than a ''housekeeping'' element of the cell.	CTR RECH BIOCHIM MACROMOLEC, CNRS, UNITE PROPRE RECH 41, INSERM, UA 249, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	MULNERLORILLON, O (corresponding author), UNIV PARIS 06, INRA,REPROD PHYSIOL LAB,CNRS,URA 1449, 4 PL JUSSIEU, F-75256 PARIS 05, FRANCE.			Morales, Julia/0000-0003-1632-5419				AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BELLE R, 1990, International Journal of Developmental Biology, V34, P111; BELLE R, 1986, CELL DIFFER DEV, V19, P253, DOI 10.1016/0045-6039(86)90102-8; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CORMIER P, 1993, NUCLEIC ACIDS RES, V21, P743, DOI 10.1093/nar/21.3.743; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JESSUS C, 1993, COMP BIOCHEM PHYS A, V106, P431, DOI 10.1016/0300-9629(93)90236-W; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; MULNERLORILLON O, 1992, EXP CELL RES, V202, P549, DOI 10.1016/0014-4827(92)90111-K; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RICHTER JD, 1982, DEV BIOL, V89, P159, DOI 10.1016/0012-1606(82)90304-9; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; Sambrook J, 1989, MOL CLONING LABORATO; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X	28	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20201	20207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051108				2022-12-27	WOS:A1994PA12600080
J	PAVELKA, MS; HAYES, SF; SILVER, RP				PAVELKA, MS; HAYES, SF; SILVER, RP			CHARACTERIZATION OF KPST, THE ATP-BINDING COMPONENT OF THE ABC-TRANSPORTER INVOLVED WITH THE EXPORT OF CAPSULAR POLYSIALIC ACID IN ESCHERICHIA-COLI K1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; NUCLEOTIDE-BINDING; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; MULTIDRUG-RESISTANCE; GENE-CLUSTER; PERIPLASMIC PERMEASES; BACTERIAL TRANSPORT; STRUCTURAL MODEL; CYSTIC-FIBROSIS	The 17-kilobase kps gene cluster of Escherichia coli K1 contains all the information necessary for the expression of capsular polysaccharide. Region 3 of the cluster encodes two genes, kpsM and kpsT, whose products belong to the (A) under bar TP-(B) under bar inding (C) under bar assette (ABC)-transporter protein family. The KpsMT system is involved with the export of capsular polysaccharide in E. coli. Earlier work indicated that interaction between KpsT and ATP is important for transport. In this study, we report that KpsT, a peripheral inner membrane protein, can be photolabeled by the ATP analog, 8-N-3[gamma-P-32]ATP. The derivatiza- tion of KpsT by this reagent is inhibited by cold ATP or ATP gamma S. Furthermore, the protein seems to require a membrane environment for efficient photolabeling, but does not require any other hps gene products. Results obtained from saturation mutagenesis of the ATP-binding consensus sequence of KpsT and the phenotypes of strains with defined mutations in the chromosomal gene, are consistent with the view that ATP-binding by KpsT is required for transport of polymer across the inner membrane. The structure of KpsT was compared to a model developed for other ABC-transport proteins, and important functional regions were determined. The results obtained from chemical mutagenesis of kpsT are consistent with the model and revealed characteristics particular to capsule transporters.	UNIV ROCHESTER, MED CTR, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; NIAID, ROCKY MT LABS, VECTORS & PATHOGENS LAB, HAMILTON, MT 59840 USA	University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026655, T32AI007362] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26655, 5-T32-AI07362] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1447, DOI 10.1111/j.1365-2958.1991.tb00791.x; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BOULNOIS GJ, 1989, MOL MICROBIOL, V3, P1819, DOI 10.1111/j.1365-2958.1989.tb00168.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FROSCH M, 1991, MOL MICROBIOL, V5, P1251, DOI 10.1111/j.1365-2958.1991.tb01899.x; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROSS RJ, 1977, J CLIN MICROBIOL, V6, P548; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KROLL JS, 1988, CELL, V53, P347, DOI 10.1016/0092-8674(88)90155-9; KRONCKE KD, 1990, J BACTERIOL, V172, P3469; KRONCKE KD, 1990, J BACTERIOL, V172, P1085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT PA, 1988, BACTERIAL CELL SURFA, P113; Levine MM, 1984, BACTERIAL VACCINES, P187; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NER SS, 1989, MOL BIOL REP, V7, P1; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PELKONEN S, 1990, CURR MICROBIOL, V21, P23, DOI 10.1007/BF02090095; Philip A.G.S., 1985, NEONATAL SEPSIS MENI; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; PUGSLEY AP, 1991, PROKARYOTIC STRUCTUR, P223; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SILVER RP, 1984, J BACTERIOL, V157, P568, DOI 10.1128/JB.157.2.568-575.1984; SILVER RP, 1993, POLYSIALIC ACID MICR, P59; Silver RP, 1990, BACTERIA, V11, P39; SMIT J, 1975, J BACTERIOL, V124, P942, DOI 10.1128/JB.124.2.942-958.1975; SMITH AN, 1990, MOL MICROBIOL, V4, P1863, DOI 10.1111/j.1365-2958.1990.tb02035.x; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1982, METHOD ENZYMOL, V83, P540; VANN WF, 1993, POLYSIALIC ACID MICR, P125; VIMR ER, 1985, J BACTERIOL, V164, P845, DOI 10.1128/JB.164.2.845-853.1985; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; VIMR ER, 1993, POLYSIALIC ACID MICR, P73; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357; WUNDER DE, 1994, J BACTERIOL, V176, P4025, DOI 10.1128/JB.176.13.4025-4033.1994; ZAPATA G, 1989, J BIOL CHEM, V264, P14769; 1991, PROGRAM MANUAL GCG P	68	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20149	20158						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051103				2022-12-27	WOS:A1994PA12600073
J	YORK, JD; SAFFITZ, JE; MAJERUS, PW				YORK, JD; SAFFITZ, JE; MAJERUS, PW			INOSITOL POLYPHOSPHATE 1-PHOSPHATASE IS PRESENT IN THE NUCLEUS AND INHIBITS DNA-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA; RAT-LIVER; INTRACELLULAR-LOCALIZATION; HETEROLOGOUS EXPRESSION; PORE COMPLEX; PHOSPHORYLATION; PROTEINS; KINASE; 1,3,4-TRISPHOSPHATE; PURIFICATION	Inositol polyphosphate 1-phosphatase, an enzyme of the phosphatidylinositol signaling pathway, hydrolyzes the 1-phosphate from inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate. We have used indirect immunofluorescence microscopy, Western blot analysis, and enzyme assays to determine the cellular localization of the enzyme. We find that the enzyme is present, but not exclusively, in the nucleus of Madin-Darby bovine kidney cells, and also in COS-7 and HeLa cells that were transiently transfected with a cDNA encoding bovine inositol polyphosphate 1-phosphatase. DNA synthesis, as measured in COS-7 and HeLa cells transiently overexpressing enzyme, was reduced 59% in cells transfected with wild-type enzyme compared with nontransfected cells or cells transfected with an inactive mutant form of the enzyme. These data demonstrate that this response is mediated by one of the substrates or products of inositol polyphosphate 1-phosphatase. We propose that overexpressed inositol polyphosphate 1-phosphatase degrades a stimulatory inositol phosphate(s) and thereby inhibits DNA synthesis.			YORK, JD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV HEMATOL ONCOL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 07088, HL 16634, HL 14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, R01HL016634, R37HL016634, P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSAL VS, 1990, J BIOL CHEM, V265, P1806; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BERGMEYER HU, 1965, METHODS ENZYMATIC AN; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GEE NS, 1988, BIOCHEM J, V253, P777, DOI 10.1042/bj2530777; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; INHORN RC, 1988, J BIOL CHEM, V263, P14559; INHORN RC, 1987, J BIOL CHEM, V262, P15946; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LITTLE L, 1987, BIOCHEM J, V248, P151, DOI 10.1042/bj2480151; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH CD, 1983, J BIOL CHEM, V258, P9368; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; WANG YL, 1993, J BIOL CHEM, V268, P5899; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YORK JD, 1994, J BIOL CHEM, V269, P7847; YORK JD, 1993, P NATL ACAD SCI USA, V90, P5833, DOI 10.1073/pnas.90.12.5833; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; YORK JD, 1994, J MOL BIOL, V236, P584, DOI 10.1006/jmbi.1994.1167	37	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19992	19999						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051083				2022-12-27	WOS:A1994PA12600052
J	LIN, TC; KARAM, G; KONIGSBERG, WH				LIN, TC; KARAM, G; KONIGSBERG, WH			ISOLATION, CHARACTERIZATION, AND KINETIC-PROPERTIES OF TRUNCATED FORMS OF T4 DNA-POLYMERASE THAT EXHIBIT 3'-5' EXONUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; DEOXYRIBONUCLEIC ACID POLYMERASE; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; AMINO-ACID; MUTATIONS; SEQUENCE; ALPHA; IDENTIFICATION; POLYMERIZATION	Limited proteolysis of T4 DNA polymerase generated a 45-kDa and 35-kDa protein complex, which had 3'-5' exonucleolytic activity but lacked polymerase activity. After partial chymotryptic digestion of the cloned and expressed 45-kDa protein derived from T4 DNA polymerase, we isolated a 27-kDa fragment (residues 96-331) that still had 3'-5' exonuclease activity, thus demonstrating that the amino acid residues required for catalysis are included within this fragment. We also show that the apparent K-m values for the 3'-5' exonuclease activity exhibited by the 27-kDa fragment are considerably greater than the apparent K-m values determined for the intact DNA polymerase on deoxyoligonucleotide substrates having more than 3 bases. In contrast, the k(cat) values for phosphodiester bond hydrolysis of 3'-terminal nucleotides are not very different when comparing intact T4 DNA polymerase with the 27-kDa fragment derived from it. Thus, participation of residues distal to 331 are not required for catalysis, but only for binding, and, based on the similarity of k(cat) values, the geometry of the residues responsible for catalysis are preserved even in the absence of the carboxyl-terminal 567 residues.			LIN, TC (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM 12607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GOULIAN M, 1968, J BIOL CHEM, V243, P627; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, IN PRESS ANN REV BIO, V63; JUNG GH, 1990, BIOCHEM BIOPH RES CO, V170, P1294, DOI 10.1016/0006-291X(90)90534-T; KLENOW H, 1970, P NATL ACAD SCI USA, V65, P168, DOI 10.1073/pnas.65.1.168; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	44	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19286	19294						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034691				2022-12-27	WOS:A1994NY33200016
J	RAYCHOWDHURY, MK; YUKAWA, M; COLLINS, LJ; MCGRAIL, SH; KENT, KC; WARE, JA				RAYCHOWDHURY, MK; YUKAWA, M; COLLINS, LJ; MCGRAIL, SH; KENT, KC; WARE, JA			ALTERNATIVE SPLICING PRODUCES A DIVERGENT CYTOPLASMIC TAIL IN THE HUMAN ENDOTHELIAL THROMBOXANE A(2), RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY-INDUCED HYPERTENSION; PLATELET-AGGREGATION; BINDING-SITES; SHAPE CHANGE; PROSTAGLANDIN; ACTIVATION; MUSCLE; CELLS; IDENTIFICATION; DISCRIMINATION	Thromboxane A(2) (TxA(2)) causes contraction of vascular smooth muscle and aggregation of platelets; paradoxically, it also induces formation of the vasodilator and antiaggregant prostacyclin by human endothelium. To determine if the molecular structure of the endothelial TxA(2) receptor differs from that of the previously characterized receptor from placenta, we isolated a putative TxA(2) receptor cDNA from a human endothelial library. The predicted amino acid sequence revealed a structure of 369 amino acids, in which a novel cytoplasmic tail replaced the carboxyl-terminal portion of the previously characterized TxA, receptor; this divergence in cytoplasmic domains resulted from the nonsplicing of a potential intron in the placenta TxA(2) receptor. Northern hybridization reveals that the expression of the TxA(2), receptor in endothelial RNA decreases 6-fold following stimulation with an endoperoxide analog. Polymerase chain reaction using oligonucleotide primers specific to each cytoplasmic domain revealed that only the novel receptor was expressed in endothelium, while both receptors were expressed in placenta. Overexpression of the endothelial TxA(2) receptor cDNA in Chinese hamster ovary cells conferred the ability to bind a known receptor antagonist and mobilize Ca2+ in response to TxA, mimetics. This finding of a new TxA(2) receptor in endothelium suggests that a family of these receptors may result from alternative splicing of the cytoplasmic (carboxyl) tail.	BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,HARVARD THORNDIKE LABS,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL47032, HL02271, HL38820] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038820, R01HL047032, R29HL038820, K04HL002271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ASHTON JH, 1986, CIRC RES, V59, P568, DOI 10.1161/01.RES.59.5.568; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CLESHAM G, 1992, CARDIOVASC RES, V26, P513, DOI 10.1093/cvr/26.5.513; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; DORN GW, 1991, AM J PHYSIOL, V261, pR145, DOI 10.1152/ajpregu.1991.261.1.R145; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; DORN GW, 1991, AM J PHYSIOL, V260, pH327, DOI 10.1152/ajpheart.1991.260.2.H327; DU XP, 1993, J BIOL CHEM, V268, P23087; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FITZGERALD DJ, 1988, J CLIN INVEST, V82, P1708, DOI 10.1172/JCI113784; FITZGERALD DJ, 1986, J CLIN INVEST, V77, P496, DOI 10.1172/JCI112329; FITZGERALD GA, 1987, FASEB J, V46, P154; FUNK CD, 1993, MOL PHARMACOL, V44, P934; FURCI L, 1991, J PHARMACOL EXP THER, V258, P74; GAIRNS JA, 1985, NEW ENGL J MED, V313, P1369; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HALUSHKA PV, 1987, FASEB J, V46, P149; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KENT KC, 1993, CIRC RES, V72, P958, DOI 10.1161/01.RES.72.5.958; LIEL N, 1993, THROMB RES, V70, P205, DOI 10.1016/0049-3848(93)90126-9; MASUDA A, 1991, BIOCHEM PHARMACOL, V42, P537, DOI 10.1016/0006-2952(91)90316-W; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGLETREE ML, 1992, J PHARMACOL EXP THER, V260, P789; PARISE LV, 1984, J PHARMACOL EXP THER, V228, P240; SIESS W, 1983, J BIOL CHEM, V258, P1236; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; WARE JA, 1993, NEW ENGL J MED, V328, P628; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	36	295	300	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19256	19261						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034687				2022-12-27	WOS:A1994NY33200012
J	ELIASSON, E; MKRTCHIAN, S; HALPERT, JR; INGELMANSUNDBERG, M				ELIASSON, E; MKRTCHIAN, S; HALPERT, JR; INGELMANSUNDBERG, M			SUBSTRATE-REGULATED, CAMP-DEPENDENT PHOSPHORYLATION, DENATURATION, AND DEGRADATION OF GLUCOCORTICOID-INDUCIBLE RAT-LIVER CYTOCHROME-P450 3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEINS; GENE; MULTIPLICITY; HEPATOCYTES; MICROSOMES; SEQUENCES; ENZYMES; LYSINE; COMMON	The major rat glucocorticoid-inducible cytochrome P450 (CYP3A1) is known to be regulated at a transcriptional level by glucocorticoids and at a post-translational level by substrate-dependent stabilization. We have investigated mechanisms of substrate/ligand stabilization using primary hepatocytes, isolated liver microsomes from dexamethasone-treated rats, and purified enzymes. Treatment of hepatocytes with glucagon caused a 3-fold increase in CYP3A1 phosphorylation as well as an enhanced degradation rate of the enzyme. Specific CYP3A1 substrates or ligands, such as erythromycin, triacetyl- oleandomycin, and clotrimazole (CTZ) protected the enzyme from degradation in hepatocytes and inhibited in a concomitant manner (r = 0.99) glucagon-induced phosphorylation of the enzyme. In vitro experiments with purified CYP3A1 and isolated liver microsomes revealed one major site (Ser(393)) phosphorylated by the catalytic subunit of cAMP-dependent kinase, a reaction inhibited by ligands. Experiments in microsomes showed the presence of an endogenous cAMP-dependent kinase active on CYP3A1. Addition of exogenous cAMP-dependent kinase increased the rate of microsomal CYP3A1 phosphorylation, a reaction further stimulated by NADPH, but inhibited by CTZ. The microsomal phosphorylation caused a pronounced denaturation of cytochrome P450, as revealed spectrophotometrically, whereas CTZ protected from this reaction. Similar effects were noted when the CYP3A1-dependent 6 beta-hydroxylation of testosterone was monitored. It is suggested that the cellular CYP3A1 level is regulated to a significant extent posttranslationally by substrate-regulated cAMP-dependent phosphorylation on Ser(393), followed by denaturation and degradation in the endoplasmic reticulum.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; UNIV ARIZONA,COLL PHARM,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721	Karolinska Institutet; University of Arizona			Ingelman-Sundberg, Magnus/ABD-9302-2021	Eliasson, Erik/0000-0002-4707-4256				BERNHARDT R, 1984, BIOCHIM BIOPHYS ACTA, V785, P186, DOI 10.1016/0167-4838(84)90143-2; COOPER KO, 1993, ARCH BIOCHEM BIOPHYS, V301, P345, DOI 10.1006/abbi.1993.1154; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V297, P228, DOI 10.1016/0003-9861(92)90666-K; ELIASSON E, 1990, P NATL ACAD SCI USA, V87, P3225, DOI 10.1073/pnas.87.8.3225; ELIASSON E, 1988, BIOCHEM BIOPH RES CO, V150, P436, DOI 10.1016/0006-291X(88)90539-6; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; HALPERT JR, 1988, ARCH BIOCHEM BIOPHYS, V263, P59, DOI 10.1016/0003-9861(88)90613-3; HOSTETLER KA, 1989, MOL PHARMACOL, V35, P279; JOHANSSON I, 1991, BIOCHEM BIOPH RES CO, V174, P37, DOI 10.1016/0006-291X(91)90481-L; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; KENELLY PJ, 1991, J BIOL CHEM, V266, P15555; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PYERIN W, 1989, EMBO J, V8, P3003, DOI 10.1002/j.1460-2075.1989.tb08450.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; TSOKOS DC, 1992, BIOCHEMISTRY-US, V31, P7155, DOI 10.1021/bi00146a018; WATKINS PB, 1986, J BIOL CHEM, V261, P6264; ZHUKOV A, 1993, BIOCHEM BIOPH RES CO, V197, P221, DOI 10.1006/bbrc.1993.2464	28	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18378	18383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034584				2022-12-27	WOS:A1994NW79800025
J	SCHRAMM, VL; HORENSTEIN, BA; KLINE, PC				SCHRAMM, VL; HORENSTEIN, BA; KLINE, PC			TRANSITION-STATE ANALYSIS AND INHIBITOR DESIGN FOR ENZYMATIC-REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOSIDE HYDROLASE; AMP NUCLEOSIDASE; CRITHIDIA-FASCICULATA; CATALYTIC MECHANISMS; ADENOSINE-DEAMINASE; ENZYMIC REACTIONS; STEADY-STATE; SECONDARY; ACID; COLLISIONS				SCHRAMM, VL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM21083, GM41916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041916, R01GM021083, R37GM041916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM MH, 1974, PROGR PHYS ORG CHEM, P1; ALBERY WJ, 1993, ADV PHYS ORG CHEM, V28, P139, DOI 10.1016/S0065-3160(08)60181-1; BIGELEISEN J, 1958, ADV CHEM PHYS, V1, P15; BIGELEISEN J, 1947, J CHEM PHYS, V15, P261, DOI 10.1063/1.1746492; BOULLITIER M, 1994, BIOCHEMISTRY-US, V33, P3994; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1987, BIOORG CHEM, V15, P283, DOI 10.1016/0045-2068(87)90026-5; CLELAND WW, 1982, METHOD ENZYMOL, V87, P625; CLELAND WW, 1977, ISOTOPE EFFECTS ENZY; COLLINGS BA, 1987, PHYS REV LETT, V59, P2551, DOI 10.1103/PhysRevLett.59.2551; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; FRISCH M, 1992, GAUSSIAN 92 USERS GU; Gandour R. D., 1978, TRANSITION STATES BI; GLASSTONE S, 1941, THEORY RATE PROCESSE; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P9917, DOI 10.1021/bi00089a007; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; Huskey W. P., 1991, ENZYME MECH ISOTOPE, P37; JENCKS WP, 1980, ACCOUNTS CHEM RES, V13, P161, DOI 10.1021/ar50150a001; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; Klinman J P, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P415; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P39, DOI 10.1021/bi00116a008; LAREAU RD, 1989, BIOCHEMISTRY-US, V28, P3619, DOI 10.1021/bi00434a070; LIU K, 1993, J CHEM PHYS, V98, P5431, DOI 10.1063/1.464892; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MERKLER DJ, 1990, BIOCHEMISTRY-US, V29, P8358, DOI 10.1021/bi00488a023; MERKLER DJ, 1993, BIOCHEMISTRY-US, V32, P12993, DOI 10.1021/bi00211a007; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; O'Leary M H, 1980, Methods Enzymol, V64, P83; PARKIN DW, 1984, J BIOL CHEM, V259, P9418; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; PARKIN DW, 1991, BIOCHEMISTRY-US, V30, P4586, DOI 10.1021/bi00232a032; PARKIN DW, 1987, BIOCHEMISTRY-US, V26, P913, DOI 10.1021/bi00377a036; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Pauling L, 1948, AM SCI, V36, P50; PECHUKAS P, 1973, J CHEM PHYS, V58, P1622, DOI 10.1063/1.1679404; POLITZER P, 1981, CHEM APPLICATIONS AT; RAINES RT, 1991, ENZYME MECH ISOTOPE, P431; RISING KA, 1994, IN PRESS J AM CHEM S; RODGERS J, 1982, J AM CHEM SOC, V104, P3263, DOI 10.1021/ja00376a003; Rose I A, 1980, Methods Enzymol, V64, P47; SCHERER NF, 1987, J CHEM PHYS, V87, P1451, DOI 10.1063/1.453280; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; SCHRAMM VL, 1991, ENZYME MECH ISOTOPE, P367; SIMS LB, 1972, J AM CHEM SOC, V94, P1364, DOI 10.1021/ja00759a059; SIMS LB, 1984, ISOTOPES ORGANIC CHE, V6, P161; SIMS LB, 1977, 337 IND U QUANT CHEM; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SREBRENI.S, 1973, CHEM PHYS LETT, V20, P419, DOI 10.1016/0009-2614(73)85188-7; STREITWIESER A, 1958, J AM CHEM SOC, V80, P2326, DOI 10.1021/ja01542a075; SUHNEL J, 1991, ENZYME MECH ISOTOPE, P3; THORNTON ER, 1967, J AM CHEM SOC, V89, P2915, DOI 10.1021/ja00988a020; TRUHLAR DG, 1983, J PHYS CHEM-US, V87, P2664, DOI 10.1021/j100238a003; VANONI MA, 1990, BIOCHEMISTRY-US, V29, P5790, DOI 10.1021/bi00476a021; WARSHEL A, 1989, P NATL ACAD SCI USA, V86, P5820, DOI 10.1073/pnas.86.15.5820; WARSHEL A, 1991, COMPUTER MODELING CH, P208; WESTHEIMER FH, 1961, CHEM REV, V61, P265, DOI 10.1021/cr60211a004; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002	61	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18259	18262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034566				2022-12-27	WOS:A1994NW79800001
J	BAUREITHEL, K; FELIX, G; BOLLER, T				BAUREITHEL, K; FELIX, G; BOLLER, T			SPECIFIC, HIGH-AFFINITY BINDING OF CHITIN FRAGMENTS TO TOMATO CELLS AND MEMBRANES - COMPETITIVE-INHIBITION OF BINDING BY DERIVATIVES OF CHITOOLIGOSACCHARIDES AND A NOD FACTOR OF RHIZOBIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RICE CELLS; SOYBEAN GLYCINE-MAX; F-SP GLYCINEA; GLYCOPEPTIDE ELICITORS; PHYTOALEXIN ELICITOR; GLYCAN SUPPRESSORS; INDUCTION; PROTEIN; OLIGOSACCHARIDES; PURIFICATION	Suspension-cultured tomato cells have a sensitive perception system for chitin fragments with a degree of polymerization (DP) greater than or equal to 4 and react to these compounds with a transient alkalinization of their culture medium (Felix, G., Regenass, M., and Boller, T. (1993) Plant. J. 4, 307-316). A chitin fragment with DP 5 was aminated at the reducing end and coupled to t-butoxycarkonyl-L-[S-35]methionine via an amidoglycine spacer. The radiolabeled chitin fragment (similar to 1000 Ci/mmol) exhibited specific, saturable, reversible binding to whole tomato cells as well as to tomato microsomal membranes with dissociation constants of 1.4 and 23 nM, respectively. Binding of the radioligand was competed by chitin fragments of different DP with IC50 values (50% inhibition of binding) that closely paralleled the concentrations inducing the alkalinization response half-maximally. Deacetylated chitooligosaccharides and N-propanoyl chitooligosaccharides were weak elicitors of the alkalinization response as well as weak competitors of radioligand binding. A lipochitooligosaccharide (Nod factor) from Rhizobium leguminosarum stimulated the alkalinization response in tomato cells half-maximally at 3 nM and competed radioligand binding to the cells with an IC50 of 8 nM. These results demonstrate the presence of a high affinity binding site for chitin fragments on the tomato cell membrane that may function as a receptor.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				BARBER MS, 1989, PHYSIOL MOL PLANT P, V34, P3, DOI 10.1016/0885-5765(89)90012-X; BASSE CW, 1992, J BIOL CHEM, V267, P10258; BASSE CW, 1992, PLANT PHYSIOL, V98, P1239, DOI 10.1104/pp.98.4.1239; BASSE CW, 1993, J BIOL CHEM, V268, P14724; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; COSIO EG, 1988, EUR J BIOCHEM, V175, P309, DOI 10.1111/j.1432-1033.1988.tb14198.x; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; Ebel J., 1992, Genes involved in plant defense., P183; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FREY T, 1993, PHYTOCHEMISTRY, V32, P543, DOI 10.1016/S0031-9422(00)95134-3; GROSSKOPF DG, 1990, FEBS LETT, V275, P177, DOI 10.1016/0014-5793(90)81466-2; KOGA D, 1992, BIOSCI BIOTECH BIOCH, V56, P280, DOI 10.1271/bbb.56.280; KUCHITSU K, 1993, PROTOPLASMA, V174, P79, DOI 10.1007/BF01404046; MANGER ID, 1992, BIOCHEMISTRY-US, V31, P10733, DOI 10.1021/bi00159a013; NACHBAR MS, 1980, J BIOL CHEM, V255, P2056; NICKERSON M, 1956, NATURE, V178, P697, DOI 10.1038/178697b0; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; REN YY, 1992, PLANT PHYSIOL, V99, P1169, DOI 10.1104/pp.99.3.1169; RENELT A, 1993, J EXP BOT, V44, P257; SCHMIDT WE, 1987, P NATL ACAD SCI USA, V84, P4117, DOI 10.1073/pnas.84.12.4117; SHARP JK, 1984, J BIOL CHEM, V259, P1321; SHIBUYA N, 1993, FEBS LETT, V329, P75, DOI 10.1016/0014-5793(93)80197-3; SPAINK H, 1993, PLANT MOL BIOL, V20, P977; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; STAEHELIN C, 1994, P NATL ACAD SCI USA, V91, P2196, DOI 10.1073/pnas.91.6.2196; STAEHELIN C, 1994, PLANT J, V5, P319, DOI 10.1111/j.1365-313X.1994.00319.x; VIJN I, 1993, SCIENCE, V260, P1764, DOI 10.1126/science.8511583; YAMADA A, 1993, BIOSCI BIOTECH BIOCH, V57, P405, DOI 10.1271/bbb.57.405	33	139	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17931	17938						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027050				2022-12-27	WOS:A1994NV42200030
J	THOMPSON, MW; MAURIZI, MR				THOMPSON, MW; MAURIZI, MR			ACTIVITY AND SPECIFICITY OF ESCHERICHIA-COLI CLPAP PROTEASE IN CLEAVING MODEL PEPTIDE-SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; MULTICATALYTIC PROTEINASE; ACTIVATED ATPASE; PROTEOLYSIS; COMPONENT; LA; DEGRADATION; SEQUENCE; CELLS; TI	Escherichia coli ClpAP protease is an ATP-dependent protease composed of the proteolytic component ClpP and a regulatory ATPase, ClpA. ClpAP protease degraded a variety of peptide bonds in protein and peptide substrates at a slow rate (k(cat) less than or equal to 30 min(-1)/subunit of ClpP), but showed very high activity (k(cat) greater than or equal to 800 min(-1)) for a synthetic peptide composed of the first 19 amino acids of ClpP, MSYSGERDNFAPHMALVPV, referred to as the propeptide. The propeptide was not degraded by ClpP alone, but was degraded in the presence of ClpA and ClpP. Degradation was activated by nonhydrolyzable analogs of ATP, indicating that nucleotide-promoted interaction between ClpA and ClpP is sufficient to activate ClpP for propeptide cleavage. The propeptide, as well as truncated forms lacking either the first 9 or the last 3 amino acids, was cleaved at the same Met-Ala bond at which autoprocessing occurs in vivo. No hydrolysis of FAPHMALVPV derivatives was observed when Met was replaced by Glu, Lys, Ser, Tyr, Ile, and D-Met, but cleavage at the same position did occur with Leu or Trp substitutions. A peptide composed of a tandem repeat of FAPHMALVPV was cleaved between both Met-Ala bonds (k(cat) values greater than or equal to 39 min(-1)). Propeptides inhibited degradation of alpha-casein by competition for a binding site on ClpA, and they stimulated the basal ATPase activity of ClpA in the absence of ClpP. Peptides and protein substrates interact at an allosteric site on ClpA, which appears to be the site at which specific substrates are recognized by the Clp protease.			THOMPSON, MW (corresponding author), NCI, CELL BIOL LAB, BLDG 37, RM 1B07, BETHESDA, MD 20892 USA.							BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; FISCHER H, 1993, J BIOL CHEM, V268, P22502; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KANAYAMA H, 1991, CANCER RES, V51, P6677; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Klapper M H, 1972, Methods Enzymol, V25, P531, DOI 10.1016/S0076-6879(72)25050-9; MA CP, 1994, J BIOL CHEM, V269, P3539; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; MAURIZI MR, 1988, UBIQUITIN SYSTEM CUR, P147; MAURIZI MR, 1994, IN PRESS METHODS ENZ; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WOO KM, 1989, J BIOL CHEM, V264, P2088; WOO KM, 1992, J BIOL CHEM, V267, P20429	36	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18201	18208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027081				2022-12-27	WOS:A1994NV42200066
J	YAGI, M; EDELHOFF, S; DISTECHE, CM; ROTH, GJ				YAGI, M; EDELHOFF, S; DISTECHE, CM; ROTH, GJ			STRUCTURAL CHARACTERIZATION AND CHROMOSOMAL LOCATION OF THE GENE ENCODING HUMAN PLATELET GLYCOPROTEIN IB-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH GLYCOPROTEINS; BERNARD-SOULIER SYNDROME; VONWILLEBRAND-FACTOR; GEL-ELECTROPHORESIS; ALPHA-CHAIN; IX; EXPRESSION; MEMBRANE; CLONING; LOCALIZATION	Human platelet glycoprotein Ib beta (GPIb beta) (M(r) 22,000) is part of the GPIb-V-IX system that constitutes the receptor for von Willebrand factor and mediates platelet adhesion in the arterial circulation. The four members of the receptor (GPs Ib alpha, Ib beta, V, and IX) share structural and functional features. Individually, GPIb beta contributes to surface expression of the receptor and participates in transmembrane signaling through phosphorylation of its intracellular domain. To define the structure of the GPIb beta gene, a cosmid clone from a human genomic library was analyzed. The transcriptional start site was located by both primer extension and the ''anchored'' polymerase chain reaction. Similar to the genes for Ib alpha, V, and IX, the Ib beta gene is compact with a single 274-base intron inserted into the 5' end of the open reading frame. The 5'-flanking region of the gene contains both GATA and ets sites that are also found in the 5' promoter regions of other described megakaryocyte/platelet genes. The GPIb beta gene was localized to chromosome 22q11.2 by fluorescence in situ hybridization. The GPIb beta gene has a simple structure, similar to that of other described megakaryocyte/platelet genes, including those of the GPIb-V-IX system.	VET ADM MED CTR 111 MED,MED SERV,HEMATOL SECT,SEATTLE,WA 98108; VET ADM MED CTR,RES SERV,HEMATOL SECT,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL39947] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039947] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNARD J, 1948, Sem Hop, V24, P3217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; EDELHOFF S, 1994, ONCOGENE, V9, P665; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1990, FEBS LETT, V274, P189, DOI 10.1016/0014-5793(90)81361-Q; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; KELLY MD, 1993, THROMB HAEMOSTASIS, V69, P1194; LANZA F, 1993, J BIOL CHEM, V268, P20801; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROTH GJ, 1991, BLOOD, V77, P5; ROTH GJ, 1989, BIOCHEM BIOPH RES CO, V160, P705, DOI 10.1016/0006-291X(89)92490-X; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; TAKEHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VICENTE V, 1990, J BIOL CHEM, V265, P274; VISVADER J, 1993, BLOOD, V82, P1493; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WENGER RH, 1989, GENE, V85, P517, DOI 10.1016/0378-1119(89)90446-0; WRIGHT SD, 1993, BLOOD, V81, P2339	35	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17424	17427						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021244				2022-12-27	WOS:A1994NU12800015
J	MELLENTINMICHELOTTI, J; JOHN, S; PENNIE, WD; WILLIAMS, T; HAGER, GL				MELLENTINMICHELOTTI, J; JOHN, S; PENNIE, WD; WILLIAMS, T; HAGER, GL			THE 5' ENHANCER OF THE MOUSE MAMMARY-TUMOR VIRUS LONG TERMINAL REPEAT CONTAINS A FUNCTIONAL AP-2 ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; MULTIPLE REGULATORY ELEMENTS; NEGATIVE REGULATION; TRANSGENIC MICE; GENE-EXPRESSION; PROMOTER; BINDING; INVITRO; REGION; DNA	The mouse mammary tumor virus (MMTV) retrovirus causes mammary adenocarcinomas in mice by proviral insertion near members of the wnt family of proto-oncogenes, leading to their deregulation and cellular transformation. The 5' end of the MMTV long terminal repeat (LTR) has been implicated in tissue-specific activation of these gems. In this study, we characterize an enhancer element (Ban2; -1075 to -978) at the 5' end of the MMTV LTR, We show that this enhancer is 8-fold more active in a murine mammary carcinoma cell fine (34i) than in a fibroblast cell line (NIH3T3), and is inactive in the liver carcinoma cell line HepG2. Mutagenesis of the enhancer reveals four cis-acting elements that are required for maximal activity, DNA-binding proteins that interact with each of the four elements have been identified, One of these factors, designated mp5, is either identical to, or closely related to, the transcription factor AP-2, The mp5/AP-2 DNA binding activity co-migrates with recombinant AP-2 and is supershifted by anti-AP-2 antibodies, We also show that the lack of enhancer activity in HepG2 cells results from the absence of AP-2 protein in these cells. Co-transfection of an AP-2 expression vector restores the activity of this enhancer in HepG2 cells, and requires an intact mp5-binding site.	NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; GARCIA M, 1986, EMBO J, V5, P127, DOI 10.1002/j.1460-2075.1986.tb04186.x; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MICHALIDES R, 1986, VIROLOGY, V154, P76, DOI 10.1016/0042-6822(86)90431-9; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOK E, 1992, J VIROL, V66, P7529, DOI 10.1128/JVI.66.12.7529-7532.1992; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; MUCHARDT C, 1992, NEW BIOL, V4, P541; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SONNENBERG A, 1986, CANCER RES, V46, P5913; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31983	31990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989375				2022-12-27	WOS:A1994PX30300099
J	DOU, YM; MCHUGH, T; LANE, WV; ROSSANT, CJ; LORING, RH				DOU, YM; MCHUGH, T; LANE, WV; ROSSANT, CJ; LORING, RH			INTERACTIONS OF DITHIOLS WITH P-AMINOPHENYLDICHLOROARSINE AND NICOTINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLARSINE OXIDE; BINDING-SITE; ALPHA-SUBUNIT; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; SULFENIC ACIDS; FREE-RADICALS; CHROMATOGRAPHY; INHIBITION; COMPLEX	Interactions of dithiols with p-aminophenyldichloroarsine (APA) and with Torpedo nicotinic receptors were studied using two approaches. First, the stability of dithiol-APA complexes in solution was studied based on quenching thiol reactions with dithiobis-(nitrobenzoic acid). A peptide corresponding to a portion of the Torpedo alpha-subunit and various 1,2 dithiols such as 2,3-dimercaptopropanesulfonic acid (DMPS), 2,3-dimercaptopropanol (BAL), and 2,3-dimercaptosuccinic acid formed stable complexes with ABA, while 1,4-dithiols, such as dithiothreitol (DTT) and 2,5 dimercapto-N,N,N'N'-tetradipamide (DTA) did not. The K-d of APA association with DTT in Tris buffer is 2 mu M. These data suggest that APA has greater affinity for reduced nicotinic receptors than for either DTT or DTA, a prediction that was experimentally confirmed, since these reagents do not reverse the effects of APA on nicotinic receptors. Second, application of DMPS and BAL, but not 2,3- dimercaptosuccinic acid, to DTT-treated receptors both reversed the effects of APA-receptor complexes and prevented alkylation by bromoacetylcholine, suggesting that DMPS and BAL ''oxidize'' reduced nicotinic receptors. The presence of air is required for this ''oxidizing'' effect, but no clear mechanism was discovered, since prevention of formation of the reactive oxygen species superoxide, hydrogen peroxide, or hydroxyl radicals failed to block oxidation. These data suggest that oxygen reacts with dithiols to produce unknown reactive species that directly oxidize reduced nicotinic receptors, although other interpretations are still possible.	NORTHEASTERN UNIV,DEPT PHARMACEUT SCI,BOSTON,MA 02115	Northeastern University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022472, R23NS022472, R29NS022472] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22472] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ADAMS E, 1990, INORG CHEM, V29, P1500, DOI 10.1021/ic00333a012; AIZENMAN E, 1990, NEURON, V5, P841, DOI 10.1016/0896-6273(90)90343-E; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; ANEL A, 1993, J BIOL CHEM, V268, P17578; BAJPAI A, 1993, BIOCHIM BIOPHYS ACTA, V1177, P291, DOI 10.1016/0167-4889(93)90125-9; BARTELS E, 1970, BIOCHIM BIOPHYS ACTA, V203, P568, DOI 10.1016/0005-2736(70)90193-8; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; BRASWELL LM, 1984, BRIT J PHARMACOL, V83, P305, DOI 10.1111/j.1476-5381.1984.tb10147.x; BROWN SB, 1989, BIOCHEM CELL BIOL, V67, P25, DOI 10.1139/o89-004; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CONROY WG, 1990, J BIOL CHEM, V265, P21642; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DOUEN AG, 1988, BIOCHIM BIOPHYS ACTA, V968, P109, DOI 10.1016/0167-4889(88)90050-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; FROST SC, 1985, J BIOL CHEM, V260, P2646; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1985, FREE RADICAL BIO MED, P25; HANNESTAD U, 1982, ANAL BIOCHEM, V126, P200, DOI 10.1016/0003-2697(82)90129-4; HANNESTAD U, 1980, J CHROMATOGR, V200, P171, DOI 10.1016/S0021-9673(00)84928-6; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; KALEF E, 1993, ANAL BIOCHEM, V212, P325, DOI 10.1006/abio.1993.1337; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1966, BIOCHIM BIOPHYS ACTA, V126, P525, DOI 10.1016/0926-6585(66)90010-0; LEES WJ, 1991, J ORG CHEM, V56, P7328, DOI 10.1021/jo00026a026; Loring R. H., 1993, Society for Neuroscience Abstracts, V19, P465; Loring R. H., 1992, Society for Neuroscience Abstracts, V18, P801; LORING RH, 1993, J TOXICOL-TOXIN REV, V12, P105, DOI 10.3109/15569549309033109; LORING RH, 1982, J BIOL CHEM, V257, P1418; LORING RH, 1992, MOL BRAIN RES, V15, P113, DOI 10.1016/0169-328X(92)90158-8; LORING RH, 1993, METHODS NEUROSCI, V12, P324; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; PIKE A, 1992, EUR J NEUROSCI, V4, P1362, DOI 10.1111/j.1460-9568.1992.tb00161.x; ROSSANT CJ, 1994, J NEUROCHEM, V62, P1368; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; TZARTOS SJ, 1990, J BIOL CHEM, V265, P21462; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	48	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20410	20416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051136				2022-12-27	WOS:A1994PB31700033
J	ROY, BP; PAICE, MG; ARCHIBALD, FS; MISRA, SK; MISIAK, LE				ROY, BP; PAICE, MG; ARCHIBALD, FS; MISRA, SK; MISIAK, LE			CREATION OF METAL-COMPLEXING AGENTS, REDUCTION OF MANGANESE-DIOXIDE, AND PROMOTION OF MANGANESE PEROXIDASE-MEDIATED MN(III) PRODUCTION BY CELLOBIOSE - QUINONE OXIDOREDUCTASE FROM TRAMETES-VERSICOLOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN MODEL COMPOUNDS; PHANEROCHAETE-CHRYSOSPORIUM; KRAFT PULP; CORIOLUS-VERSICOLOR; MN-PEROXIDASE; OXIDATION; DELIGNIFICATION; DEGRADATION; CELLULOSE; LACCASE	Culture supernatants of the white-rot fungus Trametes versicolor were found to contain Mn(III)-complexing agents able to effectively promote manganese-dependent peroxidase (MnP)-mediated oxidation of phenol red. The high molecular weight fractions of these supernatants contained carbohydrate polymers that functioned as effective Mn(III)-complexing agents. Gluconic and glucuronic acids were also found to be effective Mn(III)-complexing ligands capable of supporting MnP-mediated phenol red oxidation, as was the cellobionic acid formed from cellobiose by cellobiose:quinope oxidoreductase (CBQase) (EC 1.1.5.1). The formation of cellulose-derived sugar acid manganese-complexing agents by CBQase increased in the presence of wood pulp and cellulolytic enzymes. CBQase, while oxidizing cellobiose, reduced insoluble Mn(IV)O-2 to Mn(II) or Mn(III) by a reaction whose rate is determined by the nature of the manganese-complexing agents present. A model is proposed to explain how oxidation of carbohydrate and reduction of MnO2 and quinones by CBQase may complement oxidation by MnP, thus promoting lignin biodegradation.	PULP & PAPER RES INST CANADA,POINTE CLAIRE H9R 3J9,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL,ST ANNE BELLEVUE H9X 1C0,PQ,CANADA; CONCORDIA UNIV,DEPT PHYS,MONTREAL H3G 1M8,PQ,CANADA	McGill University; Concordia University - Canada								ADDLEMAN K, 1993, APPL ENVIRON MICROB, V59, P266, DOI 10.1128/AEM.59.1.266-273.1993; ANDER P, 1975, SVEN PAPPERSTIDN, V18, P643; ARCHIBALD F, 1992, APPL ENVIRON MICROB, V58, P1496, DOI 10.1128/AEM.58.5.1496-1499.1992; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; BAO WJ, 1992, FEBS LETT, V302, P77, DOI 10.1016/0014-5793(92)80289-S; BESS B, 1987, BIOTECHNOL APPL BIOC, V9, P310; BLANCHETTE RA, 1984, PHYTOPATHOLOGY, V74, P153, DOI 10.1094/Phyto-74-153; BLANCHETTE RA, 1984, PHYTOPATHOLOGY, V74, P725, DOI 10.1094/Phyto-74-725; BODINI ME, 1976, INORG CHEM, V15, P1538, DOI 10.1021/ic50161a015; BOURBONNAIS R, 1992, APPL MICROBIOL BIOT, V36, P823, DOI 10.1007/BF00172202; BUCHALA AJ, 1987, CARBOHYD RES, V165, P146, DOI 10.1016/0008-6215(87)80090-3; DUTTON MV, 1993, APPL MICROBIOL BIOT, V39, P5, DOI 10.1007/BF00166839; Eriksson K.-E., 1990, MICROBIAL ENZYMATIC; ERIKSSON KE, 1974, FEBS LETT, V49, P282, DOI 10.1016/0014-5793(74)80531-4; FORRESTER IT, 1988, BIOCHEM BIOPH RES CO, V157, P992, DOI 10.1016/S0006-291X(88)80972-0; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; HIGUCHI T, 1958, J BIOCHEM-TOKYO, V45, P575, DOI 10.1093/oxfordjournals.jbchem.a126902; HODE JE, 1962, CARBOHYDRATE CHEM, P380; JOHANSSON T, 1987, ACTA CHEM SCAND B, V41, P762, DOI 10.3891/acta.chem.scand.41b-0762; KENTEN RH, 1950, BIOCHEM J, V46, P67, DOI 10.1042/bj0460067; Kirk T. K., 1973, WOOD DETERIORATION I, V1, P149; KIRK TK, 1971, ANNU REV PHYTOPATHOL, V9, P185, DOI 10.1146/annurev.py.09.090171.001153; KNAN IC, 1993, ARCH BIOCHEM BIOPHYS, V302, P447; KREMER SM, 1992, FEMS MICROBIOL LETT, V92, P187, DOI 10.1111/j.1574-6968.1992.tb05257.x; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; KUAN IC, 1993, P NATL ACAD SCI USA, V90, P1242, DOI 10.1073/pnas.90.4.1242; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; MIKI K, 1987, FEBS LETT, V210, P199, DOI 10.1016/0014-5793(87)81337-6; PAICE MG, 1993, APPL ENVIRON MICROB, V59, P260, DOI 10.1128/AEM.59.1.260-265.1993; PAICE MG, 1989, TAPPI J, V72, P217; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; REID ID, 1990, TAPPI J, V73, P149; ROY BP, 1993, APPL ENVIRON MICROB, V59, P1855, DOI 10.1128/AEM.59.6.1855-1863.1993; ROY BP, 1994, ANAL BIOCHEM, V216, P291, DOI 10.1006/abio.1994.1044; STERJIADES R, 1992, PLANT PHYSIOL, V99, P1162, DOI 10.1104/pp.99.3.1162; STONE AT, 1984, ENVIRON SCI TECHNOL, V18, P617, DOI 10.1021/es00126a010; STROBOTNIK E, 1990, BIOTECHNOLOGY PULP P, P111; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; UMEZAWA T, 1991, ACS SYM SER, V460, P236; UMEZAWA T, 1986, WOOD RES, V73, P8; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; WARING WS, 1943, ARCH BIOCHEM, V1, P303; WESTERMARK U, 1974, ACTA CHEM SCAND B, VB 28, P204, DOI 10.3891/acta.chem.scand.28b-0204; Whistler R. L., 1963, METHODS CARBOHYDRATE, VII, P477; [No title captured]	48	52	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19745	19750						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051055				2022-12-27	WOS:A1994PA12600018
J	HUNT, J; MASSEY, V				HUNT, J; MASSEY, V			STUDIES OF THE REDUCTIVE HALF-REACTION OF MILK XANTHINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE; PURIFICATION; MECHANISM; INHIBITION; ENZYME; FAD	The reductive half-reaction of milk xanthine dehydrogenase (XDH) with NADH and with xanthine has been studied at pH 7.5, 25 degrees C. NADH reduces XDH to the two-electron reduced form at a rate of 18 s(-1), independent of NADH concentration over the range studied. Further reduction by NADH to the four-electron state is inhibited by excess NADH. Subsequent binding of NADH to the four-electron reduced form of the enzyme causes the redistribution of one electron from the flavin to the molybdenum center. The four-electron reduced species reached through reduction by NADH is the same as the species obtained upon reaction of NAD with fully reduced XDH. In contrast, xanthine rapidly reduces XDH to the four-electron level; further reduction is comparatively slow and is inhibited by excess xanthine. Studies using substoichiometric xanthine show that the reaction of XDH with 1 equivalent of xanthine involves rapid substrate binding and rapid reduction of the molybdenum center of the enzyme. Before the release of urate from the molybdenum active site, an electron is transferred at 15 s(-1) from the reduced molybdenum center to one of the iron-sulfur centers of XDH. Urate is then released at a rate of 13 s(-1), followed by a rapid electron redistribution within the protein. The reductive half-reaction of XDH with xanthine is rate-limiting in xanthine/ NAD turnover, which appears to occur between the two- and four-electron reduced enzyme species. The reduction of XDH by substoichiometric amounts of the fluorescent substrate xanthopterin was also studied. This reaction, monitored by changes in both absorbance and fluorescence, was found to involve the formation of two molybdenum complexes (an E(ox).S complex and an E(red).P complex) followed by the release of the product, leucopterin.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRAY RC, 1969, BIOCHEM J, V114, P725, DOI 10.1042/bj1140725; BRAY RC, 1985, BIOCHEM SOC T, V13, P560, DOI 10.1042/bst0130560; BULL C, 1981, J BIOL CHEM, V256, P2673; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1985, J BIOL CHEM, V260, P569; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1993, J BIOL CHEM, V268, P18685; KIM JH, 1993, J BIOL CHEM, V268, P44; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MORPETH FF, 1984, BIOCHEMISTRY-US, V23, P1332, DOI 10.1021/bi00301a047; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1989, J BIOL CHEM, V264, P2518; OLSON JS, 1974, J BIOL CHEM, V249, P4363; OTTOLINA G, 1989, BIOCHIM BIOPHYS ACTA, V998, P173, DOI 10.1016/0167-4838(89)90270-7; PICK FM, 1969, BIOCHEM J, V114, P735, DOI 10.1042/bj1140735; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; VALERINO DM, 1969, BIOCHIM BIOPHYS ACTA, V184, P154, DOI 10.1016/0304-4165(69)90110-X; YOU KS, 1978, TRENDS BIOCHEM SCI, V3, P265, DOI 10.1016/S0968-0004(78)95849-8	31	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18904	18914						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034647				2022-12-27	WOS:A1994NX32700034
J	KIMURA, K; HATTORI, S; KABUYAMA, Y; SHIZAWA, Y; TAKAYANAGI, J; NAKAMURA, S; TOKI, S; MATSUDA, Y; ONODERA, K; FUKUI, Y				KIMURA, K; HATTORI, S; KABUYAMA, Y; SHIZAWA, Y; TAKAYANAGI, J; NAKAMURA, S; TOKI, S; MATSUDA, Y; ONODERA, K; FUKUI, Y			NEURITE OUTGROWTH OF PC12 CELLS IS SUPPRESSED BY WORTMANNIN, A SPECIFIC INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; TRK PROTOONCOGENE PRODUCT; LIGHT CHAIN KINASE; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PHEOCHROMOCYTOMA CELLS; 85-KDA SUBUNIT; SH3 DOMAINS	The effects of wortmannin (WT), an inhibitor of phosphatidylinositol (PI) 3-kinase, on differentiation of PC12 cells were analyzed. WT inhibited PI 3-kinase activity of PC12 cells at a concentration of 10(-7) M in vivo and in vitro. Transient inhibition of PI 3-kinase activity at the time of nerve growth factor stimulation had no effect on activation of the ras protein or neurite formation by the cells. However, continuous inhibition of PI 3-kinase blocked differentiation at the step just before neurite formation. When WT was applied to cells growing neurites, elongation of the neurites was stopped at that step. These results suggest that PI 3-kinase may be involved in neurite elongation.	UNIV TOKYO,DEPT APPL BIOL CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 106,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	University of Tokyo; National Center for Neurology & Psychiatry - Japan; Kyowa Kirin Ltd			Kimura, Koutarou D./T-9645-2019; Fukui, Yasuhisa/E-8806-2010	Kimura, Koutarou D./0000-0002-3359-1578; 				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUKUI Y, 1989, ONCOGENE RES, V4, P283; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MAYER BJ, 1992, TRENDS CELL BIOL, V3, P8; MUROYA K, 1992, ONCOGENE, V7, P277; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1994, J BIOL CHEM, V269, P3563; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PELICCI G, 1992, CELL, V70, P92; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	74	341	344	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18961	18967						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034653				2022-12-27	WOS:A1994NX32700041
J	XIAO, RP; HOHL, C; ALTSCHULD, R; JONES, L; LIVINGSTON, B; ZIMAN, B; TANTINI, B; LAKATTA, EG				XIAO, RP; HOHL, C; ALTSCHULD, R; JONES, L; LIVINGSTON, B; ZIMAN, B; TANTINI, B; LAKATTA, EG			BETA(2)-ADRENERGIC RECEPTOR-STIMULATED INCREASE IN CAMP IN RAT-HEART CELLS IS NOT COUPLED TO CHANGES IN CA2+ DYNAMICS, CONTRACTILITY, OR PHOSPHOLAMBAN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; ADENYLATE-CYCLASE STIMULATION; HUMAN VENTRICULAR MYOCARDIUM; CYCLIC-AMP; PROTEIN-KINASE; SARCOPLASMIC-RETICULUM; BETA-2-ADRENERGIC RECEPTORS; INOTROPIC RESPONSES; KITTEN MYOCARDIUM; RIGHT ATRIUM	Previous studies have Shown that both beta(1)- and beta(2)-adrenergic receptors (AR) are present in rat ventricular myocytes, but stimulation of these receptor subtypes elicits qualitatively different cellular responses (Xiao, R.-P., and Lakatta, E. G. (1993) Circ. Res. 73, 286-300). In the present study, the biochemical mechanism underlying the distinct beta AR subtype actions have been investigated. Although both beta(1)AR and beta(2)AR stimulation increased total cellular cAMP in suspensions of rat ventricular myocytes to a similar extent, the maximum elevation of the membrane bound cAMP by beta(2)AR stimulation was only half of that induced by beta(1)AR stimulation, suggesting that stimulation the beta AR subtypes leads to different compartmentation of cAMP. The effects of beta(1)AR stimulation on Ca2+ transient (indexed by the transient increase in indo-1 fluorescence ration after excitation) and contraction amplitude (measured via photodiode array) and their kinetics closely paralleled the increase in cAMP. In contrast, the increase in both membrane bound and total cAMP content after beta(2)AR stimulation were completely dissociated from the effects of beta(2)AR stimulation to increase the amplitudes of cytosolic Ca2+ transient and contraction. Furthermore, beta(2)AR stimulation did not phosphorylate phospholamban to the same extent as did beta(1)AR stimulation. This finding provides a mechanism for the failure of beta(2)AR stimulation to accelerate the kinetics of the Ca-i(2+) (cytosolic Ca2+) transient and contraction. These results indicate that the effects of beta(2)AR stimulation on Ca-i(2+) transient and contraction are uncoupled from the cAMP production and cAMP-dependent protein phosphorylation and indicate that, in addition to coupling to adenylate cyclase, beta(2)AR stimulation also activates other signal transduction pathway(s) to produce changes in cytosolic Ca2+ and contraction.	NIA, GERONTOL RES CTR, CARDIOVASC SCI LAB, BALTIMORE, MD 21224 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; UNIV BOLOGNA, DEPT BIOCHEM, I-40100 BOLOGNA, ITALY	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Ohio; Ohio State University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Bologna			Yimei, Wang/AAE-4083-2019; Xiao, Rui-Ping/AAE-2629-2019; Lakatta, Edward G/AAL-1447-2020	Lakatta, Edward/0000-0002-4772-0035	NHLBI NIH HHS [HL-36240] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036240] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASS H, 1988, J MOL CELL CARDIOL, V20, P847, DOI 10.1016/S0022-2828(88)80009-9; ALBRIGHTSON CR, 1985, J INVEST DERMATOL, V85, P264, DOI 10.1111/1523-1747.ep12276748; BOREA PA, 1992, J MOL CELL CARDIOL, V24, P753, DOI 10.1016/0022-2828(92)93389-2; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRODDE OE, 1984, J CARDIOVASC PHARM, V6, P1184; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; CORBIN JD, 1977, J BIOL CHEM, V252, P910; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAYES JS, 1980, J BIOL CHEM, V255, P5113; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; IKEZONO K, 1987, N-S ARCH PHARMACOL, V335, P561; KAUMANN AJ, 1987, N-S ARCH PHARMACOL, V335, P403, DOI 10.1007/BF00165555; KAUMANN AJ, 1989, TRENDS PHARMACOL SCI, V10, P316, DOI 10.1016/0165-6147(89)90065-5; KAUMANN AJ, 1974, NATURE, V251, P515, DOI 10.1038/251515a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LEFKOWITZ RJ, 1975, BIOCHEM PHARMACOL, V24, P583, DOI 10.1016/0006-2952(75)90178-1; LEMOINE H, 1989, N-S ARCH PHARMACOL, V339, P113; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P21; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTE FD, 1993, CIRCULATION, V88, P854; MURPHY MP, 1982, CIRC RES, V51, P560, DOI 10.1161/01.RES.51.5.560; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; ODONNELL SR, 1980, LIFE SCI, V27, P671, DOI 10.1016/0024-3205(80)90008-9; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; REITER M, 1988, PHARMACOL REV, V40, P189; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SILVER PJ, 1989, AM J CARDIOL, V63, pA2, DOI 10.1016/0002-9149(89)90384-6; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WEISHAAR RE, 1987, J MOL CELL CARDIOL, V19, P1025, DOI 10.1016/S0022-2828(87)80574-6; WEISHAAR RE, 1987, CIRC RES, V61, P539, DOI 10.1161/01.RES.61.4.539; WIMSATT DK, 1990, J BIOL CHEM, V265, P14849; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; YANAGISAWA T, 1989, J CARDIOVASC PHARM, V13, P64	45	159	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19151	19156						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034672				2022-12-27	WOS:A1994NX32700068
J	ZSIGMOND, E; SCHEFFLER, E; FORTE, TM; POTENZ, R; WU, W; CHAN, L				ZSIGMOND, E; SCHEFFLER, E; FORTE, TM; POTENZ, R; WU, W; CHAN, L			TRANSGENIC MICE EXPRESSING HUMAN LIPOPROTEIN-LIPASE DRIVEN BY THE MOUSE METALLOTHIONEIN PROMOTER - A PHENOTYPE ASSOCIATED WITH INCREASED PERINATAL-MORTALITY AND REDUCED PLASMA VERY-LOW-DENSITY LIPOPROTEIN OF NORMAL SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FAMILIAL COMBINED HYPERLIPIDEMIA; RECEPTOR-RELATED PROTEIN; HEPATIC LIPASE; EVOLUTION; BINDING	We have produced transgenic mice expressing human lipoprotein lipase (LPL) driven by the mouse metallothionein I promoter. We found that integration of the LPL gene construct was associated with a high perinatal mortality. Animals that survived the first 2 weeks of life grew normally afterwards. Compared with controls, transgenic animals had higher post-heparin plasma LPL and tissue LPL activities. Immunoreactive human LPL was detected in their post-heparin plasma but not in controls. Transgenic animals had significantly lower plasma very low density lipoprotein (VLDL) while on a regular laboratory chow. By electron microscopic analysis and nondenaturing polyacrylamide gradient gel electrophoresis, the size and morphology of the plasma VLDL were very similar in transgenic and control animals, which suggests that VLDL particles acted on by the increased tissue LPL in the transgenic animals were mostly taken up by the cell without being released bads into circulation. The hypertriglyceridemia and elevated VLDL in response to sucrose feeding were completely abolished in transgenic animals. They also had lower VLDL lipids compared with control animals when they were fed a high-fat, high cholesterol diet. Feeding the mother of transgenic mice a high-fat diet during pregnancy completely reversed the high perinatal mortality associated with the integrated transgene, which suggests that the deleterious effect of LPL overexpression may be related to the depletion of some essential lipid nutrient.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720	Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	ZSIGMOND, E (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL-18574, HL-16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016512, P01HL018574, R01HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFINSEN CB, 1952, SCIENCE, V115, P583, DOI 10.1126/science.115.2996.583; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN RK, 1953, J BIOL CHEM, V204, P423; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; COCKETT MI, 1991, NUCLEIC ACIDS RES, V19, P319, DOI 10.1093/nar/19.2.319; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DATTA S, 1988, J BIOL CHEM, V263, P1107; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FORTE TM, 1979, P NATL ACAD SCI USA, V76, P5934, DOI 10.1073/pnas.76.11.5934; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HIDE WA, 1992, J LIPID RES, V33, P167; Iverius P H, 1986, Methods Enzymol, V129, P691; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KOMPIANG IP, 1976, J LIPID RES, V17, P498; LEBOEUF RC, 1993, J NUTR, V123, P547, DOI 10.1093/jn/123.3.547; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LIU MS, 1994, J BIOL CHEM, V269, P11417; Marzal-Casacuberta A., 1994, Modern Pathology, V7, p30A; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; REISER S, 1987, METABOLIC EFFECTS DI, P83; ROBINSON D. S., 1959, QUART JOUR EXPTL PHYSIOL, V44, P80; ROBINSON DS, 1983, Q J EXP PHYSL, V38, P233; ROBINSON DS, 1987, LIPOPROTEIN LIPASE, P1; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SCHOTZ MC, 1977, BIOCHIM BIOPHYS ACTA, V489, P214, DOI 10.1016/0005-2760(77)90140-0; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; SHORE B, 1953, P SOC EXP BIOL MED, V83, P216; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P201; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; ZSIGMOND E, 1992, CLIN RES, V40, pA291	40	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18757	18766						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034629				2022-12-27	WOS:A1994NX32700014
J	SCHEELE, JS; PILZ, RB; QUILLIAM, LA; BOSS, GR				SCHEELE, JS; PILZ, RB; QUILLIAM, LA; BOSS, GR			IDENTIFICATION OF A RAS-RELATED PROTEIN IN MURINE ERYTHROLEUKEMIA-CELLS THAT IS A CAMP-DEPENDENT PROTEIN-KINASE SUBSTRATE AND IS PHOSPHORYLATED DURING CHEMICALLY-INDUCED DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; REGULATORY SUBUNIT; HUMAN-PLATELETS; RETINOIC ACID; EXPRESSION; PROLIFERATION; INDUCTION; INCREASE; PRODUCT; INVITRO	Murine erythroleukemia (MEL) cells deficient in cAMP-dependent protein kinase (A-kinase) activity are impaired in chemically induced differentiation (Pilz, R. B., Eigenthaler, M., and Boss, G. R. (1992) J. Biol. Chem. 267, 16161-16167). We identified by two-dimensional polyacrylamide gel electrophoresis two low molecular weight proteins (referred to as pp 21-1 and 21-2) that were phosphorylated when parental MEL cells, but not A-kinase-deficient MEL cells, were treated with the membrane-permeable cAMP analog 8-bromo-cAMP. We showed that pp 21-1 and 21-2: (a) were direct A-kinase substrates; (b) bound GTP; and (c) belonged to the ras superfamily of proteins. The only ras-related proteins that are clearly A kinase substrates both in vitro and in vivo are Rap 1A and 1B while H- and K-Ras can be A-kinase substrates in vitro; we showed by immunological methods, phosphopeptide mapping, and migration on two-dimensional gels that pp 21-1 and 21-2 were not identical to one of these four proteins. We found a 3-fold increase of (PO4)-P-32 incorporation into pp 21-2 in hexamethylene bisacetamide-treated parental MEL cells which was not secondary to an increase in pp 21-2 protein but appeared secondary to increased phosphorylation of pp 21-2 by A-kinase. Thus, pp 21-1 and 21-2 are either new ras-related proteins or are previously identified ras-related proteins not known to be A-kinase substrates, and increased phosphorylation of pp 21-2 occurs during differentiation of MEL cells.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA 01548] Funding Source: Medline; NHLBI NIH HHS [HL 17682] Funding Source: Medline; NIGMS NIH HHS [GM 49360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DOWER NA, 1992, MAMM GENOME, V3, P162, DOI 10.1007/BF00352461; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FIRST EA, 1988, J BIOL CHEM, V263, P5170; FISCHER TH, 1991, FEBS LETT, V283, P173, DOI 10.1016/0014-5793(91)80581-M; GAZITT Y, 1978, CANCER RES, V38, P3779; GROSS RE, 1990, J BIOL CHEM, V265, P8152; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HU JS, 1988, J BIOL CHEM, V263, P19670; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSSON IL, 1982, CANCER RES, V42, P3924; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PLET A, 1982, J BIOL CHEM, V257, P889; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REPKO EM, 1989, J BIOL CHEM, V264, P9945; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAIKUMAR P, 1988, ONCOGENE RES, V8, P213; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; THOMAS J, 1991, J BIOL CHEM, V266, P10906; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P758, DOI 10.1073/pnas.87.2.758	42	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18599	18606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034608				2022-12-27	WOS:A1994NW79800059
J	ZHENG, RL; KEMP, RG				ZHENG, RL; KEMP, RG			IDENTIFICATION OF INTERACTIONS THAT STABILIZE THE TRANSITION-STATE IN ESCHERICHIA-COLI PHOSPHOFRUCTO-1-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; PHOSPHOFRUCTOKINASE; MECHANISM; RESIDUES	The activity of Escherichia coli phosphofructo-1-kinase depends upon the dissociation of a group with a pK of approximately 6.6. Mutation of the 2 active site residues most likely to be titrated in this range, Asp-127 and Asp-129, lowered activity but produced little change in the pH dependence, suggesting that these residues while important to activity were not responsible for the pH dependence of the enzyme. Alternatively, the pH dependence was thought to correspond to the negative charge on the phosphoryl group being transferred in the reaction. Mutation of Arg-72 to histidine, while lowering the activity substantially, shifted the pH optimum to approximately 6.2 with a secondary plateau on the alkaline limb that was eliminated in the double mutant R72H/ R171H. Mutation of Arg-171 alone produced only a small decrease in maximal activity and little change in pH dependence from the wild type enzyme. The data support an associative mechanism with a transition state stabilized by the interaction between the negative charge on the phosphoryl. group being transferred and the arginyl residue at position 72 on the enzyme.			ZHENG, RL (corresponding author), CHICAGO MED SCH,DEPT BIOL CHEM,N CHICAGO,IL 60064, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK DK19912] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANAS T, 1988, BIOCHIM BIOPHYS ACTA, V957, P178, DOI 10.1016/0167-4838(88)90270-1; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVILLEBONNE D, 1991, FEBS LETT, V290, P173, DOI 10.1016/0014-5793(91)81253-5; FREY PA, 1992, ENZYMES, V20, P141; GREEN PC, 1993, J BIOL CHEM, V268, P5085; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOTLARZ D, 1982, METHOD ENZYMOL, V90, P60; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE R, 1992, EUR J BIOCHEM, V207, P1109, DOI 10.1111/j.1432-1033.1992.tb17148.x; LEBRAS G, 1985, J BIOL CHEM, V260, P3450; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; ZHENG RL, 1992, J BIOL CHEM, V267, P23640	17	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18475	18479						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034595				2022-12-27	WOS:A1994NW79800040
J	AUSTIN, S; LAMBERT, J				AUSTIN, S; LAMBERT, J			PURIFICATION AND IN-VITRO ACTIVITY OF A TRUNCATED FORM OF ANFA - TRANSCRIPTIONAL ACTIVATOR PROTEIN OF ALTERNATIVE NITROGENASE FROM AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; REGULATORY PROTEINS; NUCLEOTIDE-SEQUENCE; ATPASE ACTIVITY; FIXATION GENES; NIFA; NTRC; EXPRESSION; INVITRO; PROMOTERS	The ANFA protein is the transcriptional activator of the sigma(64)-dependent anfHDGK operon, which codes for the structural genes of the third nitrogenase system in Azotobacter vinelandii. We have purified, in soluble active form, an N-terminally truncated form of the protein, Delta ANFA, which activates transcription from the anfH promoter and other sigma(54)-dependent promoters in a purified transcription system. Sequences upstream of the anfH promoter and the presence of the integration host factor protein stimulate transcription, and we have shown that Delta ANFA binds to sites situated between 200 and 300 base pairs upstream of the anfH promoter. In common with other sigma(54)-dependent activators, ANFA has a highly conserved ATP binding motif in its central domain, and we have demonstrated that ATP or GTP is required for productive complex formation and that the purified truncated protein has a constitutive ATPase activity, which is presumably required to drive open complex formation.			AUSTIN, S (corresponding author), UNIV SUSSEX, AFRC, INST PLANT SCI RES, NITROGEN FIXAT LAB, BRIGHTON BN1 9RQ, E SUSSEX, ENGLAND.							AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; AUSTIN S, 1987, MOL MICROBIOL, V1, P92, DOI 10.1111/j.1365-2958.1987.tb00532.x; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; DIXON R, 1991, MOL MICROBIOL, V5, P1657, DOI 10.1111/j.1365-2958.1991.tb01913.x; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; JOERGER RD, 1989, J BACTERIOL, V171, P3258, DOI 10.1128/jb.171.6.3258-3267.1989; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; Merrick M.J., 1992, BIOL NITROGEN FIXATI, P835; MERRICK MJ, 1993, CURR PLANT SCI BIOT, V17, P43; MINCHIN SD, 1989, EMBO J, V8, P3491, DOI 10.1002/j.1460-2075.1989.tb08514.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; TULI R, 1988, J GEN MICROBIOL, V134, P425; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WHITEHALL S, 1992, J MOL BIOL, V225, P591, DOI 10.1016/0022-2836(92)90388-Z	25	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18141	18148						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027076				2022-12-27	WOS:A1994NV42200059
J	CAMPOS, M; BEAUGE, L				CAMPOS, M; BEAUGE, L			NA+-ATPASE ACTIVITY OF NA+,K+-ATPASE - REACTIVITY OF THE E(2) FORM DURING NA+-ATPASE TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; INORGANIC-PHOSPHATE; ENZYME CONFORMATIONS; ACETYL PHOSPHATE; SODIUM-PUMP; PHOSPHORYLATION; (NA++K+)-ATPASE; PHOSPHOENZYME; STATE; INHIBITION	Based on work of Post et al. (Post, R. L. Toda, G., and Rogers, E N. (1975) J. Biol. Chem. 250, 691-701), we studied the E(2) form reactivity of Na+,K+-ATPase (EC 3.6.1.37) during Na+-ATPase turnover by following ATP hydrolysis with and without P-i and enzyme phosphorylation from P-i at 20 degrees C. For theoretical calculations we employed the Albers-Post scheme assuming that, even with no K+, E(2) exhibits the ATP regulatory site. Using available rate constants the model predicts: (i) without P-i, Na+-ATPase displays a single high affinity ATP site but becomes double Michaelian (with high and low ATP affinity) when P-i is present. (ii) Phosphorylation from P-i can be detected during Na+-ATPase (t(1/2) about 400 ms); the K-m(Pi) is substantially higher that the K-d(Pi). (iii) P-i incorporation is reduced by ATP acting with low affinity; this does not require an increase in the E(2)-E(1) transition rate. (iv) The K-m(ATP) of the regulatory site is augmented when [P-i] increases. The experimental observations, using partially purified pig kidney enzyme, agreed with the predictions. In addition they showed that: (i) extracellular Na+ can prevent P-i incorporation; this effect is additive with that of ATP but with independent K-i values. (ii) Mg2+ stimulates P-i incorporation with low affinity (K-m of 1.5 mM). (iii) beta,gamma-Methyleneadenosine 5'-triphosphate and palmitoyl-CoA antagonize P-i inhibition of Na+-ATPase. These results agree with a model where the Na+,K+-ATPase and Na+-ATPase cycles share most of their intermediate steps and enzyme conformations.			CAMPOS, M (corresponding author), INST INVEST MED M&M FERREYRA, DIV BIOFIS, CASILLA CORREO 389, RA-5000 CORDOBA, ARGENTINA.							ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; BEAUGE L, 1986, J PHYSIOL-LONDON, V375, P1; BEAUGE L, 1984, BIOCHIM BIOPHYS ACTA, V772, P411, DOI 10.1016/0005-2736(84)90159-7; BEAUGE L, 1983, BIOCHIM BIOPHYS ACTA, V729, P137, DOI 10.1016/0005-2736(83)90464-9; BEAUGE L, 1990, REGULATION POTASSIUM, P29; BEAUGE L, 1993, 11TH INT BIOPH C BUD, P30; BEAUGE LA, 1979, J PHYSIOL-LONDON, V289, P17, DOI 10.1113/jphysiol.1979.sp012722; BERBERIAN G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P217, DOI 10.1016/0005-2736(91)90374-H; BERBERIAN G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P85, DOI 10.1016/0005-2736(92)90060-Y; CAMPOS M, 1988, BIOCHIM BIOPHYS ACTA, V940, P43, DOI 10.1016/0005-2736(88)90006-5; CAMPOS M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P51, DOI 10.1016/0005-2736(92)90161-E; CORNELIUS F, 1985, BIOCHIM BIOPHYS ACTA, V818, P211, DOI 10.1016/0005-2736(85)90572-3; DEMEIS L, 1972, BIOCHEMISTRY-US, V11, P2460, DOI 10.1021/bi00763a012; FORBUSH B, 1988, SODIUM PUMP A, P229; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2186; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P189, DOI 10.1113/jphysiol.1967.sp008296; GARRAHAN PJ, 1972, J PHYSIOL-LONDON, V233, P595; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; HEGYVARY C, 1981, J BIOL CHEM, V256, P6296; HOBBS A S, 1988, P307; HOFFMAN JF, 1985, SODIUM PUMP, P551; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAPLAN JH, 1985, J GEN PHYSIOL, V85, P123, DOI 10.1085/jgp.85.1.123; KARLISH SJD, 1981, J PHYSIOL-LONDON, V312, P505, DOI 10.1113/jphysiol.1981.sp013641; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P295, DOI 10.1113/jphysiol.1982.sp014265; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KARLISH SJD, 1985, SODIUM PUMP, P485; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P448, DOI 10.1016/0005-2744(75)90269-7; MARDH S, 1977, J BIOL CHEM, V252, P633; NORBY JG, 1988, NA PLUS K PLUS PUM A, P249; PEDEMONTE CH, 1986, ARCH BIOCHEM BIOPHYS, V244, P596, DOI 10.1016/0003-9861(86)90628-4; PEDEMONTE CH, 1983, BIOCHIM BIOPHYS ACTA, V748, P245, DOI 10.1016/0167-4838(83)90301-1; PLESNER L, 1988, BIOCHIM BIOPHYS ACTA, V937, P63, DOI 10.1016/0005-2736(88)90227-1; POST RL, 1975, J BIOL CHEM, V250, P691; REPKE K, 1991, BIOL REV, V67, P31; ROBINSON JD, 1969, BIOCHEMISTRY-US, V6, P3250; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0	45	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18028	18036						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027062				2022-12-27	WOS:A1994NV42200044
J	MA, L; GAVINI, N; LIU, HI; HEDMAN, B; HODGSON, KO; BURGESS, BK				MA, L; GAVINI, N; LIU, HI; HEDMAN, B; HODGSON, KO; BURGESS, BK			LARGE-SCALE ISOLATION AND CHARACTERIZATION OF THE MOLYBDENUM-IRON CLUSTER FROM NITROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; X-RAY ABSORPTION; AZOTOBACTER-VINELANDII NITROGENASE; CLOSTRIDIUM-PASTEURIANUM; REDUCTION PROPERTIES; FEMO-COFACTOR; MOFE PROTEIN; SPECTROSCOPY; HOMOCITRATE; RESOLUTION	Here we report the large scale isolation and characterization of a species, designated MoFe cluster, that exhibits an S = 3/2 EPR signal, and the comparison of this entity to isolated FeMo cofactor in N-methylformamide and to the active site of the enzyme nitrogenase. MoFe cluster is isolated from purified nitrogenase by extraction into acidic methyl ethyl ketone and it is stable in that solvent in the absence of thiols. As initially isolated, MoFe cluster solutions exhibit an S = 1/2 EPR signal that arises from an oxidized species that can be reduced by dithionite or thiols to an EPR silent state and then to a state that exhibits an S = 3/2 EPR signal. The S = 3/2 signal is as sharp as the signal exhibited by the protein and much sharper than the signal exhibited by isolated FeMo cofactor. Circular dichroism experiments indicate that unlike the last two species, MoFe cluster does not contain the endogenous ligand R-homocitrate and thus, the sharpness of the S = 3/2 signal is an intrinsic property of the metal center and does not depend upon specific interactions with this organic ligand or with the protein. Metal analyses indicate that the metal core responsible for the S = 3/2 signal contains 6 Fe atoms per molybdenum. X-ray absorption spectroscopy experiments show that although the molybdenum atom in MoFe cluster retains its pseudo-octahedral geometry, its first coordination shell has one less iron atom than that of FeMo cofactor and there has been a significant change in the long range order of the cluster.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA; STANFORD UNIV, STANFORD SYNCHROTRON RADIAT LAB, STANFORD, CA 94309 USA	University of California System; University of California Irvine; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory					NIGMS NIH HHS [G01-GM43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BURGESS BK, 1993, ACS SYM SER, V535, P144; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURGESS BK, 1980, J BIOL CHEM, V255, P353; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; CONRADSON SD, 1985, J AM CHEM SOC, V107, P7935, DOI 10.1021/ja00312a022; Cramer S. P., 1979, PROG INORG CHEM, V25, P1, DOI [DOI 10.1002/9780470166260.CH1, 10.1002/9780470166260.ch1]; CRAMER SP, 1978, J AM CHEM SOC, V100, P2748, DOI 10.1021/ja00477a030; CRAMER SP, 1978, J AM CHEM SOC, V100, P3398, DOI 10.1021/ja00479a023; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LIU HBI, 1994, J AM CHEM SOC, V116, P2418, DOI 10.1021/ja00085a022; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; NEWTON WE, 1989, J BIOL CHEM, V264, P1924; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; RUZICKA FJ, 1974, BIOCHEM BIOPH RES CO, V58, P556, DOI 10.1016/S0006-291X(74)80456-0; SCHULTZ FA, 1985, J AM CHEM SOC, V107, P5364, DOI 10.1021/ja00305a007; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1981, P NATL ACAD SCI-BIOL, V78, P3438, DOI 10.1073/pnas.78.6.3438; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; SMITH BE, 1980, MOLYBDENUM CHEM BIOL, P179; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; YANG SS, 1982, J BIOL CHEM, V257, P8042; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685	35	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18007	18015						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027059				2022-12-27	WOS:A1994NV42200041
J	SURRATT, CK; JOHNSON, PS; MORIWAKI, A; SEIDLECK, BK; BLASCHAK, CJ; WANG, JB; UHL, GR				SURRATT, CK; JOHNSON, PS; MORIWAKI, A; SEIDLECK, BK; BLASCHAK, CJ; WANG, JB; UHL, GR			-MU OPIATE RECEPTOR - CHARGED TRANSMEMBRANE DOMAIN AMINO-ACIDS ARE CRITICAL FOR AGONIST RECOGNITION AND INTRINSIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; DELTA-OPIOID RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; SCHIFF-BASE COUNTERION; LIGAND-BINDING; RAT-BRAIN; FUNCTIONAL EXPRESSION; BOVINE RHODOPSIN; ASPARTIC-ACID	The mu opiate receptor is a principal brain site for activities of morphine, other opiate drugs, and opioid peptides in modulating pain and altering mood. Recent cloning of cDNAs encoding rat and human mu receptors reveals charged amino acid residues within putative transmembrane domains (TMs) II, III, and VI, a substantial N-terminal extracellular domain, and a C-terminal intracellular domain. Deletion of 64 N-terminal amino acids produced little effect on receptor function (Wang, J. B., Imai, Y., Eppler, C. M., Gregor, P., Spivak, C. E., and Uhl, G. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10230-10234). Further deletion of 33 C-terminal amino acids yielded a receptor at which morphine, but not the substituted enkephalin DAMGO ([D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin), inhibited adenylate cyclase. Alanine substitution for each charged TM residue in the N-terminally deleted receptor reduced affinities for morphine, DAMGO, and the opiate antagonist naloxone. Replacement of TM II Asp(114) with asparagine or glutamic acid increased p receptor affinity for naloxone. TM II and TM III glutamic acid substitutions for Asp(114) and Asp(147) reduced agonist binding affinities but allowed full inhibition of adenylate cyclase at high agonist concentrations. TM VI histidine substitution with alanine yielded a receptor that produced almost twice the cyclase inhibition displayed by the wild type receptor in parallel transient expression assays. These findings underscore the importance of charged residues in TM II, III, and VI for different receptor functions and the modest involvement of extensive portions of N and C-terminaI receptor domains in these processes.	NIDA,MOLEC NEUROBIOL BRANCH,BALTIMORE,MD 21224; NIDA,INTRAMURAL RES PROGRAM,OFF DIRECTOR,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University								BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUME AJ, 1978, P NATL ACAD SCI USA, V75, P1713, DOI 10.1073/pnas.75.4.1713; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CRAIN SM, 1987, BRAIN RES, V400, P185, DOI 10.1016/0006-8993(87)90670-6; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; EPPLER CM, 1993, J BIOL CHEM, V268, P26447; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1993, NATURE, V362, P350; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JI IH, 1991, J BIOL CHEM, V266, P14953; JOHNSON PS, 1994, NEUROREPORT, V5, P507, DOI 10.1097/00001756-199401120-00035; KENNEDY C, 1991, MOL PHARMACOL, V40, P1000; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1993, J BIOL CHEM, V268, P23055; KONG HY, 1993, MOL PHARMACOL, V44, P380; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PERT CB, 1974, MOL PHARMACOL, V10, P868; PORRECA F, 1993, HDB EXPT PHARM, V104, P21; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SEWARD E, 1991, P ROY SOC B-BIOL SCI, V244, P129, DOI 10.1098/rspb.1991.0061; SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; WANG CD, 1991, MOL PHARMACOL, V40, P168; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WOODWARD R, 1994, J NEUROCHEM, V62, P1664; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; ZHU GC, 1992, J CELL BIOCHEM, V50, P159; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	53	243	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20548	20553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051154				2022-12-27	WOS:A1994PB31700054
J	HUSKENHINDI, P; TSUCHIDA, K; PARK, M; CORRIGAN, AZ; VAUGHAN, JM; VALE, WW; FISCHER, WH				HUSKENHINDI, P; TSUCHIDA, K; PARK, M; CORRIGAN, AZ; VAUGHAN, JM; VALE, WW; FISCHER, WH			MONOMERIC ACTIVIN-A RETAINS HIGH RECEPTOR-BINDING AFFINITY BUT EXHIBITS LOW BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; FSH-RELEASING PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-2; CRYSTAL-STRUCTURE; GROWTH; INHIBIN; CLONING; DIFFERENTIATION; PURIFICATION; SUPERFAMILY	Activins are multipotent hormones/growth factors that belong to the transforming growth factor-beta (TGF beta) superfamily. Like TGF-beta s, activins have 9 conserved cysteine residues and are disulfide-bonded dimers. Based on the three-dimensional structure of TGF-beta(2), we de- duced Cys(80) in activin A to form the intermolecular disulfide bond. To obtain a monomeric form of activin, Cys(80) was exchanged for a serine residue by polymerase chain reaction mutagenesis. The mutant protein was expressed in a baculovirus/insect cell expression system. The molecular mass of this mutant activin was deter mined to be 13 kDa (consistent with a single chain form of the protein) by SDS-polyacrylamide gel electrophoresis and by laser desorption mass spectroscopy. When this mutant monomeric activin was incubated with cells that expressed either the activin type IIB receptor or both the type I and type IIB receptors, its affinity was found to be 20% of that of native activin on a mass basis. Binding affinity determined using the mouse pituitary cell line AtT 20 was 10% of that of native activin A. Biological potency, however, as determined by the mutant protein's ability to release FSH from anterior pituitary cells in primary culture and by its ability to suppress basal ACTH secretion form AtT 20 cells, was only 1% of that of the native protein. This discrepancy of an order of magnitude between binding and biological activity is consistent with a model in which dimerization of the hormone is not necessary for high affinity binding to its receptor(s) while being essential for efficient signal transduction.	SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Salk Institute			Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BILEZIKJIAN LM, 1991, MOL ENDOCRINOL, V5, P1389, DOI 10.1210/mend-5-10-1389; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; HUSKENHINDI P, 1993, 75TH ANN M END SOC L, P488; HUYLEBROECK D, 1990, MOL ENDOCRINOL, V4, P1153, DOI 10.1210/mend-4-8-1153; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; ROBERTSON DM, 1992, ENDOCRINOLOGY, V130, P1680, DOI 10.1210/en.130.3.1680; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHWALL RH, 1988, MOL ENDOCRINOL, V2, P1237, DOI 10.1210/mend-2-12-1237; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUMMERS MD, 1988, MANUAL METHODS BACUL; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	39	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19380	19384						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034704				2022-12-27	WOS:A1994NY33200030
J	WELLER, J; HILL, WE				WELLER, J; HILL, WE			PROBING THE INTERACTIONS OF POLY(U) AND TRNA(PHE) WITH NUCLEOTIDE-1530-1542 AND NUCLEOTIDE-1390-1417 OF 16-S RIBOSOMAL-RNA OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; MESSENGER-RNA; BACTERIAL-RIBOSOMES; INITIATION COMPLEX; RIBONUCLEIC-ACIDS; INTERACTION SITE; DECODING SITE; 30S SUBUNIT; HYBRIDIZATION; OLIGODEOXYRIBONUCLEOTIDES	The decoding region of 16 S rRNA (nucleotides 1396-1403) is not available to complementary DNA oligomer binding in 70 S ribosomes, despite high levels of binding of these oligomers to active 30 S ribosomal subunits. While addition of poly(U) or tRNA(Phe) alone did not affect the binding of either cDNA to 30 or 70 S ribosomes, poly(U)-directed tRNA(Phe) decreased the binding of cDNA (1396-1403) oligomers by 80% to the active 30 S ribosomal subunits. But the poly(U)-directed tRNA(Phe) cannot displace a prebound cDNA in this region, nor can the cDNA displace a prebound poly(U)-directed tRNA(Phe). A cDNA to the anti-Shine-Dalgarno region (nucleotides 1534-1541) binds equally well to 30 and 70 S ribosomal particles, but the simultaneous addition of poly(U)/tRNA(Phe) and cDNA results in a 50% decrease in binding of the cDNA. In this case the poly(U) directed tRNA(Phe) does displace the prebound cDNA, but the cDNA cannot displace a prebound poly(U)-directed tRNA(Phe). Neither cDNA oligomer inhibits the reassociation of the ribosomal subunits into 70 S particles.	UNIV MONTANA,DIV BIOL SCI,MISSOULA,MT 59812	University of Montana System; University of Montana			Weller, Joel Ira/H-3862-2019	Weller, Joel Ira/0000-0002-0668-1594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKENDORF C, 1980, EUR J BIOCHEM, V110, P599, DOI 10.1111/j.1432-1033.1980.tb04904.x; BACKENDORF C, 1981, NUCLEIC ACIDS RES, V9, P1425, DOI 10.1093/nar/9.6.1425; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHANGCHIEN LM, 1986, NUCLEIC ACIDS RES, V14, P1957, DOI 10.1093/nar/14.5.1957; DENMAN R, 1989, BIOCHEMISTRY-US, V28, P1002, DOI 10.1021/bi00429a013; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUALERZI CO, 1988, GENETICS TRANSLATION, P317; HILL WE, 1987, BIOCHIMIE, V69, P1071, DOI 10.1016/0300-9084(87)90007-1; HILL WE, 1969, J MOL BIOL, V44, P263, DOI 10.1016/0022-2836(69)90174-0; HILL WE, 1990, RIBOSOME, P253; HUI AS, 1988, EMBO J, V7, P4383, DOI 10.1002/j.1460-2075.1988.tb03337.x; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MARCONI RT, 1989, BIOCHEMISTRY-US, V28, P893, DOI 10.1021/bi00428a073; MARCONI RT, 1988, NUCLEIC ACIDS RES, V16, P1603, DOI 10.1093/nar/16.4.1603; NOLL M, 1973, J MOL BIOL, V75, P281, DOI 10.1016/0022-2836(73)90021-1; NOLLER HF, 1986, STRUCTURE FUNCTION G, P143; OAKES MI, 1986, P NATL ACAD SCI USA, V83, P275, DOI 10.1073/pnas.83.2.275; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STEITZ JA, 1980, RIBOSOMES STRUCTURE, P479; TAM MF, 1981, BIOCHEM INT, V3, P655; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WAHL GM, 1987, METHOD ENZYMOL, V152, P399; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WELLER J, 1991, BIOCHIMIE, V73, P971, DOI 10.1016/0300-9084(91)90138-Q; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZWIEB C, 1986, MOL GEN GENET, V203, P256, DOI 10.1007/BF00333963; ZWIEB C, 1986, MOL GEN GENET, V203, P264	35	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19369	19374						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034702				2022-12-27	WOS:A1994NY33200028
J	ZHENG, Y; BAGRODIA, S; CERIONE, RA				ZHENG, Y; BAGRODIA, S; CERIONE, RA			ACTIVATION OF PHOSPHOINOSITIDE 3-KINASE ACTIVITY BY CDC42HS BINDING TO P85	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP-DISSOCIATION INHIBITOR; CELL POLARITY; PROTEIN-RHO; RAS; GTP; KINASE; GENE; BCR; IDENTIFICATION; ASSOCIATION	The Ras-like GTPase Cdc42 is essential for cell polarity and bud site assembly in Saccharomyces cerevisiae by regulating cell cycle dependent reorganization of cortical cytoskeletal elements. However, its role in mammalian cells is unknown. To identify potential effecters of Cdc42Hs, we incubated lysates from NIH 3T3 fibroblasts or PC12 cells with immobilized glutathione S-transferase (GST)-Cdc42Hs fusion proteins bound to different guanine nucleotides and observed a specific association between the 85-kDa subunit (p85) of phosphatidylinositol 3-kinase (PI 3-kinase) and GTP gamma S (guanosine 5'-3-O-(thio)triphosphate)-bound GST-Cdc42Hs. Recombinant p85 formed a complex with GTP gamma S-bound CST-Cdc42Hs and with a GTPase defective GTP-bound GST-Cdc42Hs-Q61L mutant, but not with a GTP gamma S-bound, effector domain GST-Cdc42HsT35A mutant. Both the Rho-GAP homology domain of p85 and the Cdc42Hs-GAP competitively inhibited the binding of recombinant p85 to Cdc42Hs. In addition, PI 3-kinase activity immunoprecipitated from cell lysates with anti-p85 antibody was stimulated 2-4-fold by GST-Cdc42-GTP gamma S. Similar interactions were observed between p85 and GST-Rac1- GTP gamma S but not between p85 and GST-RhoA-GTP gamma S. These findings suggest that PI 3-kinase, through the Rho GAP homology domain of p85, can couple to the effector domain of Cdc42Hs and that p85 may be a target for the GTP bound forms of Cdc42Hs and Rac1.			ZHENG, Y (corresponding author), CORNELL UNIV,DEPT PHARMACOL,SCHURMAN HALL,ITHACA,NY 14853, USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, J BIOL CHEM, V266, P20840; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; UEDA T, 1990, J BIOL CHEM, V265, P9373; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	33	361	370	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18727	18730						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034624				2022-12-27	WOS:A1994NX32700007
J	CHEN, YP; OTOOLE, TE; SHIPLEY, T; FORSYTH, J; LAFLAMME, SE; YAMADA, KM; SHATTIL, SJ; GINSBERG, MH				CHEN, YP; OTOOLE, TE; SHIPLEY, T; FORSYTH, J; LAFLAMME, SE; YAMADA, KM; SHATTIL, SJ; GINSBERG, MH			INSIDE-OUT SIGNAL-TRANSDUCTION INHIBITED BY ISOLATED INTEGRIN CYTOPLASMIC DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPROTEIN-IIB-IIIA; PLATELET GPIIB-IIIA; AFFINITY MODULATION; LIGAND-BINDING; CELL-ADHESION; RECEPTOR; FIBRONECTIN; ALPHA-IIB-BETA-3; SPECIFICITY; FIBRINOGEN	The affinities of integrin alpha beta heterodimers for extracellular ligands are important regulators of cell adhesion. Intracellular signals provoke changes in the integrin extracellular domain resulting in ''activation,'' as manifested by an increase in affinity. Interactions of integrin cytoplasmic domains with intracellular elements may mediate this ''inside-out signaling.'' Here we report that overexpression of chimeras of the cytoplasmic domain of integrin beta(3) or beta(1) subunits, joined to the extracellular and transmembrane domains of the Tac subunit of the interleukin-2 receptor, reduced integrin affinity. In contrast, chimeras containing the cytoplasmic domain of alpha(5) or alpha(IIb) or of beta(3) bearing a mutation that disrupts inside out signaling lacked inhibitory activity. These data suggest that limiting quantities of intracellular factors bind to integrin beta(3) and beta(1) cytoplasmic domains to modulate ligand binding affinity. Structural mimics of these domains may provide a novel means to alter cell adhesion.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Pennsylvania			O'Toole, Timothy/I-4172-2013	Yamada, Kenneth/0000-0003-1512-6805	NHLBI NIH HHS [HL-48728, HL-40387, HL-28235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL028235, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GINSBERG MH, 1980, BLOOD, V55, P661; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085	31	174	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18307	18310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034576				2022-12-27	WOS:A1994NW79800013
J	MURTHY, MSR; PANDE, SV				MURTHY, MSR; PANDE, SV			MALONYL-COA-SENSITIVE AND MALONYL-COA-INSENSITIVE CARNITINE PALMITOYLTRANSFERASE ACTIVITIES OF MICROSOMES ARE DUE TO DIFFERENT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL OUTER-MEMBRANE; RAT-LIVER MITOCHONDRIA; ENDOPLASMIC-RETICULUM; INNER MEMBRANE; ENZYME-SYSTEM; ACYLTRANSFERASE; TRANSLOCATION; PEROXISOMES; BINDING; OCTANOYLTRANSFERASE	A carnitine palmitoyltransferase (CPT), extracted from microsomes with octyl glucoside, was purified and characterized as a 54-kDa protein and was found to show no malonyl-CoA inhibition (Murthy, M. S. R., and Bieber, L. L. (1992) Protein Exp. Purif: 3, 75-79). We show here that the malonyl-CoA-sensitive CPT of microsomes associates with their membrane, whereas the above 54-kDa CPT is a soluble luminal protein. Western blot probing with antibody to the 54-kDa CPT was found to show a positive response with the soluble microsomal fraction but not with their membranes. 2-Tetradecylglycidyl-CoA inhibited the membrane-associated CPT activity irreversibly, whereas the inhibition of the soluble CPT was largely reversible, Exposure of microsomes to [H-3]etomoxir, ATP, and CoA led to the labeling of a similar to 47-kDa peptide that associated with membranes, whereas no such peptide labeling was seen with the soluble microsomal fraction. These and other results show (a) that microsomes have malonyl-CoA-sensitive, as well as malonyl-CoA-insensitive, CPT activities, (b) that these two activities are due to distinct proteins, (c) that the malenyl-CoA-sensitive CPT of microsomes is a previously uncharacterized CPT isoform, and (d) that the [H-3]etomoxir-labeled similar to 47-kDa peptide is a likely candidate for the microsomal malonyl-CoA-sensitive CPT or its regulatory subunit.	UNIV MONTREAL, CLIN RES INST MONTREAL, INTERMEDIARY METAB LAB, MONTREAL H2W 1R7, PQ, CANADA; UNIV MONTREAL, DEPT EXPTL MED, MONTREAL H2W 1R7, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal								ABHAIRD NN, 1992, BIOCHEM J, V286, P637, DOI 10.1042/bj2860637; BALLAS LM, 1977, J BIOL CHEM, V252, P8512; BHUIYAN AKMJ, 1992, LIPIDS, V27, P392; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1990, PEDIATR RES, V27, P497, DOI 10.1203/00006450-199005000-00016; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; ESSER V, 1993, J BIOL CHEM, V268, P5817; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; LUND H, 1987, BIOCHIM BIOPHYS ACTA, V918, P67, DOI 10.1016/0005-2760(87)90010-5; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MIYAZAWA S, 1983, J BIOCHEM, V94, P529, DOI 10.1093/oxfordjournals.jbchem.a134384; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MURTHY MSR, 1993, MOL CELL BIOCHEM, V122, P133, DOI 10.1007/BF01076097; MURTHY MSR, 1992, PROTEIN EXPRES PURIF, V3, P75, DOI 10.1016/1046-5928(92)90059-6; MURTHY MSR, 1987, BIOCHEM J, V248, P727, DOI 10.1042/bj2480727; MURTHY MSR, 1993, MOL BIOL CELL S, V4, P1847; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANDE SV, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P165; PANDE SV, 1994, 16TH INT C BIOCH MOL; RAMSAY RR, 1988, BIOCHEM J, V249, P239, DOI 10.1042/bj2490239; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SINGH R, 1988, FEBS LETT, V241, P126, DOI 10.1016/0014-5793(88)81044-5; VERLEUR N, 1993, EUR J BIOCHEM, V218, P75, DOI 10.1111/j.1432-1033.1993.tb18353.x; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; ZAMMIT VA, 1989, BIOCHEM J, V263, P89, DOI 10.1042/bj2630089	38	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18283	18286						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034571				2022-12-27	WOS:A1994NW79800007
J	NALEFSKI, EA; SULTZMAN, LA; MARTIN, DM; KRIZ, RW; TOWLER, PS; KNOPF, JL; CLARK, JD				NALEFSKI, EA; SULTZMAN, LA; MARTIN, DM; KRIZ, RW; TOWLER, PS; KNOPF, JL; CLARK, JD			DELINEATION OF 2 FUNCTIONALLY DISTINCT DOMAINS OF CYTOSOLIC PHOSPHOLIPASE-A(2), A REGULATORY CA2+-DEPENDENT LIPID-BINDING DOMAIN AND A CA2+-INDEPENDENT CATALYTIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PLATELET-ACTIVATING-FACTOR; MACROPHAGE CELL-LINE; MOBILIZING PHOSPHOLIPASE-A2; LYSOPHOSPHOLIPASE ACTIVITY; COMPETITIVE INHIBITORS; INTERFACIAL CATALYSIS; RAT-KIDNEY; CALCIUM	Cytosolic phospholipase A(2) (cPLA(2)) associates with natural membranes in response to physiological increases in Ca2+, resulting in the selective hydrolysis of arachidonyl phospholipids, The isolation and sequence analysis of cPLA(2) cDNA clones from four different species revealed several highly conserved regions. The NH2-terminal conserved region is homologous to several other Ca2+-dependent lipid-binding proteins. Here we report that the first 178 residues of cPLA(2), containing the homologous Ca2+-dependent lipid-binding (CaLB) motif, and another recombinant protein containing the cPLA(2)(1-178) fragment placed at the COOH terminus of the maltose-binding protein (MBP-CaLB) associate with membranes in a Ca2+-dependent manner. cPLA(2) and MBP-CaLB also bind to synthetic liposomes at physiological Ca2+ concentrations, demonstrating that accessory proteins are not required. In contrast, Delta C2, a truncated cPLA(2) lacking the CaLB domain, fails to associate with membranes and fails to hydrolyze liposomal substrates. However, both Delta C2 and cPLA(2) hydrolyze monomeric 1-palmitoyl-2-lysophosphatidylcholine at identical rates in a Ca2+-independent fashion. These results delineate two functionally distinct domains of cPLA(2), the Ca2+-independent catalytic domain, and the regulatory CaLB domain that presents the catalytic domain to the membrane in response to elevated Ca2+.	GENET INST INC,SMALL MOLEC DRUG DISCOVERY GRP,CAMBRIDGE,MA 02140					Clark, James D./0000-0002-4801-0123				AKITA Y, 1990, J BIOL CHEM, V265, P354; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; ELDER M, 1977, PROC R SOC LON SER-A, V354, P157, DOI 10.1098/rspa.1977.0062; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUAN C, 1987, GENE, V67, P21; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; KAUFMAN R J, 1990, Technique (Philadelphia), V2, P221; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEB LA, 1986, J BIOL CHEM, V261, P467; LUO JH, 1993, J BIOL CHEM, V268, P23580; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NEAGOS GR, 1993, AM J PHYSIOL, V264, pL261, DOI 10.1152/ajplung.1993.264.3.L261; PERIN MS, 1991, J BIOL CHEM, V266, P615; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIELHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGA K, 1990, J BIOL CHEM, V265, P12363; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TANFORD C, 1980, HYDROPHOBIC EFFECT F, P111; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VENABLE ME, 1993, J LIPID RES, V34, P691; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAITE M, 1985, BIOCH LIPIDS MEMBRAN, P299; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	73	317	322	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18239	18249						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027085				2022-12-27	WOS:A1994NV42200071
J	THOMASSALGAR, S; MILLIS, AJT				THOMASSALGAR, S; MILLIS, AJT			CLUSTERIN EXPRESSION IN DIFFERENTIATING SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RAT CAROTID-ARTERY; MESSENGER-RNA; MOLECULAR-CLONING; SULFATED GLYCOPROTEIN-2; BASEMENT-MEMBRANE; TESTIS FLUID; GENE; COMPLEMENT; FIBRONECTIN	Clusterin is a heterodimeric glycoprotein, expressed by various cell types and shown to have activity in cell-cell adhesion. Cultured porcine smooth muscle cells (SMC) undergo morphological and phenotypic modulation associated with a change from a substrate attached monolayer culture to a nodular culture in which most of the cells are present in multicellular aggregations (nodules). During that transition from monolayer to nodular cell culture (>8 days) the expression of an mRNA and protein with significant homology to rat and human clusterin is increased. Clusterin expression continues in the nodular cell cultures and it is secreted at 0.3 mu g/ml/24 h as a protein with an apparent molecular mass = 80 kDa. In the presence of beta-mercaptoethanol the molecular mass is approximately 40 kDa. SMC clusterin expression is regulated by culture conditions that also affect culture morphology. SMC cultures seeded on a preformed extracellular matrix composed of Matrigel form nodules within 24 h and cultures seeded on a collagen gel form nodules in 48-72 h. We establish here that Matrigel contains clusterin and propose that endogenous clusterin supports the rapid formation of nodules. The collagen gel does not contain clusterin but facilitates clusterin expression by smooth muscle cells. Nodule formation in SMC cultures growing on collagen gel is inhibited by the addition of anticlusterin antibody to SMC growing on collagen gels and the antibody effect is eliminated by preincubation with purified plasma clusterin. These results demonstrate differential expression of SMC clusterin and suggest that clusterin has a functional role in SMC modulation.	SUNY ALBANY,DEPT BIOL SCI,CTR CELLULAR DIFFERENTIAT,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany					NHLBI NIH HHS [NHLBI HL40417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BRENNAN MJ, 1983, DEV BIOL, V97, P391, DOI 10.1016/0012-1606(83)90095-7; BRENNAN MJ, 1982, J CELL PHYSIOL, V112, P284, DOI 10.1002/jcp.1041120219; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CAREY DJ, 1991, ANNU REV PHYSIOL, V53, P161, DOI 10.1146/annurev.physiol.53.1.161; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; DIEMER V, 1992, J BIOL CHEM, V267, P5257; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRENCH LE, 1993, J CELL BIOL, V122, P1119, DOI 10.1083/jcb.122.5.1119; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; FRITZ IB, 1989, J CELL PHYSL, V140, P118; GARDEN GA, 1991, J NEUROBIOL, V22, P590, DOI 10.1002/neu.480220605; GIMBRONE MA, 1975, LAB INVEST, V33, P16; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; HOLDERBAUM D, 1986, J CELL PHYSIOL, V126, P216, DOI 10.1002/jcp.1041260210; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU G, 1989, J BIOL CHEM, V264, P10315; MAJORS A, 1993, ARTERIOSCLER THROMB, V13, P680, DOI 10.1161/01.ATV.13.5.680; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MILLIS AJT, 1986, J CELL PHYSIOL, V127, P366, DOI 10.1002/jcp.1041270304; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MOSSE PRL, 1985, LAB INVEST, V53, P556; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PAULY RR, 1992, CIRCULATION, V86, P68; RAINES EW, 1993, BRIT HEART J, V69, pS30; ROSENBERG ME, 1993, J LAB CLIN MED, V121, P205; ROSS R, 1971, J CELL BIOL, V50, P159, DOI 10.1083/jcb.50.1.159; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SEIFERT PS, 1989, J CLIN INVEST, V84, P597, DOI 10.1172/JCI114204; SENSIBAR JA, 1991, ENDOCRINOLOGY, V128, P2091, DOI 10.1210/endo-128-4-2091; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; THYBERG J, 1983, DIFFERENTIATION, V25, P156; TUNG PS, 1992, J CELL PHYSIOL, V152, P410, DOI 10.1002/jcp.1041520224; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WILSON MR, 1991, BIOCHEM BIOPH RES CO, V177, P985, DOI 10.1016/0006-291X(91)90635-K; WONG P, 1993, J BIOL CHEM, V268, P5021	54	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17879	17885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027042				2022-12-27	WOS:A1994NV42200022
J	THUERAUF, DJ; HANFORD, DS; GLEMBOTSKI, CC				THUERAUF, DJ; HANFORD, DS; GLEMBOTSKI, CC			REGULATION OF RAT-BRAIN NATRIURETIC PEPTIDE TRANSCRIPTION - A POTENTIAL ROLE FOR GATA-RELATED TRANSCRIPTION FACTORS IN MYOCARDIAL-CELL GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-ADRENERGIC STIMULATION; PROTEIN-KINASE-C; VENTRICULAR MYOCYTES; B-TYPE; HYPERTROPHY; SEQUENCES; INDUCTION; PROMOTER; PATHWAYS; UPSTREAM	GATA-binding proteins are transcription factors that regulate the stage- and tissue-specific expression of globin genes in cells of the erythroid lineage. Recently, a cardiac GATA-binding protein was found to be the earliest gene expressed during cardiogenesis; however, the target genes of this transcription factor in the heart are unknown. Since brain natriuretic peptide (BNP) is activated early in cardiac growth and development, we evaluated whether it could serve as a target gene for GATA-binding protein-mediated induction. Upon isolating and sequencing 2.5 kilobases of the rat BNP 5'-flanking sequence (FS), a variety of putative transcriptional enhancer sites were identified, including several GATA consensus sequences (WGATAR), one of which apparently serves as the major promoter site. Primary myocardial cells were transfected with BNP/luciferase fusion genes; reporter expression was strongly induced by typical growth factors such as phorbol esters, serum, or alpha(1)-adrenergic agonists, as well as by GATA-4 overexpression. Truncation analyses showed that inducibility mapped primarily to the proximal -116 base pair of the rat BNP 5'-FS, where there are two consensus GATA sites in addition to the GATA sequence at the TATA box. Point mutation analyses showed that at least one of the GATA sites was required to confer full GATA-4-inducible transcription. These results demonstrate that a proximal region of the rat BNP 5'-FS is required for growth factor- and GATA-inducible transcription, supporting the view that the BNP gene could serve as a target for GATA binding proteins during early cardiac development.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARECI RJ, 1993, MOL CELL BIOL, V13, P2235; ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DAGNINO L, 1991, MOL ENDOCRINOL, V5, P1292, DOI 10.1210/mend-5-9-1292; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KELLEY C, 1993, DEVELOPMENT, V118, P817; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; ROY RN, 1990, BIOCHEM BIOPH RES CO, V171, P416, DOI 10.1016/0006-291X(90)91409-L; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; Sambrook J, 1989, MOL CLONING LABORATO; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SEILHAMER JJ, 1989, BIOCHEM BIOPH RES CO, V165, P650, DOI 10.1016/S0006-291X(89)80015-4; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEINHELPER ME, 1993, CIRC RES, V72, P984, DOI 10.1161/01.RES.72.5.984; TAKAHASHI T, 1992, CIRC RES, V71, P9, DOI 10.1161/01.RES.71.1.9; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	35	106	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17772	17775						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027030				2022-12-27	WOS:A1994NV42200005
J	KOO, EH; SQUAZZO, SL				KOO, EH; SQUAZZO, SL			EVIDENCE THAT PRODUCTION AND RELEASE OF AMYLOID BETA-PROTEIN INVOLVES THE ENDOCYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; PEPTIDE; RECEPTOR; CELLS; IDENTIFICATION; DERIVATIVES; DEPLETION; CLEAVAGE; CLATHRIN	Amyloid beta-protein (A beta), the 40-43-amino acid polypeptide that is the principal constituent of senile plaques found in Alzheimer's disease, is constitutively produced and released into medium of cultured cells by an unclear mechanism. In this study, we report that one route of A beta generation involves the internalization of cell surface amyloid precursor protein (beta PP) via the coated pit-mediated endocytic pathway. Radiolabeled A beta can be recovered in medium following selective cell surface radioiodination, indicating that cell surface beta PP is a direct precursor to A beta. In addition, deletion of the cytoplasmic domains of beta PP or depletion of potassium in medium, both of which resulted in reduced beta PP internalization, significantly diminished A beta release. Moreover, pulse-chase experiments after surface radioiodination showed that the kinetics of beta PP secretion and A beta release was different, with the latter occurring at a significantly slower rate. We therefore hypothesize that the internalization of cell surface beta PP via coated pit-mediated endocytosis is one pathway leading to A beta generation and release into medium.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	KOO, EH (corresponding author), BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,221 LONGWOOD AVE,BOSTON,MA 02115, USA.							BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1992, ANN NY ACAD SCI, V674, P103; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Podlisny M., 1993, Society for Neuroscience Abstracts, V19, P1276; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yamazaki T., 1993, Society for Neuroscience Abstracts, V19, P396	24	884	903	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17386	17389						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021238				2022-12-27	WOS:A1994NU12800008
J	SMITH, GB; OLSEN, RW				SMITH, GB; OLSEN, RW			IDENTIFICATION OF A [H-3] MUSCIMOL PHOTOAFFINITY SUBSTRATE IN THE BOVINE GAMMA-AMINOBUTYRIC ACID(A) RECEPTOR-ALPHA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA-A RECEPTORS; AGONIST-BINDING-SITE; BENZODIAZEPINE-RECEPTOR; RAT-BRAIN; GLYCINE RECEPTOR; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; DELTA-SUBUNIT; ION CHANNELS	An amino acid which appears to be involved in an agonist binding site of the gamma-aminobutyric acid type A (GABA(A)) receptor protein has been identified by photoaffinity labeling of affinity purified bovine receptor with [H-3]muscimol and microsequencing of a chymotryptic fragment. Sequencing of a major purified labeled peptide gave the sequence Thr-Ile-Asp-Val-Phe with release of H-3 label in the fifth cycle, corresponding to Phe. These 5 residues match the published sequence for the bovine alpha 1 subunit beginning at Thr(61), following the chymotryptic substrate Tyr(60). This sequence is found in the alpha 1-3 subunits of rat and cow and alpha 5 of rat, but not in any beta. Although previous evidence tentatively suggested that the beta subunit was the major [H-3] muscimol-labeled subunit, homomeric expression studies have shown the potential for a functional gamma-aminobutyric acid binding site on all classes of subunits. The residue carrying the label, Phe(65) on alpha 1, is conserved among all GABA(A) receptor alpha subunits, gamma 2, and delta. In addition, recent data indicated that a point mutation of Phe(64) --> Leu in rat alpha 1 subunit strongly decreased agonist and antagonist affinity when coexpressed with beta 2 and gamma 2 subunits in Xenopus oocytes (Sigel, E., Baur, R., Kellenberger, S., and Malherbe, P. (1992) EMBO J. 11, 2017-2023). The photolabeled Phe residue identified in this report is the bovine homolog to the Phe(64) identified by the mutation studies of Sigel et al., to affect function in the rat GABA(A) receptor.	UNIV CALIF LOS ANGELES, DEPT MOLEC & MED PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, BRAIN RES INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, MENTAL RETARDAT RES CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCRR NIH HHS [1 S10RR05554-01] Funding Source: Medline; NINDS NIH HHS [NS28772] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028772] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1994, MOL PHARMACOL, V45, P317; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BUCHSTALLER A, 1991, NEUROSCI LETT, V129, P237, DOI 10.1016/0304-3940(91)90470-E; BURCH TP, 1983, MOL PHARMACOL, V23, P52; BUREAU M, 1988, BIOCHEM BIOPH RES CO, V153, P1006, DOI 10.1016/S0006-291X(88)81328-7; BUREAU M, 1990, MOL PHARMACOL, V37, P497; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8616, DOI 10.1021/bi00084a032; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; ENDO S, 1992, J NEUROCHEM, V59, P1444, DOI 10.1111/j.1471-4159.1992.tb08459.x; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; KAO PN, 1984, J BIOL CHEM, V259, P1662; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STEPHENSON FA, 1989, FEBS LETT, V243, P358, DOI 10.1016/0014-5793(89)80161-9; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198; WAHLSTEN JL, 1993, J RECEPTOR RES, V13, P989, DOI 10.3109/10799899309073705; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; XU M, 1993, J BIOL CHEM, V268, P21505; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; YMER S, 1989, FEBS LETT, V258, P119, DOI 10.1016/0014-5793(89)81630-8	54	132	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20380	20387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051133				2022-12-27	WOS:A1994PB31700029
J	DARNAY, BG; REDDY, SAG; AGGARWAL, BB				DARNAY, BG; REDDY, SAG; AGGARWAL, BB			PHYSICAL AND FUNCTIONAL ASSOCIATION OF A SERINE-THREONINE PROTEIN-KINASE TO THE CYTOPLASMIC DOMAIN OF THE P80 FORM OF THE HUMAN TUMOR-NECROSIS-FACTOR RECEPTOR IN HUMAN HISTIOCYTIC LYMPHOMA U-937 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NF-KAPPA-B; MOLECULAR-CLONING; MAP KINASE; ACTIVATION; PHOSPHORYLATION; EXPRESSION; INTERLEUKIN-1; ALPHA; PURIFICATION; MECHANISM	Tumor necrosis factor (TNF) binds two distinct cell surface receptors designated p60 and p80. Our previous studies indicate that a protein kinase from U-937 cells binds to and phosphorylates the p60 receptor. While the p80 receptor is phosphorylated in vivo, no association of a protein kinase has been described. We employed a fusion protein comprising of glutathione S-transferase and the cytoplasmic domain of the p80 receptor (GST-p80CD) to identify cellular proteins that might associate with this receptor. From S-35- and P-32-labeled cells, a protein of 59 kDa bound specifically to GST-p80CD. In vitro kinase reactions indicated that serine/threonine protein kinase activity associated with GST-p80CD and causes its phosphorylation. Additionally, a 59-kDa phosphoprotein was also identified after kinase reactions of proteins bound to CST-p80CD. This kinase activity required either Mg2+ or Mn2+ for optimal activity, and it phosphorylated myelin basic protein, histone H2B, and also the cytoplasmic domain of the p60 receptor. Treatment of cells with TNF increased the p80 receptor-associated kinase activity by 200%. In summary, our results provide evidence of a novel ligand-activated serine/threonine protein kinase that associates with the cytoplasmic domain of the p80 receptor and causes the phosphorylation of both forms of the TNF receptor. This p80 TNF receptor associated protein and the associated kinase described here are referred to as p80 TRAP and p80-TRAK, respectively.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BIRD TA, 1989, J IMMUNOL, V142, P126; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; DARNAY BG, 1994, J BIOL CHEM, V269; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUO H, 1993, J BIOL CHEM, V268, P11193; GUY GR, 1992, J BIOL CHEM, V267, P1846; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; PENNICA D, 1992, J BIOL CHEM, V267, P21172; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VIETOR I, 1993, J BIOL CHEM, V268, P18994	24	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19687	19690						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051045				2022-12-27	WOS:A1994PA12600008
J	ELKHARROUBI, A; VERDIN, E				ELKHARROUBI, A; VERDIN, E			PROTEIN-DNA INTERACTIONS WITHIN DNASE I-HYPERSENSITIVE SITES LOCATED DOWNSTREAM OF THE HIV-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INDUCIBLE ENHANCER ELEMENT; T-CELL ACTIVATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING-PROTEINS; C-MYC; INITIATION SITE; NUCLEAR FACTOR; MMTV PROMOTER	We have examined by in vitro footprinting a region located downstream of the human immunodeficiency virus, type 1 (HIV-1) promoter found to be hypersensitive to DNase I digestion in vivo. Recognition sites for several constitutive or inducible DNA binding factors were identified. Three AP-1 binding sites and an AP-3-like motif were situated within the R-U5 region of the long terminal repeat. A novel purine-rich motif (5-GAAAGC-GAAAGDD- 3' (D represents G, A, or T residues)), which interacts with a nuclear factor designated downstream binding factor 1 (DBF1), and two juxtaposed Sp-1 binding sites were located in the untranslated sequence immediately downstream of the 5'-long terminal repeat. Genomic footprinting of these sequence elements in the HIV-1 chronically infected cell lines revealed that the DBF1 and Sp-1 sites are occupied in vivo. Furthermore, transient transfection assays showed that point mutations in the DBF1 binding site decreased significantly the HIV-1 basal promoter activity. Taken together, these results suggest that the DBF1 play a role in the HIV-1 transcription regulation.	NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	ELKHARROUBI, A (corresponding author), NIAID, MOLEC MICROBIOL LAB, BLDG 4, RM 337, BETHESDA, MD 20892 USA.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARYA SK, 1991, AIDS RES HUM RETROV, V7, P1007, DOI 10.1089/aid.1991.7.1007; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Maxam A M, 1980, Methods Enzymol, V65, P499; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MYERS G, 1991, HUMAN RETROVIRUS AID; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SALUZ HP, 1990, LABORATORY GUIDE IN; SAMBROOK J, 1992, MOL CLONING LABORATO, V71, P853; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; WATERMAN M L, 1990, New Biologist, V2, P621; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	55	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19916	19924						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051074				2022-12-27	WOS:A1994PA12600041
J	KIRSCH, T; ISHIKAWA, Y; MWALE, F; WUTHIER, RE				KIRSCH, T; ISHIKAWA, Y; MWALE, F; WUTHIER, RE			ROLES OF THE NUCLEATIONAL CORE COMPLEX AND COLLAGENS (TYPE-II AND TYPE-X) IN CALCIFICATION OF GROWTH-PLATE CARTILAGE MATRIX VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE ACTIVITY; CII ANNEXIN-V; EPIPHYSEAL CARTILAGE; BINDING-PROTEINS; ANCHORIN-CII; CALCIUM CHANNELS; MEMBRANE; ASSOCIATION; IDENTIFICATION; FRACTIONATION	Matrix vesicles (MV) were shown to initiate mineralization in cartilage and other vertebrate tissues. However, the factors that drive this process remain to be fully elucidated. Recent studies have shown that a preformed nucleational core consisting mainly of a Ca2+- phosphatidylserine-P-i complex, is necessary for the accumulation of Ca2+ by MV. In addition, the collagens attached to the MV surface were shown to play an important role in stimulating Ca2+ uptake. In this study, we extend this knowledge by showing that both, the nucleational core and the collagens (types II and X), are co-requirements for rapid influx of Ca2+ into intact MV. MV to which collagen fragments were attached were released from hypertrophic chicken cartilage by trypsin and collagenase digestion (trypsin/collagenase-released MV (TCRMV)), while ''collagen-free'' MV were released by hyaluronidase and collagenase digestion (hyaluronidase/collagenase- released MV (HCRMV)). In contrast to TCRMV which showed active uptake of Ca2+, HCRMV showed only little uptake. However, binding of native type II collagen to HCRMV stimulated uptake of Ca2+. Sucrose gradients separated TCRMV and HCRMV into three different density fractions: a low density top fraction (SI), an intermediate density middle fraction (SII), and a high density pellet fraction (SIII). The SIII fractions of TCRMV and HCRMV contained significantly higher levels of mineral ions than did the SI and SII fractions. Only the SIII fraction of TCRMV which contained a stable nucleational core and surface-attached collagens, showed active Ca2+ uptake; all other sucrose fractions of TCRMV and HCRMV showed little or no uptake. Detergent treatment to purposely rupture the membrane greatly enhanced Ca2+ uptake by the SIII fraction of HCRMV, presumably by exposing the internal nucleational core. Addition of either native type II or type X collagen to the intact SIII fraction of HCRMV stimulated Ca2+ uptake to a level similar to that of the SIII fraction of TCRMV; however, incubation of the SI and SII fractions of either TCRMV or HCRMV with type II or X collagen did not activate Ca2+ uptake. These findings indicate that both a functional nucleational core and surface-attached collagens need to be present to support active mineralization of MV.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIAMS NIH HHS [AR 18193] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Anderson H. C., 1990, PATHOLOGY REV, P13, DOI 10.1007/978-1-4612-0485-5_2; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P46; BONUCCI E, 1970, Z ZELLFORSCH MIK ANA, V103, P192, DOI 10.1007/BF00337312; BOSKEY AL, 1976, CALCIF TISSUE RES S, V22, P197; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; Geisow MJ, 1988, MOL MECH SECRETION, P598; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005-2744(75)90151-5; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; POLLARD HB, 1991, ANN NY ACAD SCI, V266, P3228; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; THIEL C, 1991, J BIOL CHEM, V266, P14732; TIETZ NW, 1983, CLIN CHEM, V29, P751; WARNER GP, 1983, CALCIFIED TISSUE INT, V35, P327, DOI 10.1007/BF02405054; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU LNY, 1991, J BIOL CHEM, V266, P1195; WUTHIER RE, 1978, METAB BONE DIS RELAT, V1, P125, DOI 10.1016/0221-8747(78)90049-8; WUTHIER RE, 1992, BONE MINER, V17, P290, DOI 10.1016/0169-6009(92)90753-Z; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311; WUTHIER RE, 1988, ISI ATLAS SCI, P231; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	41	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20103	20109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051098				2022-12-27	WOS:A1994PA12600067
J	SCHROEDER, WT; STEWARTGALETKA, S; MANDAVILLI, S; PARRY, DAD; GOLDSMITH, L; DUVIC, M				SCHROEDER, WT; STEWARTGALETKA, S; MANDAVILLI, S; PARRY, DAD; GOLDSMITH, L; DUVIC, M			CLONING AND CHARACTERIZATION OF A NOVEL EPIDERMAL-CELL SURFACE-ANTIGEN (ESA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; ALPHA-FIBROUS PROTEINS; HELICAL COILED COILS; VULGARIS ANTIGEN; ADHESION MOLECULES; ANTIBODY PROBES; EXPRESSION; AUTOANTIBODIES; SEQUENCES; CADHERIN	We report here the isolation and characterization of a cDNA that encodes a novel extracellular epidermal molecule, epidermal surface antigen (ESA), which is thought to play a role in intercellular epidermal adhesion. Sequence analysis reveals that the 379 amino acid ESA has a molecular mass of about 41.7 kDa and an alpha-helix-rich secondary conformation. Much of this also has an heptad substructure, consistent with the formation of several bundles of alpha-helices in a compact globular structure. The ESA protein appears to consist of an NH2-terminal hydrophobic region with mixed alpha and beta structure followed by a more hydrophilic COOH-terminal region which is very rich in alpha-helix. The 2.5-kilobase ESA mRNA is expressed in cultured keratinocytes, melanocytes, fibroblasts, carcinoma, and melanoma cell lines. The ESA gene is conserved in all mammalian species examined and has been localized to human chromosome 17 (M17S1) in the same region as the gene for von Recklinghausen neurofibromatosis. The high level of expression of the ESA mRNA in human skin and in cultured cells derived from the epidermis, the appearance of ESA protein early in human development, and conservation of the ESA gene throughout mammalian evolution suggest that the novel ESA protein plays a vital role in epidermal structure and maintenance.	UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT INTERNAL MED, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MED SPECIALTIES, HOUSTON, TX 77030 USA; MASSEY UNIV, DEPT PHYS & BIOPHYS, PALMERSTON NORTH, NEW ZEALAND; UNIV ROCHESTER, MED CTR, DEPT DERMATOL, ROCHESTER, NY 14642 USA	University of Texas System; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Massey University; University of Rochester	SCHROEDER, WT (corresponding author), UNIV TEXAS, SCH MED, DEPT DERMATOL, 6431 FANNIN, HOUSTON, TX 77030 USA.				NIAMS NIH HHS [AR-30965, AR-36546, AR-40970] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR040970, R29AR036546, R29AR040970, R01AR030965] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; ANGST BD, 1990, J CELL SCI, V97, P247; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALVANICO NJ, 1991, J INVEST DERMATOL, V96, P815, DOI 10.1111/1523-1747.ep12474454; CAUGHMAN SW, 1991, PROG DERMATOL, V25, P1; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARROD DR, 1986, J CELL SCI, P221, DOI 10.1242/jcs.1986.Supplement_4.14; Harper M E, 1987, Methods Enzymol, V151, P539, DOI 10.1016/S0076-6879(87)51043-6; HASHIMOTO K, 1966, J INVEST DERMATOL, V47, P317, DOI 10.1038/jid.1966.150; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; JORDON RE, 1991, IMMUNOLOGIC DISEASES; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; KATZ AM, 1991, INT J DERMATOL, V30, P153, DOI 10.1111/j.1365-4362.1991.tb03843.x; KAYES LM, 1992, GENOMICS, V14, P369, DOI 10.1016/S0888-7543(05)80228-9; KITANO Y, 1983, BRIT J DERMATOL, V108, P555, DOI 10.1111/j.1365-2133.1983.tb01056.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KONOHANA I, 1988, J INVEST DERMATOL, V90, P708, DOI 10.1111/1523-1747.ep12560919; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOTAN R, 1988, J CELL BIOCHEM, V37, P107, DOI 10.1002/jcb.240370110; LOTAN R, 1992, GLYCOCONJUGATES COMP, P635; MANIATIS T, 1982, MOL CLONING, V1; MATSUNAK.M, 1969, ACTA DERM-VENEREOL, V49, P241; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; NEGI M, 1986, J INVEST DERMATOL, V86, P634, DOI 10.1111/1523-1747.ep12275639; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SCHROEDER WT, 1991, GENOMICS, V11, P481, DOI 10.1016/0888-7543(91)90166-C; SCHROEDER WT, 1993, CLIN RES, V41, pA777; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SHIOZAKI M, 1992, MICROSC RES TECHNIQ, V20, P305, DOI 10.1002/jemt.1070200311; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TYNER A, 1987, J CELL BIOL, V103, P1945; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	51	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19983	19991						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051082				2022-12-27	WOS:A1994PA12600051
J	HANSSON, L; STROMQVIST, M; BACKMAN, A; WALLBRANDT, P; CARLSTEIN, A; EGELRUD, T				HANSSON, L; STROMQVIST, M; BACKMAN, A; WALLBRANDT, P; CARLSTEIN, A; EGELRUD, T			CLONING, EXPRESSION, AND CHARACTERIZATION OF STRATUM-CORNEUM CHYMOTRYPTIC ENZYME - A SKIN-SPECIFIC HUMAN SERINE PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PAPILLOMA-VIRUS; ENDOGENOUS PROTEOLYSIS; DESMOGLEIN-I; DESQUAMATION; INVITRO; DEPENDENCE; EPIDERMIS	The cDNA encoding human stratum corneum chymo- tryptic enzyme (SCCE); an epidermal serine-proteinase which was recently purified from human stratum corneum, was isolated from a keratinocyte derived library. The obtained nucleotide sequence contained an open reading frame sufficient to encode a preproprotein consisting of 253 amino acid residues. Expression of two mRNA species hybridizing with SCCE cDNA, 1.2 and 2.0 kilobases, respectively, was detected in human skin. These two forms differ with respect to the length of the 3'-untranslated sequence. Analysis of mRNA derived from various human tissues showed that abundant expression of the SCCE gene was restricted to human skin. The cloned cDNA was introduced to a bovine papilloma virus-based expression system and recombinant protein was purified and characterized. The results show that recombinant SCCE is produced with a 22-amino acid residue signal peptide and a propeptide of 7 amino acid residues. Tryptic digestion removed this propeptide and yielded a proteolytically active protein with the same NH2-terminal amino acid sequence as native SCCE. The deduced amino acid sequence contains the conserved active site regions of serine proteinases. The calculated molecular mass of unglycosylated active SCCE was 24.4 kDa. The sequence indicates one tentative N-glycosylation site located near the C terminus. Recombinant SCCE was found to be heterogenous regarding glycosylation in a manner similar to that of the native enzyme.	UMEA UNIV HOSP,DEPT DERMATOL,S-90185 UMEA,SWEDEN	Umea University	HANSSON, L (corresponding author), SYMBICOM AB,POB 1451,S-90124 UMEA,SWEDEN.							Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2693; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; EGELRUD T, 1990, J INVEST DERMATOL, V95, P456, DOI 10.1111/1523-1747.ep12555620; EGELRUD T, 1989, ACTA DERM-VENEREOL, V69, P470; EGELRUD T, 1992, EUR J DERMATOL, V2, P50; ELIAS PM, 1991, ADV LIPID RES, V24, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALPRIN KM, 1972, BRIT J DERMATOL, V86, P14, DOI 10.1111/j.1365-2133.1972.tb01886.x; HANSSON L, 1993, J BIOL CHEM, V268, P26692; HORIE N, 1984, COMP BIOCHEM PHYS B, V77, P349, DOI 10.1016/0305-0491(84)90342-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDSTROM A, 1990, ARCH DERMATOL RES, V282, P234, DOI 10.1007/BF00371642; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; Odland G.F, 1991, PHYSL BIOCH MOL BIOL, P3; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; REIBEL J, 1989, DIFFERENTIATION, V41, P237, DOI 10.1111/j.1432-0436.1989.tb00752.x; Sambrook J, 1989, MOL CLONING LABORATO; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; STEINERT PM, 1991, PHYSL BIOCH MOL BIOL, P113; STROMQVIST M, 1992, BIOTECHNIQUES, V13, P744; WERTZ PW, 1991, PHYSL BIOCH MOL BIOL, P205	34	193	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19420	19426						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034709				2022-12-27	WOS:A1994NY33200036
J	KOMIYAMA, T; RAY, CA; PICKUP, DJ; HOWARD, AD; THORNBERRY, NA; PETERSON, EP; SALVESEN, G				KOMIYAMA, T; RAY, CA; PICKUP, DJ; HOWARD, AD; THORNBERRY, NA; PETERSON, EP; SALVESEN, G			INHIBITION OF INTERLEUKIN-1-BETA CONVERTING-ENZYME BY THE COWPOX VIRUS SERPIN CRMA - AN EXAMPLE OF CROSS-CLASS INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROTEINASE-INHIBITORS; DEATH GENE CED-3; ALPHA-1-PROTEINASE INHIBITOR; CELL-DEATH; SERINE PROTEASES; ALPHA-1-ANTITRYPSIN; SUBSTRATE; KINETICS; ALPHA-1-ANTICHYMOTRYPSIN; IDENTIFICATION	We reported previously that human interleukin-1 beta converting enzyme (ICE) is regulated by the CrmA serpin encoded by cowpox virus. We now report the mecha nism and kinetics of this unusual inhibition of a cysteine proteinase by a member of the serpin superfamily previously thought to inhibit serine proteinases only, CrmA possesses several characteristics typical of a number of inhibitory serpins. It is conformationally unstable, unfolding around 3 M urea, and stable to denaturation in 8 M urea upon complex formation with ICE. CrmA rapidly inhibits ICE with an association rate constant (k(on)) of 1.7 x 10(7) M(-1) s(-1), forming a tight complex with an equilibrium constant for inhibition (K-i) of less than 4 x 10(-12) M. These data indicate that CrmA is a potent inhibitor of ICE, consistent with the dramatic effects of CrmA on modify ing host responses to virus infection. The inhibition of ICE by CrmA is an example of a ''cross-class'' interaction, in which a serpin inhibits a non-serine proteinase. Since CrmA possesses characteristics shared by inhibitors of serine proteinases, we presume that ICE, though it is a cysteine proteinase, has a substrate binding geometry strikingly close to that of serine proteinases. We reason that it is the substrate binding geometry, not the catalytic mechanism of a proteinase, that dictates its reactivity with protein inhibitors.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Duke University; Duke University; Merck & Company; Merck & Company					NIAID NIH HHS [AI-32982] Funding Source: Medline; NIGMS NIH HHS [GM-38860] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032982, R01AI032982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038860] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BLACK RA, 1989, J BIOL CHEM, V264, P5323; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CERETTI DP, 1992, SCIENCE, V256, P97; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOMIYAMA T, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P305; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Salvesen, 1986, PROTEINASE INHIBITOR, P23; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	41	323	338	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19331	19337						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034697				2022-12-27	WOS:A1994NY33200022
J	MASUDA, S; OKANO, M; YAMAGISHI, K; NAGAO, M; UEDA, M; SASAKI, R				MASUDA, S; OKANO, M; YAMAGISHI, K; NAGAO, M; UEDA, M; SASAKI, R			A NOVEL SITE OF ERYTHROPOIETIN PRODUCTION - OXYGEN-DEPENDENT PRODUCTION IN CULTURED RAT ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; INDUCIBLE FACTOR-I; MESSENGER-RNA; INSITU HYBRIDIZATION; TRANSCRIPTIONAL RESPONSE; MONOCLONAL-ANTIBODIES; GENE-TRANSCRIPTION; PERITUBULAR CELLS; ENHANCER ELEMENT; COBALT EXPOSURE	It has been shown that neurons express erythropoietin (Epo) receptor, but the production of Epo protein in neural tissues has not been demonstrated. Cerebral cells of rat fetuses were cultured, and Epo in the spent medium was measured with an enzyme-linked immunoassay. Production of the immunoreactive Epo was dependent on O-2 tension for cell culture; hypoxia enhanced the production. The immunoreactive Epo purified from the spent medium stimulated the growth of Epo-dependent myeloid cells and formation of fetal liver erythroid colonies. These biological activities were completely inhibited by the anti-Epo antiserum and the extracellular domain of the Epo receptor capable of binding with Epo. When brain Epo was compared with serum Epo, brain Epo was smaller in size and more active in vitro at low ligand concentrations. These differences appear to be caused by the different extent of sialylation. Analyses with the reverse transcription-polymerase chain reaction method indicated that the regulation of Epo production by oxygen operates at the level of its mRNA. Immunochemical staining of the immortalized clonal cells revealed that astrocytes produced brain Epo. These results provide a novel site of Epo production and suggest that Epo acts on neurons in a paracrine fashion.	KYOTO UNIV, FAC AGR, DEPT FOOD SCI & TECHNOL, KYOTO 606, JAPAN; SNOW BRAND MILK PROD CO LTD, LIFE SCI RES INST, ISHIBASHI, TOCHIGI 32905, JAPAN	Kyoto University; Snow Brand Milk Products Co., Ltd.								ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BACHMANN S, 1993, J HISTOCHEM CYTOCHEM, V41, P335, DOI 10.1177/41.3.8429197; BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BERU N, 1990, J BIOL CHEM, V265, P14100; BISSELL MG, 1974, BRAIN RES, V82, P77, DOI 10.1016/0006-8993(74)90894-4; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; DONG YJ, 1993, EXP HEMATOL, V21, P483; ECKARDT KU, 1993, PFLUG ARCH EUR J PHY, V423, P356, DOI 10.1007/BF00374928; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOTO M, 1989, BLOOD, V74, P1415; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; IMAGAWA S, 1991, BLOOD, V77, P278; ISCOVE NN, 1974, J CELL PHYSIOL, V83, P309, DOI 10.1002/jcp.1040830218; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KOURY ST, 1989, BLOOD, V74, P645; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MOLLGARD K, 1986, NEUROPATH APPL NEURO, V12, P337, DOI 10.1111/j.1365-2990.1986.tb00146.x; NAGAO M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P99, DOI 10.1016/0167-4781(92)90146-Q; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, BLOOD, V81, P2503; OKANO M, 1993, BIOSCI BIOTECH BIOCH, V57, P1882, DOI 10.1271/bbb.57.1882; PORTER DL, 1993, EXP HEMATOL, V21, P399; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5; SASAKI R, 1987, METHOD ENZYMOL, V147, P328; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHUSTER SJ, 1992, BRIT J HAEMATOL, V81, P153, DOI 10.1111/j.1365-2141.1992.tb08200.x; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SUZUMURA A, 1984, BRAIN RES, V324, P379, DOI 10.1016/0006-8993(84)90054-4; TAN CC, 1992, AM J PHYSIOL, V263, pF474, DOI 10.1152/ajprenal.1992.263.3.F474; TSUCHIYA T, 1993, J BIOCHEM, V113, P395, DOI 10.1093/oxfordjournals.jbchem.a124057; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434; YASUDA Y, 1993, DEV GROWTH DIFFER, V35, P711; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640; [No title captured]	53	377	405	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19488	19493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034718				2022-12-27	WOS:A1994NY33200046
J	VANCURA, A; SESSLER, A; LEICHUS, B; KURET, J				VANCURA, A; SESSLER, A; LEICHUS, B; KURET, J			PRENYLATION MOTIF IS REQUIRED FOR PLASMA-MEMBRANE LOCALIZATION AND BIOCHEMICAL FUNCTION OF CASEIN KINASE-I IN BUDDING YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ESSENTIAL COMPONENT; NEUROSPORA-CRASSA; ADENYLYL CYCLASE; BETA-CASEIN; CELL CYCLE; PHOSPHORYLATION; RAS	The subcellular distribution of three casein kinase I (CK1) homologs, encoded by the YCK1, YCK2, and HRR25 genes, has been determined in budding yeast through a combination of subcellular fractionation and immun ofluorescence methods. Both Yck proteins are tightly associated with the plasma membrane or underlying cytoskeleton and require both high-salt and nonionic detergent for extraction. Association is mediated primarily by the prenylation motif found at the C terminus of both Yck proteins. In contrast, the third CK1 homolog, Hrr25p, is found predominantly in the nucleus and only partially in the plasma membrane. Despite partial colocalization with the Yck proteins, Hrr25p is unable to rescue the yck1 Delta yck2 Delta phenotype. However, a chimeric kinase containing the N-terminal kinase domain of Hrr25p and the C terminal region of Yck2p contains full Yck activity in vivo. These data suggest that members of the casein kinase I family have distinct but partially overlapping distributions in the cell that are mediated by their unique C-terminal regions.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory				Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM 42816] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CARMEL, 1994, J BIOL CHEM, V269, P7304; CARMEL G, 1992, ANAL BIOCHEM, V203, P274, DOI 10.1016/0003-2697(92)90313-V; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; COBB MH, 1983, J BIOL CHEM, V258, P2472; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KANG MS, 1985, J BIOL CHEM, V260, P2680; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MASON TL, 1973, J BIOL CHEM, V248, P1346; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P954; SCARBOROUGH GA, 1975, J BIOL CHEM, V250, P1106; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SIKORSKI RS, 1989, GENETICS, V122, P19; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014	54	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19271	19278						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034689				2022-12-27	WOS:A1994NY33200014
J	JOHNSON, JA; NATHANSON, NM				JOHNSON, JA; NATHANSON, NM			DIFFERENTIAL REQUIREMENTS FOR P21(RAS) AND PROTEIN-KINASE-C IN THE REGULATION OF NEURONAL GENE-EXPRESSION BY NERVE GROWTH-FACTOR AND NEUROKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NEUROBLASTOMA CELL-LINE; CYCLIC-AMP; SYMPATHETIC NEURONS; FACTOR RECEPTOR; CHOLINE-ACETYLTRANSFERASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	This study used reporter gene constructs containing regulatory regions of the c-fos, vasoactive intestinal peptide, and choline acetyltransferase genes to determine the role of p21(ras) and protein kinase C in the action of ciliary neurotrophic factor and leukemia inhibitory factor. Down-regulation of protein kinase C with phorbol ester did not affect the induction of either c-fos-beta-galactosidase or vasoactive intestinal peptide-luciferase by ciliary neurotrophic factor or leukemia inhibitory factor. In contrast, while leukemia inhibitory factor induction of choline acetyltransferase-luciferase expression was protein kinase C-independent, there appears to be both protein kinase C-dependent and -independent pathways for induction of choline acetyltransferase-luciferase by ciliary neurotrophic factor. Cotransfection of a dominant-negative mutant p21(rasN17) blocked nerve growth factor-mediated induction of c-fos-beta-galactosidase, but did not affect induction of c-fos-beta-galactosidase, vasoactive intestinal peptide-luciferase, or choline acetyltransferase-luciferase by either ciliary neurotrophic factor or leukemia inhibitory factor. Thus, in contrast to the action of nerve growth factor, gene induction by ciliary neurotrophic factor, and leukemia inhibitory factor is ras-independent in IMR-32 neuroblastoma cells.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NINDS NIH HHS [NS07332, NS26920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINK JS, 1991, J BIOL CHEM, V266, P3882; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HERSH LB, 1993, J NEUROCHEM, V61, P306, DOI 10.1111/j.1471-4159.1993.tb03569.x; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEWIS SE, 1993, ABSTR SOC NEUROSCI, V19, P1306; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LLOYD ED, 1992, J NEUROCHEM, V59, P1099, DOI 10.1111/j.1471-4159.1992.tb08352.x; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MISAWA H, 1993, J NEUROCHEM, V60, P1383, DOI 10.1111/j.1471-4159.1993.tb03299.x; MISAWA H, 1992, J BIOL CHEM, V267, P20392; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; RABINOVSKY ED, 1992, J NEUROSCI, V12, P171; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SYMES A, 1993, ABSTR SOC NEUROSCI, V19, P1306; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	61	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18856	18863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034640				2022-12-27	WOS:A1994NX32700027
J	SOH, JM; MARIANO, TM; LIM, JK; IZOTOVA, L; MIROCHNITCHENKO, O; SCHWARTZ, B; LANGER, JA; PESTKA, S				SOH, JM; MARIANO, TM; LIM, JK; IZOTOVA, L; MIROCHNITCHENKO, O; SCHWARTZ, B; LANGER, JA; PESTKA, S			EXPRESSION OF A FUNCTIONAL HUMAN TYPE-I INTERFERON RECEPTOR IN HAMSTER-CELLS - APPLICATION OF FUNCTIONAL YEAST ARTIFICIAL CHROMOSOME (YAC) SCREENING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-INTERFERON; HUMAN-LEUKOCYTE INTERFERONS; GAMMA RECEPTOR; MONOCLONAL-ANTIBODIES; IMMUNE INTERFERON; ACCESSORY FACTOR; BINDING-SITES; IFN-ALPHA; RECOMBINANT; GENE	The previously cloned human interferon alpha/beta (Hu-IFN-alpha/beta; Type I interferon) receptor cDNA appears to be only one component of a receptor complex since expression of the cDNA in mouse cells confers sensitivity only to Hu-IFN-alpha B2, but a monoclonal antibody against this cloned receptor subunit inhibits biological activities of Hu-IFN-alpha A, Hu-IFN-alpha B2, Hu-IFN-omega, and Hu-IFN-beta. Here we report that a yeast artificial chromosome (YAC) containing a segment of human chromosome 21 introduced into Chinese hamster ovary (CHO) cells confers upon these cells a greatly enhanced response to Hu-IFN-alpha A and Hu-IFN-alpha B2 as well as an increased response to Hu-IFN-omega, Hu-IFN-alpha A/D(Bgl), and Hu-IFN-beta. These responses were measured by induction of class I MHC antigens and by protection against encephalomyocarditis virus and vesicular stomatitis virus. Furthermore, these cells exhibit specific high affinity binding of Hu-IFN-alpha A and Hu-IFN-alpha B2, Hu-IFN-beta, and Hu-IFN-omega. The results indicate that all the genes necessary to reconstitute a biologically active Type I human IFN receptor complex are located within the human DNA insert of this YAC clone.			SOH, JM (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MOLEC GENET & MICROBIOL, PISCATAWAY, NJ 08854 USA.			Langer, Jerome/0000-0002-4617-3260; Lim, Jinkyu/0000-0001-6666-5759	NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNET M, 1980, NATURE, V284, P459; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENOIT P, 1993, J IMMUNOL, V150, P707; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHENG S, 1993, MAMM GENOME, V4, P338, DOI 10.1007/BF00357094; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; Cleary Cathleen M., 1992, Journal of Interferon Research, V12, pS220; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; COX DR, 1990, CYTOGENET CELL GENET, V55, P235, DOI 10.1159/000133017; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FALTYNEK CR, 1983, P NATL ACAD SCI-BIOL, V80, P3269, DOI 10.1073/pnas.80.11.3269; Familletti P C, 1981, Methods Enzymol, V78, P387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORES I, 1991, J BIOL CHEM, V266, P19875; FRIEDMAN RM, 1967, SCIENCE, V156, P1760, DOI 10.1126/science.156.3783.1760; HANNIGAN GE, 1986, EUR J BIOCHEM, V157, P187, DOI 10.1111/j.1432-1033.1986.tb09655.x; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HU RQ, 1993, J BIOL CHEM, V268, P12591; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; JUNG V, 1991, THESIS RUTGERS U PIS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1986, J BIOL CHEM, V261, P9801; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MARIANO TM, 1992, INTERFERON PRINCIPLE, P129; MOSCHERA JA, 1986, METHOD ENZYMOL, V119, P177; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PESTKA S, 1983, ARCH BIOCHEM BIOPHYS, V221, P1, DOI 10.1016/0003-9861(83)90118-2; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1984, BIOCH BIOPHYSICAL ST, P11; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; RAZIUDDIN A, 1985, 2 5A SYSTEM, P219; REHBERG E, 1982, J BIOL CHEM, V257, P1497; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; REVEL M, 1991, J INTERFERON RES S61, V11; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSE MD, 1990, METHODS YEAST GENETI, P119; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHULMAN LM, 1984, VIROLOGY, V137, P422, DOI 10.1016/0042-6822(84)90235-6; SLATE DL, 1978, J VIROL, V25, P319, DOI 10.1128/JVI.25.1.319-325.1978; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, DNA CELL BIOL, V13, P301, DOI 10.1089/dna.1994.13.301; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAEHELIN T, 1981, J BIOL CHEM, V256, P9750; TAN YH, 1973, J EXP MED, V137, P317, DOI 10.1084/jem.137.2.317; TASSONE F, 1990, AM J HUMAN GEN SA263, V47; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; WANG PY, 1994, J INTERFERON RES, V14, P41, DOI 10.1089/jir.1994.14.41	74	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18102	18110						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027072				2022-12-27	WOS:A1994NV42200054
J	YE, J; REZAIE, AR; ESMON, CT				YE, J; REZAIE, AR; ESMON, CT			GLYCOSAMINOGLYCAN CONTRIBUTIONS TO BOTH PROTEIN-C ACTIVATION AND THROMBIN INHIBITION INVOLVE A COMMON ARGININE-RICH SITE IN THROMBIN THAT INCLUDES RESIDUES ARGININE-93, ARGININE-97, AND ARGININE-101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; ANTITHROMBIN-III; ACTIVE-SITE; PROTHROMBIN FRAGMENT-2; TRANSIENT KINETICS; BLOOD-COAGULATION; FACTOR-XA; RABBIT THROMBOMODULIN; CRYSTAL-STRUCTURE	Proteoglycans play pivotal roles in the regulation of thrombin. Thrombomodulin (TM) binds thrombin through protein-protein contacts and a chondroitin sulfate moiety. The complex activates the anticoagulant zymogen, protein C. Thrombin and a thrombin mutant with Arg(93), Arg(97), and Arg(101) changed to Ala bind soluble TM lacking the chondroitin sulfate with comparable affinities, but the mutant binds TM containing chondroitin sulfate 45-fold weaker than thrombin. A simple hyperbolic relationship describes the Ca2+ dependence of protein C activation with the thrombin mutant-TM complex whether or not the TM contains chondroitin sulfate. A similar Ca2+ dependence is observed with wild type thrombin only when the TM contains chondroitin sulfate. Thus, charge neutralization of Arg(93), Arg(97), and Arg(101) mimics the functional effects of the chondroitin sulfate. The mutant and wild type thrombin are inhibited at comparable rates by antithrombin +/- the pentasaccharide capable of inducing the ''active'' antithrombin conformation, but heparin acceleration of antithrombin inhibition of the mutant is reduced by more than 95%. Binding studies revealed that the mutant has a greater than or equal to 20-fold decrease in heparin affinity. We conclude that heparin and chondroitin sulfate interact with one or more of these Arg residues. These basic residues appear to play a critical role in the regulation of thrombin activity.	OKLAHOMA MED RES FDN, HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [R01 HL-29807, R37 HL-30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1994, J BIOL CHEM, V269, P11807; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1993, THROMB HAEMOSTASIS, V69, P1044; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	46	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17965	17970						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027055				2022-12-27	WOS:A1994NV42200035
J	HAASS, C; HUNG, AY; SELKOE, DJ; TEPLOW, DB				HAASS, C; HUNG, AY; SELKOE, DJ; TEPLOW, DB			MUTATIONS ASSOCIATED WITH A LOCUS FOR FAMILIAL ALZHEIMERS-DISEASE RESULT IN ALTERNATIVE PROCESSING OF AMYLOID BETA-PROTEIN PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; MOLECULAR PATHOLOGY; PEPTIDE; GENE; IDENTIFICATION; CELLS; MECHANISM; SECRETION; FRAGMENT; CLEAVAGE	Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the extracellular deposition of amyloid beta-protein (A beta), a molecule produced by post-translational processing of the beta-amyloid precursor protein (beta APP). Mutations within the gene encoding beta APP have been linked to early onset forms of AD, but the pathogenetic mechanism(s) producing the phenotype are unknown. We analyzed the effects on beta APP processing in vitro of a naturally occurring Ala --> Gly mutation at position 692 of beta APP(770) (A692G) (Hendriks, L., Duijin, C., Cras, P, Cruts, M., van Hul, W., van Harskamp, F., Warren, A., McInnis, M., Antonarakis, S., Martin, J.-J., Hofman, A., and van Broeckhoven, C. (1992) Nature Genet. 1, 218-221), as well as the effects of five genetically engineered mutations at or near this site. Substitution of glycine or proline for Ala(692), or for Phe(690), produced relative increases in secretion of A beta and relative decreases in secretion of the p3 peptide(s) arising after alpha-secretase generation of soluble APP (APP(s)). The Phe(690) --> Pro substitution also resulted in the synthesis of truncated APP(s) molecules. The structurally conservative substitutions Ala(692) --> Val and Phe(690) --> Tyr did not exhibit these effects. Certain of the substitutions also resulted in the production of a minor peptides, previously undescribed in vitro, beginning at Ala(2), Lys(16), and Phe(19) of A beta. These data show that beta APP mutations carboxyl-terminal to alpha-secretase and beta-secretase cleavage sites can exert strong control over beta APP processing. Increased secretion of A beta may accelerate amyloidogenesis by providing more precursors for aggregation. It is also possible that truncated A beta peptides resulting from several of these mutations may accelerate amyloidogenesis through self-aggregation and/or seeding the fibrillogenesis of longer, more abundant A beta species.	BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE ON AGING [R37AG006173, R01AG006173, R35AG007911] Funding Source: NIH RePORTER; NIA NIH HHS [AG07911-06, AG06173-09] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Cai X.-D., 1993, Society for Neuroscience Abstracts, V19, P430; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TOMIYAMA T, 1994, J BIOL CHEM, V269, P10205; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I	49	267	275	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17741	17748						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021287				2022-12-27	WOS:A1994NU12800062
J	CHAMBERLIN, ME; LEI, KJ; CHOU, JY				CHAMBERLIN, ME; LEI, KJ; CHOU, JY			SUBTLE DIFFERENCES IN HUMAN PREGNANCY-SPECIFIC GLYCOPROTEIN GENE PROMOTERS ALLOW FOR DIFFERENTIAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARCINOEMBRYONIC ANTIGEN; MOLECULAR-CLONING; BETA-1-GLYCOPROTEIN GENES; MESSENGER-RNA; FAMILY; PROTEINS; CDNA; SEQUENCE; MEMBER; CELLS	Eleven pregnancy-specific glycoprotein (PSG) genes reside on human chromosome 19. The sequence of these genes is extremely similar and that similarity extends to their putative control regions. However, the expression pattern of each PSG gene differs in the placenta, the primary site of PSG synthesis. To understand the molecular mechanisms underlying differential PSG expression, we characterized promoter elements of six PSG genes. We have shown previously that nucleotides -172 to -34 with respect to the translation start site constitute a minimal promoter in the PSG12 gene (class 1). We now show that PSG1-I and PSG3 are also members of class 1 genes. In contrast, only nucleotides -172 to -80 are necessary for promoter activity in PSG5, PSG6, and PSG11 genes (class 2). Class 2 genes contain a perfect Sp1 recognition sequence (CCCCGCCC) at nucleotides -148 to -141 which is necessary for promoter activity. Placental cell extracts formed three protein-DNA complexes with nucleotides -172 to -80 of all six PSG genes. One of the components of these complexes is an Sp1-like molecule. We have previously reported activator sequences within nucleotides -83 to -34 in PSG12. We now show that a 50-kDa protein binds to this region of PSG11, and the resultant complex can be supershifted by a monoclonal antibody to PEA3.	NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; CHAN WY, 1988, DNA-J MOLEC CELL BIO, V7, P545, DOI 10.1089/dna.1.1988.7.545; CHAN WY, 1988, HUM REPROD, V3, P677, DOI 10.1093/oxfordjournals.humrep.a136766; CHOU JY, 1992, SEMIN REPROD ENDOCR, V10, P116, DOI 10.1055/s-2007-1018867; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KHAN WN, 1989, P NATL ACAD SCI USA, V86, P3332, DOI 10.1073/pnas.86.9.3332; KHAN WN, 1992, GENOMICS, V12, P780, DOI 10.1016/0888-7543(92)90309-G; KYOSTIO SRM, 1994, J VIROL, V68, P2947; LEI KJ, 1992, J BIOL CHEM, V267, P16371; LEI KJ, 1993, J BIOL CHEM, V268, P17528; LEI KJ, 1992, MOL ENDOCRINOL, V6, P703, DOI 10.1210/me.6.5.703; LESLIE KK, 1990, P NATL ACAD SCI USA, V87, P5822, DOI 10.1073/pnas.87.15.5822; LIN JN, 1979, BRIT J OBSTET GYNAEC, V86, P888; LIN TM, 1974, J CLIN INVEST, V54, P576, DOI 10.1172/JCI107794; MACDONALD DJ, 1983, AM J OBSTET GYNECOL, V147, P430, DOI 10.1016/S0002-9378(16)32239-6; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MASSON GM, 1983, BRIT J OBSTET GYNAEC, V90, P146, DOI 10.1111/j.1471-0528.1983.tb08899.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OIKAWA S, 1988, BIOCHEM BIOPH RES CO, V156, P68, DOI 10.1016/S0006-291X(88)80806-4; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V163, P1021, DOI 10.1016/0006-291X(89)92324-3; ROONEY BC, 1988, GENE, V71, P439, DOI 10.1016/0378-1119(88)90061-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SORENSEN S, 1984, TUMOUR BIOL, V5, P275; STREYDIO C, 1988, BIOCHEM BIOPH RES CO, V154, P130, DOI 10.1016/0006-291X(88)90660-2; TAMSEN L, 1983, J PERINAT MED, V11, P19, DOI 10.1515/jpme.1983.11.1.19; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TATARINOV YS, 1978, GYNECOL OBSTET INVES, V9, P65, DOI 10.1159/000300972; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P1071, DOI 10.1093/nar/10.3.1071; WATANABE S, 1988, BIOCHEM BIOPH RES CO, V152, P762, DOI 10.1016/S0006-291X(88)80103-7; WATANABE S, 1988, J BIOL CHEM, V263, P2049; WU SM, 1993, MOL CELL BIOCHEM, V122, P147, DOI 10.1007/BF01076099; WURZ H, 1981, J PERINAT MED, V2, P67; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17152	17159						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006022				2022-12-27	WOS:A1994NT84600029
J	LAXMINARAYAN, KM; CHAN, BK; TETAZ, T; BIRD, PI; MITCHELL, CA				LAXMINARAYAN, KM; CHAN, BK; TETAZ, T; BIRD, PI; MITCHELL, CA			CHARACTERIZATION OF A CDNA-ENCODING THE 43-KDA MEMBRANE-ASSOCIATED INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA; MOLECULAR-CLONING; HUMAN-PLATELETS; BOVINE BRAIN; 1,4,5-TRISPHOSPHATE; SEQUENCE; TRISPHOSPHATE; PURIFICATION; EXPRESSION; RECEPTOR	Agonist stimulation of cells results in phosphatidylinositol turnover and the generation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), which mobilizes intracellular calcium. The inositol-polyphosphate 5-phosphatase (5-phosphatase) enzymes hydrolyze Ins(1,4,5)P-3 in a signal-terminating reaction. We have isolated a 2.7-kilobase (kb) composite cDNA, encoding the 43-kDa membrane-associated 5-phosphatase, by screening a human placental lambda gt11 library, using degenerate oligonucleotides. The 2.7-kb cDNA contains a 1.1-kb open reading frame, comprising 363 amino acids, which encodes a protein of a predicted molecular mass of 42 kDa. Amino acid sequence analysis demonstrates a number of potential sites for phosphorylation by protein kinase C and a CAAX motif in the COOH terminus, which may mediate membrane localization. The recombinant enzyme was expressed in COS-7 cells, resulting in a 50-fold increase in enzyme activity in the detergent-soluble membrane fraction of the cell (nanomole of Ins(1,4,5)P-3 hydrolyzed per min/mg), but only a 2.5-fold increase in 5-phosphatase activity in the total cell homogenate. Sequence analysis demonstrated a 73-amino acid domain in the COOH terminus of the 43-kDa membrane-associated 5-phosphatase, which had 30% sequence identity and 67% similarity to a region in the 75-kDa 5-phosphatase and 34% identity and 70% similarity to a sequence in the protein that is encoded by the gene, defective in Lowe's oculocerebrorenal syndrome. As shown by RNA analysis the 43-kDa membrane-associated 5-phosphatase appears to be predominantly expressed in heart, brain, and skeletal muscle.	BOX HILL HOSP,MONASH MED SCH,DEPT MED,MELBOURNE,VIC 3128,AUSTRALIA; BAKER MED RES INST,PRAHRAN,VIC 3181,AUSTRALIA	Box Hill Hospital; Monash University; Baker Heart and Diabetes Institute				Bird, Phillip/0000-0002-6695-606X; Mitchell, Christina A/0000-0001-9372-3192				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HOLLANDE F, 1991, BIOCHEM J, V277, P293, DOI 10.1042/bj2770293; IRVINE R, 1992, NAT GENET, V1, P315, DOI 10.1038/ng0892-315; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; PALMER SC, 1994, J BIOL CHEM, V269, P3403; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sambrook J, 1989, MOL CLONING LABORATO; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; TETAZ T, 1993, TECHNIQUES PROTEIN C, V4, P389; VEDIA LMM, 1986, J BIOL CHEM, V261, P10493; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L	42	87	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17305	17310						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006039				2022-12-27	WOS:A1994NT84600050
J	RAJPUT, B; MA, J; VIJAY, IK				RAJPUT, B; MA, J; VIJAY, IK			STRUCTURE AND ORGANIZATION OF MOUSE GLCNAC-1-PHOSPHATE TRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOPROTEINS; COENZYME-A REDUCTASE; PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; ACETYL-D-GLUCOSAMINE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; MAMMARY-GLAND; DEVELOPMENTAL REGULATION; TRANSCRIPT HETEROGENEITY; OVIDUCT DIFFERENTIATION; PROTEIN GLYCOSYLATION	The gene encoding UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT), the enzyme that initiates the pathway for the biosynthesis of asparagine-linked glycoproteins, was isolated and characterized. Southern blot analyses demonstrated a single copy gene for GPT. The gene spans about 7.5 kilobase pairs of DNA and is divided into 9 exons by 8 introns. All the introns are found in the coding region, and most of them occur in segments separating the putative membrane-spanning domains. The exon/intron organization of the gene also correlates with the presence of several highly conserved regions of potential functional importance among yeast, leishmania, hamster, and mouse enzymes. Primer extension and reverse transcription-polymerase chain reaction analyses suggested the presence of several potential transcription start sites, with the closest one being approximately 200 base pairs upstream from the translation initiation codon. The 5'-flanking region lacks a typical TATA box, but is high in GC content and contains two putative Spl binding sites (GC boxes), consistent with promoters described for housekeeping genes. The 3'-end reverse transcription-polymerase chain reaction analysis indicated that the first of the two polyadenylation sites was used predominantly, in agreement with a approximately 2.0-kilobase pair GPT message seen on Northern blots of RNA from a wide variety of mouse tissues. This is the first report of cloning of a gene for an enzyme of the dolichol cycle in higher eukaryotes. A novel finding of this study is the observation of a G --> A change between the genomic sequence and nucleotide 280 in the cDNA. This could have important implications as an RNA editing mechanism for regulating the expression of the gene and therefore, protein N-glycosylation. A previous study (11) had shown that the activity of GPT was developmentally regulated in mouse mammary gland, with possible involvement by the hormone prolactin. The availability of the GPT gene with its promoter should facilitate future studies on delineating the mechanism for the hormonal regulation of GPT.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ARMANT DR, 1986, DEV BIOL, V113, P228, DOI 10.1016/0012-1606(86)90125-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHAN L, 1993, BIOESSAYS, V15, P33, DOI 10.1002/bies.950150106; CHUN KT, 1992, J BIOL CHEM, V267, P4236; DATTA AK, 1993, J BIOL CHEM, V268, P12663; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HARTOG KO, 1987, NUCLEIC ACIDS RES, V15, P3627, DOI 10.1093/nar/15.8.3627; HAYES GR, 1983, J BIOL CHEM, V258, P5095; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; KEAN EL, 1991, J BIOL CHEM, V266, P942; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, P NATL ACAD SCI USA, V84, P2145, DOI 10.1073/pnas.84.8.2145; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; MCGROGAN M, 1982, J CELL BIOCH S, V6, P862; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHMITNEY M, 1992, P NATL ACAD SCI USA, V89, P130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SNIDER MD, 1984, BIOL CARBOHYDRATES, P163; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STARR CM, 1988, ARCH BIOCHEM BIOPHYS, V237, P261; STEFFENS DL, 1989, BIOTECHNIQUES, V7, P674; VIJAY IK, 1986, EUR J BIOCHEM, V154, P57, DOI 10.1111/j.1432-1033.1986.tb09358.x; WALSH MJ, 1992, J BIOL CHEM, V267, P7026; WELPLY JK, 1985, DEV BIOL, V107, P252, DOI 10.1016/0012-1606(85)90393-8; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	62	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9590	9597						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8043075				2022-12-27	WOS:A1994NE05300032
J	YOUNG, P; OHMAN, M; XU, MQ; SHUB, DA; SJOBERG, BM				YOUNG, P; OHMAN, M; XU, MQ; SHUB, DA; SJOBERG, BM			INTRON-CONTAINING T4-BACTERIOPHAGE GENE SUNY ENCODES AN ANAEROBIC RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROUP-I INTRON; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; RNA; COMPONENTS; RIBOZYME; DNA	The function of the SunY protein, encoded by an intron-containing gene of bacteriophage T4, has remained hitherto unknown in contrast to the extensively studied self-splicing reaction of the SunY intron. Here we show that anaerobic T4 infections of Escherichia coli induce a ribonucleoside triphosphate reductase activity that is 10-30-fold higher than the bacterial host level of the corresponding enzyme. Inactivation of the T4 sunY gene (in this communication renamed nrdD) significantly decreased both the induced activity and the anaerobic production of phage, confirming the role of the T4 NrdD (SunY) protein as a phage specific anaerobic ribonucleotide reductase. With the identification of the T4 nrdD (sunY) gene product as an anaerobic ribonucleotide reductase, all known bacteriophage introns are found to share the common and as yet unexplained property of residing within genes of DNA metabolism.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	Stockholm University; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Sjoberg, Britt-Marie/0000-0001-5953-3360	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDON ST, 1992, J BACTERIOL, V174, P8073, DOI 10.1128/JB.174.24.8073-8080.1992; BELFORT M, 1990, ANNU REV GENET, V24, P363; BELFORT M, 1989, TRENDS GENET, V5, P209, DOI 10.1016/0168-9525(89)90083-8; BERGLUND O, 1969, P NATL ACAD SCI USA, V62, P829, DOI 10.1073/pnas.62.3.829; BERGLUND O, 1972, J BIOL CHEM, V247, P7270; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FRASER D, 1953, J BIOL CHEM, V205, P291; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GOTT JM, 1988, GENE DEV, V2, P1791, DOI 10.1101/gad.2.12b.1791; GOTT JM, 1986, CELL, V47, P81, DOI 10.1016/0092-8674(86)90368-5; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; KUTTER E, 1975, J MOL BIOL, V99, P591, DOI 10.1016/S0022-2836(75)80174-4; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RUSSELL RL, 1974, GENETICS, V78, P989; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; Shub DA, 1991, CURR OPIN GENET DEV, V1, P478, DOI 10.1016/S0959-437X(05)80195-9; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; SOUTHER A, 1972, J VIROL, V10, P979, DOI 10.1128/JVI.10.5.979-984.1972; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; TOMICH PK, 1974, J BIOL CHEM, V249, P7613; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; ZEEH A, 1991, J BACTERIOL, V173, P6980, DOI 10.1128/jb.173.21.6980-6985.1991	30	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20229	20232						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051113				2022-12-27	WOS:A1994PB31700006
J	ILAG, LL; LONNERBERG, P; PERSSON, H; IBANEZ, CF				ILAG, LL; LONNERBERG, P; PERSSON, H; IBANEZ, CF			ROLE OF VARIABLE BETA-HAIRPIN LOOP IN DETERMINING BIOLOGICAL SPECIFICITIES IN NEUROTROPHIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; TYROSINE PROTEIN-KINASE; MOLECULAR-CLONING; FACTOR RECEPTOR; NGF RECEPTOR; FACTOR GENE; BRAIN; EXPRESSION; BINDING	The neurotrophins are members of a family of structurally and functionally related neurotrophic factors that control the development and maintenance of vertebrate neurons. The crystal structure of nerve growth factor (NGF), the prototypic member of this family, contains three pairs of anti-parallel beta-strands connected by beta-hairpin loops, which contain most of the variable residues among the four neurotrophin proteins. Recently, amino acid residues in these variable loop regions have been implicated in the interaction between NGF and its signal-transducing receptor TrkA. In NGF, residues 40-49 (variable region II) span a very flexible and solvent-accessible beta-hairpin loop that is highly variable between different neurotrophins. To investigate the role of this domain in determining biological specificities in the neurotrophin family, we constructed a series of chimeric molecules by exchanging this variable region among three neurotrophins (i.e. NGF, neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)) that bind and activate three different Trk receptors (i.e. TrkA, -C, and -B, respectively). The chimeric molecules were analyzed for their ability to activate different Trk receptor subtypes and to promote the survival of subpopulations of peripheral neurons expressing specific types of Trk mRNAs. Exchange of the 40-49 variable loop region between NGF and NT-3 resulted in molecules capable of activating both TrkA and TrkC receptors and of rescuing neurons containing TrkA and TrkC mRNAs, indicating that this loop plays an important role in determining biological specificities in these two neurotrophins. Furthermore, variable region II from NT-4 conferred the ability to differentiate nnr5 PC12-TrkB cells to a chimeric NT-3 molecule that was originally incapable of eliciting a response in these cells. In contrast, exchanges between NGF and NT-4 did not suffice to generate molecules with broader biological specificities, suggesting that other regions in these molecules are also required. Our results support the evolutionary relationships between the three polypeptides deduced from structural comparisons.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet				Ilag, Leopold/0000-0003-3678-7100				BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CARRIERO F, 1991, MOL REPROD DEV, V29, P313, DOI 10.1002/mrd.1080290402; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; EBENDAL T, 1986, EMBO J, V5, P1483, DOI 10.1002/j.1460-2075.1986.tb04386.x; Ebendal T, 1989, NERVE GROWTH FACTORS, V12, P81; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1991, J NEUROCHEM, V57, P1033, DOI 10.1111/j.1471-4159.1991.tb08254.x; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; IBANEZ CF, 1994, IN PRESS J NEUROBIOL; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SCHWARZ MA, 1989, J NEUROCHEM, V52, P1203, DOI 10.1111/j.1471-4159.1989.tb01867.x; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402	36	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19941	19946						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051078				2022-12-27	WOS:A1994PA12600045
J	CARRERA, AC; RODRIGUEZBORLADO, L; MARTINEZALONSO, C; MERIDA, I				CARRERA, AC; RODRIGUEZBORLADO, L; MARTINEZALONSO, C; MERIDA, I			T-CELL RECEPTOR-ASSOCIATED ALPHA-PHOSPHATIDYLINOSITOL 3-KINASE BECOMES ACTIVATED BY T-CELL RECEPTOR CROSS-LINKING AND REQUIRES PP56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; TRANSFORMATION; BINDING; DOMAIN; POLYPHOSPHOINOSITIDES; EXPRESSION	The activation of a phosphatidylinositol (PI) 3-kinase is one of the earliest intracellular responses to T lymphocyte stimulation. We have used a human T cell line, Jurkat, and an antibody that recognizes the clonotype of its T cell receptor (TcR) to characterize the association of PI 3-kinase with the TcR and its activation in response to TcR cross-linking. We show that the TcR is constitutively associated with the alpha isoform of the PI 3-kinase p85 regulatory subunit. Stimulation of Jurkat cells through the TcR results in the rapid and transient activation of the associated PI 3-kinase. In addition, our results indicate that the tyrosine kinase pp56(lck) is essential for PI 3-kinase activation via the TcR.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28059 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Merida, Isabel/A-9713-2014	Merida, Isabel/0000-0003-2762-6241; Carrera, Ana/0000-0002-3999-5434				AMREIN KE, 1993, MOL CELL BIOL, V13, P10285; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARRERA AC, 1989, J BIOL CHEM, V264, P15650; CARRERA AC, 1992, J IMMUNOL, V149, P3142; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REIF K, 1993, J BIOL CHEM, V268, P10780; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMELSON LE, 1990, P NATL ACAD SCI USA, V85, P5190; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; THOMPSON PA, 1992, ONCOGENE, V7, P719; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WARD SG, 1992, J BIOL CHEM, V267, P23862; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	41	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19435	19440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034711				2022-12-27	WOS:A1994NY33200038
J	LI, XM; TSAI, P; WIEDER, ED; KRIBBEN, A; VANPUTTEN, V; SCHRIER, RW; NEMENOFF, RA				LI, XM; TSAI, P; WIEDER, ED; KRIBBEN, A; VANPUTTEN, V; SCHRIER, RW; NEMENOFF, RA			VASCULAR SMOOTH-MUSCLE CELLS GROWN ON MATRIGEL - A MODEL OF THE CONTRACTILE PHENOTYPE WITH DECREASED ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE MATRIX; ARGININE VASOPRESSIN; ANGIOTENSIN-II; MAP KINASE; HYPERTROPHY; EXPRESSION; CULTURE; INVITRO; PHOSPHORYLATION; FIBRONECTIN	Vascular smooth muscle cells have been shown to exist in two phenotypic states which have been designated proliferative and contractile. The properties of rat aortic vascular smooth muscle cells grown on Matrigel were compared with cells grown on untreated plastic culture dishes. Cells grown on Matrigel manifested at least four important properties characteristic of the contractile phenotype as compared with cells grown on plastic. The cells grown on Matrigel had altered morphology similar to in vivo studies of contractile vascular smooth muscle. The cells had a low proliferative index, showed enhanced levels of the smooth muscle isoform of alpha-actin, and had an enhanced contractile response to the vasoconstrictor arginine vasopressin. All of these changes were maintained through at least five passages and could be reversed by replating cells grown on Matrigel back to uncoated plastic dishes. Changes in post-receptor signaling pathways which could account for the altered physiologic responses of the cells were investigated. Cells grown on Matrigel showed no alterations in agonist-induced mobilization of intracellular Ca2+ or agonist-stimulated cAMP levels. However, stimulation of mitogen activated protein kinase (MAP kinase) by both vasoconstrictors and growth factors was inhibited by 50% in cells grown on Matrigel as compared with plastic. This decrease in agonist-induced MAP kinase was associated with a decrease in the levels of both p42 and p44 MAP kinase protein and a decrease in tyrosine phosphorylation of both isoforms in cells grown on Matrigel. Alterations in MAP kinase activation can account at least in part for the observed physiologic responses of contractile vascular smooth muscle. Growth of vascular smooth muscle cells on Matrigel represents a useful model to examine phenotypic-dependent alterations in post-receptor signaling.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV RENAL DIS & HYPERTENS, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIDDK NIH HHS [DK39902, DK19928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK039902] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1992, INT J CANCER, V52, P234, DOI 10.1002/ijc.2910520214; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P313; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRANOT Y, 1990, BIOCHEM BIOPH RES CO, V168, P566, DOI 10.1016/0006-291X(90)92358-7; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; HERBERT JM, 1988, ARTERY, V16, P1; KEMPSKI O, 1987, INT J DEV NEUROSCI, V5, P435, DOI 10.1016/0736-5748(87)90021-9; KINSELLA JL, 1992, EXP CELL RES, V199, P56, DOI 10.1016/0014-4827(92)90461-G; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOCHER O, 1986, DIFFERENTIATION, V32, P245, DOI 10.1111/j.1432-0436.1986.tb00580.x; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLAD WJ, 1991, HEPATOLOGY, V13, P282, DOI 10.1002/hep.1840130213; MEYERLEHNERT H, 1988, AM J PHYSIOL, V254, pF254; NIKKARI ST, 1988, ATHEROSCLEROSIS, V74, P33, DOI 10.1016/0021-9150(88)90188-8; OKADA K, 1991, AM J PHYSIOL, V260, pF39, DOI 10.1152/ajprenal.1991.260.1.F39; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SASAKI Y, 1990, ADV SEC MESS PHOSPH, V24, P345; SERRADEILLEGAL C, 1991, PEPTIDES, V12, P575, DOI 10.1016/0196-9781(91)90104-W; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHIRINSKY VP, 1991, EXP CELL RES, V194, P186, DOI 10.1016/0014-4827(91)90352-U; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q	37	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19653	19658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034734				2022-12-27	WOS:A1994NY33200070
J	BINETTE, F; CRAVENS, J; KAHOUSSI, B; HAUDENSCHILD, DR; GOETINCK, PF				BINETTE, F; CRAVENS, J; KAHOUSSI, B; HAUDENSCHILD, DR; GOETINCK, PF			LINK PROTEIN IS UBIQUITOUSLY EXPRESSED IN NON-CARTILAGINOUS TISSUES WHERE IT ENHANCES AND STABILIZES THE INTERACTION OF PROTEOGLYCANS WITH HYALURONIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CDNA CLONES; RAT CHONDROSARCOMA; BINDING REGION; MESSENGER-RNA; PG-M; SEQUENCE; DOMAINS; GENE; LOCALIZATION	Link protein (LP) is an abundant protein of cartilage which stabilizes the interaction of aggrecan with hyaluronic acid (HA). In this study we report that LP is also present in a large number of embryonic non cartilaginous tissues. We demonstrate, using RNase protection experiments, that the coding region of the LP mRNAs isolated from these tissues is identical to that present in cartilage. Furthermore, we show that the LP mRNAs are translated in non-cartilaginous tissues by the identification of LP polypeptides with monoclonal antibody 4B6/A5 in Western blots. LP is localized in the extracellular matrix of the mesoderm along the entire digestive tract and in the dermis of the embryonic skin as revealed by immunofluorescence analysis. Investigations on the interactions between LP and proteoglycans from skin and proventriculus demonstrate that LP can enhance the binding of proteoglycans from these tissues to HA. In addition, we find that the same proteoglycans bound to HA in the presence of LP are always more resistant to competition by soluble HA than in the absence of LP. Our results suggest that LP is involved in the stabilization of extracellular matrices of a wide variety of non-cartilaginous tissues.	HARVARD UNIV,SCH MED,MGH E,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School			Haudenschild, Dominik/B-2381-2008	Haudenschild, Dominik/0000-0001-9947-9864	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022016, R01HD022050] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 22016, HD 22050] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BINETTE F, 1992, MOL BIOL CELL, V3, pA224; CHRISTNER JE, 1979, J BIOL CHEM, V254, P4624; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DEAK F, 1991, NUCLEIC ACIDS RES, V19, P4983, DOI 10.1093/nar/19.18.4983; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DUDHIA J, 1989, J MOL BIOL, V206, P749, DOI 10.1016/0022-2836(89)90581-0; DUDHIA J, 1990, NUCLEIC ACIDS RES, V18, P1292, DOI 10.1093/nar/18.5.1292; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GARDELL S, 1980, BIOCHEM BIOPH RES CO, V95, P1823, DOI 10.1016/S0006-291X(80)80111-2; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEVERFISCHER PL, 1988, ARCH BIOCHEM BIOPHYS, V263, P45, DOI 10.1016/0003-9861(88)90612-1; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; OSBORNELAWRENCE SL, 1990, GENOMICS, V8, P562, DOI 10.1016/0888-7543(90)90044-U; PERIN JP, 1980, FEBS LETT, V119, P333, DOI 10.1016/0014-5793(80)80283-3; PERIN JP, 1987, J BIOL CHEM, V262, P13269; POOLE AR, 1982, J CELL BIOL, V93, P910, DOI 10.1083/jcb.93.3.910; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RHODES C, 1988, J BIOL CHEM, V263, P6063; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; SANDY JD, 1985, BIOCHEM J, V232, P613, DOI 10.1042/bj2320613; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STIRPE NS, 1989, DEVELOPMENT, V107, P23; STIRPE NS, 1990, DEV BIOL, V137, P419, DOI 10.1016/0012-1606(90)90266-L; TSONIS PA, 1988, EXP EYE RES, V46, P753, DOI 10.1016/S0014-4835(88)80061-7; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	38	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19116	19122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034670				2022-12-27	WOS:A1994NX32700063
J	DARKE, PL; CHEN, E; HALL, DL; SARDANA, MK; VELOSKI, CA; LAFEMINA, RL; SHAFER, JA; KUO, LC				DARKE, PL; CHEN, E; HALL, DL; SARDANA, MK; VELOSKI, CA; LAFEMINA, RL; SHAFER, JA; KUO, LC			PURIFICATION OF ACTIVE HERPES-SIMPLEX VIRUS-1 PROTEASE EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYPE-1 PROTEASE; CLEAVAGE SITES; IDENTIFICATION; PROTEINASE; SEQUENCE; DOMAIN; GENE; DNA	Assembly of viral capsids for replication of herpes simplex virus requires the proteolytic processing of the assembly protein ICP35. The protease responsible for this process is encoded within the 635-amino acid open reading frame of the U(L)26 gene of the virus. A simple purification scheme is given in this report for the native, mature form of the protease expressed in Escherichia coli. The scheme allows the preparation of milligram quantities of purified enzyme for elucidation of kinetic mechanism as well as for structural studies. Utilizing a 13-residue peptide substrate representing the natural cleavage site that releases the protease, k(cat) and K-m values of the purified native enzyme are 2.0 min(-1) and 0.88 mM, respectively. Thus, peptide cleavage is less efficient than reported for other viral proteases. The possibility exists that viral or cellular factors are involved in vivo for activation of the protease for herpes capsid maturation.	MERCK SHARP & DOHME LTD, RES LABS, DEPT ANTIVIRAL RES, W POINT, PA 19486 USA	Merck & Company	DARKE, PL (corresponding author), MERCK SHARP & DOHME LTD, RES LABS, DEPT BIOL CHEM, WP26-431, W POINT, PA 19486 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DIIANNI CL, 1993, J BIOL CHEM, V268, P2048; DIIANNI CL, 1993, J BIOL CHEM, V268, P25449; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; INNIS MA, 1990, PCR PROTOCOLS, P54; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	16	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18708	18711						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034621				2022-12-27	WOS:A1994NX32700002
J	GOSS, VL; HOCEVAR, BA; THOMPSON, LJ; STRATTON, CA; BURNS, DJ; FIELDS, AP				GOSS, VL; HOCEVAR, BA; THOMPSON, LJ; STRATTON, CA; BURNS, DJ; FIELDS, AP			IDENTIFICATION OF NUCLEAR BETA(II) PROTEIN-KINASE-C AS A MITOTIC LAMIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; NUCLEAR-ENVELOPE; PHOSPHORYLATION SITES; MAMMALIAN-CELLS; GROWTH-FACTOR; CDC2 KINASE; MITOSIS; DIFFERENTIATION; INVITRO; PROLIFERATION	Multisite phosphorylation of the nuclear lamins is thought to regulate the process of mitotic nuclear envelope breakdown in vivo. Here we investigate the involvement of two proposed human mitotic lamin kinases, beta(II) protein kinase C (PKC) and p34(cdc2)/cyclin B kinase, in human lamin B-1 phosphorylation in vitro and in intact cells. We find that both kinases can phosphorylate purified soluble lamin B at similar rates. However, beta(II) PKC phosphorylates interphase nuclear envelope lamin B at more than 200 times the rate of human p34(cdc2)/cyclin B kinase. beta(II) PRC-mediated phosphorylation of lamin B is confined to two sites, Ser(395) and Ser(405), within the carboxyl-terminal domain, whereas human p34(cdc2)/cyclin B kinase phosphorylates a single site, Ser(23), in the amino-terminal domain. A second potential p34(cdc2)/cyclin B kinase site within the carboxyl-terminal domain, Ser(393), is not phosphorylated by human p34(cdc2)/cyclin B kinase. However, invertebrate p34(cdc2)/cyclin B kinase from sea star exhibits a different specificity, phosphorylating both amino- and carboxyl-terminal sites. Mitotic human lamin B from intact cells is phosphorylated predominantly in its carboxyl-terminal domain. Comparative tryptic phosphopeptide mapping demonstrates that the beta(II) PKC site, Ser(405), is a prominent target of mitotic lamin B phosphorylation in vivo. beta(II) PKC translocates to the nucleus during the G(2)/M phase of cell cycle concomitant with phosphorylation of Ser(405), indicating a physiologic role for nuclear beta(II) PKC activation in mitotic lamin B phosphorylation in vivo. The presence of phosphorylation sites within the carboxyl-terminal domain of mitotic lamin B which are not phosphorylated by either beta(II) PKC or p34(cdc2)/cyclin B kinase suggests the involvement of other lamin kinase(s) in G(2)/M phase lamin B phosphorylation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; SPHINX PHARMACEUT CORP, DURHAM, NC 27707 USA	Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERACE L, 1984, J CELL SCI, P137; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LOHKA MJ, 1989, J CELL SCI, V92, P131; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; SEHY DW, 1992, J CELL BIOCHEM, V50, P255, DOI 10.1002/jcb.240500306; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	30	180	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19074	19080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034666				2022-12-27	WOS:A1994NX32700057
J	HOCKING, DC; SOTTILE, J; MCKEOWNLONGO, PJ				HOCKING, DC; SOTTILE, J; MCKEOWNLONGO, PJ			FIBRONECTINS III-1 MODULE CONTAINS A CONFORMATION-DEPENDENT BINDING-SITE FOR THE AMINO-TERMINAL REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ASSEMBLY SITES; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; CELL-SURFACE; POLYACRYLAMIDE GELS; HUMAN-FIBROBLASTS; DOMAIN; RECEPTOR; FRAGMENTS; PROTEINS	Cultured fibroblasts express binding sites for the amino-terminal region of fibronectin on their cell surface that mediate the assembly of soluble fibronectin into disulfide-stabilized fibrils. These binding sites have been termed matrix assembly sites and have been studied in binding assays using a I-125-labeled 70-kDa fragment derived from the amino terminus of fibronectin. In an attempt to isolate the protein(s) responsible for binding the 70-kDa fragment, cell surface proteins were cleaved from fibroblast monolayers by mild trypsinization. Trypsinization of monolayers generated a series of fibronectin fragments that bound the I-125-labeled 70-kDa fragment by ligand blot assay and affinity chromatography. All of the fibronectin fragments that bound the 70-kDa fragment contained the III-1 module. In solid phase binding assays, the I-125-labeled 70-kDa fragment bound preferentially to reduced fibronectin as compared with unreduced fibronectin fragments. Binding of the I-125-Iabeled 70-kDa fragment to reduced fibronectin was inhibited by a monoclonal antibody directed against the III-1 domain. Isolated III-1, however, did not bind the I-125-labeled 70-kDa fragment when adsorbed to plastic tissue culture webs. Heat denaturation of III-1 prior to adsorption conferred 70 kDa fragment binding properties on the isolated module. The I-125-labeled 70-kDa fragment did not bind to heat-denatured III-2, suggesting that 70-kDa fragment binding was a property of the III-1 module and not a general characteristic of all type III modules. The binding of I-125-labeled 70-kDa fragment to III-1 was of high affinity (K-D = 1.8 x 10(-8) M). These results indicate that a binding site for the 70-kDa amino terminus of fibronectin is contained within a cryptic site found in the first type III module of fibronectin. Unfolding of the III-1 module on the cell surface may control matrix assembly site expression and represent an important step in the initiation of cell-dependent fibronectin polymerization.	ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208	Albany Medical College			Hocking, Denise/H-7903-2012	Hocking, Denise/0000-0003-2337-0357	NHLBI NIH HHS [HL-21644] Funding Source: Medline; NIGMS NIH HHS [T32-GM-07033, P01-GM-40761] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040761, T32GM007033] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ALLIO AE, 1988, J CELL PHYSIOL, V135, P459, DOI 10.1002/jcp.1041350313; BALIAN G, 1980, J BIOL CHEM, V255, P3234; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BLYSTONE S, 1991, J BIOL CHEM, V267, P3968; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARNEMOLLA B, 1992, J BIOL CHEM, V267, P24689; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; EHRISMANN R, 1981, J BIOL CHEM, V256, P4056; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYMAN EG, 1979, J CELL BIOL, V83, P255, DOI 10.1083/jcb.83.1.255; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Hynes RO, 1990, FIBRONECTINS; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KOWALCZYK AP, 1992, J CELL PHYSIOL, V152, P126, DOI 10.1002/jcp.1041520117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MCKEOWNLONGO PJ, 1987, REV INFECT DIS, V9, P322; MOON KY, 1994, J BIOL CHEM, V269, P7651; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1984, ANNU REV MED, V35, P561, DOI 10.1146/annurev.me.35.020184.003021; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RISER BL, 1992, J CLIN INVEST, V90, P1932, DOI 10.1172/JCI116071; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU CY, 1993, J BIOL CHEM, V268, P21883; Yamada KM, 1989, FIBRONECTIN, P47	53	178	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19183	19191						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034677				2022-12-27	WOS:A1994NX32700073
J	SANDSTROM, J; NILSSON, P; KARLSSON, K; MARKLUND, SL				SANDSTROM, J; NILSSON, P; KARLSSON, K; MARKLUND, SL			10-FOLD INCREASE IN HUMAN PLASMA EXTRACELLULAR-SUPEROXIDE DISMUTASE CONTENT CAUSED BY A MUTATION IN HEPARIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; HUMAN CELL-LINES; ISOENZYMES; AFFINITY; TISSUES; EXPRESSION; DNA	Extracellular superoxide dismutase (EC-SOD) is a secretory SOD isoenzyme. 99% of EC-SOD is anchored to heparan sulfate proteoglycans in the tissue interstitium, and 1% is located in the vasculature in equilibrium between the plasma and the endothelium. Analysis of EC-SOD in plasma samples from 504 random blood donors revealed a common (2.2%) phenotypic variant displaying 10-fold increased plasma EC-SOD content. The EC-SOD in the plasma of these individuals, collected both before and after intravenous injection of heparin, displayed a reduced heparin affinity when compared with samples from normal individuals. The specific enzymatic activity was the same as that of normal enzyme. Nucleotide sequence analyses of two of the affected subjects revealed a nucleotide exchange resulting in a substitution of Arg-213 by Gly. The substitution is located in the center of the carboxyl-terminal cluster of positively charged amino acid residues, which defines the heparin-binding domain. Polymerase chain reaction-single-strand conformational polymorphism and allele-specific polymerase chain reaction showed that all 11 affected individuals are heterozygous, carrying the same single-base mutation. Recombinant EC-SOD containing this mutation had a reduced heparin affinity similar to that of EC-SOD C from variant persons. The high plasma activity can be explained by an accelerated release from the tissue interstitium heparan sulfate to the vasculature and should thus be accompanied by significantly reduced tissue EC-SOD activities.	UMEA UNIV HOSP, DEPT CLIN CHEM, S-90185 UMEA, SWEDEN; UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University; Umea University								ADACHI T, 1991, BIOCHEM J, V279, P263, DOI 10.1042/bj2790263; ADACHI T, 1992, CLIN CHIM ACTA, V212, P89, DOI 10.1016/0009-8981(92)90176-Q; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1988, J CLIN INVEST, V82, P762, DOI 10.1172/JCI113676; KARLSSON K, 1989, LAB INVEST, V60, P659; KARLSSON K, IN PRESS LAB INVEST; LEHR HA, 1992, ARTERIOSCLER THROMB, V12, P824, DOI 10.1161/01.ATV.12.7.824; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MARKLUND SL, 1986, ANN RHEUM DIS, V45, P847, DOI 10.1136/ard.45.10.847; MARKLUND SL, 1985, CRC HDB METHODS OXYG, P249; OHMAN M, 1986, CLIN SCI, V70, P365; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SANDSTROM J, 1993, BIOCHEM J, V294, P853, DOI 10.1042/bj2940853; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634	28	186	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19163	19166						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034674				2022-12-27	WOS:A1994NX32700070
J	WEIS, BC; ESSER, V; FOSTER, DW; MCGARRY, JD				WEIS, BC; ESSER, V; FOSTER, DW; MCGARRY, JD			RAT-HEART EXPRESSES 2 FORMS OF MITOCHONDRIAL CARNITINE PALMITOYLTRANSFERASE-I - THE MINOR COMPONENT IS IDENTICAL TO THE LIVER-ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FATTY-ACID OXIDATION; MALONYL-COA; INHIBITORS; KETOGENESIS; CLONING; TISSUES; SYSTEM	To begin to explore the basis for the tissue-specific expression of mitochondrial carnitine palmitoyltransferase I (CPT I), we focused on three rat tissues (liver, heart, and skeletal muscle) in which the enzyme was known to display very different properties. In Northern blot analysis, a cDNA probe corresponding to liver CPT I readily hybridized to a 4.5-kilobase species of mRNA in liver and heart, but not in skeletal muscle. Using the same probe to screen a neonatal rat heart cDNA library, a full-length clone, surprisingly having 100% sequence identity to the liver CPT I cDNA, was isolated. The paradox was resolved by two additional experiments. First, in Western blots of mitochondrial membranes, an antibody raised against liver CPT I recognized the 88-kDa protein in heart, as well as in liver, but not in skeletal muscle. Second, high specific activity [H-3]deschloroetomoxir (a covalent ligand for CPT I) reacted with a single form of CPT I in liver (similar to 88 kDa) and skeletal muscle (similar to 82 kDa), while proteins of both sizes were labeled in the cardiac myocyte. Tritiated ligand binding to the two heart proteins was blocked by excess unlabeled malonyl-CoA. It is concluded that liver and skeletal muscle each contains a single and distinct isoform of CPT I with monomeric size of similar to 88 and 82 kDa, respectively. The heart contains a CPT I protein of similar to 82 kDa in size (probably identical to the skeletal muscle protein) but, importantly, also expresses the liver-type enzyme, The results likely explain why previous studies of heart CPT I yielded an apparent K-m for carnitine and I-50 value for malonyl-CoA inhibition that were intermediate between those of the liver and skeletal muscle enzymes.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; CHEN S, 1994, IN PRESS DIABETES; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090; DUAN C, 1992, J APPL PHYSIOL, V72, P901, DOI 10.1152/jappl.1992.72.3.901; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; KERNER J, 1994, J BIOL CHEM, V269, P8209; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; REUBSAET FAG, 1990, BIOCHIM BIOPHYS ACTA, V1047, P264, DOI 10.1016/0005-2760(90)90525-3; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; YOUNG DAB, 1976, EXPERIENTIA, V32, P1389, DOI 10.1007/BF01937391	20	119	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18712	18715						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034622				2022-12-27	WOS:A1994NX32700003
J	DASILVA, L; HOWARD, OMZ; RUI, H; KIRKEN, RA; FARRAR, WL				DASILVA, L; HOWARD, OMZ; RUI, H; KIRKEN, RA; FARRAR, WL			GROWTH SIGNALING AND JAK2 ASSOCIATION MEDIATED BY MEMBRANE-PROXIMAL CYTOPLASMIC REGIONS OF PROLACTIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROPOIETIN RECEPTOR; HORMONE RECEPTOR; TYROSINE KINASE; MOLECULAR-CLONING; LYMPHOMA-CELLS; ACTIVATION; EVOLUTION; DOMAIN; IDENTIFICATION; SUPERFAMILY	Prolactin (PRL) has recently been demonstrated to induce tyrosine phosphorylation and activation of the cytoplasmic tyrosine kinase JAK2 in PRL-dependent Nb2 lymphoma cells. The present study represents an initial effort to identify cytoplasmic regions of the PRL receptor (PRLR) that are critical to growth signal generation and JAK2 activation. Variably truncated rat PRLRs were stably expressed in the murine 32D cell line. PRL-induced proliferation was mediated by the full-length receptor and the mutant G328, which contains the membrane-proximal Homology Boxes 1 and 2 characteristic of hematopoietin receptors. In contrast, mutant receptors lacking either Box 2 or both Boxes 1 and 2 were not capable of transmitting a growth signal. The mitogenic capacity of the PRLR variants correlated with JAK2 association and activation, as well as with induction of mRNA levels for the growth related gene ornithine decarboxylase. We conclude that mitogenic competence of rat PRLRs resides within the first 94 amino acids of the cytoplasmic domain. The data suggest that Homology Box 1/Box 2 region is critical to JAK2 phosphorylation and association with the PRLR. These findings mill serve as a basis for more detailed molecular characterization of PRLR domains essential for JAK2 interaction and growth signal generation.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052	FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALI S, 1991, J BIOL CHEM, V266, P20110; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERN HA, 1983, AM ZOOL, V23, P663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; GOUT PW, 1980, CANCER RES, V40, P2433; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21	29	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18267	18270						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034567				2022-12-27	WOS:A1994NW79800003
J	FUJIWARA, J; KIMURA, T; AYUSAWA, D; OISHI, M				FUJIWARA, J; KIMURA, T; AYUSAWA, D; OISHI, M			A NOVEL REGULATORY SEQUENCE AFFECTING THE CONSTITUTIVE EXPRESSION OF TISSUE-PLASMINOGEN ACTIVATOR (TPA) GENE IN HUMAN-MELANOMA (BOWES) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; MAMMALIAN-CELLS; RETINOIC ACID; PROMOTER; ELEMENT; DNA; PURIFICATION; RELEASE; REGION	In order to identify a possible enhancer-like regulatory sequence for the human tissue plasminogen activator (tPA) gene, various DNA segments in the 5'-flanking region were ligated to the chloramphenicol acetyltransferase (CAT) reporter gene driven by the tPA gene promoter, and their CAT enhancing activities were measured following transfection to human melanoma-derived Bowes cells that highly express the gene. Major and minor activities were detected in two adjacent upstream sequences, 160 base pairs (bp) (-2288 to -2129) and 102 bp (-2390 to -2289), respectively, and the former was subjected to further analysis. The CAT enhancing activity of the 160-bp sequence was greatly affected by its position and orientation in the constructs and the sequence also functioned weakly with the SV40 promoter. Deletion of any small portion from the sequence abolished the CAT enhancing activity, suggesting that the entire sequence is required for the activity. This sequence did not show a further CAT enhancing activity in Bowes cells treated with the inducers phorbol 12-myristate 13-acetate and dexamethasone and did not function in HeLa or HT1080 cells under any conditions. Taken together, the 160 bp sequence is likely to be responsible for the constitutive and/or cell type-specific expression of the tPA gene in human cells.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AOKI N, 1974, J BIOCHEM-TOKYO, V75, P731, DOI 10.1093/oxfordjournals.jbchem.a130446; BINDER BR, 1979, J BIOL CHEM, V254, P1998; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; DICKERMAN HW, 1989, ENDOCRINOLOGY, V125, P492, DOI 10.1210/endo-125-1-492; FISHER R, 1985, J BIOL CHEM, V260, P1223; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEVIN EG, 1982, J CELL BIOL, V94, P631, DOI 10.1083/jcb.94.3.631; LEVIN EG, 1988, J BIOL CHEM, V263, P9360; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEVIN EG, 1983, P NATL ACAD SCI USA, V80, P6840; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NAGATA Y, 1985, FEBS LETT, V183, P379, DOI 10.1016/0014-5793(85)80814-0; RICKLES RJ, 1989, MOL CELL BIOL, V9, P1691, DOI 10.1128/MCB.9.4.1691; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RYAN TJ, 1984, J BIOL CHEM, V259, P4324; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALLER EK, 1985, J BIOL CHEM, V260, P6354	26	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18558	18562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034604				2022-12-27	WOS:A1994NW79800052
J	ULLRICH, A; SURES, I; DEGIDIO, M; JALLAL, B; POWELL, TJ; HERBST, R; DREPS, A; AZAM, M; RUBINSTEIN, M; NATOLI, C; SHAWVER, LK; SCHLESSINGER, J; IACOBELLI, S				ULLRICH, A; SURES, I; DEGIDIO, M; JALLAL, B; POWELL, TJ; HERBST, R; DREPS, A; AZAM, M; RUBINSTEIN, M; NATOLI, C; SHAWVER, LK; SCHLESSINGER, J; IACOBELLI, S			THE SECRETED TUMOR-ASSOCIATED ANTIGEN 90K IS A POTENT IMMUNE STIMULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE BINDING PROTEIN-35; HUMAN-BREAST CANCER; MONOCLONAL-ANTIBODY; NEU ONCOGENE; SERUM; CELLS; PROGRESSION; DNA; RECEPTOR; CLONING	Immunization of mice with conditioned media from human breast cancer cells yielded the monoclonal antibody SP-2, which recognized an antigen of approximately 90-95 kDa. This protein, designated 90K, was found to be present in the serum of healthy individuals and at elevated levels in the serum of subpopulations of patients with various types of cancer and AIDS. Here we report the primary structure of the SP-2 antigen and demonstrate its relationship to a family of proteins which carry a scavenger receptor cysteine-rich domain. Northern blot analysis of normal tissues, primary tumors, and tumor-derived cell lines indicates a broad expression spectrum of the 90K gene at widely varying levels. Functional characterization reveals stimulatory effects of 90K on host defense systems, such as natural killer cell and lymphokine-activated killer cell activity, and indicates that its immunostimulatory effects may be mediated through the induction of interleukin-2 and possibly other cytokines.	UNIV G DANNUNZIO,CATTEDRA ONCOL MED,I-66100 CHIETI,ITALY; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	G d'Annunzio University of Chieti-Pescara; Max Planck Society; Weizmann Institute of Science; New York University			Natoli, Clara/E-1378-2013	Natoli, Clara/0000-0001-7295-0230				ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS NC, 1993, AIDS RES HUM RETROV, V9, P811, DOI 10.1089/aid.1993.9.811; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P218; DISIS ML, 1994, CANCER RES, V54, P16; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HO MK, 1982, J IMMUNOL, V128, P1221; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; HUYNH T, 1984, PRACTICAL APPROACHES; IACOBELLI S, 1994, BRIT J CANCER, V69, P172, DOI 10.1038/bjc.1994.29; IACOBELLI S, 1986, CANCER RES, V46, P3005; IACOBELLI S, 1993, FEBS LETT, V319, P59, DOI 10.1016/0014-5793(93)80037-U; IACOBELLI S, 1988, BREAST CANCER RES TR, V11, P19, DOI 10.1007/BF01807554; IACOBELLI S, 1988, INT J CANCER, V42, P182, DOI 10.1002/ijc.2910420207; IACOBELLI S, 1991, J INFECT DIS, V164, P819, DOI 10.1093/infdis/164.4.819; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOTHS K, 1993, J BIOL CHEM, V268, P14245; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LINSLEY PS, 1986, BIOCHEMISTRY-US, V25, P2978, DOI 10.1021/bi00358a037; LONGO G, 1993, BRIT J HAEMATOL, V85, P207, DOI 10.1111/j.1365-2141.1993.tb08674.x; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MAGDELENAT H, 1992, J IMMUNOL METHODS, V150, P133, DOI 10.1016/0022-1759(92)90072-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NATALI PG, 1982, CANCER RES, V42, P583; NATOLI C, 1993, BRIT J CANCER, V67, P564, DOI 10.1038/bjc.1993.103; NATOLI C, 1991, J INFECT DIS, V164, P616, DOI 10.1093/infdis/164.3.616; NATOLI C, 1993, J ACQ IMMUN DEF SYND, V6, P370; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAMBIA G, 1988, ANTICANCER RES, V8, P761; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WOO HJ, 1990, J BIOL CHEM, V265, P7097	39	175	186	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18401	18407						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034587				2022-12-27	WOS:A1994NW79800029
J	HSUWONG, S; KATCHMAN, SD; LEDO, I; WU, M; KHILLAN, J; BASHIR, MM; ROSENBLOOM, J; UITTO, J				HSUWONG, S; KATCHMAN, SD; LEDO, I; WU, M; KHILLAN, J; BASHIR, MM; ROSENBLOOM, J; UITTO, J			TISSUE-SPECIFIC AND DEVELOPMENTALLY-REGULATED EXPRESSION OF HUMAN ELASTIN PROMOTER ACTIVITY IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST-CULTURES; GROWTH-FACTOR-BETA; GENE-EXPRESSION; LIGAMENT FIBROBLASTS; 5'-FLANKING REGION; MESSENGER-RNA; CELLS; DELINEATION; CDNA; DNA	We have recently cloned the entire human elastin gene, including similar to 5.2 kilobases of the 5'-flanking sequences. To examine tissue-specific expression of the elastin gene, we have developed a transgenic mouse line that expresses the human elastin promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene. Assay of CAT activity in different tissues revealed the highest expression in the lungs and aorta, while lower levels were detected in the kidneys, heart, brain, and skin; this distribution parallels the accumulation of elastin in developing animals. Comparison of CAT activity in the lungs of fetal (15-day gestation) and newborn (5-day postnatal) animals revealed significantly (similar to 4-fold) higher activity in the fetal tissue. The relatively high activity in the lungs progressively declined during the postnatal period up to 6 months. The promoter activity in the aorta remained constant from 5 days to 3 months and then gradually declined, while in the skin, the activity peaked at 3 months, returning thereafter to the control (5-day) level. Thus, there is evidence for developmentally regulated, tissue specific expression of the elastin promoter in vivo as tested in these transgenic mice.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; UNIV PENN,SCH DENT,DEPT HISTOL & ANAT,PHILADELPHIA,PA 19104	Jefferson University; Jefferson University; University of Pennsylvania					NIAMS NIH HHS [R01-AR28450, P01-AR38923, P01-AR20553] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, R01AR028450, P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASHIR MM, 1989, J BIOL CHEM, V264, P8887; Burton K., 1968, METHODS ENZYMOLOGY B, V12B, P163; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; GIRO MG, 1985, J CLIN INVEST, V75, P672, DOI 10.1172/JCI111746; GIRO MG, 1984, COLLAGEN REL RES, V4, P24; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOGAN B, 1986, MANIPULATING MOUSE E; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; MAUVIEL A, 1993, J BIOL CHEM, V268, P6520; MECHAM RP, 1985, J BIOL CHEM, V260, P3255; MECHAM RP, 1984, J BIOL CHEM, V259, P2414; OLSEN DR, 1988, J BIOL CHEM, V263, P6465; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; ROSENBLOOM J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P145; Sambrook J, 1989, MOL CLONING LABORATO; UITTO J, 1991, BIOCHEM SOC T, V19, P824, DOI 10.1042/bst0190824; UITTO J, 1992, PHYSL BIOCH MOL BIOL, P530; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003	23	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18072	18075						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027067				2022-12-27	WOS:A1994NV42200049
J	MIMOUNI, M; BONTEMPS, F; VANDENBERGHE, G				MIMOUNI, M; BONTEMPS, F; VANDENBERGHE, G			KINETIC-STUDIES OF RAT-LIVER ADENOSINE KINASE - EXPLANATION OF EXCHANGE-REACTION BETWEEN ADENOSINE AND AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOXIC HEPATOCYTES; METABOLISM; MECHANISM; VANADATE; PROTEINS; BINDING	Rat liver adenosine kinase can catalyze an exchange reaction between adenosine and AMP in the absence of ATP (Bontemps, F., Mimouni, M., and Van den Berghe, G. (1993) Biochem. J. 290, 679-684), suggesting a classical ping-pong mechanism. Contrary to expectations, formation of a phosphorylenzyme intermediate could not be demonstrated by incubating the enzyme with [gamma-P-32] ATP. Although initial velocity measurements in function of the concentration of adenosine or Mg.ATP, at various fixed concentrations of Mg.ATP or adenosine, generated parallel line patterns, inhibition studies revealed that competitive inhibition was only observed between ADP and ATP. This indicates an Ordered Bi Bi mechanism in which ATP binds first to the enzyme, and ADP is released last. The adenosine-AMP exchange reaction was found to be potently stimulated by ADP, and the basal exchange reaction, i.e. measured in the absence of added ADP, could be accounted for by a slight (0.001%) contamination by ADP of analytical grade AMP. The ADP requirement of the adenosine-AMP exchange reaction explains its occurrence in an Ordered Ri Bi mechanism. Stimulation of the exchange reaction between AMP and adenosine by increasing concentrations of ADP/ATP, and stimulation followed by inhibition of the exchange reaction between ADP and ATP by increasing concentrations of AMP/adenosine, corroborated the proposed mechanism.	UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,PHYSIOL CHEM LAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								Anderson E. P., 1973, ENZYMES, P49; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; Arch J R, 1978, Essays Biochem, V14, P82; BHAUMIK D, 1988, MOL BIOCHEM PARASIT, V28, P181, DOI 10.1016/0166-6851(88)90002-3; BONTEMPS F, 1993, BIOCHEM J, V290, P671, DOI 10.1042/bj2900671; BONTEMPS F, 1993, BIOCHEM J, V290, P679, DOI 10.1042/bj2900679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CH, 1983, BIOCHEMISTRY-US, V22, P600, DOI 10.1021/bi00272a012; CLIMENT F, 1981, BIOCHEM BIOPH RES CO, V101, P570, DOI 10.1016/0006-291X(81)91297-3; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; FROMM HJ, 1962, J BIOL CHEM, V237, P1661; FROMM HJ, 1968, BIOCHEM BIOPH RES CO, V32, P672, DOI 10.1016/0006-291X(68)90291-X; GARVEY EP, 1992, ARCH BIOCHEM BIOPHYS, V296, P161, DOI 10.1016/0003-9861(92)90558-E; HARTWICK RA, 1975, J CHROMATOGR, V112, P651, DOI 10.1016/S0021-9673(00)99994-1; HAWKINS CF, 1987, BIOCHEMISTRY-US, V26, P1982, DOI 10.1021/bi00381a030; HENDERSON JF, 1972, J BIOL CHEM, V247, P1972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU BR, 1992, METABOLISM, V41, P457, DOI 10.1016/0026-0495(92)90199-K; MANNERVIK B, 1973, BIOCHEM BIOPH RES CO, V53, P1151, DOI 10.1016/0006-291X(73)90585-8; MIMOUNI M, 1993, PHARM WORLD SCI, V15, pF22; OSULLIVAN WJ, 1964, BIOCHEMISTRY-US, V3, P18, DOI 10.1021/bi00889a005; PALELLA TD, 1980, J BIOL CHEM, V255, P5264; ROTLLAN P, 1985, EUR J BIOCHEM, V151, P365, DOI 10.1111/j.1432-1033.1985.tb09110.x; SEGEL I, 1975, ENZYME KINETICS, P833; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SMITH E, 1969, J BIOL CHEM, V244, P4224; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	27	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17820	17825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027035				2022-12-27	WOS:A1994NV42200013
J	KOENIG, JA; EDWARDSON, JM				KOENIG, JA; EDWARDSON, JM			KINETIC-ANALYSIS OF THE TRAFFICKING OF MUSCARINIC ACETYLCHOLINE-RECEPTORS BETWEEN THE PLASMA-MEMBRANE AND INTRACELLULAR COMPARTMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; CHOLINERGIC RECEPTORS; DOWN-REGULATION; PROTEIN-KINASE; NEUROBLASTOMA-CELLS; CHICK HEART; PHOSPHOINOSITIDE HYDROLYSIS; AGONIST; DESENSITIZATION; INTERNALIZATION	We have studied the kinetics of muscarinic receptor trafficking between the plasma membrane and intracellular compartments in NG108-15 cells. A model of trafficking is proposed that includes four transport steps, delivery to the plasma membrane from the Golgi complex (linear) and endosomes (exponential), internalization from the plasma membrane into endosomes (exponential), and a degradative route from endosomes into lysosomes (linear). Based upon this model, a general equation has been derived that describes changes in receptor number at the plasma membrane and in endosomes in response to agonist stimulation. By following the movement of receptors into and out of the plasma membrane under various experimental conditions, it has been possible to determine the values of the four rate constants in the general equation and also the size of the endosomal receptor pool created by agonist stimulation. The consequences of changes in these constants for receptor trafficking are demonstrated. The model accounts for the effect of varying the duration of agonist stimulation on the size of the endosomal receptor pool and also permits an estimation of the receptor trafficking that underlies the well-established phenomenon of agonist-induced receptor internalization.	UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND	University of Cambridge				Koenig, Jennifer/0000-0002-2137-834X				BAUMGOLD J, 1989, NEUROPHARMACOLOGY, V28, P1253, DOI 10.1016/0028-3908(89)90219-0; CIOFFI CL, 1990, J NEUROCHEM, V54, P1725, DOI 10.1111/j.1471-4159.1990.tb01227.x; CIOFFI CL, 1989, BIOCHEM PHARMACOL, V38, P1827, DOI 10.1016/0006-2952(89)90418-8; EVA C, 1990, J PHARMACOL EXP THER, V253, P257; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; GALPER JB, 1980, J BIOL CHEM, V255, P9571; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HAGA T, 1993, LIFE SCI, V52, P421, DOI 10.1016/0024-3205(93)90297-G; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOOVER RK, 1990, J PHARMACOL EXP THER, V253, P185; HUNTER DD, 1986, J NEUROSCI, V6, P3739; JAMIESON JD, 1968, J CELL BIOL, V39, P580, DOI 10.1083/jcb.39.3.580; KANBA S, 1990, BIOCHEM PHARMACOL, V40, P1005, DOI 10.1016/0006-2952(90)90486-5; KOENIG JA, 1994, BRIT J PHARMACOL, V111, P1023, DOI 10.1111/j.1476-5381.1994.tb14846.x; KOENIG JA, 1993, BRIT J PHARMACOL, V110, pP70; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LILES WC, 1986, J BIOL CHEM, V261, P5307; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MORO O, 1993, J BIOL CHEM, V268, P6862; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; RAY P, 1989, J NEUROCHEM, V52, P402, DOI 10.1111/j.1471-4159.1989.tb09135.x; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; YOUNG JM, 1972, J PHARM PHARMACOL, V24, P950, DOI 10.1111/j.2042-7158.1972.tb08925.x	32	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17174	17182						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006025				2022-12-27	WOS:A1994NT84600032
J	KIM, GD; CARR, IC; ANDERSON, LA; ZABAVNIK, J; EIDNE, KA; MILLIGAN, G				KIM, GD; CARR, IC; ANDERSON, LA; ZABAVNIK, J; EIDNE, KA; MILLIGAN, G			THE LONG ISOFORM OF THE RAT THYROTROPIN-RELEASING-HORMONE RECEPTOR DOWN-REGULATES G(Q) PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; GLIOMA HYBRID-CELLS; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; MUSCARINIC RECEPTOR; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; PITUITARY-CELLS; CHO CELLS	A cDNA encoding the long isoform of the rat thyrotropin releasing hormone (TRH) receptor was expressed stably in HEK-293 cells. Polymerase chain reaction analysis confirmed expression of mRNA encoding only the long and not the short isoform. Activation of this receptor with TRH caused a large stimulation in production of inositol phosphates but did not produce either activation of basal or inhibition of forskolin-amplified adenylyl cyclase activity. Sustained exposure of these transfected cells to TRH resulted in a substantial reduction in cellular levels of G(q) alpha-like immunoreactivity from some 12 to 5 pmol/mg of membrane protein without significant alterations in cellular levels of the alpha subunits of G(s), G(i)1, G(i)2, G(i)3, or G(o). Equivalent experiments in GH3 cells also indicated a marked down-regulation of G(q) alpha/G(11)alpha. Dose-response curves indicated that 20 nM TRH produced half-maximal down-regulation of cellular G(q)-like immunoreactivity in the transfected HEK-293 cells and that half-maximal loss was produced within 3-4 h. Separation of the transfected HEK-293 cell membranes in SDS-polyacrylamide gel electrophoresis conditions able to resolve individual members of the G(q) family of G proteins demonstrated the presence of two related G-proteins. Both of the expressed G(q)-like G-proteins were observed to be downregulated in parallel by TRH. The similarity of dose response curves and time-courses for loss of the two G-proteins indicates that the long isoform of the rat TRH receptor does not functionally select between these two transducer proteins. In GH3 cells both G(q) alpha and G(11)alpha, which are expressed at similar levels, were observed to be down-regulated equivalently by treatment with TRH.	UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PHARMACOL,GLASGOW G12 8QQ,SCOTLAND; CTR REPROD BIOL,MRC,REPROD BIOL UNIT,EDINBURGH EH3 9EW,SCOTLAND	University of Glasgow; University of Glasgow			Zabavnik, Jelka/AAK-9742-2021; Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; GREEN A, 1990, J BIOL CHEM, V265, P5206; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; KIM GD, 1994, IN PRESS BIOCH BIOPH; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1987, BIOCHEM J, V245, P501, DOI 10.1042/bj2450501; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MILLIGAN G, 1987, J BIOL CHEM, V262, P8626; MILLIGAN G, 1989, BIOCHEM J, V260, P837, DOI 10.1042/bj2600837; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MULLANEY I, 1993, BIOCHEM J, V289, P125, DOI 10.1042/bj2890125; MULLANEY I, 1993, FEBS LETT, V324, P241, DOI 10.1016/0014-5793(93)81401-K; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEEL MC, 1993, MOL PHARMACOL, V43, P694; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; VALLAR L, 1990, J BIOL CHEM, V265, P10320	40	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19933	19940						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051077				2022-12-27	WOS:A1994PA12600044
J	FALANY, CN; JOHNSON, MR; BARNES, S; DIASIO, RB				FALANY, CN; JOHNSON, MR; BARNES, S; DIASIO, RB			GLYCINE AND TAURINE CONJUGATION OF BILE-ACIDS BY A SINGLE ENZYME - MOLECULAR-CLONING AND EXPRESSION OF HUMAN LIVER BILE-ACID COA-AMINO ACID N-ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; CHOLYL-COA; BOVINE LIVER; COENZYME-A; RAT-LIVER; PURIFICATION; ACETYLTRANSFERASE; SUBSTRATE	In order to establish whether a single enzyme in human liver was capable of conjugating bile acids with both glycine and taurine, a cDNA encoding human liver bile acid-CoA:amino acid N-acyltransferase (hBAT) has been isolated and characterized. A specific immunoaffinity-purified rabbit anti-hBAT polyclonal antibody was used to screen a lambda Zap XR human liver cDNA library resulting in the isolation of two unique clones. hBATS and hBAT9 (1669 and 1491 base pairs in length, respectively) were isolated following screening of 4 x 10(5) clones of the cDNA library. Restriction mapping and sequence analysis demonstrated that the cDNAs were identical except hBAT8 contained an additional 178 bases of 5' sequence; hBAT8 was completely sequenced, characterized, and used for all subsequent studies. hBAT8 consisted of a 184-nudeotide 5'-nontranslated region, an open reading frame of 1,254 bases predicting a protein of 418 amino acids with a molecular mass of 46,296 Da, and a 3'-nontranslated region of 209 nucleotides followed by a poly(A)(+) tail. The identity of the cDNA was confirmed by the following findings: 1) the open reading frame began with an ATG codon and was followed by a nucleotide sequence which, when translated, corresponded exactly to the first 17 NH2-terminal amino acids of purified human liver BAT; 2) cytosol of Escherichia coli XL1-Blue cells transfected with hBAT8 subcloned into an expression vector, pKK233-2, demonstrated significant enzymatic activity for the conjugation of both taurine and glycine with cholic acid; 3) bacterial expression of hBAT8 generated a protein that comigrated with hBAT from human liver during SDS-polyacrylamide gel electrophoresis and cross-reacted with a specific polyclonal rabbit anti-hBAT antibody during immunoblot analysis; 4) kinetic characteristics of the expressed enzyme were very similar to those reported for purified liver BAT. These data demonstrate that a single cDNA is present in human liver which codes for a protein capable of catalyzing the conjugation of cholic acid with both glycine and taurine.	UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	FALANY, CN (corresponding author), UNIV ALABAMA,DEPT PHARMACOL,101 VOLKER HALL,BIRMINGHAM,AL 35294, USA.				PHS HHS [40530] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZUBA B, 1986, J BIOL CHEM, V261, P6260; CZUBA B, 1980, J BIOL CHEM, V255, P5296; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; DAVIS LG, 1986, BASIC METHODS MOL BI, P211; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; HAGEY LR, 1992, THESIS U CALIFORNIA; HARLOW E, 1988, ANTIBODIES LABORATOR; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; JOHNSON MR, 1990, BIOCHEM PHARMACOL, V40, P1241, DOI 10.1016/0006-2952(90)90389-3; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; JOHNSON MR, 1989, ANAL BIOCHEM, V182, P360, DOI 10.1016/0003-2697(89)90608-8; KILLENBERG PG, 1978, J LIPID RES, V19, P24; KILLENBERG PG, 1978, J BIOL CHEM, V253, P1005; KWAKYE JB, 1991, COMP BIOCHEM PHYS B, V100, P131, DOI 10.1016/0305-0491(91)90095-U; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; SANGER F, 1977, P NATL ACAD SCI USA, V86, P4076; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; SCHERSTEN T, 1971, METAB CONJUGATION, P75; VESSEY DA, 1979, J BIOL CHEM, V254, P2059; ZHANG RW, 1992, AM J PHYSIOL, V262, pG351, DOI 10.1152/ajpgi.1992.262.2.G351	22	148	155	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19375	19379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034703				2022-12-27	WOS:A1994NY33200029
J	SCHULLEK, JR; RUF, W; EDGINGTON, TS				SCHULLEK, JR; RUF, W; EDGINGTON, TS			KEY LIGAND INTERFACE RESIDUES IN TISSUE FACTOR CONTRIBUTE INDEPENDENTLY TO FACTOR VIIA BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY; COMPLEX; SITES; COAGULATION; RECOGNITION; ASSOCIATION; ACTIVATION; DOMAIN	Scanning alanine mutagenesis of the cell surface pro- tease receptor tissue factor suggested importance of residues Lys(20), Ile(22), Asp(58), Arg(135), and Phe(140) for binding of ligand, the serine protease coagulation factor VIIa. Ligand binding by single alanine replacement mutants was characterized by functional assays which concordantly demonstrated a calculated 1-2.5 kcal/mol reduction in free energy of binding as a result of each of the mutations. Catalytic and proteolytic function appeared to be not impaired by the residue replacements, indicating that these residues are not specifically required for the catalytic enhancement of VIIa produced by the assembly with tissue factor. Multiple mutations were further combined in one mutant protein to assess whether these residues provide independent contacts with the ligand VIIa. The Lys(20)/Asp(58) and the Arg(135)/Phe(140) residue pairs did not independently contribute to the binding of ligand. In contrast, the combination with Ile(22) consistently produced a further decrease in affinity for VIIa, demonstrating that this residue acts as an independent contact site for the ligand VIIa. The total contribution of the five residues to the free energy of binding of VIIa at 37 degrees C was calculated to be 5.4 kcal/mol representing approximately one-third of the total binding energy.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ITO W, 1993, J BIOL CHEM, V268, P16639; JANIN J, 1990, J BIOL CHEM, V265, P16027; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; OBRIEN DP, 1993, BIOCHEM J, V292, P7, DOI 10.1042/bj2920007; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; RUF W, 1993, METHOD ENZYMOL, V222, P209; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	19	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19399	19403						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034706				2022-12-27	WOS:A1994NY33200033
J	HEALY, AM; GELEHRTER, TD				HEALY, AM; GELEHRTER, TD			INDUCTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN HEPG2 HUMAN HEPATOMA-CELLS BY MEDIATORS OF THE ACUTE-PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MESSENGER-RNA; EPIDERMAL GROWTH-FACTOR; TUMOR NECROSIS FACTOR; PLASMA-PROTEIN GENES; HEP-G2 CELLS; POSTTRANSCRIPTIONAL REGULATION; STIMULATING FACTORS; ENDOTHELIAL-CELLS; EXPRESSION; INTERLEUKIN-1	The liver plays a central role in the systemic acute phase response of an organism to injury. Plasminogen activator inhibitor-1 (PAI-1), a major regulator of fibrinolysis, is an important component of the acute phase response in humans. The source of plasma PAI-1 has been a matter of controversy, but recent in situ hybridization experiments have demonstrated that human hepatocytes express the PAI-1 gene in vivo. However, little is known about regulation of human hepatic PAI-1 gene expression by mediators of the acute phase response. We have analyzed the regulation of PAI-1 mRNA accumulation by interleukin (IL)-1, IL-6, and dexamethasone, known mediators of the acute phase response, in HepG2 cells, a highly differentiated human hepatoma cell line that produces a broad spectrum of acute phase proteins including PAI-1. Incubation of HepG2 cells with IL-1 resulted in a rapid and transient 40-fold induction of the 3.2-kilobase PAI-1 mRNA and a 30-fold induction of the 2.2-kilobase PAI-1 mRNA Although IL-6 alone had only a modest effect on PAI-1 expression, in combination with IL-1, it caused a synergistic induction of PAI-1 mRNA accumulation. Dexamethasone alone did not increase PAI-1 mRNA accumulation but enhanced it in combination with IL-1. Using nuclear run-on experiments, we determined that the mechanism by which IL-1 alone, or in combination with IL-6, induced PAI-1 mRMA accumulation was to cause a 10-15-fold, transient stimulation of PAI-1 gene transcription. We found no evidence of an effect of these cytokines on PAI-1 mRNA stability. These data demonstrate that mediators of the acute phase response induce the accumulation of PAI-1 mRNA in human hepatoma cells by rapidly and transiently increasing the transcription of the PAI-1 gene.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	HEALY, AM (corresponding author), UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDT A, 1992, BIOCHIM BIOPHYS ACTA, V1138, P149, DOI 10.1016/0925-4439(92)90055-R; Ausubel FM, 1988, MOL REPROD DEV; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BEVAN S, 1991, J IMMUNOL, V147, P2574; BOOTH NA, 1994, HAEMOSTASIS THROMBOS, P699; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBOER JP, 1991, THROMB HAEMOSTASIS, V65, P181; FATTAL PG, 1992, J BIOL CHEM, V267, P12412; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fey G H, 1990, Prog Liver Dis, V9, P89; GELEHRTER TD, 1987, MOL ENDOCRINOL, V1, P97, DOI 10.1210/mend-1-1-97; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOPKINS WE, 1991, NUCLEIC ACIDS RES, V19, P163, DOI 10.1093/nar/19.1.163; HUBER K, 1991, THROMB RES, V62, P491, DOI 10.1016/0049-3848(91)90022-O; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JUHANVAGUE I, 1985, PROGR FIBRINOLYSIS, V7, P146; KLUFT C, 1985, SCAND J CLIN LAB INV, V45, P605, DOI 10.3109/00365518509155267; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KRUITHOF EKO, 1988, THROMB HAEMOSTASIS, V59, P7; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LEVIN EG, 1983, J LAB CLIN MED, V102, P500; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; MATSUSHIMA K, 1986, J IMMUNOL, V137, P3183; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SPRENGERS ED, 1985, J LAB CLIN MED, V105, P751; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; YE K, 1992, IMMUNOLOGY, V75, P427	47	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19095	19100						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034668				2022-12-27	WOS:A1994NX32700060
J	HUANG, JC; SANCAR, A				HUANG, JC; SANCAR, A			DETERMINATION OF MINIMUM SUBSTRATE SIZE FOR HUMAN EXCINUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION NUCLEASE; STRANDED-DNA ENDONUCLEASE; HUMAN CELL-EXTRACTS; (A)BC EXCINUCLEASE; ESCHERICHIA-COLI; DAMAGED DNA; REPAIR; TRANSCRIPTION; PURIFICATION; PROTEINS	Human cells remove bulky adducts from DNA by excising single-stranded fragments 27-29 nucleotides in length by an enzyme system consisting of at least 14 polypeptides. All of the previous work on characterizing the excision reaction was conducted with plasmids 3 or 8 kilobases in length. To determine if the size and tertiary structure of DNA play a role in the excision reaction and to find out if large DNA fragments are necessary to contact all of the subunits of the excinuclease, we performed experiments with circular DNA and with linear DNA fragments of various sizes. We found that the human excinuclease is capable of removing DNA adducts from linear and covalently closed circular DNAs with about the same efficiency. Furthermore, we found that the excinuclease can remove a thymine dimer or a psoralen-thymine monoadduct from linear fragments provided that the distance between the lesion and the 5'-terminus of the damaged strand is greater than or equal to 60 nucleotides and the distance between the lesion and the 3'-terminus is greater than or equal to 44 nucleotides. Thus, the minimum size substrate for human excinuclease is similar to 100 base pairs in length.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HOEIJMAKERS JHJ, 1990, MUTAT RES, V236, P223, DOI 10.1016/0921-8777(90)90007-R; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHI YB, 1987, NUCLEIC ACIDS RES, V15, P6843, DOI 10.1093/nar/15.17.6843; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SUNG P, 1993, J BIOL CHEM, V268, P26391; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005	25	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19034	19040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034661				2022-12-27	WOS:A1994NX32700051
J	WEIS, K; GRIFFITHS, G; LAMOND, AI				WEIS, K; GRIFFITHS, G; LAMOND, AI			THE ENDOPLASMIC-RETICULUM CALCIUM-BINDING PROTEIN OF 55 KDA IS A NOVEL EF-HAND PROTEIN RETAINED IN THE ENDOPLASMIC-RETICULUM BY A CARBOXYL-TERMINAL HIS-ASP-GLU-LEU MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; LUMINAL ER PROTEINS; DISULFIDE ISOMERASE; SECRETORY PROTEINS; SEQUENCE-ANALYSIS; DNA-POLYMERASE; MESSENGER-RNA; HIGH-AFFINITY; RECEPTOR; GRP94	We have identified a new human Ca2+-binding protein that is specifically localized in the endoplasmic reticulum (ER). The protein is termed ERC-55, i.e. ER calcium-binding protein of 55 kDa. ERC-55 is a single copy gene and is encoded by an approximately 1900-base mRNA, which shows a ubiquitous expression pattern. The ERC-55 protein comprises an amino-terminal signal sequence followed by six copies of the EF-hand Ca2+ binding motif. Ca2+ binding was demonstrated directly for recombinant ERC-55 using the Ca-45(2+) overlay technique. The carboxyl-terminal sequence His-Asp-Glu-Leu (HDEL) is required for retention of ERC-55 in the ER. Deletion of HDEL results in slow secretion into the medium. In pulse-chase experiments, approximately 50% of the HDEL deletion mutant is secreted, whereas no detectable secretion is observed with the wild-type protein. This represents the first example of an endogenous human protein that is retained in the ER by an HDEL rather than Lys-Asp-Glu-Leu (KDEL) carboxyl-terminal tetrapeptide. Comparative sequence analysis indicates that ERC-55, together with the recently identified protein reticulocalbin (Ozawa and Muramatsu, 1993), constitute a new subfamily of the EF-hand superfamily of Ca2+-binding proteins that are specifically located in the ER.			WEIS, K (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, POSTFACH 102209, D-69012 HEIDELBERG, GERMANY.		Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X; Lamond, Angus/0000-0001-6204-6045				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; DANG CV, 1985, J BIOL CHEM, V260, P9713; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARLOW E, 1988, ANTIBODIES LABORATOR; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LOCKER JK, 1994, J CELL BIOL, V124, P55; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MACER DRJ, 1988, J CELL SCI, V91, P61; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OZAWA M, 1993, J BIOL CHEM, V268, P699; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROBBI M, 1991, J BIOL CHEM, V266, P20498; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; Stelzer E H, 1991, Semin Cell Biol, V2, P145; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAN PN, 1989, J BIOL CHEM, V264, P17494; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILSON DW, 1993, J BIOL CHEM, V268, P7465; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368	67	83	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19142	19150						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034671				2022-12-27	WOS:A1994NX32700067
J	ZARA, J; LEHRMAN, MA				ZARA, J; LEHRMAN, MA			ROLE OF THE CARBOXYL-TERMINUS IN STABLE EXPRESSION OF HAMSTER UDP-GLCNAC-DOLICHOL-P GLCNAC-1-P TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; ENDOPLASMIC-RETICULUM; DOLICHOL RECOGNITION; MOLECULAR-CLONING; OVARY CELLS; SEQUENCE; GENE; ENZYME; CDNA; PROTEINS	In order to examine the function of the carboxyl terminus of UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase (GPT), an endoplasmic reticulum enzyme that synthesizes GlcNAc-P-P-dolichol and, thus, catalyzes the committed step for N-linked glycosylation, a series of carboxyl-terminal truncation mutations was examined. Removal of the last 11 amino acids (398-408) from GPT had no significant effect on catalytic activity, thermal stability, tunicamycin binding, reticular localization, or consumption of cellular dolichol-P. However, in the absence of residues 398-408, the removal of three additional residues (Phe(395)-Ser(396)-Ile(397)), or their change to Leu(395)-Met(396)-Trp(397) fully eliminated enzyme expression in vivo. By reattaching residues 398-408 to Leu(395)-Met(396)-Trp(397), expression was restored. Thus, the carboxyl-terminal region of GPT is essential for stable expression. Either of two sequences (395-397 and 398-408) is sufficient for expression, but neither is necessary. Expression of GPT in the absence of residues 398-408 specifically required the Phe(395)-Ser(396)-Ile(397) sequence, since most scramble and termination mutations within this sequence were inhibitory. One scramble mutant (Ile(395)-Ser(396)-Phe(397)-Stop(398)) was enzymatically active, but unusually thermolabile. Thus, the function of Phe(395)-Ser(396)-Ile(397) may be to stabilize GPT.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA AK, 1993, J BIOL CHEM, V268, P12663; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; ROBBEN J, 1993, J BIOL CHEM, V268, P24555; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895	23	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19108	19115						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034669				2022-12-27	WOS:A1994NX32700062
J	LI, ZY; DEMPLE, B				LI, ZY; DEMPLE, B			SOXS, AN ACTIVATOR OF SUPEROXIDE STRESS GENES IN ESCHERICHIA-COLI - PURIFICATION AND INTERACTION WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; RESPONSE REGULON; NITRIC-OXIDE; ARAC PROTEIN; MOLECULAR CHARACTERIZATION; POSITIVE CONTROL; REDOX STRESS; LOCUS; REPRESSION; EXPRESSION	A genetic response of Escherichia coli to nitric oxide or to superoxide-generating agents such as paraquat is controlled by the soxRS locus. The intracellular redox signals generated by these agents are sensed by the SoxR protein which, when activated, functions as a potent activator of soxS transcription. The resulting increased level of SoxS protein then activates similar to 10 genes that constitute the soxRS regulon. Although the SoxS protein is homologous to the COOH-terminal region of the AraC family of regulatory proteins, the mechanism by which SoxS protein activates the soxRS regulon promoters is unknown. We identified in extracts of cells expressing high levels of SoxS protein a DNA binding activity specific for fragments containing soxRS-regulated promoters. This binding activity was purified to physical homogeneity and proved to be the SoxS protein, as confirmed by NH2-terminal amino acid sequencing. The purified SoxS protein bound specifically to the promoters of the micF, zwf, nfo, and sodA genes. Multiple DNA-protein complexes were formed by SoxS in a concentration-dependent fashion with each of these prometers. This binding of SoxS protein also facilitated the subsequent binding of E. coli RNA polymerase to both the micF and the nfo promoters. The binding sites of SoxS in the zwf and micF promoters were identified by DNase I footprinting, which revealed an extended protected region immediately upstream of the respective -35 sites. These results indicate that the small SoxS protein (M(r) of only 12,900) is a direct transcriptional activator of the oxidative stress genes of the soxRS regulon, although the possible involvement of other proteins in transcription activation by SoxS has not been ruled out.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NCI NIH HHS [CA37831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ARIZA RR, 1994, J BACTERIOL, V176, P143, DOI 10.1128/JB.176.1.143-148.1994; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P752; COHEN SP, 1993, J BACTERIOL, V175, P7856, DOI 10.1128/JB.175.24.7856-7862.1993; COHEN SP, 1993, J BACTERIOL, V175, P1484, DOI 10.1128/JB.175.5.1484-1492.1993; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GAMBINO L, 1993, J BACTERIOL, V175, P2888, DOI 10.1128/JB.175.10.2888-2894.1993; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; HACHLER H, 1991, J BACTERIOL, V173, P5532; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; MENON KP, 1990, P NATL ACAD SCI USA, V87, P3708, DOI 10.1073/pnas.87.10.3708; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; RAMOTAR D, 1993, J BIOL CHEM, V268, P20533; ROWLEY DL, 1991, J BACTERIOL, V173, P968, DOI 10.1128/jb.173.3.968-977.1991; Sambrook J, 1989, MOL CLONING LABORATO; Sies H., 1991, OXIDATIVE STRESS OXI; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	39	134	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18371	18377						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034583				2022-12-27	WOS:A1994NW79800024
J	REID, RJD; ZHANG, F; BENSON, S; ANDERSON, D				REID, RJD; ZHANG, F; BENSON, S; ANDERSON, D			PROBING THE STRUCTURE OF BACTERIOPHAGE-PHI-29 PROHEAD RNA WITH SPECIFIC MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; DNA-GP3; NUCLEOTIDES; BINDING; SIZE	Bacteriophage phi 29 of Bacillus subtilis packages its double-stranded DNA genome into a preformed prohead in an ATP-dependent reaction. A 174-residue phi 29-encoded RNA molecule (pRNA) is a structural component of the prohead and is essential for DNA packaging. The secondary and tertiary structures of the prohead binding site on pRNA have been probed using a series of specific mutant pRNAs and by measuring binding to RNA-free proheads and in vitro packaging of the DNA-gene product 3 (DNA.gp3) complex. A pseudoknot in pRNA inferred from phylogenetic studies was confirmed with specific mutations, and this pseudoknot was necessary for DNA.gp3 packaging activity. pRNA was truncated progressively from the 5' and 3' ends to isolate the prohead binding site, and three truncated pRNAs of 79, 71, and 62 residues retained prohead binding activity but could not reconstitute proheads for DNA.gp3 pack aging. Mutation resulting in changes of the D hairpin loop and its connecting residues within the prohead binding site of pRNA and DNA packaging studies demonstrated that some alteration of secondary structure in this helix was permissible. The analyses provided fur ther confirmation of a discrete prohead binding domain in pRNA and further delineated specific structural requirements for DNA.gp3 packaging activity which may not be required for prohead binding.	UNIV MINNESOTA,DEPT MICROBIOL & ORAL SCI,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT GENET & CELL BIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537				BAILEY S, 1990, J BIOL CHEM, V265, P22365; BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; BJORNSTI MA, 1981, P NATL ACAD SCI-BIOL, V78, P5861, DOI 10.1073/pnas.78.9.5861; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; LOGEL J, 1992, BIOTECHNIQUES, V13, P604; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; ROMANIUK PJ, 1989, BIOCHEMISTRY-US, V28, P1388, DOI 10.1021/bi00429a067; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	19	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18656	18661						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034614				2022-12-27	WOS:A1994NW79800067
J	CHIRON, MF; FRYLING, CM; FITZGERALD, DJ				CHIRON, MF; FRYLING, CM; FITZGERALD, DJ			CLEAVAGE OF PSEUDOMONAS-EXOTOXIN AND DIPHTHERIA-TOXIN BY A FURIN-LIKE ENZYME PREPARED FROM BEEF-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN FAMILY; KEX2-LIKE ENDOPROTEASE; PROTECTIVE ANTIGEN; CELLULAR PROTEASE; MEDIATED CLEAVAGE; FRAGMENT; CYTOSOL; SITE; EXPRESSION; ACTIVATION	Pseudomonas exotoxin (PE) is cleaved within mammalian cells between Arg(279) and Gly(280) to generate an enzymatically active COOH terminal fragment of 37 kDa which translocates to the cytosol and ADP-ribosylates elongation factor 2. A protease, with toxin cleaving activity, was prepared from beef liver and subsequently characterized. After achieving a 500-fold enrichment in several chromatographic steps, a soluble form of this protease was identified as a furin-like enzyme. It cleaved PE on the COOH-terminal side of the sequence of RQPR (amino acids 276-279) producing the same fragments as those generated within cells. Cleavage had a pH optimum of 5.0-5.5, was inhibited by EDTA or p-hydroxymercuribenzoate but not by O-phenanthroline, N-ethylmaleimide, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane, or PMSF (or other well known inhibitors of serine proteases). The beef protease cleaved PE with an apparent K-m of 7 mu M. A mutant form of PE, PEala281, was cleaved at the same site, with the same pH optimum, a similar K-m (9 mu M) but with a V-max 150 times faster than was seen with the native toxin. Mutational analysis of the amino acids located just before the site of cleavage, confirmed the importance of arginines at P-1 and P-4. It was also noted that the introduction of a dibasic pair at 278-279 did not increase toxicity or appreciably improve the rate of cleavage. Unnicked diphtheria toxin (DT) was also cleaved by the beef protease; cleavage was on the COOH terminal side of the sequence RVRR (amino acids 190-193), was seen at pH values ranging from 5.5 to 8.5 and had an optimum at pH 8.0. Recombinant furin cleaved PE, PEala281, and DT with the same characteristics as the beef protease. In addition, Western blot analysis revealed that anti-furin antibodies reacted specifically with components in the beef protease preparation. Immunodepletion experiments showed that all toxin-cleavage activity could be removed from the beef protease using anti-furin anti-bodies. The relevance of furin-mediated cleavage was further assessed by adding nicked toxins to intact cells. Nicked PE and DT both killed cells at a faster rate than their unnicked counterparts.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FARAHBAKHSH ZT, 1987, J BIOL CHEM, V262, P2256; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1992, 92ND ANN M AM SOC MI; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRIS RE, 1986, INFECT IMMUN, V52, P445, DOI 10.1128/IAI.52.2.445-453.1986; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUER CP, 1993, CANCER RES, V53, P340; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; ZDANOVSKY AG, 1993, J BIOL CHEM, V268, P21791	37	112	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18167	18176						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027078				2022-12-27	WOS:A1994NV42200062
J	KITAGAWA, H; PAULSON, JC				KITAGAWA, H; PAULSON, JC			DIFFERENTIAL EXPRESSION OF 5 SIALYLTRANSFERASE GENES IN HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; N-LINKED OLIGOSACCHARIDES; CELL-ADHESION; VASCULAR ENDOTHELIUM; SIALIC-ACID; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; ENZYMATIC CHARACTERIZATION; BOVINE COLOSTRUM; MESSENGER-RNAS	Cell type-specific expression of specific carbohydrate structures on cell surface glycoproteins and glycolipids is increasingly recognized for providing information relevant to cell-cell interactions in developing and adult organisms. Sialyltransferases contribute to the diversity in carbohydrate structure through their attachment of sialic acid in various terminal positions on glycolipid and on glycoprotein (N-linked and O-linked) carbohydrate groups. In this report, differential expression of five sialyltransferase genes in human tissues is evaluated as a potential mechanism to account for cell type-specific variation in terminal sialoside structures produced by a cell. For this analysis, the complete cDNA of the human Gal beta 1,3GalNAc alpha 2,3-sialyltransferase and a partial cDNA of the developmentally regulated STX gene were cloned. Northern analysis was performed using these cDNAs and those of three previously cloned human sialyltransferase genes as probes. Each of the five sialyltransferase genes exhibits dramatic differential expression in the 16 adult and 5 fetal human tissues examined, and expression of each gene appears to be independently regulated. Comparison with fragmentary earlier studies of the expression of several of the same enzymes in rat tissues suggests that the overall pattern of expression is largely conserved.	CYTEL CORP, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM & MOLEC BIOL, SAN DIEGO, CA 92121 USA	Scripps Research Institute			Kitagawa, Hiroshi/AAJ-1344-2020; Paulson, James/AAG-3565-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; 	NIGMS NIH HHS [GM27904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CAPON C, 1992, J BIOL CHEM, V267, P19248; ENGEL P, 1993, J IMMUNOL, V150, P4719; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; GAUDINO JJ, 1994, J AM CHEM SOC, V116, P1149, DOI 10.1021/ja00082a054; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HANAOKA K, 1989, J BIOL CHEM, V264, P9842; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MUROI K, 1992, BLOOD, V79, P713; OHANLON TP, 1992, GLYCOBIOLOGY, V2, P257, DOI 10.1093/glycob/2.3.257; OHMORI K, 1993, BLOOD, V81, P101; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; POWELL LD, 1993, J BIOL CHEM, V268, P7019; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REARICK JI, 1979, J BIOL CHEM, V254, P4444; Rosen S D, 1993, Semin Immunol, V5, P237, DOI 10.1006/smim.1993.1028; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SGROI D, 1993, J BIOL CHEM, V268, P7011; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKADA A, 1993, CANCER RES, V53, P354; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	54	213	223	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17872	17878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027041				2022-12-27	WOS:A1994NV42200021
J	LANGFORD, CK; LITTLE, BM; KAVANAUGH, MP; LANDFEAR, SM				LANGFORD, CK; LITTLE, BM; KAVANAUGH, MP; LANDFEAR, SM			FUNCTIONAL EXPRESSION OF 2 GLUCOSE-TRANSPORTER ISOFORMS FROM THE PARASITIC PROTOZOAN LEISHMANIA-ENRIETTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR SEQUESTRATION; TRYPANOSOMA-BRUCEI; NH2 TERMINUS; DONOVANI; PROMASTIGOTES; METABOLISM; INSULIN; AMASTIGOTES; MEMBRANE; PROTEIN	The parasitic protozoan Leishmania enriettii contains a family of tandemly repeated genes, designated Pro-1, that encode proteins with significant sequence similarity to mammalian facilitative glucose transporters. Pro-1 mRNAs are expressed almost exclusively in the promastigote or insect stage of the parasite life cycle. The Pro-1 tandem repeat encodes two isoforms of the putative transporter, iso-1 and iso-2, which have identical predicted amino acid sequences except for their NH2-terminal hydrophilic domains. We have now expressed both iso-1 and iso-2 by microinjecting their RNAs into Xenopus oocytes and assaying these oocytes for transport of various radiolabeled ligands. Both iso-1 and iso-2 transport [H-3]2-deoxy-D-glucose, confirming that each protein is a bona fide glucose transporter. Each isoform also transports fructose and, to a much lesser degree, mannose. Compounds which inhibit 2-deoxy-D-glucose transport in L. enriettii promastigotes also inhibit transport in the microinjected oocytes expressing each isoform, indicating that the substrate specificities and pharmacological properties of each isoform are similar to those measured for 2-deoxy-D-glucose transport in intact parasites. The K-m for transport of 2-deoxyglucose in oocytes expressing iso-1 is similar to that for oocytes expressing iso-2. These results reveal that both transporter isoforms have closely related functional properties and that the difference in their structures may serve some other purpose such as differential subcellular localization.	OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University					NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NIGMS NIH HHS [GM48709] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920, K04AI001162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLUM JJ, 1993, PARASITOL TODAY, V9, P118, DOI 10.1016/0169-4758(93)90168-F; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; CAIRNS BR, 1989, P NATL ACAD SCI USA, V85, P2130; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES A, 1987, J BIOL CHEM, V262, P9347; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; HASPEL HC, 1988, J BIOL CHEM, V263, P398; Heytler P G, 1979, Methods Enzymol, V55, P462; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KABACK HR, 1992, INT REV CYTOL, V137A, P97; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MUKKADA AJ, 1985, SCIENCE, V229, P1099, DOI 10.1126/science.4035350; MUNOZANTONIA T, 1991, MOL BIOCHEM PARASIT, V47, P73, DOI 10.1016/0166-6851(91)90149-Z; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHLEIN Y, 1986, Parasitology Today, V2, P175, DOI 10.1016/0169-4758(86)90150-X; SHANAHAN MF, 1986, BIOCHIM BIOPHYS ACTA, V887, P121, DOI 10.1016/0167-4889(86)90132-1; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; STACK SP, 1990, MOL CELL BIOL, V10, P6785, DOI 10.1128/MCB.10.12.6785; STEIN DA, 1990, NUCLEIC ACIDS RES, V18, P1549, DOI 10.1093/nar/18.6.1549; TERKUILE BH, 1993, PARASITOL TODAY, V9, P206, DOI 10.1016/0169-4758(93)90009-5; TERKUILE BH, 1993, MOL BIOCHEM PARASIT, V60, P313, DOI 10.1016/0166-6851(93)90142-K; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WARDZALA LJ, 1978, J BIOL CHEM, V253, P8002; WYLER DJ, 1990, MODERN PARASITE BIOL, P428; ZILBERSTEIN D, 1993, ADV PARASIT, V32, P261, DOI 10.1016/S0065-308X(08)60209-2; ZILBERSTEIN D, 1984, MOL BIOCHEM PARASIT, V12, P327, DOI 10.1016/0166-6851(84)90089-6; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	36	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17939	17943						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027051				2022-12-27	WOS:A1994NV42200031
J	MAYFIELD, C; EBBINGHAUS, S; GEE, J; JONES, D; RODU, B; SQUIBB, M; MILLER, D				MAYFIELD, C; EBBINGHAUS, S; GEE, J; JONES, D; RODU, B; SQUIBB, M; MILLER, D			TRIPLEX FORMATION BY THE HUMAN HA-RAS PROMOTER INHIBITS SP1 BINDING AND IN-VITRO TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; PROTO-ONCOGENE PROMOTER; C-MYC PROMOTER; HELIX FORMATION; DNA; OLIGONUCLEOTIDES; SEQUENCE; OLIGODEOXYNUCLEOTIDES; CLEAVAGE; INVITRO	The central role of the ras oncogenes in the pathogenesis of a wide variety of human malignancies is well established. Toward developing specific transcriptional inhibitors of the human Ha-ras oncogene, we have designed oligonucleotides to target a region of the Ha-ras promoter (-8 to -28) which contains two of the three Sp1 binding sites essential for transcriptional activity. Gel mobility analysis and DNase I footprinting demonstrate that an oligonucleotide (HR21ap) forms a sequence-specific triple helix with its target site in an antiparallel orientation with respect to the purine-rich duplex strand through predominantly G*G:C triplets. Within the Ha-ras promoter, HR21ap binds exclusively to the proximal target Sp1 sites over a similar nontarget distal sequence which, like the target, contains a consensus Sp1 site. Protein binding assays demonstrate that triplex formation by HR21ap inhibits Sp1 binding to the Ha-ras promoter. Moreover, oligonucleotide-directed triplex formation arrests Ha-ras promoter-dependent transcription in vitro, The results presented here suggest that tripler formation by the Ha-ras promoter targeted oligonucleotide may provide a means to specifically inhibit transcription of this oncogene in vivo.	UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, DEPT ORAL PATHOL, BIRMINGHAM, AL 35294 USA; BIRMINGHAM VET AFFAIRS MED CTR, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	MAYFIELD, C (corresponding author), UNIV ALABAMA, DEPT MED, BOLDEN LAB, BIRMINGHAM, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA42337, NCI-CN-25428-33, R01 CA42664] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEAL PA, 1992, NUCLEIC ACIDS RES, V20, P2773, DOI 10.1093/nar/20.11.2773; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUME SW, 1992, NUCLEIC ACIDS RES, V20, P1777; BOS JL, 1989, CANCER RES, V49, P4682; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DURLAND RH, 1990, JERUS SYM Q, V23, P565; FERDOROVA OS, 1988, FEBS LETT, V228, P273; GEE JE, 1992, J BIOL CHEM, V267, P11163; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAWCZYK SH, 1992, BIOCHEMISTRY-US, V89, P3761; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; ORSEN FM, 1991, NUCLEIC ACIDS RES, V19, P3435; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; ROY C, 1993, NUCLEIC ACIDS RES, V21, P2845, DOI 10.1093/nar/21.12.2845; SHEA RG, 1990, NUCLEIC ACIDS RES, V18, P4859, DOI 10.1093/nar/18.16.4859; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	34	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18232	18238						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027084				2022-12-27	WOS:A1994NV42200070
J	TOKUNAGA, F; GOTO, T; KOIDE, T; MURAKAMI, Y; HAYASHI, S; TAMURA, T; TANAKA, K; ICHIHARA, A				TOKUNAGA, F; GOTO, T; KOIDE, T; MURAKAMI, Y; HAYASHI, S; TAMURA, T; TANAKA, K; ICHIHARA, A			ATP-DEPENDENT AND ANTIZYME-DEPENDENT ENDOPROTEOLYSIS OF ORNITHINE DECARBOXYLASE TO OLIGOPEPTIDES BY THE 26-S PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; RAT-LIVER; PROTEINASE; COMPLEX; PURIFICATION; DEGRADATION; CLEAVAGE	Previously we reported that ornithine decarboxylase (ODC) is degraded ATP-dependently by the 26 S proteasome in the presence of antizyme (AZ), an ODC inhibitor (Murakami, Y., Matsufuji, S., Kameji, T., Hayashi, S., Igarashi, K., Tamura, T., Tanaka, K., and Ichihara, A. (1992) Nature 360, 597-599). Here we examined the cleavage of ODC by the 26 S proteasome. When ODC purified from ODC-overproducing cells was incubated with the 26 S proteasome and with AZ fused with maltose-binding protein (MBP) in the presence of ATP, ODC was degraded specifically without appreciable breakdown of MBP-AZ. The major degradation products of ODC, which were separated by high performance liquid chromatography on a reverse-phase column, were identified by N-terminal amino acid sequencing. The 26 S proteasome generated a variety of short peptides of 5-11 amino acid residues derived from regions throughout the ODC sequence. No detectable amounts of free amino acid residues were produced, indicating endoproteolytic degradation of ODC by the 26 S proteasome. Their major sites for cleavage of ODC by the 26 S proteasome were on the carboxyl sides of neutral/hydrophobic amino acid residues, but a few were on those of acidic or basic amino acid residues. These results demonstrate that the 26 S proteasome causes exhaustive endoproteolysis of the naturally occurring short-lived protein ODC in a multicatalytic and ATP-dependent manner.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HARIMA,HYOGO 67812,JAPAN; JIKEI UNIV,SCH MED,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN	Tokushima University; University of Hyogo; Jikei University			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Tokunaga, Fuminori/0000-0003-3626-9119				DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG A, 1992, NATURE, V357, P75; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1993, FEBS LETT, V336, P34, DOI 10.1016/0014-5793(93)81603-W; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; TAKAHASHI T, 1993, J BIOCHEM-TOKYO, V113, P225, DOI 10.1093/oxfordjournals.jbchem.a124030; TANAKA K, 1992, NEW BIOL, V4, P173; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	23	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17382	17385						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021237				2022-12-27	WOS:A1994NU12800007
J	ZER, H; PRASIL, O; OHAD, I				ZER, H; PRASIL, O; OHAD, I			ROLE OF PLASTOQUINOL OXIDOREDUCTION IN REGULATION OF PHOTOCHEMICAL-REACTION CENTER IID1 PROTEIN-TURNOVER IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED D1-PROTEIN DEGRADATION; PHOTOSYSTEM-II; THERMO-LUMINESCENCE; CHLAMYDOMONAS-REINHARDTII; PHOTOINHIBITION INVIVO; MOLECULAR MECHANISM; CHLOROPHYLL-A; D-1 PROTEIN; D1 PROTEIN; LIGHT	The light-induced turnover of the D1 protein subunit of reaction center II (RCII) was investigated in Chlamydomonas reinhardtii y-1 (control) and D-6, AC(208), and B-4 mutants lacking cytochrome b(6)/f, plastocyanin or photo system I activity, respectively, and, thus, impaired in light-dependent plastoquinol (PQH(2)) oxidation. Charge recombination assayed by thermoluminescence measurements indicated similar RCII properties in control and mutant cells. The D1 protein is not degraded in the mutants during photoinactivation; however, RCII-D1 is irreversibly altered, and the protein is degraded when the cells are incubated in low light permitting slow reoxidation of the PQH(2) pool. Photoinactivation precedes D1 degradation also in the control cells. Thus, in vivo under physiological conditions photoinactivation and ''tagging'' of RCII-D1 are resolved from the degradation process. RCII activity in photoinactivated cells may be recovered only following D1 degradation and replacement. Recovery may occur either in the light or dark in the absence of de novo chlorophyll synthesis. The degradation of the photoinactivated RCII-D1 protein is a prerequisite for the synthesis and stable integration of new D1 indicating that tagged D1 is still assembled in the inactive reaction centers. The physiological implication of these results is that oxidation of the PQH(2) pool in photoinactivated cells affects RCII-D1 protein degradation and replacement, and, thus, D1 turnover in vivo is regulated by the turnover of PQ at the binding site of the secondary stable electron acceptor quinone of RCII.	ACAD SCI CZECH REPUBL,INST MICROBIOL,CR-37981 TREBON,CZECH REPUBLIC	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	ZER, H (corresponding author), HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.		Prasil, Ondrej/H-2454-2014	Prasil, Ondrej/0000-0002-0012-4359				ADIR N, 1990, J BIOL CHEM, V265, P12563; ADIR N, 1988, J BIOL CHEM, V263, P283; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSSON B, 1992, J PHOTOCH PHOTOBIO B, V15, P15, DOI 10.1016/1011-1344(92)87003-R; ARNTZ B, 1986, FEBS LETT, V194, P43, DOI 10.1016/0014-5793(86)80048-5; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ASADA K, 1987, TOPICS PHOTOSYNTHESI, V9, P227; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; CRITCHLEY C, 1988, AUST J PLANT PHYSIOL, V15, P27, DOI 10.1071/PP9880027; DEMETER S, 1989, PHYSIOL PLANTARUM, V75, P121, DOI 10.1111/j.1399-3054.1989.tb02073.x; DUCRUET JM, 1992, PHOTOSYNTH RES, V33, P15, DOI 10.1007/BF00032979; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; FARINEAU J, 1993, PHOTOSYNTH RES, V36, P25, DOI 10.1007/BF00018072; GAL A, 1990, J BIOL CHEM, V265, P19742; GONG H, 1992, J BIOL CHEM, V266, P21293; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; KIRILOVSKY D, 1988, BIOCHIM BIOPHYS ACTA, V933, P124, DOI 10.1016/0005-2728(88)90062-X; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KIRILOVSKY DL, 1989, PLANT MOL BIOL, V13, P355, DOI 10.1007/BF00015547; KRIEGER A, 1992, PHOTOSYNTHETICA, V27, P89; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NEDBAL L, 1992, P NATL ACAD SCI USA, V89, P7929, DOI 10.1073/pnas.89.17.7929; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; OHAD I, 1990, J BIOL CHEM, V265, P1972; OHAD I, 1988, BIOCHIM BIOPHYS ACTA, V933, P288, DOI 10.1016/0005-2728(88)90036-9; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; OHAD N, 1990, Z NATURFORSCH C, V45, P402; ONO T, 1989, BIOCHIM BIOPHYS ACTA, V973, P443, DOI 10.1016/S0005-2728(89)80386-X; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P245; QUINN J, 1993, J BIOL CHEM, V268, P7832; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SCHLODDER E, 1987, BIOCHIM BIOPHYS ACTA, V890, P23, DOI 10.1016/0005-2728(87)90064-8; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SCHUSTER G, 1984, BIOCHIM BIOPHYS ACTA, V767, P596, DOI 10.1016/0005-2728(84)90061-6; SUNDBY C, 1993, J BIOL CHEM, V268, P25476; TOPF J, 1992, PHOTOSYNTH RES, V32, P59, DOI 10.1007/BF00028798; TREBST A, 1990, Z NATURFORSCH C, V45, P765; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; VANGORKOM HJ, 1985, PHOTOSYNTH RES, V6, P97, DOI 10.1007/BF00032785; VANWIJK KJ, 1993, PLANTA, V189, P359, DOI 10.1007/BF00194432; VASS I, 1981, BIOCHIM BIOPHYS ACTA, V634, P140, DOI 10.1016/0005-2728(81)90134-1; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VASS I, 1992, PHOTOSYSTEMS STRUCTU, V11, P259; WEIS E, 1987, BIOCHIM BIOPHYS ACTA, V894, P198, DOI 10.1016/0005-2728(87)90190-3	54	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17670	17676						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021278				2022-12-27	WOS:A1994NU12800052
J	BARBERA, A; RODRIGUEZGIL, JE; GUINOVART, JJ				BARBERA, A; RODRIGUEZGIL, JE; GUINOVART, JJ			INSULIN-LIKE ACTIONS OF TUNGSTATE IN DIABETIC RATS - NORMALIZATION OF HEPATIC GLUCOSE-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 2,6-BISPHOSPHATE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLYCOGEN-SYNTHASE; BLOOD-GLUCOSE; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; ISOLATED HEPATOCYTES; VANADATE TREATMENT; LIVER-GLYCOGEN; RESTORES	Oral administration of tungstate for 15 days normalized glycemia in streptozotocin-induced diabetic rats. Simultaneously, the alterations in hepatic glucose metabolism due to diabetes were almost completely counteracted by this treatment. Thus, 6-phosphofructo-2-kinase, L-pyruvate kinase, and glycogen phosphorylase alpha activities reached levels similar to those observed in healthy animals. Hepatic levels of fructose 2,6-bisphosphate and glycogen also recovered. However, the recovery of glucokinase activity and hepatic levels of glucose 6-phosphate was only partial. The total activity of glycogen synthase increased, although the activation state was not recovered. Moreover, mRNA levels of hepatic glucokinase, glycogen phosphorylase, and phosphoenol-pyruvate carboxykinase were also normalized. Tungstate administration in healthy animals also affected all these parameters, although to a much lesser extent. All these effects were similar to those previously reported for vanadate, suggesting a common mechanism of action in vivo.	UNIV BARCELONA, SCH CHEM, DEPT BIOCHEM & PHYSIOL, E-08028 BARCELONA, SPAIN	University of Barcelona			Rodriguez-Gil, Joan E./F-8748-2016	Rodriguez-Gil, Joan E./0000-0002-1112-9884; Barbera, Albert/0000-0003-4080-3572				BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; BENDAYAN M, 1989, DIABETOLOGIA, V32, P561; BOLLEN M, 1990, BIOCHEM J, V267, P269, DOI 10.1042/bj2670269; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOSCH F, 1992, J BIOL CHEM, V267, P2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; BROWN D, 1983, FED PROC, V209, P1145; CHALLISS RAJ, 1987, BIOCHEM PHARMACOL, V36, P357, DOI 10.1016/0006-2952(87)90294-2; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; FAGIN JA, 1987, DIABETES, V36, P1448, DOI 10.2337/diabetes.36.12.1448; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FILLAT C, 1992, BIOCHEM J, V282, P659, DOI 10.1042/bj2820659; GIL J, 1988, J BIOL CHEM, V263, P1868; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOMEZFOIX AM, 1988, BIOCHEM J, V255, P507; Gresser M. J., 1987, ADV PROTEIN PHOSPHAT, V4, P35; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEINZ A, 1982, J LAB CLIN MED, V100, P593; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JACKSON TK, 1988, DIABETES, V37, P1234, DOI 10.2337/diabetes.37.9.1234; KENDERICK MJ, 1992, METALS BIOL SYSTEMS, P121; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LARDY H, 1984, CURR TOP CELL REGUL, V24, P171; MACKAY KM, 1989, INTRO MODERN INORGAN, P218; MCNEILL JH, 1991, DIABETES, V40, P1675, DOI 10.2337/diabetes.40.12.1675; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MIRALPEIX M, 1991, DIABETES, V40, P462, DOI 10.2337/diabetes.40.4.462; MIRALPEIX M, 1992, DIABETOLOGIA, V35, P243, DOI 10.1007/BF00400924; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; RIDER MH, 1990, EUR J BIOCHEM, V190, P53, DOI 10.1111/j.1432-1033.1990.tb15544.x; RODRIGUEZGIL JE, 1993, ARCH BIOCHEM BIOPHYS, V301, P411, DOI 10.1006/abbi.1993.1164; RODRIGUEZGIL JE, 1991, DIABETES, V40, P1355, DOI 10.2337/diabetes.40.10.1355; RUBINSON KA, 1981, PROC R SOC SER B-BIO, V212, P65, DOI 10.1098/rspb.1981.0025; SAKURAI H, 1990, J ENDOCRINOL, V126, P451, DOI 10.1677/joe.0.1260451; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SHECHTER Y, 1988, DIABETES NUTR METAB, V1, P1; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; TAMURA S, 1984, J BIOL CHEM, V259, P6650; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VILLARPALASI C, 1989, BIOCHEM J, V262, P563, DOI 10.1042/bj2620563; [No title captured]	51	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20047	20053						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051090				2022-12-27	WOS:A1994PA12600059
J	KRIAJEVSKA, MV; CARDENAS, MN; GRIGORIAN, MS; AMBARTSUMIAN, NS; GEORGIEV, GP; LUKANIDIN, EM				KRIAJEVSKA, MV; CARDENAS, MN; GRIGORIAN, MS; AMBARTSUMIAN, NS; GEORGIEV, GP; LUKANIDIN, EM			NONMUSCLE MYOSIN HEAVY-CHAIN AS A POSSIBLE TARGET FOR PROTEIN ENCODED BY METASTASIS-RELATED MTS-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; MAMMARY ADENOCARCINOMA; CELL-LINE; S-100; P9KA; IDENTIFICATION; CALVASCULIN; CULTURE	The mts-1 gene is associated with the expression of the metastatic phenotype of tumor cells. The protein product of the mts-1 gene belongs to the S100 family of Ca2+-binding proteins with unknown biochemical function. In the present work, monoclonal anti-Mts-1 antibodies were used to isolate and characterize Mts-1 protein possible targets. Mts-1 protein can be immunoprecipitated by both anti-Mts-1 and anti-myosin antibodies as a complex with myosin from lysates of different mouse and human cell lines. Precipitation of myosin by anti-Mts-1 antibodies is specific and depends on the presence of Mts-1 protein. Ca2+-dependent association between Mts-1 protein and the heavy chain of non-muscle myosin was demonstrated by blot overlay technique. Furthermore, association between myosin and Mts-1 was confirmed by sucrose gradient analysis. Finally, immunofluorescent staining of the mouse mammary adenocarcinoma cell line showed that Mts-1 protein is co-localized with the myosin complex. The data suggest that the target for Mts-1 protein is a heavy chain of non-muscle myosin.	MOSCOW GENE BIOL INST,MOSCOW 117334,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	KRIAJEVSKA, MV (corresponding author), DANISH CANC SOC,DEPT MOLEC CANC BIOL,STRANDBLVD 49,71,DK-2100 COPENHAGEN,DENMARK.							BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BIANCHI R, 1992, BIOCHIM BIOPHYS ACTA, V1160, P67, DOI 10.1016/0167-4838(92)90039-G; CARDENAS MAN, 1993, RUSS J BIOORG CHEM, V19, P204; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVIES BR, 1993, ONCOGENE, V8, P999; DEAR TN, 1989, CANCER RES, V49, P5323; DEAR TN, 1988, CANCER RES, V48, P5203; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1988, J BIOL CHEM, V263, P106; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FODSTAD O, 1986, INT J CANCER, V38, P33, DOI 10.1002/ijc.2910380107; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HARLOW E, 1988, ANTIBODIES LABORATOR, P465; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; NOWELL PC, 1986, CANCER RES, V46, P2203; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; PHILLIPS SM, 1990, J NATL CANCER I, V82, P199, DOI 10.1093/jnci/82.3.199; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WATANABE Y, 1992, ARCH BIOCHEM BIOPHYS, V292, P563, DOI 10.1016/0003-9861(92)90031-Q	29	164	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19679	19682						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051043				2022-12-27	WOS:A1994PA12600006
J	OCHSNER, UA; FIECHTER, A; REISER, J				OCHSNER, UA; FIECHTER, A; REISER, J			ISOLATION, CHARACTERIZATION, AND EXPRESSION IN ESCHERICHIA-COLI OF THE PSEUDOMONAS-AERUGINOSA RHLAB GENES ENCODING A RHAMNOSYLTRANSFERASE INVOLVED IN RHAMNOLIPID BIOSURFACTANT SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUOUS CULTURE; SEQUENCE-ANALYSIS; ALGD PROMOTER; PROTEIN; DNA; VECTORS; SITE; HYDROPHOBICITY; BIOSYNTHESIS; POLYMERASE	Transposon Tn5-GrM-induced mutant strains of Pseudomonas aeruginosa which are unable to produce rhamnolipid biosurfactants and lack rhamnosyltransferase activity have been isolated. The DNA regions flanking the transposon were cloned and used as specific probes for the isolation of the corresponding wildtype genes from a P. aeruginosa wild-type cosmid gene library. Single cosmid clones capable of restoring rhamnolipid synthesis in the mutant strains were isolated and further subcloned and sequenced, resulting in the identification of two genes (rhlAB) which are organized as an operon upstream of the previously identified rhlR regulatory gene. The RhlA protein (32.5 kDa) harbors a putative signal sequence, suggesting that this protein is located in the periplasm, while the RhlB protein (47 kDa) contains at least two putative membrane-spanning domains. The expression of the rhlAB genes was found to be enhanced 20-fold during the stationary phase of growth under conditions of nitrogen limitation, as measured by using rhlA::lacZ fusions. Moreover, the transcriptional activation of the rhlAB genes appears to depend on a functional RhlR regulatory protein. The sequence upstream of the rhlA promoter contains two inverted repeats which define putative binding sites for the RhlR regulator, The controlled expression of the rhlAB genes in Escherichia coli led to the formation of active rhamnosyltransferase. This provides direct evidence for the fact that the rhamnosyltransferase encoding genes have been identified.	ETH HONGGERBERG,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BARNESS R, 1989, J GEN MICROBIOL, V135, P2277; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUNSTER L, 1989, APPL ENVIRON MICROB, V55, P1340, DOI 10.1128/AEM.55.6.1340-1345.1989; Burger M, 1966, METHODS ENZYMOLOGY, V588, P441; BURGER MM, 1963, J BIOL CHEM, V238, P2595; Chandrasekaran EV, 1980, METHODS CARBOHYDRATE, P89; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DAVIS RW, 1980, ADV BACTERIAL GENET, P120; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DERETIC V, 1989, Bio-Technology (New York), V7, P1249; DERETIC V, 1987, BIO-TECHNOL, V5, P469, DOI 10.1038/nbt0587-469; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSTER A, 1990, TRENDS GENET, V6, P141, DOI 10.1016/0168-9525(90)90135-S; FUJIWARA S, 1993, J BACTERIOL, V175, P5452, DOI 10.1128/JB.175.17.5452-5459.1993; GUERRASANTOS L, 1984, APPL ENVIRON MICROB, V48, P301, DOI 10.1128/AEM.48.2.301-305.1984; GUERRASANTOS LH, 1986, APPL MICROBIOL BIOT, V24, P443; HAUSER G, 1957, J BIOL CHEM, V224, P91; HAUSER G, 1958, J BIOL CHEM, V233, P287; HAUSER G, 1954, J BACTERIOL, V68, P645, DOI 10.1128/JB.68.6.645-654.1954; HOLLOWAY BW, 1969, BACTERIOL REV, V33, P419, DOI 10.1128/MMBR.33.3.419-443.1969; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; ISHIMOTO KS, 1989, P NATL ACAD SCI USA, V86, P1954, DOI 10.1073/pnas.86.6.1954; JARVIS FG, 1949, J AM CHEM SOC, V71, P4124, DOI 10.1021/ja01180a073; KOCH AK, 1991, J BACTERIOL, V173, P4212, DOI 10.1128/jb.173.13.4212-4219.1991; KOCH AK, 1992, THESIS SWISS FEDERAL; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang S., 1987, BIOSURFACTANTS BIOTE; MATSUYAMA T, 1987, APPL ENVIRON MICROB, V53, P1186, DOI 10.1128/AEM.53.5.1186-1188.1987; MOHR CD, 1992, J BACTERIOL, V174, P6624, DOI 10.1128/JB.174.20.6624-6633.1992; MOHR CD, 1991, J BACTERIOL, V173, P5136, DOI 10.1128/jb.173.16.5136-5143.1991; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; OCHSNER RA, 1993, THESIS SWISS FEDERAL; OCHSNER UA, 1994, J BACTERIOL, V176, P2044, DOI 10.1128/jb.176.7.2044-2054.1994; POTTER AA, 1985, RECOMBINANT DNA METH, P147; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROSENBERG M, 1981, APPL ENVIRON MICROB, V42, P375, DOI 10.1128/AEM.42.2.375-377.1981; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIZER HP, 1991, GENE, V103, P87, DOI 10.1016/0378-1119(91)90396-S; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIEGMUND I, 1991, BIOTECHNOL TECH, V5, P265, DOI 10.1007/BF02438660; SINGH M, 1986, J SCI IND RES INDIA, V45, P413; Smith H O, 1980, Methods Enzymol, V65, P371; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WAGNER F, 1984, 3RD P EUR C BIOT, V1, P1; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; WOODS DR, 1993, FEMS MICROBIOL REV, V11, P273, DOI 10.1111/j.1574-6976.1993.tb00001.x; ZHAO GS, 1992, J BIOL CHEM, V267, P2487	59	224	245	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19787	19795						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051059				2022-12-27	WOS:A1994PA12600023
J	EMORI, Y; SUGAYA, R; AKIMARU, H; HIGASHIJIMA, S; SHISHIDO, E; SAIGO, K; HOMMA, Y				EMORI, Y; SUGAYA, R; AKIMARU, H; HIGASHIJIMA, S; SHISHIDO, E; SAIGO, K; HOMMA, Y			DROSOPHILA PHOSPHOLIPASE C-GAMMA EXPRESSED PREDOMINANTLY IN BLASTODERM CELLS AT CELLULARIZATION AND IN ENDODERMAL CELLS DURING LATER EMBRYONIC STAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; RECEPTOR; GENE; SEQUENCE; GROWTH; PDGF; SRC; IDENTIFICATION; PLC-GAMMA-1	A Drosophila gene encoding a gamma-type isozyme of phosphoinositide-specific phospholipase C (PLC) was isolated and characterized. The gene, termed plc-gamma d, was mapped at position 14B-C of the X chromosome. The encoded protein, termed PLC-gamma D, contains X and Y regions, common to all known PLC isozymes. The two re- gions are split by a Z region that comprises two src homology 2 and one src homology 3 domains and is characteristic of gamma-type mammalian PLC (PLC-gamma 1 and -gamma 2). The deduced amino acid sequence of PLC-gamma D shows overall similarity to mammalian PLC-gamma s; no large dele- tion was observed except the short C-terminal extended region. In particular, the two split catalytic domains (X and Y regions) and the regulatory Z region including the src homology 2 and src homology 3 domains are well conserved. The mRNA is expressed throughout development, but expression is relatively higher during the embryonic stage, suggesting fundamental and important roles in both cell proliferation and differentiation. Distribution of the mRNA during embryogenesis, as analyzed by whole mount in situ hybridization, revealed that the mRNA emerges and reaches maximum levels at the cellular blastoderm stage and then decreases rapidly to a lower level. In later embryonic stages, invaginated anterior and posterior midgut primordia show high levels of mRNA expression, and fused midgut also maintains a high level of expression. In other tissues and cells, the mRNA was detected at lower levels. These results indicate that Drosophila PLC-gamma may be involved in universal cellular processes mediated possibly by receptor tyrosine kinases during embryogenesis and may also play specific roles during cellularization and midgut differentiation.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN		EMORI, Y (corresponding author), UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.			Shishido, Emiko/0000-0002-2474-1343; Higashijima, Shin-ichi/0000-0001-6350-4992				BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ENGELS WR, 1986, FOCUS, V8, P6; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6041; GRANJA C, 1991, J BIOL CHEM, V266, P16277; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIGASHIJIMA S, 1992, GENE DEV, V6, P1005, DOI 10.1101/gad.6.6.1005; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOJIMA T, 1991, P NATL ACAD SCI USA, V88, P4343, DOI 10.1073/pnas.88.10.4343; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MASAI I, 1991, J BIOCHEM-TOKYO, V109, P867, DOI 10.1093/oxfordjournals.jbchem.a123472; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sambrook J, 1989, MOL CLONING LABORATO; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGAYA R, 1994, J BIOCHEM, V115, P150, DOI 10.1093/oxfordjournals.jbchem.a124292; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAUZ D, 1989, CHROMOSOMA, V98, P81; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19474	19479						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034716				2022-12-27	WOS:A1994NY33200044
J	GIBBS, FEM; WILKINSON, MC; RUDLAND, PS; BARRACLOUGH, R				GIBBS, FEM; WILKINSON, MC; RUDLAND, PS; BARRACLOUGH, R			INTERACTIONS IN-VITRO OF P9KA, THE RAT S-100-RELATED, METASTASIS-INDUCING, CALCIUM-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GROWTH-FACTOR; GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; MESSENGER-RNA; ION-BINDING; CALMODULIN; GENE; FIBROBLASTS; TRANSFORMATION	The S-100 proteins are a structurally related family displaying diverse intracellular and extracellular interactions. One such protein p9Ka (also known as calvasculin), or its mRNA (also known as CAPL, 42A, 18A2, mts, pEL 98), becomes elevated upon changes in the growth and differentiation of cells. Overexpression of p9Ka in benign rat mammary cells induces the metastatic phenotype. In order to help understand the role of p9Ka in these processes, the molecular properties of recombinant rat p9Ka have been studied. Recombinant p9Ka forms multimers in vitro, which are not due to intermolecular disulfide bridges, it binds 2 mol of calcium ions/mol of protein, and the binding of calcium ions is strongly antagonized by monovalent and divalent cations tested. Immunofluorescence studies indicate that p9Ka is located on cytoskeletal elements in a pattern which is identical to actin filaments stained with phalloidin. In vitro, it is shown that recombinant p9Ka binds to sites on at least two intracellular polypeptides. These sites display the same binding capacity for p9Ka in extracts of cultured rat mammary cells which show widely differing levels of expression of natural p9Ka. The results suggest that the production of p9Ka, and not of its target molecules, may be associated with the changes seen in cultured cells.	UNIV LIVERPOOL, DEPT BIOCHEM, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194; Wilkinson, Mark/0000-0003-3109-6888	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRACLOUGH R, 1979, EUR J BIOCHEM, V94, P165, DOI 10.1111/j.1432-1033.1979.tb12883.x; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1984, J CELL BIOL, V99, P550, DOI 10.1083/jcb.99.2.550; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; DAVIES BR, 1993, ONCOGENE, V8, P999; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FELDMANN K, 1978, ANAL BIOCHEM, V88, P225, DOI 10.1016/0003-2697(78)90414-1; GIBBS FEM, 1993, THESIS U LIVERPOOL; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUZNICKI J, 1987, BIOCHEM J, V247, P663, DOI 10.1042/bj2470663; KUZNICKI J, 1991, NOVEL CALCIUM BINDIN, P157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHKY P, 1977, ANAL BIOCHEM, V82, P158, DOI 10.1016/0003-2697(77)90144-0; LENGSFEL.AM, 1974, P NATL ACAD SCI USA, V71, P2803, DOI 10.1073/pnas.71.7.2803; LINSE S, 1991, J BIOL CHEM, V266, P8050; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MOORE BW, 1965, J BIOL CHEM, V240, P1647; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLANS AS, 1994, J BIOL CHEM, V269, P6233; RUTTER GA, 1989, BIOCHEM J, V263, P453, DOI 10.1042/bj2630453; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WATANABE Y, 1992, ARCH BIOCHEM BIOPHYS, V292, P563, DOI 10.1016/0003-9861(92)90031-Q; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; WOJDA U, 1992, 2ND P EUR S CALC BIN; YAMADA T, 1986, BIOCHEM BIOPH RES CO, V135, P837, DOI 10.1016/0006-291X(86)91004-1	54	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18992	18999						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034656				2022-12-27	WOS:A1994NX32700045
J	HATAHET, Z; KOW, YW; PURMAL, AA; CUNNINGHAM, RP; WALLACE, SS				HATAHET, Z; KOW, YW; PURMAL, AA; CUNNINGHAM, RP; WALLACE, SS			NEW SUBSTRATES FOR OLD ENZYMES - 5-HYDROXY-2'-DEOXYCYTIDINE AND 5-HYDROXY-2'-DEOXYURIDINE ARE SUBSTRATES FOR ESCHERICHIA-COLI ENDONUCLEASE-III AND FORMAMIDOPYRIMIDINE DNA N-GLYCOSYLASE, WHILE 5-HYDROXY-2'-DEOXYURIDINE IS A SUBSTRATE FOR URACIL DNA N-GLYCOSYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; POLYMERASE-I; AP SITES; RADIATION; EXCISION; 8-HYDROXYGUANINE; SPECIFICITY; MECHANISMS; RESIDUES; LESIONS	5-Hydroxy-2'-deoxycytidine (5-OHdC) and 5-hydroxy-2'-deoxyuridine (5-OHdU) are major products of oxidative DNA damage with mutagenic potential. Until now, no enzymatic activity responsible for their removal has been identified. We report here that both 5-OHdC and 5-OHdU are substrates for Escherichia coli endonuclease III and formamidopyrimidine DNA N-glycosylase (FPG). 5-OHdU is also a substrate for uracil DNA N-glycosylase. Consistent with their mechanisms of action on previously described substrates, endonuclease III removes 5-OHdC and 5-OHdU via a N-glycosylase/beta-elimination reaction, FPG follows a N-glycosylase/beta,delta-elimination reaction, and uracil N-glycosylase removes 5-OHdU by N-glycosylase action leaving behind an abasic site. Endonuclease III removes both lesions more efficiently than FPG, and both endonuclease III and FPG remove 5-OHdC slightly more efficiently than 5-OHdU. Uracil DNA N-glycosylase removes 5-OHdU more efficiently than the other two enzymes and has no activity on 5-OHdC even when present in great excess. Analysis of crude extracts obtained from wild type and endonuclease III deletion mutants of E. coli correlated well with data obtained with the purified enzymes.	UNIV VERMONT, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA; UNIV VERMONT, MARKEY CTR MOLEC GENET, BURLINGTON, VT 05405 USA; SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA	University of Vermont; University of Vermont; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Wallace, Susan S./0000-0002-3906-0321	NCI NIH HHS [R37CA33657] Funding Source: Medline; NIGMS NIH HHS [GM 37216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BAILLY V, 1984, FEBS LETT, V178, P223, DOI 10.1016/0014-5793(84)80605-5; BRIEMER LH, 1984, J BIOL CHEM, V259, P5543; CADET J, 1985, INT J RADIAT BIOL, V47, P127, DOI 10.1080/09553008514550201; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; HATAHET Z, 1993, NUCLEIC ACIDS RES, V21, P1563, DOI 10.1093/nar/21.7.1563; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IDE H, 1987, BIOCHEMISTRY-US, V26, P964, DOI 10.1021/bi00377a042; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KOW YW, 1990, UCLA SYM BI, V136, P81; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; RICHARDS RG, 1984, ADV ENZYME REGUL, V22, P157, DOI 10.1016/0065-2571(84)90013-X; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1981, P NATL ACAD SCI-BIOL, V78, P1773, DOI 10.1073/pnas.78.3.1773; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; VONSONNTAG C, 1986, INT J RADIAT BIOL, V49, P1; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WALLACE S S, 1987, British Journal of Cancer, V55, P118; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WEISS RB, 1986, NUCLEIC ACIDS RES, V14, P6621, DOI 10.1093/nar/14.16.6621; 1994, US BIOCH LIFE SCI RE, P248	39	302	305	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18814	18820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034633				2022-12-27	WOS:A1994NX32700020
J	GIRARD, JP; BAGNI, C; CAIZERGUESFERRER, M; AMALRIC, F; LAPEYRE, B				GIRARD, JP; BAGNI, C; CAIZERGUESFERRER, M; AMALRIC, F; LAPEYRE, B			IDENTIFICATION OF A SEGMENT OF THE SMALL NUCLEOLAR RIBONUCLEOPROTEIN-ASSOCIATED PROTEIN GAR1 THAT IS SUFFICIENT FOR NUCLEOLAR ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; YEAST SACCHAROMYCES-CEREVISIAE; SEQUENCE REQUIREMENTS; TARGETING SEQUENCES; SPECIFICALLY BINDS; RIBOSOMAL-PROTEIN; PRERIBOSOMAL RNA; XENOPUS-LAEVIS; FIBRILLARIN; TRANSPORT	GAR1 is a 25-kDa nucleolar protein that is essential for yeast cell growth. The protein is associated with a subset of small nucleolar RNAs and is required for pre-rRNA processing. By expressing in yeast various deletions of GAR1 fused to a reporter protein, we have searched for which particular domain of GAR1 can account for its nucleolar localization. We report here that the glycine/arginine-rich domains of GAR1, which are shared by several other nucleolar proteins, are neither sufficient nor required for the steady-state accumulation of the fusion protein in the nucleolus. We further demonstrate that the central domain of GAR1 is both sufficient to target the beta-galactosidase to the yeast nucleolus and to restore the growth of a strain deficient in GAR1. As opposed to the other characterized nucleolar proteins, the nucleolar targeting domain of GAR1 does not exhibit any homology with the SV40 T-antigen-type nuclear localization sequence. Moreover, none of the modified GAR1 proteins that we examined has allowed us to distinguish the nuclear and nucleolar targeting domains. The presence in GAR1 of a single domain that is responsible for both nuclear entry and nucleolar accumulation suggests that GAR1 either could be carried piggyback by another nucleolar component, possibly as part of a small nucleolar ribonucleoprotein particle, or could be transported to the nucleolus by using a pathway different from the other nucleolar proteins.	LAB BIOL MOLEC EUCARYOTE,F-31062 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691; Bagni, Claudia/0000-0002-4419-210X				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; ANDERSEN J, 1991, BIOESSAYS, V13, P57, DOI 10.1002/bies.950130203; BASERGA SJ, 1992, GENE DEV, V6, P1120, DOI 10.1101/gad.6.6.1120; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURGEOIS CA, 1988, INT REV CYTOL, V111, P1, DOI 10.1016/S0074-7696(08)61730-1; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CLARK MW, 1990, J CELL BIOL, V111, P1741, DOI 10.1083/jcb.111.5.1741; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P88; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GIRARD JP, 1993, NUCLEIC ACIDS RES, V21, P2149, DOI 10.1093/nar/21.9.2149; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HURT EC, 1992, INT REV CYTOL, V136, P145, DOI 10.1016/S0074-7696(08)62052-5; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LASKEY RA, 1993, CELL, V74, P385; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MEIER UT, 1992, CELL, V70, P127; MESSMER B, 1993, EUR J CELL BIOL, V61, P369; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILLEVIS.WW, 1973, EXP CELL RES, V80, P313, DOI 10.1016/0014-4827(73)90302-9; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081	50	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18499	18506						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034598				2022-12-27	WOS:A1994NW79800044
J	LI, WZ; LIN, P; FRYDMAN, J; BOAL, TR; CARDILLO, TS; RICHARD, LM; TOTH, D; LICHTMAN, MA; HARTL, FU; SHERMAN, F; SEGEL, GB				LI, WZ; LIN, P; FRYDMAN, J; BOAL, TR; CARDILLO, TS; RICHARD, LM; TOTH, D; LICHTMAN, MA; HARTL, FU; SHERMAN, F; SEGEL, GB			TCP20, A SUBUNIT OF THE EUKARYOTIC TRIC CHAPERONIN FROM HUMANS AND YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; POLYACRYLAMIDE-GEL; ESCHERICHIA-COLI; CENTRAL CAVITY; GENE; GROEL	Members of the Hsp60 chaperonin family, such as Escherichia coli GroEL/S and the eukaryotic cytosolic chaperonin complex, TRiC (TCP ring complex), are double toroid complexes capable of assisting the folding of proteins in vitro in an ATP-dependent fashion. TRiC differs from the GroEL chaperonin in that it has a hetero rather than homo-oligomeric subunit composition and lacks a GroES-like regulatory cofactor. We have established greater than 57% identity between a protein en coded by the TCP20 gene from a human cDNA library and the newly identified protein encoded by the TCP20 gene located on the right arm of chromosome TV of the yeast Saccharomyces cerevisiae. These Tcp20 proteins showed approximately 30% identity to Tcp1, a known subunit of TRiC, Gel filtration, followed by Western analysis of purified bovine testis TRiC with a Tcp20-specific antibody, indicated that Tcp20 is a subunit of the hetero-oligomeric TRiC. Gene disruption experiments showed that TCP20, like TCP1, is an essential gene in yeast, consistent with the view that TRiC is required for folding of key proteins. The amino acid sequence similarities and the derived evolutionary relationships established that the human and yeast Tcp20 proteins represent members of a new family of subunits of TRiC chaperonins.	UNIV ROCHESTER, SCH MED & DENT, DEPT PEDIAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA; SLOAN KETTERING INST, ROCKEFELLER RES LABS, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943	NATIONAL CANCER INSTITUTE [R01CA034691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA34691] Funding Source: Medline; NHLBI NIH HHS [HL08365] Funding Source: Medline; NIGMS NIH HHS [R01 GM48742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CARAZO JM, 1991, J STRUCT BIOL, V106, P211, DOI 10.1016/1047-8477(91)90071-4; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1989, TECHNIQUE, V1, P165; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JOHNSON RB, 1989, GENE, V84, P295, DOI 10.1016/0378-1119(89)90503-9; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KIRCHHOFF C, 1990, NUCLEIC ACIDS RES, V18, P4247, DOI 10.1093/nar/18.14.4247; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINK AJ, 1991, GENETICS, V127, P681; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; MORITA T, 1991, BIOCHIM BIOPHYS ACTA, V1129, P96, DOI 10.1016/0167-4781(91)90219-C; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD TK, 1992, PLANT MOL BIOL, V18, P873, DOI 10.1007/BF00019202; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL GB, 1992, P NATL ACAD SCI USA, V89, P6060, DOI 10.1073/pnas.89.13.6060; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1987, METHODS YEAST GENETI, P163; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SILVER LM, 1979, CELL, V17, P275, DOI 10.1016/0092-8674(79)90153-3; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P317; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; WOODLOCK TJ, 1993, J BIOL CHEM, V268, P16020; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	71	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18616	18622						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034610				2022-12-27	WOS:A1994NW79800061
J	OKABAYASHI, Y; KIDO, Y; OKUTANI, T; SUGIMOTO, Y; SAKAGUCHI, K; KASUGA, M				OKABAYASHI, Y; KIDO, Y; OKUTANI, T; SUGIMOTO, Y; SAKAGUCHI, K; KASUGA, M			TYROSINE-1148 AND TYROSINE-1173 OF ACTIVATED HUMAN EPIDERMAL GROWTH-FACTOR RECEPTORS ARE BINDING-SITES OF SHC IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; AUTOPHOSPHORYLATION SITES; NUCLEOTIDE EXCHANGE; EGF RECEPTOR; GRB2; RAS; DOMAINS; PROTEIN	Autophosphorylation of receptor tyrosine kinases provides binding sites for signaling proteins containing Src homology 2 (SH2) domains. We determined the binding sites of Shc, SH2-containing adaptor protein, within epidermal growth factor (EGF) receptors, using Chinese hamster ovary cells overexpressing EGF receptor mutants in which autophosphorylation sites, either alone or in combination, were replaced by phenylalanine. Binding of Shc to EGF receptor mutants lacking single tyrosine residues at 1148 or 1173 decreased by similar to 60 or similar to 15%, respectively, whereas other single point mutants bound the wild-type level of Shc. Binding of Shc markedly decreased in mutants lacking both tyrosine residues at 1148 and 1173. In peptide inhibition assay, phosphorylated nonameric peptide representing tyrosine 1148, DNPDpYQQDF, but not pentameric peptide, pYQQDF, inhibited the binding of glutathione S-transferase-Shc SH2 domain fusion protein to in vitro autophosphorylated EGF receptors, suggesting that N-terminal sequences adjacent to phosphotyrosine are necessary for the association of Shc. Based on results of peptide inhibition assays in which phosphorylated peptides representing tyrosines 992, 1148, and 1173 inhibited Shc binding to the receptor, we constructed another EGF receptor mutant in which one of these tyrosine residues was retained. The amount of Shc bound to mutant receptors retaining tyrosines 1148, 1173, or 992 was similar to 80, similar to 40, or similar to 10% of wild-type level, respectively. These results indicate that tyrosine 1148 of activated human EGF receptors is a major binding site of Shc and tyrosine 1173 is a secondary binding site in intact cells.			OKABAYASHI, Y (corresponding author), KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	28	106	109	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18674	18678						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034616				2022-12-27	WOS:A1994NW79800070
J	SOYEZ, D; VANHERP, F; ROSSIER, J; LECAER, JP; TENSEN, CP; LAFONT, R				SOYEZ, D; VANHERP, F; ROSSIER, J; LECAER, JP; TENSEN, CP; LAFONT, R			EVIDENCE FOR A CONFORMATIONAL POLYMORPHISM OF INVERTEBRATE NEUROHORMONES - D-AMINO-ACID RESIDUE IN CRUSTACEAN HYPERGLYCEMIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOBSTER HOMARUS-AMERICANUS; SINUS GLAND; SKIN; NEUROPEPTIDES; DERMORPHIN; SEQUENCE; HORMONE	Several large peptidic neurohormones have been isolated in crustaceans. In lobster and other related species, each of these neurohormones, and particularly the crustacean hyperglycemic hormone, occurs as two isoforms having the same peptidic sequence and molecular mass. We report here that these isoforms differ by the configuration of a single amino acid residue. The third residue (Phe(3)) of the lobster hyperglycemic hormones is in either the L- or D-configuration. In addition, we have shown that the biological activity of the two isoforms differs when considering the kinetics of their hyperglycemic effect.	CATHOLIC UNIV NIJMEGEN,FAC SCI,DEPT EXPTL ZOOL,6525 ED NIJMEGEN,NETHERLANDS; CNRS,INST ALFRED FESSARD,F-91198 GIF SUR YVETTE,FRANCE	Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	SOYEZ, D (corresponding author), ECOLE NORMALE SUPER,BIOCHIM & PHYSIOL DEV LAB,CNRS,URA 686,46 RUE ULM,F-75230 PARIS,FRANCE.			Tensen, Cornelis/0000-0002-5325-1888				ERSPAMER V, 1992, INT J DEV NEUROSCI, V10, P3, DOI 10.1016/0736-5748(92)90003-I; HUBERMAN A, 1986, COMP BIOCHEM PHYS B, V85, P197, DOI 10.1016/0305-0491(86)90243-9; Keller R., 1984, P145; KELLER R, 1992, EXPERIENTIA, V48, P439, DOI 10.1007/BF01928162; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MUNEOKA Y, 1992, EXPERIENTIA, V48, P448, DOI 10.1007/BF01928163; NEWCOMB RW, 1983, J COMP PHYSIOL, V153, P207, DOI 10.1007/BF00689624; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SCALONI A, 1991, ANAL BIOCHEM, V197, P305, DOI 10.1016/0003-2697(91)90396-B; SOYEZ D, 1990, GEN COMP ENDOCR, V79, P261, DOI 10.1016/0016-6480(90)90112-Y; SOYEZ D, 1987, J EXP ZOOL, V244, P479, DOI 10.1002/jez.1402440314; SOYEZ D, 1991, NEUROPEPTIDES, V20, P25, DOI 10.1016/0143-4179(91)90036-I; TENSEN CP, 1989, INVERTEBR REPROD DEV, V16, P155, DOI 10.1080/07924259.1989.9672072; TENSEN CP, 1991, EUR J BIOCHEM, V200, P103, DOI 10.1111/j.1432-1033.1991.tb21054.x; TENSEN CP, 1991, PEPTIDES, V1221, P241	18	135	137	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18295	18298						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034574				2022-12-27	WOS:A1994NW79800010
J	TRAPANI, JA; SMYTH, MJ; APOSTOLIDIS, VA; DAWSON, M; BROWNE, KA				TRAPANI, JA; SMYTH, MJ; APOSTOLIDIS, VA; DAWSON, M; BROWNE, KA			GRANULE SERINE PROTEASES ARE NORMAL NUCLEAR CONSTITUENTS OF NATURAL-KILLER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASE; CYTOTOXIC LYMPHOCYTE-T; PORE-FORMING PROTEIN; GRANZYME-A; MOLECULAR-CLONING; DNA FRAGMENTATION; BINDING-PROTEIN; PURIFICATION; PERFORIN; LYSIS	One mechanism by which cytotoxic T lymphocytes and natural killer cells inflict target cell death depends upon secreting the contents of their specialized cytoplasmic granules, containing a pore-forming protein, perforin, and a family of homologous serine proteases (''granzymes'') with various enzyme activities. We used a granzyme B-specific mouse anti-human monoclonal antibody 2C5 and Western blotting to demonstrate that nuclear extracts of human interleukin-2-stimulated pe ripheral blood mononuclear cells, the human NK leukemia cell line YT, and the rat NK leukemia cell line RNR-16 contain abundant granzyme B. In interleukin-2-activated peripheral blood mononuclear cells, more than 50% of the total cellular granzyme B was present in the nuclear lysate. Nuclear granzyme B had an apparent molecular mass of similar to 32 kDa in human cells and similar to 30 kDa in RNK-16 and was eluted from immobilized heparin at the same NaCl concentration as granzyme B from cytoplasmic granules. Granzyme B that was affinity-purified with 2C5 from the nuclei of YT or human LAK cells was capable of efficiently cleaving synthetic peptide thiobenzyl ester substrates with the same specificity (peptide cleavage after aspartic acid) as granule-localized granzyme B. By contrast perforin, which colocalizes with granzymes in cytotoxic granules, was not detectable in nuclear lysates. Granzyme B was also demonstrated to be present in the nucleus and cytoplasmic granules of YT by immunohistochemical staining with monospecific anti granzyme E antisera. Other protease activities (tryptase and peptide cleavage after methio- nine) were also readily detectable in nuclear and cyto plasmic lysates of YT, RNK-16, and LAK cells, as determined by the cleavage of the synthetic substrates N alpha-benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT) and Boc-Ala-Ala-Met-S-benzyl, except that BLT-esterase activity was absent from the nucleus of YT. The localization of serine proteases in the nucleus was restricted to lymphocytes with cytotoxic capacity, as non cytotoxic cell lines expressed high levels of peptide cleavage after methionine and tryptase activities in their cytoplasm, but possessed no nuclear serine protease activity. Furthermore, non cytotoxic monkey kidney COS-7 cells transfected with an SV40-driven expression plasmid incorporating full length human granzyme B cDNA contained abundant cytoplasmic granzyme B, but demonstrated minimal nuclear granzyme B accumulation. We conclude that serine proteases of NK cells are not restricted to cytolytic granules and, further, that their capacity to access the nucleus may have implications for the role of these enzymes in eliciting target cell death.			TRAPANI, JA (corresponding author), AUSTIN RES INST,CELLULAR CYTOTOX LAB,STUDLEY RD,HEIDELBERG,VIC 3084,AUSTRALIA.		Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERKE G, 1991, IMMUNOL TODAY, V12, P396, DOI 10.1016/0167-5699(91)90138-J; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; GEISBERG M, 1991, TISSUE ANTIGENS, V35, P229; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GREENBERG AH, 1993, P EMBO WORKSHOP CELL, P32; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HUDIG D, 1991, J IMMUNOL, V147, P1360; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; KUMMER JA, 1993, J IMMUNOL METHODS, V163, P77, DOI 10.1016/0022-1759(93)90241-X; LIU CC, 1986, J EXP MED, V164, P2061, DOI 10.1084/jem.164.6.2061; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MULLEREBERHARD HJ, 1988, IMMUNOL REV, V103, P87, DOI 10.1111/j.1600-065X.1988.tb00751.x; NORTHEMANN W, 1985, J BIOL CHEM, V260, P6200; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OJCIUS DM, 1991, J IMMUNOL, V146, P4427; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; PODACK ER, 1983, NATURE, V302, P442, DOI 10.1038/302442a0; POE M, 1991, J BIOL CHEM, V266, P98; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SAYERS TJ, 1992, J IMMUNOL, V148, P292; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMYTH MJ, 1992, J BIOL CHEM, V267, P24118; STACKER SA, 1987, MUCINS BREAST CANCER, P217; TALENTO A, 1992, J IMMUNOL, V149, P4009; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; TSCHOPP J, 1986, NATURE, V322, P831, DOI 10.1038/322831a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3; YOUNG JDE, 1986, SCIENCE, V233, P184, DOI 10.1126/science.2425429; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	45	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18359	18365						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034581				2022-12-27	WOS:A1994NW79800022
J	KIM, J; KLEIN, PG; MULLET, JE				KIM, J; KLEIN, PG; MULLET, JE			SYNTHESIS AND TURNOVER OF PHOTOSYSTEM-II REACTION-CENTER PROTEIN D1 - RIBOSOME PAUSING INCREASES DURING CHLOROPLAST DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; RHODOBACTER-SPHAEROIDES R-26; ILLUMINATED BARLEY SEEDLINGS; CHLOROPHYLL-A-APOPROTEINS; RHODOPSEUDOMONAS-VIRIDIS; MEMBRANE POLYPEPTIDE; THYLAKOID-MEMBRANE; BINDING PROTEIN; PSAA-PSAB; TRANSLATION	The chloroplast photosystem II reaction center protein D1 contains five membrane-spanning helices and binds chlorophyll, carotenoid, quinone, iron, and probably manganese. Turnover of pulse-labeled D1 in isolated plastids was found to involve cleavage between helix IV and helix V, which releases a 23-kDa N-terminal peptide and two C-terminal peptides of 10 and 8 kDa. Ribosomes pause at specific sites during translation of D1, which results in the accumulation of D1 translation intermediates. Pulse-labeling assays followed by poly some isolation and immunoprecipitation identified paused D1 translation intermediates of 9, 12.5, 15-18, 20, 21, 24, and 28-32 kDa. Ribosome pausing was not altered when dark grown seedlings were illuminated for up to 1 h, even though this treatment stimulated accumulation of chlorophyll and D1. However, illumination of plants for 16-72 h resulted in increased ribosome pausing and the build-up of D1 translation intermediates. We hypothesize that ribosome pausing during synthesis of D1 im proves the efficiency of chlorophyll binding to D1 nascent chains and enhances accumulation of D1 in mature chloroplasts, which have reduced rates of chlorophyll biosynthesis.	TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA; UNIV KENTUCKY, DEPT HORT & LANDSCAPE ARCHITECTURE, LEXINGTON, KY 40517 USA	Texas A&M University System; Texas A&M University College Station; University of Kentucky				Kim, Jungmook/0000-0003-1735-5564	NIGMS NIH HHS [GM37987] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADIR N, 1990, J BIOL CHEM, V265, P12563; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; CHRISTOPHER DA, 1994, PLANT PHYSIOL, V104, P1119, DOI 10.1104/pp.104.4.1119; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DINER BA, 1988, J BIOL CHEM, V263, P8972; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; GAMBLE PE, 1989, J BIOL CHEM, V264, P7236; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HERRIN DL, 1992, J BIOL CHEM, V267, P8260; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; KIM JK, 1992, ANAL BIOCHEM, V206, P183, DOI 10.1016/S0003-2697(05)80031-4; KIM JM, 1991, J BIOL CHEM, V266, P14931; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; LIPP J, 1987, J BIOL CHEM, V262, P1680; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; TREBST A, 1986, Z NATURFORSCH C, V41, P240; WETTERN M, 1985, PLANTA, V166, P474, DOI 10.1007/BF00391271; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	33	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17918	17923						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027048				2022-12-27	WOS:A1994NV42200028
J	ZAPATA, JM; MARTINEZ, MA; SIERRA, JM				ZAPATA, JM; MARTINEZ, MA; SIERRA, JM			PURIFICATION AND CHARACTERIZATION OF EUKARYOTIC POLYPEPTIDE-CHAIN INITIATION-FACTOR 4F FROM DROSOPHILA-MELANOGASTER EMBRYOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA CAP; INFECTED HELA-CELLS; YEAST SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; TRANSLATIONAL CONTROL; PHOSPHORYLATION SITE; SECONDARY STRUCTURE; WHEAT-GERM; COMPLEX	The eukaryotic polypeptide chain initiation factor 4F (eIF-4F), purified by m(7)GTP-Sepharose chromatography from whole extracts of Drosophila melanogaster embryos, consists of two subunits, the previously identified eIF-4E (35 kDa) (Maroto, F. G., and Sierra, J. M. (1989) Mol. Cell. Biol. 9, 2181-2190) and another of 200 kDa. Both subunits cosedimented through a sucrose density gradient containing 0.5 M KCl. In contrast to rabbit reticulocyte eIF-4F, we did not find any RNA-dependent ATPase associated with the Drosophila factor. As shown previously for eIF-4E, the p200 subunit was also required for the translation of endogenous mRNAs in cell-free systems from Drosophila embryos. Only the eIF-4E subunit was able to cross-link to the m(7)G cap structure. However, an efficient cross-linking of the p200 subunit to an uncapped mRNA was observed. Both subunits were phosphorylated in vitro by protein kinase C from rat brain. As an extension of our previous results (Zapata, J. M., Maroto, F. G., and Sierra, J. M. (1991) J. Biol. Chem. 266, 16007-16014) we found that the translation of the heat shock mRNAs was independent of both of the eIF-4F subunits.	CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid			Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DORN R, 1993, MOL GEN GENET, V237, P233, DOI 10.1007/BF00282805; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1984, BIOCHEMISTRY-US, V23, P2456, DOI 10.1021/bi00306a021; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GOYER C, 1989, J BIOL CHEM, V264, P7603; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LANKER S, 1992, J BIOL CHEM, V267, P21167; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; MAROTO FG, 1989, MOL CELL BIOL, V9, P2181, DOI 10.1128/MCB.9.5.2181; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MATEU MG, 1987, EUR J BIOCHEM, V162, P221, DOI 10.1111/j.1432-1033.1987.tb10564.x; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; YAN RQ, 1992, J BIOL CHEM, V267, P23226; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	40	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18047	18052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027064				2022-12-27	WOS:A1994NV42200046
J	JOSEPH, CK; WRIGHT, SD; BORNMANN, WG; RANDOLPH, JT; KUMAR, ER; BITTMAN, R; LIU, J; KOLESNICK, RN				JOSEPH, CK; WRIGHT, SD; BORNMANN, WG; RANDOLPH, JT; KUMAR, ER; BITTMAN, R; LIU, J; KOLESNICK, RN			BACTERIAL LIPOPOLYSACCHARIDE HAS STRUCTURAL SIMILARITY TO CERAMIDE AND STIMULATES CERAMIDE-ACTIVATED PROTEIN-KINASE IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; LIPID-A; BIOLOGICAL-ACTIVITIES; MEDIATED BIOLOGY; BINDING-PROTEIN; HL-60 CELLS; FREE SYSTEM	Bacterial lipopolysaccharide (LPS), tumor necrosis factor (TNF)-alpha and interleukin-1 beta (IL-1 beta) stimulate similar cellular responses. TNF-alpha and IL-1 beta are known to initiate signaling through a pathway involving hydrolysis of sphingomyelin to ceramide (Kolesnick, R. N., and Golde, D. W. (1994) Cell 77, 325-328). In this system, ceramide acts as a second messenger stimulating a ceramide-activated serine/threonine protein kinase. The present studies demonstrate that LPS, like TNF and IL-1, stimulates ceramide activated protein kinase activity in human leukemia (HL-60) cells and in freshly isolated human neutrophils. Lipid A, the biologically active core of LPS, enhanced kinase activity in a time- and concentration-dependent manner. As little as 10 nM lipid A was effective, and a maximal effect occurred with 500 nM lipid A, increasing kinase activity 5-fold. Native LPS similarly induced kinase activation. This effect of LPS was markedly enhanced by LPS binding protein and required the LPS receptor CD14. In contrast to TNF and IL-1, LPS did not cause sphingomyelin hydrolysis and thus stimulates ceramide-activated protein kinase without generating ceramide. Molecular modeling showed strong structural similarity between ceramide and a region of lipid A. Based on these observations, we propose that LPS stimulates cells by mimicking the second messenger function of ceramide.	MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PREPARAT SYNTHESIS CORE FACIL,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; CUNY QUEENS COLL,DEPT CHEM & BIOCHEM,FLUSHING,NY 11367	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Rockefeller University; City University of New York (CUNY) System; Queens College NY (CUNY)					NCI NIH HHS [NCI-P3-CA-08748, CA-57400] Funding Source: Medline; NIAID NIH HHS [AI-30556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057400, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGASRA O, 1992, P NATL ACAD SCI USA, V89, P6285, DOI 10.1073/pnas.89.14.6285; BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BULUSU MARC, 1992, J MED CHEM, V35, P3463, DOI 10.1021/jm00097a003; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DVIS RJ, 1993, J BIOL CHEM, V268, P14553; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1993, J BIOL CHEM, V268, P25009; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASTOWSKY M, 1991, EUR J BIOCHEM, V197, P707, DOI 10.1111/j.1432-1033.1991.tb15962.x; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSAMA T, 1990, CHEM PHARM BULL, V38, P3366, DOI 10.1248/cpb.38.3366; LAM C, 1991, ANTIMICROB AGENTS CH, V35, P500, DOI 10.1128/AAC.35.3.500; LAME, 1993, OK, V61, P2015; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU J, 1994, J BIOL CHEM, V269, P3047; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHOLZ D, 1992, J MED CHEM, V35, P2070, DOI 10.1021/jm00089a019; SHUMANN RR, 1990, SCIENCE, V249, P1429; Tracey K J, 1990, Adv Surg, V23, P21; VYPLEL H, 1991, J MED CHEM, V34, P2759, DOI 10.1021/jm00113a013; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	45	147	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17606	17610						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021269				2022-12-27	WOS:A1994NU12800043
J	PIEDAGNEL, R; PRIE, D; CASSINGENA, R; RONCO, PM; LELONGT, B				PIEDAGNEL, R; PRIE, D; CASSINGENA, R; RONCO, PM; LELONGT, B			SV40 LARGE-T ONCOGENE INHIBITS TRANSCRIPTION OF PERLECAN-RELATED PROTEOGLYCANS BUT STIMULATES HYALURONAN SYNTHESIS IN A TEMPERATURE-SENSITIVE RENAL-TUBULE PRINCIPAL CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; HAMSTER-KIDNEY CELLS; ROUS-SARCOMA VIRUS; SIMIAN VIRUS-40; GLYCOSAMINOGLYCAN SYNTHESIS; ADHESION MOLECULES; TRANSFORMED-CELLS; SKIN FIBROBLASTS	We have analyzed the effects of SV40 large-T oncogene on proteoglycan (PG) synthesis in a temperature-sensitive SV40-transformed renal cell line. Cells shifted from permissive (33 degrees C) to restrictive (39.5 degrees C) temperature, acquired within 48 h the phenotype of principal cells of the renal collecting tubule. They then synthesized hyaluronan, a large-sized PG, small amounts of free GAG chains, and a major similar to 130-kDa kDa heparan sulfate-PG. Sulfated PGs were localized in a basement membrane-like layer and possessed the same core protein (61-70 kDa) derived from perlecan. Expression of large-T oncogene at the permissive temperature induced dramatic alterations of the extracellular matrix, and a 4- and 12 fold reduction in cell-associated and medium-released sulfated PGs, due to a similar to 50% decrease in perlecan mRNA content and gene transcription. This contrasted with a 2-fold increase in actin gene transcription and a 10- and 2-fold rise in the hyaluronan content in cells and medium, respectively. These alterations did not occur in a control cell line (RC.SV3) derived from the same tubule segment but infected with wild-type SV40 strain. They are thus most likely related to the functional state of large-T oncogene and may take part in the early steps of transformation.	HOP TENON,INSERM,U64,F-75970 PARIS 20,FRANCE; UER XAVIER BICHAT,UNITE 251,F-75870 PARIS 18,FRANCE; CNRS,UPR 42,VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)			lelongt, brigitte/N-3746-2017; Piedagnel, Remi/C-7427-2017; Ronco, Pierre/AAC-8390-2022	lelongt, brigitte/0000-0002-9308-8798; Piedagnel, Remi/0000-0002-5931-1271				AMANUMA K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P336, DOI 10.1016/S0167-4889(97)90009-4; ANGELLO JC, 1982, CANCER RES, V42, P2207; ANGELLO JC, 1982, CANCER RES, V42, P4975; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; EKBLOM P, 1991, KIDNEY INT, V39, P394, DOI 10.1038/ki.1991.51; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; GLIMELIUS B, 1978, BIOCHEM J, V172, P443, DOI 10.1042/bj1720443; GOLDBERG RL, 1984, J BIOL CHEM, V259, P9440; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; IOZZO RV, 1985, LAB INVEST, V53, P373; IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; LACY BE, 1987, J CELL BIOL, V105, P1395, DOI 10.1083/jcb.105.3.1395; LAMBERG SI, 1986, J INVEST DERMATOL, V86, P659, DOI 10.1111/1523-1747.ep12275707; LELONGT B, 1988, P NATL ACAD SCI USA, V85, P9047, DOI 10.1073/pnas.85.23.9047; LELONGT B, 1992, J BIOL CHEM, V267, P23815; LELONGT B, 1992, J CELL PHYSL, V154, P175; Meyer K, 1939, P SOC EXP BIOL MED, V42, P797; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MONTENARH M, 1992, ONCOGENE, V7, P1673; MORSE BS, 1967, AM J MED, V42, P996, DOI 10.1016/0002-9343(67)90080-0; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OHKUBO Y, 1983, CANCER RES, V43, P2712; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PRIE D, 1991, J CELL BIOL, V113, P951, DOI 10.1083/jcb.113.4.951; PRIE D, 1994, IN PRESS AM J PHYSL, V266; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SATOH C, 1973, P NATL ACAD SCI USA, V70, P54, DOI 10.1073/pnas.70.1.54; SHANLEY DJ, 1983, J BIOL CHEM, V258, P810; SUGAHARA K, 1985, J BIOCHEM-TOKYO, V98, P875, DOI 10.1093/oxfordjournals.jbchem.a135367; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; UNDERHILL CB, 1981, EXP CELL RES, V131, P419, DOI 10.1016/0014-4827(81)90248-2; UNDERHILL CB, 1985, J BIOL CHEM, V260, P8128; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128; VOYLES BA, 1976, BIOCHIM BIOPHYS ACTA, V444, P269, DOI 10.1016/0304-4165(76)90244-0; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310	42	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17469	17476						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021252				2022-12-27	WOS:A1994NU12800023
J	NORIOKA, S; OHTA, S; OHARA, T; LIM, SI; SAKIYAMA, F				NORIOKA, S; OHTA, S; OHARA, T; LIM, SI; SAKIYAMA, F			IDENTIFICATION OF 3 CATALYTIC TRIAD CONSTITUENTS AND ASP-225 ESSENTIAL FOR FUNCTION OF LYSINE-SPECIFIC SERINE-PROTEASE, ACHROMOBACTER PROTEASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOROTHIOATE-MODIFIED DNA; PANCREATIC TRYPSIN-INHIBITOR; LYTICUS M497-1; BINDING POCKET; CRYSTALLOGRAPHIC REFINEMENT; SUBSTRATE-SPECIFICITY; PROTEOLYTIC-ENZYME; CRYSTAL-STRUCTURE; RESOLUTION; PROTEINS	Achromobacter protease I is a lysine-specific serine protease that Achromobacter lyticus M497-1 extracellularly secretes. The structural aspects necessary for the protease to function were investigated by means of site-directed mutagenesis to identify the constituents of the catalytic triad and the amino acid residue responsible for lysine specificity. The precursor molecules, which were produced by substitution of His-57, Asp-113, or Ser-194 for alanine, could not be converted to the mature form. In contrast, a precursor of a mutant in which either His-56 or Ser-193 is converted to alanine was perfectly processed autocatalytically and attained full protease activity. Substitution of Glu-190, one of the two candidates for determining lysine specificity, to glutamine, aspartic acid, or leucine had no or little effect on both proteolytic activity and substrate specificity. However, the kinetic parameters were subtly different from one another, depending on the nature of substituents in these mutants. The substitution of the other candidate, Asp-225, for asparagine or leucine resulted in the failure of maturation to the active forms. However, the precursor of the D225E mutant slowly matured and was essentially inactive. The observed reduction of protease activity is largely due to a decrease in the affinity of lysine to the protease. These results suggest that His-57, Asp-113 and Ser-194 are the three constituents of the catalytic triad in Achromobacter protease I and that Asp-225 plays a critical role in restricted substrate specificity as a lysyl endopeptidase.	OSAKA UNIV,INST PROT RES,PROT ENGN RES CTR,SUITA,OSAKA 565,JAPAN	Osaka University	NORIOKA, S (corresponding author), OSAKA UNIV,DIV PROT CHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Ohta, shigeki/L-1677-2013; Ohta, Shigeki/Y-4455-2019	Ohta, Shigeki/0000-0003-2994-4278				BODE W, 1984, EUR J BIOCHEM, V144, P185, DOI 10.1111/j.1432-1033.1984.tb08447.x; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; KREIL G, 1981, ANNU REV BIOCHEM, V50, P317, DOI 10.1146/annurev.bi.50.070181.001533; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASAKI T, 1978, AGR BIOL CHEM TOKYO, V42, P1443, DOI 10.1080/00021369.1978.10863183; MASUI Y, 1984, BIO-TECHNOL, V2, P81, DOI 10.1038/nbt0184-81; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; OHARA T, 1989, J BIOL CHEM, V264, P20625; PERONA JJ, 1993, J MOL BIOL, V230, P934, DOI 10.1006/jmbi.1993.1211; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; SAKIYAMA F, 1990, Journal of Protein Chemistry, V9, P297; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNASAWA S, 1989, J BIOL CHEM, V264, P3832; TSUNASAWA S, 1985, J BIOCHEM-TOKYO, V97, P701, DOI 10.1093/oxfordjournals.jbchem.a135108; TSUNASAWA S, 1987, J BIOCHEM, V101, P111, DOI 10.1093/oxfordjournals.jbchem.a121882	23	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17025	17029						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006007				2022-12-27	WOS:A1994NT84600009
J	OYAMADA, H; MURAYAMA, T; TAKAGI, T; IINO, M; IWABE, N; MIYATA, T; OGAWA, Y; ENDO, M				OYAMADA, H; MURAYAMA, T; TAKAGI, T; IINO, M; IWABE, N; MIYATA, T; OGAWA, Y; ENDO, M			PRIMARY STRUCTURE AND DISTRIBUTION OF RYANODINE BINDING-PROTEIN ISOFORMS OF THE BULLFROG SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CA-2+-INDUCED CA-2+ RELEASE; DEPENDENT CHARGE MOVEMENT; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; CARDIAC-MUSCLE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; RECEPTOR CDNA; CELLS	We have cloned two groups of cDNAs which encode isoforms of ryanodine-binding protein/Ca2+ release channel of the bullfrog skeletal muscle sarcoplasmic reticulum. One of the cDNA groups encodes the protein of 5,037 (or 5,031 with a deletion) amino acids with a molecular weight of 571,262 (or 570,607), which is identified as the alpha-isoform of the ryanodine-binding protein based on the amino acid sequence of three tryptic fragments of the purified protein. The other group of cDNAs encodes the protein of 4,868 amino acids with molecular weight of 553,029, which contains the sequences of three proteolytic fragments derived from the beta-isoform protein. About 70% of the amino acid sequence identity is present between alpha- and beta-isoforms of the bullfrog. The primary structure of the alpha-isoform is highly (80%) homologous to the ryanodine-binding protein cloned from rabbit skeletal muscle (type 1). The beta-isoform, on the other hand, is more than 85% identical with that from the rabbit brain (type 3), while it has only 67% overall identity with type 1. Analyses of RNA from various tissues of the bullfrog demonstrate that the beta-isoform is widely expressed, while the alpha-isoform is expressed mainly in skeletal muscle. A phylogenetic analysis of the ryanodine binding protein/Ca2+ release channel family suggests that the various types of Ca2+ release channels have evolved from an ancestor gene. Possible differential roles of alpha- and beta-isoforms of ryanodine-binding protein in Ca2+ release mechanisms including skeletal muscle excitation contraction coupling were discussed.	JUNTENDO UNIV, SCH MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT PHARMACOL, TOKYO 113, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN	Juntendo University; University of Tokyo; Kyoto University								ADRIAN RH, 1970, J PHYSIOL-LONDON, V208, P645, DOI 10.1113/jphysiol.1970.sp009140; AIREY JA, 1993, DEV DYNAM, V197, P169, DOI 10.1002/aja.1001970303; AIREY JA, 1990, J BIOL CHEM, V265, P14187; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P245, DOI 10.1113/jphysiol.1976.sp011232; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; FRANZINIARMSTRONG C, 1991, DEV BIOL, V146, P364, DOI 10.1016/0012-1606(91)90238-X; FRANZINIARMSTRONG C, 1975, FED PROC, V34, P1382; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Hille B., 1992, IONIC CHANNELS EXCIT; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IINO M, 1992, BIOCHEM BIOPH RES CO, V185, P713, DOI 10.1016/0006-291X(92)91684-I; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; IMAGAWA T, 1992, J BIOCHEM-TOKYO, V112, P508, DOI 10.1093/oxfordjournals.jbchem.a123930; INUI M, 1987, J BIOL CHEM, V262, P1740; JENDEN DJ, 1969, PHARMACOL REV, V21, P1; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOVACS L, 1978, J PHYSIOL-LONDON, V277, P483, DOI 10.1113/jphysiol.1978.sp012286; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRESTINGER RH, 1976, COLD SPRING HARB SYM, V52, P449; KUREBAYASHI K, 1988, NUCLEIC ACIDS S SER, V19, P61; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1992, J MUSCLE RES CELL M, V13, P394, DOI 10.1007/BF01738035; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SEILER S, 1984, J BIOL CHEM, V259, P8550; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUTKO JL, 1985, FED PROC, V44, P2984; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	71	96	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17206	17214						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006029				2022-12-27	WOS:A1994NT84600036
J	CALDWELL, GA; WANG, SH; XUE, CB; JIANG, Y; LU, HF; NAIDER, F; BECKER, JM				CALDWELL, GA; WANG, SH; XUE, CB; JIANG, Y; LU, HF; NAIDER, F; BECKER, JM			MOLECULAR DETERMINANTS OF BIOACTIVITY OF THE SACCHAROMYCES-CEREVISIAE LIPOPEPTIDE MATING PHEROMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; A-FACTOR; RAS PROTEIN; PEPTIDE ANALOGS; GENE ENCODES; G1 ARREST; YEAST; PRENYLATION; CELLS; SYSTEM	The a-factor of Saccharomyces cerevisiae (YIIKGVFWDPAC(Farnesyl)-OCH3) is a peptide pheromone in which post-translational modification with a farnesyl isoprenoid and carboxyl methyl group is required for export and bioactivity. Truncated and carboxyl-terminal modified analogs of the a-factor were synthesized in order to determine the effect of such modifications on bioactivity. Bioactivity studies on carboxyl-terminal analogs in which the chirality, the cysteine thioether, and the carboxyl ester were varied in an attempt to study the influence of topology on a-factor activity indicate that the hydrophobicity conferred by the farnesyl moiety and not its specific spatial orientation is a key determinant of a-factor potency. Analyses on truncated a-factors suggest that sequential removal of NH2-terminal residues leads to a gradient of potency loss, with some amino acids exhibiting a slightly greater contribution to bioactivity than others. Random oligonucleotide targeted mutagenesis of the gene encoding a-factor was coupled to a biological screen to identify altered a-factor peptides which are secreted yet exhibit a loss of a-factor bioactivity. Transformants exhibiting this phenotype were examined to identify codon changes presumably responsible for the altered phenotype, thus indicating residues that may contribute significantly to a-factor bioactivity.	UNIV TENNESSEE,PROGRAM CELLULAR MOLEC & DEV BIOL,KNOXVILLE,TN 37996; UNIV TENNESSEE,DEPT MICROBIOL,KNOXVILLE,TN 37996; CUNY COLL STATEN ISL,DEPT CHEM,STATEN ISL,NY 10301	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY)				Caldwell, Guy/0000-0002-8283-9090	NIGMS NIH HHS [GM-46520] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BAFFI RA, 1984, J BACTERIOL, V158, P1152, DOI 10.1128/JB.158.3.1152-1156.1984; BETZ R, 1987, J BIOL CHEM, V262, P546; BETZ R, 1979, EUR J BIOCHEM, V95, P469, DOI 10.1111/j.1432-1033.1979.tb12986.x; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CALDWELL GA, 1993, PROMEGA NOTES, V44, P6; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EPAND RF, 1993, BIOCHEMISTRY-US, V32, P8368, DOI 10.1021/bi00083a041; ERIOTOUBARGIOTA E, 1992, BIOCHEMISTRY-US, V31, P551, DOI 10.1021/bi00117a036; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P142; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOUNARIDES JS, 1991, BIOCHEM BIOPH RES CO, V181, P1125, DOI 10.1016/0006-291X(91)92055-O; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HRYEYNA CA, 1991, EMBO J, V10, P1699; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MARCUS S, 1991, MOL CELL BIOL, V11, P1030, DOI 10.1128/MCB.11.2.1030; MARCUS S, 1990, BIOCHEM BIOPH RES CO, V172, P1310, DOI 10.1016/0006-291X(90)91592-G; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; RATHS SK, 1988, J BIOL CHEM, V263, P17333; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SIKORSKI RS, 1989, GENETICS, V122, P19; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; Sprague G. F., 1993, MOL CELLULAR BIOL YE, P657; STERNE RE, 1989, THESIS ANN ARBOR; STOTZLER D, 1976, EUR J BIOCHEM, V65, P257, DOI 10.1111/j.1432-1033.1976.tb10412.x; XUE CB, 1990, INT J PEPT PROT RES, V36, P362; XUE CB, 1992, TETRAHEDRON LETT, V33, P1435, DOI 10.1016/S0040-4039(00)91640-X; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X; XUE CB, 1989, J BIOL CHEM, V264, P19161; XUE CB, 1991, INT J PEPT PROT RES, V37, P476	51	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19817	19825						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051063				2022-12-27	WOS:A1994PA12600027
J	MITRA, A; SONG, LX; FRICKER, LD				MITRA, A; SONG, LX; FRICKER, LD			THE C-TERMINAL REGION OF CARBOXYPEPTIDASE-E IS INVOLVED IN MEMBRANE-BINDING AND INTRACELLULAR ROUTING IN ATT-20 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-PROCESSING ENZYME; SECRETORY GRANULES; ENKEPHALIN CONVERTASE; SEQUENCE-ANALYSIS; CDNA; IDENTIFICATION; PURIFICATION; LOCALIZATION; PROTEINS; VESICLES	Carboxypeptidase E (CPE), a neuropeptide processing enzyme, is present in neuroendocrine tissues in soluble and membrane-associated forms. The membrane-associated forms do not contain a conventional transmembrane-spanning domain; instead, the C-terminal region of CPE has been proposed to form an amphiphilic helix which binds to the membrane. To test this, and to investigate the possible contribution of this C-terminal sequence to the intracellular sorting of CPE into the regulated pathway, the C-terminal region of CPE was attached to albumin and the recombinant proteins expressed in AtT-20 cells. Albumin itself showed little association with membranes under the conditions examined. A construct containing albumin with only 9 residues of CPE, corresponding to a highly charged region immediately preceding the potential amphiphilic helix region, showed generally similar membrane binding and secretion rates as albumin alone. When the C-terminal 51 amino acids of CPE were attached to the C terminus of albumin and the recombinant protein detected with an antisera raised against the C terminus of CPE, virtually all of the protein was membrane-associated. This finding suggests that the C-terminal region of CPE functions as a membrane anchor. The secretion of albumin with the C-terminal region of CPE was stimulated by a phorbol ester and by forskolin, although the magnitude of the stimulation was smaller than the effect of these compounds on the secretion of CPE. These results imply that the C-terminal region of CPE contains the membrane anchor and contributes to the sorting of this protein into the regulated pathway.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [DA-04494, DA-00194] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, R01DA004494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MAINS RE, 1984, ENDOCRINOLOGY, V115, P1683, DOI 10.1210/endo-115-5-1683; MANSER E, 1991, BIOCHEM J, V280, P695, DOI 10.1042/bj2800695; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; SAMBROK J, 1989, MOL CLONING LABORATO; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D	25	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19876	19881						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051069				2022-12-27	WOS:A1994PA12600035
J	WU, HY; LOZANO, G				WU, HY; LOZANO, G			NF-KAPPA-B ACTIVATION OF P53 - A POTENTIAL MECHANISM FOR SUPPRESSING CELL-GROWTH IN RESPONSE TO STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; WILD-TYPE P53; LONG TERMINAL REPEAT; DNA-BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; 65-KD SUBUNIT; FACTOR-ALPHA; CYCLE CONTROL	The tumor suppressor p53 is a potent transcriptional activator that has been shown to regulate its own expression. In earlier studies, deletion analysis and site-specific mutagenesis identified the p53-responsive element that fits the p53 consensus sequence. In addition, the p53-responsive element was predicted to be a binding site for NF-kappa B. In this study, we showed that NF-kappa B present in HeLa nuclear extracts could bind the same DNA element in a sequence-specific manner. Co-transfection experiments showed that the p65 subunit of NF-kappa B, but not the p50 subunit, could activate the p53 promoter. In HeLa cells, tumor necrosis factor alpha (TNF-alpha) induced NF-kappa B activity. The p53 promoter was also induced by TNF-alpha under the same conditions. Both p65 transactivation and TNF-alpha induction of the p53 promoter depended on an intact NF-kappa B site. Detailed mutational analysis of the p53 and NF-kappa B responsive elements allowed differentiation of these two responses. Thus, we show that NF-kappa B activates p53 and that this activation is inducible by TNF-alpha. Since NF-kappa B induction occurs as a response to stress and p53 arrests cells in G(1)/S, where repair may be initiated, activation of p53 by NF-kappa B could be a mechanism by which cells can recover from stress.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GINSBERG D, 1990, ONCOGENE, V5, P1285; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JOHNSON P, 1990, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OROURKE RW, 1990, ONCOGENE, V5, P1829; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OTT L, 1977, INTRO STAT METHODS D, P112; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1989, ONCOGENE, V4, P945; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P5470; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	74	326	328	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20067	20074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051093				2022-12-27	WOS:A1994PA12600062
J	YAMASHITA, H; TENDIJKE, P; FRANZEN, P; MIYAZONO, K; HELDIN, CH				YAMASHITA, H; TENDIJKE, P; FRANZEN, P; MIYAZONO, K; HELDIN, CH			FORMATION OF HETEROOLIGOMERIC COMPLEXES OF TYPE-I AND TYPE-II RECEPTORS FOR TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; HUMAN ENDOTHELIAL-CELLS; EXPRESSION CLONING; IDENTIFICATION; ACTIVIN; RESPONSIVENESS; BETAGLYCAN; COMPONENT; ENDOGLIN; FAMILY	Transforming growth factor-beta (TGF-beta) transduces signals through a heteromeric complex of type I (T beta R-I) and type II (T beta R-II) TGF-beta receptors. To determine the stoichiometry of this complex we used analysis by affinity labeling with I-125-TGF-beta 1 and covalent cross-linking with disuccinimidyl suberate and immunoprecipitation using T beta R-I- or T beta R-II-specific antisera, followed by two-dimensional gel electrophoresis under nonreducing (first dimension) and reducing (second dimension) conditions. Dimers composed of T beta R-I and/or T beta R-II were observed on mink lung epithelial cells as well as COS-1 cells transfected with T beta R-I and T beta R-II cDNAs. Homodimers of T beta R-I could be demonstrated on these cells after dissociation of T beta R-Il by sodium dodecyl sulfate treatment. On the cell surface of mink lung epithelial cell mutants that express only T beta R-II and do not respond to TGF-beta, and on COS-1 cells transfected with only T beta R-II, only homodimers of T beta R-II were seen. The facts that T beta R-I does not bind TGF-beta in the absence of T beta R-II and that T beta R-II forms a signaling complex with T beta R-I, together with our observations that homodimers of T beta R-I and T beta R-II are seen on responsive cells, support the notion that TGF-beta induces the formation of hetero-oligomeric receptor complexes, most likely a heterotetramer containing two molecules each of T beta R-I and T beta R-II.			YAMASHITA, H (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOBEL G, 1975, J CELL BIOL, V67, P835; Burt David W., 1994, Progress in Growth Factor Research, V5, P99; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAZONO K, 1994, ADV IMMUNOL, V55, P180; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	32	260	268	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20172	20178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051105				2022-12-27	WOS:A1994PA12600076
J	SHESTAKOV, SV; ANBUDURAI, PR; STANBEKOVA, GE; GADZHIEV, A; LIND, LK; PAKRASI, HB				SHESTAKOV, SV; ANBUDURAI, PR; STANBEKOVA, GE; GADZHIEV, A; LIND, LK; PAKRASI, HB			MOLECULAR-CLONING AND CHARACTERIZATION OF THE CTPA GENE ENCODING A CARBOXYL-TERMINAL PROCESSING PROTEASE - ANALYSIS OF A SPONTANEOUS PHOTOSYSTEM-II-DEFICIENT MUTANT STRAIN OF THE CYANOBACTERIUM SYNECHOCYSTIS SP PCC-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MEMBRANE POLYPEPTIDE; PHOTOSYNTHETIC OXYGEN EVOLUTION; ANABAENA-VARIABILIS ATCC-29413; LOW-FLUORESCENT MUTANTS; MN-STABILIZING PROTEIN; SCENEDESMUS-OBLIQUUS; SP PCC-6803; DELETION MUTAGENESIS; PARTIAL-PURIFICATION; NUCLEOTIDE-SEQUENCE	A nitrofurantoin enrichment technique was used to isolate a spontaneous photosynthesis-deficient mutant strain of the unicellular cyanobacterium Synechocystis sp. PCC 6803. This mutant, SK18, lacked any photosystem II (PSII) activity, but had normal photosystem I. The SK18 mutant strain could not be complemented with known genes encoding various structural proteins of PSII, but could be complemented with a recombinant plasmid pSL523 containing a 1.4-kilobase pair EcoRI fragment of the chromosomal DNA from wild-type Synechocystis 6803 cells. Determination of the nucleotide sequence of this DNA fragment revealed a previously unidentified open reading frame (ORF) encoding a 427-residue-long polypeptide. Hydrophobicity analysis of the amino acid sequence suggested that this protein is largely hydrophilic. A stretch of the first 31 amino-terminal residues of the polypeptide resembled a bacterial signal peptide and may be responsible for the translocation of this protein to the lumen space of the thylakoid membranes. The spontaneous mutation in the SK18 strain was identified to be a single nucleotide change introducing a premature termination codon in this ORF. The predicted sequence of the encoded protein showed significant similarity to that of the Pre protein, a carboxyl-terminal processing protease in Escherichia coli. We suggest that the cyanobacterial protein encoded by ORF427 is a similar processing protease and name the gene ctpA (carboxyl-terminal processing protease).	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA; MOSCOW MV LOMONOSOV STATE UNIV, DEPT GENET, MOSCOW 119899, RUSSIA	Washington University (WUSTL); Lomonosov Moscow State University			Stanbekova, Gulshan/N-6607-2015	Polimbetova, Nailya/0000-0002-2806-3009; Stanbekova, Gulshan/0000-0002-7819-6475	NIGMS NIH HHS [GM45797] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; ANBUDURAI PR, 1994, IN PRESS P NATL ACAD; ASTIER C, 1984, J BACTERIOL, V158, P659, DOI 10.1128/JB.158.2.659-664.1984; BOVY A, 1992, PLANT MOL BIOL, V19, P491, DOI 10.1007/BF00023397; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; BRAND SN, 1992, PLANT MOL BIOL, V20, P481, DOI 10.1007/BF00040607; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHUNG S, 1992, RES PHOTOSYNTHESIS, V1, P69; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINER BA, 1988, J BIOL CHEM, V263, P8972; DZELZKALNS VA, 1988, EMBO J, V7, P333, DOI 10.1002/j.1460-2075.1988.tb02817.x; ERMAKOVA SY, 1993, PHOTOSYNTH RES, V37, P139, DOI 10.1007/BF02187472; Fork D., 1986, LIGHT EMISSION PLANT, P451, DOI [10.1016/B978-0-12-294310-2.50022-6, DOI 10.1016/B978-0-12-294310-2.50022-6]; GREER KL, 1992, PLANT MOL BIOL, V19, P355, DOI 10.1007/BF00023383; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; ISLAM MR, 1993, J BIOL CHEM, V268, P22627; JOSET F, 1988, METHOD ENZYMOL, V167, P728; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MENON NK, 1993, FEBS LETT, V331, P91, DOI 10.1016/0014-5793(93)80303-C; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1980, FEBS LETT, V114, P61, DOI 10.1016/0014-5793(80)80861-1; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; NYHUS KJ, 1993, MOL MICROBIOL, V9, P979, DOI 10.1111/j.1365-2958.1993.tb01227.x; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; PAKRASI HB, 1992, CURRENT TOPICS PHOTO, V11, P231; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SHESTAKOV SV, 1989, P USSR ACAD SCI, V306, P211; SHESTAKOV SV, 1987, OXFORD SURVEYS PLANT, V4, P137; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; STANBEKOVA GE, 1992, BIOL NAUKI, V4, P35; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; THEROUX SJ, 1990, J BACTERIOL, V172, P4497, DOI 10.1128/jb.172.8.4497-4504.1990; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VERMAAS WFJ, 1986, P NATL ACAD SCI USA, V83, P9474, DOI 10.1073/pnas.83.24.9474; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	57	90	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19354	19359						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034700				2022-12-27	WOS:A1994NY33200026
J	HARDY, DM; GARBERS, DL				HARDY, DM; GARBERS, DL			SPECIES-SPECIFIC BINDING OF SPERM PROTEINS TO THE EXTRACELLULAR-MATRIX (ZONA-PELLUCIDA) OF THE EGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOAR SPERMATOZOA; ACROSOMAL EXOCYTOSIS; MOUSE; PIG; HAMSTER; IDENTIFICATION; GLYCOPROTEINS; PURIFICATION; PROACROSIN; RECEPTOR	The zona pellucida is an extracellular matrix surrounding the mammalian egg where species-specific gamete recognition and signaling occur. Pig zona pellucida were isolated in large amounts and used as an affinity matrix for detergent-solubilized, biotinylated membrane proteins of pig spermatozoa. On non-reducing SDS-polyacrylamide gel electrophoresis, specifically bound sperm proteins migrated with M(r) 170,000, 150,000, 130,000, 56,000, and 50,000 (p50). Disulfide bond reduction separated each of the M(r) 130,000-170,000 proteins into M(r) 105,000 (p105) and M(r) 45,000 (p45) subunits, indicating that these high M(r) proteins are related. Based on two-dimensional electrophoresis, the M(r) 56,000 band was composed of three to four proteins that migrated with M(r) 56,000-62,000 (p56-62) in the second (reducing) dimension. p50 bound to heterologous zona pellucida (murine, bovine) and to Xenopus laevis oocyte envelopes, demonstrating a lack of species specificity to its binding and was identified as proacrosin/acrosin based on amino acid sequences of two tryptic peptides and its interaction with monospecific antibodies to proacrosin. In contrast, p105/p45 and one or more of the p56-62 proteins bound to pig zona pellucida but not to the egg extracellular matrices of the other species; these proteins therefore exhibited the species-specific binding to the zona pellucida expected for molecules involved in specific gamete adhesion. Amino acid sequences of nine tryptic peptides derived from p105/p45 did not match peptide sequences in existing databases, establishing it as a unique protein. These (p105/p45 and at least one p56-62 protein) are the first sperm membrane proteins to be identified that bind in a species specific manner to the egg extracellular matrix.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093				BABA T, 1989, J BIOL CHEM, V264, P11920; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; CHERR GN, 1986, DEV BIOL, V114, P119, DOI 10.1016/0012-1606(86)90388-X; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FLORMAN HM, 1988, DEV BIOL, V128, P453, DOI 10.1016/0012-1606(88)90307-7; GILLIS G, 1978, PREP BIOCHEM, V8, P363, DOI 10.1080/10826067809412288; HARDY DM, 1987, BIOL REPROD, V37, P189, DOI 10.1095/biolreprod37.1.189; HARDY DM, 1993, MOL BIOL MALE REPROD, P233; HEDRICK JL, 1991, METHOD CELL BIOL, V36, P231; JONAKOVA V, 1991, FEBS LETT, V280, P183, DOI 10.1016/0014-5793(91)80233-S; JONES R, 1987, EXP CELL RES, V171, P503, DOI 10.1016/0014-4827(87)90182-0; KINLOCH RA, 1990, DEV BIOL, V142, P414, DOI 10.1016/0012-1606(90)90363-N; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MOLLER CC, 1990, DEV BIOL, V137, P276, DOI 10.1016/0012-1606(90)90254-G; ORAND MG, 1985, J EXP ZOOL, V235, P423, DOI 10.1002/jez.1402350314; PARRY RV, 1992, MOL REPROD DEV, V33, P108, DOI 10.1002/mrd.1080330115; PETERSON RN, 1980, SCIENCE, V207, P73, DOI 10.1126/science.7188647; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; PRIMAKOFF P, 1988, BIOL REPROD, V38, P921, DOI 10.1095/biolreprod38.4.921; SACCO AG, 1989, BIOL REPROD, V41, P523, DOI 10.1095/biolreprod41.3.523; SCHMELL ED, 1980, BIOL REPROD, V23, P1075, DOI 10.1095/biolreprod23.5.1075; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SHUR BD, 1989, BIOCHIM BIOPHYS ACTA, V988, P389, DOI 10.1016/0304-4157(89)90012-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOPFERPETERSEN E, 1987, FEBS LETT, V226, P38, DOI 10.1016/0014-5793(87)80546-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URCH UA, 1991, DEVELOPMENT, V111, P1165; UTO N, 1988, J EXP ZOOL, V248, P113, DOI 10.1002/jez.1402480115; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; Yanagimachi R., 1981, FERTILIZATION EMBRYO, P81; YUREWICZ EC, 1993, BIOCHIM BIOPHYS ACTA, V1174, P211, DOI 10.1016/0167-4781(93)90119-X	40	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19000	19004						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034657				2022-12-27	WOS:A1994NX32700046
J	BISCHOF, O; KRUFT, V; WITTMANNLIEBOLD, B				BISCHOF, O; KRUFT, V; WITTMANNLIEBOLD, B			ANALYSIS OF THE PUROMYCIN FINDING SITE IN THE 70-S RIBOSOME OF ESCHERICHIA-COLI AT THE PEPTIDE LEVEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS RIBOSOMES; LINKED AMINO-ACIDS; ARYL AZIDE ANALOG; CROSS-LINKING; LARGE SUBUNIT; RNA BINDING; PROTEINS; IDENTIFICATION; COMPONENTS; PHOTOINCORPORATION	Photoinduced cross-linking of Escherichia coli 70 S ribosomes with [H-3]puromycin has led to the labeling of ribosomal proteins S7, S14, S18, L18, and L29. Proteolytic fragmentation of these proteins and separation of the peptide mixtures by C-18 reversed-phase high performance liquid chromatography resulted in six puromycin-labeled peptides which were applied to sequence analysis. The following peptides were found labeled: Pro(1)-Lys(10) of S7, Ala(28)-Lys(46) and Ala(7)-Lys(11) of S14, Asp(24)-Lys(29) of S18, Tyr(64)-Lys(68) of L18, and Thr(55)-Lys(60) of L29. For the first time the molecular environment of an antibiotic in the procaryotic ribosome is presented at the peptide level.	MAX DELBRUCK CTR MOLEC MED, PROT CHEM ABT, D-13125 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Bischof, Oliver/K-1548-2019					BERGMANN U, 1993, BIOCHEMISTRY-US, V32, P2880, DOI 10.1021/bi00062a020; BOCHKAREVA ES, 1971, FEBS LETT, V19, P121, DOI 10.1016/0014-5793(71)80493-3; BRIMACOMBE R, 1990, RIBOSOME, P93; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; BROCKMOLLER J, 1986, BIOL CHEM H-S, V367, P925, DOI 10.1515/bchm3.1986.367.2.925; BROSIUS J, 1975, FEBS LETT, V56, P359, DOI 10.1016/0014-5793(75)81127-6; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CHANG FN, 1970, P NATL ACAD SCI USA, V67, P1321, DOI 10.1073/pnas.67.3.1321; COOPERMAN BS, 1988, METHOD ENZYMOL, V164, P341; COOPERMAN BS, 1975, P NATL ACAD SCI USA, V72, P2974, DOI 10.1073/pnas.72.8.2974; FRANCESCHI FJ, 1990, J BIOL CHEM, V265, P16676; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GINZBURG I, 1973, J MOL BIOL, V79, P481, DOI 10.1016/0022-2836(73)90400-2; GIRSHOVI.AS, 1974, DOKL AKAD NAUK SSSR+, V217, P1201; GIRSHOVICH AS, 1974, FEBS LETT, V45, P213, DOI 10.1016/0014-5793(74)80847-1; GOLDMAN RA, 1983, BIOCHEMISTRY-US, V22, P359, DOI 10.1021/bi00271a020; GRANT PG, 1979, BIOCHEMISTRY-US, V18, P2149, DOI 10.1021/bi00578a003; GRANT PG, 1983, J BIOL CHEM, V258, P1305; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HELD WA, 1973, J BIOL CHEM, V248, P5720; HERWIG S, 1993, J BIOL CHEM, V268, P4643; JAYNES EN, 1978, BIOCHEMISTRY-US, V17, P561, DOI 10.1021/bi00597a001; KALTSCHMIDT E, 1970, MOL GEN GENET, V109, P303, DOI 10.1007/BF00267700; KAMP RM, 1986, ADV METHODS PROTEIN, P8; KERLAVAGE AR, 1986, BIOCHEMISTRY-US, V25, P8002, DOI 10.1021/bi00372a032; KRUFT V, 1991, BIOCHEMISTRY-US, V30, P11781, DOI 10.1021/bi00115a007; LELONG JC, 1974, P NATL ACAD SCI USA, V71, P248, DOI 10.1073/pnas.71.2.248; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MOLLER K, 1975, MOL GEN GENET, V141, P343, DOI 10.1007/BF00331455; MOLLER K, 1978, J MOL BIOL, V126, P489, DOI 10.1016/0022-2836(78)90055-4; MONRO RE, 1969, COLD SPRING HARB SYM, V34, P357, DOI 10.1101/SQB.1969.034.01.042; MORRISON CA, 1973, MOL GEN GENET, V127, P359, DOI 10.1007/BF00267106; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3797, DOI 10.1021/bi00259a013; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3809, DOI 10.1021/bi00259a014; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OAKES MI, 1990, RIBOSOME, P180; OFENGAND J, 1984, A BENZON S, V19, P293; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; RANDALLH.LL, 1972, MOL GEN GENET, V115, P234, DOI 10.1007/BF00268887; REINBOLT J, 1978, FEBS LETT, V91, P297, DOI 10.1016/0014-5793(78)81196-X; RODNINA MV, 1993, TRANSLATIONAL APPARATUS, P317; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WEITZMANN C, 1985, BIOCHEMISTRY-US, V24, P2268, DOI 10.1021/bi00330a022; WITTMANNLIEBOLD B, 1980, BIOCHEM INT, V1, P436; WOWER I, 1981, NUCLEIC ACIDS RES, V9, P4285, DOI 10.1093/nar/9.17.4285; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; YAGUCHI M, 1975, FEBS LETT, V59, P217, DOI 10.1016/0014-5793(75)80378-4; YAGUCHI M, 1983, FEBS LETT, V154, P21, DOI 10.1016/0014-5793(83)80869-2	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18315	18319						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034577				2022-12-27	WOS:A1994NW79800015
J	OLIVERA, A; ZHANG, H; CARLSON, RO; MATTIE, ME; SCHMIDT, RR; SPIEGEL, S				OLIVERA, A; ZHANG, H; CARLSON, RO; MATTIE, ME; SCHMIDT, RR; SPIEGEL, S			STEREOSPECIFICITY OF SPHINGOSINE-INDUCED INTRACELLULAR CALCIUM MOBILIZATION AND CELLULAR PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; LONG-CHAIN BASES; HUMAN-NEUTROPHILS; CELLS; INHIBITION; FIBROBLASTS; INVITRO; SPHINGOSINE-1-PHOSPHATE; ACTIVATION	Sphingosine is a positive regulator of cell growth in Swiss 3T3 fibroblasts (Zhang, H., Buckley, N. E., Gibson, K., and Spiegel, S. (1990) J. Biol. Chem. 265, 76-81). The present study investigated the stereospecificity of sphingosine-induced cell proliferation and its mitogenic signal transduction mechanisms. D-(+)-erythro Stereoisomers (cis and trans) stimulated DNA synthesis, whereas neither L-(-)-threo-sphingosine (cis or trans) nor DL-threo-dihydrosphingosine had any effect. Previously, we have shown that sphingosine-1-phosphate may mediate the mitogenic effect of sphingosine (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). However, no major differences were found in the formation of D-(+)-erythro and L-(-)-threo- sphingosine-1-phosphate derived from the respective sphingosine isomers in intact cells. Thus, the stereospecificity of the response to sphingosine may reside at the level of specific intracellular targets for sphingosine-1-phosphate. Sphingosine-1-phosphate triggers dual signal transduction pathways of activation of phospholipase D leading to increases in the levels of phosphatidic acid and mobilization of calcium from internal stores. Both D-(+)-erythro- and L-(-)-threo-sphingosine isomers induced similar increases in phosphatidic acid concomitant with identical decreases in phosphatidylcholinelevels. In contrast, only the D-(+)-erythro-stereoisomers (cis and trans) were effective in releasing calcium from intracellular stores. Our results suggest that the formation of phosphatidic acid is not sufficient to mediate sphingosine-stimulated DNA synthesis. However, the stereospecificity of the sphingosine-induced mobilization of calcium from internal stores seems to correlate with the induction of DNA synthesis by sphingosine stereoisomers.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; UNIV KONSTANZ,DEPT CHEM,D-78434 CONSTANCE,GERMANY	Georgetown University; University of Konstanz					NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO R, 1992, J BIOL CHEM, V267, P23459; DESAI NN, 1992, J BIOL CHEM, V267, P23122; GHOSH P, 1987, BIOTECHNOL APPL BIOC, V9, P401; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; IGARASHI Y, 1989, J BIOL CHEM, V264, P14354; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KIMURA S, 1992, BIOCHEM PHARMACOL, V44, P1585; LAVIE Y, 1990, BIOCHEM BIOPH RES CO, V167, P607; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MANDON EC, 1991, J BIOL CHEM, V266, P11522; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1989, J BIOL CHEM, V264, P6773; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1745, DOI 10.1515/bchm2.1968.349.2.1745; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WANG E, 1992, NUTRITION, V122, P1706; WILSON E, 1988, J BIOL CHEM, V263, P9304; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	47	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17924	17930						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027049				2022-12-27	WOS:A1994NV42200029
J	TAKAHASHI, T; MATSUSHITA, K; WELSH, MJ; STOKES, JB				TAKAHASHI, T; MATSUSHITA, K; WELSH, MJ; STOKES, JB			EFFECT OF CAMP ON INTRACELLULAR AND EXTRACELLULAR ATP CONTENT OF CL--SECRETING EPITHELIA AND 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CANINE TRACHEAL EPITHELIUM; CFTR CHLORIDE CHANNEL; CYSTIC-FIBROSIS; CELL LINE; ION-TRANSPORT; PHOSPHORYLATION; ADENOSINE; MEMBRANE; PROTEIN	ATP may play an important role in the regulation of Cl- secretion in epithelial cells. Previous studies have suggested that ATP may regulate Cl- secretion in at least two ways. First, cytoplasmic ATP is required for the opening of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels. Thus, an increase in metabolic activity associated with cAMP-stimulated Cl- secretion might decrease cellular levels of ATP, thereby decreasing the activity of CFTR Cl- channels. Second, cAMP-dependent opening of CFTR channels might allow the efflux of ATP through the channels into the mucosal solution. An increase in extracellular ATP could in turn activate apical membrane receptors that stimulate other Cl- channels. We tested the hypothesis that acute stimulation of Cl- secretion would produce changes in cell ATP concentration and/or in ATP concentration in the mucosal fluid. We found that in an intestinal epithelial cell line (T84) and in primary cultures of airway epithelia, cAMP-dependent stimulation of Cl- secretion did not alter cell ATP content. Moreover, cAMP agonists did not increase the ATP or nucleotide content of the mucosal fluid. In contrast, when 3T3 fibroblasts stably expressing CFTR were stimulated with cAMP agonists, cell ATP levels decreased. In addition, 3T3 cells appear to have a pathway that allows leakage of ATP into the extracellular fluid; this pathway is not affected by the presence or activation of CFTR. We interpret the data to suggest that changes in intracellular ATP probably do not regulate CFTR in Cl--secreting epithelia under physiologic conditions and that secretion of ATP probably plays a minor role in control of transepithelial Cl- transport.	DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,EPITHELIAL TRANSPORT LAB,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL-42385] Funding Source: Medline; NIDDK NIH HHS [DK-25231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; BARRETT KE, 1989, AM J PHYSIOL, V256, pC197; BECK JS, 1991, AM J PHYSIOL, V261, pF634, DOI 10.1152/ajprenal.1991.261.4.F634; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CANTIELLO HF, 1993, N AM CYSTIC FIBROSIS, pA22; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHO S, 1992, AM J PHYSIOL, V262, pC67; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KONDO M, 1991, AM J PHYSIOL, V261, pL106, DOI 10.1152/ajplung.1991.261.2.L106; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P86; LYNCH RM, 1987, AM J PHYSIOL, V253, pC269, DOI 10.1152/ajpcell.1987.253.2.C269; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; OSTEDGAARD LS, 1992, AM J PHYSIOL, V263, pL104, DOI 10.1152/ajplung.1992.263.1.L104; PRATT AD, 1986, AM J PHYSIOL, V251, pC167, DOI 10.1152/ajpcell.1986.251.2.C167; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; Reisin I. L., 1992, Journal of General Physiology, V100, p33A; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; STOKES JB, 1987, AM J PHYSIOL, V253, pF251, DOI 10.1152/ajprenal.1987.253.2.F251; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WELSH MJ, 1985, J MEMBRANE BIOL, V88, P149, DOI 10.1007/BF01868429; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713	40	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17853	17857						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027039				2022-12-27	WOS:A1994NV42200018
J	ANGOTTI, E; MELE, E; COSTANZO, F; AVVEDIMENTO, EV				ANGOTTI, E; MELE, E; COSTANZO, F; AVVEDIMENTO, EV			A POLYMORPHISM (G-]A TRANSITION) IN THE -78 POSITION OF THE APOLIPOPROTEIN-A-I PROMOTER INCREASES TRANSCRIPTION EFFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-DENSITY-LIPOPROTEIN; TISSUE-SPECIFIC EXPRESSION; CORONARY HEART-DISEASE; AIV GENE-CLUSTER; DNA POLYMORPHISMS; APO-AI; C-III; CIII; ATHEROSCLEROSIS; HYPERTRIGLYCERIDEMIA	A G --> A transition at -78 base pairs from the transcription start site of the apolipoprotein A-I (apoA-I) gene has been associated with increased apoA-I serum levels in humans. We report here that this mutation (G --> A) increases significantly (5-7-fold) the expression of a reporter gene fused to the apoA-I promoter in human liver and intestine cells. In addition, the presence of A at -78 base pairs from the transcription start site of the gene significantly decreases the binding affinity of a nuclear factor present in liver and intestine cells. We suggest that the reduced affinity of this factor increases the transcription efficiency of the promoter and explains why individuals carrying the A allele have high serum apoA-I levels.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Universita Mediterranea di Reggio Calabria			Costanzo, Francesco Saverio/K-3168-2018	Costanzo, Francesco Saverio/0000-0002-3096-9416				CHEUNG P, 1984, P NATL ACAD SCI-BIOL, V81, P508, DOI 10.1073/pnas.81.2.508; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; HUMPHRIES SE, 1988, ATHEROSCLEROSIS, V72, P89, DOI 10.1016/0021-9150(88)90069-X; JEENAH M, 1990, MOL BIOL MED, V7, P233; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MARASCO O, 1993, HUM GENET, V91, P169; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; ORDOVAS JM, 1986, NEW ENGL J MED, V314, P671, DOI 10.1056/NEJM198603133141102; PAGANI F, 1990, J LIPID RES, V31, P1371; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULHAYASE H, 1992, HUM GENET, V88, P439, DOI 10.1007/BF00215679; PINTO M, 1983, BIOL CELL, V47, P323; REES A, 1986, HUM GENET, V72, P168; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; TYBJAERGHANSEN A, 1993, ATHEROSCLEROSIS, V100, P157, DOI 10.1016/0021-9150(93)90202-6; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	32	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17371	17374						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021234				2022-12-27	WOS:A1994NU12800004
J	DAVAIL, S; FELLER, G; NARINX, E; GERDAY, C				DAVAIL, S; FELLER, G; NARINX, E; GERDAY, C			COLD ADAPTATION OF PROTEINS - PURIFICATION, CHARACTERIZATION, AND SEQUENCE OF THE HEAT-LABILE SUBTILISIN FROM THE ANTARCTIC PSYCHROPHILE BACILLUS TA41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EGLIN-C; NUCLEOTIDE-SEQUENCE; 1.4-A RESOLUTION; THERMITASE; CARLSBERG; CLONING; SERINE; GENE; INHIBITOR	The gene of subtilisin S41, an alkaline protease secreted by the psychrophile Bacillus TA41, encodes for a preproenzyme of 419 amino acids residues. The nucleotide sequence and NH2- and COOH-terminal amino acid sequencing of the purified enzyme indicate that the mature subtilisin S41 is composed of 309 residues with a predicted M(r) = 31,224. Subtilisin S41 shares most of its properties with mesophilic subtilisins (structure of the precursor, 52% amino acid sequence identity, alkaline pH optimum, broad specificity, Ca2+ binding) but is characterized by a higher specific activity on macromolecular substrate, by a shift of the optimum of activity toward low temperatures, and by a low thermal stability. The enzyme also differs by an acidic pI (5.3) and the presence of one disulfide bond. It is proposed that the psychrophilic enzyme possesses a more flexible molecular structure when compared to mesophilic and thermophilic subtilases in order to compensate for the reduction of reaction rates at low temperatures. The model of subtilisin S41 indeed reveals several features able to induce a more flexible, heat-labile conformation: the occurrence of four extended surface loops, a very hydrophilic surface through 11 extra Asp residues, and the lack of several salt bridges and aromatic-aromatic interactions. The low affinity of the Ca1 calcium binding site (K-d(app) = 10(-6) M), resulting possibly from one chelating side chain substitution and the stacking of Gly residues, also reflect a less compact conformation. The difference of free energy of stabilization between subtilisin S41 and a mesophilic subtilisin suggests that the balance of exo and endothermically formed weak bonds is critical for the enzyme flexibility.	UNIV LIEGE,INST CHEM B6,BIOCHEM LAB,B-4000 LIEGE,BELGIUM	University of Liege								BENDER ML, 1966, J AM CHEM SOC, V88, P5890, DOI 10.1021/ja00976a034; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1992, J MOL BIOL, V223, P427, DOI 10.1016/0022-2836(92)90662-4; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; DAVAIL S, 1992, GENE, V119, P143, DOI 10.1016/0378-1119(92)90080-9; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; Di Prisco G., 1991, LIFE EXTREME CONDITI; FELLER G, 1991, DNA CELL BIOL, V10, P381, DOI 10.1089/dna.1991.10.381; FELLER G, 1992, J BIOL CHEM, V267, P5217; FONTANA A, 1991, LIFE EXTREME CONDITI, P89; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; Hochachka P. W., 1984, BIOCH ADAPTATION; JACOBS M, 1985, NUCLEIC ACIDS RES, V13, P8913, DOI 10.1093/nar/13.24.8913; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Klemm P, 1984, Methods Mol Biol, V1, P255, DOI 10.1385/0-89603-062-8:255; Markland F. S., 1971, ENZYMES, V3, P561, DOI 10.1016/S1874-6047(08)60407-2; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MELOUN B, 1985, FEBS LETT, V183, P195, DOI 10.1016/0014-5793(85)80775-4; NEDKOV P, 1983, H-S Z PHYSIOL CHEM, V364, P1537, DOI 10.1515/bchm2.1983.364.2.1537; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; RENTIERDELRUE F, 1993, J MOL BIOL, V229, P85, DOI 10.1006/jmbi.1993.1010; ROBERTSON SP, 1982, J BIOL CHEM, V257, P1743; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; SVENDSEN IB, 1976, CARLSBERG RES COMMUN, V41, P237, DOI 10.1007/BF02906260; TEPLYAKOV AV, 1990, J MOL BIOL, V214, P261, DOI 10.1016/0022-2836(90)90160-N; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WONG SL, 1986, J BIOL CHEM, V261, P176	31	225	241	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17448	17453						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021248				2022-12-27	WOS:A1994NU12800019
J	LALLI, E; SASSONECORSI, P				LALLI, E; SASSONECORSI, P			SIGNAL-TRANSDUCTION AND GENE-REGULATION - THE NUCLEAR RESPONSE TO CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR CREB; DEPENDENT PROTEIN-KINASE; LEUCINE ZIPPER PROTEINS; ELEMENT-BINDING PROTEIN; CYCLIC-AMP; SOMATOSTATIN GENE; PHOSPHORYLATION; ACTIVATOR; FAMILY; IDENTIFICATION		FAC MED STRASBOURG,CNRS,INSERM,U184,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Lalli, Enzo/F-7052-2013	Lalli, Enzo/0000-0002-0584-5681				BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	41	352	355	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17359	17362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021233				2022-12-27	WOS:A1994NU12800001
J	KIM, YG; LI, L; CHANDRASEGARAN, S				KIM, YG; LI, L; CHANDRASEGARAN, S			INSERTION AND DELETION MUTANTS OF FOKI RESTRICTION-ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFICATION SYSTEM; DNA-BINDING; CLEAVAGE; RECOGNITION; SEQUENCE; ENZYMES; DOMAINS; SITES	FokI restriction endonuclease recognizes the nonpalindromic pentadeoxyribonucleotide, 5'-GGATG-3':5'CATCC-3' in duplex DNA and cleaves 9 and 13 nucleotides away from the recognition site, We have reported the presence of two distinct and separable protein domains within this enzyme: one for the sequence-specific recognition of DNA (the DNA binding domain) and the other for the endonucleases activity (the cleavage domain), Our studies have suggested that the two domains are connected by a linker region, which appears to be amenable for repositioning of the DNA-sequence recognition domain with respect to the catalytic domain, Here, we report the construction of several insertion (4-, 8-, 12-, 18-, 19-, or 23-amino acid residues) and deletion (4- or 7-amino acid residues) mutants of the linker region of FokI endonuclease. The mutant enzymes were purified, and their cleavage properties were characterized, The mutants have the same DNA sequence specificity as the wild-type enzyme, However, compared with the wild-type enzyme, the insertion mutants cleave predominantly one nucleotide further away from the recognition site on both strands of the DNA substrate, The four-codon deletion mutant shows relaxed specificity at the cut site while the seven-codon deletion appears to inactivate the enzyme, The DNA binding and cleavage domains of FokI appear to be Linked by a relatively malleable linker, No simple linear relationship exists between the linker length and the distance of the cut site from the recognition site, Furthermore, the four-codon insertion mutants cleave DNA substrates containing hemi-methylated FokI sites; they do not cleave fully methylated substrates, These results are best explained as a consequence of protein-protein interactions between the domains.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM 42140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KITA K, 1989, J BIOL CHEM, V264, P5751; KITA K, 1989, NUCLEIC ACIDS RES, V17, P8741, DOI 10.1093/nar/17.21.8741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; LI L, 1993, P NATL ACAD SCI USA, V90, P2764, DOI 10.1073/pnas.90.7.2764; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PODHAJSKA AJ, 1985, GENE, V40, P175, DOI 10.1016/0378-1119(85)90040-X; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SUGIMURA H, 1992, J COMPUT ASSIST TOMO, V16, P73, DOI 10.1097/00004728-199201000-00013; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WAUGH DS, 1994, J BIOL CHEM, V269, P12298	20	31	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31978	31982						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989374				2022-12-27	WOS:A1994PX30300098
J	CHAUVIN, F; BRAND, L; ROSEMAN, S				CHAUVIN, F; BRAND, L; ROSEMAN, S			SUGAR-TRANSPORT BY THE BACTERIAL PHOSPHOTRANSFERASE SYSTEM - CHARACTERIZATION OF THE ESCHERICHIA-COLI ENZYME-I MONOMER/DIMER TRANSITION KINETICS BY FLUORESCENCE ANISOTROPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; INTRINSIC FLUORESCENCE; PHOSPHOENOLPYRUVATE; ASSOCIATION; BINDING; RATES	Enzyme I of the bacterial phosphoenolpyruvate: glycose phosphotransferase system (PTS) exists in a monomer/dimer (M/D) equilibrium. These two forms are functionally different, and their interconversion may be a means of regulating the PTS. The M/D equilibrium was studied by fluorescence anisotropy of a pyrene derivative (Chauvin, F., Brand, L., and Roseman, S. (1994) J. Biol. Chem. 269, 20263-20269). In this paper, the kinetics of the transition is investigated. The following apparent rate constants were found for the M/D transition of phospho-Enzyme I in the presence of Mg2+ and PEP at 6 degrees C: k(A)* = 3.4 x 10(3) M(-1) s(-1) and k(D)* = 1.04 x 10(-3) s(-1). The association rate is especially slow, 2-3 orders of magnitude slower than the average dimerization rate determined for other proteins. Furthermore, the rate of quaternary structure changes matches that of enzymatic activity changes, as well as that of tertiary structure changes (Chauvin, F., Toptygin, D.,Roseman, S., and Brand, L. (1992) Biophys. Chem. 44, 163-173). Finally, the effect of two ligands is shown; PEP increases the relaxation rate by 3-fold at 23 degrees C, and Mg2+ addition causes a 4-fold increase in the relaxation rate.			CHAUVIN, F (corresponding author), JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,DEPT BIOL,BALTIMORE,MD 21218, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011632, R01GM038759, R37GM038759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11632, GM38759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernasconi C. F., 1976, RELAXATION KINETICS; BURNS DL, 1982, J BIOL CHEM, V257, P8638; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1992, BIOPHYS CHEM, V44, P163, DOI 10.1016/0301-4622(92)80049-B; Fersht A., 1985, ENZYME STRUCTURE MEC; HAN MK, 1990, J BIOL CHEM, V265, P1996; IP SHC, 1976, BIOCHEMISTRY-US, V15, P654, DOI 10.1021/bi00648a032; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; LIU KDF, 1983, P NATL ACAD SCI-BIOL, V80, P7142, DOI 10.1073/pnas.80.23.7142; MASON PW, 1981, J BIOL CHEM, V256, P1861; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NEYROZ P, 1987, J BIOL CHEM, V262, P15900; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RAMAN CS, 1992, BIOCHEMISTRY-US, V31, P10370, DOI 10.1021/bi00157a027; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	20	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20270	20274						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051119				2022-12-27	WOS:A1994PB31700012
J	HINTERDORFER, P; BABER, G; TAMM, LK				HINTERDORFER, P; BABER, G; TAMM, LK			RECONSTITUTION OF MEMBRANE-FUSION SITES - A TOTAL INTERNAL-REFLECTION FLUORESCENCE MICROSCOPY STUDY OF INFLUENZA HEMAGGLUTININ-MEDIATED MEMBRANE-FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPORTED PHOSPHOLIPID-BILAYERS; VIRAL ENVELOPE PROTEIN; VIRUS HEMAGGLUTININ; SIALIC-ACID; PLANAR MEMBRANES; CELL-FUSION; GANGLIOSIDES; ANTIBODIES; RECEPTOR; VESICLES	Influenza hemagglutinin (HA, strain A/PR/8/34) was purified and reconstituted into supported planar membranes in a two-step process: 1) HA was purified by C(12)E(8) detergent solubiIization followed by detergent removal with Biobeads; (2) the purified HA was then incorporated into ''viroplanes,'' i.e. supported planar membranes which contained the viral membrane proteins. This step was accomplished by a spontaneous reaction of the HA-proteoliposomes with a phospholipid monolayer that was supported on a quartz microscope slide. The reconstitution of the HA into the planar membranes was followed by total internal reflection fluorescence microscopy (TIRFM) using fluorescein-labeled HA. By changing the solution concentration of HA, surface concentrations between 2.4 x 10(4) and 4.3 x 10(4) HA monomers mu m(2) were reached. Greater than 90% of all HA molecules were oriented with their ectodomain facing away from the substrate toward the large aqueous compartment of the measuring cell. Binding experiments with conformation-sensitive monoclonal antibodies against HA established that the reconstituted HA could undergo the low pH-induced conformational change in the supported bilayer. Binding of vesicles containing the fluorescent lipid analog N-(7-nitro-2,1,3-benzoxadiazol-4-yl)egg phosphatidylethanolamine was also measured by TIRFM. Vesicle binding was promoted when sialic acid-containing gangliosides or negatively charged lipids were included in these target membranes. Membrane fusion of the HA bound vesicles was monitored by measuring long range (over several micrometers) lateral diffusion coefficients of the lipids in the bound layer by fluorescence recovery after photobleaching. The vesicles did not fuse at pH 7.4, but efficient vesicle fusion occurred on the viroplanes after acidification of the environment with pH 5 buffer. This fusion reaction was only observed when the bound vesicles exceeded a critical threshold surface concentration. The successful reconstitution of membrane fusion sites in a planar supported membrane system opens new possibilities for studying fusion intermediates by localized spectroscopy and microscopy.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Virginia			Hinterdorfer, Peter/C-4235-2013	Hinterdorfer, Peter/0000-0003-2583-1305	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030557, R37AI030557] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI030557, R01 AI30557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXELROD D, 1984, ANNU REV BIOPHYS BIO, V13, P247, DOI 10.1146/annurev.bb.13.060184.001335; BERGELSON LD, 1982, EUR J BIOCHEM, V128, P467; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; CLAGUE MJ, 1991, J VIROL, V65, P2402, DOI 10.1128/JVI.65.5.2402-2407.1991; CLAGUE MJ, 1993, VIRAL FUSION MECHANI, P113; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; HSIEH HV, 1992, BIOCHEMISTRY-US, V31, P11562, DOI 10.1021/bi00161a039; KALB E, 1990, BIOCHEMISTRY-US, V29, P1607, DOI 10.1021/bi00458a036; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; KALB E, 1992, THIN SOLID FILMS, V210, P763, DOI 10.1016/0040-6090(92)90397-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBYPHELPS K, 1984, CELL MOTIL CYTOSKEL, V4, P137, DOI 10.1002/cm.970040207; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; NILES WD, 1991, J GEN PHYSIOL, V97, P1121, DOI 10.1085/jgp.97.6.1121; POGLITSCH CL, 1990, BIOCHEMISTRY-US, V29, P248, DOI 10.1021/bi00453a033; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SMITH BA, 1978, P NATL ACAD SCI USA, V75, P2759, DOI 10.1073/pnas.75.6.2759; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; SUZUKI Y, 1986, J BIOL CHEM, V261, P7057; Tamm L., 1993, OPTICAL MICROSCOPY E, P295; Tamm L. K., 1993, MOL LUMINESCENCE SPE, P253; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; TBWBIN J, 1979, P NATL ACAD SCI USA, V76, P4350; Thompson N. L., 1988, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V5, P109; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YEWDELL JW, 1993, J VIROL, V67, P933, DOI 10.1128/JVI.67.2.933-942.1993; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983	45	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20360	20368						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051131				2022-12-27	WOS:A1994PB31700026
J	PREISIGMULLER, R; GUHNEMANNSCHAFER, K; KINDL, H				PREISIGMULLER, R; GUHNEMANNSCHAFER, K; KINDL, H			DOMAINS OF THE TETRAFUNCTIONAL PROTEIN ACTING IN GLYOXYSOMAL FATTY-ACID BETA-OXIDATION - DEMONSTRATION OF EPIMERASE AND ISOMERASE ACTIVITIES ON A PEPTIDE LACKING HYDRATASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; BIFUNCTIONAL ENZYME; PLANT PEROXISOMES; ESCHERICHIA-COLI; DEHYDROGENASE; PURIFICATION; SEQUENCE; SYSTEM; GENE; EPIMERIZATION	Peroxisomes from different eukaryotic organisms house a multifunctional protein acting in fatty acid beta-oxidation. In plant glyoxysomes, one of the isoforms of this protein contains the activities of L-3-hydroxyacyl-CoA hydrolyase (EC 4.2.1.17), L-3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.211), D-3-hydroxyacyl-CoA epimerase, and Delta(3),Delta(2)- enoyl-CoA isomerase (EC 5.3.3.8). This was demonstrated after molecular cloning of a cDNA coding for a protein of 79047 Da and its bacterial expression. Chromatographic purification yielded a monomeric protein exhibiting all four activities. In addition, mutant forms were prepared, and peptides representing single domains were purified. Peptides containing the N-terminal region showed D-3-hydroxyacyl-CoA epimerase and Delta(3),Delta(2)-enoyl-CoA isomerase activities but lacked 2-trans-enoyl-CoA hydratase and L-3-hydroxyacyl-CoA dehydrogenase activities. Using the N-terminal fragment, we demonstrated that the D-3-hydroxyacyl-CoA converting activity is actually an epimerase rather than part of a combined water eliminating and water attaching system. The C-terminal half of the multifunctional protein represents the dehydrogenase domain.	UNIV MARBURG,DEPT BIOCHEM,D-35032 MARBURG,GERMANY	Philipps University Marburg								BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P170, DOI 10.1016/0003-9861(88)90625-X; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P161, DOI 10.1016/0003-9861(88)90624-8; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BIRKTOFT JJ, 1987, P NATL ACAD SCI USA, V84, P8262, DOI 10.1073/pnas.84.23.8262; BITAR KG, 1980, FEBS LETT, V116, P196, DOI 10.1016/0014-5793(80)80642-9; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; ENGELAND K, 1991, EUR J BIOCHEM, V196, P699, DOI 10.1111/j.1432-1033.1991.tb15868.x; ENGELAND K, 1991, EUR J BIOCHEM, V200, P1717; FREVERT J, 1980, H-S Z PHYSIOL CHEM, V361, P537, DOI 10.1515/bchm2.1980.361.1.537; GLASER L, ENZYMES, V6, P355; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1993, BIOCHIMIE, V75, P175, DOI 10.1016/0300-9084(93)90075-4; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; ISHII N, 1987, J BIOL CHEM, V262, P8144; KINDL H, 1992, CELL BIOCHEM FUNCT, V10, P153, DOI 10.1002/cbf.290100304; KINDL H, 1993, BIOCHIMIE, V75, P225, DOI 10.1016/0300-9084(93)90080-C; KINDL H, 1987, BIOCH PLANTS, V9, P31; LI JX, 1990, J BIOL CHEM, V265, P13629; MALILA LH, 1993, J BIOL CHEM, V268, P21578; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SCHWARZ E, 1987, NATURE, V272, P410; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; YANG SY, 1993, J BIOL CHEM, V268, P6588; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023	32	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20475	20481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051146				2022-12-27	WOS:A1994PB31700043
J	SCHIAVO, G; MALIZIO, C; TRIMBLE, WS; DELAURETO, PP; MILAN, G; SUGIYAMA, H; JOHNSON, EA; MONTECUCCO, C				SCHIAVO, G; MALIZIO, C; TRIMBLE, WS; DELAURETO, PP; MILAN, G; SUGIYAMA, H; JOHNSON, EA; MONTECUCCO, C			BOTULINUM-G NEUROTOXIN CLEAVES VAMP/SYNAPTOBREVIN AT A SINGLE ALA-ALA PEPTIDE-BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE-PROTEIN; NEUROTRANSMITTER RELEASE; TETANUS-TOXIN; PROTEOLYTIC CLEAVAGE; SYNAPTIC VESICLES; ZINC; IDENTIFICATION; SYNAPTOBREVIN; FUSION; GENES	Similarly to other serotypes, botulinum neurotoxin serotype G (BoNT/G) contains the zinc binding motif of zinc endopeptidases. Highly purified preparations of BoNT/G show a zinc-dependent protease activity specific for VAMP/synaptobrevin, a membrane protein of synaptic vesicles. The two neuronal VAMP isoforms are cleaved with similar rates at one Ala-Ala peptide bond present in the same region, out of the several such peptide bonds present in their sequences. This site of cleavage is unique among the eight clostridial neurotoxins. VAMP proteolysis is displayed only after reduction of the single interchain disulfide bond present in the toxin, and it is inhibited by EDTA o-phenanthroline and captopril.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35121 PADUA,ITALY; UNIV PADUA,CRIBI,I-35121 PADUA,ITALY; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA	University of Padua; University of Padua; University of Wisconsin System; University of Wisconsin Madison; University of Toronto; University of Toronto	SCHIAVO, G (corresponding author), UNIV PADUA,CTR CNR BIOMEMBRANE,VIA TRIESTE 75,I-35121 PADUA,ITALY.			Schiavo, Giampietro/0000-0002-4319-8745	Telethon [473] Funding Source: Medline	Telethon(Fondazione Telethon)		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CAMPBELLK, 1993, BIOCHIM BIOPHYS ACTA, V1216, P487; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIMENEZ DF, 1970, ZENTBL BAKTERIOLOG P, V215, P221; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOBERG LJ, 1978, APPL ENVIRON MICROB, V35, P878, DOI 10.1128/AEM.35.5.878-880.1978; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATARNELLO T, 1993, NATURE, V364, P581, DOI 10.1038/364581b0; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Schiavo G, 1993, Trends Microbiol, V1, P170, DOI 10.1016/0966-842X(93)90086-7; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; Smith L. D. S., 1988, BOTULISM ORGANISM IT; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SONNABEND O, 1981, J INFECT DIS, V143, P22, DOI 10.1093/infdis/143.1.22; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VIDT DG, 1982, NEW ENGL J MED, V306, P214	35	161	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20213	20216						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051110				2022-12-27	WOS:A1994PB31700002
J	HAQUE, SJ; WILLIAMS, BRG				HAQUE, SJ; WILLIAMS, BRG			IDENTIFICATION AND CHARACTERIZATION OF AN INTERFERON (IFN)-STIMULATED RESPONSE ELEMENT-IFN-STIMULATED GENE FACTOR 3-INDEPENDENT SIGNALING PATHWAY FOR IFN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; REGULATORY ELEMENTS; GAMMA-INTERFERON; GROWTH-FACTOR; TRANSDUCTION PATHWAYS; SYNTHETASE GENE; NUCLEAR FACTORS; E1A ONCOGENE	Transcriptional activation of genes containing the interferon (IFN)-stimulated response element (ISRE) by IFN-alpha is known to be mediated through the post-translational activation of IFN-stimulated gene factor 3 (ISGF3) and its subsequent interactions with the ISRE. We have identified an ISRE-ISGF3-independent signaling pathway used by IFN-alpha for the induction of the IFN regulatory factor 1 (IRF-1) gene. A minimal functional promoter of the IRF-1 gene does not contain an ISRE, but we have shown that transcription of the IRF-1 gene is activated by IFN-alpha in cell lines that do not produce ISGF3 activity due to the absence of functional ISGF3-gamma (p48) polypeptide. This ISRE-ISGF3-independent pathway for IFN-alpha signaling involves a cis-acting enhancer element located in the IRF-1 promoter, termed the inverted repeat (IR) element, and its cognate trans-acting factor, IR-binding factor alpha (IRBF-alpha). IFN-gamma also activates a transcription factor(s) that forms a different complex (IRBF-gamma) with the IR element. Protein tyrosine kinase (tyk2) activity is required for the induction of IRBF-alpha, but not IRBF-gamma. The p91 subunit of ISGF3 is necessary for the formation of both IRBF-alpha and IRBF-gamma.	CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1991, HORMONAL CONTROL GEN, P349; SHAN B, 1989, VIROLOGY, V170, P277; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	63	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19523	19529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034722				2022-12-27	WOS:A1994NY33200051
J	DAN, N; CUTLER, DF				DAN, N; CUTLER, DF			TRANSCYTOSIS AND PROCESSING OF INTRINSIC FACTOR-COBALAMIN IN CACO-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-MEDIATED ABSORPTION; GUINEA-PIG ILEUM; EPITHELIAL-CELLS; LINE CACO-2; TRANSPORT; LOCALIZATION; VITAMIN-B12; RECEPTOR; DOG; EXPRESSION	Intracellular events within enterocytes following receptor-mediated endocytosis of intrinsic factor-cobalamin (IF-Cbl) are poorly understood. We have examined the fate of IF and Cbl in filter grown Caco-2 cells which express both IF receptors and transcobalamin II and which transcytose Cbl. Uptake of IF-Cbl from the apical surface leads to the intracellular accumulation of Cbl in a process that reaches an equilibrium between internalization and secretion only after a 20-h continuous incubation. Transcytosed Cbl is detectable in the basolateral medium 4 h after the onset of endocytosis. Cbl is released from the basolateral surface with the same kinetics irrespective of from which cell surface endocytosis of IF-Cbl took place. Following uptake, internalized IF is degraded with a half-time of 4 h. Leupeptin causes a partial block in the proteolysis of IF, an intracellular accumulation of Cbl bound to IF, and a decrease in transcytosis of Cbl. Finally, an analysis of intracellular Cbl during transcytosis shows that free Cbl is present within cells during transcytosis.	UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London				Cutler, Daniel/0000-0002-4288-7530				ALLEN RH, 1973, J BIOL CHEM, V248, P3670; BATT RM, 1989, AM J PHYSIOL, V257, pG344, DOI 10.1152/ajpgi.1989.257.3.G344; BOOTH CC, 1956, BRIT J HAEMATOL, V2, P223, DOI 10.1111/j.1365-2141.1956.tb06695.x; BOOTH CC, 1957, BRIT J HAEMATOL, V3, P253, DOI 10.1111/j.1365-2141.1957.tb05794.x; COOPER BA, 1968, BRIT J HAEMATOL, V14, P73, DOI 10.1111/j.1365-2141.1968.tb01474.x; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; DIX CJ, 1990, BIOMEDICINE PHYSL VI, P367; DOSCHERHOLMEN A, 1957, J CLIN INVEST, V36, P1551, DOI 10.1172/JCI103552; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GUEANT JL, 1988, GUT, V29, P1370, DOI 10.1136/gut.29.10.1370; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HERBERT V, 1959, J CLIN INVEST, V38, P102, DOI 10.1172/JCI103779; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P97, DOI 10.1016/0304-4165(90)90179-Z; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1028, P25, DOI 10.1016/0005-2736(90)90261-L; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; HORADAGODA NU, 1985, BIOCHIM BIOPHYS ACTA, V838, P206, DOI 10.1016/0304-4165(85)90080-7; HUGHSON EJ, 1989, J CELL SCI, V94, P327; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; JACOB E, 1971, CLIN EXP IMMUNOL, V8, P517; JENKINS WJ, 1981, GUT, V22, P617, DOI 10.1136/gut.22.8.617; KAPADIA CR, 1983, J CLIN INVEST, V71, P440, DOI 10.1172/JCI110788; LEVINE JS, 1984, J CELL BIOL, V98, P1111, DOI 10.1083/jcb.98.3.1111; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; OKUDA K, 1960, AM J PHYSIOL, V199, P84, DOI 10.1152/ajplegacy.1960.199.1.84; PETERS TJ, 1970, BRIT J HAEMATOL, V19, P369, DOI 10.1111/j.1365-2141.1970.tb01634.x; PINTO M, 1983, BIOL CELL, V47, P323; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1992, BIOCHEM BIOPH RES CO, V182, P439, DOI 10.1016/0006-291X(92)91751-B; RAMASAMY M, 1989, AM J PHYSIOL, V257, pG791, DOI 10.1152/ajpgi.1989.257.5.G791; ROBERTSON JA, 1985, GASTROENTEROLOGY, V89, P1353, DOI 10.1016/0016-5085(85)90655-9; ROBERTSON JA, 1985, GASTROENTEROLOGY, V88, P908, DOI 10.1016/S0016-5085(85)80007-X; ROSENTHAL HL, 1970, AM J PHYSIOL, V218, P358, DOI 10.1152/ajplegacy.1970.218.2.358; SEETHARAM B, 1985, AM J PHYSIOL, V248, pG326, DOI 10.1152/ajpgi.1985.248.3.G326	34	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18849	18855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034639				2022-12-27	WOS:A1994NX32700026
J	WILHELMSSON, A; WHITELAW, ML; GUSTAFSSON, JA; POELLINGER, L				WILHELMSSON, A; WHITELAW, ML; GUSTAFSSON, JA; POELLINGER, L			AGONISTIC AND ANTAGONISTIC EFFECTS OF ALPHA-NAPHTHOFLAVONE ON DIOXIN RECEPTOR FUNCTION - ROLE OF THE BASIC REGION HELIX-LOOP-HELIX DIOXIN RECEPTOR PARTNER FACTOR ARNT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; CYP1A1 GENE-EXPRESSION; HEAT-SHOCK PROTEIN; XENOBIOTIC-RESPONSIVE ELEMENT; NUCLEAR TRANSLOCATOR PROTEIN; DNA-BINDING ACTIVITY; AH-RECEPTOR; LIGAND; CLONING; DOMAINS	The dioxin receptor is a ligand-dependent transcription factor that binds to target DNA sequences (xenobiotic responsive elements, XREs) following ligand-dependent dimerization with its partner factor, Arnt (aryl hydrocarbon receptor nuclear translocator). Both factors contain an N-terminal basic region helix-loop-helix motif mediating dimerization and subsequent DNA binding. In this study we investigate the possible role of Arnt in agonistic and antagonistic effects of the dioxin receptor ligand alpha-naphthoflavone (ANF). Using specific antisera for the ligand binding dioxin receptor and Arnt, respectively, we show that exposure of the dioxin receptor tor to ANF in vitro induced recruitment of Arnt, thus stimulating binding of the heteromeric complex to XRE. In transient transfection assays, ANF at high concentrations stimulated expression of an XRE-driven reporter gene. This agonistic effect of ANF is, therefore, most likely attributable to ANF stimulation of dioxin receptor-Arnt heterodimerization and subsequent binding of the complex to XRE. Using a minimal XRE-driven reporter gene construct, we could further confirm earlier studies showing that ANF antagonizes the effect of a dioxin receptor agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin. Next we employed chimeric receptor constructs containing amino acids 1-500 of the human glucocorticoid receptor fused to dioxin receptor fragments lacking the very N-terminal basic region helix-loop-helix dimerization and DNA binding motif. These chimeric receptor constructs show dioxin responsiveness upon transient transfection into mutant Arnt-deficient hepatoma cells and are, thus, functionally uncoupled from Arnt. Importantly, dioxin-dependent activation of the chimeric receptors was inhibited in the presence of ANF, demonstrating that dimerization of dioxin receptor with Arnt was not necessary for manifestation of the antagonistic effect of ANF. Rather, dioxin receptor sequences, which confer dioxin regulation upon a heterologous DNA binding and transactivating domain, also mediated the antagonistic effects of ANF.	KAROLINSKA INST,HUDDINGE UNIV HOSP F60,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BERGHARD A, 1992, CARCINOGENESIS, V13, P651, DOI 10.1093/carcin/13.4.651; BLANK JA, 1987, MOL PHARMACOL, V32, P168; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GASIEWICZ TA, 1991, MOL PHARMACOL, V40, P607; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V298, P389, DOI 10.1016/0003-9861(92)90426-W; MERCHANT M, 1990, ARCH BIOCHEM BIOPHYS, V281, P84, DOI 10.1016/0003-9861(90)90416-V; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SANTOSTEFANO M, 1993, MOL PHARMACOL, V43, P200; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	40	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19028	19033						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034660				2022-12-27	WOS:A1994NX32700050
J	SHENNAN, KIJ; TAYLOR, NA; DOCHERTY, K				SHENNAN, KIJ; TAYLOR, NA; DOCHERTY, K			CALCIUM-DEPENDENT AND PH-DEPENDENT AGGREGATION AND MEMBRANE ASSOCIATION OF THE PRECURSOR OF THE PROHORMONE CONVERTASE PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOGRANIN-A; PROCESSING ENDOPROTEASES; SECRETORY PROTEINS; SECRETOGRANIN-II; IDENTIFICATION; BINDING; CELLS; KEX2; WIDESPREAD; LANGERHANS	PC2 is a subtilisin-like protease which is thought to be involved in the processing of prohormones and proneuropeptides in neuroendocrine cells. The mature 68-kDa enzyme is generated by intracellular proteolytic processing of a 75-KDa pro-PC2 polypeptide. Neuroendocrine cells contain at least two secretory pathways: the regulated pathway whereby secreted products are concentrated, stored in granules, and released in response to external stimulation of the cell, and the constitutive pathway, whereby secretory and plasma membrane proteins are continuously transported to the cell surface without prior concentration or storage. An important step in the sorting of proteins into these pathways is thought to involve the aggregation of proteins destined for storage granules. To define the mechanisms in the intracellular sorting of PC2 to secretory vesicles, the present study was undertaken to investigate the aggregation and membrane association properties of precursor and mature forms of PC2. Using material expressed in microinjected Xenopus oocytes, it was demonstrated that the 75-kDa pro-PC2 polypeptide undergoes calcium- and acid pH-dependent aggregation. Calcium exhibited an effect on the aggregation of pro-PC2 at pH 7.0 and 6.5, whereas below 6.5 aggregation was independent of calcium. Association of pro-PC2 with membranes was observed at pH 5.5, but not at pH 7.0, 6.5, nor 6.0. The mature 68-kDa PC2 polypeptide remained soluble under conditions that caused aggregation and membrane association of the 75-kDa propolypeptide. Deletion of COOH-terminal sequences had no effect on the association of pro-PC2 with membranes, whereas a peptide corresponding to amino acids 57-85 of the propeptide was able to partially compete the membrane associated pro-PC2 away from the membranes.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham				Docherty, Kevin/0000-0001-6765-2060				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GORR SU, 1988, BONE MINER, V4, P144; GUEST PC, 1992, J BIOL CHEM, V267, P22401; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LEISER M, 1989, J BIOL CHEM, V264, P2792; MAINS RE, 1988, J BIOL CHEM, V263, P7887; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHIELDS D, 1991, PEPTIDE BIOSYNTHESIS, P37; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023	29	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18646	18650						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034613				2022-12-27	WOS:A1994NW79800065
J	TANIGUCHI, H; MANENTI, S; SUZUKI, M; TITANI, K				TANIGUCHI, H; MANENTI, S; SUZUKI, M; TITANI, K			MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS), A MAJOR PROTEIN-KINASE-C SUBSTRATE, IS AN IN-VIVO SUBSTRATE OF PROLINE-DIRECTED PROTEIN KINASE(S) - A MASS SPECTROSCOPIC ANALYSIS OF THE POSTTRANSLATIONAL MODIFICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TAU-PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; CELLULAR SUBSTRATE; BOVINE BRAIN; PHOSPHORYLATION; 80-KDA; GROWTH; SITES; PURIFICATION; FIBROBLASTS	Myristoylated alanine-rich C kinase substrate (MARCKS), a major in vivo substrate protein of protein kinase C, isolated from calf brain contains various species phosphorylated to different degrees. To establish the in vivo phosphorylation sites, the protein was digested with lysyl endoprotease, and the digests were analyzed by the capillary high performance liquid chromatography interfaced on-line to an electrospray mass spectrometer. Six out of 17 peptides were found to be phosphorylated. Of the 7 phosphorylated serine residues identified by Edman degradation, only 1 was within the known phosphorylation domain by protein kinase C. All the other phosphorylated serine residues originated from the N-terminal half of the molecule and were immediately followed by proline. Therefore, MARCKS, a major in vivo substrate of protein kinase C, is also an in vivo substrate of proline-directed protein kinase(s) such as mitogen-activated protein kinase or Cdk5 kinase.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND	University of Basel	TANIGUCHI, H (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMESS B, 1992, FEBS LETT, V297, P285; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JAMES G, 1989, J BIOL CHEM, V264, P20928; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MIYASAKA H, 1993, J BIOL CHEM, V268, P22695; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SPENCER SA, 1992, J BIOL CHEM, V267, P9059; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	27	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18299	18302						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034575				2022-12-27	WOS:A1994NW79800011
J	HUANG, QQ; YAO, SYM; RITZEL, MWL; PATERSON, ARP; CASS, CE; YOUNG, JD				HUANG, QQ; YAO, SYM; RITZEL, MWL; PATERSON, ARP; CASS, CE; YOUNG, JD			CLONING AND FUNCTIONAL EXPRESSION OF A COMPLEMENTARY-DNA ENCODING A MAMMALIAN NUCLEOSIDE TRANSPORT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; PYRIMIDINE NUCLEOSIDES; RABBIT; CELLS; PERMEATION; NITROBENZYLTHIOINOSINE; IDENTIFICATION; SPECIFICITY; PREDICTION	Expression screening in Xenopus oocytes was used to isolate a cDNA from rat jejunal epithelium encoding a Na+-dependent nucleoside transport protein (named cNT1). The cDNA sequence of cNT1 predicts a protein of 648 amino acids (relative molecular mass 71,000) with 14 potential transmembrane domains. Data base searches indicate significant sequence similarity to the NUPC proton/nucleoside symporter of Escherichia coli, There is no sequence similarity between cNT1 and proteins of mammalian origin. Functionally, cNT1 exhibited the transport characteristics of the nucleoside transport system cit (selective for pyrimidine nucleosides and adenosine) and accepted both 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC) as permeants (K-m = 0.49 and 0.51 mM, respectively). The demonstration of transport of AZT by cNT1 expressed in Xenopus oocytes provides the first direct evidence that AZT enters cells by transporter-mediated processes, as well as by passive diffusion. Consistent with the tissue distribution of system cit transport activity, transcripts for cNT1 were detected in kidney as well as jejunum. cNT1 therefore belongs to a potential new gene family and may be involved in the intestinal absorption and renal handling of pyrimidine nucleoside analogs used to treat acquired immunodeficiency syndrome (AIDS).	UNIV ALBERTA,DEPT PHYSIOL,MEMBRANE TRANSPORT GRP,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,AB,CANADA	University of Alberta; University of Alberta; University of Alberta								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; BLEASBY AJ, 1990, PROTEIN ENG, V3, P153, DOI 10.1093/protein/3.3.153; CHAN TCK, 1992, EUR J HAEMATOL, V49, P71; CHAN TCK, 1993, BIOCHEM PHARMACOL, V46, P273, DOI 10.1016/0006-2952(93)90414-R; DOMIN BA, 1993, BIOCHEM PHARMACOL, V46, P725, DOI 10.1016/0006-2952(93)90560-J; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; HANDSCHUMACHER RE, 1993, CANC METABOLISM, P712; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Jacobson K.A., 1990, PURINES CELLULAR SIG; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; JARVIS SM, 1991, BIOCHEM J, V278, P605, DOI 10.1042/bj2780605; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; MELVIN GC, 1990, RES COMMUN CHEM PATH, V70, P193; Munch-Petersen A., 1983, METABOLISM NUCLEOTID; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PATERSON ARP, 1983, REGULATORY FUNCTION, P203; PATERSON ARP, 1991, ROLE ADENOSINE ADENI, P133; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; STEIN WD, 1986, TRANSPORT DIFFUSION, P397; TERASAKI T, 1993, BIOL PHARM BULL, V16, P493; TURNER RJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P161, DOI 10.1016/0167-4838(93)90078-6; ULLMAN B, 1989, J PHYSL, V601, P416; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG CD, 1991, MOL PHARMACOL, V40, P168; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU XC, 1992, J BIOL CHEM, V267, P8813; YOUNG JD, 1983, BIOSCIENCE REP, V3, P309, DOI 10.1007/BF01122895; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	38	193	198	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17757	17760						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027026				2022-12-27	WOS:A1994NV42200001
J	REED, JC; BIDWAI, AP; GLOVER, CVC				REED, JC; BIDWAI, AP; GLOVER, CVC			CLONING AND DISRUPTION OF CKB2, THE GENE ENCODING THE 32-KDA REGULATORY BETA'-SUBUNIT OF SACCHAROMYCES-CEREVISIAE CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA-SUBUNIT; CATALYTIC SUBUNIT; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; DEVELOPMENTAL REGULATION; NUCLEOTIDE-SEQUENCE; CELLULAR-REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS	Casein kinase II of Saccharomyces cerevisiae is composed of two distinct catalytic subunits, alpha and alpha', and two distinct regulatory subunits, beta and beta' (Padmanabha, R. and Glover, C. V. C. (1987) J. Biol. Chem. 262, 1829-1835; Bidwai, A. P., Reed, J. C., and Glover, C. V. C. (1994) Arch. Biochem. Biophys. 309, 348-355). We report here the cloning, sequencing, and disruption of the CKB2 gene encoding the beta'-subunit. The deduced amino acid sequence of Ckb2 displays only 40-45% identity to other beta-subunit sequences reported to date, allowing a better definition of conserved features of this protein. Most notable is the conservation of a cysteine containing sequence, CPX(3)C-X(22)-CPXC, which may constitute a novel metal-binding motif. The degree of sequence divergence of Ckb2 is comparable to that of the Drosophila Stellate protein, a testis-specific protein of unknown function, suggesting that the latter may function as a second beta-subunit in Drosophila. CKB2 is located on the right arm of chromosome XV between the HIR2 and WHI2 loci and has not been previously identified genetically. Haploid and homozygous diploid cells harboring a ckb2 null allele are viable, demonstrating that the beta'-subunit does not have an essential function distinct from that of beta. Strains lacking a functional CKB2 gene appear to grow normally on both fermentable and non-fermentable carbon sources, mate and sporulate normally, and display normal resistance to nitrogen starvation and heat shock. However, haploid strains harboring disruptions of both the beta' gene and either of the catalytic subunit genes exhibit a synthetic phenotype consisting of slow growth and flocculation in rich glucose medium. The occurrence of this synthetic phenotype implies that the beta'-subunit interacts physically and/or functionally with both the alpha- and alpha'-subunits in vivo.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia								AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERG JM, 1990, J BIOL CHEM, V265, P6513; BIDWAI AP, 1994, ARCH BIOCHEM BIOPHYS, V309, P348, DOI 10.1006/abbi.1994.1123; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BIRNBAUM MJ, 1991, BIOCHEM BIOPH RES CO, V181, P524, DOI 10.1016/0006-291X(91)91220-7; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CALLEJA GB, 1987, YEASTS, V2, P165; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; GATICA M, 1993, FEBS LETT, V315, P173, DOI 10.1016/0014-5793(93)81157-U; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HANNA DE, 1992, THESIS U GEORGIA ATH; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HU E, 1991, J BIOL CHEM, V266, P19796; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; JEDLICKI A, 1992, FEBS LETT, V297, P280, DOI 10.1016/0014-5793(92)80556-V; KELLY DE, 1988, GENE, V66, P205, DOI 10.1016/0378-1119(88)90357-5; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KOPATZ I, 1990, NUCLEIC ACIDS RES, V18, P3639, DOI 10.1093/nar/18.12.3639; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LIVAK KJ, 1990, GENETICS, V124, P303; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1983, FEBS LETT, V162, P235, DOI 10.1016/0014-5793(83)80762-5; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MIZOGUCHI T, 1993, PLANT MOL BIOL, V21, P279, DOI 10.1007/BF00019944; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; Sherman F., 1986, METHODS YEAST GENETI; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	58	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18192	18200						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027080				2022-12-27	WOS:A1994NV42200065
J	OHNO, S; MIZUNO, K; ADACHI, Y; HATA, A; AKITA, Y; AKIMOTO, K; OSADA, S; HIRAI, S; SUZUKI, K				OHNO, S; MIZUNO, K; ADACHI, Y; HATA, A; AKITA, Y; AKIMOTO, K; OSADA, S; HIRAI, S; SUZUKI, K			ACTIVATION OF NOVEL PROTEIN-KINASES C-DELTA AND C-EPSILON UPON MITOGENIC STIMULATION OF QUIESCENT RAT 3Y1 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; DIFFERENTIAL DOWN-REGULATION; 2 DISTINCT CLASSES; PHORBOL ESTER; NPKC-EPSILON; GH4C1 CELLS; 3T3 CELLS; PHOSPHORYLATION; EXPRESSION; FAMILY	Rat fibroblast 3Y1 cells express at least three protein kinase C species, conventional PKC alpha (cPKC alpha), novel PKC delta (nPKC delta), and novel PKC epsilon (nPKC epsilon). The stimula tion of quiescent 3Y1 cells by serum (or epidermal growth factor (EGF)) but not 12-O-tetradecanoylphorbol-13-acetate (TPA) results in the induction of DNA synthesis. Upon stimulation by serum or EGF, endogenous PKC species showed no indication of activation such as translocation or down-regulation, whereas TPA or synthetic diacylglycerol caused activation of all these PKC species when judged by these criteria. The only indication of activation observed upon serum or EGF stimulation was an upward shift in the electrophoretic mobility of nPKC delta. The phosphorylation levels of endogenous PKC members determined by in vivo metabolic labeling experiments revealed increased phosphorylation of both nPKC delta and nPKC epsilon, but only a slight increase for cPKC alpha in response to serum or EGF. On the other hand, TPA caused increased phosphorylation of all three PKC species. Overexpression of these PKC members by introduction of the corresponding cDNA expression plasmids resulted in the enhancement of the cell response to TPA when monitored in terms of transcriptional activation through TPA- or serum-responsive elements. Such enhancement in transcriptional activation by overexpression of cPKC alpha, nPKC delta, or nPKC epsilon was also observed in response to diacylglycerol, indicating that all these PKC species are activated by diacylglycerol in cells. In contrast to these nonphysiological stimuli, serum (or EGF) stimulation of 3Y1 cells that overexpress the respective PKC members revealed a clear difference between cPKC and nPKC, in that overexpression of nPKC delta or nPKC epsilon resulted in a large increase in TPA- or serum-responsive element activation, whereas the overexpression of cPKC alpha increased activation only very slightly. These results indicate that the mitogenic stimulation of quiescent 3Y1 cells results in selective activation of endogenous nPKC members and that the modes of activation of cPKC and nPKC differ from each other.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science; University of Tokyo	OHNO, S (corresponding author), YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, 3-9 FUKU URA, YOKOHAMA 236, JAPAN.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1990, J BIOL CHEM, V265, P354; AKITA Y, 1994, J BIOL CHEM, V269, P4653; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLUMBERG PM, 1988, CANCER RES, V48, P1; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1992, J BIOL CHEM, V267, P12892; CACACE AM, 1993, ONCOGENE, V8, P2095; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVERHART LP, 1973, METHDOS CELL BIOL, V7, P320; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HATA A, 1993, J BIOL CHEM, V268, P9122; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAWAHARA Y, 1980, BIOCHEM BIOPH RES CO, V97, P309, DOI 10.1016/S0006-291X(80)80169-0; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISHIMA K, 1994, IN PRESS BIOCH BIOPH; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MOLINA CA, 1991, CANCER RES, V51, P4624; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	47	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17495	17501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021256				2022-12-27	WOS:A1994NU12800027
J	TURNER, N; FORSTOVA, J; REES, A; PUSEY, CD; MASON, PJ				TURNER, N; FORSTOVA, J; REES, A; PUSEY, CD; MASON, PJ			PRODUCTION AND CHARACTERIZATION OF RECOMBINANT GOODPASTURE ANTIGEN IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; NONCOLLAGENOUS DOMAIN; MONOCLONAL-ANTIBODY; ALPHA-3(IV) CHAIN; SPECIFICITY; AUTOANTIBODIES; HETEROGENEITY; LOCALIZATION; DROSOPHILA	The Goodpasture antigen is the target of anti-basement membrane autoantibodies in Goodpasture's disease, a severe human autoimmune disease characterized by glomerulonephritis and lung hemorrhage. It has been identified as the NC1 domain of the alpha 3 chain of type IV collagen (alpha 3(IV)NC1), a minority component of glomerular basement membrane (GBM). Protocols for obtaining pure human antigen are laborious and low yielding and require cadaver kidneys. Recombinant (alpha 3(TV)NC1 produced in Escherichia coli has been insoluble and poorly recognized by patients' autoantibodies. We have used the baculovirus expression system to produce the antigen as a soluble product in Sf9 cells. A transfer vector was constructed from cDNAs encoding the leader peptide, NH2 terminus, and 7 S domain of the human alpha 1 chain of type IV collagen and was joined inframe to the NC1 domain and COOH terminus of the human alpha 3 chain under the control of the polyhedrin promoter. It therefore encodes a hybrid ''mini''-collagen chain from which the majority of the central triple helical region has been deleted. The recombinant antigen was seen on SDS-polyacrylamide gel electrophoresis and Western blots of supernatants at its predicted molecular size of 41 kDa and as dimers of 82 kDa. It reacted strongly with human autoantibodies by Western blotting and enzyme-linked immunosorbent assay, inhibited binding of autoantibodies to human GBM, and bound two monoclonal antibodies known to recognize human alpha 3(IV)NC1. A common alternatively spliced variant alpha 3(IV)NC1 mRNA, leading to a truncated NC1 domain of 60 amino acids, was expressed as a fusion protein with the same alpha 1 NH2-terminal sequence. It failed to be exported from the cell and was not recognized by autoantibodies. Other NC1 domains could be expressed in the same way. These recombinant molecules should prove invaluable for the in vitro study of the immunopathogenesis of Goodpasture's disease, and the approach provides a means by which interactions between the different type IV collagen chains found in GBM could be studied in vitro.	ROYAL POSTGRAD MED SCH, DEPT VIROL, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HEMATOL, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London	TURNER, N (corresponding author), ROYAL POSTGRAD MED SCH, DEPT MED, RENAL UNIT, DUCANE RD, LONDON W12 0NN, ENGLAND.		Mason, Philip J/B-1087-2008; Forstova, Jitka/L-7328-2017	Forstova, Jitka/0000-0003-0219-506X; Turner, Neil/0000-0003-4547-873X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNAL D, 1993, J BIOL CHEM, V268, P12090; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLUMBERG B, 1987, J BIOL CHEM, V262, P5947; BOOTHANDFORD RP, 1987, J BIOL CHEM, V262, P12475; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; BYGREN P, 1985, LANCET, V2, P1295; CASHMAN SJ, 1988, J PATHOL, V155, P61, DOI 10.1002/path.1711550110; CECCHINI JP, 1987, EUR J BIOCHEM, V165, P587, DOI 10.1111/j.1432-1033.1987.tb11480.x; DERRY CJ, 1991, CLIN EXP IMMUNOL, V86, P457; DERRY CJ, 1994, IN PRESS EXP NEPHROL; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; Feng Lili, 1992, Journal of the American Society of Nephrology, V3, P629; FISH AJ, 1984, CLIN EXP IMMUNOL, V55, P58; HUDSON BG, 1989, LAB INVEST, V61, P256; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEFALIDES NA, 1993, KIDNEY INT, V43, P85, DOI 10.1038/ki.1993.15; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; LOCKWOOD CM, 1976, LANCET, V1, P711; MCCOY RC, 1982, KIDNEY INT, V21, P642, DOI 10.1038/ki.1982.72; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PUSEY CD, 1987, LAB INVEST, V56, P23; Rees A J, 1984, Kidney Int, V26, P445; SAUS J, 1988, J BIOL CHEM, V263, P13374; SAVAGE COS, 1986, KIDNEY INT, V30, P107, DOI 10.1038/ki.1986.158; SAXENA R, 1989, CLIN EXP IMMUNOL, V78, P31; Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TSAO T, 1990, J BIOL CHEM, V265, P5188; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WIESLANDER J, 1985, ANN NY ACAD SCI, V460, P363, DOI 10.1111/j.1749-6632.1985.tb51183.x; WIESLANDER J, 1983, KIDNEY INT, V23, P855, DOI 10.1038/ki.1983.106; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; YAMADA K, 1990, BIOCHEM J, V272, P633, DOI 10.1042/bj2720633; YOSHIOKA K, 1985, J IMMUNOL, V134, P3831; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	44	19	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17141	17145						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006020				2022-12-27	WOS:A1994NT84600027
J	HOLLOWAY, DE; MARSH, ENG				HOLLOWAY, DE; MARSH, ENG			ADENOSYLCOBALAMIN-DEPENDENT GLUTAMATE MUTASE FROM CLOSTRIDIUM-TETANOMORPHYUM - OVEREXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND CHARACTERIZATION OF THE RECOMBINANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; METHYLMALONYL-COA MUTASE; PROPIONIBACTERIUM-SHERMANII; METHIONINE SYNTHASE; EXPRESSION; GENES; BINDING; CLONING; SYSTEM	The genes encoding both components, MutE and MutS, of adenosylcobalamin-dependent glutamate mutase from Clostridium tetanomorphum have been overexpressed in Escherichia coli. This has allowed MutE to be obtained in homogeneous form, free of inhibiting cobamides and traces of MutS. MutE binds MutS cooperatively, with a Hill coefficient of 1.3. The recombinant enzyme has an unchanged K-m for L-glutamate, but a much higher specific activity than those previously reported for preparations from clostridia. The apparent K-m for adenosylcobalamin was dependent upon the concentration of MutS and varied between 18 mu M with equimolar concentrations of MutS and MutE and 5.8 mu M with a 5-fold molar excess of MutS over MutE present in the assay. The dissociation constant for adenosylcobalamin was measured directly using equilibrium gel filtration. In the presence of equimolar amounts of MutE and MutS, the apparent K-d was 5.4 mu M but this decreased to 1.8 mu M when MutS was present at a 5-fold molar excess, No binding of adenosylcobalamin to MutE was observed in the absence of MutS. This suggests that the (minimal) function for MutS, whose role in the reaction has been unclear until now, is to form part of the adenosylcobalamin-binding site. It seems likely that MutS is representative of a cobalamin-binding domain conserved across several cobalamin-dependent enzymes.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge			Marsh, Neil/G-7553-2016; Holloway, Daniel E/S-4944-2016	Marsh, Neil/0000-0003-1713-1683; Holloway, Daniel E/0000-0003-0155-6978	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BABIOR BM, 1979, CRC CR REV BIOCH MOL, V6, P35, DOI 10.3109/10409237909105424; BARKER HA, 1964, J BIOL CHEM, V239, P3260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; FRANCALANCI F, 1986, BIOCHEM J, V236, P489, DOI 10.1042/bj2360489; GOLDING BT, 1986, ENZYME MECHANISMS, P404; HOLLOWAY DE, 1993, FEBS LETT, V317, P44, DOI 10.1016/0014-5793(93)81488-L; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; LEUTBECHER U, 1992, EUR J BIOCHEM, V205, P759, DOI 10.1111/j.1432-1033.1992.tb16840.x; LUSCHINSKY CL, 1992, J MOL BIOL, V225, P557, DOI 10.1016/0022-2836(92)90940-L; MARSH EN, 1993, BIOCHEM J, V290, P551, DOI 10.1042/bj2900551; MARSH EN, 1988, J MOL BIOL, V200, P421; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; Sambrook J, 1989, MOL CLONING LABORATO; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI F, 1966, J BIOL CHEM, V241, P878; SWITZER RL, 1967, J BIOL CHEM, V242, P2658; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	22	56	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20425	20430						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051138				2022-12-27	WOS:A1994PB31700035
J	GRINSTEIN, S; BUTLER, JR; FURUYA, W; LALLEMAIN, G; DOWNEY, GP				GRINSTEIN, S; BUTLER, JR; FURUYA, W; LALLEMAIN, G; DOWNEY, GP			CHEMOTACTIC PEPTIDES INDUCE PHOSPHORYLATION AND ACTIVATION OF MEK-1 IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PERITONEAL NEUTROPHILS; COLONY-STIMULATING FACTOR; PROTEIN KINASE-C; INDUCED TYROSINE PHOSPHORYLATION; RESPIRATORY BURST OXIDASE; SIGNAL-REGULATED KINASES; MAP KINASE; NADPH-OXIDASE; GENE-PRODUCT; MEMBRANE	Extracellular signal-regulated kinase (Erk) (mitogen-activated protein (MAP) kinase) is rapidly activated when neutrophils are stimulated. Several isoforms of MAP/Erk kinase (MEK), a kinase capable of phosphorylating and activating Erk, have been identified, but their distribution and differential roles in leukocytes are unknown. We studied the effect of chemotactic stimulation on MEK-1, using isoform-specific antibodies. MEK-1 was found to be phosphorylated on serine and threonine residues in unstimulated human neutrophils. Stimulation by the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) enhanced serine/threonine phosphorylation of MEK-1, while reducing its elec trophoretic mobility. MEK-1 activity, measured as autophosphorylation or as phosphorylation of a glutathione S-transferase-Erk fusion protein, was undetectable in unstimulated cells but became evident after treatment with chemoattractant. Phosphorylation and activation of MEK-1 were rapid and transient, peaking after 1-2 min and returning to base line by 10 min. Experiments using electropermeabilized cells indicated that elevation of cytosolic Ca2+ is not required for activation of MEK-1 by fMLP. Moreover, MEK-1 was not stimulated by either platelet-activating factor or thapsigargin, which increase Ca2+ to levels comparable with those attained in chemoattractant-activated cells. In contrast, activation of MEK-1 was induced by phorbol esters, and the stimulatory effect of fMLP was blocked by an antagonist of protein kinase C. Stimulation of MEK-1 was also blocked by concentrations of erbstatin that prevent the fMLP-induced accumulation of tyrosine-phosphorylated proteins. The data suggest that MEK-1 is largely responsible for the activation of Erk in chemoattractant-stimulated neutrophils and that protein kinase C and/or tyrosine kinases mediate this effect, whereas elevated cytosolic Ca2+ is not essential.	UNIV NICE,CTR BIOCHIM,CNR,F-06108 NICE,FRANCE; UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ON,CANADA	UDICE-French Research Universities; Universite Cote d'Azur; University of Toronto	GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ON,CANADA.			Downey, Gregory P/0000-0003-3253-5862				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BERKOW RL, 1990, BLOOD, V75, P2445; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1993, J BIOL CHEM, V268, P17326; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P464; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HALLETT MB, 1984, CELL CALCIUM, V5, P1, DOI 10.1016/0143-4160(84)90150-7; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HUANG CK, 1988, J BIOL CHEM, V263, P13144; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1991, J LEUKOCYTE BIOL, V49, P158, DOI 10.1002/jlb.49.2.158; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KRAUSE KH, 1990, CLIN BIOCHEM, V23, P159, DOI 10.1016/0009-9120(90)80030-M; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NACCACHE PH, 1990, BLOOD, V76, P2098; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OKUDA K, 1992, BLOOD, V79, P2880; QUILLIAM LA, 1992, CELL MOL MECH INFLAM, V3, P25; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAINES MA, 1992, BLOOD, V79, P3350; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; Snyderman R, 1992, INFLAMMATION BASIC P; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAUBER AI, 1987, BLOOD, V69, P711; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	48	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19313	19320						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034695				2022-12-27	WOS:A1994NY33200020
J	WALKE, W; STAPLE, J; ADAMS, L; GNEGY, M; CHAHINE, K; GOLDMAN, D				WALKE, W; STAPLE, J; ADAMS, L; GNEGY, M; CHAHINE, K; GOLDMAN, D			CALCIUM-DEPENDENT REGULATION OF RAT AND CHICK MUSCLE NICOTINIC ACETYLCHOLINE-RECEPTOR (NACHR) GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPSILON-SUBUNIT GENE; SKELETAL-MUSCLE; ELECTRICAL-ACTIVITY; MOUSE MUSCLE; NUCLEOTIDE-SEQUENCE; FUNCTIONAL-ANALYSIS; REPORTER GENE; MESSENGER-RNA; BINDING-SITES	Muscle depolarization leads to decreased expression of nicotinic acetylcholine receptor (nAChR) genes in extrajunctional regions of the muscle fiber with little effect on their expression at the neuromuscular junction (NMJ). Depolarization dependent decreases in nAChR gene expression have been linked to a cAMP-dependent signaling system in rat (Chahine, K. G., Baracchini, E., and Goldman, D. (1993) J. Biol. Chem. 2893-2898), and a calcium-dependent protein kinase C (PKC) signaling system in chick (Klarsfeld, A., Laufer, R., Fontaine, B., Devillers-Thiery, A., Bubreuil, C., and Changeux, J. P. (1989) Neuron 2, 1229-1236). We report here on experiments investigating the role of calcium and PKC in regulating rat muscle nAChR gene expression, These studies indicate that depolarization-dependent regulation of rat muscle nAChR gene expression is independent of PKC activity. However, these genes are regulated by a calcium-dependent signal transduction system. Calcium influx across the plasma membrane decreases nAChR gene expression in inactive rat myotubes, Surprisingly, this influx of extracellular calcium is most effective at reducing nAChR epsilon-subunit gene expression. We also provide evidence that a similar signal transduction system is capable of regulating nAChR gene expression in chick muscle. Based on these data we propose that calcium, in addition to mediating depolarization-dependent regulation of nAChR expression, may also participate in restricting their expression to the neuromuscular junctions of adult muscle fibers.	UNIV MICHIGAN,MENTAL HLTH RES INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MENTAL HLTH RES INST,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CRIADO M, 1988, NUCLEIC ACIDS RES, V16, P10920, DOI 10.1093/nar/16.22.10920; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUCLERT A, 1993, P NATL ACAD SCI USA, V90, P3043, DOI 10.1073/pnas.90.7.3043; EVANS S, 1987, J BIOL CHEM, V262, P4911; FORREST JW, 1981, NEUROSCIENCE, V6, P741, DOI 10.1016/0306-4522(81)90157-3; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOROVITZ O, 1989, J CELL BIOL, V108, P1823, DOI 10.1083/jcb.108.5.1823; HUANG CF, 1994, FEBS LETT, V338, P277, DOI 10.1016/0014-5793(94)80283-1; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAYNES JB, 1986, MOL CELL BIOL, V7, P951; JO SA, 1992, DEVELOPMENT, V115, P673; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; KIRILOVSKY J, 1989, NEUROSCIENCE, V32, P289, DOI 10.1016/0306-4522(89)90079-1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; LAUFER R, 1991, EUR J BIOCHEM, V202, P813, DOI 10.1111/j.1432-1033.1991.tb16437.x; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMANAMAN JL, 1981, J NEUROSCI, V1, P771, DOI 10.1523/JNEUROSCI.01-07-00771.1981; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NANNINGA LB, 1971, BIOCHEMISTRY-US, V10, P2449, DOI 10.1021/bi00789a004; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PEZZEMENTI L, 1981, J BIOL CHEM, V256, P2651; PIASCIK MT, 1980, J BIOL CHEM, V255, P4176; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SAMBROOK J, 1989, MOL CLONING LABORATO, P122; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIERRA F, 1986, MOL CELL BIOL, V6, P4067, DOI 10.1128/MCB.6.11.4067; SIMON AM, 1992, DEVELOPMENT, V114, P545; SMILOWITZ H, 1988, J NEUROSCI RES, V19, P321, DOI 10.1002/jnr.490190307; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523	52	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19447	19456						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034713				2022-12-27	WOS:A1994NY33200040
J	CHOU, MY; LI, SC; KISO, M; HASEGAWA, A; LI, YT				CHOU, MY; LI, SC; KISO, M; HASEGAWA, A; LI, YT			PURIFICATION AND CHARACTERIZATION OF SIALIDASE-L, A NEUAC-ALPHA-2-]3GAL-SPECIFIC SIALIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; ACID; GLYCANASE; LINKAGE; ISOMER; LEECH	Sialidase L releases 2,7-anhydro-NeuAc from sialoglycoconjugates (Li, Y.-T., Nakagawa, H., Ross, S. A., Hansson, G., and Li, S.-C. (1990) J. Biol. Chem. 265, 21629-21633). This enzyme has been purified more than 10,000-fold from Macrobdella leech. The final preparation gives a single protein band on SDS-polyacrylamide gel electrophoresis with the molecular mass of 84 kDa. The pI is determined to be 6.0 using isoelectric focusing. With -methylumbelliferyl-alpha-NeuAc as substrate, the pH optimum is between pH 5.5-7.0. Unlike regular sialidases, sialidase L is not inhibited by 2-deoxy-2,3-dehydro-NeuAc. Two of the seven tryptic peptides derived from sialidase L contain the consensus repeat S X-D-X-G-X-T-W that has been found in the regular sialidases. Among various sialoglycoconjugates tested, sialidase L cleaves only the NeuAc alpha 2-->3Gal linkage. NeuAc alpha 2-->6Gal, NeuAc alpha 2-->6GalNAc, NeuAc alpha 2-->6GlcNAc, NeuAc alpha 2-->8-NeuAc, and NeuAc alpha 2-->9NeuAc linkages are not hydrolyzed. At pH 7.0, sialidase L and Clostridial sialidase release 46 and 92% of sialic acid, respectively, from bovine fetuin, indicating that sialidase L selectively cleaves NeuAc alpha 2-->3Gal linkages in fetuin. Sialidase L is the first sialidase found to exhibit a strict specificity toward the hydrolysis of the NeuAc alpha 2-->3Gal linkage, and it should become useful for the selective cleavage of NeuAc alpha 2-->3Gal linkages in sialoglycoconjugates without destroying other sialosyl linkages.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112; GIFU UNIV,DEPT APPL BIOORGAN CHEM,GIFU,JAPAN	Tulane University; Gifu University					NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P195; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HARRIS G, 1954, CHEM IND-LONDON, P249; HASEGAWA A, 1992, BIOSCI BIOTECH BIOCH, V56, P535, DOI 10.1271/bbb.56.535; HASEGAWA A, 1992, CARBOHYD RES, V224, P185, DOI 10.1016/0008-6215(92)84104-Z; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; HOYER LL, 1991, J BIOCHEM-TOKYO, V110, P462, DOI 10.1093/oxfordjournals.jbchem.a123603; KAHN S, 1991, P NATL ACAD SCI USA, V88, P4481, DOI 10.1073/pnas.88.10.4481; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P729, DOI 10.1080/07328309108543946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1990, J BIOL CHEM, V265, P21629; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; MURASE T, 1989, CARBOHYD RES, V188, P71, DOI 10.1016/0008-6215(89)84060-1; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; SINNOTT ML, 1993, J AM CHEM SOC, V115, P3334, DOI 10.1021/ja00061a044; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SWEELEY CC, 1993, ADV LIPID RES, V26, P235; TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1; WEIMER HE, 1953, AM REV TUBERC PULM, V68, P594; ZHOU B, 1989, J BIOL CHEM, V264, P12272	24	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18821	18826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034634				2022-12-27	WOS:A1994NX32700021
J	KAI, M; SAKANE, F; IMAI, S; WADA, I; KANOH, H				KAI, M; SAKANE, F; IMAI, S; WADA, I; KANOH, H			MOLECULAR-CLONING OF A DIACYLGLYCEROL KINASE ISOZYME PREDOMINANTLY EXPRESSED IN HUMAN RETINA WITH A TRUNCATED AND INACTIVE ENZYME EXPRESSION IN MOST OTHER HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; RAT-BRAIN; PHOSPHOLIPASE-C; ZINC-FINGER; HAND MOTIFS; PIG BRAIN; 80 KDA; PURIFICATION; DROSOPHILA; PHOSPHORYLATION	In order to clone novel diacylglycerol kinase (DGK) isozymes, we first obtained a DGK-related cDNA fragment by polymerase chain reaction using the human hepatoma cell line HepG2 mRNA and degenerated primers. The amplified fragment was subsequently used as a probe for screening the cDNA library from HepG2 cells. We obtained a cDNA clone coding for a novel DGK isozyme (designated DGK gamma) comprised of 791 amino acid residues. The amino acid sequence of DGK gamma was 52 and 62% identical to those of previously sequenced porcine 80-kDa and rat 90-kDa enzymes, respectively. DGK gamma, although initially cloned from the HepG2 cDNA libraries, was unexpectedly expressed in the human retina abundantly and to a much lesser extent in the brain. Other human tissues, including the liver and HepG2 cells, contained extremely low levels of DGK gamma mRNA. Furthermore, HepG2 cells and most of the human tissues except for the retina and brain expressed a truncated DGK gamma with an internal deletion of 25 amino acid residues (Ile(451)-Gly(475)). When transfected into COS-7 cells, the nontruncated cDNA gave phosphatidylserine-dependent DGK activity with no apparent specificity with regard to the acyl compositions of diacylglycerol. In contrast the truncated cDNA failed to give DGK activity in spite of the expression of its mRNA and enzyme protein in COS cells, thus demonstrating that the truncated DGK gamma is catalytically inactive. The sequence comparison of the three cloned DGKs revealed the presence of four highly conserved regions including the two sets each of EF-hand and zinc finger structures. Although the implication of the catalytically inactive form of DGK gamma remains unknown, this work further demonstrates the occurrence of multiple animal DGK isozymes with a conserved basic structure but with markedly different expression patterns depending on the cell types.	SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,SAPPORO 060,JAPAN				Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P598; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INOUE H, 1989, J BIOL CHEM, V264, P5996; KAHN DW, 1991, P NATL ACAD SCI USA, V88, P6137, DOI 10.1073/pnas.88.14.6137; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; KATO M, 1990, J BIOL CHEM, V265, P794; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KNAOH H, 1993, CELL SIGNAL, V5, P495; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kretsinger R H, 1979, Adv Cyclic Nucleotide Res, V11, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MASAI I, 1991, J BIOCHEM-TOKYO, V109, P867, DOI 10.1093/oxfordjournals.jbchem.a123472; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHMIDT SY, 1983, J BIOL CHEM, V258, P6863; SEYFRED MA, 1984, BIOCHEM BIOPH RES CO, V123, P121, DOI 10.1016/0006-291X(84)90388-7; STRYER L, 1991, J BIOL CHEM, V266, P10711; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; XIA Z, 1993, BIOCHEM J, V295, P457, DOI 10.1042/bj2950457; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YAMADA K, 1988, BIOCHEM J, V255, P601	47	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18492	18498						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034597				2022-12-27	WOS:A1994NW79800043
J	MYERS, JC; YANG, HG; DIPPOLITO, JA; PRESENTE, A; MILLER, MK; DION, AS				MYERS, JC; YANG, HG; DIPPOLITO, JA; PRESENTE, A; MILLER, MK; DION, AS			THE TRIPLE-HELICAL REGION OF HUMAN TYPE-XIX COLLAGEN CONSISTS OF MULTIPLE COLLAGENOUS SUBDOMAINS AND EXHIBITS LIMITED SEQUENCE HOMOLOGY TO ALPHA-1(XVI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EXTRACELLULAR-MATRIX; PROTEINS; CHAIN; CLONING; GENE; FIBRILS; CDNA; IDENTIFICATION; TRANSCRIPTS	We previously isolated a clone from a human rhabdomyosarcoma (RH) cDNA library coding for a collagen chain different from those constituting the 18 reported types (Myers, J. C., Sun, M. J., D'Ippolito, J. A, Jabs, E. W., Neilson, E. G., and Dion, A. S. (1993) Gene (Amst.) 123, 211-217). The sequence translated to a 186-amino acid noncollagenous region, a 524-residue three-subdomain collagenous region, and a presumed 8-amino acid COOH-terminal peptide. To further elucidate the primary structure of this collagen, we have now determined the sequence of additional cDNA clones. Overlapping 3' clones, found to diverge exactly where the noncollagenous 8-residue COOH sequence began, encode two additional collagenous subdomains of 168 and 70 residues and a 19-residue COOH-terminal peptide. Analysis of genomic DNA spanning the region in question revealed several 45- and 51-base pair exons linked by 4 introns totaling over 5 kilobases (kb). A 2-kb intron, absent from the clones coding for the extended collagenous region, was used in Northern blot hybridization to detect an apparently prevalent splicing intermediate 2 kb larger than the major 12.4-kb RH transcript. Therefore, the triple-helical region of this collagen chain is likely to be composed of 832 amino acids divided into five collagenous subdomains separated by 20-44 residue interruptions. Two interruptions are similar in sequence and position to those located in the type XVI chain. Furthermore, the arrangement of 2 cysteines near the COOH terminus and two imperfections in collagenous subdomain 1 are conserved in the related subclass composed of type IX, XII, XIV, and XVI collagens. However, in contrast to the COOH-terminal interchain bridging in this latter collagen group, molecular modeling strongly predicts that the cysteines in RH collagen participate in intrachain disulfide bonds. Taken together, the data clearly show that RH collagen does not represent another chain of one of the known collagen types. We propose that it be designated the alpha 1 chain of type XIX collagen.	CTR MOLEC MED & IMMUNOL,GARDEN STATE CANC CTR,INST MOLEC GENET,NEWARK,NJ 07103		MYERS, JC (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,RM 342,ANAT CHEM BLDG,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL41882] Funding Source: Medline; NIAMS NIH HHS [AR20553] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMBERG B, 1990, EXTRACELLULAR MATRIX, P115; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DION AS, 1994, J MOL GRAPHICS, V12, P41, DOI 10.1016/0263-7855(94)80008-1; DUBLET B, 1991, J BIOL CHEM, V266, P6853; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; HAREL R, 1992, J BIOL CHEM, V267, P10070; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KIEL, 1993, KIELTY GM, P103; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; KORNBLIHTT AR, 1988, BIOL REV, V63, P465, DOI 10.1111/j.1469-185X.1988.tb00668.x; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TIKKA L, 1991, J BIOL CHEM, V266, P17713; VANDERREST M, 1993, CURR OPIN STRUC BIOL, V3, P430, DOI 10.1016/S0959-440X(05)80117-4; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1991, J CELL BIOL, V115, P2814; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	42	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18549	18557						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034603				2022-12-27	WOS:A1994NW79800051
J	CONESE, M; OLSON, D; BLASI, F				CONESE, M; OLSON, D; BLASI, F			PROTEASE NEXIN-1-UROKINASE COMPLEXES ARE INTERNALIZED AND DEGRADED THROUGH A MECHANISM THAT REQUIRES BOTH UROKINASE RECEPTOR AND ALPHA(2)-MACROGLOBULIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; EXTRACELLULAR-MATRIX DEGRADATION; GLIA-DERIVED NEXIN; NEURITE-PROMOTING FACTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; SERINE PROTEASES; BOUND UROKINASE; CELL-SURFACE; TYPE-1 COMPLEX; PHORBOL ESTER	After binding to its receptor (uPAR), active cell-surface urokinase (uPA) is not internalized while the complex formed by uPA with plasminogen activator inhibitor type 1 (PAI-1) is internalized and degraded. Internalization and degradation require binding to uPAR and subsequently an interaction with the alpha(2)-macroglobulin receptor (alpha(2)-MR). To analyze the generality of this mechanism, we studied the internalization of uPA by recombinant protease nexin-1 (rPN-1), an inhibitor of thrombin, uPA, and plasmin. I-125-uPA.rPN-1 complexes bound specifically to uPAR; internalization occurred efficiently, and its time course was essentially the same as for uPA.PAI-1. Internalization required binding to uPAR since it could be blocked by the anti-uPAR monoclonal antibodies, by the uPAR antagonist amino-terminal fragment of uPA, and by the removal of uPAR by the treatment of cells with phosphatidylinositol-specific phospholipase C.As for uPA.PAI-1, the internalization of uPA.rPN-1 also required alpha(2)-MR, since it could be inhibited by the 39-kDa alpha(2)-macroglobulin receptor/low density lipoprotein receptor-associated protein, a ligand for the alpha(2)-MR. Finally, we show by ligand blot analysis that the uPA.rPN-1 complex, like uPA.PAI-1 but unlike free uPA, bound specifically to both uPAR and alpha(2)-MR.	SAN RAFFAELE RES INST,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGANISMI,I-20132 MILAN,ITALY; UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN K,DENMARK	University of Milan; University of Copenhagen			Conese, Massimo/AAB-7926-2019	Conese, Massimo/0000-0003-3465-6641; Blasi, Francesco/0000-0001-9406-1784	Telethon [168] Funding Source: Medline	Telethon(Fondazione Telethon)		AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BERGMAN BL, 1986, P NATL ACAD SCI USA, V83, P996, DOI 10.1073/pnas.83.4.996; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; CUNNINGHAM DD, 1986, J CELL BIOCHEM, V32, P281, DOI 10.1002/jcb.240320405; EATON DL, 1983, J CELL BIOL, V97, P323, DOI 10.1083/jcb.97.2.323; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GLOOR S, 1986, CELL, V47, P687; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HALFTER W, 1989, EUR J NEUROSCI, V1, P297, DOI 10.1111/j.1460-9568.1989.tb00797.x; HEARING VJ, 1988, CANCER RES, V48, P1270; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MASUCCI MT, 1991, J BIOL CHEM, V266, P8655; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; REICH R, 1988, CANCER RES, V48, P3307; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SMITH JW, 1985, J CELL BIOL, V101, P428; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; STEPHENS RW, 1985, BLOOD, V66, P333; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1993, EMBO J, V12, P1871, DOI 10.1002/j.1460-2075.1993.tb05835.x; WHITE EA, 1993, THROMB HAEMOSTASIS, V69, P119; WUN TC, 1989, J BIOL CHEM, V264, P7862; ZURN AD, 1988, DEV NEUROSCI-BASEL, V10, P17, DOI 10.1159/000111951	57	86	88	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17886	17892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027043				2022-12-27	WOS:A1994NV42200023
J	FLEISCHER, B; XIE, JP; MAYRLEITNER, M; SHEARS, SB; PALMER, DJ; FLEISCHER, S				FLEISCHER, B; XIE, JP; MAYRLEITNER, M; SHEARS, SB; PALMER, DJ; FLEISCHER, S			GOLGI COATOMER BINDS, AND FORMS K+-SELECTIVE CHANNELS GATED BY, INOSITOL POLYPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN ASSEMBLY PROTEIN; PLANAR LIPID BILAYERS; COATED VESICLES; ION CHANNELS; RECEPTOR; PURIFICATION; TRANSPORT; MEMBRANES; COMPLEX; PHOSPHATES	Coatomer is a distinct type of coat protein complex involved in the formation of specific Golgi intercisternal transport vesicles. Direct binding studies using purified coatomer isolated from bovine liver cytosol show that coatomer specifically binds both inositol 1,3,4,5-tetrakisphosphate ((1,3,4,5)IP4) and inositol hexakisphosphate (IP6) with subnanomolar affinities (0,1 and 0.2 nM, respectively). Diphosphoinositol pentakisphosphate (PP-IP5) is an efficient competitor for both (1,3,4,5)IP4 and IF, binding to coatomer, Inositol 1,3,4,5,6-pentakisphosphate ((1,3,4,5,6)IP,) is a poor inhibitor of IF, binding, whereas little or no competition is detected with inositol 1,4,5-trisphosphate ((1,4,5)I-P-3). Coatomer displays ion channel activity when reconstituted into planar bilayers which is preferentially permeable to K+. Permeability ratios of the channel are P-K+/P-Cl- similar to 8.0 and PK+/P-N(a+) similar to 7.1, indicating a cation-selective channel with selectivity of K+ over Na+. In symmetrical 500 mM KCl, the smallest observable unitary channel conductance is 8.3 picosiemens. The coatomer channel activity is normally active with long open times (0.1 to several seconds) and is selectively blocked by 10 mu M (1,3,4,5)IP4, 1 mu M IP6, and 0.27 mu M PP-IP5; even lower concentrations are sufficient to induce channel flicker. The channel activity is not affected by (1,4,5)IP3, or (1,3,4,5,6)IP5. Thus, the channel activity of coatomer is modulated by the inositol polyphosphates which exhibit tight binding to the complex.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA; NIEHS, CELLULAR & MOLEC PHARMACOL LAB, INOSITOL LIPID SECT, RES TRIANGLE PK, NC 27709 USA; SLOAN KETTERING INST, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Memorial Sloan Kettering Cancer Center			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BECK KA, 1991, J BIOL CHEM, V266, P4442; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; KIJIMA Y, 1993, J BIOL CHEM, V268, P16253; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P105; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NICOLETTI F, 1990, MOL PHARMACOL, V37, P689; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; POYNER DR, 1992, BIOCHEM BIOPH RES CO, V268, P1032; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; XIE J, 1994, IN PRESS BIOCHEMISTR; XIE JP, 1993, BIOPHYS J, V64, pA195	33	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17826	17832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027036				2022-12-27	WOS:A1994NV42200014
J	TANTIN, D; CAREY, M				TANTIN, D; CAREY, M			A HETERODUPLEX TEMPLATE CIRCUMVENTS THE ENERGETIC REQUIREMENT FOR ATP DURING ACTIVATED TRANSCRIPTION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-TERMINAL DOMAIN; GAL4 DERIVATIVES; DNA-REPAIR; INITIATION; MECHANISM; PROMOTER; INVITRO; GENE; PHOSPHORYLATION; MUTATIONS	Unlike most eukaryotic and prokaryotic RNA polymerases, promoter-specific transcription by RNA polymerase II requires hydrolysis of the ATP beta-gamma phosphoanhydride bond. Here we show that a template containing a 10-base pair DNA mismatch encompassing the start site circumvents this requirement such that the non-hydrolyzable ATP analogues, ATP gamma S (adenosine 5'-O-(thiotriphosphate)) and AMP-PNP (adenyl-5'-yl imidodiphosphate), support both basal and GAL4-VP16 activated transcription in a reconstituted HeLa cell in. vitro transcription system. The results imply that ATP regulates either opening of the template at the start site or a closely associated step.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Carey, Michael/0000-0003-3899-6280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46424, GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LOFQUIST AK, 1993, NUCLEIC ACIDS RES, V21, P3233; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PRIOR TW, 1993, HUM MOL GENET, V2, P311, DOI 10.1093/hmg/2.3.311; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Soto D, 1992, PCR Methods Appl, V2, P96; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TRIPATARA A, 1993, J MOL BIOL, V233, P349, DOI 10.1006/jmbi.1993.1516; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	27	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17397	17400						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021241				2022-12-27	WOS:A1994NU12800011
J	MULLER, F; SEO, YS; HURWITZ, J				MULLER, F; SEO, YS; HURWITZ, J			REPLICATION OF BOVINE PAPILLOMAVIRUS TYPE-1 ORIGIN-CONTAINING DNA IN CRUDE EXTRACTS AND WITH PURIFIED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; SV40 T-ANTIGEN; INVITRO REPLICATION; RNA-POLYMERASE; BINDING-SITE; CLONED GENES; E2 PROTEINS; E1 PROTEIN; PHOSPHORYLATION	The in vitro replication of DNA containing the bovine papillomavirus (BPV-1) origin has been carried out with cell-free extracts from mouse FM3A and human HeLa cells. DNA synthesis required the El protein, the minimal origin of replication (nucleotides 7911-22 of the BPV-1 genome), and, at low levels of FM3A extract, the addition of the human single-stranded DNA binding protein (also called RP-A or RF-A). The E2 protein was not absolutely required, but could stimulate DNA synthesis at low levels of E1. DNA synthesis was also recon stituted using purified proteins from HeLa cells. These protein factors included human single-stranded DNA-binding protein, topoisomerase I, and DNA polymerase (pol) alpha-primase complex. At low concentrations of pol alpha-primase complex, the formation of high molecular weight products was dependent on the addition of DNA polymerase delta holoenzyme containing proliferating cell nuclear antigen and activator 1, also called RF-C. We have overexpressed and isolated the E1 protein from bacteria. This protein also supported BPV DNA synthesis, both in crude extracts and with purified proteins suggesting that E1 phosphorylation is not required for BPV DNA replication in vitro.			MULLER, F (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,GRAD PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Seo, Yeonsoo/C-1605-2011		NCI NIH HHS [CA56539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056539] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; EKI T, 1991, J VIROL, V65, P4874, DOI 10.1128/JVI.65.9.4874-4881.1991; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; LUSKY M, 1993, J BIOL CHEM, V268, P15795; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P6347, DOI 10.1073/pnas.83.17.6347; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	48	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17086	17094						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006013				2022-12-27	WOS:A1994NT84600019
J	LANDRO, JA; SCHIMMEL, P				LANDRO, JA; SCHIMMEL, P			ZINC-DEPENDENT CELL-GROWTH CONFERRED BY MUTANT TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSFER-RNA-SYNTHETASE; GLUTAMINYL-TRANSFER RNA; METAL-BINDING SITE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; DNA RECOGNITION; GENE; RESOLUTION; PROTEIN	We present evidence that zinc bound near the C terminus of a long tRNA synthetase polypeptide, and at a location far in the sequence from the catalytic domain, is needed to sustain cell growth and is, therefore, essential for enzyme function. Several class I and class II tRNA synthetases contain bound zinc, including the 939-amino acid class I Escherichia coli isoleucyl-tRNA synthetase, which has two zinc atoms coordinated to cysteine sulfhydryls. The functional significance of these bound zinc atoms has been unclear. Like other class I tRNA synthetases, the isoleucine enzyme has a class-defining conserved N-terminal domain that contains the catalytic site. The C-terminal domain is variable in sequence and structure and not conserved among all of the class I enzymes. Using split proteins, we localized a zinc binding site to the C-terminal end of isoleucyl-tRNA synthetase. Serine substitutions of single cysteines at a thiol-containing putative zinc binding site that is less than 40 amino acids from the C terminus confer a zinc-dependent growth phenotype on cells harboring the mutant enzymes. We propose that zinc bound near the C terminus is part of a structure that interacts directly or indirectly with the active site. A structure at the C terminus that provides a functional link between the conserved N-terminal catalytic and non-conserved C-terminal domain may be common to several class I enzymes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUECHTER DD, 1993, CRIT REV BIOCHEM MOL, V28, P309, DOI 10.3109/10409239309078438; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FOURMY D, 1993, J MOL BIOL, V231, P1068, DOI 10.1006/jmbi.1993.1352; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; JOHNSTON M, 1988, NATURE, V334, P353; KIM S, 1993, BIOCHEMISTRY-US, V32, P13026, DOI 10.1021/bi00211a011; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; NUREKI O, 1991, J BIOL CHEM, V266, P3268; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1993, J BIOMOL STRUCT DYN, V11, P571, DOI 10.1080/07391102.1993.10508016; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHIBA K, 1992, J BIOL CHEM, V267, P22703; SHIBA K, 1994, IN PRESS P NATL ACAD, V91; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; XU B, 1993, J BIOL CHEM, V268, P16259; XU B, 1994, BIOCHEMISTRY-US, V33, P398, DOI 10.1021/bi00168a002	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20217	20220						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051111				2022-12-27	WOS:A1994PB31700003
J	MUECKLER, M; WENG, WF; KRUSE, M				MUECKLER, M; WENG, WF; KRUSE, M			GLUTAMINE-161 OF GLUT1 GLUCOSE-TRANSPORTER IS CRITICAL FOR TRANSPORT ACTIVITY AND EXOFACIAL LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; AMINO-ACID; TRYPTOPHAN-412; SUBSTITUTION; CELLS	The possible role of 5 transmembrane amino acid residues in the function of the Glut1 glucose transporter was investigated by site-directed mutagenesis. The residues were chosen based on their containing hydroxyl or amide side chains capable of hydrogen bonding to glucose and their complete conservation in Glut1 through Glut5. Asn(100), Gln(101), Gln(200), Tyr(292), and Tyr(293) were individually replaced by hydrophobic and/or polar residues, and the mutants were analyzed by expression in Xenopus oocytes. Substitution of leucine or asparagine for Gln(161) reduced the relative transport activity of Glut1 by 50- and 10-fold, respectively, as measured by uptake of 2-deoxyglucose normalized to the plasma membrane content of the mutant transporters. Substitutions at the other residues had either a modest (similar to 2-fold) effect or no effect on the relative transport activity. The K-i for binding of the exofacial ligand 4,6-O-ethylidene-alpha-D-glucose to Glut1 was increased by 18-fold upon substitution of asparagine for Gln(161). The K-m for zero-trans influx of 2-deoxyglucose was not affected by the substitution of asparagine for Gln(161), but the catalytic turnover was decreased by 7.5-fold. These data, combined with the high degree of conservation of Gln(161) among the specific members of the 12-helix membrane transporter superfamily that transport hexoses, support the contention that Gln(161) forms part of the exofacial substrate-binding site of these molecules. However, the decreased transport activity resulting from mutations at Gln(161) is likely due to an additional effect on the rate of a conformational change involved in net substrate uptake. This constitutes the first evidence that a residue within the NH2-terminal half of Glut1 is critical for transport function.			MUECKLER, M (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER GF, 1978, J PHYSIOL-LONDON, V278, P377, DOI 10.1113/jphysiol.1978.sp012310; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LIENHARD GE, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0192-86; Lowe A.G., 1989, RED BLOOD CELL MEMBR, P597; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER M, 1989, STRUCTURE FUNCTION G, P31; WANG JF, 1986, P NATL ACAD SCI USA, V83, P3277, DOI 10.1073/pnas.83.10.3277	22	85	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20533	20538						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051152				2022-12-27	WOS:A1994PB31700052
J	SCHNEIDER, E; WILKEN, S; SCHMID, R				SCHNEIDER, E; WILKEN, S; SCHMID, R			NUCLEOTIDE-INDUCED CONFORMATIONAL-CHANGES OF MALK, A BACTERIAL ATP BINDING CASSETTE TRANSPORTER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; MALTOSE TRANSPORT; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ADENYLATE KINASE; CYSTIC-FIBROSIS; PERIPLASMIC PERMEASES; MULTIDRUG-RESISTANCE; STRUCTURAL MODEL; MECHANISM	Nucleotide-induced structural rearrangements of MalK, the ATP-hydrolyzing component of the ATP binding cassette transporter for maltose from Salmonella typhimurium were investigated by means of analysis of intrinsic tryptophan fluorescence and limited proteolysis. ATP was found to decrease the tryptophan fluorescence of purified MalK by 37 +/- 1%. ADP or adenosine 5'-O-(3-(thio)triphosphate) (ATP gamma S) caused similar quenching while AMP was rather ineffective. Mg2+ ions were not required. Exposure of MalK to increasing concentrations of trypsin and subsequent analysis by SDS polyacrylamide gel electrophoresis and immunoblotting revealed the formation of three major transiently stable peptide fragments of 24 (T2), 23 (T3), and 20 kDa (T4), respectively. In addition, a minor rapidly degraded fragment of 33 kDa (T1) was observed. However, in the presence of MgATP, fragment T1 as well as a substantial fraction of native MalK were strongly protected against proteolytic attack. Similar protection against the protease was observed in the presence of MgGTP or, to a lesser extent, MgCTP. In contrast, MgADP, ATP in the presence of EDTA, CaATP or nonhydrolyzable nucleotides such as MgATP gamma S or MgAMP-PNP (beta,gamma-imidoadenosine-5'-triphosphate) failed to significantly affect the susceptibility of MalK to the protease. MgATP similarly affected the tryptic digestion pattern of a mutant protein (MalKK42R) that exhibits only a much reduced ATPase activity but has retained the capability to bind nucleotides. N-terminal protein sequence analysis of the peptides revealed cleavage by trypsin at Arg(66) (T1), Arg(146) (T2), Arg(153) (T3), and Arg(185) (T4), respectively. These results indicate that (i) nucleotide binding to MalK is accompanied by a global conformational change of the protein; (ii) a very specific interaction occurs with substrates of the MalK-ATPase, resulting in structural changes that involve the helical domain from Arg(66) to Arg(146); and (iii) the C-terminal half of MalK is rather resistant to proteolysis.			SCHNEIDER, E (corresponding author), UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, ARBEITSGRP MIKROBIOL, BARBARASTR 11, D-49069 OSNABRUCK, GERMANY.							AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CUI JS, 1993, J BIOL CHEM, V268, P5040; DAHL MK, 1989, MOL GEN GENET, V218, P199, DOI 10.1007/BF00331269; DASSA E, 1993, NATO ADV SCI INST SE, V245, P91; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1990, J BIOL CHEM, V265, P21005; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SANDERS CR, 1989, BIOCHEMISTRY-US, V28, P9028, DOI 10.1021/bi00449a011; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TOMASSELLI AG, 1983, EUR J BIOCHEM, V132, P109, DOI 10.1111/j.1432-1033.1983.tb07333.x; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; WALTER C, 1992, FEBS LETT, V303, P1; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	40	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20456	20461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051143				2022-12-27	WOS:A1994PB31700040
J	SYLVESTER, SL; APRHYS, CMJ; LUETHYMARTINDALE, JD; HOLBROOK, NJ				SYLVESTER, SL; APRHYS, CMJ; LUETHYMARTINDALE, JD; HOLBROOK, NJ			INDUCTION OF GADD153, A CCAAT ENHANCER-BINDING PROTEIN (C/EBP)-RELATED GENE, DURING THE ACUTE-PHASE RESPONSE IN RATS - EVIDENCE FOR THE INVOLVEMENT OF C/EBPS IN REGULATING ITS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; LEUCINE ZIPPER; MESSENGER-RNA; INTERLEUKIN-6; NF-IL6; FAMILY; TRANSCRIPTION; ACTIVATION; ISOFORMS; PROMOTER	CCAAT/enhancer-binding proteins (C/EBPs) comprise a homologous group of transcriptional regulators that control liver and fat differentiation and are involved in regulating the expression of acute phase reactants during the host response to inflammation. GADD153, a unique member of the C/EBP family, has been proposed to act as a dominant negative inhibitor of other C/EBPs, but little is known about its expression in liver or its role in the processes described above. We have examined its expression during the acute phase response (APR) and have shown that like C/EBP beta and C/EBP delta, GADD153 mRNA is markedly induced in livers of rats treated with lipopolysaccharide to initiate the APR. Interestingly, its induction is temporally delayed relative to that of C/EBP beta and C/EBP delta but is similar to that of acute phase reactants shown to be regulated by C/EBPs. Footprint analysis of the GADD153 promoter showed binding of proteins in liver extracts of both untreated and lipopolysaccharide-injected rats to a putative C/EBP regulatory site. Gel shift analysis showed that although present constitutively, binding activity was increased in extracts from lipopolysaccharide-treated animals. Both C/EBP alpha and C/EBP beta were shown to contribute to the binding activity with the contribution by C/EBP beta increasing during the APR. Support for the functional role of this C/EBP-binding site and its interaction with C/EBPs in regulating GADD153 expression was obtained with cultured HepG2 hepatoma cells in which overexpression of C/EBP beta was found to transactivate expression of a plasmid containing the GADD153 promoter linked to a reporter gene. These findings suggest that the GADD153 gene is itself regulated by C/EBPs during the host response to inflammation and that GADD153 is likely to contribute to the regulation of other genes whose expression is altered during the APR.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, ANN NY ACAD SCI, V55, P80; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOI AMK, 1992, EXP CELL RES, V199, P1; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fey G H, 1990, Prog Liver Dis, V9, P89; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; ISSHIKI H, 1991, NEW BIOL, V3, P63; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RHYS CM, 1989, J VIROL, V63, P2798; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	34	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20119	20125						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051100				2022-12-27	WOS:A1994PA12600069
J	QIU, ZH; LESLIE, CC				QIU, ZH; LESLIE, CC			PROTEIN KINASE C-DEPENDENT AND KINASE-C-INDEPENDENT PATHWAYS OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN MACROPHAGES BY STIMULI THAT ACTIVATE PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID; MAP KINASE; CYTOSOLIC PHOSPHOLIPASE-A2; CELLS; PHOSPHORYLATION; RELEASE; INHIBITION; EXPRESSION; ALPHA	The activation of mitogen-activated protein kinase (MAP kinase) in macrophages and the involvement of protein kinase C (PKC) in MAP kinase activation was investigated in macrophages exposed to agents that have previously been shown to activate the 85-kDa cytosolic phospholipase A(2) (PLA(2)) and induce arachidonic acid release. Phorbol 12-myristate 13-acetate (PMA) and zymosan maximally stimulated MAP kinase activity by 5 and 15 min, respectively, whereas the response to okadaic acid was maximal by 60-90 min. MAP kinase activation correlated with tyrosine phosphorylation of p44 MAP kinase in PMA-stimulated cells and p44 and p42 MAP kinases in zymosan- and okadaic acid stimulated cells. MAP kinase activity was not elevated in A23187-stimulated macrophages. Inhibition of PKC with the inhibitor, bisindolylmaleimide (GF109203X), or by prolonged exposure to PMA suppressed both arachidonic acid release and MAP kinase activation in PMA- and zymosan-stimulated macrophages but not in okadaic acid or A23187-treated cells. However, prolonged exposure to PMA did not suppress the increased cytosolic PLA(2) activity in agonist-treated macrophages. This approach was complicated since initial exposure to PMA to down-regulate PKC increased cytosolic PLA(2) activity which remained elevated for 16 h. In contrast, GF109203X treatment suppressed the increase in cytosolic PLA(2) activity in response to zymosan and PMA but not to okadaic acid or A23187. The results demonstrate that PMA and zymosan trigger PKC activation that leads to the activation of MAP kinase and PLA(2), whereas these responses are PKC independent in okadaic acid-treated cells. In addition, the results are consistent with a role for MAP kinase activation in regulating the activation of the 85-kDa PLA(2) and arachidonic acid release in PMA-, zymosan-, and okadaic acid-stimulated cells, whereas these responses in A23187-treated cells are MAP kinase- and PKC-independent.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL 34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DOLE VP, 1960, J BIOL CHEM, V235, P2595; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; GODSON C, 1993, J BIOL CHEM, V268, P11946; HUWILER A, 1993, EUR J BIOCHEM, V217, P69, DOI 10.1111/j.1432-1033.1993.tb18219.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LESLIE CC, 1994, IN PRESS MOL CELL BI; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; SHARP JD, 1991, J BIOL CHEM, V266, P14850; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	29	196	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19480	19487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034717				2022-12-27	WOS:A1994NY33200045
J	CAVENAGH, MM; BREINER, M; SCHURMANN, A; ROSENWALD, AG; TERUI, T; ZHANG, CJ; RANDAZZO, PA; ADAMS, M; JOOST, HG; KAHN, RA				CAVENAGH, MM; BREINER, M; SCHURMANN, A; ROSENWALD, AG; TERUI, T; ZHANG, CJ; RANDAZZO, PA; ADAMS, M; JOOST, HG; KAHN, RA			ADP-RIBOSYLATION FACTOR (ARF)-LIKE-3, A NEW MEMBER OF THE ARF FAMILY OF GTP-BINDING PROTEINS CLONED FROM HUMAN AND RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; RNA-POLYMERASE; GENES; AMPLIFICATION; DROSOPHILA; EXPRESSION; COFACTOR; BOVINE; BRAIN	The human and rat homologues of a new member of the ADP-ribosylation factor (ARF) family of 21-kDa GTP-binding proteins, termed Arl3, were identified as an expressed sequence tag (human) and as a product of polymerase chain reaction amplification using degenerate probes derived from conserved sequences in members of the ARF family (rat). Alignments of the full-length open reading frames of the human and rat homologues revealed the encoded proteins to be over 97% identical to each other and 43% identical to human ARF1. Northern blots of mRNA from seven human tissues and four rat tissues revealed the presence of a ubiquitous band of about 1 kilobase in length that hybridized with the corresponding Arl3 probes. A number of human tumor cell lines expressed Arl3, as determined by immunoblotting with an Arl-specific antibody, raised against a peptide derived from the human Arl3 sequence. The level of Arl3 expressed in these cell lines was on the order of 0.01% of total cell protein. Purified recombinant human Arl3 was shown to bind guanine nucleotides but lacks ARF activity and intrinsic or ARF GTPase-activating protein-stimulated GTPase activity. In contrast to ARF proteins, the Arl3 protein has reduced dependence on phospholipids and magnesium for guanine nucleotide exchange. Thus, Arl3 is a ubiquitously expressed GTP-binding protein in the ARF family with distinctive biochemical properties consistent with its having unique, but unknown, role(s) in cell physiology.	NCI,DIV CANC TREATMENT,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892; INST GENOM RES,GAITHERSBURG,MD 20878; RHEIN WESTFAL TH AACHEN,FAK MED,INST PHARMAKOL & TOXIKOL,D-52057 AACHEN,GERMANY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); J. Craig Venter Institute; RWTH Aachen University			Kahn, Richard/ABD-2666-2020; Joost, Hans-Georg/J-4462-2013	Kahn, Richard/0000-0002-0259-0601; Joost, Hans-Georg/0000-0002-5860-606X; Schurmann, Annette/0000-0002-4113-4377				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Battey, 1986, BASIC METHODS MOL BI; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROST SC, 1985, J BIOL CHEM, V260, P2646; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, HDB EXPT PHARM GTPAS, P529; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	26	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18937	18942						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034651				2022-12-27	WOS:A1994NX32700038
J	HAUSRATH, AC; MATTHEWS, BW				HAUSRATH, AC; MATTHEWS, BW			REDETERMINATION AND REFINEMENT OF THE COMPLEX OF BENZYLSUCCINIC ACID WITH THERMOLYSIN AND ITS RELATION TO THE COMPLEX WITH CARBOXYPEPTIDASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; DIPEPTIDE INHIBITORS; CRYSTAL-STRUCTURE; ZINC PEPTIDASES; RESOLUTION; BINDING; CATALYSIS; PROGRAM	The complex of benzylsuccinic acid with thermolysin has been redetermined at 1.7-Angstrom resolution and refined to a crystallographic residual of 15.7%. In contrast to the prior study, which was to 2.3-Angstrom resolution, and with-out the benefit of refinement (Bolognesi, M. C. and Matthews, B. W. (1979) J. Biol. Chem. 254, 634-639), the present analysis shows that it is the D- rather than the L-isomer of benzylsuccinic acid that binds. The stereochemistry of the zinc-carboxylate interaction is now seen to be syn, as is also observed in all known zinc-carboxylate complexes of both thermolysin and carboxypeptidase A. The mode of binding of the beta-carboxylate resembles the presumed geometry of the tetrahedral transition state and, as such, is consistent with the commonly accepted mechanism of action of thermolysin and of carboxypeptidase A.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon; University of Oregon					NIGMS NIH HHS [GM20066] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM020066] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLOGNESI MC, 1979, J BIOL CHEM, V254, P634; BREDDAM K, 1985, CARLSBERG RES COMMUN, V50, P199, DOI 10.1007/BF02907146; BYERS LD, 1972, J BIOL CHEM, V247, P606; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P49, DOI 10.1093/protein/4.1.49; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1987, J AM CHEM SOC, V109, P5536, DOI 10.1021/ja00252a046; CHRISTIANSON DW, 1988, J AM CHEM SOC, V110, P5560, DOI 10.1021/ja00224a047; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; MANGANI S, 1992, J MOL BIOL, V223, P573, DOI 10.1016/0022-2836(92)90671-6; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MONZINGO AF, 1984, BIOCHEMISTRY-US, V23, P5724, DOI 10.1021/bi00319a010; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; ZHANG XJ, 1993, J APPL CRYSTALLOGR, V26, P457, DOI 10.1107/S0021889892013165	20	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18839	18842						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034637				2022-12-27	WOS:A1994NX32700024
J	MCILVAIN, JM; BURKHARDT, JK; HAMMALVAREZ, S; ARGON, Y; SHEETZ, MP				MCILVAIN, JM; BURKHARDT, JK; HAMMALVAREZ, S; ARGON, Y; SHEETZ, MP			REGULATION OF KINESIN ACTIVITY BY PHOSPHORYLATION OF KINESIN-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; LIGHT-CHAINS; MEMBRANOUS ORGANELLES; CYTOPLASMIC DYNEIN; VESICLE TRANSPORT; HEAVY-CHAIN; T-CELLS; BINDING; MOTILITY; IDENTIFICATION	The mechanochemical motor proteins of the kinesin and cytoplasmic dynein families play important roles in microtubule-based intracellular motility. Although movement and distribution of organelles like secretory granules, vesicles, endoplasmic reticulum, and chromosomes depend on the activity of these motor proteins, little is known about the regulation of this movement. We report here that the hyperphosphorylation of components of the kinesin complex by treatment with okadaic acid increases kinesin motor activity at least 2-fold. The stimulation was observed using both a granule motility assay and a microtubule gliding assay, indicating that phosphorylation enhances the activity of the motor itself, rather than the affinity of the motor for membrane organelles. Under stimulatory conditions, three proteins that co-purify with kinesin (with mobilities of 150, 79, and 73 kDa) are consistently hyperphosphorylated. Dephosphorylation of these proteins reduces kinesin activity to basal levels. Therefore, we conclude that kinesin motor activity is directly modulated by the phosphorylation state of kinesin-associated proteins.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA	Duke University	MCILVAIN, JM (corresponding author), DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA.			Hamm-Alvarez, Sarah/0000-0001-8195-5703	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; ARGON Y, 1984, J IMMUNOL, V133, P1627; BLACKMAN MA, 1992, J EXP MED, V176, P275, DOI 10.1084/jem.176.1.275; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BURKHARDT JK, 1993, J CELL SCI, V104, P151; COHN SA, 1989, J BIOL CHEM, V264, P4290; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HEUSER J, 1988, CELL MOTIL CYTOSKEL, V11, P202; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; INGOLD AL, 1988, CELL MOTIL CYTOSKEL, V10, P482; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUO SC, 1991, J CELL SCI, P135; LIN SXH, 1993, J CELL SCI, V105, P579; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1993, METHOD CELL BIOL, V39, P228; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SATO YR, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1989, CELL MOVEMENT, V2, P295; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YU H, 1992, J BIOL CHEM, V267, P20457	38	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19176	19182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034676				2022-12-27	WOS:A1994NX32700072
J	GULVE, EA; REN, JM; MARSHALL, BA; GAO, JP; HANSEN, PA; HOLLOSZY, JO; MUECKLER, M				GULVE, EA; REN, JM; MARSHALL, BA; GAO, JP; HANSEN, PA; HOLLOSZY, JO; MUECKLER, M			GLUCOSE-TRANSPORT ACTIVITY IN SKELETAL-MUSCLES FROM TRANSGENIC MICE OVEREXPRESSING GLUT1 - INCREASED BASAL TRANSPORT IS ASSOCIATED WITH A DEFECTIVE RESPONSE TO DIVERSE STIMULI THAT ACTIVATE GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; INSULIN RESISTANCE; EPITROCHLEARIS MUSCLE; RAT MUSCLE; RECEPTOR; EXERCISE; SYSTEM; OBESE; HOMEOSTASIS; RECRUITMENT	Glucose transport activity was examined in transgenic mice overexpressing the human GLUT1 glucose transporter in skeletal muscles. Basal transport activity measured in vitro with the glucose analog 2-deoxy-D-glucose (1 mM) was increased 2-8-fold in four different muscle preparations. Incubation of muscles from control nontransgenic littermates with a maximally effective concentration of insulin or with insulin-like growth factor-1 resulted in glucose transport rates that were 2-3-fold higher than basal. In contrast, insulin did not stimulate glucose transport activity in three different muscle preparations from transgenic animals; insulin-like growth factor-1 was similarly ineffective. Activation of System A amino acid transport activity (measured with the nonmetabolizable analog alpha-methylaminoisobutyrate) by insulin was not impaired in muscles from transgenic mice, indicating that the defect does not involve the insulin receptor. In skeletal muscle, glucose transport can be activated by muscle contractions or hypoxia via a pathway separate from that activated by insulin. Incubation of muscles under hypoxic conditions or stimulation of muscles to contract in situ did not increase glucose transport activity in muscles from GLUT1-overexpressing mice, in contrast to the stimulatory effects measured in muscles from control animals. These data suggest that increased glucose flux per se into skeletal muscle results in resistance of GLUT4 to activation by insulin and various other stimuli that activate glucose transport by mechanisms distinct from that of insulin, GLUT1-overexpressing mice thus provide a new model system for studying the effects of glucose-induced resistance to activation of glucose transport.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NIA NIH HHS [AG00078] Funding Source: Medline; NIDDK NIH HHS [DK18986, DK38495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495, R01DK018986] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CARLSEN RC, 1985, CAN J PHYSIOL PHARM, V63, P958, DOI 10.1139/y85-158; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; DOLAN PL, 1993, BIOCHEM J, V289, P423, DOI 10.1042/bj2890423; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; GAO JP, 1994, AM J PHYSIOL, V266, pE186, DOI 10.1152/ajpendo.1994.266.2.E186; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GARVEY WT, 1987, J BIOL CHEM, V262, P18; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; GULVE EA, 1991, AM J PHYSIOL, V260, pC88, DOI 10.1152/ajpcell.1991.260.1.C88; HAGER SR, 1991, AM J PHYSIOL, V260, pE353, DOI 10.1152/ajpendo.1991.260.3.E353; HAGER SR, 1991, BIOCHEM BIOPH RES CO, V181, P240, DOI 10.1016/S0006-291X(05)81408-1; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLLOSZY J O, 1986, Diabetes Metabolism Reviews, V1, P409; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; MANDARINO L, 1984, DIABETOLOGIA, V27, P358, DOI 10.1007/BF00304850; MARONI BJ, 1986, AM J PHYSIOL, V251, pF74, DOI 10.1152/ajprenal.1986.251.1.F74; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MIKINES KJ, 1991, J APPL PHYSIOL, V70, P1245, DOI 10.1152/jappl.1991.70.3.1245; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NESHER R, 1980, AM J PHYSIOL, V239, pE454, DOI 10.1152/ajpendo.1980.239.6.E454; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; REN JM, 1993, J BIOL CHEM, V268, P1611; RIGGS TR, 1973, J BIOL CHEM, V248, P6450; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SOWELL MO, 1988, AM J PHYSIOL, V255, pE159, DOI 10.1152/ajpendo.1988.255.2.E159; WATANABE T, 1984, J BIOL CHEM, V259, P3117; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	41	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18366	18370						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034582				2022-12-27	WOS:A1994NW79800023
J	HE, TC; JIANG, N; ZHUANG, HM; QUELLE, DE; WOJCHOWSKI, DM				HE, TC; JIANG, N; ZHUANG, HM; QUELLE, DE; WOJCHOWSKI, DM			THE EXTENDED BOX-2 SUBDOMAIN OF ERYTHROPOIETIN RECEPTOR IS NONESSENTIAL FOR JAK2 ACTIVATION YET CRITICAL FOR EFFICIENT MITOGENESIS IN FDC-ER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; TYROSINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; CYTOSOLIC DOMAINS; GROWTH-FACTOR; PHOSPHORYLATION; PROTEIN; ASSOCIATION; EXPRESSION	The development of erythroid progenitor cells depends upon exposure to the glycoprotein hormone, erythropoietin (EPO). Binding of EPO to its transmembrane receptor leads to the rapid tyrosine phosphorylation of several cellular targets including Shc, Raf-1, Gap(120), the cloned EPO receptor (EPOR), pp100/97, and a M(2) 130,000 EPO-activated receptor-associated Janus protein tyrosine kinase, Jak2. A membrane proximal cytosolic region of the EPOR recently has been shown to be essential for the activation of Jak2 and sufficient for EPO-induced mitogenesis. This cytosolic region in eludes 8-12 amino acid box 1 and box 2 subdomains, which are conserved in certain class I receptors as well as a more distal 10-40 amino acid subdomain (extended box 2 subdomain, ExBx2), which likewise is implicated in mitogenic signaling. Through the expression of EPOR carboxyl-terminal truncation mutants in FDC-P1 cells, we presently show that an EPOR form truncated within the ExBx2 domain efficiently activates Jak2, yet is deficient in mitogenesis. Efficient expression of this mutant receptor at the cell surface and its ability to activate Jak2 indicate that poor mitogenic activity does not result from aberrant transport or folding. Rather, failure of this mutant to support proliferation above nominal rates underlines an apparent role for the EPOR ExBx2 subdomain in the activation of a distinct primary mitogenic effector.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, University Pk, PA 16802 USA; PENN STATE UNIV, INTERCOLL GRAD PROGRAM GENET, University Pk, PA 16802 USA; PENN STATE UNIV, DEPT VET SCI, University Pk, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, University Pk, PA 16802 USA; ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital				Quelle, Dawn/0000-0001-8776-0122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003042, R01HL044491] Funding Source: NIH RePORTER; NHLBI NIH HHS [K04HL03042, R01HL44491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAI CH, 1991, BLOOD, V78, P2493; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GREGORY CJ, 1977, BLOOD, V49, P855; HE TC, 1993, BLOOD, V82, P3530; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; IHLE JN, 1982, J IMMUNOL, V129, P1377; ISCOVE NN, 1977, CELL TISSUE KINET, V10, P323, DOI 10.1111/j.1365-2184.1977.tb00300.x; JONES SS, 1990, BLOOD, V76, P31; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KRANTZ SB, 1991, BLOOD, V77, P419; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAL K, 1993, SCIENCE, V366, P580; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TORTI M, 1992, J BIOL CHEM, V267, P8293; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	41	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18291	18294						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034573				2022-12-27	WOS:A1994NW79800009
J	VASISHT, V; GREENE, V; ARJUN, I; LEVINGER, L				VASISHT, V; GREENE, V; ARJUN, I; LEVINGER, L			POINT MUTATIONS DISTAL TO THE PROCESSING SITE AFFECT DROSOPHILA PRE-5-S RNA PROCESSING - LONG-RANGE COOPERATION AND A BREATHING MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; BINDING-SITE; 5-S RNA; XENOPUS-OOCYTES; PROTEIN COMPLEX; MAJOR GROOVE; 3' END; INVITRO; DOMAINS; TRANSCRIPTION	Drosophila pre-5 S RNA, which consists of five conserved stem-loop domains and a 15-nucleotide 3' tail, is 3'-end processed to 120 nucleotide mature 5 S RNA be- fore ribosome assembly. Large deletions in stems II and III, all of stems IV and V, and loop C prohibit Drosophila 5 S RNA processing; deletion of stem IV and half of V does not (Preiser, P. R., and Levinger, L. (1991a) J. Biol. Chem. 266, 7509-7516). Several point mutations in stem I reduce, while certain neighboring sequence changes stimulate, processing (Levinger, L., Vasisht, V., Greene, V., and Arjun, I. (1992) J. Biol. Chem. 267, 23683-23687). Herein we extend this 5 S RNA fine structure analysis to regions farther from the processing site. Most point mutations in loop B, stem III, and loop C severely inhibit processing. One loop C substitution stimulates processing; when combined with stimulatory sequence changes in stem I and loop A, these dispersed mutations improve processing manyfold, perhaps by stabilizing a required conformation or strengthening a protein-binding site. Central stem II sequence changes inhibit processing; several adjacent sequence substitutions which weaken base pairing improve processing. Combining these re- sults with earlier work from stem I and loop A, we hypothesize that slight reduction in base pairing may improve groove access of polypeptide chains to essential contact positions.	CUNY YORK COLL,JAMAICA,NY 11451	City University of New York (CUNY) System; York College NY (CUNY)					NIGMS NIH HHS [GM4603, GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1993, MOL CELL BIOL, V13, P6819, DOI 10.1128/MCB.13.11.6819; BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; BAUDIN F, 1989, NUCLEIC ACIDS RES, V5, P2043; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BROW DA, 1987, J BIOL CHEM, V262, P13953; BROW DA, 1987, J BIOL CHEM, V262, P13959; BRUNEL C, 1992, J MOL BIOL, V215, P103; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; DELIHAS N, 1982, NUCLEIC ACIDS RES, V10, P7323, DOI 10.1093/nar/10.22.7323; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3908; ESCHALIER G, 1970, IN VITRO, V6, P162; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; GLOVER DM, 1988, FRONTIERS MOL BIOL T; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; JOACHIMIAK A, 1990, INT J BIOL MACROMOL, V12, P321, DOI 10.1016/0141-8130(90)90022-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVINGER L, 1992, J BIOL CHEM, V267, P23683; LEVINGER L, 1994, IN PRESS BIOTECHNOL, V4; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; PREISER P, 1993, J BIOL CHEM, V268, P11553; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PREISER PR, 1991, J BIOL CHEM, V266, P23602; PRICE DH, 1987, J BIOL CHEM, V262, P3244; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; ROMANIUK P, 1987, NUCLEIC ACIDS RES, V6, P2737; ROMBY P, 1988, BIOCHEMISTRY-US, V27, P4721, DOI 10.1021/bi00413a021; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP S, 1984, NUCLEIC ACIDS RES, V12, P7617, DOI 10.1093/nar/12.20.7617; STAHL DA, 1984, J BIOL CHEM, V259, P1448; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZHANG P, 1989, NUCLEIC ACIDS RES, V18, P7295	48	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18468	18474						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034594				2022-12-27	WOS:A1994NW79800039
J	BOSMA, PJ; SEPPEN, J; GOLDHOORN, B; BAKKER, C; ELFERINK, RPJO; CHOWDHURY, JR; CHOWDHURY, NR; JANSEN, PLM				BOSMA, PJ; SEPPEN, J; GOLDHOORN, B; BAKKER, C; ELFERINK, RPJO; CHOWDHURY, JR; CHOWDHURY, NR; JANSEN, PLM			BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IS THE ONLY RELEVANT BILIRUBIN GLUCURONIDATING ISOFORM IN MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRIGLER-NAJJAR SYNDROME; UGT1 GENE-COMPLEX; SYNDROME TYPE-I; URIDINE 5'-DIPHOSPHATE-GLUCURONOSYLTRANSFERASE; GUNN-RATS; BILE; IDENTIFICATION; MUTATION; PHENOL; DISEASE	Crigler-Najjar syndrome type I (CN-I) is caused by an inherited absence of UDP-glucuronosyltransferase activity toward bilirubin (B-UGT), resulting in severe non-hemolytic unconjugated hyperbilirubinemia. Based on the expression of cDNAs in COS cells, two UGT isoforms in human liver, B UGT(1) and B-UGT(2), have been reported to catalyze bilirubin glucuronidation. These isoforms, which are derived from a single gene, ugt1, have identical carboxyl-terminal domains that are encoded by four consecutive exons shared by both isoforms. A critical lesion in any of these common exons should inactivate both B-UGT isoforms, giving rise to CN-I. The aminoterminal domains of the B-UGT isoforms are unique, each being encoded by a different 5' exon. If both B-UGT isoforms contribute significantly to bilirubin glucuronidation, a mutation in one of these unique 5' exons should affect a single isoform, while the other isoforms should provide residual B-UGT activity. However, in two patients with CN-I, we found a mutation only in the unique exon of B-UGT(1), the other exons being normal. To clarify this apparent paradox, we expressed the cDNA for each B-UGT isoform in COS cells and determined the specific B-UGT activity. These studies show that only B-UGT(1) has quantitatively significant catalytic activity. Furthermore, we show that the mutation in B-UGT(1) observed in each of the two CN-I patients inactivates B-UGT(1). Together, the results indicate that B-UGT(1) is the only physiologically relevant isoform in bilirubin glucuronidation.	UNIV AMSTERDAM,ACAD MED CTR,DIV GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; UNIV GRONINGEN HOSP,DIV GASTROENTEROL & HEPATOL,9713 EZ GRONINGEN,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Yeshiva University; Albert Einstein College of Medicine; University of Groningen	BOSMA, PJ (corresponding author), ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,1300 MORRIS PK AVE,BRONX,NY 10461, USA.			Seppen, Jurgen/0000-0001-9689-9919	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046057, R01DK039137] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 46057, R01-DK 39137, P30-DK 41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aono S., 1993, Teratology, V48, P520; ARIAS IM, 1962, J CLIN INVEST, V41, P2233, DOI 10.1172/JCI104682; ARIAS IM, 1969, AM J MED, V47, P395, DOI 10.1016/0002-9343(69)90224-1; BLANCKAERT N, 1977, BIOCHEM J, V164, P237, DOI 10.1042/bj1640237; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BOSMA PJ, 1992, FASEB J, V6, P2859, DOI 10.1096/fasebj.6.10.1634050; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; CHOWDHURY JR, 1990, PRINCIPLES PRACTICE, P1135; CHOWDHURY JR, 1991, J BIOL CHEM, V266, P18294; CRIGLER JF, 1952, PEDIATRICS, V10, P169; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUHAMEL G, 1984, J HEPATOL, V1, P47; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; FEVERY J, 1977, J CLIN INVEST, V60, P970, DOI 10.1172/JCI108877; FEVERY J, 1972, J CLIN INVEST, V51, P2482, DOI 10.1172/JCI107062; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; KAUFMAN SS, 1986, HEPATOLOGY, V6, P1259, DOI 10.1002/hep.1840060606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOGHRABI N, 1993, AM J HUM GENET, V53, P722; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PETERS WHM, 1987, GASTROENTEROLOGY, V93, P162, DOI 10.1016/0016-5085(87)90329-5; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1991, BIOCHEM BIOPH RES CO, V177, P1161, DOI 10.1016/0006-291X(91)90661-P; SINAASAPPEL M, 1991, GASTROENTEROLOGY, V100, P783, DOI 10.1016/0016-5085(91)80026-6; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANES HHG, 1993, CYTOGENET CELL GENET, V63, P114, DOI 10.1159/000133513; VANES HHG, 1990, J CLIN INVEST, V85, P1199, DOI 10.1172/JCI114553; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	34	341	349	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17960	17964						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027054				2022-12-27	WOS:A1994NV42200034
J	PLATANIAS, LC; UDDIN, S; COLAMONICI, OR				PLATANIAS, LC; UDDIN, S; COLAMONICI, OR			TYROSINE PHOSPHORYLATION OF THE ALPHA-SUBUNIT AND BETA-SUBUNITS OF THE TYPE-I INTERFERON RECEPTOR - INTERFERON-BETA SELECTIVELY INDUCES TYROSINE PHOSPHORYLATION OF AN ALPHA-SUBUNIT ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IFN-ALPHA; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; KINASE; CELLS; OMEGA; JAK	We studied the phosphorylation of the alpha and beta subunits of the Type I inteferon (IFN) receptor induced by Type I IFNs in the human U-266 and MOLT-4 cell lines. Both IFN-alpha and IFN-beta induced tyrosine phosphorylation of the beta subunit of the receptor. The Type I IFN-induced tyrosine phosphorylation of the beta subunit was rapid and transient, being detectable within 1 min of Type I IFN treatment and gradually diminishing to almost base-line levels by 60 min. All Type I IFNs studied were found to induce tyrosine phosphorylation of the alpha subunit of the Type I IFN receptor, the p135(tyk2) and JAK-1 tyrosine kinases, and the ISGF3 alpha components. Interestingly, IFN-beta, but not IFN-alpha or IFN-omega, induced tyrosine phosphorylation of an alpha subunit-associated protein with an apparent molecular mass of similar to-100 kDa (p100). These data suggest the existence of a common signaling pathway(s) for Type I IFNs involving the alpha and beta subunits of the receptor, the tyrosine kinases p135(tyk2) and JAK-1, and the ISGF3 alpha components. However, differences between the signaling pathways of different Type I IFNs exist, as suggested by tyrosine phosphorylation of an alpha subunit-associated protein only in response to IFN-beta.	EDWARD HINES VET ADM MED CTR,MAYWOOD,IL 60153; UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Tennessee System; University of Tennessee Health Science Center	PLATANIAS, LC (corresponding author), LOYOLA UNIV,DEPT MED,DIV HEMATOL ONCOL,MAYWOOD,IL 60153, USA.			Uddin, Shahab/0000-0003-1886-6710				BENOIT P, 1993, J IMMUNOL, V150, P707; BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; FLORES I, 1991, J BIOL CHEM, V266, P19875; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY D, 1990, New Biologist, V2, P923; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8	27	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17761	17764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027027				2022-12-27	WOS:A1994NV42200002
J	BOKAR, JA; RATHSHAMBAUGH, ME; LUDWICZAK, R; NARAYAN, P; ROTTMAN, F				BOKAR, JA; RATHSHAMBAUGH, ME; LUDWICZAK, R; NARAYAN, P; ROTTMAN, F			CHARACTERIZATION AND PARTIAL-PURIFICATION OF MESSENGER-RNA N-6-ADENOSINE METHYLTRANSFERASE FROM HELA-CELL NUCLEI - INTERNAL MESSENGER-RNA METHYLATION REQUIRES A MULTISUBUNIT COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SARCOMA VIRUS GENOME; HETEROGENEOUS NUCLEAR; SEQUENCE SPECIFICITY; N-6-METHYLADENOSINE RESIDUES; NUCLEOTIDE-SEQUENCES; ADENOSINE RESIDUES; CAPPING ENZYME; 5' TERMINUS; N6-METHYLADENOSINE	N-6-Methyladenosine is found at internal positions of mRNA in higher eukaryotes. This post-transcriptional modification occurs at a frequency of one to three methylations/average mRNA molecule in mammalian cell lines and is sequence-specific. A highly conserved consensus recognition site for the methyltransferase has been determined from both viral and cellular messages, consisting of the sequence Pu(G/A)AC(U/A) (with A being methylated). Despite the ubiquity and the specificity of this modification, little is known about the mechanism of formation of N-6-methyladenosine. Utilizing an in vitro methylation system from HeLa cell nuclear extracts, and a substrate RNA derived from the mRNA coding for bovine prolactin, the mRNA N-6-adenosine methyltransferase has been characterized and partially purified. Unique among other characterized nucleic acid methyltransferases, the enzyme is composed of three components which are separable under non denaturing conditions. The molecular masses of the components are 30, 200, and 875 kDa as determined by gel filtration and glycerol gradient sedimentation. The 800-kDa component appears to contain the S-adenosylmethionine binding site on a 70-KDa subunit. The 875-kDa component has affinity for single-stranded DNA-agarose, suggesting that it may contain the mRNA-binding site. N-6-Adenosine methyltransferase is not sensitive to treatment with micrococcal nuclease, nor to immunodepletion using an anti trimethylguanosine antibody, suggesting that it does not contain an essential RNA component.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT INTERNAL MED, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NCI NIH HHS [CA31810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONI Y, 1979, J VIROL, V32, P52, DOI 10.1128/JVI.32.1.52-60.1979; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BEEMON K, 1977, J MOL BIOL, V113, P165, DOI 10.1016/0022-2836(77)90047-X; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; CAMPER SA, 1984, MOL CELL BIOL, V4, P538, DOI 10.1128/MCB.4.3.538; CANAANI D, 1979, NUCLEIC ACIDS RES, V6, P2879, DOI 10.1093/nar/6.8.2879; CARROLL SM, 1990, MOL CELL BIOL, V10, P4456, DOI 10.1128/MCB.10.9.4456; CHENKIANG S, 1979, J MOL BIOL, V135, P733, DOI 10.1016/0022-2836(79)90174-8; CONG PJ, 1992, J BIOL CHEM, V267, P16424; CSEPANY T, 1990, J BIOL CHEM, V265, P20117; DESROSIERS RC, 1975, BIOCHEMISTRY-US, V14, P4367, DOI 10.1021/bi00691a004; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMOCK K, 1977, BIOCHEMISTRY-US, V16, P471, DOI 10.1021/bi00622a021; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FINKEL D, 1983, VIROLOGY, V131, P409, DOI 10.1016/0042-6822(83)90508-1; HARPER JE, 1990, NUCLEIC ACIDS RES, V18, P5735, DOI 10.1093/nar/18.19.5735; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HOROWITZ S, 1984, P NATL ACAD SCI-BIOL, V81, P5667, DOI 10.1073/pnas.81.18.5667; IZZO P, 1977, BIOCHEMISTRY-US, V16, P3576, DOI 10.1021/bi00635a012; KANE SE, 1985, MOL CELL BIOL, V5, P2298, DOI 10.1128/MCB.5.9.2298; KANE SE, 1987, J BIOL CHEM, V262, P3422; KRUG RM, 1976, J VIROL, V20, P45, DOI 10.1128/JVI.20.1.45-53.1976; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; LAVI U, 1977, NUCLEIC ACIDS RES, V4, P63, DOI 10.1093/nar/4.1.63; MADEN BEH, 1986, J MOL BIOL, V189, P681, DOI 10.1016/0022-2836(86)90498-5; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MOSS B, 1977, J VIROL, V23, P234, DOI 10.1128/JVI.23.2.234-239.1977; NARAYAN P, 1992, ADV ENZYMOL RAMB, V65, P255; NARAYAN P, 1988, SCIENCE, V242, P1159, DOI 10.1126/science.3187541; NARAYAN P, 1994, NUCLEIC ACIDS RES, V22, P419, DOI 10.1093/nar/22.3.419; NARAYAN P, 1987, MOL CELL BIOL, V7, P1572, DOI 10.1128/MCB.7.4.1572; PARKER KA, 1989, METHOD ENZYMOL, V180, P454; PERRY RP, 1974, CELL, V1, P37, DOI 10.1016/0092-8674(74)90153-6; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; RANSOHOFF RM, 1987, ANTIVIR RES, V7, P317, DOI 10.1016/0166-3542(87)90014-3; SCHIBLER U, 1977, J MOL BIOL, V115, P695, DOI 10.1016/0022-2836(77)90110-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOM S, 1990, J BIOL CHEM, V265, P4278; STOLTZFUS CM, 1976, J VIROL, V18, P586, DOI 10.1128/JVI.18.2.586-595.1976; STOLTZFUS CM, 1982, J VIROL, V42, P918, DOI 10.1128/JVI.42.3.918-931.1982; TUCK MT, 1992, BIOCHEM J, V288, P233, DOI 10.1042/bj2880233; WEI CM, 1977, BIOCHEMISTRY-US, V16, P1672, DOI 10.1021/bi00627a023; WEI CM, 1976, BIOCHEMISTRY-US, V15, P397, DOI 10.1021/bi00647a024; WOLD WSM, 1976, BIOCHEM BIOPH RES CO, V68, P643, DOI 10.1016/0006-291X(76)91194-3; ZEITLIN S, 1984, CELL, V39, P589, DOI 10.1016/0092-8674(84)90466-5	47	233	257	3	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17697	17704						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021282				2022-12-27	WOS:A1994NU12800056
J	MAHANTY, SK; RAO, US; NICHOLAS, RA; SCARBOROUGH, GA				MAHANTY, SK; RAO, US; NICHOLAS, RA; SCARBOROUGH, GA			HIGH-YIELD EXPRESSION OF THE NEUROSPORA-CRASSA PLASMA-MEMBRANE H+-ATPASE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; PURIFICATION; PROTEIN; MUTAGENESIS; CELLS; TRANSFORMATION; OVEREXPRESSION; CATALYSIS	A simple system for high yield expression of the neurospora plasma membrane H+-ATPase is described Two neurospora H+-ATPase cDNAs differing only in a few bases preceding the coding region were cloned into a high copy number yeast expression vector under the control of the constitutive promoter of the yeast plasma membrane H+-ATPase, and the resulting plasmids were used to transform Saccharomyces cerevisiae strain RS-72, which requires a plasmid-borne functional plasma membrane H+-ATPase for growth in glucose medium (Villalba, J. M., Palmgren, M. G., Berberian, G. E., Ferguson, C., and Serrano, R. (1992) J. Biol. Chem. 267, 12341-12349. Both plasmids supported growth of the cells, indicating that the neurospora ATPase is expressed in functional form in yeast. Western blots of membranes from the transformants confirmed that the neurospora ATPase is expressed in the yeast cells, with production in the range of several percent of the yeast membrane protein, Importantly, when the expressed, recombinant neurospora ATPase molecules are solubilized from the membranes with lysolecithin and subjected to glycerol gradient centrifugation, they migrate to a position indistinguishable from that of the native ATPase and display a comparable specific ATPase activity, indicating that the great majority of the recombinant neurospora ATPase molecules produced in yeast fold in a natural manner, This expression system thus appears to be ideal for site-directed mutagenesis studies of the neurospora ATPase molecule.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIGMS NIH HHS [GM24784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM024784, R01GM024784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1981, J BIOL CHEM, V256, P3165; BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CIGAN AM, 1987, GENE, V59, P1; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DAME JB, 1980, BIOCHEMISTRY-US, V19, P2931, DOI 10.1021/bi00554a018; ECKHARDT AE, 1976, ANAL BIOCHEM, V73, P192, DOI 10.1016/0003-2697(76)90154-8; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1986, TRENDS BIOCHEM SCI, V11, P321, DOI 10.1016/0968-0004(86)90289-6; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARLOW E, 1988, ANTIBODIES; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO R, 1993, J BIOL CHEM, V268, P6708; Sambrook J, 1989, MOL CLONING; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCARBOROUGH GA, 1994, IN PRESS ACTA CRYS D; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SCARBOROUGH GA, 1988, METHOD ENZYMOL, V157, P574; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SERRANO R, 1992, BIOCHEM SOC T, V20, P562, DOI 10.1042/bst0200562; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; Serrano R., 1990, The plant plasma membrane., P127; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; SUMMERS MD, 1988, B TEXAS AGR EXPT STA, V1555; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17705	17712						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021283				2022-12-27	WOS:A1994NU12800057
J	BEAUMONT, C; SEYHAN, A; YACHOU, AK; GRANDCHAMP, B; JONES, R				BEAUMONT, C; SEYHAN, A; YACHOU, AK; GRANDCHAMP, B; JONES, R			MOUSE FERRITIN-H SUBUNIT GENE - FUNCTIONAL-ANALYSIS OF THE PROMOTER AND IDENTIFICATION OF AN UPSTREAM REGULATORY ELEMENT ACTIVE IN ERYTHYROID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; PORPHOBILINOGEN DEAMINASE GENE; MESSENGER-RNA; BINDING-PROTEIN; ERYTHROLEUKEMIC CELLS; HEAVY-CHAIN; EXPRESSION; TRANSCRIPTION; INDUCTION; INVITRO	Ferritin synthesis is regulated at the translational level by iron, but it is likely that transcriptional regulation of H and L genes is responsible for tissue-specific distribution of H and L mRNAs. In order to define the regions important for transcriptional regulation of the mouse ferritin H gene, we have linked the promoter, including the transcription start site, and 5 kilobases of upstream sequence to a reporter gene (human growth hormone). This construct and a series of 5' deletion mutants have been used to transfect erythroid (K562, mouse erythroleukemia (MEL)) and hepatoma (HepG(2)) cell lines. Measurement of growth hormone in the culture medium and analysis of ferritin-growth hormone transcripts by a ribonuclease protection assay revealed that a 140-base pair minimal promoter is sufficient to confer a high level of expression to the reporter gene in both cell types. In addition, a 180-base pair fragment, lying 4.5 kilobases upstream of the ferritin transcription start site, functions like an inducible enhancer during N,N'-hexamethylene-bis-acetamide-induced differentiation of MEL cells. A perfect match to a consensus binding motif to the erythroid transcription factor NF-E2 is present in this regulatory element, but the mutant NF-E2 enhancer retains the inducible activity in stably transfected MEL cells, and the results from gel retardation assays suggest that protein-DNA complexes that form in vitro between the ferritin enhancer and MEL nuclear extracts do not contain NF-E2. Thus, nuclear factors that mediate inducibility of the ferritin enhancer remain to be identified.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Oxford	BEAUMONT, C (corresponding author), FAC XAVIER BICHAT,INSERM,U409,16 RUE HENRI HUCHARD,F-75018 PARIS,FRANCE.		Seyhan, Attila/G-3603-2017	Seyhan, Attila/0000-0002-6264-1482; Seyhan, Attila A/0000-0003-1276-8466				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BEAUMONT C, 1984, EXP CELL RES, V154, P575; BEAUMONT C, 1994, IN PRESS PROGR IRON; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CAMPBELL PL, 1990, GENE DEV, V4, P1252, DOI 10.1101/gad.4.7.1252; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLIN Y, 1990, J BIOL CHEM, V265, P16729; COLUCCIDAMATO LG, 1989, BIOCHEM BIOPH RES CO, V165, P506, DOI 10.1016/0006-291X(89)91098-X; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; GRANDCHAMP B, 1987, EUR J BIOCHEM, V162, P105, DOI 10.1111/j.1432-1033.1987.tb10548.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHGO Y, 1980, J BIOL CHEM, V255, P5195; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; MARKS PA, 1987, CANCER RES, V47, P659; MATTIA E, 1990, BIOCHEM J, V267, P553, DOI 10.1042/bj2670553; MCCLARTY GA, 1990, J BIOL CHEM, V265, P7539; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PATTANAPANYASAT K, 1987, CLIN SCI, V73, P605, DOI 10.1042/cs0730605; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; POTTER CG, 1991, ANAL BIOCHEM, V197, P121, DOI 10.1016/0003-2697(91)90366-2; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WHITE K, 1988, J BIOL CHEM, V263, P8938; YACHOU AK, 1991, GENOMICS, V10, P531, DOI 10.1016/0888-7543(91)90432-E	47	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20281	20288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051121				2022-12-27	WOS:A1994PB31700014
J	CHAUVIN, F; BRAND, L; ROSEMAN, S				CHAUVIN, F; BRAND, L; ROSEMAN, S			SUGAR-TRANSPORT BY THE BACTERIAL PHOSPHOTRANSFERASE SYSTEM - CHARACTERIZATION OF THE ESCHERICHIA-COLI ENZYME-I MONOMER/DIMER EQUILIBRIUM BY FLUORESCENCE ANISOTROPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; INTRINSIC FLUORESCENCE; MEMBRANE-VESICLES; PHOSPHOENOLPYRUVATE; ASSOCIATION; PHOSPHATE; KINASE	Enzyme I (EI), the first protein of the bacterial phosphotransferase system (PTS), exists in a monomer/dimer (M/D) equilibrium. We have proposed that the two species are functionally different and that their interconversion may regulate sugar transport via the PTS. The C-terminal Cys of Escherichia coli EI was reacted with pyrene maleimide (Han, M. K., Roseman, S., and Brand, L. (1990) J. Biol. Chem. 265, 1985-1995), and the pyrene conjugate used to characterize the M/D equilibrium by fluorescence anisotropy. The properties of unlabeled and pyrene-labeled EI are indistinguishable. Values for the apparent association constant, K'(eq), and the steady-state anisotropy of the monomer and the dimer were obtained under a variety of conditions. K'(eq) increases 23-fold, from 0.45 x 10(5) to 10.7 x 10(5) M(-1) as the temperature increases from 6 to 30 degrees C; the association appears to be entropically driven. Under all conditions tested, the K'(eq) for phospho-EI is 6-12-fold less than for dephospho-EI. For phospho-EI, PEP and Mg2+ induce a 240-fold increase of K'(eq) when both ligands are present. Based on these data, EI was preincubated under conditions that change K'(eq), and the initial activities of the different species were determined at 37 degrees C in a PTS sugar phosphorylation assay with PEP as the phosphoryl donor. The initial rate depends on the M/D ratio; it is maximal when EI is 100% dimer, and zero when EI is 100% monomer. In the latter case, the rate gradually increases in the assay mixture. The results have important implications for how the PTS regulates sugar transport and other physiological phenomena.			CHAUVIN, F (corresponding author), JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,DEPT BIOL,BALTIMORE,MD 21218, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759, R01GM011632] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38759, GM11632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENESKI DA, 1982, J BIOL CHEM, V257, P4565; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; CHAUVIN F, 1992, BIOPHYS CHEM, V44, P163, DOI 10.1016/0301-4622(92)80049-B; DANNELLY HK, 1992, P NATL ACAD SCI USA, V89, P11274, DOI 10.1073/pnas.89.23.11274; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FOX DK, 1986, J BIOL CHEM, V261, P3498; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAN MK, 1990, J BIOL CHEM, V265, P1996; HAN MK, 1990, J BIOL CHEM, V265, P1985; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LIU KDF, 1983, P NATL ACAD SCI-BIOL, V80, P7142, DOI 10.1073/pnas.80.23.7142; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON PW, 1981, J BIOL CHEM, V256, P1861; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MISSET O, 1980, BIOCHEMISTRY-US, V19, P883, DOI 10.1021/bi00546a009; NEYROZ P, 1987, J BIOL CHEM, V262, P15900; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1980, J BIOL CHEM, V255, P8579; SIMONI RD, 1973, J BIOL CHEM, V248, P966; STOCK JB, 1982, J BIOL CHEM, V257, P4543; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	28	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20263	20269						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051118				2022-12-27	WOS:A1994PB31700011
J	DARNAY, BG; REDDY, SAG; AGGARWAL, BB				DARNAY, BG; REDDY, SAG; AGGARWAL, BB			IDENTIFICATION OF A PROTEIN-KINASE ASSOCIATED WITH THE CYTOPLASMIC DOMAIN OF THE P60 TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL TRANSDUCTION PATHWAY; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING; GENE-EXPRESSION; HL-60 CELLS; MAP KINASE; ACTIVATION	Tumor necrosis factor (TNF) has been shown to bind two distinct receptors, designated p60 and p80, with high affinity, resulting, within minutes, in phosphorylation of several proteins, The receptors themselves do not exhibit protein kinase activity nor have any associated proteins been identified. We employed the glutathione-S-transferase (GST) fusion protein system consisting of the cytoplasmic domain of p60 (GST-p60CD Delta 1) as a probe to help us identify receptor-associated proteins from human histiocytic lymphoma U-937 cells. We found that a protein of approximately 52 kDa (pp52) bound to GST-p60CD Delta 1 from [S-35]methionine- and P-32-labeled cells. The associated protein was phosphorylated on serine and threonine residues. Furthermore, we identified serine/threonine kinase activity associated with p60CD Delta 1 that required either Mn2+ or Mg2+ for optimal activity. The preferred substrates for this kinase, in addition to p60CD Delta 1, included casein and histone H1, but not histone H2B, myelin basic protein, enolase, or the cytoplasmic domain of p80, As was the case in U-937 cells, p60CD Delta 1-associated kinase activity was also identified in human breast adenocarcinoma MCF-7 cells and human foreskin fibroblasts. TNF stimulation of MCF-7 and foreskin fibroblasts for 5-15 min induced approximately 50 and 240% increases in phosphorylation of p60CD Delta 1, respectively. Thus, our results provide the first evidence for protein kinase activity that is specifically associated with the cytoplasmic domain of the p60 form of the TNF receptor and causes its phosphorylation. This p60 TNF receptor-associated protein and the associated kinase described here are referred to as p60-TRAP and p60-TRAK, respectively.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIRD TA, 1989, J IMMUNOL, V142, P126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUO H, 1993, J BIOL CHEM, V268, P11193; GUY GR, 1992, J BIOL CHEM, V267, P1846; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HATEKEYAMA M, 1991, SCIENCE, V252, P1523; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; PENNICA D, 1992, J BIOL CHEM, V267, P21172; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG ZH, 1993, J BIOL CHEM, V268, P20520	50	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20299	20304						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051124				2022-12-27	WOS:A1994PB31700017
J	LEE, JH; SCHOLL, D; NIXON, BT; HOOVER, TR				LEE, JH; SCHOLL, D; NIXON, BT; HOOVER, TR			CONSTITUTIVE ATP HYDROLYSIS AND TRANSCRIPTION ACTIVATION BY A STABLE, TRUNCATED FORM OF RHIZOBIUM-MELILOTI DCTD, A O(54)-DEPENDENT TRANSCRIPTIONAL ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; BINDING-PROTEIN NTRC; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; RNA-POLYMERASE; REGULATORY PROTEINS; SIGNAL-TRANSDUCTION; ENTERIC BACTERIA; GENE-PRODUCTS; PROMOTER	The dctD gene product (DCTD) activates transcription from dctA by the sigma(54)-holoenzyme form of RNA polymerase in Rhizobium meliloti. We have purified a constitutively active form of R. meliloti DCTD that lacks 142 amino acid residues from the N terminus (designated DCTDL143). Purified DCTDL143 recognized the DCTD-binding sites at the dctA promoter region and catalyzed the isomerization of closed complexes between sigma(54)-holoenzyme and the dctA promoter to open complexes. Like the related sigma(54)-dependent activators NTRC and NIFA a purine nucleoside triphosphate with a hydrolyzable beta-gamma bond was required prior to transcription initiation for this isomerization. DCTDL143 hydrolyzed purine nucleoside triphosphates but not pyrimidine nucleoside triphosphates. As observed with NTRC-phosphate, the specific activity for the ATPase of DCTDL143 was strongly dependent on the enzyme concentration and was stimulated by DNA fragments bearing the binding sites for the protein. These DNA fragments increased the V-max for MgATP hydrolysis but did not significantly lower the apparent K-m for MgATP. These data are consistent with the idea proposed for related activators that DCTDL143 must assemble into an active, oligomeric form before it can hydrolyze MgATP and presumably activate transcription.	UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIVERSITY PK, PA 16802 USA	University System of Georgia; University of Georgia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			/AAD-2121-2020	/0000-0003-1101-8030	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040404, R55GM040404] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40404] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; BERGER DK, 1993, CURR PLANT SCI BIOT, V17, P435; BOLTON E, 1986, ARCH MICROBIOL, V144, P142, DOI 10.1007/BF00414724; BUCK M, 1987, MOL MICROBIOL, V1, P243, DOI 10.1111/j.1365-2958.1987.tb00518.x; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; DRUMMOND MH, 1990, MOL MICROBIOL, V4, P29, DOI 10.1111/j.1365-2958.1990.tb02012.x; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; ENGELKE T, 1987, J GEN MICROBIOL, V133, P3019; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; JIANG J, 1989, J BACTERIOL, V171, P5244, DOI 10.1128/jb.171.10.5244-5253.1989; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEDEBUR H, 1990, J BACTERIOL, V172, P3888, DOI 10.1128/jb.172.7.3888-3897.1990; LEDEBUR H, 1992, MOL MICROBIOL, V6, P3479, DOI 10.1111/j.1365-2958.1992.tb01783.x; LEE F, 1977, P NATL ACAD SCI USA, V74, P4365, DOI 10.1073/pnas.74.10.4365; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; Maxam A M, 1980, Methods Enzymol, V65, P499; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; NEFF NF, 1978, J BIOL CHEM, V253, P2455; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Ronson C. W., 1985, Nitrogen fixation research progress. Proceedings of the 6th International Symposium on Nitrogen Fixation, Corvallis, OR, USA, August 4-10. 1985., P201; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; ROTLLAN P, 1986, ANAL BIOCHEM, V159, P377, DOI 10.1016/0003-2697(86)90356-8; Sambrook J, 1989, MOL CLONING LABORATO; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWYER WH, 1973, J BIOL CHEM, V248, P8429; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS DS, 1992, TRANSCRIPTIONAL REGU, P667; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535	53	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20401	20409						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051135				2022-12-27	WOS:A1994PB31700032
J	SKOKOTAS, A; WROBLESKI, M; HILL, TM				SKOKOTAS, A; WROBLESKI, M; HILL, TM			ISOLATION AND CHARACTERIZATION OF MUTANTS OF TUS, THE REPLICATION ARREST PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINUS TER SITE; DNA-REPLICATION; BINDING PROTEIN; ANTIGEN HELICASE; CHROMOSOME; TERMINATION; SEQUENCE; INVITRO; GENE; IDENTIFICATION	Mutations in the tus gene of Escherichia coli, which encodes the replication arrest protein Tus, were isolated using a selection scheme based on the plasmid pHV750T2(+), which transforms tus mutants at a much higher frequency than wild type strains. Seven mutants containing single nucleotide substitutions were isolated, and all of these mutants showed reduced or complete loss of DNA binding and replication arrest activity. Two of the mutant proteins, containing a valine (A173V) or threonine (A173T) in place of the alanine normally found at amino acid 173, were purified and characterized further. A173T had a 4100-fold lower affinity for Ter sites than wild type Tus and was unable to halt DNA replication in vivo or inhibit DnaB-catalyzed strand displacement in an in vitro helicase assay. A173V showed a 130-fold lower affinity for Ter sites than wild type Tus but was still able to arrest DNA replication in vivo, suggesting that protein-protein interactions were responsible for Tus-mediated arrest of DNA replication. In addition, we found that A173V was a weak inhibitor of DnaB-catalyzed strand displacement in vitro, yet halted DNA replication in vivo at 75% of the efficiency of wild type Tus. We concluded from these observations that the standard in vitro helicase assay was inadequate for measuring Tus activity.	DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, PHILADELPHIA, PA 19104 USA	Drexel University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043193, R29GM043193] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABARZUA P, 1984, J BIOL CHEM, V259, P4286; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; COSKUNARI FF, 1994, J BIOL CHEM, V269, P4027; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1987, MOL GEN GENET, V210, P394, DOI 10.1007/BF00327188; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NATARAJAN S, 1991, P NATL ACAD SCI USA, V88, P3867, DOI 10.1073/pnas.88.9.3867; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; OHNO K, 1991, BIOCHIM BIOPHYS ACTA, V1090, P9, DOI 10.1016/0167-4781(91)90030-P; PELLETIER AJ, 1989, J BACTERIOL, V171, P1739, DOI 10.1128/jb.171.3.1739-1741.1989; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74	37	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20446	20455						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051142				2022-12-27	WOS:A1994PB31700039
J	CHICHEPORTICHE, Y; VASSALLI, P				CHICHEPORTICHE, Y; VASSALLI, P			TUMOR-NECROSIS-FACTOR INDUCES A BLOCK IN THE COTRANSLATION OF FC-GAMMA-RIIB MESSENGER-RNA IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; TRANSFERRIN RECEPTOR; MONOCLONAL-ANTIBODY; RICH SEQUENCES; LIPOPOLYSACCHARIDE; EXPRESSION; CELLS; IGG; TRANSCRIPTION	Macrophage activation results in the secretion of various proteins, such as inflammatory cytokines and proteases. In parallel, cell morphology is altered, and the repertoire of cell surface proteins is modified. One of the main functions of macrophages is phagocytosis via Fc gamma-receptors (Fc gamma R). This study explores the modulation of Fc gamma Rs and their mRNAs following activation of macrophages by tumor necrosis factor. It shows that the cell surface expression of Fc gamma RI and Fc gamma RIIb is strongly reduced in macrophages cultured in the presence of tumor necrosis factor, whereas the mRNA of the Fc gamma RIIb is strongly increased as the result of an increase in mRNA stability. Thus, Fc gamma RIIb expression is modulated during macrophage activation by a new mechanism involving posttranscriptional regulation.	CTR MED UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALEVY YG, 1993, MOL IMMUNOL, V30, P775, DOI 10.1016/0161-5890(93)90149-6; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; AUWERX J, 1992, LEUKEMIA RES, V16, P317, DOI 10.1016/0145-2126(92)90070-N; CHEN BDM, 1983, J IMMUNOL, V130, P2256; COLLART MA, 1987, J IMMUNOL, V139, P949; COMBER PG, 1992, CELL IMMUNOL, V145, P324, DOI 10.1016/0008-8749(92)90335-M; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; EZEKOWITZ RAB, 1981, J EXP MED, V154, P60, DOI 10.1084/jem.154.1.60; EZEKOWITZ RAB, 1985, MONONUCLEAR PHAGOCYT, P513; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAGAMI M, 1989, J LEUKOCYTE BIOL, V45, P311, DOI 10.1002/jlb.45.4.311; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LENNETTE DA, 1978, AM J CLIN PATHOL, V69, P647; LEWIS VA, 1986, NATURE, V324, P372, DOI 10.1038/324372a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MELLMAN IS, 1980, J EXP MED, V152, P1048, DOI 10.1084/jem.152.4.1048; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SEARS DW, 1990, J IMMUNOL, V144, P371; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; SHIBATA T, 1990, INT IMMUNOL, V2, P1133, DOI 10.1093/intimm/2.12.1133; STEARNE PA, 1985, J IMMUNOL, V134, P3474; SUNDARAM R, 1993, J LEUKOCYTE BIOL, V54, P81, DOI 10.1002/jlb.54.1.81; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Unkeless J C, 1984, Contemp Top Immunobiol, V14, P171; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGEL SN, 1979, INFECT IMMUN, V25, P328, DOI 10.1128/IAI.25.1.328-336.1979; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	39	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20134	20138						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051101				2022-12-27	WOS:A1994PA12600071
J	CHOI, SY; FALLER, DV				CHOI, SY; FALLER, DV			THE LONG TERMINAL REPEATS OF A MURINE RETROVIRUS ENCODE A TRANSACTIVATOR FOR CELLULAR GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TOXIC LYMPHOCYTES-T; LEUKEMIA-VIRUS; DISEASE SPECIFICITY; ANTIGEN EXPRESSION; ENHANCER ELEMENT; CELLS; INFECTION; INDUCTION; SEQUENCES; ALTERS	Type C RNA leukemia viruses cause lymphoid neoplasia after an extended latent period by an unknown mechanism. Infection of human or murine cells with murine leukemia viruses rapidly increases the expression of genes belonging to the immunoglobulin superfamily and involved in T-lymphocyte activation, including the class I major histocompatibility complex antigens. We report here that the long terminal repeat (LTR) of Moloney murine leukemia virus encodes a novel trans-activator, which induces transcription and expression of class I major histocompatibility complex genes. The portion of the LTR responsible for trans-activation lies within the U3 region and can be excised from the LTR while maintaining its activity. Analysis of the U3 region of the LTR and its flanking sequences suggests that functional or regulatory elements for the trans-activity exist between nucleotides 32 and 219 of the LTR sequences. The region of the LTR identified here as important in trans activation has been shown recently to be a critical determinant of leukemogenicity and latency of Moloney murine leukemia virus. These findings suggest a novel mechanism of retrovirus-induced activation of cellular gene expression, potentially contributing to leukemogenesis.	BOSTON UNIV,MED CTR,SCH MED,CANC RES CTR,BOSTON,MA 02118	Boston University								ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARBOSA JA, 1984, P NATL ACAD SCI-BIOL, V81, P7549, DOI 10.1073/pnas.81.23.7549; BRIGHTMAN BK, 1991, P NATL ACAD SCI USA, V88, P2264, DOI 10.1073/pnas.88.6.2264; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAZAN R, 1976, CELL IMMUNOL, V23, P356, DOI 10.1016/0008-8749(76)90200-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUMAKOV I, 1982, J VIROL, V42, P1088, DOI 10.1128/JVI.42.3.1088-1098.1982; DAVIS B, 1985, NATURE, V314, P550, DOI 10.1038/314550a0; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; FALLER DV, 1988, J CELL BIOCHEM, V36, P297, DOI 10.1002/jcb.240360310; FALLER DV, 1994, IN PRESS MODULATION; FLYER DC, 1985, J IMMUNOL, V135, P2287; FLYER DC, 1983, NATURE, V305, P815, DOI 10.1038/305815a0; GORSKAFLIPOT I, 1992, J VIROL, V66, P7201, DOI 10.1128/JVI.66.12.7201-7210.1992; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HASSAN Y, 1990, CARCINOGENESIS, V11, P2097, DOI 10.1093/carcin/11.12.2097; HENLEY SL, 1984, ADV EXP MED BIOL, V172, P365; KAWASHIMA K, 1976, J EXP MED, V144, P193, DOI 10.1084/jem.144.1.193; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KOKA P, 1991, J IMMUNOL, V146, P2417; LEE JC, 1981, NATURE, V289, P407, DOI 10.1038/289407a0; LICHTMAN AH, 1987, J IMMUNOL, V138, P3276; LICHTMAN AH, 1986, NATURE, V324, P489, DOI 10.1038/324489a0; MERUELO D, 1978, J EXP MED, V147, P470, DOI 10.1084/jem.147.2.470; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PETRARCA MA, 1988, MICROB PATHOGENESIS, V5, P319, DOI 10.1016/0882-4010(88)90033-2; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; SAVARD P, 1987, J VIROL, V61, P3266, DOI 10.1128/JVI.61.10.3266-3275.1987; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; VANBEVEREN C, 1985, RNA TUMOR VIRUSES, V2, P766; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; VASMEL WLE, 1988, J VIROL, V62, P3156, DOI 10.1128/JVI.62.9.3156-3166.1988; WILSON LD, 1987, MOL CELL BIOL, V7, P2406, DOI 10.1128/MCB.7.7.2406	35	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19691	19694						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051046				2022-12-27	WOS:A1994PA12600009
J	DEVIVO, M; IYENGAR, R				DEVIVO, M; IYENGAR, R			ACTIVATED G(Q)-ALPHA POTENTIATES PLATELET-DERIVED GROWTH FACTOR-STIMULATED MITOGENESIS IN CONFLUENT CELL-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PHOSPHOLIPASE-C; PROTEIN-KINASE; ALPHA-SUBUNITS; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; DNA-SYNTHESIS; GQ; FIBROBLASTS	We studied the effects of activation of the G(q)-alpha signaling pathway on mitogenesis by expressing a mutant (Q209L), activated alpha-subunit of G(q) (alpha(q)*) in NM-3T3 cells. A clonal NIH-3T3 cell line expressing alpha(q)* in an inducible manner was isolated. Expression of alpha(q)* is induced with dexamethasone, allowing the use of non-induced cells as controls for the effects of alpha(q)* expression. We found that, by itself, expression of alpha(q)* did not increase either DNA synthesis or mitogen-activated protein (MAP) kinase activity in serum-starved cells. Because alpha(q)* transforms cells grown in the presence of serum (De Vivo M., Chen, J., Codina, J., and Iyengar, R. (1992) J. Biol. Chem. 267, 18263-18266), we tested whether growth factor-stimulated signaling and mitogenesis were affected by expression of alpha(q)*. Platelet-derived growth factor (PDGF) stimulated thymidine incorporation modestly (50%) in contact-inhibited, confluent cell cultures. In cells expressing alpha(q)*, PDGF stimulated DNA synthesis up to 3-fold over basal. Concomitant with the potentiation of PDGF-stimulated DNA synthesis, expression of alpha(q)* potentiated PDGF-stimulated p44 MAP kinase activity. PDGF was much more effective in stimulating both DNA synthesis and p44 MAP kinase activity in subconfluent cell cultures and expression of alpha(q)* exerted little or no effect on PDGF-stimulated effects in subconfluent cells. These data show that cooperation between signaling pathways may occur in a cell state-specific fashion. Such cooperation in part may be responsible for the triggering of complex cellular responses such as cell transformation.			DEVIVO, M (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029, USA.				NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HESLEY L, 1992, MOL BIOL CELL, V3, P545; JHON DY, 1993, J BIOL CHEM, V268, P6654; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SMRKA A, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WU DQ, 1992, J BIOL CHEM, V267, P1811	20	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19671	19674						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051041				2022-12-27	WOS:A1994PA12600004
J	WOLLBERG, P; SODERQVIST, H; NELSON, BD				WOLLBERG, P; SODERQVIST, H; NELSON, BD			MITOGEN ACTIVATION OF HUMAN PERIPHERAL T-LYMPHOCYTES INDUCES THE FORMATION OF NEW CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN NUCLEAR-COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 SYNTHESIS; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; ANTIGEN RECEPTOR; FACTOR CREB; CAMP; CELLS; PHOSPHORYLATION; INHIBITION; KINASE	A large body of evidence indicates that experimental agents which raise cellular cAMP levels inhibit T cell growth and division. By contrast, many studies have reported that mitogen activation of T cells increases cAMP levels, implying a positive physiological role for cAMP in the activation process. In the present study we demonstrate that mitogen activation of human peripheral T lymphocytes induces nuclear factors that form complexes with cyclic AMP response element-binding protein (CREB). Four complexes are identified by the electrophoretic mobility shift assay, two of which are induced by mitogen activation. All four complexes contain CREB and are bound to the cAMP response element (CRE) core sequence (TGACGTCA), as indicated by antibody and oligonucleotide competition experiments. Binding of the four complexes to CRE is prevented by dephosphorylation of nuclear extracts and is restored by rephosphorylation with cAMP dependent protein kinase or endogenous kinases. Similar complexes are detected in nuclear extracts of Jurkat cells. Mitogen induction of the electrophoretic mobility shift assay complexes is not accounted for by protein phosphorylation or by induction of CREB. Rather, the data indicate that mitogen increases the levels of a nuclear factor(s) that dimerizes with CREB. Induction of new CREE complexes implies a physiological role for cAMP in mitogen activation of T lymphocytes.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University								AUSSEL C, 1988, J IMMUNOL, V140, P215; BOHM S, 1993, J BIOL CHEM, V268, P3952; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRAR WL, 1987, J IMMUNOL, V139, P2075; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUKASAWA KM, 1986, BIOCHEM J, V235, P435, DOI 10.1042/bj2350435; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; HADDEN JW, 1976, P NATL ACAD SCI USA, V73, P1717, DOI 10.1073/pnas.73.5.1717; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOU EW, 1987, BIOCHEM BIOPH RES CO, V147, P501, DOI 10.1016/S0006-291X(87)80149-3; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; KAEVER V, 1985, BIOCHIM BIOPHYS ACTA, V846, P216, DOI 10.1016/0167-4889(85)90068-0; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KWASTWELFELD J, 1989, J BIOL CHEM, V264, P6941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LERNER A, 1988, J IMMUNOL, V140, P936; LINGK DS, 1990, J IMMUNOL, V145, P449; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARJANOVIC S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P1, DOI 10.1016/0167-4781(90)90113-G; MARJANOVIC S, 1988, BIOCHIM BIOPHYS ACTA, V970, P372; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARY D, 1987, J IMMUNOL, V139, P1179; MARY D, 1989, J BIOL CHEM, V264, P14498; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MIROSSAY L, 1992, INT J ONCOL, V1, P373; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUNOZ E, 1990, J IMMUNOL, V144, P964; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAKIGAWA M, 1981, CELL IMMUNOL, V58, P29, DOI 10.1016/0008-8749(81)90146-5; WANG T, 1978, SCIENCE, V201, P155, DOI 10.1126/science.208147; WATSON J, 1976, J IMMUNOL, V117, P1656; WEDNER HJ, 1975, J IMMUNOL, V115, P1682; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	51	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19719	19724						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051051				2022-12-27	WOS:A1994PA12600014
J	GOODMAN, L; STEIN, GH				GOODMAN, L; STEIN, GH			BASAL AND INDUCED AMOUNTS OF INTERLEUKIN-6 MESSENGER-RNA DECLINE PROGRESSIVELY WITH AGE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-DIPLOID FIBROBLASTS; INVITRO PROLIFERATIVE CAPACITY; DIFFERENTIATION FACTOR BSF-2; RETINOBLASTOMA GENE-PRODUCT; SENESCENT HUMAN-FIBROBLASTS; DNA-SYNTHESIS; GROWTH-FACTOR; DONOR AGE; INFECTIOUS-DISEASES	Interleukin-6 (IL-6) is a multi-functional cytokine that plays a role in the body's response to injury and infection. IL-6 expression is induced in young human diploid fibroblasts (HDF) in response to a number of agents including fetal bovine serum, 12-O-tetradecanoylphorbol-13-acetate, double-stranded RNA, and forskolin. In contrast, we find that senescent HDF are markedly deficient in their ability to express IL-6 in response to serum, double-stranded RNA, and 12-O-tetradecanoylphorbol-13-acetate, whereas forskolin is still an effective inducer for senescent cells. Thus, specific pathways for stimulating IL-6 expression appear to be blocked in senescent HDF. The basal amount of IL-6 mRNA in unstimulated senescent HDF is also much lower than in unstimulated young quiescent HDF. Likewise, the amount of IL-6 protein produced by senescent HDF is decreased at least 10-fold. Both the basal and induced levels of IL-6 declined progressively with aging of the HDF in culture, e.g. IL-6 cannot be induced above the young basal level by approximately 65% of life span completed. If a similar decrease in IL-6 expression takes place in HDF in vivo, it could contribute to the decline in wound healing and the increase in the number and severity of infections experienced by aged individuals.			GOODMAN, L (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, CAMPUS BOX 347, BOULDER, CO 80309 USA.			Goodman, Laurie/0000-0001-9724-5976	NIA NIH HHS [AG00947, AG05579] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERMAN EL, 1978, IN VITRO CELL DEV B, V14, P951; BRUCE SA, 1991, EXP GERONTOL, V26, P17, DOI 10.1016/0531-5565(91)90058-T; BRUCE SA, 1986, MECH AGEING DEV, V34, P151, DOI 10.1016/0047-6374(86)90032-1; BURMER GC, 1982, J CELL BIOL, V94, P187, DOI 10.1083/jcb.94.1.187; CHEN KY, 1986, J CELL PHYSIOL, V128, P27, DOI 10.1002/jcp.1041280106; CHEN YF, 1993, EXP GERONTOL, V28, P145, DOI 10.1016/0531-5565(93)90004-W; CHOI HS, 1990, J BIOL CHEM, V265, P18005; DAYNES RA, 1993, J IMMUNOL, V150, P5219; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; DUNCAN MR, 1991, J INVEST DERMATOL, V97, P686, DOI 10.1111/1523-1747.ep12483971; FORD HR, 1989, ARCH SURG-CHICAGO, V124, P1422; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FOSTER KD, 1992, AM J PHYSIOL, V262, pR211, DOI 10.1152/ajpregu.1992.262.2.R211; GLADSTONE JL, 1976, MED CLIN N AM, V60, P1225, DOI 10.1016/S0025-7125(16)31878-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANUKOGLU I, 1983, J MOL BIOL, V163, P673, DOI 10.1016/0022-2836(83)90117-1; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HELFGOTT DC, 1987, J EXP MED, V166, P1300, DOI 10.1084/jem.166.5.1300; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; KOHASE M, 1987, J CELL PHYSIOL, V132, P271, DOI 10.1002/jcp.1041320211; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; MARTIN GM, 1970, LAB INVEST, V23, P86; MAY LT, 1986, P NATL ACAD SCI USA, V83, P8957, DOI 10.1073/pnas.83.23.8957; MILLER D, 1991, J GERONTOL, V46, pM176, DOI 10.1093/geronj/46.5.M176; NISHIDA T, 1992, J CELL PHYSIOL, V153, P1, DOI 10.1002/jcp.1041530102; NORMAN DC, 1988, J GERONTOL, V43, pM80, DOI 10.1093/geronj/43.4.M80; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; PEREIRASMITH OM, 1985, EXP CELL RES, V160, P297, DOI 10.1016/0014-4827(85)90177-6; PEREIRASMITH OM, 1982, SOMAT CELL GENET, V8, P731, DOI 10.1007/BF01543015; QUIRINIA A, 1991, MECH AGEING DEV, V58, P221, DOI 10.1016/0047-6374(91)90094-G; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUWE WD, 1988, EXP GERONTOL, V23, P103, DOI 10.1016/0531-5565(88)90075-7; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SEHGAL PB, 1987, P NATL ACAD SCI USA, V84, P3663, DOI 10.1073/pnas.84.11.3663; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STAATZ WD, 1980, INVEST OPHTH VIS SCI, V19, P983; STEIN GH, 1982, P NATL ACAD SCI-BIOL, V79, P5287, DOI 10.1073/pnas.79.17.5287; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; Stenn K.S., 1988, MOL CELLULAR BIOL WO, P321; TASSIN J, 1979, EXP CELL RES, V123, P388, DOI 10.1016/0014-4827(79)90483-X; WALTHER Z, 1988, J IMMUNOL, V140, P974; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; WEI J, 1992, LIFE SCI, V51, P1953, DOI 10.1016/0024-3205(92)90112-3; WILBRINK B, 1991, BRIT J RHEUMATOL, V30, P265; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6; YOSHIKAWA TT, 1983, J AM GERIATR SOC, V31, P34, DOI 10.1111/j.1532-5415.1983.tb06285.x; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	64	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19250	19255						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034686				2022-12-27	WOS:A1994NY33200011
J	KUBO, M; KINCAID, RL; RANSOM, JT				KUBO, M; KINCAID, RL; RANSOM, JT			ACTIVATION OF THE INTERLEUKIN-4 GENE IS CONTROLLED BY THE UNIQUE CALCINEURIN-DEPENDENT TRANSCRIPTIONAL FACTOR NF(P)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-T CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; REGULATORY ELEMENTS; MESSENGER-RNA; CROSS-LINKAGE; FC-EPSILON; NON-B; PROMOTER; EXPRESSION	Cyclosporin A sensitive promoter activity that is induced by the T cell antigen receptor was identified in the region between base pairs -147 and -17 of the mouse interleukin (IL)-4 gene. Here, we identify a transcriptional factor, NF(P), that binds a sequence from -75 to -69 (ATTTTCC) of the mouse IL-4 gene which corresponds to the human IL-4 gene P sequence. Expression of NF(P) was associated with positive regulation of the IL-4 gene and cyclosporin A sensitivity. The P sequence is homologous to the binding site for the positive transcriptional regulator of the IL-2 gene nuclear factor of activated T cells (NFAT). Binding of NF(P) to the P sequence was completely inhibited by an oligonucleotide corresponding to the NFAT binding site. Like NFAT, NF(P) was also found in the cytosol of resting T cells but translocated to the nucleus via a cyclosporin A-sensitive mechanism after T cell activation. Overexpression of a constitutively active calcineurin caused translocation of NF(P) from the cytosol to the nucleus. NF(P) purified on an oligonucleotide affinity column was 90 kDa, which is smaller than the 12O-kDa reported for cNFAT. Purified NP(P) did not bind the NFAT consensus sequence, even in the presence of AP-1 protein. Our results suggest that the NF(P) molecule is not identical to the cNFAT molecule.	SYNTEX INC,DISCOVERY RES,DEPT INFLAMMAT BIOL & IMMUNOL,PALO ALTO,CA 94304; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Syntex Corporation; GlaxoSmithKline; Human Genome Sciences Inc								ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; EMMEL EA, 1989, SCIENCE, V246, P1618; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NORTHROP JP, 1994, IN PRESS NATURE; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PICCINNI MP, 1991, P NATL ACAD SCI USA, V88, P8656, DOI 10.1073/pnas.88.19.8656; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TARA D, 1993, J IMMUNOL, V151, P3617; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TOKUMITSU H, 1993, BIOCHEM BIOPH RES CO, V196, P737, DOI 10.1006/bbrc.1993.2311; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WANG SC, 1991, TRANSPLANT P, V23, P2920	32	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19441	19446						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034712				2022-12-27	WOS:A1994NY33200039
J	LEE, RT; YANG, GC; KIANG, J; BINGHAM, JB; GOLGHER, D; LEE, YC				LEE, RT; YANG, GC; KIANG, J; BINGHAM, JB; GOLGHER, D; LEE, YC			MAJOR LECTIN OF ALLIGATOR LIVER IS SPECIFIC FOR MANNOSE L-FUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; GALACTOSIDE-BINDING PROTEIN; LIGAND-BINDING; CLUSTER GLYCOSIDES; RABBIT HEPATOCYTES; RECEPTOR; GLYCOPROTEINS; ACETYLGALACTOSAMINE; IMMOBILIZATION; ENDOCYTOSIS	We surveyed the calcium-requiring (C-type) lectins in alligator liver. The major lectin purified by affinity chromatography was termed alligator hepatic lectin (AHL) and was found to be specific for mannose/L-fucose. AHL contained approximately equal amounts of 21- and 23-kDa bands upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Binding characteristics of AHL were similar to those of hepatic lectins of other classes in that 1) only terminal monosaccharide was recognized, and 2) the affinity increased exponentially when neoglycoproteins containing increasing numbers of mannose or L-fucose were used as ligand. However, unlike mammalian and chicken hepatic lectins, which exist as hexamers in Triton-containing solutions, AHL was present mainly as monomers, although small amounts of dimer and higher oligomers were present in equilibrium. Mannose binding proteins and mannose-specific lectins of macrophages bind N-acetylmannosamine, glucose, and N-acetylglucosamine in addition to mannose, indicating that the nature and orientation of the C-2 substituent are not important to these lectins. In contrast, AHL shows a strict requirement for the presence of an axial hydroxyl group at the C-2 position (i.e. mannose).	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University	LEE, RT (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-09970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL N, 1993, J BIOL CHEM, V268, P14932; ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CONNOLLY DT, 1981, J BIOL CHEM, V256, P2940; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FUKUDA M, 1971, BIOCHEM J, V123, P407, DOI 10.1042/bj1230407; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; KAWASAKI T, 1987, VERTEBRATE LECTINS, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; Lee Y C, 1988, Adv Exp Med Biol, V228, P105; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; LEE YC, 1982, GLYCOCONJUGATES, V4, P57; LEHMAN MA, 1986, J BIOL CHEM, V261, P7419; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LUNNEY J, 1976, P NATL ACAD SCI USA, V73, P341, DOI 10.1073/pnas.73.2.341; MORI K, 1983, ARCH BIOCHEM BIOPHYS, V222, P542, DOI 10.1016/0003-9861(83)90552-0; NEUMANN NP, 1967, BIOCHEMISTRY-US, V6, P468, DOI 10.1021/bi00854a015; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Porath J, 1976, Methods Enzymol, V44, P19; REGOECZI E, 1975, NATURE, V254, P699, DOI 10.1038/254699a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STULTS NL, 1983, ANAL BIOCHEM, V135, P392, DOI 10.1016/0003-2697(83)90701-7; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; WEIGEL PH, 1979, CARBOHYD RES, V70, P83, DOI 10.1016/S0008-6215(00)83272-3	36	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19617	19625						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034730				2022-12-27	WOS:A1994NY33200065
J	SCHLENSOG, V; LUTZ, S; BOCK, A				SCHLENSOG, V; LUTZ, S; BOCK, A			PURIFICATION AND DNA-BINDING PROPERTIES OF FHLA, THE TRANSCRIPTIONAL ACTIVATOR OF THE FORMATE HYDROGENLYASE SYSTEM FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CLONING VECTORS; DEHYDROGENASE; EXPRESSION; SEQUENCES; OPERON; PROMOTERS; PROTEIN; FDHF; PHOSPHORYLATION	FHLA is the transcriptional activator for the expression of the genes coding for components of the formate hydrogenlyase system of Escherichia coli. The cloned FhlA gene was overexpressed under selected growth conditions, and a purification protocol for the FHLA protein was developed. Purified FHLA in the native state is a homotetramer. It binds to the upstream regulatory sequences of the fdhF gene and of the intergenic region between the divergently transcribed hyc and hyp operons. An additional binding site of FHLA located between the hycA and hycB genes was identified. While binding to the hypA-hycA intergenic region is responsible for activation of expression of the hyc operon, the newly identified site is required for the activation of the sigma(54)-dependent promoter located upstream of the hyp operon. Formate seems to have no effect on the DNA binding properties of FHLA. The binding sites of FHLA were characterized by DNase I footprinting; sequence motifs putatively involved in the interaction with FHLA are described.	UNIV MUNICH,LEHRSTUHL MIKROBIOL,D-80638 MUNICH,GERMANY	University of Munich								BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; BEGG YA, 1977, FEMS MICROBIOL LETT, V2, P47, DOI 10.1111/j.1574-6968.1977.tb00905.x; BERGER SL, 1987, METHOD ENZYMOL, V152, P725; BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BIRKMANN A, 1987, MOL GEN GENET, V210, P535, DOI 10.1007/BF00327209; BIRKMANN A, 1987, ARCH MICROBIOL, V148, P44, DOI 10.1007/BF00429646; BIRKMANN A, 1989, MOL MICROBIOL, V3, P697, DOI 10.1111/j.1365-2958.1989.tb00218.x; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; BUCHANANWOLLASTON V, 1981, NATURE, V294, P776, DOI 10.1038/294776a0; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRAY CP, 1978, P NATL ACAD SCI USA, V75, P50, DOI 10.1073/pnas.75.1.50; HOPPER S, 1994, J BIOL CHEM, V269, P19597; KARUBE I, 1984, FEMS MICROBIOL LETT, V25, P165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; LUTZ S, 1990, MOL MICROBIOL, V4, P13, DOI 10.1111/j.1365-2958.1990.tb02010.x; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; PECHER A, 1985, ARCH MICROBIOL, V141, P359, DOI 10.1007/BF00428850; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; ROSSMANN R, 1991, MOL MICROBIOL, V5, P2807, DOI 10.1111/j.1365-2958.1991.tb01989.x; Sambrook J, 1989, MOL CLONING LABORATO; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; SCHLENSOG V, 1989, ARCH MICROBIOL, V152, P83, DOI 10.1007/BF00447016; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19590	19596						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034727				2022-12-27	WOS:A1994NY33200061
J	KUROSAWA, N; KOJIMA, N; INOUE, M; HAMAMOTO, T; TSUJI, S				KUROSAWA, N; KOJIMA, N; INOUE, M; HAMAMOTO, T; TSUJI, S			CLONING AND EXPRESSION OF GAL-BETA-1,3GALNAC-SPECIFIC GALNAC ALPHA-2,6-SIALYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE GENE FAMILY; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; CARBOHYDRATE STRUCTURES; MOLECULAR-CLONING; BIOSYNTHESIS; FETUIN	A cDNA clone encoding a new type of GalNAc alpha 2,6-sialyltransferase (ST6GalNAc II) with a structure similar to that of a previously cloned GalNAc alpha 2,6-sialyltransferase (ST6GalNAc I; Kurosawa, N., Hamamoto, T., Lee, Y.-C., Nakaoka, T., Kojima, N., and Tsuji, S. (1994) J. Biol. Chem. 269, 1402-1409) was obtained from chicken testes. The predicted amino acid sequence of ST6GalNAc II encodes a protein with type II transmembrane topology, as found for other glycosyltransferases, and showed 32% identity with that of ST6GalNAc I. Transfection of the full length ST6GalNAc II gene into COS cells led to GalNAc alpha 2,6-sialyltransferase activity with a different substrate specificity from that of ST6GalNAc I. Moreover, asialofetuin after treatment with P-galactosidase did not serve as an acceptor for this enzyme. C-14-Sialylated oligosaccharides obtained from resialylated asialobovine submaxillary mucin with this enzyme were identical to Gal beta 1,3([C-14]NeuAc alpha 2,6)GalNAc-ol but not [C-14]NeuAc alpha 2,6GalNAc-ol. These results clearly show that the expressed enzyme is a novel type of sialyltransferase that requires beta-galactoside residues linked to GalNAc residues, whereas sialic acid residues linked to galactose residues are not essential for the activity.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,DEPT GLYCO MOLEC BIOL,WAKO,SAITAMA 35101,JAPAN	RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BERGH MLE, 1983, J BIOL CHEM, V258, P7430; CARLSON DM, 1968, J BIOL CHEM, V243, P616; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRUNDLER G, 1984, LIEBIGS ANN CHEM, P1826; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; KIMBER SJ, 1989, BIOCHEM SOC T, V17, P23, DOI 10.1042/bst0170023; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; OEMRAWSINGH I, 1974, ARCH ORAL BIOL, V19, P615, DOI 10.1016/0003-9969(74)90129-0; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; REARICK JI, 1979, J BIOL CHEM, V254, P4444; Roos E, 1984, Biochim Biophys Acta, V738, P263; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEIGANDT H, 1967, J NEUROCHEM, V14, P671; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011	38	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19048	19053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034663				2022-12-27	WOS:A1994NX32700053
J	LAPIDUS, RG; SOKOLOVE, PM				LAPIDUS, RG; SOKOLOVE, PM			THE MITOCHONDRIAL PERMEABILITY TRANSITION - INTERACTIONS OF SPERMINE, ADP, AND INORGANIC-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; INNER MEMBRANE; CYCLOSPORINE-A; INHIBITION; MECHANISM; PORE; NUCLEOTIDES	Mitochondria that have accumulated Ca2+ can be induced to undergo a permeability transition: the inner membrane becomes nonselectively permeable to small (<1500 daltons) solutes. Our laboratory has recently identified the polyamine spermine as an inhibitor of the permeability transition of isolated rat heart and liver mitochondria. Here, we have used swelling of liver mitochondria as an indicator of transition occurrence to investigate the connection between spermine, another transition antagonist, ADP, and several key triggering agents: P-i, Ca2+, and t-butyl hydroperoxide (t-BH). Our results demonstrate that: 1) ADP strongly inhibits only the swelling induced by P-i; transitions induced by t-BH and Ca2+ are minimally affected. 2) The sensitivity of the permeability transition to P-i is enhanced in mitochondria depleted of adenine nucleotides. 3) Incubation with P-i decreases mitochondrial ADP and ATP content. 4) Spermine inhibits less well in adenine nucleotide-depleted than control mitochondria, regardless of triggering agent. 5) Spermine and ADP act synergistically to inhibit the transition. 6) ADP replenishment makes P-i a worse triggering agent. Triggering by Ca2+ and t-BH is enhanced. 7) P-i overcomes spermine inhibition; Ca2+ and t-BH do not. We propose that P-i triggers the transition by lowering the matrix concentration of the inhibitor ADP and that spermine inhibits the transition by enhancing ADP effectiveness. In addition, these data clearly distinguish the triggering action of P-i from that of Ca2+ and t-BH.	UNIV MARYLAND, SCH MED, DEPT PHARMACOL & EXPTL THERAPEUT, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore								ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ASIMAKIS G, 1988, AM J PHYSIOL, V241, P11672; AUSTIN J, 1984, J BIOL CHEM, V259, P154; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; DIXON M, 1979, ENZYMES, P137; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HILLE B, 1992, IONIC CHANNELS EXCIT, P62; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V855, P201, DOI 10.1016/0005-2736(86)90166-5; KRASINSKAYA IP, 1991, FEBS LETT, V290, P52, DOI 10.1016/0014-5793(91)81223-U; LAPIDUS RG, 1992, FEBS LETT, V313, P314, DOI 10.1016/0014-5793(92)81217-A; LAPIDUS RG, 1993, ARCH BIOCHEM BIOPHYS, V306, P246, DOI 10.1006/abbi.1993.1507; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; MEISNER H, 1968, J BIOL CHEM, V243, P3631; NOSEK MT, 1992, ARCH BIOCHEM BIOPHYS, V296, P691, DOI 10.1016/0003-9861(92)90628-A; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; SOKOLOVE PM, 1993, BIOPHYS J, V64, pA79; TEDESCHI H, 1958, BIOCHIM BIOPHYS ACTA, V58, P52; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139	33	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18931	18936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034650				2022-12-27	WOS:A1994NX32700037
J	MALY, FE; QUILLIAM, LA; DORSEUIL, O; DER, CJ; BOKOCH, GM				MALY, FE; QUILLIAM, LA; DORSEUIL, O; DER, CJ; BOKOCH, GM			ACTIVATED OR DOMINANT INHIBITORY MUTANTS OF RAP1A DECREASE THE OXIDATIVE BURST OF EPSTEIN-BARR VIRUS-TRANSFORMED HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; CHRONIC GRANULOMATOUS-DISEASE; NADPH OXIDASE ACTIVATION; CELL-LINES; SUPEROXIDE GENERATION; HUMAN-NEUTROPHILS; CYTOCHROME-B; RAS; LYMPHOBLASTS; SYSTEM	Rap1A is a GTP-binding protein of the Ras superfamily that is highly abundant in phagocyte membranes. Although Rap1A copurifies with cytochrome b(558), a component of the superoxide-generating NADPH oxidase complex of human phagocytes and B lymphocytes, the involvement of Rap1A in the regulation of the oxidative burst in these cells has not been clearly established. Therefore, we have stably transfected human Epstein-Barr virus-transformed B lymphocytes that possess an activable NADPH oxidase complex with cDNAs for mutants of Rap1A ''locked'' in a GTP-bound (63E) and GDP-bound (17N) state. Both the 17N and 63E mutants of Rap1A inhibited phorbol ester-stimulated O-2(radical-anion) production by 50 and 80%, respectively, while transfection with cDNA for wild-type Rap1A had no effect on the respiratory burst. No effects of the Rap1A mutants on cell viability proliferation, expression of cell-surface markers, or phorbol 12-myristate 13-acetate stimulated interleukin-8 generation were detected. These data demonstrate that Rap1A is a regulator of O-2(radical-anion) formation in intact cells. Furthermore, the inhibitory effect of both GTP as well as GDP-bound mutants indicates that Rap1A functions in a dynamic cycle as opposed to a unidirectional pathway, as is the case for the other NADPH oxidase regulatory GTP-binding protein, Rac.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; Scripps Research Institute	MALY, FE (corresponding author), UNIV ZURICH, INST PHYSIOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NIGMS NIH HHS [GM44428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURUKAWA K, 1992, SCAND J IMMUNOL, V35, P561, DOI 10.1111/j.1365-3083.1992.tb03255.x; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HANCOCK JT, 1989, BIOCHEM J, V262, P373, DOI 10.1042/bj2620373; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; MALY FE, 1989, J IMMUNOL, V142, P1260; MALY FE, 1988, ANAL BIOCHEM, V168, P462, DOI 10.1016/0003-2697(88)90344-2; MALY FE, 1988, J IMMUNOL, V140, P2334; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUERERMALY CC, 1994, IMMUNOLOGY, V81, P85; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SMYTH MJ, 1991, J IMMUNOL, V146, P3815; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; UCKUN FM, 1990, BLOOD, V76, P1908; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006	34	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18743	18746						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034626				2022-12-27	WOS:A1994NX32700011
J	MOFFAT, JG; TATE, WP				MOFFAT, JG; TATE, WP			A SINGLE PROTEOLYTIC CLEAVAGE IN RELEASE FACTOR-2 STABILIZES RIBOSOME BINDING AND ABOLISHES PEPTIDYL-TRANSFER-RNA HYDROLYSIS ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; FACTOR-II; TRANSFER RNA; CHAIN TERMINATION; PROTEINS; SUBUNIT; DOMAIN	The structural and functional organization of Escherichia coli polypeptide chain release factors 1 and 2 (RF-1 and RF-2) was investigated by limited proteolysis with trypsin and chymotrypsin. A protease-sensitive site was found in a similar position in both factors at the beginning of a highly conserved region in the C-terminal part of the proteins. Chymotrypsin cleavage of RF-2 yielded a nicked form with the fragments associated. This nicked factor lost in vitro peptidyl-tRNA hydrolysis activity (a peptidyltransferase function) but had enhanced in vitro codon-ribosome binding activity (a decoding site function). It inhibited codon-dependent f[H-3]Met-tRNA hydrolysis activity of intact RF-1 and RF-2, presumably as a result of an increased affinity for ribosomes. These data are consistent with a model whereby the release factor acts like a tRNA analog spanning the decoding and peptidyltransferase centers on the ribosome. The proteolytic sensitivity of the RFs most likely reflects an exposed surface loop. We propose that this loop interacts with the ribosomal peptidyltransferase site and that the stabilization of factor:ribosome binding upon cleavage could be explained by conformational coupling between domains on the factor for codon-ribosome binding at the decoding site and interraction with peptidyltransferase.	UNIV OTAGO,DEPT BIOCHEM,DUNEDIN,NEW ZEALAND; UNIV OTAGO,CTR GENE RES,DUNEDIN,NEW ZEALAND	University of Otago; University of Otago								BROWN CM, 1993, NUCLEIC ACIDS RES, V12, P2109; CASKEY CT, 1971, P NATL ACAD SCI USA, V68, P3163, DOI 10.1073/pnas.68.12.3163; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; JORGENSEN F, 1993, J MOL BIOL, V230, P41, DOI 10.1006/jmbi.1993.1124; KURLAND CG, 1990, RIBOSOME, P513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOFFAT JG, 1991, BIOCHIMIE, V73, P1113, DOI 10.1016/0300-9084(91)90154-S; MOFFAT JG, 1993, EUR J BIOCHEM, V231, P749; NIERHAUS KH, 1993, MOL MICROBIOL, V9, P661, DOI 10.1111/j.1365-2958.1993.tb01726.x; NOLLER HF, 1993, FASEB J, V7, P87, DOI 10.1096/fasebj.7.1.8422979; OLSON HM, 1991, J BIOL CHEM, V266, P1898; PASCARELLA S, 1992, J MOL BIOL, V224, P461, DOI 10.1016/0022-2836(92)91008-D; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; RHEINBERGER HJ, 1990, RIBOSOME, P318; STOFFLER G, 1982, J BIOL CHEM, V257, P4203; SUMPTER VG, 1991, EUR J BIOCHEM, V196, P255, DOI 10.1111/j.1432-1033.1991.tb15812.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; TATE WP, 1984, J BIOL CHEM, V259, P7317; TATE WP, 1986, J BIOL CHEM, V261, P2289; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; VOGEL Z, 1969, BIOCHEMISTRY-US, V8, P5161, DOI 10.1021/bi00840a070	24	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18899	18903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034646				2022-12-27	WOS:A1994NX32700033
J	RADLEY, E; ALDERTON, RP; KELLY, A; TROWSDALE, J; BECK, S				RADLEY, E; ALDERTON, RP; KELLY, A; TROWSDALE, J; BECK, S			GENOMIC ORGANIZATION OF HLA-DMA AND HLA-DMB - COMPARISON OF THE GENE ORGANIZATION OF ALL 6 CLASS-II FAMILIES IN THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; EXON-INTRON ORGANIZATION; NF-KAPPA-B; BETA GENE; EDITING PROGRAM; GLOBIN GENE; CHAIN GENE; DP REGION; DQ-ALPHA; ANTIGEN	The genomic nucleotide sequences of HLA-DMA and HLA-DMB have been determined and their gene organizations have been compared with other human class II genes. The following features were found to be highly conserved throughout all human class II families. (i) All alpha genes are composed of 5 exons and all beta genes of 6 exons. (ii) The intron exon boundary classes of exons 1-4 (alpha genes) and exons 1-5 (beta genes) are 100% conserved. Only the last boundary class which falls within the cytoplasmic domain appears to be variable. (ii) The size of exon 3 (membrane proximal domain) is also 100% conserved except for DMA (-1 codon) and DMB (+1 codon). The position and a possible functional implication of this deletion/insertion are discussed. Our findings confirm and extend the evidence based on sequence homology that DMA and DMB are different from typical class II genes suggesting that they may originate from a time prior to the divergence of the main class II genes. In addition we have identified various new repeat sequences within class II genes. Analysis of their classification and distribution reveal single and multiple repeat mediated recombination events. One of these events seems to have partially replaced exon 1 in DPA2. The possibility of this event causing DPA2 to become a pseudogene is discussed.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ANDERSSON G, 1987, J BIOL CHEM, V262, P8748; AUFFRAY C, 1987, IMMUNOGENETICS, V26, P63, DOI 10.1007/BF00345456; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BANVILLE D, 1989, J MOL BIOL, V207, P481, DOI 10.1016/0022-2836(89)90458-0; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BECK S, 1993, ANAL BIOCHEM, V212, P498, DOI 10.1006/abio.1993.1359; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLANCK G, 1990, HUM IMMUNOL, V27, P265, DOI 10.1016/0198-8859(90)90056-U; BOSS JM, 1985, MOL CELL BIOL, V5, P2677, DOI 10.1128/MCB.5.10.2677; BOSS JM, 1984, P NATL ACAD SCI-BIOL, V81, P5199, DOI 10.1073/pnas.81.16.5199; BRIATA P, 1989, P NATL ACAD SCI USA, V86, P1003, DOI 10.1073/pnas.86.3.1003; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; Finnegan DJ, 1992, CURR OPIN GENET DEV, V2, P861, DOI 10.1016/S0959-437X(05)80108-X; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GORGA JC, 1992, CRIT REV IMMUNOL, V11, P305; GRAHOVAC B, 1993, HUM IMMUNOL, V37, P75, DOI 10.1016/0198-8859(93)90145-Q; GUSTAFSSON K, 1987, J BIOL CHEM, V262, P8778; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; HUGHES AL, 1993, IMMUNOGENETICS, V37, P337, DOI 10.1007/BF00216798; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JONSSON AK, 1987, J BIOL CHEM, V262, P8767; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KASAHARA M, 1992, P NATL ACAD SCI USA, V89, P6688, DOI 10.1073/pnas.89.15.6688; KELLY A, 1985, NUCLEIC ACIDS RES, V13, P1607, DOI 10.1093/nar/13.5.1607; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KHURSHID F, 1993, ANAL BIOCHEM, V208, P138, DOI 10.1006/abio.1993.1019; KLEIN J, 1986, NATURAL HIST MAJOR H; LARHAMMAR D, 1983, P NATL ACAD SCI-BIOL, V80, P7313, DOI 10.1073/pnas.80.23.7313; LAWRANCE SK, 1985, NUCLEIC ACIDS RES, V13, P7515, DOI 10.1093/nar/13.20.7515; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; MAYER WE, 1993, P NATL ACAD SCI USA, V90, P10720, DOI 10.1073/pnas.90.22.10720; NEEFJES JJ, 1993, CURR OPIN IMMUNOL, V5, P27, DOI 10.1016/0952-7915(93)90077-6; ONO H, 1993, IMMUNOGENETICS, V38, P223; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANDERSON F, 1994, IMMUNOGENETICS, V39, P56; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAMBOECK A, 1983, NUCLEIC ACIDS RES, V11, P8663, DOI 10.1093/nar/11.24.8663; SCHENNING L, 1984, EMBO J, V3, P447, DOI 10.1002/j.1460-2075.1984.tb01826.x; SCHNEIDER S, 1991, MOL BIOL EVOL, V8, P753; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; STADEN R, 1987, COMPUTER HANDLING DN, P173; SUGAWARA M, 1991, P NATL ACAD SCI USA, V88, P10347, DOI 10.1073/pnas.88.22.10347; SULTMANN H, 1993, IMMUNOGENETICS, V38, P408, DOI 10.1007/BF00184521; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG JAT, 1985, NUCLEIC ACIDS RES, V13, P8883, DOI 10.1093/nar/13.24.8883	63	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18834	18838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034636				2022-12-27	WOS:A1994NX32700023
J	WICK, M; BURGER, C; BRUSSELBACH, S; LUCIBELLO, FC; MULLER, R				WICK, M; BURGER, C; BRUSSELBACH, S; LUCIBELLO, FC; MULLER, R			A NOVEL MEMBER OF HUMAN TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP) GENE FAMILY IS REGULATED DURING G(1) PROGRESSION, MITOGENIC STIMULATION, DIFFERENTIATION, AND SENESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PROMYELOCYTIC LEUKEMIA-CELLS; C-FOS GENE; HUMAN HEMATOPOIETIC-CELLS; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; MESSENGER-RNA; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PROTO-ONCOGENE	We have identified in the human diploid fibroblast cell line WI-38 a novel serum-inducible gene, mitogen-inducible gene 5 (mig-5), of the delayed-early class, which represents a new member of the family of human tissue inhibitors of metalloproteinases (TIMPs). The deduced Mig-5 protein shares the highest degree of homology with chicken TIMP-3 (74% identity) and is more distantly related to human TIMP-1 and TIMP-2 (30-38% identity), indicating that mig-5 may represent the human homolog of chicken TIMP-3. In contrast to TIMP-1 and TIMP-2, mig-5 mRNA expression is not only induced in response to mitogenic stimulation but also is subject to cell cycle regulation in normally proliferating WI-38 fibroblasts and HL-60 myeloid cells, showing a clear peak around mid-G(1). In agreement with this observation, differentiation of HL-60 cells to either granulocytic or macrophage-like cells leads to increased levels of mig-5 mRNA concomitant with a block in G(1). In contrast, mig-5 expression is decreased in senescent human fibroblasts, suggesting that these cells may be blocked at a stage in G(1) before or after the phase of maximum mig-5 expression. Since in contrast to the vast majority of other known mitogen-inducible genes, mig-5 expression is periodically up-regulated in G(1), this gene should represent an invaluable tool for the analysis of cell cycle progression, terminal differentiation, and replicative senescence.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRASELMANN S, 1992, J CELL SCI, P97; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BURGER C, 1994, J CELL SCI, V107, P241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUIS D, 1990, MOL CELL BIOL, V10, P4243; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KOEFFLER HP, 1980, BLOOD, V56, P344; KOEFFLER HP, 1983, BLOOD, V62, P709; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; MULLER R, 1983, MOL CELL BIOL, V3, P1062; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SEWING A, 1993, J CELL SCI, V104, P545; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VINCENT S, 1993, ONCOGENE, V8, P1603; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WICK M, 1994, J CELL SCI, V107, P227	65	133	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18953	18960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034652				2022-12-27	WOS:A1994NX32700040
J	GARCIAARRANZ, M; MALDONADO, AM; MAZON, MJ; PORTILLO, F				GARCIAARRANZ, M; MALDONADO, AM; MAZON, MJ; PORTILLO, F			TRANSCRIPTIONAL CONTROL OF YEAST PLASMA-MEMBRANE H+-ATPASE BY GLUCOSE - CLONING AND CHARACTERIZATION OF A NEW GENE INVOLVED IN THIS REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; INVIVO ACTIVATION; ESCHERICHIA-COLI; SENSITIVE METHOD; BINDING-FACTOR; PROTEIN; SEQUENCE; UPSTREAM; DOMAIN	The expression of the ATPase gene (PMA1) is regulated by glucose (Rao, R., Drummond-Barbosa, D., and Slayman, C. W. (1993) Yeast 9, 1075-1084) and by the TUF/RAP1/GRF1 transcription factor (Capieaux, E., Vignais, M.-L., Sentenac, A., and Goffeau, A (1989) J. Biol. Chem. 264, 7437-7446). In this work, we describe the isolation of mutations on seven genes that affect the levels of ATPase. One of these genes (APA1) was cloned by complementation and shown to encode a protein with six putative transmembrane stretches. Expression of APA1 gene is regulated by the carbon source and requires the protein GCR1. Deletion of APA1 causes a defective regulation of the PMA1 expression by glucose but has not noticeable effect on the expression of other TUF-regulated genes. Nevertheless the expression of glucose-repressible HXT3 and SNF3 genes is significantly reduced. These results suggest a model in which APA1 acts on a glucose-signaling pathway that controls the expression of several genes that are transcriptionally regulated by glucose.	UNIV AUTONOMA MADRID, FAC MED, INST INVEST BIOMED, CSIC, DEPT BIOQUIM, E-28029 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Garcia-Arranz, Mariano/L-7884-2019; Calpena, María Jesús Mazón/E-9168-2016	Calpena, María Jesús Mazón/0000-0003-4151-4051; Maldonado Alconada, Ana Maria/0000-0002-9357-012X; Portillo Perez, Francisco/0000-0003-4922-346X				AMIGO L, 1993, BIOCHIM BIOPHYS ACTA, V1151, P83, DOI 10.1016/0005-2736(93)90074-A; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BENITO B, 1992, FEBS LETT, V300, P271, DOI 10.1016/0014-5793(92)80861-A; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERASO P, 1987, FEBS LETT, V224, P187, DOI 10.1016/0014-5793(87)80445-3; ERASO P, 1987, EUR J BIOCHEM, V165, P671, DOI 10.1111/j.1432-1033.1987.tb11493.x; GABER RF, 1992, INT REV CYTOL, V137A, P299; GANCEDO JM, 1985, TRENDS BIOCHEM SCI, V10, P210, DOI 10.1016/0968-0004(85)90194-X; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1993, YEAST, V9, P691, DOI 10.1002/yea.320090703; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEER RJ, 1985, CURR GENET, V9, P273, DOI 10.1007/BF00419955; LENTZEN H, 1987, J BIOTECHNOL, V6, P281, DOI 10.1016/0168-1656(87)90059-9; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Miller J.H., 1972, EXPT MOL GENETICS; MONK BC, 1991, J BIOL CHEM, V266, P18097; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLIVER SG, 1992, NATURE, V357, P657; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1986, J BACTERIOL, V168, P1254, DOI 10.1128/jb.168.3.1254-1257.1986; RAO R, 1993, YEAST, V9, P1075, DOI 10.1002/yea.320091006; ROSA MF, 1991, APPL ENVIRON MICROB, V57, P830, DOI 10.1128/AEM.57.3.830-835.1991; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Serrano R., 1991, MOL CELLULAR BIOL YE, P523; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RJ, 1989, GENETICS, V112, P19; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; TORNOW J, 1993, EMBO J, V12, P2431, DOI 10.1002/j.1460-2075.1993.tb05897.x; TUDURI P, 1985, BIOCHEM BIOPH RES CO, V133, P917, DOI 10.1016/0006-291X(85)91223-9; UEMURA H, 1990, MOL CELL BIOL, V10, P6389, DOI 10.1128/MCB.10.12.6389; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	61	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18076	18082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027068				2022-12-27	WOS:A1994NV42200050
J	MUECKLER, M; KRUSE, M; STRUBE, M; RIGGS, AC; CHIU, KC; PERMUTT, MA				MUECKLER, M; KRUSE, M; STRUBE, M; RIGGS, AC; CHIU, KC; PERMUTT, MA			A MUTATION IN THE GLUT2 GLUCOSE-TRANSPORTER GENE OF A DIABETIC PATIENT ABOLISHES TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC BETA-CELLS; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; INSULIN-SECRETION; LIVER; SEQUENCE; HYPERGLYCEMIA; HOMEOSTASIS; CLONING; ISOFORM	Gluts2 the facilitative glucose transporter isoform expressed in pancreatic beta cells, is believed to play a role in glucose-stimulated insulin secretion. Two polymorphisms that result in amino acid substitutions have been reported in the human Glut2 gene (Tanizawa, Y., Riggs, A. C., Chiu, K. C., Janssen, R. C., Bell, D. S. H., Go, R. P. C., Roseman, J. M., Acton, R. T., and Permutt, M. A. (1994) Diabetologia 37, 420-427). A threonine 110 --> isoleucine substitution was present at equal frequency in diabetic and control populations, and a valine 197 --> isoleucine substitution was discovered in a single allele of a patient with non-insulin dependent diabetes. The effect of these amino acid changes on glucose transport activity was tested by expression of the mutant proteins in Xenopus oocytes. The polymorphism at threonine 110 had no effect on the expression of Glut2 protein or the uptake of 2-deoxyglucose. Remarkably, however, the highly conservative valine 197 --> isoleucine amino acid change abolished transport activity of the Glut2 transporter expressed in Xenopus oocytes. This represents the first known dysfunctional mutation in a human facilitative glucose transporter protein. The presence of this mutation in a diabetic patient suggests that defects in Glut2 expression may be causally involved in the pathogenesis of non-insulin dependent diabetes.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL)	MUECKLER, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK43695, DK38495, DK16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695, R01DK016746, R37DK016746, R01DK038495] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN C, 1992, DIABETES, V41, P1320, DOI 10.2337/diabetes.41.10.1320; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KELLER K, 1989, J BIOL CHEM, V264, P18884; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1986, NATURE, V322, P549, DOI 10.1038/322549a0; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; Schulz G. E., 1979, PRINCIPLES PROTEIN S; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; TANIZAWA Y, 1994, DIABETOLOGIA, V37, P420, DOI 10.1007/BF00408481; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409	24	85	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17765	17767						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027028				2022-12-27	WOS:A1994NV42200003
J	RUAN, HJ; HILL, JR; FATEMIENAINIE, S; MORRIS, DR				RUAN, HJ; HILL, JR; FATEMIENAINIE, S; MORRIS, DR			CELL-SPECIFIC TRANSLATIONAL REGULATION OF S-ADENOSYLMETHIONINE DECARBOXYLASE MESSENGER-RNA - INFLUENCE OF THE STRUCTURE OF THE 5' TRANSCRIPT LEADER ON REGULATION BY THE UPSTREAM OPEN READING FRAME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; MESSENGER-RNA; 5'-NONCODING SEQUENCES; INITIATION; GENE; SITE; AUG; SELECTION; RIBOSOMES; YEAST	A small upstream open reading frame (uORF), located 14 nucleotides from the cap in the 5' transcript leader (5' TL) of the mRNA encoding S-adenosylmethionine decarboxylase (AdoMetDC), suppresses translation of the downstream cistron in normal T cells and T cell lines. In the present study, we examined the structural features of the 5' TL that overcome this suppressive influence in cells of nonlymphoid origin. Initiation at the downstream cistron in nonlymphoid cells is by a cap-dependent mechanism that requires ribosome scanning along the 5' TL and does not involve an internal ribosome entry site. Extending the uORF so that it overlapped the major cistron by 101 nucleotides had no effect on translation of the downstream cistron in either HeLa or Jurkat cells. When the distance between the uORF and the cap was extended to 47 nucleotides, using sequence previously found to be neutral, translation of the major cistron was inhibited 5-fold in HeLa cells and the mRNA was moved from polysomes to monosomes, a location identical to that of the wild type mRNA in Jurkat cells. Therefore, in contrast to T cells, initiation at the uORF seems to be relatively infrequent in non-lymphoid cells due to its proximity to the cap, allowing efficient translation of the downstream cistron.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011		NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIGMS NIH HHS [GM07266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MACH M, 1986, J BIOL CHEM, V261, P1697; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMBROOK J, 1990, MOL CLONING LABORATO; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WHITE MW, 1988, PHYSL POLYAMINES, P331	37	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17905	17910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027046				2022-12-27	WOS:A1994NV42200026
J	XIA, HY; PUETT, D				XIA, HY; PUETT, D			IDENTIFICATION OF CONSERVED AMINO-ACID-RESIDUES IN THE BETA-SUBUNIT OF HUMAN CHORIOGONADOTROPIN IMPORTANT IN HOLOPROTEIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; ASPARAGINE-LINKED OLIGOSACCHARIDES; GLYCOPROTEIN HORMONES; LUTEINIZING-HORMONE; RECEPTOR-BINDING; ALPHA-SUBUNIT; BIOLOGICAL-ACTIVITY; DISULFIDE BONDS; CELLS	The beta subunits of mammalian glycoprotein hormones contain 20 invariant amino acid residues, including 12 Cys residues that form six disulfide bonds, as well as other highly conserved residues. Such stringent conservation suggests an important role for those residues in chain folding, holoprotein formation, or receptor binding/activation, but not receptor specificity. Using site-directed mutagenesis, we have prepared and characterized replacements of 14 conserved non-Cys residues in human choriogonadotropin beta for which there is little, if any, information available: Pro(7), Thr(32), Tyr(37), Thr(40), Val(56), Tyr(59), Phe(64), Pro(70), Gly(71), Ser(81), Tyr(82), Val(84), Ala(85), and Ser(87). The cDNAs were subcloned into a pRSV mammalian expression vector and transiently transfected into Chinese hamster ovary cells containing a stably integrated gene for bovine alpha. Holoprotein formation was assessed by radioimmunoassays, and in vitro competitive binding and steroidogenic assays were used to determine potencies. Our results demonstrated that Tyr(37), Thr(40), Tyr(59), and Ala(85) participate directly or indirectly in holoprotein formation, as may Ser(81). Replacements of the other conserved amino acid residues resulted in no significant change in subunit assembly or receptor binding/activation as measured, although an Arg at position 81 or 82 reduced secretion. This study has identified several amino acid residues of the beta subunit that are important in alpha binding and has raised interesting questions on the constraints that maintain conservation of amino acid residues during evolution.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,REPROD SCI LAB,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,ENDOCRINOL LAB,MIAMI,FL 33101	University System of Georgia; University of Georgia; University of Miami; University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P97, DOI 10.1677/jme.0.0050097; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN WY, 1991, J BIOL CHEM, V266, P6246; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; Gordon WL, 1985, LUTEINIZING HORMONE, P173; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG JN, 1993, J BIOL CHEM, V268, P9311; KAETZEL DM, 1985, P NATL ACAD SCI USA, V82, P7280, DOI 10.1073/pnas.82.21.7280; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MERZ WE, 1992, EXP CLIN ENDOCRINOL, V100, P4, DOI 10.1055/s-0029-1211164; MISE T, 1981, J BIOL CHEM, V256, P6587; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PUETT D, 1994, GLYCOPROTEIN HORMONE, P122; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337; XIA HY, 1993, MOL CELL ENDOCRINOL, V92, pR1, DOI 10.1016/0303-7207(93)90086-Y; ZERVOS PH, 1988, BIOTECHNIQUES, V6, P238	34	12	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17944	17953						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027052				2022-12-27	WOS:A1994NV42200032
J	BUCHBERGER, A; RAGGE, K; ARNOLD, HH				BUCHBERGER, A; RAGGE, K; ARNOLD, HH			THE MYOGENIN GENE IS ACTIVATED DURING MYOCYTE DIFFERENTIATION BY PREEXISTING, NOT NEWLY SYNTHESIZED TRANSCRIPTION FACTOR MEF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE REGULATORY GENE; ENHANCER-BINDING-FACTOR; MOUSE EMBRYOGENESIS; SKELETAL-MUSCLE; MYOD FAMILY; EXPRESSION; ELEMENTS; PROTEINS; MYF-5; INACTIVATION	The myogenin gene, a member of the gene family encoding muscle-specific basic-helix-loop-helix transcription factors, is activated in myoblasts at the onset of differentiation and can be induced in fibroblasts by forced expression of MyoD or its relatives. Here, we report that a small proximal promoter region of the Myf-4 gene, the human myogenin homolog, suffices to direct muscle-specific expression and up-regulation by MyoD. The minimal promoter contains an E-box and a MEF-2 consensus element. Paradoxically, we find that the MEF-2 binding site but not the E box is necessary for cell type-specific expression and activation by MyoD in tissue culture cells. This suggests an activating mechanism which is independent of direct protein interactions at the E-box. MEF-2 binding complexes were detected in myoblasts and myotubes, as well as in fibroblasts with no strict correlation to myogenin expression. Moreover, transcription of myogenin could be induced in the presence of potent inhibitors of protein synthesis. From these results we conclude that myogenin expression is not mediated primarily through de novo synthesis of MEF-2 but rather involves a post translational mode of activation.	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST BIOCHEM & BIOTECHNOL,DEPT CELL & MOLEC BIOL,D-38106 BRAUNSCHWEIG,GERMANY	Braunschweig University of Technology								ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; ARNOLD HH, 1993, ADV DEV BIOCH, V2, P111; ARNOLD HH, 1993, CELL MOL BIOL RES, V39, P303; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1994, IN PRESS DEV BIOL; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCKINGHAM M, 1992, TRENDS GENET, V8, P114; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MONTARRAS D, 1991, NEW BIOL, V3, P592; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	44	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17289	17296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006037				2022-12-27	WOS:A1994NT84600048
J	WALMSLEY, AR; MARTIN, GEM; HENDERSON, PJF				WALMSLEY, AR; MARTIN, GEM; HENDERSON, PJF			8-ANILINO-1-NAPHTHALENESULFONATE IS A FLUORESCENT-PROBE OF CONFORMATIONAL-CHANGES IN THE D-GALACTOSE-H+ SYMPORT PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; GLUT1 GLUCOSE TRANSPORTER; RED BLOOD-CELLS; HUMAN-ERYTHROCYTE; LIGAND-BINDING; CYTOCHALASIN-B; FACILITATED DIFFUSION; XENOPUS OOCYTES; SEQUENCE MOTIF; HALF-TURNOVER	The binding of sugars and antibiotics to the overexpressed D-galactose-H+ symport protein (GalP) can be monitored from changes in the fluorescence of 8-anilinol-naphthalenesulfonate (ANS) equilibrated with inside-out vesicles. Transported sugars, such as D-glucose and D-galactose, cause an enhancement in the ANS fluorescence of up to 13%. Nontransported sugars that have little, if any, affinity for GalP, such as L-galactose and L-glucose, have no effect upon the ANS fluorescence. Cytochalasin B and forskolin, which are potent inhibitors of the transporter, produce little change in the fluorescence, but are capable of reversing the D-galactose/D-glucose enhancement in fluorescence. Sugars that bind to GalP but are not transported, such as methyl-beta-D-glucose, produce only a slight quench in the ANS fluorescence, but again reverse the enhancement in fluorescence induced by transported sugars. A simple interpretation is that the increase in ANS fluorescence is attributable to the sugar-induced reorientation of the transporter from an inward- to an outward-facing conformation. Nontransported sugars and antibiotics, which are thought to bind at the inner membrane face of the transporter, are able to reverse the fluorescence enhancement by binding to the inward-facing conformation. The postulated reorientation process was sufficiently slow to follow its progress by stopped-flow fluorometry. The K-d for the binding of D-galactose to the inward-facing site was 7.22 (+/- 1.49) mM, and the rate constants for outward and inward reorientation of the transporter were 4.06 (+/- 0.16) s(-1) and 1.36 (+/- 0.18) s(-1), respectively. The overall K-d values for a range of sugars and antibiotics have been determined, and the involvement of each sugar hydroxyl group in the recognition and translocation processes has been assessed.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	WALMSLEY, AR (corresponding author), UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, KREBS INST BIOMOLEC RES, 5TH COURT, WESTERN BANK, SHEFFIELD S10 2UH, ENGLAND.		Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BALDWIN SA, 1981, TRENDS BIOCHEM SCI, V6, P208, DOI 10.1016/0968-0004(81)90076-1; BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BASSO LA, 1993, EUR J BIOCHEM, V213, P935, DOI 10.1111/j.1432-1033.1993.tb17838.x; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P186, DOI 10.1016/0005-2736(78)90140-2; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; Fersht AR., 1977, ENZYME STRUCTURE MEC; FUTAI M, 1978, BACTERIAL TRANSPORT, P7; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GORGA FR, 1982, BIOCHEMISTRY-US, V21, P1905, DOI 10.1021/bi00537a031; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENDERSON PJF, 1983, BIOCHIM BIOPHYS ACTA, V732, P204, DOI 10.1016/0005-2736(83)90204-3; HENDERSON PJF, 1977, BIOCHEM J, V168, P15, DOI 10.1042/bj1680015; HENDERSON PJF, 1983, BIOCH METABOLIC PROC, P339; HORNE P, 1983, BIOCHEM J, V210, P699, DOI 10.1042/bj2100699; JANOSHAZI A, 1993, J MEMBRANE BIOL, V132, P167; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; LOWE AG, 1987, BIOCHIM BIOPHYS ACTA, V903, P547, DOI 10.1016/0005-2736(87)90063-0; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; MACPHERSON AJS, 1981, BIOCHEM J, V196, P269, DOI 10.1042/bj1960269; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MARTIN GEM, 1993, THESIS U CAMBRIDGE; MAY JM, 1993, BIOCHEMISTRY-US, V32, P2907, DOI 10.1021/bi00062a022; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; REES WD, 1981, BIOCHIM BIOPHYS ACTA, V646, P251, DOI 10.1016/0005-2736(81)90331-X; ROBERTS PE, 1992, THESIS U CAMBRIDGE; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WALMSLEY AR, 1987, BIOCHIM BIOPHYS ACTA, V901, P229, DOI 10.1016/0005-2736(87)90119-2; WALMSLEY AR, 1993, EUR J BIOCHEM, V215, P43, DOI 10.1111/j.1432-1033.1993.tb18005.x; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WALMSLEY AR, 1994, EUR J BIOCHEM, V221, P513, DOI 10.1111/j.1432-1033.1994.tb18763.x; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YI CK, 1992, BIOCHEM J, V283, P643, DOI 10.1042/bj2830643	55	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17009	17019						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006005				2022-12-27	WOS:A1994NT84600007
J	HARANO, T; MIZUNO, K				HARANO, T; MIZUNO, K			PHORBOL ESTER-INDUCED ACTIVATION OF A MEMBRANE-BOUND CANDIDATE PRO-TRANSFORMING GROWTH-FACTOR-ALPHA PROCESSING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR CSF-1; PAIRED BASIC RESIDUES; TGF-ALPHA; CELL-SURFACE; PLASMA-MEMBRANES; RAT-LIVER; PRECURSOR; RECEPTORS; EXPRESSION; CLEAVAGE	Transforming growth factor-alpha (TGF-alpha) is synthesized and transported to the cell surface as a membrane-anchored precursor (proTGF-alpha) that is converted to the soluble form by proteolytic cleavage. ProTGF-alpha cleavage is activated in response to tumor-promoting phorbol ester or to calcium ionophore. Mechanism(s) controlling conversion of the membrane-anchored precursor to the soluble TGF-alpha are unknown, and the responsible protease has not been identified, Using the fluorogenic substrate succinyl-Ala-Ala-Ala-4-methylcoumaryl-7-amide (Suc-Ala-Ala-Ala-MCA), containing the sequence similar to the cleavage sites for proTGF-alpha processing, we identified a putative candidate proTGF-alpha-converting enzyme in the membrane fractions of Chinese hamster ovary (CHO) cells. The enzyme activity was about 5-6-fold increased by exposure of the cells with phorbol ester or with calcium ionophore. The enzyme activity was released from the cells by trypsin added exogenously; hence, the activity probably locates on the outer surface of the cell membrane. The enzyme was partially purified from membranes of phorbol ester-treated CHO cells. The molecular mass of the enzyme was estimated to be about 84 kDa by gel filtration analysis. Inhibitor profile of the enzyme, including inhibition by serine protease inhibitors and no inhibition by elastatinal, coincides with that previously reported for proTGF-alpha cleavage activity on CHO cells. These findings suggest that the enzyme is a processing protease involved in the cleavage of proTGF-alpha and that induction of proTGF-alpha conversion by phorbol ester or by calcium ionophore can be attributed to activation of the processing protease. In the cell-free reconstitution system, the membrane-bound Suc-Ala-Ala-Ala-MCA-hydrolyzing enzyme from CHO cells was also activated by phorbol ester in the presence of the soluble fraction, ATP, and vanadate. Requirement of vanadate, an inhibitor for protein phosphatases, for activation of the enzyme in this system suggests that phosphorylation-dephosphorylation probably plays a key role in the regulated cleavage of proTGF-alpha.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University			Mizuno, Kensaku/G-8631-2015					ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BIORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CHIDA K, 1986, J BIOL CHEM, V261, P3013; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOBASHI Y, 1991, ONCOGENE, V6, P1151; DOWING JR, 1989, MOL CELL BIOL, V9, P2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IKEHARA Y, 1977, BIOCHIM BIOPHYS ACTA, V470, P202, DOI 10.1016/0005-2736(77)90100-6; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; MUMFORD RA, 1980, J BIOL CHEM, V255, P2227; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEIN J, 1991, ONCOGENE, V6, P601; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20305	20311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051125				2022-12-27	WOS:A1994PB31700018
J	PFAFF, M; TANGEMANN, K; MULLER, B; GURRATH, M; MULLER, G; KESSLER, H; TIMPL, R; ENGEL, J				PFAFF, M; TANGEMANN, K; MULLER, B; GURRATH, M; MULLER, G; KESSLER, H; TIMPL, R; ENGEL, J			SELECTIVE RECOGNITION OF CYCLIC RGD PEPTIDES OF NMR DEFINED CONFORMATION BY ALPHA-II-BETA-3, ALPHA-V-BETA-3, AND ALPHA-5-BETA-1 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; GPIIB-IIIA; BINDING; ANTAGONISTS; FIBRINOGEN; SPECIFICITY; FIBRONECTIN; SEQUENCE; RECEPTOR	The binding of purified fibrinogen receptor alpha IIb beta 3, vitronectin receptor alpha V beta 3, and fibronectin receptor alpha 5 beta 1 to their corresponding ligands in solid-phase binding assays was used to examine the inhibitory activity of various linear and cyclic penta- and hexapeptides of different conformation containing RGD or RAD sequences. Cyclic peptides with different defined backbone conformations were designed by introducing a single D-amino acid or a proline at different positions in the ring. The data were calibrated for alpha IIb beta 3 integrin incorporated into a planar lipid bilayer by a physical method (total internal reflection fluorescence microscopy) which yielded K-D = 1.7 mu M for a linear RGD peptide and K-D = 0.03 mu M for fibrinogen. With this integrin, three cyclic hexapeptides ([GRGDFL], [ARGDFV], [GRGDFV]) were 2-4-fold more inhibitory than the linear GRGDS peptide in solid-phase assays and showed similar inhibition as the fibrinogen ligand. Six peptides had the same or a 2-fold lower activity as the linear reference peptide, and three peptides were up to 7-fold less active. Replacement of Arg or Asp by their stereoisomers or Gly by Ala resulted in a 100-1000-fold reduction in activity. With the two other integrins, a single cyclic pentapeptide [RGDFV] was 10-fold more active (alpha V beta 3) or equal in activity (alpha 5 beta 1) to linear GRGDS, while all of the other cyclic peptides were moderately or distinctly less active. Changes in the RGD sequence caused a less dramatic reduction in binding strength for alpha V beta 3 and or alpha 5 beta 1 than for alpha IIb beta 3. inhibitory activity was compared with the distance between the C-beta atoms of Arg and Asp residues as determined by NMR and indicated that the optimum distance is in the range of 0.75-0.85 nm for alpha IIb beta 3 and at or below 0.67 nm for alpha V beta 3 and alpha 5 beta 1. This indicates that alpha IIb beta 3 is less sensitive to variations in the RGD backbone structure and can accommodate a larger distance than the integrins alpha V beta 3 and alpha 5 beta 1.	UNIV BASEL,BIOCTR,BIOPHYS CHEM ABT,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; TECH UNIV MUNICH,INST ORGAN CHEM,D-85748 MUNICH,GERMANY	University of Basel; Max Planck Society; Technical University of Munich			Kessler, Horst/C-1178-2010					AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; CONNORS KA, 1987, BINDING CONSTANTS ME, P42; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KALB E, 1990, BIOCHEMISTRY-US, V29, P1607, DOI 10.1021/bi00458a036; KALB E, 1991, J BIOL CHEM, V266, P19052; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KUMAGAI H, 1991, BIOCHEM BIOPH RES CO, V177, P74, DOI 10.1016/0006-291X(91)91950-H; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LENDER A, 1993, INT J PEPT PROT RES, V42, P509; MULLER B, 1993, J BIOL CHEM, V268, P6800; MULLER G, 1992, ANGEW CHEM INT EDIT, V31, P326, DOI 10.1002/anie.199203261; NICHOLS AJ, 1992, TRENDS PHARMACOL SCI, V13, P413, DOI 10.1016/0165-6147(92)90126-Q; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	32	483	518	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20233	20238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051114				2022-12-27	WOS:A1994PB31700007
J	SAVENKOVA, MI; MUELLER, DM; HEINECKE, JW				SAVENKOVA, MI; MUELLER, DM; HEINECKE, JW			TYROSYL RADICAL GENERATED BY MYELOPEROXIDASE IS A PHYSIOLOGICAL CATALYST FOR THE INITIATION OF LIPID-PEROXIDATION IN LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; HYPOCHLOROUS ACID; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; HYDROGEN-PEROXIDE; APOLIPOPROTEIN-B; AMINO-ACIDS	Myeloperoxidase, a heme protein secreted by activated phagocytes, is expressed in human atherosclerotic lesions. The enzyme uses H2O2 generated by the cells to oxidize L-tyrosine to tyrosyl radical, a catalyst for protein dityrosine synthesis. We have explored the possibility that tyrosyl radical initiates lipid peroxidation, which may be of pivotal importance in transforming low density lipoprotein (LDL) into atherogenic particles. Exposure of LDL to L-tyrosine and activated human neutrophils caused peroxidation of LDL lipids. LDL oxidation required L-tyrosine but was independent of free metal ions; catalase and heme poisons were inhibitory. Incubation of LDL with L-tyrosine, myeloperoxidase, and H2O2 likewise caused lipid peroxidation, and this reaction was inhibited by heme poisons and catalase. Replacement of L-tyrosine with O-methyltyrosine, which cannot form tyrosyl radical, inhibited LDL oxidation by both activated neutrophils and myeloperoxidase. The antioxidants ascorbate and probucol, but not vitamin E, inhibited LDL oxidation by myeloperoxidase, H2O2, and L-tyrosine. Ascorbate blocked dityrosine synthesis, while probucol scavenged chain-propagating peroxyl radicals in the lipid phase of LDL. These results indicate that tyrosyl radical stimulates LDL lipid peroxidation. In striking contrast to other cell-mediated mechanisms for LDL oxidation, the myeloperoxidase-catalyzed reaction is independent of free metal ions. This raises the possibility that tyrosyl radical generated by myeloperoxidase is of physiological importance in making LDL atherogenic.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Savenkova, Marina/AAN-9927-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029920] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD29920] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AESCHBACH R, 1976, BIOCHIM BIOPHYS ACTA, V439, P292, DOI 10.1016/0005-2795(76)90064-7; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ATOR MA, 1987, J BIOL CHEM, V262, P14954; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOYD HC, 1989, AM J PATHOL, V135, P815; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHUNG BH, 1980, J LIPID RES, V21, P284; CRAWFORD CG, 1978, LIFE SCI, V23, P1255, DOI 10.1016/0024-3205(78)90503-9; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DAUGHERTY A, IN PRESS J CLIN INVE; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DOLE VP, 1960, J BIOL CHEM, V235, P2595; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HEINECKE JW, IN PRESS BIOCHEMISTR; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KIM EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P324, DOI 10.1016/0003-9861(91)90202-T; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KUHN H, 1990, J BIOL CHEM, V265, P1454; LEHRER SS, 1967, BIOCHEMISTRY-US, V6, P757, DOI 10.1021/bi00855a017; LINDER M, 1991, NUTRITIONAL BIOCH ME, P98; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; Musso H., 1963, ANGEW CHEM INT EDIT, V2, P723, DOI DOI 10.1002/ANIE.196307231; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NIKI E, 1984, J BIOL CHEM, V259, P4177; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; RANKIN SM, 1991, J LIPID RES, V32, P449; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1993, J LIPID RES, V34, P1219; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; STEINBRECHER UP, 1988, BIOCHIM BIOPHYS ACTA, V959, P20, DOI 10.1016/0005-2760(88)90145-2; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; TIEN M, 1982, BIOCHEM BIOPH RES CO, V107, P279, DOI 10.1016/0006-291X(82)91701-6; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WIELAND E, 1993, P NATL ACAD SCI USA, V90, P5929, DOI 10.1073/pnas.90.13.5929; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	84	298	305	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20394	20400						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051134				2022-12-27	WOS:A1994PB31700031
J	WATTS, BA; GOOD, DW				WATTS, BA; GOOD, DW			APICAL MEMBRANE NA+/H+ EXCHANGE IN RAT MEDULLARY THICK ASCENDING LIMB - PH(I)-DEPENDENCE AND INHIBITION BY HYPEROSMOLALITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; NA-H EXCHANGE; INTRACELLULAR-PH; BICARBONATE ABSORPTION; GROWTH-FACTORS; TRANSPORT; DEPENDENCE; ANTIPORTER; KIDNEY; SENSITIVITY	Apical membrane Na+/H+ exchange mediates virtually all of transepithelial HCO3- absorption in the rat medullary thick ascending limb (MTAL). Regulation of the apical exchanger by intracellular pH (pH(i)) and hyperosmolality was studied in the isolated, perfused MTAL by measurement of pH(i) using the fluorescent probe 2',7'bis-(carboxyethyl)-5,6-carboxyfluorescein. Under isosmotic conditions (290 mosmol/kg H2O), the Na+/H+ exchange rate increased sigmoidally over the pH(i) range 7.8 to 6.5 (Hill coefficient = 2.1), consistent with cooperative activation of the exchanger by internal H+. The exchanger had a high apparent affinity for intracellular H+ (apparent pK = 7.36), which resulted in the exchanger being maximally active at resting pH(i) and insensitive to changes in pH(i) over the physiologic py. range (6.5-7.2). Hyperosmolality (590 mosmol/kg H2O) inhibited Na+/H+ exchange by at least 35% at all pH(i) values studied and induced pH(i) dependence of the exchanger between 6.5 and 7.2. The inhibition by hyperosmolality appeared to be the result of an acid shift of the pH(i) dependence curve of the exchanger. These functional properties of apical membrane Na+/H+ exchange can account for our previous observations that hyperosmolality inhibited net HCO3- absorption and that the rate of HCO3- absorption did not correlate with pH(i). Apical membrane Na+/H+ exchange in the MTAL differs functionally from Na+/H+ exchange in other cell types in which exchanger activity is stimulated rather than inhibited by hyperosmolality.	UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001745, R01DK038217] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01745, DK38217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTENBERG GA, 1990, J GEN PHYSIOL, V95, P369, DOI 10.1085/jgp.95.2.369; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; GOOD D W, 1991, Journal of the American Society of Nephrology, V2, P701; GOOD DW, 1990, AM J PHYSIOL, V258, pF1345, DOI 10.1152/ajprenal.1990.258.5.F1345; GOOD DW, 1994, ANNU REV PHYSIOL, V56, P623, DOI 10.1146/annurev.ph.56.030194.003203; GOOD DW, 1984, AM J PHYSIOL, V247, pF35, DOI 10.1152/ajprenal.1984.247.1.F35; GOOD DW, 1992, J CLIN INVEST, V89, P184, DOI 10.1172/JCI115560; GOOD DW, 1987, J CLIN INVEST, V80, P1358, DOI 10.1172/JCI113213; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; GREEN J, 1988, J BIOL CHEM, V263, P5012; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1988, NAPLUS HPLUS EXCHANG; HAGGERTY JG, 1988, AM J PHYSIOL, V255, pC495, DOI 10.1152/ajpcell.1988.255.4.C495; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; KIRK KL, 1984, J MEMBRANE BIOL, V79, P53, DOI 10.1007/BF01868526; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MONTROSE MH, 1988, NA H EXCHANGE, P57; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PARIS S, 1984, J BIOL CHEM, V259, P989; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SEIFTER JL, 1986, J CLIN INVEST, V78, P859, DOI 10.1172/JCI112671; SJAASTAD MD, 1992, AM J PHYSIOL, V262, pC164, DOI 10.1152/ajpcell.1992.262.1.C164; TAKAICHI K, 1993, AM J PHYSIOL, V264, pC944, DOI 10.1152/ajpcell.1993.264.4.C944; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WALL SM, 1988, AM J PHYSIOL, V255, pF331, DOI 10.1152/ajprenal.1988.255.2.F331; WATTS B A III, 1991, Journal of the American Society of Nephrology, V2, P715; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; YU FH, 1993, J BIOL CHEM, V268, P25536	37	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20250	20255						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051116				2022-12-27	WOS:A1994PB31700009
J	ARSHAVSKY, VY; DUMKE, CL; ZHU, Y; ARTEMYEV, NO; SKIBA, NP; HAMM, HE; BOWNDS, MD				ARSHAVSKY, VY; DUMKE, CL; ZHU, Y; ARTEMYEV, NO; SKIBA, NP; HAMM, HE; BOWNDS, MD			REGULATION OF TRANSDUCIN GTPASE ACTIVITY IN BOVINE ROD OUTER SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP-PHOSPHODIESTERASE; GAMMA-SUBUNIT; G-PROTEIN; INHIBITORY SUBUNIT; RETINAL RODS; VERTEBRATE PHOTORECEPTORS; VISUAL TRANSDUCTION; SIGNAL TRANSDUCTION; SYNTHETIC PEPTIDES	The photoreceptor G-protein, transducin, belongs to the class of heterotrimeric GTP-binding proteins that transfer information from activated seven-span membrane receptors to effector enzymes or ion channels. Like other G-proteins, transducin acts as a molecular clock. It is activated by photoexcited rhodopsin which catalyzes the exchange of transducin-bound GDP for GTP and then stays active until bound GTP is hydrolyzed by an intrinsic GTPase activity. Our previous study on the components of the amphibian phototransduction cascade (Arshavsky, V.Y., and Bownds, M. D. (1992) Nature 357, 416-417) has shown that transducin GTPase can be significantly accelerated by the target enzyme, cGMP phosphodiesterase (PDE), and more specifically its gamma-subunit (PDE(gamma)). Here we report that an analogous mechanism is present in bovine photoreceptors. Addition of recombinant PDE(gamma) to the test photoreceptor membranes which retain transducin but are depleted of endogenous PDE causes a significant acceleration of transducin GTPase activity. A similar effect was observed with the PDE holoenzyme, but not with the complex of PDE alpha and beta-subunits prepared by a limited proteolysis of PDE with trypsin. The activating effect of PDE(gamma) is increased as test membrane concentration increases, exceeding 20-fold at rhodopsin concentrations over 80 mu M and approaching the rate of the photore sponse turnoff. This suggests either that photoreceptor membranes contain a further factor which is essential for PDE-dependent regulation of transducin-bound GTP hydrolysis or that components of the phototransduction cascade interact in a cooperative manner. We also report that the GTPase-activating epitope is located within the C-terminal third of PDE(gamma): the peptide corresponding to the 25 C-terminal amino acid residues of PDE(gamma) can accelerate transducin GTPase almost as well as the full length PDE(gamma). A part of the GTPase activating epitope is located within the 3 C-terminal amino acid residues: the truncation PDE(gamma) mutant lacking these residues accelerates transducin GTPase considerably less than the whole length PDE(gamma).	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY 06062, EY 10336, EY 00463] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010336] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, IN PRESS J BIOL CHEM; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Artemyev Nikolai O., 1993, Methods (Orlando), V5, P220, DOI 10.1006/meth.1993.1027; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Detwiler P B, 1992, Curr Opin Neurobiol, V2, P433, DOI 10.1016/0959-4388(92)90176-L; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GODCHAUX W, 1979, J BIOL CHEM, V254, P7874; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MILLS JS, 1993, BIOPHYS J, V64, pA383; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; OSTROY SE, 1977, BIOCHIM BIOPHYS ACTA, V463, P91, DOI 10.1016/0304-4173(77)90004-0; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899	40	79	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19882	19887						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051070				2022-12-27	WOS:A1994PA12600036
J	COULOMBE, B; LI, J; GREENBLATT, J				COULOMBE, B; LI, J; GREENBLATT, J			TOPOLOGICAL LOCALIZATION OF THE HUMAN TRANSCRIPTION FACTOR-IIA, FACTOR-IIB, TATA BOX-BINDING PROTEIN, AND RNA-POLYMERASE-II-ASSOCIATED PROTEIN-30 ON A CLASS-II PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL INITIATION-FACTOR; ACTIVATION DOMAIN BINDS; MINOR-GROOVE; CRYSTAL-STRUCTURE; BASIC REPEAT; MINIMAL SET; P53 BINDS; WILD-TYPE; COMPLEX; IDENTIFICATION	The human general transcription factors IIA and IIB bind directly to the TATA box-binding protein (TBP), and modulate transcription initiation by RNA polymerase II. RAP30, the small subunit of TFIIF, binds to TFIIB and RNA polymerase II and recruits RNA polymerase II to a preinitiation complex containing TBP and TFIIB. By using the adenovirus 2 major late promoter tagged site-specifically with the photoactivatible cross-linking reagent N(3)R-dUMP we have localized TBP, two subunits of TFIIA (A35 and A21), TFIIB, and RAP30 along promoter DNA. TFIIA cross-linked to the coding strand opposite TBP at the TATA box and cross-linked upstream of TBP around position -40. RAP30 crosslinked strongly and TFIIB weakly to the coding strand just downstream of TBP at -19. We interpret these data in the context of a molecular structure for the TBP promoter complex.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ON,CANADA	University of Toronto; University of Toronto								BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BENGAL E, 1991, MOL CELL BIOL, V8, P1602; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY S, 1991, SCIENCE, V248, P1550; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Coulombe Benoit, 1992, Gene Expression, V2, P99; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GERARD M, 1991, J BIOL CHEM, V266, P20940; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LILJELUND P, 1993, MOL GEN GENET, V241, P694, DOI 10.1007/BF00279913; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRINGER KF, 1991, NATURE, V351, P588; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	57	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19962	19967						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051080				2022-12-27	WOS:A1994PA12600048
J	KIKUCHI, A; WILLIAMS, LT				KIKUCHI, A; WILLIAMS, LT			THE POSTTRANSLATIONAL MODIFICATION OF RAS P21 IS IMPORTANT FOR RAF-1 ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR TYROSINE KINASES; PROTEIN-KINASE; MAP KINASE; HA-RAS; ADAPTER PROTEIN; IN-VITRO; CELLS; BINDING	Raf-1, a serine/threonine kinase, is required for the mitogenic action of ras p21. It has been recently demonstrated that ras p21 directly associates with Raf-1. The C-terminal region of ras p21 is modified by farnesylation and carboxyl methylation. This modification is necessary for ras p21 function. To elucidate the role of posttranslational modification of ras p21 in Raf-1 activation, we examined ras p21-dependent Raf-1 activity in baculovirus/Sf9 cells overexpressing Raf-1 and ras p21. Coexpression of Raf-1 with v-ras p21 in Sf9 cells stimulated the autophosphorylating activity of Raf-1. The activity of Raf-1, as assessed by its ability to activate extracellular signal-regulated kinase kinase (MEK) in vitro, was also increased when Raf-1 was coexpressed with v-ras p21. However, neither the autophosphorylating activity of Raf-1 nor its ability to activate MEK was stimulated by v-ras p21 mutants which are not post-translationally modified. Raf-1 formed a complex with v-ras p21 and the v-ras p21 mutants in Sf9 cells. These results indicate that the post-translational modification of ras p21 is necessary for Raf-1 activation but that the association of Raf-1 with ras p21 is not sufficient to activate Raf-1.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AELST VL, 1993, P NATL ACAD SCI USA, V90, P6213; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, J BIOL CHEM, V268, P3025; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE PN, 1990, ONCOGENE, V5, P1045; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20054	20059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051091				2022-12-27	WOS:A1994PA12600060
J	SHI, WP; WU, JH; ROSEN, BP				SHI, WP; WU, JH; ROSEN, BP			IDENTIFICATION OF A PUTATIVE METAL-BINDING SITE IN A NEW FAMILY OF METALLOREGULATORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; ACTING REGULATORY PROTEIN; ESCHERICHIA-COLI; ANION PUMP; DNA; EXPRESSION; PLASMIDS; ARSENATE; ATPASE; ION	The transcription of the ars operon is negatively controlled by the ArsR repressor and induced by arsenite and antimonite. Using hydroxylamine mutagenesis, four arsR mutants were isolated; three were selected for inability to respond to inducers: C32Y, C32F, and C34Y. Each of the three altered proteins still bound specifically to the ars operator, but inducers were less effective in effecting the release of the altered proteins from the DNA. Each of the mutant arsR genes in trans with a reporter gene controlled by the ars promoter repressed expression of the reporter gene, and addition of inducer did not relieve repression. These results suggest that the altered ArsR proteins are defective in the inducer binding site. The fourth arsR mutation, resulting in a H50Y alteration, produced constitutive expression. His-50 is located within a putative helix-turn-helix region of the ArsR protein. We propose that cysteines Cys-32 and Cys-34 in the ArsR protein comprise part of a metal binding motif found in members of the ArsR family of metalloregulatory proteins.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P2515, DOI 10.1093/nar/21.10.2515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CRUSE WBT, 1972, ACTA CRYSTALL B-STRU, VB 28, P1325, DOI 10.1107/S0567740872004236; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; Sambrook J, 1989, MOL CLONING LABORATO; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER S, 1993, MOL MICROBIOL, V8, P637, DOI 10.1111/j.1365-2958.1993.tb01607.x; TISA LS, 1990, J BIOL CHEM, V265, P190; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x; WU JH, 1993, J BIOL CHEM, V268, P52; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; WU JH, 1992, J BIOL CHEM, V267, P12570	26	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19826	19829						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051064				2022-12-27	WOS:A1994PA12600028
J	HOPPER, S; BABST, M; SCHLENSOG, V; FISCHER, HM; HENNECKE, H; BOCK, A				HOPPER, S; BABST, M; SCHLENSOG, V; FISCHER, HM; HENNECKE, H; BOCK, A			REGULATED EXPRESSION IN-VITRO OF GENES-CODING FOR FORMATE HYDROGENLYASE COMPONENTS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; KLEBSIELLA-PNEUMONIAE; TRANSCRIPTIONAL ACTIVATOR; SALMONELLA-TYPHIMURIUM; NIFH PROMOTER; SIGMA-FACTOR; DNA; SEQUENCES; LYASE; MUTATIONS	Purified FHLA, the transcriptional activator of the formate regulon from Escherichia coli, is able to efficiently stimulate transcription from the sigma(54)-dependent promoters of the fdhF, hyp, and hyc transcriptional units. Expression was dependent on the presence of sigma(54), of the upstream activatory sequence (UAS), and of formate. Hypophosphite, a formate analogue, could substitute for formate in vitro suggesting that formate per se was active in regulation. The integration host factor (IHF) had a direct effect on the expression (in vivo and in vitro) of the hyp and hyc genes but not of the fdhF gene. Binding of IHF within the region between the hyp and the hyc operon could be shown. A model is proposed for the transcriptional regulation of the inversely oriented hyp and hyc operons. It involves two upstream regulatory sequences, one between the hyp and the hyc operon (IR1), and the other between hycA and hycB (IR2). The UAS situated within IR1 is responsible for activation of the hyc operon, that within IR2 for activation of the hyp operon. A supramolecular transcription complex is proposed which involves the binding of IHF to a site located between the UAS and the promoter responsible for transcription of the hyc operon.	UNIV MUNICH, LEHRSTUHL MIKROBIOL, D-80638 MUNICH, GERMANY; ETH ZENTRUM, INST MIKROBIOL, CH-8092 ZURICH, SWITZERLAND	University of Munich; ETH Zurich								ARTZ SW, 1975, P NATL ACAD SCI USA, V72, P3453, DOI 10.1073/pnas.72.9.3453; AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BIRKMANN A, 1987, MOL GEN GENET, V210, P535, DOI 10.1007/BF00327209; BIRKMANN A, 1987, ARCH MICROBIOL, V148, P44, DOI 10.1007/BF00429646; BIRKMANN A, 1989, MOL MICROBIOL, V3, P697, DOI 10.1111/j.1365-2958.1989.tb00218.x; BUCK M, 1987, MOL MICROBIOL, V1, P243, DOI 10.1111/j.1365-2958.1987.tb00518.x; BUCK M, 1987, NUCLEIC ACIDS RES, V15, P9945, DOI 10.1093/nar/15.23.9945; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CONTRERAS A, 1988, NUCLEIC ACIDS RES, V16, P4025, DOI 10.1093/nar/16.9.4025; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GUBLER M, 1989, MOL MICROBIOL, V3, P149, DOI 10.1111/j.1365-2958.1989.tb01804.x; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; LUTZ S, 1990, MOL MICROBIOL, V4, P13, DOI 10.1111/j.1365-2958.1990.tb02010.x; LUTZ S, 1990, THESIS LUDWIGMAXIMIL; MACNEIL T, 1982, MOL GEN GENET, V188, P325, DOI 10.1007/BF00332696; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; Miller J.H., 1972, EXPT MOL GENETICS; PECHER A, 1985, ARCH MICROBIOL, V141, P359, DOI 10.1007/BF00428850; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; POPHAM D, 1991, J BIOL CHEM, V266, P19510; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; ROSSMANN R, 1991, MOL MICROBIOL, V5, P2807, DOI 10.1111/j.1365-2958.1991.tb01989.x; Sambrook J, 1989, MOL CLONING LABORATO; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SANTERO E, 1992, J MOL BIOL, V227, P602, DOI 10.1016/0022-2836(92)90211-2; SAWERS G, 1991, J BACTERIOL, V173, P4983, DOI 10.1128/jb.173.16.4983-4993.1991; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; SCHLENSOG V, 1994, J BIOL CHEM, V269, P19590; SCHLENSOG V, 1989, ARCH MICROBIOL, V152, P83, DOI 10.1007/BF00447016; SCHLENSOG V, 1993, THESIS LUDWIGMAXIMIL; SEUTER M, 1992, MOL MICROBIOL, V6, P1523; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SIRKO A, 1993, J BACTERIOL, V175, P5769, DOI 10.1128/JB.175.18.5769-5777.1993; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; TSUI P, 1990, MOL GEN GENET, V223, P349, DOI 10.1007/BF00265076; WONG PK, 1987, J BACTERIOL, V169, P2876, DOI 10.1128/jb.169.6.2876-2880.1987	45	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19597	19604						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034728				2022-12-27	WOS:A1994NY33200062
J	MACDOUGALD, OA; CORNELIUS, P; LIN, FT; CHEN, SS; LANE, MD				MACDOUGALD, OA; CORNELIUS, P; LIN, FT; CHEN, SS; LANE, MD			GLUCOCORTICOIDS RECIPROCALLY REGULATE EXPRESSION OF THE CCAAT/ENHANCER-BINDING PROTEIN-ALPHA AND PROTEIN-DELTA GENES IN 3T3-L1 ADIPOCYTES AND WHITE ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; ALPHA-1-ACID GLYCOPROTEIN GENE; MESSENGER-RNA LEVELS; 3 C/EBP ISOFORMS; C-JUN; RESPONSE ELEMENTS; RECEPTOR; DEXAMETHASONE; TRANSCRIPTION; INSULIN	Glucocorticoid agonists, i.e. dexamethasone or triamcinolone acetonide, rapidly induce expression of CCAAT/enhancer-binding protein (C/EBP) delta and repress expression of C/EBP alpha in fully differentiated 3T3-L1 adipocytes. Within 30 min of glucocorticoid treatment, the cellular level of C/EBP delta rises dramatically, increasing >100 fold within 6 h. Concurrently, the level of C/EBP alpha decreases, reaching a minimum within 4 h. The dexamethasone concentration dependence and steroid specificity of these responses suggest that both processes are mediated by the glucocorticoid receptor. The reciprocal effects of dexamethasone on the steady-state levels of C/EBP alpha and C/EBP delta can be accounted for kinetically and quantitatively by changes in their mRNA levels and by the transcription rates of their respective genes. The glucocorticoid-induced changes in expression of the C/EBP isoforms are correlated with the transcriptional activation of the SCD1 gene, an adipocyte gene known to be transactivated by C/EBP isoforms. Glucocorticoids also regulate expression of the C/EBP isoforms in vivo. Within 4 h of administration of dexamethasone or triamcinolone acetonide to adult rats, expression of C/EBP delta is induced in white adipose tissue while expression of C/EBP alpha is repressed. Like the response in 3T3-L1 adipocytes, the effects of dexamethasone on C/EBP alpha in white adipose tissue are rapid and transient.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				MacDougald, Ormond/0000-0001-6907-7960				ALAM T, 1992, J BIOL CHEM, V267, P5021; APPEL B, 1992, AM J PHYSIOL, V262, pE695, DOI 10.1152/ajpendo.1992.262.5.E695; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELKS ML, 1983, J BIOL CHEM, V258, P8582; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FAIN JN, 1963, J BIOL CHEM, V238, P54; FAIN JN, 1965, J BIOL CHEM, V240, P3522; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; GARVEY WT, 1989, MOL ENDOCRINOL, V3, P1132, DOI 10.1210/mend-3-7-1132; HAINQUE B, 1987, BIOCHIM BIOPHYS ACTA, V931, P347, DOI 10.1016/0167-4889(87)90226-6; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JEANRENAUD B, 1960, J BIOL CHEM, V235, P2217; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; LAI E, 1982, J BIOL CHEM, V257, P6691; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE H, 1991, FEBS LETT, V280, P134, DOI 10.1016/0014-5793(91)80221-N; LEPAR GJ, 1989, MOL ENDOCRINOL, V3, P1207, DOI 10.1210/mend-3-8-1207; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEYUHAS O, 1976, BIOCHEM J, V158, P9, DOI 10.1042/bj1580009; MEYUHAS O, 1976, BIOCHEM J, V158, P1; MOUSTAID N, 1990, BIOCHEM MED METAB B, V43, P93, DOI 10.1016/0885-4505(90)90013-Q; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PLESTED CP, 1987, BIOCHEM J, V247, P459, DOI 10.1042/bj2470459; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; RICE KM, 1992, J BIOL CHEM, V267, P10163; ROS M, 1989, BIOCHEM J, V260, P271, DOI 10.1042/bj2600271; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHIWEK DR, 1987, ENDOCRINOLOGY, V120, P469, DOI 10.1210/endo-120-2-469; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; THULASI R, 1993, J BIOL CHEM, V268, P18306; TOKUYAMA K, 1987, AM J PHYSIOL, V252, pE202, DOI 10.1152/ajpendo.1987.252.2.E202; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	65	122	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19041	19047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034662				2022-12-27	WOS:A1994NX32700052
J	WALS, PA; KATZ, J				WALS, PA; KATZ, J			GLUCOSE-GLUCOSE 6-PHOSPHATE CYCLING IN HEPATOCYTES DETERMINED BY INCORPORATION OF (HOH)-H-3 AND D2O - EFFECT OF GLYCOSYNS AND FRUCTOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; GLYCOGEN-SYNTHESIS; PHOSPHORYLATION; GLUCOKINASE; METABOLISM; STIMULATION; PROGLYCOSYN	The phosphorylation of glucose and recycling between glucose and glucose-6-P was determined in hepatocytes from fasted rats by a novel method. The cells were incubated with [U-C-14]glucose as sole substrate in media containing (HOH)-H-3 and D2O. Recycling was calculated from the yield of protons in glucose and glycogen. Results with (HOH)-H-3 and D2O were identical. Phosphorylation was obtained as the sum of recycling plus the U-C-14 yields in products. At 10 mm glucose, more than 4 out of 5 molecules of glucose-6-P were recycled. About 1.2 mu mol of glucose min/g of liver was phosphorylated, 1 mu mol was recycled, and 0.2 mu mol was glycolyzed. The effect of two phenacylimidazolium compounds (designated as glycosyns) and low concentrations of fructose (0.05-0.2 mM) on phosphorylation and recycling were examined. The glycosyns doubled glucose uptake, mainly as glycogen, nearly abolished glycolysis, and decreased recycling from 80 to 50-60%. There was little change in phosphorylation. Fructose doubled the yield of tritium from [2-H-3]glucose in short term incubations (20-30 min), confirming the results of Van Schaftingen ((1993) Diabetologia 36, 582-588). The effect was tran- sient, and cells became refractory to fructose. There was no glycogen synthesis and little effect on recycling. A new phenacylimidazolium compound stimulated glycogen synthesis and suppressed glycolysis and recycling, like the compound designated as proglycosyn by Yamanuchi et al. ((1992) Arch. Biochem. Biophys. 294, 609-615). This new compound (glycosyn-2) was fully active at lower concentrations (maximal effect at 0.02 mM).	CEDARS SINAI MED CTR,LOS ANGELES,CA 90048	Cedars Sinai Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036449] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK36449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM B, 1964, J BIOL CHEM, V239, P2102; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CAHILL GF, 1959, AM J MED, V26, P264, DOI 10.1016/0002-9343(59)90316-X; CLARK DG, 1979, BIOCHEM J, V184, P501, DOI 10.1042/bj1840501; CLINE GW, 1993, ACTA DIABETOL, V30, P72; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; GRUNNET N, 1978, BIOCHEM J, V172, P595, DOI 10.1042/bj1720595; GUO ZK, 1992, ANAL BIOCHEM, V204, P273, DOI 10.1016/0003-2697(92)90238-3; GUO ZK, 1991, J BIOL CHEM, V266, P22323; HARRIS RA, 1989, J BIOL CHEM, V264, P14674; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATZ J, 1978, J BIOL CHEM, V253, P4530; KATZ J, 1975, EUR J BIOCHEM, V60, P91, DOI 10.1111/j.1432-1033.1975.tb20979.x; Katz J, 1976, Curr Top Cell Regul, V10, P237; KATZ J, 1972, BIOCHEM J, V128, P879, DOI 10.1042/bj1280879; KATZ J, 1965, J BIOL CHEM, V240, P1484; KATZ J, 1991, AM J PHYSIOL, V262, pE332; LAHTELA JT, 1990, AM J PHYSIOL, V259, pE389, DOI 10.1152/ajpendo.1990.259.3.E389; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; MCCRAW EF, 1967, P SOC EXP BIOL MED, V126, P232; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; ROGNSTAD R, 1974, EUR J BIOCHEM, V47, P33; SINGH J, 1982, FEBS LETT, V150, P325, DOI 10.1016/0014-5793(82)80761-8; TIPPET PS, 1993, ARCH BIOCHEM BIOPHYS, V222, P285; VANDERCAMMEN A, 1991, EUT J BIOCH, V200, P345; VANSCHAFTINGEN E, 1993, DIABETOLOGIA, V36, P581, DOI 10.1007/BF00404065; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1991, FASEB J, V5, P326, DOI 10.1096/fasebj.5.3.2001793; VANSCHAFTINGEN E, 1993, EUR J BIOCHEM, V218, P745; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; WALS PA, 1981, BIOCHEM BIOPH RES CO, V100, P1543, DOI 10.1016/0006-291X(81)90694-X; WALS PA, 1993, INT J BIOCHEM, V23, P1561; YAMANOUCHI K, 1992, ARCH BIOCHEM BIOPHYS, V294, P609, DOI 10.1016/0003-9861(92)90732-C	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18343	18352						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034579				2022-12-27	WOS:A1994NW79800020
J	BURGARD, S; NETT, JH; SAUER, HE; KAGAWA, Y; SCHAFER, HJ; WISE, JG; VOGEL, PD; TROMMER, WE				BURGARD, S; NETT, JH; SAUER, HE; KAGAWA, Y; SCHAFER, HJ; WISE, JG; VOGEL, PD; TROMMER, WE			EFFECTS OF MAGNESIUM-IONS ON THE RELATIVE CONFORMATION OF NUCLEOTIDE-BINDING SITES OF F-1-ATPASES AS STUDIED BY ELECTRON-SPIN-RESONANCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; KINASE-LIKE ORIENTATION; ESCHERICHIA-COLI; BETA-SUBUNIT; NONCATALYTIC SITES; ADENYLATE KINASE; OXIDATIVE-PHOSPHORYLATION; CHLOROPLAST-F1 ATPASE; ADENINE-NUCLEOTIDES; F1 ATPASE	Cations like Mg2+ play an important role in the catalytic mechanism of F-1-ATPases. In this study we applied ESR spectroscopy and used the ATP analog 2-azido-2',3'-(2,2,5,5-tetramethyl-3 -pyrroline-1-oxyl-3-carboxylic acid ester)ATP (2-N-3-SL-ATP) to investigate the effects of Mg2+ ions on the structure of the nucleotide binding sites of F-1-ATPases from beef heart mitochondria (MF(1)) and from the thermophilic bacterium PS3 (TF1). The results demonstrated that Mg2+ ions not only influenced the binding of the nucleotide analogs to F-1 but also altered the structure and geometry of the nucleotide binding sites. We observed that the dipolar interactions that are indicative of the close proximity of enzyme-bound 2-N-3-SL-ANP (Vogel, P. D., Nett, J. H., Sauer, H. E., Schmadel, K., Cross, R. L., and Trommer, W.E. (1992) J. Biol. Chem. 267, 11982-11986) were only detectable in MF(1)-ATPase when the enzyme was preincubated with Mg2+ ions. In the absence of Mg2+, the enzyme exhibited ESR spectra indicative of spin label bound in at least two different environments (binding sites) with no dipolar interactions visible. TF1-ATPase did not exhibit clear dipolar interactions in the presence or absence of Mg2+. The ESR spectra of TF1 in the absence of Mg2+ indicated two different environments of the spin labels. Subsequent addition of Mg2+, however, led to exactly the same spectra as if the enzyme was incubated with the ions, indicating a rearrangement of the nucleotide binding sites. In summary, clear differences in the structures of the nucleotide binding sites of MF(1) and TE(1) in the presence or absence of Mg2+ were observed. Conformational differences between F-1-bound spin-labeled nucleotides were also observed between TF1- and MF(1)-ATPases.	UNIV KAISERSLAUTERN, FACHBEREICH CHEM BIOCHEM, D-67663 KAISERSLAUTERN, GERMANY; UNIV MAINZ, INST BIOCHEM, D-55128 MAINZ, GERMANY; JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	University of Kaiserslautern; Johannes Gutenberg University of Mainz; Jichi Medical University				Vogel, Pia/0000-0002-8135-4649; Wise, John/0000-0001-5398-8794				BETH AH, 1984, J BIOL CHEM, V259, P9717; BICKELSANDKOTTER S, 1987, BIOCHIM BIOPHYS ACTA, V893, P342, DOI 10.1016/0005-2728(87)90055-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1988, BIOCHIM BIOPHYS ACTA, V934, P397, DOI 10.1016/0005-2728(88)90097-7; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GUERRERO KJ, 1989, BIOCHEM BIOPH RES CO, V154, P854; JAKOBS P, 1989, FEBS LETT, V254, P8, DOI 10.1016/0014-5793(89)80998-6; JOST P, 1975, SPIN LABELING THEORY, P251; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MOUDRIANAKIS EN, 1976, J BIOL CHEM, V251, P7796; PARK JH, 1989, BIOL MAGN RESON, V8, P547; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1975, ELECTRON TRANSFER CH, P135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAFER HJ, 1989, FEBS LETT, V253, P264, DOI 10.1016/0014-5793(89)80972-X; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TIEDGE H, 1982, EUR J BIOCHEM, V127, P291, DOI 10.1111/j.1432-1033.1982.tb06869.x; TROMMER WE, 1987, PYRIDINE NUCLEOTID A, V2, P613; TROMMER WE, 1992, BIOACTIVE SPIN LABEL, P405; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0; WILDER RT, 1989, BIOCHIM BIOPHYS ACTA, V997, P65, DOI 10.1016/0167-4838(89)90136-2; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; [No title captured]	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17815	17819						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027034				2022-12-27	WOS:A1994NV42200012
J	HSU, SC; MOLDAY, RS				HSU, SC; MOLDAY, RS			GLUCOSE-METABOLISM IN PHOTORECEPTOR OUTER SEGMENTS - ITS ROLE IN PHOTOTRANSDUCTION AND IN NADPH-REQUIRING REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENERGY PHOSPHATE; GLUTATHIONE-REDUCTASE; HUMAN-ERYTHROCYTES; PLASMA-MEMBRANE; ROD; GLYCOLYSIS; ENZYME; CELLS; DEHYDROGENASE; PURIFICATION	Glucose metabolism in the photoreceptor rod outer segment produces both ATP (GTP) and NADPH to support phototransduction and NADPH requiring processes in this organelle. Glycolysis in isolated bovine rod outer segments produces 44.0 +/- 6.4 nmol of ATP/min/mg of protein or 5.7 mM ATP/min. This rate of ATP production is more than sufficient to maintain the basal rate of cGMP synthesis (0.86 mM cGMP/min) in the dark requiring 1.7 mM ATP/min. Following photoexcitation, the 4.5-fold increase in the turnover of cGMP requires an ATP synthesis rate of up to 7.7 mM ATP/min (Ames, A., Walseth, T. F, Heyman, R. A, Barad, M., Graeff, R. M., and Goldberg, N. D. (1986) J. Biol. Chem. 261, 13034-13042). Under these conditions the rate of ATP production by glycolysis as measured in isolated rod outer segments is not sufficient for the regeneration of cGMP. Additional energy is most likely provided by the phosphocreatine shuttle which transports high energy phosphate groups in the form of creatine phosphate from the rod inner segment to the rod outer segment for conversion to ATP. The hexose monophosphate pathway in bovine rod outer segments can produce up to 39.8 +/- 2.2 nmol of NADPH/min/mg of protein. This rate of NADPH production is sufficient to support both the reduction of retinal to retinol (1.2 +/- 0.2 nmol of NADP/min/mg of protein) following the photobleaching of rhodopsin and glutathione reduction (1.2 +/- 0.1 nmol of NADPH/min/mg of protein) for the protection of rod outer segments from oxidative damage. These studies provide insight into the contribution of anaerobic glycolysis and the hexose monophosphate pathway in providing energy and nucleotides for phototransduction and other outer segment processes.	UNIV BRITISH COLUMBIA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia								ACAN NL, 1989, FEBS LETT, V250, P72, DOI 10.1016/0014-5793(89)80687-8; ALBRECHT V, 1971, EUR J BIOCHEM, V20, P44, DOI 10.1111/j.1432-1033.1971.tb01360.x; AMES A, 1986, J BIOL CHEM, V261, P3034; BERNE RM, 1988, PHYSL BLOOD COMPONEN, P359; BRESNICK GH, 1970, INVEST OPHTH VISUAL, V9, P372; BRIN M, 1958, J BIOL CHEM, V230, P307; CLEGG JS, 1988, BIOCHEM J, V255, P335; COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DELUCA M, 1983, ARCH BIOCHEM BIOPHYS, V226, P285, DOI 10.1016/0003-9861(83)90295-3; DONTSOV AE, 1978, BIOCHEMISTRY-MOSCOW+, V43, P471; EASTERBY JS, 1982, METHOD ENZYMOL, V90, P11; EVANS E, 1972, MICROVASC RES, V4, P335, DOI 10.1016/0026-2862(72)90069-6; FARNSWORTH CC, 1976, BIOCHIM BIOPHYS ACTA, V443, P556, DOI 10.1016/0005-2787(76)90517-7; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; FUTTERMAN S, 1961, J BIOL CHEM, V236, P1652; FUTTERMAN SIDNEY, 1963, JOUR BIOL CHEM, V238, P1145; GAETANI GD, 1974, P NATL ACAD SCI USA, V71, P3584, DOI 10.1073/pnas.71.9.3584; GREGERSEN MI, 1961, MED PHYSL TOTAL BODY, P301; HARRIS BG, 1982, METHOD ENZYMOL, V90, P45; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HSU SC, 1991, J BIOL CHEM, V266, P21745; HSU SC, 1990, J BIOL CHEM, V265, P13308; II I, 1974, BIOCHIM BIOPHYS ACTA, V350, P151; KAGAN VE, 1973, BIOCHIM BIOPHYS ACTA, V330, P76, DOI 10.1016/0005-2736(73)90285-X; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KELETI T, 1989, PROG BIOPHYS MOL BIO, V53, P105, DOI 10.1016/0079-6107(89)90016-3; KULBE KD, 1982, METHOD ENZYMOL, V90, P115; LEE CY, 1982, METHOD ENZYMOL, V90, P121; LOLLEY RN, 1969, J CELL PHYSIOL, V73, P9, DOI 10.1002/jcp.1040730103; LOPEZESCALERA R, 1991, BIOCHEMISTRY-US, V30, P8970, DOI 10.1021/bi00101a009; LOWRY OH, 1961, J BIOL CHEM, V236, P2813; LOWRY OH, 1956, J BIOL CHEM, V220, P879; MAGNANI M, 1980, J BIOL CHEM, V255, P1752; MATCHINSKY FM, 1968, J NEUROCHEM, V15, P643; MCCONNELL DG, 1969, BIOCHIM BIOPHYS ACTA, V184, P11, DOI 10.1016/0304-4165(69)90093-2; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; NIELSEN NC, 1970, BIOCHIM BIOPHYS ACTA, V211, P10, DOI 10.1016/0005-2736(70)90118-5; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; SCHNETKAMP PPM, 1979, BIOCHIM BIOPHYS ACTA, V552, P379, DOI 10.1016/0005-2736(79)90182-2; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; SCOTT EM, 1963, J BIOL CHEM, V238, P3928; SHICHI H, 1983, BIOCH VISION, P36; SRERE PA, 1990, FEBS LETT, V268, P360, DOI 10.1016/0014-5793(90)81286-W; STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P39, DOI 10.1016/0005-2744(69)90280-0; THOMSON MJ, 1977, LIFE SCI, V22, P335; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALLIMANN T, 1986, P NATL ACAD SCI USA, V83, P3816, DOI 10.1073/pnas.83.11.3816; WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667; WINKLER BS, 1981, BIOCH PHYSL EYE, P227	53	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17954	17959						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027053				2022-12-27	WOS:A1994NV42200033
J	THOMPSON, MW; SINGH, SK; MAURIZI, MR				THOMPSON, MW; SINGH, SK; MAURIZI, MR			PROCESSIVE DEGRADATION OF PROTEINS BY THE ATP-DEPENDENT CLP PROTEASE FROM ESCHERICHIA-COLI - REQUIREMENT FOR THE MULTIPLE ARRAY OF ACTIVE-SITES IN CLPP BUT NOT ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; LA; COMPONENT; PROTEOLYSIS; BREAKDOWN; COMPLEX; TI; UBIQUITIN; MECHANISM; SEQUENCE	ClpP, the proteolytic component of the ATP-dependent ClpAP protease, is composed of 12 identical subunits and has intrinsic degradative activity against short peptides. Degradation of proteins and some peptides by ClpP requires the regulatory component ClpA and ATP. Peptide and protein substrates have been used to distinguish the roles of nucleotide binding and nucleotide hydrolysis in the activation of ClpAP protease. ATP binding alone promoted interaction between ClpA and ClpP, affected the substrate response curves for very short peptides, and activated degradation of larger peptides that were not degraded by ClpP alone. ATP hydrolysis did not increase in proportion to the increase in peptide bond hydrolysis of short peptides. However, ATP hydrolysis was strictly required for degradation of proteins such as alpha-casein; there was no indication of even limited cleavage of protein substrates when nonhydrolyzable analogs of ATP were used. Most large peptides and proteins were degraded in multiple sites without release of high molecular weight intermediates. Partial inactivation of ClpP with diisopropyl fluorophosphate produced ClpP with one to three active subunits/dodecamer. When only a few active sites were available in the active complex of ClpAP, degradation of large peptides and proteins released significant amounts of high molecular weight intermediates. Thus, processive degradation of protein substrates is a function of the multiple array of proteolytic active sites within the ClpP dodecamer.	NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FISCHER H, 1993, J BIOL CHEM, V268, P22502; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; MENON AS, 1987, J BIOL CHEM, V262, P722; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WOO KM, 1989, J BIOL CHEM, V264, P2088	24	154	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18209	18215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027082				2022-12-27	WOS:A1994NV42200067
J	CRIDER, BP; XIE, XS; STONE, DK				CRIDER, BP; XIE, XS; STONE, DK			BAFILOMYCIN INHIBITS PROTON FLOW-THROUGH THE H+ CHANNEL OF VACUOLAR PROTON PUMPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSLOCATING COMPLEX; RECONSTITUTION; ATPASE; CELLS	Vacuolar-type proton-translocating ATPases are complex heterooligomers that are characterized by a specific inhibition by bafilomycin A(1). These enzymes have a peripheral ATP hydrolytic domain as well as a transmembranous sector. The transmembranous sector has been isolated by glycerol gradient centrifugation, and this subcomplex is composed of polypeptides of 116, 39, and 17 kDa. Both this sector and native holoenzyme were reconstituted into potassium-loaded (150 mM KCl) liposomes prepared from pure lipids. When diluted into potassium free buffer, a valinomycin-induced membrane potential did not drive proton uptake, as assessed by acridine orange quenching. In contrast, pretreat ment of both the reconstituted proton pump and iso lated transmembranous sector at pH 4.2 activated a la tent proton conductance. Bafilomycin A(1) (1 nM) inhibited ATP-energized proton pumping catalyzed by the proton pump, as well as membrane potential-driven proton flow through both the acid-activated proton pump and the isolated proton pore, Thus bafilomycin A, inhibits vacuolar proton pumps by blocking proton conduction through the proton pore, which we term V-B.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FORGAC M, 1992, J EXP BIOL, V172, P155; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MARQUARDT D, 1991, JNCI-J NATL CANCER I, V83, P1098, DOI 10.1093/jnci/83.15.1098; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1988, KIDNEY INT, V33, P403; SUN SZ, 1987, J BIOL CHEM, V262, P14790; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859	15	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17379	17381						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021236				2022-12-27	WOS:A1994NU12800006
J	FILONENKO, VV; DEUTSCHER, MP				FILONENKO, VV; DEUTSCHER, MP			EVIDENCE FOR SIMILAR STRUCTURAL ORGANIZATION OF THE MULTIENZYME AMINOACYL-TRANSFER-RNA SYNTHETASE COMPLEX IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSFER RNA-SYNTHETASE; SUBUNIT	Although aminoacyl-tRNA synthetases from higher eukaryotic cells are routinely isolated as components of a multienzyme complex, it has remained unclear how closely the isolated complex reflects a structure that exists within the cell. To answer this question, we have used chemical cross-linking and immunological detection to identify the nearest neighbor(s) of arginyl-tRNA synthetase both in the isolated, purified complex and in saponin-permeabilized cells, which retain much of the structural organization of intact cells. Our results show that arginyl-tRNA synthetase is cross-linked primarily both in vitro and in vivo to a single protein, an as yet uncharacterized 38-kDa polypeptide known to be present in synthetase complexes from many sources. These data demonstrate that the isolated, multienzyme aminoacyl-tRNA synthetase complex reflects a defined structure that also pre-exists in the cell and that the 38-kDa polypeptide is an integral component of this complex.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06032 USA; UKRAINIAN ACAD SCI, INST MOLEC BIOL & GENET, KIEV 252627, UKRAINE	University of Connecticut; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU			Filonenko, Valeriy V/D-5447-2015	Filonenko, Valeriy V/0000-0003-1839-3335	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Filonenko V V, 1991, Biomed Sci, V2, P289; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; NEGRUTSKII BS, 1992, P NATL ACAD SCI USA, V89, P3601, DOI 10.1073/pnas.89.8.3601; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; OGATA K, 1991, J BIOCHEM-TOKYO, V110, P1030, DOI 10.1093/oxfordjournals.jbchem.a123673; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; SIVARAM P, 1988, J BIOL CHEM, V263, P18891; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843	13	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17375	17378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021235				2022-12-27	WOS:A1994NU12800005
J	GUTHMILLER, P; VANPILSUM, JF; BOEN, JR; MCGUIRE, DM				GUTHMILLER, P; VANPILSUM, JF; BOEN, JR; MCGUIRE, DM			CLONING AND SEQUENCING OF RAT-KIDNEY L-ARGININE-GLYCINE AMIDINOTRANSFERASE - STUDIES ON THE MECHANISMS OF REGULATION BY GROWTH-HORMONE AND CREATINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID; MESSENGER-RNA; PROTEIN; TRANSAMIDINASE; MITOCHONDRIA; PURIFICATION; TRANSPORT; THYROXINE; LIVER	L-Arginine-glycine amidinotransferase (transamidinase) is the first and rate-limiting step in creatine biosynthesis. Rats fed a creatine-supplemented diet or hypophysectomized rats have only 20% of the kidney transamidinase activity as intact rats fed a creatine-free diet. A cDNA clone corresponding to transamidinase was isolated by immunoscreening of a lambda gt11 expression library prepared from rat kidney mRNA. The transamidinase cDNA had an open reading frame containing the known sequence of the amino terminal peptide of transamidinase. Based on the cDNA sequence, transamidinase is synthesized as a precursor with an aminoterminal extension of 50 amino acids, consistent with its mitochondrial localization. Comparison of the transamidinase sequence with the protein data base identified only a single, related protein. Remarkably, this protein, which has a 37% amino acid identity with transamidinase, is also an amidinotransferase, catalyzing streptomycin biosynthesis in Streptomyces griseus. Transamidinase cDNA was used to investigate the regulation of mRNA levels by creatine and growth hormone. Hypophysectomized rats were fed a creatine-free or a creatine-supplemented diet and maintained with and with out injections of growth hormone. An excellent correlation was found between changes in transamidinase activity and mRNA levels in response to creatine and growth hormone. Thus, the regulation of transamidinase by creatine and growth hormone is at a pretranslational level. In addition, the two effecters do not act independently but interact at a pretranslational level to control transamidinase gene expression.	ST CLOUD STATE UNIV, DEPT SCI BIOL, ST CLOUD, MN 56301 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	Saint Cloud State University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037923] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37923-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE P, 1977, STATISTICAL METHODS, P97; Borsook H, 1941, J BIOL CHEM, V138, P389; BROWN MS, 1980, J LIPID RES, V21, P505; CARLSON M, 1973, P SOC EXP BIOL MED, V143, P1256; CHATTERJEE B, 1983, J BIOL CHEM, V258, P688; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONCONI F, 1965, J BIOL CHEM, V240, P2461; DETOMA FJ, 1987, EXPT IMMUNOLOGY GUID, P7; FITCH CD, 1960, J BIOL CHEM, V235, P2362; GRAZI E, 1965, J BIOL CHEM, V240, P2465; GROSS MD, 1985, HYBRIDOMA, V4, P257, DOI 10.1089/hyb.1985.4.257; GROSS MD, 1986, ARCH BIOCHEM BIOPHYS, V251, P747, DOI 10.1016/0003-9861(86)90385-1; GROSS MD, 1988, J NUTR, V118, P1403, DOI 10.1093/jn/118.11.1403; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KURTZ DT, 1977, P NATL ACAD SCI USA, V74, P4791, DOI 10.1073/pnas.74.11.4791; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGUIRE DM, 1980, J BIOL CHEM, V255, P1152; MCGUIRE DM, 1984, J BIOL CHEM, V259, P2034; MCGUIRE DM, 1986, J HISTOCHEM CYTOCHEM, V34, P429, DOI 10.1177/34.4.3512696; NORSTEDT G, 1990, ACTA PAEDIATR SCAND, P79; PISANO JJ, 1963, ARCH BIOCHEM BIOPHYS, V100, P323, DOI 10.1016/0003-9861(63)90080-8; RATNER S, 1956, ARCH BIOCHEM BIOPHYS, V63, P277, DOI 10.1016/0003-9861(56)90044-3; RATNER S, 1956, ARCH BIOCHEM BIOPHYS, V63, P296, DOI 10.1016/0003-9861(56)90045-5; ROBERTS CT, 1986, J BIOL CHEM, V261, P25; SAMBOROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIM GK, 1979, CELL, V18, P1303, DOI 10.1016/0092-8674(79)90241-1; UNGAR F, 1966, ENDOCRINOLOGY, V78, P1238, DOI 10.1210/endo-78-6-1238; Van Pilsum J F, 1970, Endocrinology, V87, P1237; VANPILSUM JF, 1970, ANAL BIOCHEM, V35, P277, DOI 10.1016/0003-2697(70)90035-7; VANPILSUM JF, 1957, P SOC EXP BIOL MED, V95, P96; VANPILSUM JF, 1967, J NUTR, V91, P383, DOI 10.1093/jn/91.3_Suppl.383; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; WALKER JB, 1956, J BIOL CHEM, V218, P549; WALKER JB, 1958, J BIOL CHEM, V231, P1; WALKER MS, 1966, J BIOL CHEM, V241, P1262; WLAKER JB, 1956, BIOCHIM BIOPHYS ACTA, V36, P574	39	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17556	17560						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021264				2022-12-27	WOS:A1994NU12800036
J	KENGEN, SWM; DEBOK, FAM; VANLOO, ND; DIJKEMA, C; STAMS, AJM; DEVOS, WM				KENGEN, SWM; DEBOK, FAM; VANLOO, ND; DIJKEMA, C; STAMS, AJM; DEVOS, WM			EVIDENCE FOR THE OPERATION OF A NOVEL EMBDEN-MEYERHOF PATHWAY THAT INVOLVES ADP-DEPENDENT KINASES DURING SUGAR FERMENTATION BY PYROCOCCUS-FURIOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 6-PHOSPHATE 1-PHOSPHOTRANSFERASE; ENTNER-DOUDOROFF PATHWAY; IRON-SULFUR PROTEIN; HYPERTHERMOPHILIC ARCHAEBACTERIUM; GLYCOLYTIC PATHWAY; ARCHAEON; PYROPHOSPHATE; METABOLISM; TUNGSTEN; ENZYME	The main pathway for the fermentation of maltose or cellobiose by the hyperthermophile Pyrococcus furiosus was investigated by in vivo NMR and by enzyme measurements. Addition of [1-C-13]glucose to cell suspensions resulted in the formation of C-2-labeled acetate and C-3- labeled alanine. No label was recovered in CO2 or HCO3-. In the presence of [3-C-13]glucose, the label ended up in the C-1 atom of alanine and in HCO3- and CO2. These labeling patterns indicate that glucose is converted along an Embden-Meyerhof pathway, and they disagree with the previously proposed nonphosphorylated Entner-Doudoroff pathway (pyroglycolysis). The NMR data were supported by enzyme measurements. Hexokinase (8.7 units/mg), phosphoglucose isomerase (6.8 units/mg), phosphofructokinase (0.81 unit/mg), and aldolase (0.26 unit/mg) were present in cell-free extracts (specific activities at 90 degrees C). Remarkably, the two kinases required ADP as the phosphoryl group donor instead of ATP. No activity was found with pyrophosphate. These are the first descriptions of ADP-dependent (AMP-forming) kinases to date. Since P. furiosus is a phylogenetically ancient organism, these enzymes may represent an ancestral kind of metabolism.			KENGEN, SWM (corresponding author), AGR UNIV WAGENINGEN,DEPT MICROBIOL,HESSELINK VAN SUCHTELENWEG 4,6703 CT WAGENINGEN,NETHERLANDS.		Stams, Alfons/C-8167-2014	Stams, Alfons/0000-0001-7840-6500; Kengen, Serve/0000-0001-6139-8946				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1255, DOI 10.1128/AEM.56.5.1255-1262.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; CONWAY T, 1992, FEMS MICROBIOL LETT, V103, P1; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; DEROSA M, 1984, BIOCHEM J, V24, P407; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FOTHERGILLGILMORE LA, 1986, TRENDS BIOCHEM SCI, V11, P47, DOI 10.1016/0968-0004(86)90233-1; KENGEN SWM, 1994, FEMS MICROBIOL LETT, V117, P305, DOI 10.1016/0378-1097(94)90576-2; KENGEN SWM, 1994, ARCH MICROBIOL, V161, P168, DOI 10.1007/BF00276479; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Lehninger A.L, 1975, BIOCHEMISTRY-US; MERTENS E, 1991, FEBS LETT, V285, P1, DOI 10.1016/0014-5793(91)80711-B; MERTENS E, 1990, MOL BIOCHEM PARASIT, V40, P147, DOI 10.1016/0166-6851(90)90088-4; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; REEVES RE, 1974, J BIOL CHEM, V249, P7737; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHAFER T, 1991, ARCH MICROBIOL, V155, P366; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHICHO RN, 1993, ARCH MICROBIOL, V159, P380, DOI 10.1007/BF00290921; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TETAS M, 1963, BIOCHEMISTRY-US, V2, P350, DOI 10.1021/bi00902a030; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	28	171	177	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17537	17541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021261				2022-12-27	WOS:A1994NU12800033
J	OHMORI, Y; TEBO, J; NEDOSPASOV, S; HAMILTON, TA				OHMORI, Y; TEBO, J; NEDOSPASOV, S; HAMILTON, TA			KAPPA-B BINDING-ACTIVITY IN A MURINE MACROPHAGE-LIKE CELL-LINE - SEQUENCE-SPECIFIC DIFFERENCES IN KAPPA-B BINDING AND TRANSCRIPTIONAL ACTIVATION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; DNA-BINDING; NUCLEAR FACTOR; C-REL; P65 SUBUNIT; COOPERATIVE INTERACTION; PERITONEAL-MACROPHAGES; SIGNAL TRANSDUCTION; INTERLEUKIN-6 GENE	The role of two distinct kappa B sequence motifs found in the promoter of the murine IP-10 gene was studied in the transcriptional response of macrophages to lipopolysaccharides (LPS). When the murine macrophage cell line RAW 264.7 was stimulated with LPS, at least three different kappa B sequence specific complex-forming activities were observed in nuclear extracts as assayed by electrophoretic mobility shift assay (EMSA). These three complexes were distinguished from one another in terms of time of appearance following stimulation and selectivity for one of the two different kappa B sequence motifs. The participation of individual members of the Rel homology family of kappa B sequence binding factors was assessed by use of specific antibodies in combination with either EMSA or UV-cross-linking to radiolabeled, BrdUrd-substituted oligonucleotide probes. The C1 complex contained predominantly NF kappa B1 (p50). The C2 complex contained NF kappa B1, RelA (p65), and perhaps other factors. The C3 complex contained predominantly c-Rel. Both kappa B sequences were able to mediate reporter gene transcription in LPS-stimulated macrophages, but the sites behaved differentially in cells co-transfected with expression vectors encoding different members of the Rel homology family. The results indicate that LPS activates several different forms of kappa B binding activity in murine macrophages which are composed of at least three different members of the Rel homology family. These binding activities exhibit differential recognition of and functional activation through the two distinct kappa B sequence motifs.	VA ENGELHARDT MOLEC BIOL INST,CYTOKINE MOLEC BIOL UNIT,MOSCOW 117984,RUSSIA; NCI,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	OHMORI, Y (corresponding author), CLEVELAND CLIN FDN,DEPT IMMUNOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/L-1990-2015	Ohmori, Yoshihiro/0000-0002-6069-357X; Hamilton, Thomas/0000-0002-9817-242X	NATIONAL CANCER INSTITUTE [R01CA039621, P01CA048919] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48919, CA 39621] Funding Source: Medline; NHLBI NIH HHS [HL 29582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams DO, 1992, NATURAL IMMUNE SYSTE, P75; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; Ausubel F.M., 1987, CURRENT PROTOCOL MOL; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNELL E, 1989, ONCOGENE, V4, P935; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; DROUET C, 1991, J IMMUNOL, V147, P1694; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HAMILTON TA, 1989, IMMUNOPHARMACOLOGY, P231; HAMILTON TA, 1993, MACROPHAGE PATHOGEN, P83; HAMILTON TA, 1992, MONONUCLEAR PHAGOCYT, P47; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUROI M, 1993, J BIOL CHEM, V268, P19534; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHMORI Y, 1992, J IMMUNOL, V148, P538; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WIDMER U, 1993, J IMMUNOL, V150, P4996; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHENG S, 1993, J BIOL CHEM, V268, P17233	73	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17684	17690						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021280				2022-12-27	WOS:A1994NU12800054
J	SUZUKI, T; SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S				SUZUKI, T; SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S			PURIFICATION AND ENZYMATIC-PROPERTIES OF PEPTIDE-N-GLYCANASE FROM C3H MOUSE-DERIVED L-929 FIBROBLAST CELLS - POSSIBLE WIDESPREAD OCCURRENCE OF POSTTRANSLATIONAL, REMODIFICATION OF PROTEINS BY N-DEGLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCANS; RICIN A-CHAIN; ORYZIAS-LATIPES; GLYCOSIDASE-F; GLYCOPROTEIN PRECURSOR; UNFERTILIZED EGGS; CONCANAVALIN-A; MEDAKA FISH; FLAVOBACTERIUM-MENINGOSEPTICUM; FREE SIALOOLIGOSACCHARIDES	Recently, we found the occurrence of N-deglycosylating enzyme, peptide:N-glycanase (PNGase), in mammalian cells and observed that PNGase is a rather common enzyme involved in post-translational remodification of proteins (Suzuki, T., Seko, A., Kitajima, K., Inoue, Y., and Inoue, S. (1993) Biochem. Biophys. Res. Commun. 194, 1124-1130). We report here a 460-fold purification to homogeneity with 11.5% yield of PNGase from crude extract of C3H mouse-derived L-929 fibroblast cells, The purified enzyme, designated as L-929 PNGase, had the apparent molecular weight of 212,000 and was composed of two 105,000 subunits. Although this enzyme was capable of hydrolyzing structurally diverse natural glycopeptide substrates bearing high mannose, hybrid, and complex-type glycan units, the activity was completely inhibited by the presence of the fucose residue either (alpha-1-->3- or alpha-1-->6-linked to the proximal GlcNAc residue. The enzyme showed maximal activity at pH near 7. This and the inability to act on glycoasparagine strongly support our view that this enzyme would not be involved in lysosomal degradation pathway. L-929 PNGase was characterized by having distinctly a low K-m value, which may be of physiological significance. Possible wide occurrence of N-deglycosylation of glycoproteins was shown by a data bank survey of the protein sequences showing discrepancies between those determined directly (-D-X-(S/T)-) and those deduced from cDNA sequencing (-N-X-(S/T)). We propose here that PNGase-catalyzed N-deglycosylation is a functionally important universal feature in living cells.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN	University of Tokyo; Showa University			Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014	Suzuki, Tadashi/0000-0003-1030-7631; 				AUSTEN BM, 1977, J BIOL CHEM, V252, P8142; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOSTIAN KA, 1983, CELL, V32, P169, DOI 10.1016/0092-8674(83)90507-X; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CHU FK, 1986, J BIOL CHEM, V261, P172; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOXWELL BMJ, 1985, BIOCHIM BIOPHYS ACTA, V840, P193, DOI 10.1016/0304-4165(85)90119-9; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; HERMAN EM, 1985, PLANTA, V165, P23, DOI 10.1007/BF00392207; INOUE S, 1989, J BIOL CHEM, V264, P18520; INOUE S, 1993, GLYCOCONJUGATE J, V10, P223, DOI 10.1007/BF01209812; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1992, J BIOL CHEM, V267, P24287; JACOBSON RS, 1991, J ALLERGY CLIN IMMUN, V89, P292; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KALINSKI A, 1992, J BIOL CHEM, V267, P12068; KIMURA Y, 1990, AGR BIOL CHEM TOKYO, V54, P157, DOI 10.1080/00021369.1990.10869890; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; KITO K, 1969, J CHROMATOGR, V44, P205, DOI 10.1016/S0021-9673(01)92526-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LHEONOULD S, 1992, GLYCOCONJUGATE J, V9, P191; MESHI T, 1981, MOL GEN GENET, V184, P20, DOI 10.1007/BF00271189; MIN W, 1992, EMBO J, V11, P1302; MUSSAR KJ, 1989, J BIOCHEM BIOPH METH, V20, P53, DOI 10.1016/0165-022X(89)90081-X; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; NOMOTO H, 1983, EUR J BIOCHEM, V135, P243, DOI 10.1111/j.1432-1033.1983.tb07644.x; NOMOTO H, 1992, BIOSCI BIOTECH BIOCH, V56, P1090, DOI 10.1271/bbb.56.1090; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; PRIEM B, 1990, GLYCOCONJUGATE J, V7, P121, DOI 10.1007/BF01050375; RAMAKRISHNAN S, 1982, BIOCHIM BIOPHYS ACTA, V719, P341, DOI 10.1016/0304-4165(82)90108-8; REES MW, 1975, BIOCHIM BIOPHYS ACTA, V393, P15, DOI 10.1016/0005-2795(75)90211-1; REES MW, 1974, BIOMED MASS SPECTROM, V1, P237, DOI 10.1002/bms.1200010407; SEKO A, 1991, BIOCHEM BIOPH RES CO, V180, P1165, DOI 10.1016/S0006-291X(05)81318-X; SEKO A, 1989, J BIOL CHEM, V264, P15922; SEKO A, 1991, J BIOL CHEM, V266, P22110; SHELDON PS, 1992, EMBO J, V11, P1297, DOI 10.1002/j.1460-2075.1992.tb05173.x; STEERS E, 1965, J BIOL CHEM, V240, P2478; SUGIYAMA K, 1983, BIOCHEM BIOPH RES CO, V112, P155, DOI 10.1016/0006-291X(83)91810-7; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; SUZUKI T, 1993, GLYCOCONJUGATE J, V10, P223, DOI 10.1007/BF01209813; TAGA EM, 1984, BIOCHEMISTRY-US, V23, P815, DOI 10.1021/bi00300a006; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; TAGUCHI T, 1994, J BIOL CHEM, V269, P8762; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VIERULA PJ, 1989, J BIOL CHEM, V264, P1108; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301; YOSHITAKE S, 1978, AGR BIOL CHEM TOKYO, V42, P1267, DOI 10.1080/00021369.1978.10863144	57	128	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17611	17618						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021270				2022-12-27	WOS:A1994NU12800044
J	LIBRACH, CL; FEIGENBAUM, SL; BASS, KE; CUI, TY; VERASTAS, N; SADOVSKY, Y; QUIGLEY, JP; FRENCH, DL; FISHER, SJ				LIBRACH, CL; FEIGENBAUM, SL; BASS, KE; CUI, TY; VERASTAS, N; SADOVSKY, Y; QUIGLEY, JP; FRENCH, DL; FISHER, SJ			INTERLEUKIN-1-BETA REGULATES HUMAN CYTOTROPHOBLAST METALLOPROTEINASE ACTIVITY AND INVASION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN-LUNG FIBROBLASTS; NECROSIS-FACTOR-ALPHA; IV COLLAGENASE; HUMAN TROPHOBLAST; HUMAN-PLACENTA; HUMAN-MONOCYTES; IL-1 RECEPTORS; II RECEPTOR; EXPRESSION	During early human pregnancy, fetal cytotrophoblasts rapidly invade the uterus. This process has many similarities to tumor invasion, except that the extent and the timing of cytotrophoblast invasion are carefully regulated. Therefore, this system is particularly useful for studying mechanisms that regulate invasive processes. Previously, we showed that production and activation of the 92-kDa type IV collagenase (matrix metalloproteinase(MMP)-9) is necessary for cytotrophoblast invasion in vitro. In other systems, interleukin (IL)-1 beta is an important regulator of matrix-degrading metalloproteinases. Therefore, we investigated trophoblast production of IL-1 beta and its receptors, as well as the effects of this cytokine on cytotrophoblast metalloproteinase activity and invasion. The results showed that release of IL-1 beta parallels the invasive potential of the cytotrophoblasts; the highest levels are produced by first trimester cells and the lowest levels by term cells. Immunoprecipitation showed that cytotrophoblasts express the 80-kDa type I IL-1 receptor, suggesting that autocrine effects are possible. IL-1 beta stimulated trophoblast MMP-9 secretion (by a mechanism that required nascent mRNA and protein synthesis) as well as metalloproteinase activity and invasion of Matrigel. Increasing (by lipopolysaccharide treatment) or decreasing (by glucocorticoid treatment) IL-1 beta production had parallel effects on MMP-9 secretion, metalloproteinase activity, and invasion. Because IL-1 beta and corticosteroids are present in high concentrations at the maternal-fetal interface, normal trophoblast invasion may be regulated, in part, by their opposing actions. In contrast, stimulation of cytotrophoblast IL-1 beta secretion by lipopolysaccharide may play a role in the sequela of infected fetal membranes.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV TORONTO,TORONTO GEN HOSP,DEPT OBSTET & GYNECOL,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,TORONTO GEN HOSP,DEPT REPROD BIOL,TORONTO M5G 2C4,ON,CANADA; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA055852] Funding Source: NIH RePORTER; NCI NIH HHS [CA5585201] Funding Source: Medline; NICHD NIH HHS [HD 26732] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APLIN JD, 1991, J CELL SCI, V99, P681; BUTLER LD, 1989, J NEUROIMMUNOL, V24, P143, DOI 10.1016/0165-5728(89)90108-2; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; DINARELLO CA, 1989, IMMUNOL TODAY, V10, P49, DOI 10.1016/0167-5699(89)90304-6; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; ELLIS SA, 1990, J IMMUNOL, V144, P731; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GERRETSEN G, 1981, BRIT J OBSTET GYNAEC, V88, P876, DOI 10.1111/j.1471-0528.1981.tb02222.x; Hayat MA, 1973, PRINCIPLES TECHNIQUE, V3, P237; HORUK R, 1987, J BIOL CHEM, V262, P16275; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HUNT JS, 1989, J REPROD IMMUNOL, V16, P1, DOI 10.1016/0165-0378(89)90002-8; JAFFE RB, 1986, REPRODUCTIVE ENDOCRI, P758; KAUMA S, 1990, AM J OBSTET GYNECOL, V163, P1430, DOI 10.1016/0002-9378(90)90601-3; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Main E.K., 1987, TROPHOBLAST RES, V2, P149; MASUHIRO K, 1991, J CLIN ENDOCR METAB, V72, P594, DOI 10.1210/jcem-72-3-594; MURLAS C, 1982, J APPL PHYSIOL, V52, P1084, DOI 10.1152/jappl.1982.52.4.1084; NESTLER JE, 1993, ENDOCRINOLOGY, V132, P566, DOI 10.1210/en.132.2.566; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; OGATA Y, 1992, EXP CELL RES, V201, P245, DOI 10.1016/0014-4827(92)90271-9; PAULESU L, 1991, LYMPHOKINE CYTOK RES, V10, P443; PETRAGLIA F, 1990, AM J OBSTET GYNECOL, V163, P1307, DOI 10.1016/0002-9378(90)90711-F; PIJNENBORG R, 1990, TROPH RES, V4, P33; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; RINGLER GE, 1989, ENDOCRINOLOGY, V124, P1625, DOI 10.1210/endo-124-4-1625; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; ROMERO R, 1989, AM J OBSTET GYNECOL, V160, P1117, DOI 10.1016/0002-9378(89)90172-5; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1993, ONCOGENE, V8, P395; Savage N, 1989, Cytokine, V1, P23, DOI 10.1016/1043-4666(89)91045-4; SHIRAKAWA F, 1987, J IMMUNOL, V138, P4243; SPITZ IM, 1993, NEW ENGL J MED, V329, P404; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHL J, 1989, J IMMUNOL, V142, P1576; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WAHL SM, 1993, P NATL ACAD SCI USA, V90, P4577, DOI 10.1073/pnas.90.10.4577; WEINGARTEN H, 1985, BIOCHEMISTRY-US, V24, P6730, DOI 10.1021/bi00344a064; WERB Z, 1978, J EXP MED, V147, P1695, DOI 10.1084/jem.147.6.1695; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YAGEL S, 1989, J CLIN ENDOCR METAB, V68, P992, DOI 10.1210/jcem-68-5-992; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	59	264	274	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17125	17131						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006017				2022-12-27	WOS:A1994NT84600024
J	CHOUDHURY, K; SUNDARAMOORTHY, M; HICKMAN, A; YONETANI, T; WOEHL, E; DUNN, MF; POULOS, TL				CHOUDHURY, K; SUNDARAMOORTHY, M; HICKMAN, A; YONETANI, T; WOEHL, E; DUNN, MF; POULOS, TL			ROLE OF THE PROXIMAL LIGAND IN PEROXIDASE CATALYSIS - CRYSTALLOGRAPHIC, KINETIC, AND SPECTRAL STUDIES OF CYTOCHROME-C PEROXIDASE PROXIMAL LIGAND MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL SITE; ELECTRON-TRANSFER; COMPOUND-I; CRYSTAL-STRUCTURE; STOPPED-FLOW; HEME; MUTAGENESIS; REDUCTION; ES; TRYPTOPHAN-51	The role of the proximal histidine ligand in peroxidase function was studied by replacing the His side chain in cytochrome c peroxidase with Gln, Glu, or Cys. In addition, a double mutant was prepared where His-175 is converted to Gln and the site of free radical formation in Compound I, Trp-191 (Sivaraja, M., Goodin, D. B., Smith, M., and Hoffman, B. M. (1989) Science 245, 738-740), is converted to Phe. With the exception of the His-175 --> Cys mutant, the proximal ligand mutants retain high levels of enzyme activity. Stopped flow studies show that replacing the His ligand with Gln has only a modest effect on the rate of Compound I formation demonstrating that the precise nature of the proximal ligand is not important in achieving a high rate of peroxide O-O bond cleavage. The double mutant, His-175 --> Gln/Trp-191 --> Phe, also forms Compound I rapidly but the initial product formed is very likely a long-lived porphyrin pi cation radical that slowly converts to a species more closely resembling the heme oxyferryl center of wild type Compound I. The relevance of these studies to the cytochrome c peroxidase-cytochrome c electron transfer system are discussed.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV CALIF RIVERSIDE,DEPT BIOCHEM 015,RIVERSIDE,CA 92521	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Pennsylvania; University of California System; University of California Riverside					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048130, R01GM042614] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14508] Funding Source: Medline; NIGMS NIH HHS [GM 42614, GM 48130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ASAKURA T, 1969, J BIOL CHEM, V244, P4573; BALNY C, 1987, FEBS LETT, V221, P349, DOI 10.1016/0014-5793(87)80954-7; BRUNGER AT, 1992, X PLOR 3 1; BRZOVIC PS, 1993, BIOANALYTICAL INSTRU, P191; CHOUDHURY K, 1992, J BIOL CHEM, V267, P25656; CONKLIN KT, 1988, J AM CHEM SOC, V110, P3345, DOI 10.1021/ja00219a001; CONROY CW, 1978, BIOCHIM BIOPHYS ACTA, V537, P619; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Fowler RM, 1935, J RES NAT BUR STAND, V15, P493, DOI 10.6028/jres.015.032; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HO PS, 1983, J BIOL CHEM, V258, P4356; HO PS, 1984, BIOCHEMISTRY-US, V23, P4122, DOI 10.1021/bi00313a017; HORI H, 1985, J BIOL CHEM, V260, P349; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MEYER HW, 1952, HELV CHIM ACTA, V35, P1444, DOI 10.1002/hlca.19520350503; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; POULOS TL, 1993, J BIOL CHEM, V268, P4429; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SUMMERS FE, 1988, J BIOL CHEM, V263, P14267; SUNDARAMOORTHY M, 1991, J AM CHEM SOC, V113, P7755, DOI 10.1021/ja00020a044; TAKIO K, 1980, ARCH BIOCHEM BIOPHYS, V203, P615, DOI 10.1016/0003-9861(80)90219-2; YONETANI T, 1987, J BIOL CHEM, V262, P9547; Yonetani T., 1976, ENZYMES, P345; [No title captured]	40	98	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20239	20249						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051115				2022-12-27	WOS:A1994PB31700008
J	LAZAR, J; DESVERGNE, B; ZIMMERMAN, EC; ZIMMER, DB; MAGNUSON, MA; NIKODEM, VM				LAZAR, J; DESVERGNE, B; ZIMMERMAN, EC; ZIMMER, DB; MAGNUSON, MA; NIKODEM, VM			A ROLE FOR INTRONIC SEQUENCES ON EXPRESSION OF THYROID-HORMONE RECEPTOR-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; DOMAIN TRANSCRIPTION FACTORS; RESPONSE ELEMENT; REGULATORY ELEMENTS; MEDIATES INDUCTION; C-ERBA-1 GENE; OCTAMER MOTIF; DNA-BINDING; 1ST INTRON; PROTEIN	We have cloned and characterized the organization of the rat thyroid hormone receptor alpha (THR) gene. Multiple transcription start sites were mapped by RNA primer extension analyses. The promoter of the rat THR alpha gene does not contain a TATA or CAAT box. Deletion analyses of the 5' region of THR alpha gene and transfection assays, using NIH3T3 and NG108-15 cells, revealed that the sequences from -137 to +205 (+205 resides in the first intron) are necessary for efficient expression of this gene. This region contains two positively acting elements, the sequence -137 to -60 upstream from the major start of transcription and three copies of an AGG sequence located in the first intron. In contrast, two octamer-binding motifs in the first intron function as the negative regulatory elements. Gel mobility shift assays showed that the purine-rich sequence and the octamer-binding motifs bind to a protein(s) present in NIH3T3 and NG108-15 cells, the recipients in transient transfection assays. Genomic sequence comparison of THR alpha and beta revealed the presence of the purine-rich track in both genes, while the octamer-binding motifs were found only in the alpha gene. These results might explain the differential regulation of THR alpha and beta gene expression previously noted.	NIDDKD,GENET & BIOCHEM BRANCH,MECHANISMS GENE REGULAT SECT,BETHESDA,MD 20892; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Vanderbilt University			Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Desvergne, Beatrice/C-8892-2016	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Desvergne, Beatrice/0000-0001-5483-288X				ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BROOKS AR, 1989, NUCLEIC ACIDS RES, V17, P9395, DOI 10.1093/nar/17.22.9395; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EATON S, 1987, P NATL ACAD SCI USA, V84, P7634, DOI 10.1073/pnas.84.21.7634; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIDA T, 1993, BIOCHEM BIOPH RES CO, V191, P831, DOI 10.1006/bbrc.1993.1292; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAUDET V, 1993, ONCOGENE, V8, P975; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; SAKURAI A, 1992, BIOCHEM BIOPH RES CO, V185, P78, DOI 10.1016/S0006-291X(05)80957-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20352	20359						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051130				2022-12-27	WOS:A1994PB31700025
J	MAKHINA, EN; KELLY, AJ; LOPATIN, AN; MERCER, RW; NICHOLS, CG				MAKHINA, EN; KELLY, AJ; LOPATIN, AN; MERCER, RW; NICHOLS, CG			CLONING AND EXPRESSION OF A NOVEL HUMAN BRAIN INWARD RECTIFIER POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOMALOUS RECTIFICATION; FUNCTIONAL EXPRESSION; K+ CHANNEL; EGG CELL; PROTEIN; NEURONS; MUTATIONS; CURRENTS; MEMBRANE; STARFISH	A complementary DNA encoding an inward rectifier K+ channel (HRK1) was isolated from human hippocampus using a 392-base pair cDNA (HHCMD37) as a probe. HRK1 shows sequence similarity to three recently cloned inwardly rectifying potassium channels (IRK1, GIRK1, and ROMK1, 60, 42, and 37%, respectively) and has a similar proposed topology of two membrane spanning domains that correspond to the inner core structure of voltage gated K+ channels. When HRK1 was expressed in Xenopus oocytes, large inward K+ currents were observed below the K+ reversal potential but very little outward K+ current was observed. In on-cell membrane patches, single channel conductance (g) was estimated to be 10 picosiemens by both direct measurement and noise analysis, in 102 mM external [K+]. HRK1 currents were blocked by external Ba2+ and Cs+ (K(0) = 183 mu M, and K(-130) = 30 mu M, respectively), and internal tetraethylammonium ion (K(0) = 62 mu M), but were insensitive to external tetraethylammonium ion. The functional properties of HRK1 are very similar to those of glial cell inward rectifier K+ channels and HRK1 may represent a glial cell inward rectifier.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Nichols, Colin/D-6336-2012; Mercer, Robert/F-5918-2012		NIGMS NIH HHS [GM39746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039746, R29GM039746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BREW H, 1986, NATURE, V324, P466, DOI 10.1038/324466a0; BRISMAR T, 1989, BRAIN RES, V480, P249, DOI 10.1016/0006-8993(89)90190-X; CONSTANTI A, 1983, J PHYSIOL-LONDON, V335, P153, DOI 10.1113/jphysiol.1983.sp014526; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; CSERR HF, 1986, ANN NY ACAD SCI, V481, P1, DOI 10.1111/j.1749-6632.1986.tb27134.x; CUI J, 1992, J PHYSIOL-LONDON, V457, P229, DOI 10.1113/jphysiol.1992.sp019375; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HESTRIN S, 1987, J PHYSIOL-LONDON, V390, P319, DOI 10.1113/jphysiol.1987.sp016703; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; KANDEL ER, 1966, J PHYSIOL-LONDON, V183, P287, DOI 10.1113/jphysiol.1966.sp007867; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPATIN AN, 1993, RECEPTOR CHANNEL, V1, P279; LUX HD, 1974, EPILEPSIA, V15, P375, DOI 10.1111/j.1528-1157.1974.tb04015.x; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; NEWMAN EA, 1985, TRENDS NEUROSCI, V8, P156, DOI 10.1016/0166-2236(85)90061-X; NEWMAN EA, 1993, J NEUROSCI, V13, P3333; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; NICHOLSON C, 1978, J NEUROPHYSIOL, V41, P1026, DOI 10.1152/jn.1978.41.4.1026; OHMORI H, 1981, P NATL ACAD SCI-BIOL, V78, P4960, DOI 10.1073/pnas.78.8.4960; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	39	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20468	20474						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051145				2022-12-27	WOS:A1994PB31700042
J	MERELLO, S; XAVIER, MT; PARODI, AJ				MERELLO, S; XAVIER, MT; PARODI, AJ			NOVEL (RHAMNOSYL AND RIBOSYL) AND UNCOMMON (XYLOSYL) MONOSACCHARIDE RESIDUES ARE PRESENT IN ASPARAGINE-LINKED OLIGOSACCHARIDES OF THE TRYPANOSOMATID-BLASTOCRITHIDIA CULICIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSYLATION; GLYCOPROTEINS	BLastocrithidia culicis is a trypanosomatid protozoon that transfers Man(6)GlcNAc(2) in protein N-glycosylation. Compounds containing mannosyl, xylosyl, and rhamnosyl residues were found among the endo-beta-N-acetylglu- cosaminidase H-sensitive oligosaccharides of whole cell glycoproteins of this parasite. The compositions of some of them were as follows: Man(5)GlcNA(2), Man(6)GlcNAc(2), Rha(1)Man(5)GlcNAc(2), Rha(2)Man(6)GlcNAc(2), Xyl(1)Rha(2)Man(6)GlcNAc(2), Xyl(1)Rha(3)Man(6)GlcNAc(2), and Xyl(2)Rha(3)Man(6)GlcNAc(2). On the other hand, oligosaccharides containing mannosyl, xylosyl, rhamnosyl, and ribosyl units were liberated from endo-beta-N-acetylglucosaminidase-resistant glycopeptides upon treatment with N-glycanase. This is the first report on the presence of ribosyl units in eukaryote glycoconjugates, of rhamnosyl residues in asparagine-linked oligosaccharides, and of xylosyl units in high mannose-type compounds.	INST INVEST BIOQUIM FUNDACION CAMPOMAR,RA-1405 BUENOS AIRES,DF,ARGENTINA	Leloir Institute								BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1991, TRENDS GENET, V7, P139, DOI 10.1016/0168-9525(91)90374-Y; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; ENGEL JC, 1985, J BIOL CHEM, V260, P105; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; FISCHER RL, 1991, ANNU REV PLANT PHYS, V42, P675, DOI 10.1146/annurev.pp.42.060191.003331; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MALEY F, 1978, GLYCOPROTEINS GLYCOL, P86; MENDELZON DH, 1986, MOL BIOCHEM PARASIT, V18, P355, DOI 10.1016/0166-6851(86)90092-7; OGATA S, 1982, ANAL BIOCHEM, V119, P351, DOI 10.1016/0003-2697(82)90597-8; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PARODI AJ, 1981, P NATL ACAD SCI-BIOL, V78, P6201, DOI 10.1073/pnas.78.10.6201; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; PREVIATO JO, 1986, MOL BIOCHEM PARASIT, V18, P343, DOI 10.1016/0166-6851(86)90091-5; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; SUTHERLAND IW, 1985, ANNU REV MICROBIOL, V39, P243; SUTHERLAND IW, 1973, J GEN MICROBIOL, V74, P259, DOI 10.1099/00221287-74-2-259; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WALSH C, 1991, TRENDS BIOCHEM SCI, V16, P305, DOI 10.1016/0968-0004(91)90124-E	20	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20294	20298						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051123				2022-12-27	WOS:A1994PB31700016
J	MIMS, MP; DARNULE, AT; TOVAR, RW; POWNALL, HJ; SPARROW, DA; SPARROW, JT; VIA, DP; SMITH, LC				MIMS, MP; DARNULE, AT; TOVAR, RW; POWNALL, HJ; SPARROW, DA; SPARROW, JT; VIA, DP; SMITH, LC			A NONEXCHANGEABLE APOLIPOPROTEIN-E PEPTIDE THAT MEDIATES BINDING TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; HEPARAN-SULFATE PROTEOGLYCANS; CULTURED-CELLS; III HYPERLIPOPROTEINEMIA; PLASMA-LIPOPROTEINS; PARTICLE-SIZE; LDL RECEPTOR; E APOPROTEIN; ATHEROSCLEROSIS; METABOLISM	ApoE is a 34-kDa apoprotein that mediates lipoprotein binding to the low density lipoprotein (LDL) receptor and to the LDL receptor-related protein. Receptor binding is mediated by a highly basic, alpha-helical sequence of similar to 15 amino acids that interacts with cysteine-rich repeat regions of the receptor. To determine the relationship between the receptor binding and lipid associating properties of apoE, we have synthesized a series of apoE peptides containing all (residues 129-169) or part (residues 139-169, 144-169, and 148-169) of the receptor-binding domain. The lipophilicity of these peptides was increased by modification of their N termini by acylation with either palmitic acid (C-16-apoE peptide) or the N,N-distearyl derivative of glycine (diC(18)-Gly-apoE peptide). The unmodified peptides demonstrated low affinity for lipid surfaces (K-d > 10(-5) M) and moderate alpha-helicity in the presence of lipid (40%) and had no effect on LDL uptake by fibroblasts. N-Palmitoyl peptides had increased affinity for lipid (K-d similar to 10(-6) M) and increased alpha-helicity (55%) in the presence of lipid. The addition of the C-16-apoE-(129-169)-peptide to I-125-LDL enhanced its uptake and degradation by fibroblasts 8-10-fold; however, <50% of the degradation was mediated by the LDL receptor. By contrast, the diC(18)-Gly-apoE-(129-169)-peptide was essentially nonexchangeable (K-d less than or equal to 10(-9) M) and highly helical (78%) in the presence of lipid. The addition of the diC(18)-Gly-apoE-(129-169)-peptide to I-125-LDL enhanced the specific uptake and degradation of LDL by both LDL receptor mediated and non-LDL receptor-mediated mechanisms. Uptake and degradation of methylated LDL containing diC(18)-Gly-apoE-(129-169) revealed that the lipoprotein-bound peptide is the active agent. In agreement with this finding a mutant diC(18)-Gly-apoE peptide (Arg(142) --> Gln) was much less effective than the wild-type peptide in potentiating binding, uptake, and degradation of I-125-LDL. Complexes of diC(18)-Gly-apoE-(129-169), apoA-I, and In summary, the receptor binding properties of apoE depend on its association with phospholipid; transfer of peptide fragments of the receptor-binding domain of apoE from the aqueous phase to a lipid surface converts them from a random coil to an alpha-helical conformation that is recognized by the LDL receptor, Moreover, since the N,N-distearylglycyl peptide is nonexchangeable, the data indicate that it can be used to probe the structural requirements for ligand binding and the processing of apoE-containing lipoproteins. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine containing four to six copies of the peptide/particle displayed an affinity for the LDL receptor similar to that of apoE-L-alpha-dimyristoylphosphatidyl-choline discs containing four copies of apoE.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHYSIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Pownall, Henry/0000-0001-8412-506X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046860, R01HL030914, R01HL034111] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34111, HL46860, HL30914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADDOCK DT, 1992, CIRCULATION S, V86, P1; CARDIN AD, 1989, ANN NY ACAD SCI, V556, P186; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4170; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DYER CA, 1991, J BIOL CHEM, V266, P22803; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; HORIE Y, 1992, J BIOL CHEM, V267, P1962; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAHLEY RW, 1981, J CLIN INVEST, V68, P1197, DOI 10.1172/JCI110365; MIMS MP, 1990, BIOCHEMISTRY-US, V29, P6639, DOI 10.1021/bi00480a013; MIMS MP, 1986, BIOCHEMISTRY-US, V25, P474, DOI 10.1021/bi00350a030; MIMS MP, 1992, CIRCULATION, V86, P551; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PONSIN G, 1986, J CLIN INVEST, V77, P559, DOI 10.1172/JCI112337; PONSIN G, 1984, BIOCHEMISTRY-US, V23, P5337, DOI 10.1021/bi00317a036; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW JT, 1976, J ORG CHEM, V41, P1350, DOI 10.1021/jo00870a013; SPARROW JT, 1985, BIOCHEMISTRY-US, V24, P6984, DOI 10.1021/bi00345a035; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TANFORD C, 1980, HYDROPHOBIC EFFECT, P53; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1992, ATHEROSCLEROSIS, V9, P29; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZANNIS VI, 1980, J BIOL CHEM, V255, P1759; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20539	20547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051153				2022-12-27	WOS:A1994PB31700053
J	TEIXEIRA, SMR; RUSSELL, DG; KIRCHHOFF, LV; DONELSON, JE				TEIXEIRA, SMR; RUSSELL, DG; KIRCHHOFF, LV; DONELSON, JE			A DIFFERENTIALLY EXPRESSED GENE FAMILY ENCODING AMASTIN A SURFACE PROTEIN OF TRYPANOSOMA-CRUZI AMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-SIALIDASE; LEISHMANIA; BRUCEI; TRANSCRIPTION; GLYCOPROTEIN; CELLS; FORMS	A new family of closely related glycoproteins, collectively called amastins, has been found on the surface of the amastigote form of Trypanosoma cruzi. The gene family encoding these amastigote-specific proteins was identified by differentially screening an amastigote cDNA library with reverse transcribed poly(A)(+) RNA from amastigote and epimastigote stages of the parasite. Amastins are encoded by eight or more tandem genes, at least five of which are distinguished by nucleotide point changes. The 1.4-kilobase amastin mRNAs are 50 times more abundant in amastigotes than in epimastigotes or trypomastigotes. The amastin genes are transcribed to an equal extent in both amastigotes and epimastigotes, indicating that the stage-specific amastin mRNA levels are determined by a post-transcriptional mechanism. Sequence determination of full-length cDNAs reveals an open reading frame encoding 174 amino acids and a 700-base pair 3'-untranslated region. Nascent amastins contain four distinct hydrophobic regions of 20-30 amino acids each, 2 at internal locations and 1 each at the N and C termini.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242; UNIV IOWA,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; WASHINGTON UNIV,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Howard Hughes Medical Institute; University of Iowa; Washington University (WUSTL)			Donelson, John E/F-5795-2010; Russell, David G/D-4533-2009; Russell, David G/N-5280-2019; TEIXEIRA, SANTUZA MR/I-8137-2013	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X; 	NIAID NIH HHS [AI 34207, AI 26889, AI 24711] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024711, R01AI034207, R01AI026889, R21AI126889] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NW, 1988, J EXP MED, V167, P300, DOI 10.1084/jem.167.2.300; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; DEARRUDA MV, 1990, MOL BIOCHEM PARASIT, V40, P35, DOI 10.1016/0166-6851(90)90077-Y; DECARVALHO TU, 1983, Z PARASITENKD, V69, P571; Fourney R.M., 1988, FOCUS, V10, P5; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAHN S, 1991, P NATL ACAD SCI USA, V88, P4481, DOI 10.1073/pnas.88.10.4481; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; Kriegler M., 1990, GENE TRANSFER EXPRES; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEY V, 1988, J EXP MED, V168, P649, DOI 10.1084/jem.168.2.649; MCCABE R E, 1984, Infection and Immunity, V46, P373; PAN AA, 1989, J IMMUNOL, V143, P1001; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PIZZI T, 1957, THESIS U CHILE SANTI; RUSSELL DG, 1992, J CELL SCI, V103, P1193; Sambrook J, 1989, MOL CLONING LABORATO; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1993, PARASITOL TODAY, V9, P218, DOI 10.1016/0169-4758(93)90017-A; SILVA LHP, 1953, FOLIA CLIN BIOL, V20, P197; Silveira FT, 1979, HILEIA MED BELEM, V1, P61; VILLALTA F, 1982, J PROTOZOOL, V29, P570, DOI 10.1111/j.1550-7408.1982.tb01338.x; WILLIAMS DM, 1976, J INFECT DIS, V134, P610, DOI 10.1093/infdis/134.6.610; WILSON ME, 1989, J IMMUNOL, V143, P678	25	94	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20509	20516						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051148				2022-12-27	WOS:A1994PB31700048
J	REITH, W; KOBR, M; EMERY, P; DURAND, B; SIEGRIST, CA; MACH, B				REITH, W; KOBR, M; EMERY, P; DURAND, B; SIEGRIST, CA; MACH, B			COOPERATIVE BINDING BETWEEN FACTOR-RFX AND FACTOR-X2BP TO THE X-BOX AND X2-BOX OF MHC CLASS-II PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX GENES; TRANS-ACTING PROTEIN; HLA-DR-ALPHA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; B-CELLS; GAL4 DERIVATIVES; RESPONSE ELEMENT; PLASMA-CELLS; C-FOS	Transcription of major histocompatibility complex (MHC) class II genes is controlled primarily by the promoter, which contains several conserved cis-acting elements, including the X, X2, and Y boxes. We show here that RFX, the X box-binding protein that is deficient in certain MHC class II regulatory mutants, binds cooperatively with an X2 box-binding protein (X2bp) to form an RFX.X2bp.DNA complex in which the interaction of the two factors with their target sites is strongly stabilized. A functional role of this RFX.X2bp complex is consistent with mutational analysis of the X and X2 boxes of the DRA and DRB1 class II promoters. Together with previous results demonstrating cooperative binding between RFX and the Y box-binding protein NF-Y, our results indicate that RFX plays a central role in promoting cooperative binding interactions required for stable occupation of the MHC class II promoter. This may explain why the highly specific defect in binding of RFX observed in certain MHC class II regulatory mutants is associated in vivo with a bare promoter in which all of the cis-acting elements, including the X, X2, and Y boxes, are unoccupied.	UNIV GENEVA,CTR MED,SCH MED,DEPT GENET & MICROBIOL,JEANTET LAB MOLEC GENET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			DURAND, Benedicte/AAE-5658-2021	DURAND, Benedicte/0000-0002-8530-0613				AMALDI I, 1989, J IMMUNOL, V142, P999; ANDERSSON G, 1990, J IMMUNOL, V145, P3456; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EMERY P, 1993, HUM IMMUNOL, V38, P137, DOI 10.1016/0198-8859(93)90531-5; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Griscelli C, 1989, Immunodefic Rev, V1, P135; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HASEGAWA SL, 1993, J IMMUNOL, V150, P1781; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P1243, DOI 10.1093/nar/19.6.1243; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HIRAI S-I, 1989, New Biologist, V1, P181; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KARA CJ, 1991, CURR OPIN IMMUNOL, V3, P16, DOI 10.1016/0952-7915(91)90070-H; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIOU HC, 1988, SCIENCE, V242, P69, DOI 10.1126/science.3140376; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MACH B, 1994, IMMUNOL REV, V138, P207, DOI 10.1111/j.1600-065X.1994.tb00853.x; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SEIDL C, 1992, J IMMUNOL, V148, P1576; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; SLOAN JH, 1992, J IMMUNOL, V148, P2591; STIMAC E, 1991, J IMMUNOL, V146, P4398; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	58	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20020	20025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051086				2022-12-27	WOS:A1994PA12600055
J	SINGER, WD; MILLER, RT; STERNWEIS, PC				SINGER, WD; MILLER, RT; STERNWEIS, PC			PURIFICATION AND CHARACTERIZATION OF THE ALPHA-SUBUNIT OF G(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; PHOSPHOLIPASE-C ISOZYMES; BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; G-PROTEINS; REGULATORY PROTEINS; ADENYLATE-CYCLASE; IMMUNOLOGICAL IDENTIFICATION; AFFINITY-CHROMATOGRAPHY; ESCHERICHIA-COLI	Specific antisera were produced to peptides representing the carboxyl terminus of alpha(13), a recently identified alpha subunit of the heterotrimeric guanine nucleotide-binding proteins (G proteins). Immunodetection with the antisera indicated that the 43 kDa protein is expressed ubiquitously at low levels (0.005-0.05% of membrane protein) in tissues and cultured cells. A combination of conventional and immunoaffinity chromatographic techniques was used to purify small quantities of alpha(13) from bovine brain. Quantities of protein sufficient for biochemical analysis could be produced by concurrent expression of alpha(13) with G protein beta(2) and gamma(2) subunits using a baculovirus system. The rate of dissociation of GDP from recombinant alpha(13) (r alpha(13)) is slow (0.01-0.02 min(-1) at 30 degrees C), and relatively high concentrations of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) are required to observe nucleotide binding. This binding was reduced significantly in the presence of 20 mM Mg2+. Rates of hydrolysis of GTP by alpha(13) were limited by nucleotide exchange; attempts to measure the intrinsic rate of hydrolysis indicate that it is greater than 0.2 min(-1). Stoichiometric concentrations of beta gamma subunits inhibited binding of GTP gamma S to and hydrolysis of GTP by alpha(13). By reconstitution, the purified alpha(13) did not affect the activity of several known effector enzymes. The availability of purified r alpha(13) and knowledge of its biochemical properties will allow further characterization of its interactions with receptors and effecters.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK41726] Funding Source: Medline; NIGMS NIH HHS [R01-GM31954, F32-GM1539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SMRCKA AV, 1993, METHODS NEUROSCI, V18, P72; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Summers MD, 1987, TEXAS AGR EXPT STATI; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721	56	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19796	19802						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051060				2022-12-27	WOS:A1994PA12600024
J	FISCHER, GA; CLEMENTI, E; RAICHMAN, M; SUDHOF, T; ULLRICH, A; MELDOLESI, J				FISCHER, GA; CLEMENTI, E; RAICHMAN, M; SUDHOF, T; ULLRICH, A; MELDOLESI, J			STABLE EXPRESSION OF TRUNCATED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR SUBUNITS IN 3T3 FIBROBLASTS - COORDINATE SIGNALING CHANGES AND DIFFERENTIAL SUPPRESSION OF CELL-GROWTH AND TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; HUMAN EGF RECEPTOR; 1,4,5-TRISPHOSPHATE RECEPTOR; TYROSINE PHOSPHORYLATION; AUTOPHOSPHORYLATION SITES; KINASE-ACTIVITY; INSP3 RECEPTOR; POINT MUTATION; CALCIUM; MITOGENESIS	Stable clones of NIH 3T3 fibroblasts transfected with the cDNA of either the wild-type or deletion forms of the rat type I (or cerebellar) inositol 1,4,5-trisphosphate (IP3) receptor (IP(3)R) were investigated. The Delta form, missing the NH2-terminal sequence that includes the IP3-binding site, is expected to be still assembled with wild-type subunits to yield a tetrameric Ca2+ channel across the endoplasmic reticulum membrane; the s form, missing the membrane-spanning sequences, is expected to remain as a soluble monomer in the cytosol. With respect to control clones transfected with the vector only, the synthesis of IP(3)Rs was markedly stimulated in the receptor-transfected clones. The mass accumulation, however, was increased only moderately (deletion forms = 15-30% of the endogenous IP(3)R), apparently because of a compensatory increase in receptor turnover. Coordinate changes in IP3 generation and Ca2+ release were revealed in the Delta clones by experiments in both intact and permeabilized cells. In these clones, the IP(3)R was more sensitive to IP3, and IP3 generation at the ATP P-2u surface receptor was decreased. This latter effect was due neither to a defect in G protein coupling nor to changes in phospholipase C expression, but to down-regulation of the P-2u receptor. In the cells expressing the s- and Delta-IP(3)R subunits, no differences with respect to the controls were observed in epidermal growth factor-induced DNA synthesis, whereas long-term growth stimulated by serum was reduced. Even more marked, especially in the Delta clones (-90%), was the inhibition of cell transformation induced by autocrine stimulation with transforming growth factor a of the overexpressed epidermal growth factor receptors or by other growth factor receptors and oncogenes (platelet-derived growth factor/platelet-derived growth factor receptor beta, HER2/neu, and v-erbB). These effects appear not to be connected to the signaling processes mediated by tyrosine phosphorylation since the latter was unchanged in the Delta clones. These results demonstrate for the first time (a) that the changes in cellular homeostasis directly in duced by deleted IP(3)R subunits (increased receptor synthesis and increased IP(3)R sensitivity) are largely compensated by indirect coordinate changes apparently aimed to keep near normal the signaling properties of the cells; (b) that modulation of intracellular Ca2+ channels induces profound consequences that differentially affect growth and oncogenesis; and (c) that IP(3)Rs and the Ca2+ stores are important cross-roads of intracellular signaling pathways.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY; UNIV MILAN,CNR,DEPT PHARMACOL,I-20132 MILAN,ITALY; UNIV MILAN,CTR CYTOPHARMACOL,I-20132 MILAN,ITALY; UNIV MILAN,B CECCARELLI CTR,I-20132 MILAN,ITALY; UNIV MILAN,SCI INST SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY; UNIV TEXAS,HOWARD HUGHES MED INST,DEPT MOLEC GENET,DALLAS,TX 75235	Max Planck Society; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; University of Milan; University of Milan; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas								ALDERSON BH, 1989, ARCH BIOCHEM BIOPHYS, V272, P162, DOI 10.1016/0003-9861(89)90207-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FENDLY BM, 1990, CANCER RES, V50, P1550; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTMANN T, 1986, EXP CELL RES, V163, P279, DOI 10.1016/0014-4827(86)90582-3; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; L'allemain G, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000255; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MASSOGLIA S, 1990, MOL CELL BIOL, V10, P3048, DOI 10.1128/MCB.10.6.3048; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERRIN D, 1991, FEBS LETT, V294, P47, DOI 10.1016/0014-5793(91)81340-E; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POZZAN T, 1994, IN PRESS PHYSL REV; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VONRUDEN T, 1988, EMBO J, V7, P2749, DOI 10.1002/j.1460-2075.1988.tb03129.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19216	19224						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034682				2022-12-27	WOS:A1994NY33200006
J	DITTRICH, E; ROSEJOHN, S; GERHARTZ, C; MULLBERG, J; STOYAN, T; YASUKAWA, K; HEINRICH, PC; GRAEVE, L				DITTRICH, E; ROSEJOHN, S; GERHARTZ, C; MULLBERG, J; STOYAN, T; YASUKAWA, K; HEINRICH, PC; GRAEVE, L			IDENTIFICATION OF A REGION WITHIN THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-6 (IL-6) SIGNAL TRANSDUCER GP130 IMPORTANT FOR LIGAND-INDUCED ENDOCYTOSIS OF THE IL-6 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN TRAFFICKING; ACUTE-PHASE RESPONSE; MOLECULAR-CLONING; DOWN-REGULATION; INTERNALIZATION; EXPRESSION; CELLS; BIOLOGY; BINDING; MOTIF	Interleukin-6 (IL-6) exerts its action via a cell surface receptor complex consisting of two subunits, the IL-6 receptor and the signal transducer gp130. We have studied the role of both transmembrane proteins for IL-6 internalization and ligand-induced down-regulation of cell surface receptors. Co-expression of wild-type and mutant forms of both the IL-6 receptor and gp130 in transiently transfected COS-7 cells revealed that gp130 is essential for efficient endocytosis and receptor down-regulation. Whereas the cytoplasmic domain of the IL-6 receptor is not significantly involved in the internalization process, deletion of the corresponding domain of gp130 resulted in an almost complete loss of the ability to endocytose IL-6. Mutants with different truncations within the intracellular domain of gp130 revealed that a 10-amino acid sequence TQPLLDSEER is crucial for efficient internalization. Since this sequence contains a putative di-leucine internalization motif, we suggest that a di-leucine motif directs the receptor mediated endocytosis of the IL-6 receptor complex.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; TOSOH CORP,BIOTECHNOL RES LAB,AYASE,KANAGAWA 252,JAPAN	RWTH Aachen University; Tosoh Corporation			Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MULLBERG J, 1994, J IMMUNOL, V52, P4958; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NESBITT JE, 1992, J BIOL CHEM, V267, P5739; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; SAITO T, 1993, J IMMUNOL METHODS, V163, P217, DOI 10.1016/0022-1759(93)90125-Q; Sambrook J, 1989, MOL CLONING LABORATO; SCHOOLTINK H, 1991, BIOCHEM J, V277, P659, DOI 10.1042/bj2770659; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEHGAL PB, 1990, ANN NY ACAD SCI, V557, P1; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAGUCHI M, 1992, J BIOL CHEM, V267, P22035; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	40	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19014	19020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034658				2022-12-27	WOS:A1994NX32700048
J	KATO, M; WANG, HM; BERNFIELD, M; GALLAGHER, JT; TURNBULL, JE				KATO, M; WANG, HM; BERNFIELD, M; GALLAGHER, JT; TURNBULL, JE			CELL-SURFACE SYNDECAN-1 ON DISTINCT CELL-TYPES DIFFERS IN FINE-STRUCTURE AND LIGAND-BINDING OF ITS HEPARAN-SULFATE CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; LOW-DENSITY-LIPOPROTEIN; INTEGRAL MEMBRANE PROTEOGLYCAN; IDURONATE 2-SULFATE RESIDUES; EXTRACELLULAR-MATRIX; CHONDROITIN SULFATE; MOLECULAR-CLONING; BASEMENT-MEMBRANE; I COLLAGEN	Heparan sulfate (HS) can bind a large variety of biological effectors, including extracellular matrix components, growth factors, chemokines, degradative enzymes, and protease inhibitors. Where studied, HS is known to be structurally heterogeneous and to vary in sulfation pattern between cells and tissues. Because heparan sulfate can represent several distinct proteoglycans, we asked whether the structural variation in the heparan sulfate chains of a single species of cell surface proteoglycan is a reproducible, differentiated characteristic and whether the variation can result in distinct biological functions. We studied the molecular structure and binding affinity for type I collagen and fibroblast growth factor-2 of syndecan-1 purified from the surfaces of MMuMG normal murine mammary gland epithelia, NIH/3T3 fibroblasts, and BALB/3T3 endothelioid cells. Syndecan-1 from these cell types varied in molecular mass largely due to variation in the length of the HS chains. Although the highly sulfated and N-acetylated domains in these HS chains were organized similarly, the number of highly sulfated domains differed. The disaccharide compositions were also similar except for reproducible and consistent differences in the amount of hexuronic acid-N-sulfated-6-O-sulfated glucosamine and 2-O-sulfated hexuronic acid-N-sulfated glucosamine. These differences were confirmed by oligosaccharide mapping, which showed cell type-specific variations in the composition of the highly sulfated domains. These structural variations correlated with cell type-specific differences in the affinity of syndecan-1 and its isolated HS chains for type I collagen. However, no differences in affinity for fibroblast growth factor-2 were detected. The results indicate that the size, fine structure, and ligand affinity of the HS chains on a single proteoglycan species differ in a consistent and reproducible manner between cell types. Thus, the variation in structure and binding ability of HS on syndecan-1 is a differentiated characteristic of the cell type that can enable cells to respond distinctly to the HS-binding effectors in the cellular microenvironment.	UNIV MANCHESTER, CHRISTIE HOSP, CANC RES CAMPAIGN, DEPT MED ONCOL, MANCHESTER M20 9BX, ENGLAND; HARVARD UNIV, SCH MED, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Harvard University; Harvard Medical School	KATO, M (corresponding author), UNIV MANCHESTER, CHRISTIE HOSP, DEPT CLIN RES, WILMSLOW RD, MANCHESTER M20 9BX, ENGLAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006763, R01HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NCI NIH HHS [CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; DAVID G, 1985, J BIOL CHEM, V260, P1067; DAVID G, 1981, J NATL CANCER I, V67, P719; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1988, J CELL BIOL, V106, P2203, DOI 10.1083/jcb.106.6.2203; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; KODA JE, 1984, J BIOL CHEM, V259, P1763; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P886; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MULDER M, 1993, J BIOL CHEM, V268, P9369; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON PN, 1987, BIOCHEM J, V243, P175, DOI 10.1042/bj2430175; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WALKER A, 1994, J BIOL CHEM, V269, P931; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	58	170	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18881	18890						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034644				2022-12-27	WOS:A1994NX32700031
J	SHEN, L; DAHLBACK, B				SHEN, L; DAHLBACK, B			FACTOR-V AND PROTEIN-S AS SYNERGISTIC COFACTORS TO ACTIVATED PROTEIN-C IN DEGRADATION OF FACTOR VIIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA	Inherited resistance to activated protein C (APC) is a recently identified major cause of thrombosis. It is associated with a mutation in the factor V gene affecting one of the cleavage sites for APC. APC resistance was recently found to be corrected by factor V, suggesting that factor V may have anticoagulant properties as a cofactor to APC. To elucidate this further, we have studied the effect of factor V and protein S, which is a known cofactor to APC, on APC-mediated degradation of factor VIIIa in a purified system. The APC-mediated degradation of factor VIIIa was monitored by a factor X activation reaction using purified factor IXa, phospholipid, and calcium. In the presence of both factor V and protein S, APC was found to inhibit factor VIIIa activity efficiently. APC alone or together with factor V was ineffective, whereas APC in combination with protein S was less efficient than when factor V was also included in the reaction. Two monoclonal antibodies, one against protein S and the other directed toward factor V, were found to inhibit the APC cofactor activity of the factor V-protein S mixture. Factor Va did not express APC cofactor activity, and addition of excess factor Va over factor V did not inhibit the APC cofactor function of a factor V-protein S mixture. In conclusion, the results suggest that factor V and protein S work in synergy as phospholipid-bound cofactors to APC.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University				Dahlback, Bjorn/0000-0003-1546-0328				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1974, THROMB RES, V2, P509; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	15	288	301	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18735	18738						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034625				2022-12-27	WOS:A1994NX32700009
J	LADROR, US; SNYDER, SW; WANG, GT; HOLZMAN, TF; KRAFFT, GA				LADROR, US; SNYDER, SW; WANG, GT; HOLZMAN, TF; KRAFFT, GA			CLEAVAGE AT THE AMINO AND CARBOXYL TERMINI OF ALZHEIMERS AMYLOID-BETA BY CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PRECURSOR; SOLUBLE DERIVATIVES; DISEASE; PEPTIDE; FRAGMENTS; CELLS; NEUROTOXICITY; PROTEASES; GENERATE; MUTATION	Amyloid beta (A beta) is a 39-43-residue protein that originates from proteolysis of the beta-protein precursor (beta PP) and accumulates in senile plaques in brains of Alzheimer's disease (AD) patients. Mutant beta PP, which incorporates an AD causing double mutation at positions 687-688, has been shown to enhance A beta production in transfected cells. In this work we investigate the susceptibility of the mutant beta PP sequence to proteolytic cleavage by proteinases from human brain. Internally quenched fluorogenic substrates were used that encompass the NH2-terminal sequence of A beta from wild-type beta PP, the double mutant, and the two single substitutions. Proteinase activity in brain extract cleaved the mutant substrate 100-fold faster than the wild-type substrate and the partial mutants 25-fold faster. The major cleavage site in all substrates was at the amyloidogenic Asp(1) site. The brain activity appeared to be cathepsin D (CD), as indicated by similarities to purified CD in 1) the rate and site of substrates cleavage, 2) the pH optima, and 3) the sensitivity to pepstatin A. The increased activity against the mutant substrate was not shared by cathepsins B and C, pepsin, HIV proteinase, and Candida albicans Asp-proteinase. Furthermore, CD cleaved a substrate that incorporates the COOH terminus of A beta at positions equivalent to Thr(43) and Ala(42), at ratios of 68% and 32%, respectively. CD degraded A beta 1-40 into six fragments but A beta 1-42 was completely resistant to digestion, probably because of its aggregation characteristics. These results indicate that CD is capable of producing the cleavages resulting in A beta production and that it may prove to be a suitable therapeutic target.	ABBOTT LABS,DRUG DESIGN & DELIVERY,ABBOTT PK,IL 60064	Abbott Laboratories			Snyder, Seth/C-4370-2008; Snyder, Seth/V-9955-2019	Snyder, Seth/0000-0001-6232-1668; Snyder, Seth/0000-0001-6232-1668	NIA NIH HHS [AG10481] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010481] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYASAKA N, 1993, J DENT RES, V72, P502, DOI 10.1177/00220345930720020601; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; GOATE AM, 1992, BIOESSAYS, V14, P727; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRINDE B, 1980, BIOCHIM BIOPHYS ACTA, V632, P73, DOI 10.1016/0304-4165(80)90250-0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HOLZMAN TF, 1994, MODERN ANAL ULTRACEN; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; KRIEGER TJ, 1992, BIOCHEMISTRY-US, V31, P428; LADROR US, 1994, IN PRESS J PROTEIN C; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; MINOR LK, 1991, EXP MOL PATHOL, V54, P159, DOI 10.1016/0014-4800(91)90028-V; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MUTO N, 1988, J BIOCHEM-TOKYO, V103, P629, DOI 10.1093/oxfordjournals.jbchem.a122318; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PASTERNACK JM, 1992, BIOCHEMISTRY-US, V31, P10936, DOI 10.1021/bi00159a038; Podlisny M., 1993, Society for Neuroscience Abstracts, V19, P1276; Sapirstein V., 1993, Society for Neuroscience Abstracts, V19, P1276; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1993, J BIOL CHEM, V268, P16602; USAMI M, 1993, J NEUROCHEM, V61, P239, DOI 10.1111/j.1471-4159.1993.tb03560.x; WILLIAMS KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P298, DOI 10.1006/abbi.1993.1426; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	36	126	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18422	18428						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034590				2022-12-27	WOS:A1994NW79800032
J	BUBUNENKO, MG; SUBRAMANIAN, AR				BUBUNENKO, MG; SUBRAMANIAN, AR			RECOGNITION OF NOVEL AND DIVERGENT HIGHER-PLANT CHLOROPLAST RIBOSOMAL-PROTEINS BY ESCHERICHIA-COLI RIBOSOME DURING IN-VIVO ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; NUCLEOTIDE-SEQUENCE; CDNA CLONE; SPINACH; GENE; EXPRESSION; RNA; IDENTIFICATION; ORGANIZATION; PRECURSOR	Architecture of higher plant chloroplast ribosomes involves additional protein domains over that found in the Escherichia coli ribosome, although the rRNAs in these two kinds of ribosomes are very similar in length and sequence (Subramanian, A. R. (1993) Trends Biochem. Sci. 18, 177-180). Here, we show that two chloroplast-specific protein domains (a novel chloroplast ribosomal protein of the 30 S subunit, called Psrp-1 or S22, and a divergent protein of the 50 S subunit with long terminal extensions and low homology to its E. coli counterpart, L21) are both incorporated in E. coli ribosomes and polysomes when their gene constructs are expressed in E. coli. Also, the 67-residue NH2-terminal extension in chloroplast L21 by itself is incorporated. Thus, our results indicate preexisting binding sites for novel chloroplast-specific ribosomal proteins/domains on eubacterial ribosomes. Additionally, we observed cleavage of the chloroplast-targeting transit peptide (present in the expressed Psrp-1 precursor), indicating protease(s) of the required specificity in E. coli cells. The expression of chloroplast L21 with its NH2-terminal extension was inhibitory to E. coli growth, suggesting a drastic effect of the latter on some property of L21. Expression of Psrp-1 was neutral, consistent with a function only in chloroplast translation. Based on analysis of the assembly of Psrp-1 and various L21 fragments in E. coli ribosomes, a general model for studying ribosomal protein-ribosome interactions is suggested.	MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Max Planck Society								Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BISANZSEYER C, 1992, PLANT MOL BIOL, V18, P337, DOI 10.1007/BF00034960; BOURQUE DP, 1990, TRANSLATIONAL APPARA, P85; BOYNTON JE, 1980, RIBOSOMES STRUCTURE, P903; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; CAPEL MS, 1982, J BIOL CHEM, V257, P7746; CHOLI T, 1993, BIOL CHEM H-S, V374, P377, DOI 10.1515/bchm3.1993.374.1-6.377; DABBS ER, 1991, BIOCHIMIE, V73, P639, DOI 10.1016/0300-9084(91)90043-Z; DORNE AM, 1984, MOL GEN GENET, V193, P129, DOI 10.1007/BF00327425; GANTT JS, 1988, CURR GENET, V14, P519, DOI 10.1007/BF00521278; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; GIESE K, 1991, FEBS LETT, V288, P72, DOI 10.1016/0014-5793(91)81005-S; GILLHAM NW, 1990, TRANSLATIONAL APPARA, P127; GRAY MW, 1990, MOL BIOL PLASTIDS, P303; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KOSSEL H, 1990, TRANSLATIONAL APPARA, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGRANGE T, 1993, MOL CELL BIOL, V13, P2614, DOI 10.1128/MCB.13.4.2614; LAGRANGE T, 1990, TRANSLATIONAL APPARA, P107; LIU XQ, 1989, J BIOL CHEM, V264, P16100; MARTIN W, 1990, CURR GENET, V18, P553, DOI 10.1007/BF00327027; MEADOWS JW, 1991, PLANT MOL BIOL, V17, P1241, DOI 10.1007/BF00028739; Miller JH, 1972, DETERMINATION VIABLE, P31; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT J, 1993, J BIOL CHEM, V268, P27447; SCHMIDT J, 1993, BIOCHEM MOL BIOL INT, V29, P25; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SMOOKER PM, 1990, J BIOL CHEM, V265, P16699; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUBRAMANIAN AR, 1990, RIBOSOME, P655; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1973, J MOL BIOL, V74, P45; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1990, MOL BIOL PLASTIDS, P191; SUGIURA M, 1990, TRANSLATIONAL APPARA, P59; UMEZONO K, 1987, TRENDS GENET, V3, P281; Vasiliev V. D., 1986, STRUCTURE FUNCTION G, P128; WEGLOHNER W, 1993, TRANSLATIONAL APPARATUS, P701; WEGLOHNER W, 1991, FEBS LETT, V279, P193, DOI 10.1016/0014-5793(91)80147-U; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZHOU DX, 1990, MOL GEN GENET, V223, P167, DOI 10.1007/BF00315812	45	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18223	18231						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027083				2022-12-27	WOS:A1994NV42200069
J	PRIES, F; VANDENWIJNGAARD, AJ; BOS, R; PENTENGA, M; JANSSEN, DB				PRIES, F; VANDENWIJNGAARD, AJ; BOS, R; PENTENGA, M; JANSSEN, DB			THE ROLE OF SPONTANEOUS CAP DOMAIN MUTATIONS IN HALOALKANE DEHALOGENASE SPECIFICITY AND EVOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHOBACTER-AUTOTROPHICUS GJ10; LIPOPROTEIN-LIPASE; ALPHA-HELIX; DNA; DEGRADATION; MECHANISM; CLONING; 1,2-DICHLOROETHANE; REPLICATION; SEQUENCES	The first step in the utilization of the xenobiotic chlorinated hydrocarbon 1,2-dichloroethane by Xanthobacter autotrophicus is catalyzed by haloalkane dehalogenase (DhlA). The enzyme hydrolyses 1-haloalkanes to the corresponding alcohols. This allows the organism to grow also on short-chain (C-2-C-4) 1-chloro-n-alkanes. We have expressed DhlA in a strain of Pseudomonas that grows on long-chain alcohols and have selected 12 independent mutants that utilize 1-chlorohexane. Six different mutant enzymes with improved K-m or V-max values with 1-chlorohexane were obtained. The sequences of the mutated dhlA genes showed that several mutants had the same 11-amino acid deletion, two mutants carried a different point mutation, and three mutants had different tandem repeats. All mutations occurred in a region encoding the N-terminal part of the cap domain of DhlA, and it is concluded that this part of the protein is involved in the evolution of activity toward xenobiotic substrates.	UNIV GRONINGEN,DEPT BIOCHEM,9747 AG GRONINGEN,NETHERLANDS	University of Groningen								BRON S, 1991, MOL GEN GENET, V226, P88, DOI 10.1007/BF00273591; CLARKE P, 1984, MICROBIAL DEGRADATIO, P11; DEREWENDA ZS, 1992, J MOL BIOL, V227, P818, DOI 10.1016/0022-2836(92)90225-9; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; GAILLARD C, 1980, NATURE, V283, P218, DOI 10.1038/283218a0; GSCHWEND PM, 1985, SCIENCE, V227, P1033, DOI 10.1126/science.227.4690.1033; HARAYAMA S, 1991, J BACTERIOL, V173, P7540, DOI 10.1128/jb.173.23.7540-7548.1991; HARDIE DWF, 1964, KIRKOTHMER ENCY CHEM, V5, P148; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KASTENS AS, 1962, CHLORINE ITS MANUFAC, P310; KEUNING S, 1985, J BACTERIOL, V163, P635, DOI 10.1128/JB.163.2.635-639.1985; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MEYER RJ, 1977, BIOCHIM BIOPHYS ACTA, V478, P109, DOI 10.1016/0005-2787(77)90249-0; MOLLET B, 1991, MOL GEN GENET, V227, P17, DOI 10.1007/BF00260700; OLDENHUIS R, 1989, APPL MICROBIOL BIOT, V30, P211, DOI 10.1007/BF00264013; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; STREISINGER G, 1985, GENETICS, V109, P633; TIMMIS KN, 1990, ADV AP BIOT, V4, P61; VANDENWIJNGAARD AJ, 1992, APPL ENVIRON MICROB, V58, P976, DOI 10.1128/AEM.58.3.976-983.1992; VERSCHUEREN KHG, 1993, BIOCHEMISTRY-US, V32, P9031, DOI 10.1021/bi00086a008; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	73	75	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17490	17494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021255				2022-12-27	WOS:A1994NU12800026
J	QIAN, NX; RUSSELL, M; BUHL, AM; JOHNSON, GL				QIAN, NX; RUSSELL, M; BUHL, AM; JOHNSON, GL			EXPRESSION OF GTPASE-DEFICIENT G-ALPHA(16) INHIBITS SWISS 3T3 CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; RECEPTOR ACTIVATION; ADENYLYL CYCLASES; IN-VITRO; CAMP; RAF	Expression of the GTPase-deficient G alpha(16) polypeptide G alpha(16Q212L), a member of the G(q) family of heterotrimeric G proteins, constitutively activated phospholipase C beta activity in Swiss 3T3 cells. Expression of G alpha(16Q212L) appears to persistently stimulate a low level of protein kinase C activity which also increases protein kinase A activity in Swiss 3T3 cells. Growth of G alpha(16Q212L) expressing cells was significantly inhibited relative to wild type Swiss 3T3 cells. Bombesin stimulated DNA synthesis was completely inhibited in G alpha(16Q212L) expressing clones, whereas the growth responses to platelet-derived growth factor (PDGF) and serum were inhibited 50-80% relative to wild-type cells. In addition to the inhibition of cell growth, G alpha(16Q212L) expression significantly inhibited the stimulation of protein kinase C, Raf-1, MEK, mitogen-activated protein kinase, phospholipase A(2) activity, and Ca2+ mobilization in response to PDGF. In contrast, PDGF receptor activation of phospholipase C gamma, phosphatidylinositol 3-kinase, and Ras GTP loading was similar in wild-type and G alpha(16Q212L) expressing clones. PDGF regulation of membrane ruffling and actin fiber assembly, responses mediated in part by phosphatidylinositol 3-kinase, were unaffected in G alpha(16Q212L) expressing clones. The growth inhibitory action of G alpha(l6Q212L) expression in Swiss 3T3 cells is downstream of the initial SH2 domain-encoded signal transduction proteins regulated in response to PDGF receptor autophosphorylation. The findings demonstrate that constitutively activated G alpha(16Q212L) persistently activates phospholipase C activity and effectively inhibits a subset of cytoplasmic signal transduction pathways involved in growth factor tyrosine kinase receptor stimulation of cell growth. G(16)/G(q)- regulated signal transduction can acutely stimulate specific response pathways involved in mitogenesis; but persistent activation of G(16)/G(q)-regulated effecters, including phospholipase C beta, inhibit tyrosine kinase initiated mitogenesis. One role for G(16)/G(q) response systems may be to modulate growth factor receptor signaling.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA09313, CA58187] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BATTEY JF, 1991, P NATL ACAD SCI USA, V90, P4077; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENG HC, 1986, J BIOL CHEM, V261, P989; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KRYRIAKIS JM, 1992, NATURE, V358, P417; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TARVER AP, 1987, J BIOL CHEM, V262, P17268; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WENNSTROM S, 1993, ONCOGENE, V9, P621; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WU DQ, 1992, J BIOL CHEM, V267, P1811; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17417	17423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021243				2022-12-27	WOS:A1994NU12800014
J	CHEN, LM; CHERN, YJ; ONG, SJ; TAI, JH				CHEN, LM; CHERN, YJ; ONG, SJ; TAI, JH			MOLECULAR-CLONING AND CHARACTERIZATION OF A RAS-RELATED GENE OF RAN/TC4/SPI1 SUBFAMILY IN GIARDIA-LAMBLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE NUCLEOTIDE-BINDING; CHROMOSOME CONDENSATION; BIOCHEMICAL-PROPERTIES; SEQUENCE-ANALYSIS; CELL-CYCLE; RCC1; IDENTIFICATION; LOCALIZATION; SUPERFAMILY	The significance of Ras-like proteins in the protozoa is relatively unexplored. In this report, a gene encoding a Ras-like nuclear (Ran) protein was identified in Giardia lamblia by a polymerase chain reaction-based cloning strategy. The sequence analyses suggest that the gene was intronless, and had short 5'-untranslated leader sequences in the corresponding mRNA up to -2, -4, or -29 bases upstream of the first initiation codon. The full-length cDNA sequence predicted a protein comprising 226 amino acids, in which the highly conserved functional motifs of the Ras superfamily were all preserved. This protein showed 52% identity to human TC4 and 50% identity to yeast Spi1 proteins, suggesting that it is closely related to the Ran proteins, and it was therefore designated gRan. gRan produced from recombinant Escherichia coli exhibited GTP binding activity by an overlay assay. In good agreement with the predicted size of gRan, a 27-kDa protein was identified in a lysate of G. lamblia by Western blotting using antiserum raised against recombinant gRan. The protein was further localized in both nuclei of G. lamblia by immunofluorescence staining. Recombinant gRan exhibited low affinity for GTP with a K-d value of 16.8 mu M. The affinity was enhanced to a K-d value of 2.2 mu M in the presence of 10 mM Mg2+. The intrinsic GTPase activity of gRan was observed only in the presence of 10 mM Mg2+ and had an estimated K-m of 5.6 mu M and a K-cat of 0.33/h. These observations demonstrate the presence of Ras-like proteins in the most primitive eukaryotic cells, G. lamblia, and infer that the Ran protein may play a functional role in the nuclei of this organism.	ACAD SINICA,INST BIOMED SCI,DIV INFECT DIS,TAIPEI 11529,TAIWAN; ACAD SINICA,INST BIOMED SCI,DIV MOLEC & CELLULAR NEUROBIOL,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PARASITOL,TAIPEI 100,TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University			Tai, Jung-Hsiang/S-7019-2018; Chern, Yijuang/S-7013-2018	Chern, Yijuang/0000-0002-5842-5429				ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; BUSH J, 1993, NUCLEIC ACIDS RES, V21, P1675, DOI 10.1093/nar/21.7.1675; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISSANAYAKE S, 1992, MOL BIOCHEM PARASIT, V56, P259, DOI 10.1016/0166-6851(92)90175-J; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUPREE P, 1992, GENE, V120, P325, DOI 10.1016/0378-1119(92)90118-9; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARLOW E, 1988, ANTIBODIES LABORATOR; KABNICK KS, 1990, J CELL SCI, V95, P353; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; LI JKK, 1989, J VIROL METHODS, V26, P3, DOI 10.1016/0166-0934(89)90069-4; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; REINER DS, 1990, EUR J CELL BIOL, V53, P142; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; Sambrook J, 1989, MOL CLONING LABORATO; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; TAI JH, 1993, EXP PARASITOL, V76, P165, DOI 10.1006/expr.1993.1019; TRUEB J, 1992, FEBS LETT, V306, P181, DOI 10.1016/0014-5793(92)80995-S; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YANG C, 1993, EUR J BIOCHEM, V217, P1027, DOI 10.1111/j.1432-1033.1993.tb18334.x	42	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17297	17304						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006038				2022-12-27	WOS:A1994NT84600049
J	LAYTON, MJ; LOCK, P; METCALF, D; NICOLA, NA				LAYTON, MJ; LOCK, P; METCALF, D; NICOLA, NA			CROSS-SPECIES RECEPTOR-BINDING CHARACTERISTICS OF HUMAN AND MOUSE LEUKEMIA INHIBITORY FACTOR SUGGEST A COMPLEX BINDING INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; FACTOR LIF; CELLS; DIFFERENTIATION; HORMONES; AFFINITY; PROTEIN; GP130; SERUM	Leukemia inhibitory factor (LIF) is a pleiotropic cytokine whose activities appear to be mediated through a single heterodimeric receptor complex. Human LIF (hLIF) can bind to and activate mouse LIF (mLIF) receptors but mLIF is unable to bind to hLIF receptors. Cross-species competition of mLIF and hLIF for binding to the mLIF receptor was found to be dependent on which ligand was used as the radioactive tracer (Layton, M. J., Cross, B. A., Metcalf, D., Ward, L. D., Simpson, R. J., and Nicola, N. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8616-8620), and this phenomenon was investigated in the present study. We found that hLIF bound to the low affinity mLIF receptor with a 100-500-fold higher primary affinity and lower kinetic dissociation rate than mLIF, but both ligands displayed a single rate of ligand dissociation. In contrast, the binding of hLIF to low and high affinity hLIF receptors revealed two classes of binding site. The observed tracer-dependent phenomena suggested that both mLIF and hLIF interfere with the binding of each other to the mLIF receptor. A model is presented in which hLIF binds to two sites on mLIF and hLIF receptors, one of which interferes with the common site for mLIF. This model may reconcile some of the observed complexities of LIF/LIF receptor interactions.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,COOPERAT RES CTR CELLULAR GROWTH FACTORS,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital			Layton, Meredith/E-9171-2014; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889; Lock, Peter/0000-0003-4421-3609	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BODARD A, 1992, J BIOL CHEM, V267, P3214; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; KASTELEIN RA, 1993, ONCOGENE, V8, P231; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nicola NA, 1988, GROWTH FACTORS, V1, P29, DOI 10.3109/08977198809000244; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TOMIDA M, 1984, FEBS LETT, V178, P291, DOI 10.1016/0014-5793(84)80619-5; YAMAGUCHIYAMAMOTO Y, 1993, LEUKEMIA RES, V17, P515, DOI 10.1016/0145-2126(93)90127-7	27	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17048	17055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006010				2022-12-27	WOS:A1994NT84600013
J	TOMILO, M; WILKINSON, KS; RYAN, P				TOMILO, M; WILKINSON, KS; RYAN, P			CAN A SIGNAL SEQUENCE BECOME TOO HYDROPHOBIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; GLYCOPROTEIN-GIII; TERMINAL REGION; POSITIVE CHARGE; PEPTIDE; TRANSLOCATION; LOCALIZATION; SECRETION; MEMBRANE	We have characterized several mutants that contain alterations in the hydrophilic domain (N region) of the pseudorabies virus glycoprotein gC signal sequence. In general, our results agree with previous findings and indicate that basic residues in the N region are not essential for efficient export of gC in infected cells, While reducing the N region to a net neutral charge led to a slight impairment of membrane translocation, a substantial gC export defect was not observed until a net negative charge was introduced, However, there was one exception to this pattern, The substitution of a leucine for an arginine at the carboxyl terminus of the N region led to a considerable export defect despite maintaining a net positive charge, As a consequence of the substitution, the mutant signal sequence was 1.5 times more hydrophobic than wild type, but we found that the defect could be largely corrected if an additional alteration that lessened the overall hydrophobicity of the gC signal sequence was incorporated, We suggest that an upper limit of hydrophobicity may exist for eukaryotic signal sequences; exceeding this value could lead to an export defect.	UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NIAID NIH HHS [AI28520] Funding Source: Medline; NIDDK NIH HHS [GR DK07405] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007405] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIRD P, 1990, J BIOL CHEM, V265, P8420; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENQUIST LW, 1988, J VIROL, V62, P3565, DOI 10.1128/JVI.62.10.3565-3573.1988; FERENCI T, 1987, J BACTERIOL, V169, P5339, DOI 10.1128/jb.169.12.5339-5342.1987; FLYNN SJ, 1993, J VIROL, V67, P2646, DOI 10.1128/JVI.67.5.2646-2654.1993; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIKITA C, 1992, J BIOL CHEM, V267, P12375; HOLLAND TC, 1983, J VIROL, V46, P649, DOI 10.1128/JVI.46.2.649-652.1983; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; POWERS L, 1994, J VIROL, V68, P2787, DOI 10.1128/JVI.68.5.2787-2794.1994; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROBBINS AK, 1986, J VIROL, V59, P635, DOI 10.1128/JVI.59.3.635-645.1986; RYAN JP, 1987, J VIROL, V61, P2962, DOI 10.1128/JVI.61.10.2962-2972.1987; RYAN JP, 1986, J BIOL CHEM, V261, P3389; RYAN P, 1993, VIRUS GENES, V7, P5, DOI 10.1007/BF01702345; SZCZESNASKORUPA E, 1989, MOL ENDOCRINOL, V3, P174, DOI 10.1210/mend-3-1-174; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	28	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					32016	32021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989378				2022-12-27	WOS:A1994PX30300103
J	CHU, E; VOELLER, DM; MORRISON, PF; JONES, KL; TAKECHI, T; MALEY, GF; MALEY, F; ALLEGRA, CJ				CHU, E; VOELLER, DM; MORRISON, PF; JONES, KL; TAKECHI, T; MALEY, GF; MALEY, F; ALLEGRA, CJ			THE EFFECT OF REDUCING REAGENTS ON BINDING OF THYMIDYLATE SYNTHASE PROTEIN TO THYMIDYLATE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION; REDOX REGULATION; COAT PROTEIN; SYNTHETASE; SEQUENCE; SITE; DNA; INVITRO; BACTERIOPHAGE-T4; TRANSLATION	Human thymidylate synthase (TS) protein specifically binds to its own TS mRNA and functions as a translational repressor. In the presence of reducing agents, the RNA binding activity of TS protein is significantly enhanced. In contrast, treatment of TS protein with the oxidizing agent diamide inhibits RNA binding. Scatchard analysis reveals that in the presence of the reducing agent 2-mercaptoethanol, the TS protein/TS mRNA interaction changes from low (K-d = 66 nM) to high (K-d = 2.6 nM) apparent affinity. The catalytic activity of TS is increased by up to 6.5-fold in the presence of 2-mercaptoethanol. These studies demonstrate that the interaction between TS protein and its target TS mRNA is sensitive to the presence of reducing reagents and is dependent upon a reversible sulfhydryl switch mechanism.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center	CHU, E (corresponding author), USN HOSP,NCI,NAVY MED ONCOL BRANCH,BLDG 8,RM 5101,8901 WISCONSIN AVE,BETHESDA,MD 20889, USA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; BELLISARIO RL, 1976, P NATL ACAD SCI USA, V73, P1848, DOI 10.1073/pnas.73.6.1848; BERNARDI A, 1972, P NATL ACAD SCI USA, V69, P3033, DOI 10.1073/pnas.69.10.3033; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CHU E, 1990, MOL PHARMACOL, V38, P410; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DANENBERG KD, 1979, J BIOL CHEM, V254, P4345; DANENBERG PV, 1977, BIOCHIM BIOPHYS ACTA, V473, P73, DOI 10.1016/0304-419X(77)90001-4; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAINAUT P, 1993, CANCER RES, V53, P4469; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOONTZ SW, 1979, J BIOL CHEM, V254, P12277; LEARY RP, 1975, J BIOL CHEM, V250, P4864; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; PERRYMAN SM, 1986, MOL BIOL EVOL, V3, P313; PLESE PC, 1977, J BIOL CHEM, V252, P6139; RODE W, 1980, BIOCHEM PHARMACOL, V29, P723, DOI 10.1016/0006-2952(80)90547-X; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; SANTI DV, 1978, ENZYME ACTIVATED IRR, P291; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STARZYK RM, 1982, NATURE, V298, P136, DOI 10.1038/298136a0; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Voeller D. M., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P447; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WATAYA Y, 1980, J BIOL CHEM, V255, P5538; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	38	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20289	20293						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051122				2022-12-27	WOS:A1994PB31700015
J	CONNELLY, PW; MAGUIRE, GF; VEZINA, C; HEGELE, RA; KUKSIS, A				CONNELLY, PW; MAGUIRE, GF; VEZINA, C; HEGELE, RA; KUKSIS, A			KINETICS OF LIPOLYSIS OF VERY-LOW-DENSITY LIPOPROTEINS BY LIPOPROTEIN-LIPASE - IMPORTANCE OF PARTICLE NUMBER AND NONCOMPETITIVE INHIBITION BY PARTICLES WITH LOW TRIGLYCERIDE CONTENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-C-II; CORONARY-ARTERY DISEASE; HEPATIC LIPASE; PLASMA-LIPOPROTEINS; GEL-ELECTROPHORESIS; HEPARIN-SEPHAROSE; RICH LIPOPROTEINS; TRANSGENIC MICE; APO-CIII; DEFICIENCY	Our objective was to identify the major compositional factor(s) of very low density lipoprotein which determines its properties as a substrate for lipoprotein lipase. Human very low density lipoprotein was fractionated by preparative electrophoresis. The apparent K-m was significantly lower for pre-beta very low density lipoprotein compared with beta very low density lipoprotein when calculated on the basis of triglyceride concentration. When the triglyceride concentration was adjusted for the triglyceride/apolipoprotein B ratio, the apparent K-m was not different among very low density lipoprotein fractions. This implied that very low density lipoprotein particle number was of primary importance. To test this hypothesis further, rabbit cholesterol-rich very low density lipoprotein and human intermediate density lipoprotein and low density lipoprotein, from a patient with hepatic lipase deficiency, were added to the incubations. Each of these fractions functioned as noncompetitive inhibitors of lipolysis. We speculate that the saturation of lipoprotein lipase by an excess number of particles is a characteristic of human hyperlipoproteinemias that predispose to coronary heart disease and that are commonly classified as familial combined hyperlipoproteinemia or hyperapobetalipoproteinemia.	UNIV TORONTO,DEPT MED,TORONTO M5B 1A6,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5B 1A6,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5B 1A6,ON,CANADA; UNIV TORONTO,ST MICHAELS HOSP,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5B 1A6,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Hegele, Robert/AAF-6482-2020; Connelly, Philip W/B-7583-2012; Hegele, Robert/G-3301-2011	Hegele, Robert/0000-0003-2861-5325; Connelly, Philip W/0000-0001-7244-6843; 				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ALAUPOVIC P, 1991, J LIPID RES, V32, P9; BENGTSSON G, 1983, FEBS LETT, V154, P211, DOI 10.1016/0014-5793(83)80906-5; BENGTSSON G, 1977, BIOCHEM J, V167, P109, DOI 10.1042/bj1670109; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; BROCKMAN HL, 1984, LIPASES, P4; BRUNZELL JD, 1973, J CLIN INVEST, V52, P1578, DOI 10.1172/JCI107334; CATAPANO AL, 1987, CHEM PHYS LIPIDS, V45, P39, DOI 10.1016/0009-3084(87)90038-7; CHUNG BH, 1982, J BIOL CHEM, V257, P7472; CLARK AB, 1985, J BIOL CHEM, V260, P4778; CONNELLY PW, 1993, J LIPID RES, V34, P1717; CONNELLY PW, 1988, J BIOL CHEM, V263, P14184; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; CONNELLY PW, 1994, IN PRESS METHODS ENZ; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; FIELDING CJ, 1970, BIOCHIM BIOPHYS ACTA, V206, P118, DOI 10.1016/0005-2744(70)90088-4; GATT S, 1977, BIOCHIM BIOPHYS ACTA, V488, P13, DOI 10.1016/0005-2760(77)90118-7; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HABERBOSCH W, 1984, BIOCHIM BIOPHYS ACTA, V793, P49, DOI 10.1016/0005-2760(84)90052-3; HAVEL RJ, 1992, SEMIN LIVER DIS, V12, P356, DOI 10.1055/s-2008-1040405; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HEGELE RA, 1991, ARTERIOSCLER THROMB, V11, P1303, DOI 10.1161/01.ATV.11.5.1303; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JACKSON RL, 1986, BIOCHIM BIOPHYS ACTA, V875, P211, DOI 10.1016/0005-2760(86)90170-0; JONES HB, 1951, AM J MED, V11, P358, DOI 10.1016/0002-9343(51)90171-4; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; KWITEROVICH PO, 1993, AM J CARDIOL, V71, P631, DOI 10.1016/0002-9149(93)91002-Y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE GF, 1989, J LIPID RES, V30, P757; MAGUIRE GF, 1975, CLIN BIOCHEM, V8, P161, DOI 10.1016/S0009-9120(75)91675-6; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MCCONATHY WJ, 1992, J LIPID RES, V33, P995; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; POAPST M, 1985, ARTERIOSCLEROSIS, V5, P381, DOI 10.1161/01.ATV.5.4.381; QUARFORDT SH, 1977, BIOCHEM BIOPH RES CO, V78, P302, DOI 10.1016/0006-291X(77)91254-2; SAHEKI S, 1991, CLIN CHIM ACTA, V204, P155, DOI 10.1016/0009-8981(91)90227-4; SAXENA U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P161, DOI 10.1016/0005-2760(90)90291-5; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SMALL DM, 1991, ANNU REV NUTR, V11, P413, DOI 10.1146/annurev.nu.11.070191.002213; Smith L.C., 1984, P263; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STEINER G, 1987, CIRCULATION, V75, P124, DOI 10.1161/01.CIR.75.1.124; TAJIMA S, 1984, J BIOCHEM, V96, P1753, DOI 10.1093/oxfordjournals.jbchem.a135008; VOLLER A, 1979, ENZYME LINKED IMMUNO, P1; WANG CS, 1985, BIOCHIM BIOPHYS ACTA, V837, P111; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WANG CS, 1981, CLIN CHEM, V27, P663; Weisgraber K H, 1986, Methods Enzymol, V129, P145; 1982, DHEW NIH75628 PUBL	52	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20554	20560						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051155				2022-12-27	WOS:A1994PB31700055
J	LAMONTAGNE, S; POTIER, M				LAMONTAGNE, S; POTIER, M			MODULATION OF HUMAN SAPOSIN-B SPHINGOLIPID-BINDING SPECIFICITY BY ALTERNATIVE SPLICING - A STUDY WITH SAPOSIN-B-DERIVED SYNTHETIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN; CEREBROSIDE SULFATASE; PROSAPOSIN; GANGLIOSIDES; PRECURSOR; SEQUENCE; GENE; CREM	The saposins A, B, C, and D, produced by proteolytic maturation of the same precursor protein, prosaposin, are sphingolipid-binding proteins which function as activators for lysosomal enzymes involved in sphingolipid hydrolysis. The alternative splicing of the prosaposin gene results in the inclusion or exclusion of exon 8 into transcribed prosaposin mRNA through the use of alternative acceptor sites. The relative abundance of each alternatively spliced mRNA was determined by reverse transcription-polymerase chain reaction in various human tissues and cell lines. Exon 8 codes for only three amino acid residues, Gln-Asp-Gln, in the saposin B domain of prosaposin. The prosaposin mRNA containing exon 8 is the major species in cultured skin fibroblasts, brain, and pituitary glands together with a smaller amount of mRNA devoid of exon 8, whereas the prosaposin mRNA detected in liver and lymphoblasts was devoid of exon 8 insertion. Previous structural modeling studies on saposin B have suggested that the Gln-Asp-Gln insertion occurs in an amphipathic alpha-helix region of the protein which is implicated in the binding of G(M1)-ganglioside. We report that synthetic peptides containing the alpha-helix, with and without the Gln-Asp-Gln insertion, have different binding affinities for G(M1)-ganglioside, sulfatide, and sphingomyelin. The insertion of the Gln-Asp-Gln sequence completely abolishes the capacity of the peptide to bind G(M1)-ganglioside, whereas its affinity for sulfatide and sphingomyelin is increased about 4-fold and almost 2-fold, respectively. No significant binding of glucosylceramide was observed with both peptides. These results suggest that alternative splicing of prosaposin mRNA may change binding specificity of saposin B presumably to adapt to the variable sphingolipid composition of tissues.	UNIV MONTREAL,HOP ST JUSTINE,SERV GENET MED,MONTREAL H3T 1C5,PQ,CANADA; UNIV MONTREAL,DEPT PEDIAT,MONTREAL H3T 1C5,PQ,CANADA; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3T 1C5,PQ,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal								[Anonymous], 1967, FLUORESCENCE PHOSPHO; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISCHER G, 1977, BIOCHIM BIOPHYS ACTA, V481, P561, DOI 10.1016/0005-2744(77)90288-1; FORMISANO S, 1979, BIOCHEMISTRY-US, V18, P1119, DOI 10.1021/bi00573a028; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; LI SC, 1985, J BIOL CHEM, V260, P1867; LIN D, 1990, P NATL ACAD SCI USA, V87, P8516, DOI 10.1073/pnas.87.21.8516; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; POTIER M, 1988, BIOCHEM BIOPH RES CO, V155, P32, DOI 10.1016/S0006-291X(88)81045-3; Sambrook J, 1989, MOL CLONING LABORATO; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SASTRY PS, 1985, PROG LIPID RES, V24, P68; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOEDA S, 1993, J BIOL CHEM, V268, P18519; WENGER DA, 1984, MOL BASIS LYSOSOMAL; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	24	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20528	20532						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051151				2022-12-27	WOS:A1994PB31700051
J	MANTOVANI, R; LIO, XY; PESSARA, U; VANHUISJDUIJNEN, RH; BENOIST, C; MATHIS, D				MANTOVANI, R; LIO, XY; PESSARA, U; VANHUISJDUIJNEN, RH; BENOIST, C; MATHIS, D			DOMINANT-NEGATIVE ANALOGS OF NF-YA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-PROTEIN; DNA-BINDING; KAPPA-B; TRANSCRIPTION FACTOR; CLASS-II; HETEROLOGOUS SUBUNITS; DISPLACEMENT PROTEIN; GENE-TRANSCRIPTION; SEQUENCE IDENTITY; RNA-POLYMERASE	NF-Y is a highly conserved heteromeric CCAAT-binding transcription factor involved in the function of several promoters. The NF-YA subunit contains a domain of high homology to yeast HAP2, which we show to be necessary and sufficient to mediate interactions with the NF-YB subunit and with DNA. Using protein affinity columns derivatized with amino acid substitution mutants, we further dissect this region into two functionally separable subdomains. The subunit association function resides in a 21-amino acid stretch, which is almost perfectly conserved among different species, while interaction with DNA resides in another short segment. We also show that DNA-binding mutants act as dominant repressors of NF-Y.DNA complex formation and of NF-Y-dependent transcription.	INST CHIM BIOL, CNRS, GENET MOLEC EUCARYOTES LAB, F-67000 STRASBOURG, FRANCE; INST CHIM BIOL, INSERM, U184, UNITE BIOL MOLEC, F-67000 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Hooft van Huijsduijnen, Rob/B-3653-2009	Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INOSTROZA JA, 1992, CELL, V70, P477; KIM CG, 1990, J BIOL CHEM, V265, P13362; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LI Z, 1993, NUCLEIC ACIDS RES, V21, P4639, DOI 10.1093/nar/21.19.4639; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VIVILLE S, 1991, J IMMUNOL, V146, P3211; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x	42	205	210	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20340	20346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051128				2022-12-27	WOS:A1994PB31700023
J	LIEBERSBACH, BF; SANDERSON, RD				LIEBERSBACH, BF; SANDERSON, RD			EXPRESSION OF SYNDECAN-1 INHIBITS CELL INVASION INTO TYPE-I COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; HEPARAN-SULFATE PROTEOGLYCANS; E-CADHERIN EXPRESSION; HUMAN-MELANOMA CELLS; EXTRACELLULAR-MATRIX; MALIGNANT TRANSFORMATION; SURFACE PROTEOGLYCAN; CHONDROITIN SULFATE; TUMOR-CELLS	Before cells can invade the extracellular matrix, they must alter their expression of adhesion receptors. Syndecan-1 is a cell surface proteoglycan that binds cells to matrix and undergoes changes in expression during development, during differentiation of some cell types, and following malignant transformation in some tumors. To determine if changes in syndecan-1 expression influence cell invasion, we employed a model system in which human B lymphoid cells invade type I collagen gels. Examination of a panel of cell lines reveals that those lines not expressing syndecan-1 invade and migrate within collagen. In contrast, cell lines expressing syndecan-1 fail to invade. To directly assess the effect of syndecan-1 on invasion, ARH-77 cells, which do not express syndecan-1 and readily invade collagen, were transfected with a cDNA for syndecan-1. The syndecan-1-positive transfectants exhibit a drastically reduced ability to invade as compared to parental cells. This inhibition of invasion by syndecan-1 is reversed by preincubating gels with heparin or by growing cells in chlorate, an inhibitor of glycosaminoglycan sulfation. These results demonstrate that expression of syndecan-1 inhibits cell invasion into collagen and that loss of syndecan-1 expression may be necessary prior to the migration of normal or metastatic cells.	UNIV ARKANSAS MED SCI HOSP,DEPT PATHOL SLOT 517,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT ANAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,MCCLURE MUSCULOSKELETAL RES CTR,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences					NCI NIH HHS [CA55879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MLM, 1991, J BIOCHEM BIOPH METH, V22, P207, DOI 10.1016/0165-022X(91)90069-9; APPLEGATE KG, 1990, CANCER RES, V50, P7153; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIRCH M, 1991, CANCER RES, V51, P6660; BURK KH, 1978, CANCER RES, V38, P2508; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CULP LA, 1978, J CELL BIOL, V79, P788, DOI 10.1083/jcb.79.3.788; DAVID G, 1983, J BIOL CHEM, V258, P7338; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HORST E, 1990, LEUKEMIA, V4, P595; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; INKI P, 1992, LAB INVEST, V62, P225; INOUE H, 1992, J BIOCHEM-TOKYO, V111, P407, DOI 10.1093/oxfordjournals.jbchem.a123770; IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1991, BIOCHEM SOC T, V19, P1069, DOI 10.1042/bst0191069; KATO M, 1990, Journal of Cell Biology, V111, p263A; KODA JE, 1984, J BIOL CHEM, V259, P1763; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1986, CANCER RES, V46, P1; MANGAKIS N, 1990, B CANCER, V77, P235; MATSUOKA Y, 1967, P SOC EXP BIOL MED, V125, P1246; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; REVILLION F, 1993, ANTICANCER RES, V13, P1625; RIDLEY RC, 1993, BLOOD, V81, P767; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; SANANTONIO JD, 1994, IN PRESS GLYCOBIOLOG, V6; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCHOR SL, 1980, J CELL SCI, V41, P159; SCHUBERT D, 1980, J BIOL CHEM, V255, P1564; SNEED TB, 1994, CELL IMMUNOL, V153, P456, DOI 10.1006/cimm.1994.1042; SOIFER D, 1991, J NEUROSCI RES, V30, P63, DOI 10.1002/jnr.490300108; STAMATOGLOU SC, 1983, J CELL BIOL, V96, P1820, DOI 10.1083/jcb.96.6.1820; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TIMAR J, 1992, AM J PATHOL, V141, P467; UNDERHILL CB, 1975, BIOCHEM BIOPH RES CO, V63, P448, DOI 10.1016/0006-291X(75)90708-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WINTERBOURNE DJ, 1978, J BIOL CHEM, V253, P5109; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x	51	148	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20013	20019						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051085				2022-12-27	WOS:A1994PA12600054
J	MAEKAWA, S; MUROFUSHI, H; NAKAMURA, S				MAEKAWA, S; MUROFUSHI, H; NAKAMURA, S			INHIBITORY EFFECT OF CALMODULIN ON PHOSPHORYLATION OF NAP-22 WITH PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; PURIFICATION; NEUROMODULIN; DOMAIN; SITE; SUBSTRATE; BRAIN; IDENTIFICATION; PEPTIDE; FAMILY	NAP-22, a recently identified neural tissue-enriched acidic protein, was shown to be a substrate of protein kinase C in vitro. Its phosphorylation site was assigned as Ser(6) using deleted mutants expressed in Escherichia coli. Calmodulin inhibited this phosphorylation reaction. This inhibitory effect of calmodulin was dose-dependent and much stronger than its inhibitory effect to the phosphorylation of neuromodulin (GAP-43) with protein kinase C. The dissociation constant of NAP-22 and calmodulin obtained using the fluorescence change of dansyl-labeled calmodulin was much lower than that of neuromodulin and calmodulin. The phosphorylation of NAP-22 inhibited the association with calmodulin.	NATL CTR NEUROL & PSYCHIAT, NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN	National Center for Neurology & Psychiatry - Japan	MAEKAWA, S (corresponding author), UNIV TOKYO, GRAD SCH, DIV SCI, BUNKYO KU, HONGO, TOKYO 113, JAPAN.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; ERNEUX C, 1993, EUR J BIOCHEM, V214, P467; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAEKAWA S, 1994, BBA-GENE STRUCT EXPR, V1218, P119, DOI 10.1016/0167-4781(94)90113-9; MAEKAWA S, 1980, BIOCHEM BIOPH RES CO, V97, P621, DOI 10.1016/0006-291X(80)90309-5; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MORI A, 1991, BIOCHEMISTRY-US, V30, P9340; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	24	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19462	19465						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034714				2022-12-27	WOS:A1994NY33200042
J	KATZ, RW; KOENIG, RJ				KATZ, RW; KOENIG, RJ			SPECIFICITY AND MECHANISM OF THYROID-HORMONE INDUCTION FROM AN OCTAMER RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; VITAMIN-D RECEPTOR; DNA-BINDING; PROMOTER ELEMENTS; NUCLEAR RECEPTORS; GENE-EXPRESSION; ACID RECEPTORS; DIRECT REPEAT; T3 RECEPTOR; HALF-SITE	Thyroid hormone response elements are specific DNA sequences that allow thyroid hormone receptors to confer ligand-dependent regulation of gene expression. The response elements characterized to date have been composed of varying arrangements of multiple copies of a conserved hexameric sequence. The traditional consensus half-site of these response elements is the sequence 5'-AGGTCA, although we have demonstrated recently that the optimal thyroid hormone receptor monomer binding site is 2 base pairs larger, 5'-TAAGGTCA. Since other members of this family of nuclear receptors also have been shown to use varying arrangements of the traditional hexamer sequence as response elements, we examined whether the octamer sequence was specific as a thyroid hormone response element. The studies reported here demonstrate that only thyroid hormone receptors confer ligand responsiveness to a reporter gene containing a single copy of the octamer sequence as a response element and that qualitative and quantitative differences in the binding of related nuclear receptors to this sequence can account for this functional specificity. We also have shown that thyroid hormone induction from the octamer response element occurs independently of retinoid X receptors, in contrast to the induction from traditional complex thyroid hormone response elements.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL & METAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDCR NIH HHS [DE00301] Funding Source: Medline; NIDDK NIH HHS [DK44155] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K11DE000301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Baldwin A.S.J., 1989, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; DOZIN B, 1986, J BIOL CHEM, V261, P290; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NISHIKAWA J, 1993, J BIOL CHEM, V268, P19739; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	43	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18915	18920						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034648				2022-12-27	WOS:A1994NX32700035
J	ZHENG, LM; DEAN, DR				ZHENG, LM; DEAN, DR			CATALYTIC FORMATION OF A NITROGENASE IRON-SULFUR CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AZOTOBACTER-VINELANDII NITROGENASE; FE-PROTEIN; RHODANESE; BIOSYNTHESIS; MGATP; NIFS	Biological nitrogen fixation is catalyzed by nitrogenase, an enzyme comprised of two component proteins called the Fe protein and the MoFe protein. Both nitrogenase component proteins contain metalloclusters. The Azotobacter vinelandii nifS gene product (NifS), which is required for full activation of the nitrogenase component proteins, is a pyridoxal phosphate enzyme and is able to catalyze the desulfurization of L-cysteine to yield sulfur and L-alanine (Zheng, L., White, R. H., Cash, V. L., Jack, R. F., and Dean, D. R, (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2754-2758). An enzyme-bound persulfide that was identified as an intermediate in the cysteine desulfurization reaction catalyzed by NifS has been suggested as a possible S-donor in formation of the iron-sulfide cores of the nitrogenase metalloclusters. In the present work it is shown that NifS is able to effectively catalyze activation of an apo-form of the Fe protein that was prepared by removal of its Fe4S4 cluster using the chelator, alpha,alpha'-dipyridyl. The reconstitution reaction includes apo-Fe protein, NifS, L-cysteine, ferrous ion, dithiothreitol, and MgATP. Reconstitution of the inactive apo-Fe protein catalyzed by NifS results in 80-95% recovery of the original activity and yields an Fe protein having the normal electron paramagnetic resonance spectral properties associated with the Fe protein's Fe4S4 cluster. An altered NifS protein, NifS-Ala(325) which lacks the desulfurase activity and is unable to form the NifS bound persulfide, is not able to catalyze reactivation of the apo-Fe protein. These in vitro results support the proposal that NifS activity provides the inorganic sulfide necessary for in vivo formation of the nitrogenase metalloclusters. Moreover, because NifS has recently been shown to be a member of a highly homologous gene family, it appears that pyridoxal phosphate chemistry might play a general role in iron-sulfur cluster assembly.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & ANAEROB MICROBIOL,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University								ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BONAMI F, 1985, INORG CHEM, V24, P4331; BONAMI F, 1985, EUR J BIOCHEM, V148, P67; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V11, P369, DOI 10.1016/0968-0004(86)90206-9; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DEITS TL, 1989, J BIOL CHEM, V264, P6619; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN KS, 1983, J AM CHEM SOC, V105, P3905, DOI 10.1021/ja00350a028; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOLM RH, 1977, BIOL ASPECTS INORGAN, P71; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; IBERS JA, 1980, SCIENCE, V209, P223, DOI 10.1126/science.7384796; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; MALKIN R, 1966, BIOCHEM BIOPH RES CO, V23, P822, DOI 10.1016/0006-291X(66)90561-4; PAGANI S, 1984, EUR J BIOCHEM, V142, P361, DOI 10.1111/j.1432-1033.1984.tb08295.x; PAGANI S, 1987, BIOCHEM J, V244, P485, DOI 10.1042/bj2440485; SANDBERG W, 1987, TRENDS BIOCHEM SCI, V12, P56, DOI 10.1016/0968-0004(87)90028-4; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	29	172	175	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18723	18726						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034623				2022-12-27	WOS:A1994NX32700006
J	DU, XP; HARRIS, SJ; TETAZ, TJ; GINSBERG, MH; BERNDT, MC				DU, XP; HARRIS, SJ; TETAZ, TJ; GINSBERG, MH; BERNDT, MC			ASSOCIATION OF A PHOSPHOLIPASE A(2) (14-3-3-PROTEIN) WITH THE PLATELET GLYCOPROTEIN IB-IX COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VONWILLEBRAND-FACTOR BINDING; CALCIUM-DEPENDENT EXOCYTOSIS; KINASE-C; CYTOSOLIC PHOSPHOLIPASE-A2; MEMBRANE SKELETON; SHEAR-STRESS; IDENTIFICATION; ACTIVATION; ADHESION; PURIFICATION	Platelet adhesion to subendothelial von Willebrand factor involves receptor recognition by the platelet glycoprotein (GP) Ib-IX and initiates activation signals that contribute to primary hemostasis. We show here that GPIb-IX is specifically associated with an intracellular 29-kDa protein. The physicochemical characteristics and amino acid sequence of this protein indicate that it is identical to the human zeta-isoform 14-3-3 protein, previously characterized as a platelet phospholipase A(2) (PLA(2)). As activation of PLA(2) is an early event in GPIb-IX-mediated signaling, this result suggests that ligand occupancy of GPIb-IX may directly activate PLA(2), leading to platelet activation.	BAKER MED RES INST, VASC BIOL LAB, PRAHRAN, VIC 3181, AUSTRALIA	Baker Heart and Diabetes Institute	DU, XP (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Berndt, Michael C/D-5580-2012	Harris, Simon/0000-0002-5869-6704	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL028235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48728, HL28235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; Booth W J, 1990, Platelets, V1, P169, DOI 10.3109/09537109009005485; CHOW TW, 1992, BLOOD, V80, P113; COTE GP, 1981, J BIOL CHEM, V256, P1004; DAVIES GE, 1981, ANAL BIOCHEM, V115, P383, DOI 10.1016/0003-2697(81)90021-X; DU XP, 1993, J BIOL CHEM, V268, P23087; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KROLL MH, 1993, J BIOL CHEM, V268, P3520; LEOB LA, 1986, J BIOL CHEM, V261, P10567; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; TETAZ T, 1993, TECHNIQUES PROTEIN C, V4, P389; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VICENTE V, 1990, J BIOL CHEM, V265, P274; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707; ZUPAN LA, 1991, FEBS LETT, V284, P27, DOI 10.1016/0014-5793(91)80753-P	28	116	119	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18287	18290						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034572				2022-12-27	WOS:A1994NW79800008
J	FATATIS, A; CAPORASO, R; IANNOTTI, E; BASSI, A; DIRENZO, G; ANNUNZIATO, L				FATATIS, A; CAPORASO, R; IANNOTTI, E; BASSI, A; DIRENZO, G; ANNUNZIATO, L			RELATIONSHIP BETWEEN TIME OF ACTIVATION OF PHOSPHOLIPASE C-LINKED PLASMA-MEMBRANE RECEPTORS AND RELOADING OF INTRACELLULAR CA2+ STORES IN LAN-1 HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ENTRY; TUMOR PROMOTER; INOSITOL; BRADYKININ; RELEASE; CA-2+-ATPASE; THAPSIGARGIN; ENDOTHELIN; ELEVATION; NG108-15	The effect of sequential stimulation of different inositol (1,4,5)-trisphosphate (IP3)-linked receptors on the functioning of intracellular Ca2+ stores was evaluated in single LAN-1 human neuroblastoma cells by means of fura-2 microfluorimetry. Homologous restimulation both in the absence and in the presence of extracellular Ca2+ with endothelin-1 (ET-1), Lys-bradykinin (BK), and ATP did not elicit an intracellular Ca2+ increase, whereas a [Ca2+](i) elevation after carbachol (CCh) re-exposure was obtained only in the presence of extracellular Ca2+. Since thapsigargin and ionomycin, in the absence of extracellular Ca2+, were still able to release Ca2+ after ET-1, BK, and ATP but not after CCh, it can be argued that in the first case the stores were not completely depleted. This evidence was also confirmed by the fact that LAN-1 cells, sequentially exposed in different order to ET-1, BK, ATP, and upon extracellular Ca2+ removal, showed an increase of [Ca2+](i) although progressively reduced in magnitude. By contrast, when CCh was perfused as the first agonist, it completely precluded any further Ca2+ mobilization by the other three agonists. In addition, the lack of potentiation of the Ca2+ response when BK and ET-1 were superfused together and the potentiation of Ca2+ response elicited by ET-1 after BK, when the plasma membrane Ca2+ efflux pathways were blocked by lanthanum during the first agonist exposure, indicated that LAN-1 cells can recycle cytoplasmic Ca2+ when exposed to ET-1, BK, ATP but not when exposed to CCh. This inhibitory effect of CCh (perfused for 90 s) on Ca2+ refilling was strictly dependent on the time of receptor occupancy since the exposure to CCh for a shorter period (15 s) produced the same effect on Ca2+ refilling when ET-1, BK, and ATP were perfused, as first agonist, for 90 s. Furthermore, the entity of Ca2+ refilling after 15 s of BK receptor occupancy was similar to that observed after 90 s. This seems to suggest that the receptors for ET-1, BK, and ATP maintain the transductional mechanisms in an activated state for a time shorter than the time of receptor occupancy. This was confirmed by the fact that IP3 levels during a 90-s BK exposure fell to prestimulated value within 30 s, whereas after CCh they reached a sustained plateau phase, after the peak.	UNIV NAPLES FEDERICO II,SCH MED,DEPT NEUROSCI,PHARMACOL SECT,I-80131 NAPLES,ITALY	University of Naples Federico II			Di Renzo, Gian C./P-3819-2017	Di Renzo, Gian C./0000-0003-4467-240X; ANNUNZIATO, LUCIO/0000-0002-8534-8270				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHAN J, 1991, J PHARMACOL EXP THER, V258, P524; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FATATIS A, 1992, J NEUROCHEM, V59, P1, DOI 10.1111/j.1471-4159.1992.tb08868.x; Fatatis A, 1992, Funct Neurol, V7, P239; FATATIS A, 1992, 22ND ANN M SOC NEUR; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LESLIE BA, 1988, CELL CALCIUM, P9; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NEGULESCU PA, 1988, AM J PHYSIOL, V254, pC498, DOI 10.1152/ajpcell.1988.254.4.C498; PENNISTON JT, 1983, CALCIUM CELL FUNCTIO, P99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAHA S, 1993, J CELL PHYSIOL, V154, P623, DOI 10.1002/jcp.1041540322; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THAYER SA, 1988, J NEUROSCI, V8, P4089; THELER JM, 1992, J BIOL CHEM, V267, P18110; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YOREK MA, 1993, BIOCHIM BIOPHYS ACTA, V1177, P215, DOI 10.1016/0167-4889(93)90043-O; YUE TL, 1990, NEUROPEPTIDES, P7	29	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18021	18027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027061				2022-12-27	WOS:A1994NV42200043
J	MATHAI, JC; SITARAMAM, V				MATHAI, JC; SITARAMAM, V			STRETCH SENSITIVITY OF TRANSMEMBRANE MOBILITY OF HYDROGEN-PEROXIDE THROUGH VOIDS IN THE BILAYER - ROLE OF CARDIOLIPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; CELL CHIP28 PROTEIN; RED-CELL; FLUORESCENCE POLARIZATION; BIOLOGICAL-MEMBRANES; WATER PERMEABILITY; PHYSICAL INTEGRITY; VARIABLE POROSITY; DIFFUSION; VOLUME	Availability of voids for diffusion of quinone in the membrane was shown to be the rate-limiting step in electron transport in mitochondria and chloroplasts (Mathai, J. C., Sauna, Z. E., John, O., and Sitaramam, V (1993) J. Biol. Chem. 268, 15442-15454). The primary role of voids in these diffusion-controlled reactions required a more rigorous documentation of the role of diffusion in membranes by independent measurements. The transbilayer diffusion of hydrogen peroxide as monitored by occluded catalase activity was developed as a kinetically valid probe to specifically address this question. This in turn led to unique results on the mechanistic basis of stretch (= hypo-osmotic) activation of hydrogen peroxide permeation via such voids. The rate of peroxide permeation is shown to be markedly stretch sensitive in some cells/organelles (e.g. peroxisomes) and insensitive in others (e.g. erythrocytes); this was equally true of liposomes prepared from lipids extracted from the corresponding cells/organelles. The molecular basis of stretch sensitivity was uncovered using specific binary mixtures of lipids: while pure phosphatidyl choline liposomes were stretch insensitive, these became sensitive when doped only with specific lipids, viz. cardiolipin and cerebrosides. Cholesterol abolished this stretch sensitivity in ternary mixtures. Induction of stretch sensitivity by cardiolipin was marked by lowering of activation energy for peroxide diffusion, a negative temperature coefficient for glucose permeation while further addition of cholesterol reversed these phenomena. The steady state fluorescence polarization studies revealed intimate correlations between anisotropy, hydrogen peroxide diffusion, and stretch sensitivity consistent with presence of voids in these binary mixtures.	UNIV POONA,DEPT ZOOL,POONA 411007,MAHARASHTRA,INDIA	Savitribai Phule Pune University								ABRAHAM MH, 1990, J CHEM SOC PERK T 2, P291, DOI 10.1039/p29900000291; BANGHAM AD, 1962, ADV LIPID RES, V1, P65; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; BUNOW B, 1980, J THEOR BIOL, V84, P611, DOI 10.1016/S0022-5193(80)80023-3; CARRUTHERS A, 1983, BIOCHEMISTRY-US, V22, P5797, DOI 10.1021/bi00294a018; CASTILLO E, 1991, ENZYME MICROB TECH, V13, P127, DOI 10.1016/0141-0229(91)90167-9; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; DELRIO LA, 1977, ANAL BIOCHEM, V80, P409, DOI 10.1016/0003-2697(77)90662-5; ELAMRANI K, 1983, BIOCHIM BIOPHYS ACTA, V727, P22, DOI 10.1016/0005-2736(83)90364-4; FISHER KA, 1983, BIOPHYSICS-USSR, P413; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; KENNEDY EP, 1982, P NATL ACAD SCI-BIOL, V79, P1092, DOI 10.1073/pnas.79.4.1092; LEE AG, 1975, PROG BIOPHYS MOL BIO, V29, P1; MATHAI JC, 1989, BIOCHIM BIOPHYS ACTA, V976, P214, DOI 10.1016/S0005-2728(89)80233-6; MATHAI JC, 1993, J BIOL CHEM, V268, P15442; MATHAI JC, 1987, BIOCHEM EDUC, V15, P147, DOI 10.1016/0307-4412(87)90052-5; MEHLY AC, 1954, METHODS BIOCH ANAL A, V1, P357; MILLS JW, 1987, CURR TOP MEMBR TRANS, V30, P75; MLEKODAY HJ, 1983, J GEN PHYSIOL, V81, P213, DOI 10.1085/jgp.81.2.213; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; OLEARY TJ, 1987, P NATL ACAD SCI USA, V84, P429, DOI 10.1073/pnas.84.2.429; PAPAHADJOPOULOS D, 1973, BIOCHIM BIOPHYS ACTA, V311, P330, DOI 10.1016/0005-2736(73)90314-3; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RAO NM, 1987, THESIS OSMANIA U HYD; SAMBASIVARAO D, 1983, BIOCHIM BIOPHYS ACTA, V722, P256, DOI 10.1016/0005-2728(83)90072-5; SAMBASIVARAO D, 1986, BIOCHIM BIOPHYS ACTA, V857, P48, DOI 10.1016/0005-2736(86)90097-0; SAMBASIVARAO D, 1988, BIOCHIM BIOPHYS ACTA, V933, P200, DOI 10.1016/0005-2728(88)90071-0; SAMBASIVARAO D, 1985, BIOCHIM BIOPHYS ACTA, V806, P195, DOI 10.1016/0005-2728(85)90097-0; SARMA MKJ, 1983, BIOCHEM BIOPH RES CO, V105, P362; SCALETTAR BA, 1991, P NATL ACAD SCI USA, V88, P8057, DOI 10.1073/pnas.88.18.8057; SEEMAN P, 1969, BIOCHIM BIOPHYS ACTA, V183, P476, DOI 10.1016/0005-2736(69)90162-X; SHAAFI RI, 1977, MEMBRANE TRANSPORT R, P221; SHANUBHOGUE A, 1992, J BIOCHEM BIOPH METH, V25, P95, DOI 10.1016/0165-022X(92)90002-R; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SITARAMAM V, 1988, J SCI IND RES INDIA, V47, P395; SITARAMAM V, 1989, MOL CELL BIOCHEM, V91, P91, DOI 10.1007/BF00228083; SITARAMAM V, 1987, J BIOSCIENCE, V11, P89, DOI 10.1007/BF02704661; SITARAMAM V, 1981, P NATL ACAD SCI USA, V78, P3440; SITARAMAM V, 1992, BIOMEMBRANE STRUCTUR, P123; SOMOGYI B, 1984, BIOCHIM BIOPHYS ACTA, V768, P81, DOI 10.1016/0304-4173(84)90001-6; Stein WD., 1986, TRANSPORT DIFFUSION, P69; VILLALAIN J, 1991, CHEM PHYS LIPIDS, V59, P9, DOI 10.1016/0009-3084(91)90058-J; WAGGONER AS, 1970, P NATL ACAD SCI USA, V67, P579, DOI 10.1073/pnas.67.2.579; WELCH G R, 1982, Progress in Biophysics and Molecular Biology, V39, P109; WILLS ED, 1969, BIOCHEM J, V113, P315, DOI 10.1042/bj1130315; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; [No title captured]	50	65	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17784	17793						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027032				2022-12-27	WOS:A1994NV42200008
J	MCDONALD, BJ; MOSS, SJ				MCDONALD, BJ; MOSS, SJ			DIFFERENTIAL PHOSPHORYLATION OF INTRACELLULAR DOMAINS OF GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR SUBUNITS BY CALCIUM/CALMODULIN TYPE 2-DEPENDENT PROTEIN-KINASE AND CGMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTOR; MOLECULAR-BIOLOGY; GABAA RECEPTOR; BETA-SUBUNIT; 2 FORMS; EXPRESSION; SITES; POTENTIATION; ACTIVATION; EXISTENCE	gamma-Aminobutyric acid type A receptor subunits (GABA(A)) can be divided into five classes, alpha, beta, gamma, delta, and rho, based on sequence homology. We have used purified fusion proteins of the major intracellular domain of GABA(A) receptor subunits produced in Escherichia coli to examine the phosphorylation of these subunits by cGMP-dependent protein kinase (PKG) and multifunctional calcium/calmodulin-dependent protein kinase (CAM KII). Both PKG and CAM KII phosphorylated a purified beta(1) subunit fusion. Both of these kinases phosphorylated serine 409 within the beta(1) subunit; in addition, CAM KII also phosphorylated serine 384 as determined by site-specific mutagenesis. Fusion proteins of the major intracellular domains of the gamma(2)S and gamma(2)L subunits were produced. These proteins differ by 8 amino acids (LLRMFSFK). Both the gamma(2)L and gamma(2)S fusion proteins were excellent substrates of CAM KII. However, the gamma(2)L fusion protein was phosphorylated to higher stoichiometry due to the phosphorylation of serine 343 within this 8 amino acid insertion. Both the gamma(2)L and gamma(2)S subunits were phosphorylated on common residues by CAM KII identified as serine 348 and threonine 350. These results identify specific sites of phosphorylation for CAM KII and PKG within GABA(A) receptor subunits, suggesting a role for these two kinases in modulating GABA(A) receptor function in vivo.	UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London; University of London; University College London								BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; GLAUM SR, 1993, J NEUROSCI, V13, P1636; GLENCOURSE TA, 1993, EUR J NEUROSCI, V4, P271; HARVEY RJ, 1994, J NEUROCHEM, V62, P10; HARVEY RJ, 1993, FEBS LETT, V331, P211, DOI 10.1016/0014-5793(93)80339-V; KANO M, 1992, NEUROREPORT, V3, P563, DOI 10.1097/00001756-199207000-00004; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, IN PRESS NEURON; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIUS RA, 1993, TRENDS PHARMACOL SCI, V14, P403, DOI 10.1016/0165-6147(93)90062-O; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; MACHU TK, 1993, J NEUROCHEM, V61, P1375; MILES K, 1988, MOL NEUROBIOL, V2, P91, DOI 10.1007/BF02935341; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1990, EUR J PHARM-MOLEC PH, V189, P77, DOI 10.1016/0922-4106(90)90232-M; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SETZLER A, 1992, ION CHANNELS, V3, P83; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VERUKI ML, 1992, J NEUROPHYSIOL, V67, P791, DOI 10.1152/jn.1992.67.4.791; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; YMER S, 1989, EMBO J, V8, P1865	38	127	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18111	18117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027073				2022-12-27	WOS:A1994NV42200055
J	CHIANG, JYL; STROUP, D				CHIANG, JYL; STROUP, D			IDENTIFICATION AND CHARACTERIZATION OF A PUTATIVE BILE ACID-RESPONSIVE ELEMENT IN CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; DNA-BINDING PROTEINS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; RECEPTOR SUPERFAMILY; DEHYDROGENASE GENE; THYROID-HORMONE; NUCLEAR FACTOR; LIVER; RAT	Nucleotide sequences of a 7997-base pair SacI fragment spanning 3643 base pairs of the upstream promoter region to exon 4 of the rat cholesterol 7 alpha-hydroxylase gene (CYP7) have been determined. DNase I footprinting and electrophoretic mobility shift assay of the proximal promoter from nucleotides -346 to +36 revealed two protected regions which specifically shifted proteins in rat liver nuclear extracts. Footprint A (nucleotides -81 to -35) contained a cluster of overlapping sequence motifs of TGT3, steroid/thyroid hormone response elements (7 alpha TRE), hepatocyte nuclear factors 1 and 4, and CAAT/enhancer-binding protein alpha and has been shown to confer bile acid repression of the CYP7 gene promoter activity. Footprint B (nucleotides -148 to -129) contained a sequence motif HNF4. When footprint A (-101 to -49) or 7 alpha TRE (-73 to -55) sequence was linked upstream to a heterologous SV40 promoter/ luciferase plasmid and transiently transfected into HepG2 cells, taurodeoxycholate suppressed the SV40 promoter activity. Electrophoretic mobility shift assays revealed that one or two bands shifted by the 7 alpha TRE or by a direct repeat sequence in 7 alpha TRE were absent when liver nuclear extracts of deoxycholic acid-treated rats were used. Similar gel shift patterns were also observed when human 7 alpha TRE or human liver nuclear extracts were used. The rat direct repeat sequence interacted with two polypeptides (M(r) = 57,000 and 116,000) in both rat and human liver nuclear extracts. These results suggest that hydrophobic bile acids may suppress the CYP7 gene expression by binding to a bile acid receptor which interacts with and prevents the binding of liver nuclear protein(s) to a bile acid-responsive element and that the core of bile acid-responsive element is a direct repeat.			CHIANG, JYL (corresponding author), NE OHIO UNIV, DEPT BIOCHEM & MOLEC PATHOL, 4209 STATE ROUTE 44, POB 95, ROOTSTOWN, OH 44272 USA.			Chiang, John/0000-0001-9360-7650	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044442] Funding Source: Medline; NIGMS NIH HHS [GM31584] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CHIANG JYL, 1990, J BIOL CHEM, V265, P3889; CHIANG JYL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P337, DOI 10.1016/0167-4781(92)90175-Y; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; LI YC, 1990, J BIOL CHEM, V265, P12012; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER S, 1993, J BIOL CHEM, V268, P16831; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MYANT NB, 1977, J LIPID RES, V18, P135; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PAULWEBER B, 1991, J BIOL CHEM, V266, P24149; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANGE EF, 1989, J CLIN INVEST, V84, P173, DOI 10.1172/JCI114137; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; THOMPSON JF, 1993, BIOCHIM BIOPHYS ACTA, V1168, P239, DOI 10.1016/0005-2760(93)90130-2; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG DP, 1994, GENOMICS, V20, P320, DOI 10.1006/geno.1994.1177; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	43	137	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17502	17507						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021257				2022-12-27	WOS:A1994NU12800028
J	HOLMAN, GD; LEGGIO, LL; CUSHMAN, SW				HOLMAN, GD; LEGGIO, LL; CUSHMAN, SW			INSULIN-STIMULATED GLUT4 GLUCOSE-TRANSPORTER RECYCLING - A PROBLEM IN MEMBRANE-PROTEIN SUBCELLULAR TRAFFICKING THROUGH MULTIPLE POOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; RECEPTOR-MEDIATED ENDOCYTOSIS; EPIDERMAL GROWTH-FACTOR; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTORS; PLASMA-MEMBRANE; PHORBOL ESTER; SURFACE; TRANSLOCATION; VESICLES	The subcellular trafficking of GLUT4 in isolated rat adipose cells and 3T3-L1 adipocytes exhibits many of the properties observed in regulated secretory processes and neurosecretion. GLUT4 is sorted and sequestered from endosomes into a specialized secretory compartment in the basal state and the initial stimulation of its exocytosis by insulin is more rapid than its recycling through the endosomes and secretory compartment during the steady-state response to insulin. We present a mathematical analysis which shows that this behavior is inconsistent with a simple 2-pool model with one plasma membrane and one intracellular compartment, but that a 3-pool model, with two intracellular compartments, can simulate these properties. We extend this model to include the presence of occluded pools in the plasma membrane. Our analysis compares the behavior expected when these occluded pools are precursors in stimulation and/or clathrin-associated-like intermediates in endocytosis. The presence of a precursor occluded pool can account for a lag between the appearance of GLUT4 in the membrane and before the full stimulation of glucose transport activity. The analysis also shows that since the pool size of the occluded GLUT4 is relatively small, the formation of endocytic occluded intermediates such as GLUT4 in clathrin-coated pits is likely to be slow compared with the rate of endocytosis of the coated vesicles.	UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND; NIDDK,EXPTL DIABET METAB & NUTR SECT,BETHESDA,MD 20892	University of Bath; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Leggio, Leila Lo/B-4287-2015	Leggio, Leila Lo/0000-0002-5135-0882; Holman, Geoffrey/0000-0001-7045-1358				BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DUNNKW, 1992, J CELL BIOL, V117, P301; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; GIBBS EM, 1986, J BIOL CHEM, V261, P3944; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KOZKA IJ, 1993, DIABETES, V42, P1159, DOI 10.2337/diabetes.42.8.1159; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; MAJOR S, 1993, J CELL BIOL, V121, P1257; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; QUON MJ, 1991, J THEOR BIOL, V150, P93, DOI 10.1016/S0022-5193(05)80477-1; QUON MJ, 1994, AM J PHYSIOL, V266, pE144, DOI 10.1152/ajpendo.1994.266.1.E144; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YANAI S, 1991, AM J PHYSIOL, V260, pC457, DOI 10.1152/ajpcell.1991.260.3.C457; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600	44	154	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17516	17524						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021259				2022-12-27	WOS:A1994NU12800030
J	LI, ZP; MATSUOKA, S; HRYSHKO, LV; NICOLL, DA; BERSOHN, MM; BURKE, EP; LIFTON, RP; PHILIPSON, KD				LI, ZP; MATSUOKA, S; HRYSHKO, LV; NICOLL, DA; BERSOHN, MM; BURKE, EP; LIFTON, RP; PHILIPSON, KD			CLONING OF THE NCX2 ISOFORM OF THE PLASMA-MEMBRANE NA+-CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; FUNCTIONAL EXPRESSION; NA+/CA2+ EXCHANGER; DYNAMIC PROPERTIES; MOLECULAR-CLONING; SIGNAL-SEQUENCE; STEADY-STATE; LOCALIZATION; PROTEIN; CDNA	The Na+-Ca2+ exchanger is an important regulator of cellular Ca2+ levels, and one isoform of this transporter, NCX1, has been cloned previously (Nicoll, D. A., Longoni, S., and Philipson, K. D. (1990) Science 250, 562-565). We now report the cloning of a second isoform (NCX2) of the Na+-Ca2+ exchanger which was present in a rat brain cDNAlibrary. NCX2 is predicted to code for a protein of 921 amino acids. NCX1 and NCX2 are 61 and 65% identical at the nucleotide and amino acid levels, respectively, and are the products of different genes. The genes for NCX1 and NCX2 are located on human chromosomes 2 and 14, respectively. Hydropathy profiles of the two exchangers are very similar. Transcripts of NCX2 are detected in brain and skeletal muscle. NCX2 was expressed in Xenopus oocytes and Na+-Ca2+ exchange activity was analyzed electrophysiologically by the giant inside-out, excised patch technique. Outward currents were evoked by the application of Na+ with the exchanger operating in the reversed mode (extracellular Ca2+ exchanging for intracellular Na+). The affinity for Na+ (30 mM) and the current-voltage relationship of NCX2 are similar to those for NCX1. Like NCX1, NCX2 is secondarily regulated by intracellular Ca2+, but the affinity of NCX2 for regulatory Ca2+ (1.5 mu M) upon initial application of Na+ is lower than that of NCX1 (0.3 mu M). The existence of multiple Na+-Ca2+ exchanger isoforms may provide flexibility for regulation and expression.	UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; VET ADM MED CTR,CARDIOL SECT,LOS ANGELES,CA 90073; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; Yale University; Yale University; Yale University				Hryshko, Larry/0000-0003-1079-8549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101, R01HL048509, R37HL048509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101, HL48509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURDEAU JE, 1993, J AM SOC NEPHROL, V4, P105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; JUHASZOVA M, 1994, AM J PHYSIOL, V266, pC234, DOI 10.1152/ajpcell.1994.266.1.C234; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1993, J BIOL CHEM, V268, P11489; LUTHER PW, 1992, J NEUROSCI, V12, P4898; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; Philipson K D, 1993, Int Rev Cytol, V137C, P199; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; SHIEH BH, 1992, GENOMICS, V12, P616, DOI 10.1016/0888-7543(92)90459-6; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	29	300	310	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17434	17439						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021246				2022-12-27	WOS:A1994NU12800017
J	MADSHUS, IH				MADSHUS, IH			THE N-TERMINAL ALPHA-HELIX OF FRAGMENT-B OF DIPHTHERIA-TOXIN PROMOTES TRANSLOCATION OF FRAGMENT-A INTO THE CYTOPLASM OF EUKARYOTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE TRANSLOCATION; LOW PH; VERO CELLS; BINDING DOMAIN; A-FRAGMENT; CHANNELS; RECEPTOR; ENTRY; EXPRESSION; PROTEINS	Diphtheria toxin consists of two parts, fragments A and B. Fragment A has enzymatic activity inhibiting protein synthesis. Fragment B binds to cellular receptors and, upon exposure to low pH, inserts into the membrane, forms cation-selective channels, and facilitates translocation of fragment A Previous data have suggested that the N-terminal part of fragment B, including the amphipathic alpha-helix TH1, plays an active role during translocation of fragment A (Madshus, I. H., Wiedlocha, A., and Sandvig, R. (1994) J Biol. Chem. 269, 4648-4652). When replacing charged residues in TH1 with uncharged amino acids, translocation of fragment A was strongly inhibited, virtually without affecting binding of the toxin or channel activity. These data suggest that TH1 may act as a targeting/anchoring sequence. In a mutant with eight positive charges and one negative charge in TH1, increased specific binding was observed, even if TH1 was outside the toxin's binding domain. This suggests that TH1 could be important in binding to parts of the translocation machinery. Fragment A associated with this mutant fragment B was translocated 10 fold more efficiently than wild-type toxin. The fact that this mutant TH1 efficiently promoted translocation, while a hydrophobic TH1 did not, suggests that TH1 does not interact with the hydrophobic part of the membrane phospholipids.	NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY	University of Oslo								CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; ESBENSEN QY, 1993, BIOCHEM J, V294, P663, DOI 10.1042/bj2940663; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FU H, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P379; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; MADSHUS IH, 1992, INFECT IMMUN, V60, P3296, DOI 10.1128/IAI.60.8.3296-3302.1992; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; OLSNES S, 1980, J BIOL CHEM, V255, P284; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077	29	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17723	17729						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021285				2022-12-27	WOS:A1994NU12800059
J	PATTON, DE; ISOM, LL; CATTERALL, WA; GOLDIN, AL				PATTON, DE; ISOM, LL; CATTERALL, WA; GOLDIN, AL			THE ADULT-RAT BRAIN BETA(1) SUBUNIT MODIFIES ACTIVATION AND INACTIVATION GATING OF MULTIPLE SODIUM-CHANNEL ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC-CELL LINE; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; MESSENGER-RNAS; CLONED CDNA; BETA-1-SUBUNIT; PURIFICATION; TETRODOTOXIN; TOXIN	The sodium channel from adult rat brain consists of a high molecular weight alpha subunit associated with low molecular weight subunits termed beta(1) and beta(2). Coexpression of beta(1) accelerates the macroscopic kinetics of inactivation of adult rat brain IIA, embryonic rat brain III, and rat skeletal muscle SkM1 sodium channel alpha subunits. In addition, beta(1) accelerates the kinetics of activation, as observed with a non-inactivating rat brain IIA. mutant. Analysis of the effects of beta(1) on the slowly inactivating brain III alpha subunit shows that both of these effects may be the result of changes in the modal gating behavior of the sodium channels expressed in Xenopus oocytes. Although the adult rat brain beta(1) subunit modulates the functional properties of rat skeletal muscle and embryonic brain III sodium channel alpha subunits, mRNA hybridizing to a beta(1) subunit cDNA probe was only faintly detected in RNA from adult skeletal muscle and not at all in RNA from embryonic brains. These results indicate that the adult rat brain beta(1) subunit can modify the modal gating properties of sodium channel alpha subunits with which it is not normally associated, suggesting the presence of conserved domains for interactions between the different alpha and beta(1) subunits of the sodium channel.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of California System; University of California Irvine; University of Washington; University of Washington Seattle			; Goldin, Alan/A-8385-2015	Isom, Lori/0000-0002-9479-6729; Goldin, Alan/0000-0001-7159-0288	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, R01NS026729, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15751, NS26729, NS25704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; ALDRICH RW, 1987, J NEUROSCI, V7, P418; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; COLE KS, 1960, BIOPHYS J, V1, P1, DOI 10.1016/S0006-3495(60)86871-3; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P497, DOI 10.1113/jphysiol.1952.sp004719; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P470; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	36	170	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17649	17655						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021275				2022-12-27	WOS:A1994NU12800049
J	ZHOU, A; MAINS, RE				ZHOU, A; MAINS, RE			ENDOPROTEOLYTIC PROCESSING OF PROOPIOMELANOCORTIN AND PROHORMONE CONVERTASE-1 AND CONVERTASE-2 IN NEUROENDOCRINE CELLS OVEREXPRESSING PROHORMONE CONVERTASE-1 OR CONVERTASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MICROINJECTED XENOPUS OOCYTES; ATT-20 CELLS; PC2; CLEAVAGE; FURIN; BIOSYNTHESIS; PITUITARY; ENZYMES; KEX2	AtT-20 mouse corticotrope tumor cell lines overexpressing the prohormone convertases PC1 or PC2 were established and used to examine prohormone and pro hormone convertase biosynthetic processing. On a molar basis, wild-type AtT20 cells synthesize about 20% as much PC1 as the endogenous prohormone, proopiomelanocortin (POMC). Kinetic, oligosaccharide, and temperature blockade analyses established that proPC1 is converted to PC1 in the endoplasmic reticulum at a rate independent of the level of PC1 or PC2 expression. In contrast, proPC2 is converted to PC2 primarily in a post-trans-Golgi compartment. PC1 is further shortened from its COOH-terminal end in a post-trans-Golgi compartment in a step that is accelerated at higher levels of PC1 expression, but unaltered by PC2 overexpression. The initial steps in POMC processing are speeded up by overexpression of PC1, and overexpression of PC1 leads to more extensive cleavage of POMC to smaller products. However, even when the rate of PC1 synthesis exceeds that for POMC by 2-fold, PC1 does not cleave the Lys Lys or Arg-Lys bonds cleaved upon overexpression of PC2.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University				Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-00097] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BLOOMQUIST BT, 1993, CELL PHYSIOL BIOCHEM, V3, P197, DOI 10.1159/000154684; BRADSHAW RA, 1990, PROG BRAIN RES, V86, P157; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1992, FEBS LETT, V310, P235, DOI 10.1016/0014-5793(92)81339-N; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1990, J BIOL CHEM, V265, P8436; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; YOUNG RW, 1965, ANAL BIOCHEM, V11, P389, DOI 10.1016/0003-2697(65)90030-8; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1993, NOV ANN M SOC NEUR A	39	168	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17440	17447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021247				2022-12-27	WOS:A1994NU12800018
J	FERNANDES, J; TANG, DM; LEONE, G; LEE, PWK				FERNANDES, J; TANG, DM; LEONE, G; LEE, PWK			BINDING OF REOVIRUS TO RECEPTOR LEADS TO CONFORMATIONAL-CHANGES IN VIRAL CAPSID PROTEINS THAT ARE REVERSIBLE UPON VIRUS DETACHMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ATTACHMENT PROTEIN; MAMMALIAN REOVIRUSES; TYPE-3 REOVIRUS; POLIOVIRUS; PARTICLES; PROTEIN-SIGMA-1; SIGMA-1; RESOLUTION; VIRIONS	A conformational change was detected in reovirus upon its attachment to mouse L fibroblasts. Specifically, the capsid proteins of cell-bound virions became more resistant to pepsin digestion. Similar observations were made using glutaraldehyde-fixed cells or plasma membranes instead of live cells, indicating that virus internalization was not necessary for this effect. This conformational change was totally reversible, since bound virions reverted back to the pepsin-sensitive state upon release from the cell surface. Not unexpectedly, a conformational change was also detected in the reovirus cell attachment protein sigma 1 when it alone bound to cells. The alteration was mapped, by deletion mutagenesis, to a region proximal to the N-terminal (virion-anchoring) end of the protein and was also found to be reversible. Structural changes in sigma 1 were also detectable following its interaction with sialic acid (conjugated to bovine serum albumin) shown previously to be the minimal receptor determinant recognized by reovirus. These results suggest that upon cell attachment, a signal is transmitted from the C-terminal receptor-binding region of sigma 1 to the N terminus in a ripple-like progression that eventually leads to conformational changes in the other reovirus capsid proteins. An altered conformational state may be necessary for subsequent viral entry and programmed disassembly of viral capsids inside susceptible cells.	UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY T2N 1N4,AB,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba			Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300; Tang, Damu/0000-0002-3282-9521				ARMSTRONG GD, 1984, VIROLOGY, V138, P37, DOI 10.1016/0042-6822(84)90145-4; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BENTZ J, 1993, VIRAL FUSION MECHANI; CHOI AHC, 1990, VIROLOGY, V178, P316, DOI 10.1016/0042-6822(90)90412-K; CHOI AHC, 1988, VIROLOGY, V163, P191, DOI 10.1016/0042-6822(88)90246-2; CO MS, 1985, P NATL ACAD SCI USA, V82, P5315, DOI 10.1073/pnas.82.16.5315; CO MS, 1985, P NATL ACAD SCI USA, V82, P1494, DOI 10.1073/pnas.82.5.1494; CROWELL RL, 1971, J VIROL, V8, P509, DOI 10.1128/JVI.8.4.509-515.1971; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DESENA J, 1977, VIROLOGY, V78, P554, DOI 10.1016/0042-6822(77)90130-1; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; FENWICK ML, 1973, J CELL SCI, V13, P403; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GENTSCH JR, 1987, VIROLOGY, V161, P245, DOI 10.1016/0042-6822(87)90192-9; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LONBERGHOLM K, 1972, J VIROL, V9, P29, DOI 10.1128/JVI.9.1.29-40.1972; LUCIAJANDRIS P, 1993, J VIROL, V67, P5339, DOI 10.1128/JVI.67.9.5339-5345.1993; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; MCCRAE MA, 1978, VIROLOGY, V89, P578, DOI 10.1016/0042-6822(78)90199-X; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SAWUTZ DG, 1987, LIFE SCI, V40, P399, DOI 10.1016/0024-3205(87)90142-1; SHARPE AH, 1985, NEW ENGL J MED, V312, P486, DOI 10.1056/NEJM198502213120806; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8	39	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17043	17047						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006009				2022-12-27	WOS:A1994NT84600012
J	PENG, SB; CRIDER, BP; XIE, XS; STONE, DK				PENG, SB; CRIDER, BP; XIE, XS; STONE, DK			ALTERNATIVE MESSENGER-RNA SPLICING GENERATES TISSUE-SPECIFIC ISOFORMS OF 116-KDA POLYPEPTIDE OF VACUOLAR PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; CDNA SEQUENCE; SULFOLOBUS-ACIDOCALDARIUS; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING COMPLEX; MOLECULAR-CLONING; ALPHA-SUBUNIT; BETA-SUBUNIT; GENE ENCODES; HIGHER-PLANT	The cDNA encoding the 116-kDa polypeptide of the bovine brain vacuolar-type proton translocating ATPases has been cloned and sequenced. One of five clones differed from all others in that it contained an 18-base pair deletion within the coding region, whereas it was identical to the other clones in overlapping coding and noncoding regions, indicating that this heterogeneity arises through an alternative splicing mechanism. By conventional Northern analysis, only one 4.1-kilobase mRNA was identified in bovine brain, heart, kidney, liver, and spleen. However, a polymerase chain reaction-based analysis revealed two species of mRNA with a tissue specific distribution. Type I, containing the 18-base pair insert, was found in brain, whereas the truncated (Type II) form was found in all tissues examined. Similar tissue distributions of rat mRNA were observed. The deletion site accounting for this variability occurs within a predicted protease sensitivity motif (PEST site), suggesting that differences in the biological half-life of the two 116-kDa isoforms may exist.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK RO1-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; GU HH, 1993, J BIOL CHEM, V268, P7372; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRATA R, 1990, J BIOL CHEM, V265, P6726; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI S, 1991, J BIOL CHEM, V266, P16078; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON H, 1989, J BIOL CHEM, V264, P1775; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; STONE DK, 1988, KIDNEY INT, V33, P403; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TAKASE K, 1993, J BIOL CHEM, V268, P11610; VNAHILLE B, 1993, J BIOL CHEM, V268, P7075; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1988, J BIOL CHEM, V263, P9859; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	39	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17262	17266						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006034				2022-12-27	WOS:A1994NT84600044
J	WU, GD; CHEN, LL; FORSLUND, K; TRABER, PG				WU, GD; CHEN, LL; FORSLUND, K; TRABER, PG			HEPATOCYTE NUCLEAR FACTOR-1-ALPHA (HNF-1-ALPHA) AND HNF-1-BETA REGULATE TRANSCRIPTION VIA 2 ELEMENTS IN AN INTESTINE-SPECIFIC PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE GENE; HUMAN-COLON CARCINOMA; DNA-BINDING PROTEINS; CRYPT-VILLUS AXIS; MESSENGER-RNA; MOLECULAR-CLONING; LEUCINE ZIPPER; CELL-LINE; FACTOR-I; EXPRESSION	Hepatocyte nuclear factor-1 alpha (HNF-1 alpha) and HNF-1 beta are transcription factors that contain a divergent homeodomain, bind to DNA as homo- or heterodimers, and act to regulate transcription of many genes that are expressed primarily in liver. We show that HNF-1 alpha and HNF-1 beta act as regulatory factors for transcription of sucrase-isomaltase (SI), the gene for which is expressed exclusively in absorptive enterocytes of the small intestine. HNF-1 alpha and HNF-1 beta bind to two evolutionarily conserved sites in the SI promoter, previously named SIF2 and SIF3, with different relative affinities. HNF-1 alpha binds to the SIF3 element with greater affinity than to the SIF2 element, whereas HNF-1 beta binds to both elements equally. Co-transfection experiments demonstrated that HNF-1 alpha is able to increase transcriptional initiation from a minimal SI intestine-specific promoter. In contrast, HNF-1 beta has no functional effect on transcription of the SI promoter. The functional and DNA binding differences of HNF-1 alpha and HNF-1 beta on elements in the SI promoter suggest that these transcription factors may play a role in the complex spatial patterns of SI gene expression in the intestine.	UNIV PENN, SCH MED, DEPT INTERNAL MED, DIV GASTROENTEROL, PHILADELPHIA, PA 19104 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center					NIDDK NIH HHS [DK44621] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BOLL W, 1991, AM J HUM GENET, V48, P889; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Henning Susan J., 1987, PHYSL GASTROINTESTIN, V1, P285; HOFFMAN L R, 1991, Gastroenterology, V100, pA828; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; Kaufman M.H., 1992, ATLAS MOUSE DEV; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; Lorenzsonn V, 1987, GASTROENTEROLOGY, V92, P98, DOI 10.1016/0016-5085(87)90844-4; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIURA N, 1993, EUR J CELL BIOL, V60, P376; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; PINTO M, 1983, BIOL CELL, V47, P323; QUINN LA, 1979, CANCER RES, V39, P4914; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU GD, 1992, J BIOL CHEM, V267, P7863; WU GD, 1993, GASTROENTEROLOGY, V104, pA290	40	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17080	17085						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006012				2022-12-27	WOS:A1994NT84600018
J	SAGAMI, H; MORITA, Y; OGURA, K				SAGAMI, H; MORITA, Y; OGURA, K			PURIFICATION AND PROPERTIES OF GERANYLGERANYL-DIPHOSPHATE SYNTHASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; FARNESYL DIPHOSPHATE; RAT-LIVER; PROTEINS; PYROPHOSPHATES; STIMULATION; SYNTHETASE; INHIBITION; RAS-P21; CYCLASE	Geranylgeranyl-diphosphate synthase was purified to homogeneity from bovine brain in a one-step procedure employing an affinity column. For the construction of the affinity column, a farnesyl diphosphate analog, O-(6-amino-1-hexyl)-P-farnesylmethyl phosphonophosphate, was synthesized and linked to the spacer of the matrix of Affi-Gel 10 via the amino group. The native enzyme appeared to be a homooligomer (150-195 kDa) with a molecular mass of the monomer of 37.5 kDa. The pI for the enzyme was 6.2. The K-m values for dimethylallyl diphosphate, geranyl diphosphate, and farnesyl diphosphate were estimated to be 33, 0.80, and 0.74 mu M, respectively. The K-m value for isopentenyl diphosphate in the reaction with isopentenyl diphosphate and farnesyl diphosphate was 2 mu M. The reaction velocities for the formation of geranylgeranyl diphosphate from dimethylallyl diphosphate, geranyl diphosphate, and farnesyl diphosphate were in the ratio of 0.004:0.145:1. The intermediate farnesyl diphosphate was formed in the reaction with geranyl diphosphate as an allylic primer. Geranylgeranyl diphosphate acted as a competitive inhibitor against farnesyl diphosphate with an approximate K-i value of 1.2 mu M in the condensation reaction of farnesyl diphosphate with isopentenyl diphosphate. Farnesyl-diphosphate synthase catalyzing the formation of farnesyl diphosphate from dimethylallyl diphosphate and isopentenyl diphosphate was also purified to homogeneity from the same organ by similar affinity chromatography using a geranyl diphosphate analog, O-(6-amino-1-hexyl)-P-geranylmethyl phosphonophosphate, as a ligand. This enzyme was a homodimer with a monomeric molecular mass of 40.0 kDa. These results indicate that geranylgeranyl diphosphate, a lipid precursor for the biosynthesis of a majority of prenylated proteins, is synthesized from dimethylallyl diphosphate and isopentenyl diphosphate by the action of farnesyl-diphosphate synthase catalyzing the reaction of C-5 --> C-15, followed by the action of geranylgeranyl diphosphate synthase catalyzing a single reaction of C-15 --> C-20, and that geranylgeranyl diphosphate can down-regulate its own synthesis through the inhibition of the geranylgeranyl-diphosphate synthase action.			SAGAMI, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN.		Morita-fujimura, Yuiko/N-4804-2014; fujimura, yuiko/M-7393-2013					BARTLETT DL, 1985, METHOD ENZYMOL, V110, P171; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRINKHAUS FL, 1988, ARCH BIOCHEM BIOPHYS, V266, P607, DOI 10.1016/0003-9861(88)90293-7; CHEN AJ, 1993, J BIOL CHEM, V268, P11002; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DOGBO O, 1987, BIOCHIM BIOPHYS ACTA, V920, P140, DOI 10.1016/0005-2760(87)90253-0; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; ITOH T, 1993, J BIOL CHEM, V268, P3025; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAFERRIERE A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P167, DOI 10.1016/0167-4838(91)90054-4; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; LUTZ RJ, 1992, J BIOL CHEM, V267, P7983; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1993, J BIOCHEM-TOKYO, V114, P118, DOI 10.1093/oxfordjournals.jbchem.a124125; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SAGAMI H, 1993, J BIOCHEM-TOKYO, V114, P112, DOI 10.1093/oxfordjournals.jbchem.a124124; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TACHIBANA A, 1993, BIOSCI BIOTECH BIOCH, V57, P1129, DOI 10.1271/bbb.57.1129; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6	28	57	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20561	20566						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051156				2022-12-27	WOS:A1994PB31700056
J	SPAGNUOLO, C; DEMARTINO, F; BOFFI, A; ROUSSEAU, DL; CHIANCONE, E				SPAGNUOLO, C; DEMARTINO, F; BOFFI, A; ROUSSEAU, DL; CHIANCONE, E			COORDINATION AND SPIN-STATE EQUILIBRIA AS A FUNCTION OF PH, IONIC-STRENGTH, AND PROTEIN-CONCENTRATION IN OXIDIZED DIMERIC SCAPHARCA-INAEQUIVALVIS HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; TETRAMERIC HEMOGLOBINS; OXIDATION REACTION; HEME-PROTEINS; PORPHYRIN; FE	The oxidized homodimeric Scapharca inaequivalvis hemoglobin undergoes changes in coordination and spin state as a function of pH, ionic strength, and protein concentration which have been monitored by optical absorption spectroscopy. Three species contribute to the spectra between pH 5.8 and 8.7: (i) a hexacoordinate high spin aquomet derivative, whose concentration is essentially constant over the whole pH range analyzed; (ii) a pentacoordinate high spin component which prevails at alkaline pH values, and (iii) a hexacoordinate low spin hemichrome, which is formed at acid pH. The contribution of each of the components to the observed spectra was calculated with the singular value decomposition procedure and has been described quantitatively in terms of a linkage scheme which accounts for the change in heme coordination and for the observation that the high spin to low spin transition entails dissociation into monomers. An important feature of the linkage scheme is the cooperative binding of protons to aquomet dimers. Stopped flow experiments to study the kinetics indicate that dissociation into monomers is the rate-limiting process. The unusually strong tendency of oxidized HbI to loose the heme-bound water molecule is discussed in terms of strain in the iron-proximal histidine bond.	AT&T BELL LABS,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs	SPAGNUOLO, C (corresponding author), UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY.							BOFFI A, 1991, J BIOL CHEM, V266, P17898; BOFFI A, 1994, J BIOL CHEM, V269, P20437; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; Eaton W A, 1981, Methods Enzymol, V76, P175; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; INUBUSHI T, 1988, FEBS LETT, V235, P87, DOI 10.1016/0014-5793(88)81239-0; RAKSHIT G, 1974, BIOCHEMISTRY-US, V13, P5317, DOI 10.1021/bi00723a010; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SPAGNUOLO C, 1988, BIOCHIM BIOPHYS ACTA, V956, P119, DOI 10.1016/0167-4838(88)90257-9; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; VERZILI D, 1982, BIOCHIM BIOPHYS ACTA, V704, P215, DOI 10.1016/0167-4838(82)90148-0; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028	18	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20441	20445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051141				2022-12-27	WOS:A1994PB31700038
J	DRISCOLL, DM; ZHANG, QW				DRISCOLL, DM; ZHANG, QW			EXPRESSION AND CHARACTERIZATION OF P27, THE CATALYTIC SUBUNIT OF THE APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SEQUENCE REQUIREMENTS; ADENOSINE-DEAMINASE; CYTIDINE DEAMINASE; RAT; HETEROGENEITY; PROTEINS; CLONING; SITE	An RNA editing mechanism converts C to U at nucleotide 6666 in apolipoprotein B (apoB) mRNA The catalytic subunit of the editing enzyme, p27, was recently cloned. When expressed in Xenopus oocytes, p27 required other proteins to edit apoB mRNA in vitro (Teng, B., Burant, C. E, and Davidson, N. O. (1993) Science 260, 1816-1819). In this study, we expressed p27 in McArdle 7777 cells, which edit apoB mRNA with low efficiency. The levels of editing enzyme increased 10-fold, and editing of the endogenous apoB mRNA increased 2-fold in p27-transfected cells. These results demonstrate that p27 is involved in editing in mammalian cells. p27 was also expressed in COS cells, which do not synthesize apoB and lack editing activity. Extracts from p27-transfected cells acquired the ability to edit apoB mRNA only when extracts from other tissues were added. This reconstituted enzyme had the same sequence specificity as the native enzyme. The activity that complemented p27 function was detected in baboon liver and in tissues. that do not synthesize apoB, including kidney and testis. The COS expression system was used to analyze the structure and function of p27, which contains a putative zinc finger (His(61), Cys(93), and Cys(96)) similar to other cytidine deaminases. Site-directed mutagenesis of His(61) to Arg, Pro(92) to Leu, or Cys(96) to Ser abolished p27 activity. The zinc finger in p27 may be required for catalysis, protein-protein interactions, or binding to apoB mRNA.			DRISCOLL, DM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,9500 EUCLID AVE,NC-10,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL45478] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045478, R01HL045478] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1993, J LIPID RES, V34, P1367; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; LAU PP, 1991, J BIOL CHEM, V266, P20550; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sambrook J, 1989, MOL CLONING LABORATO; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHARFF AJ, 1992, J MOL BIOL, V226, P917, DOI 10.1016/0022-2836(92)91040-V; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WU JH, 1990, J BIOL CHEM, V265, P12312; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003	26	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19843	19847						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051066				2022-12-27	WOS:A1994PA12600031
J	DONG, DLY; HART, GW				DONG, DLY; HART, GW			PURIFICATION AND CHARACTERIZATION OF AN O-GLCNAC SELECTIVE N-ACETYL-BETA-D-GLUCOSAMINIDASE FROM RAT SPLEEN CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC PROTEINS; HEXOSAMINIDASE-C; LINKED GLCNAC; ACETYLGLUCOSAMINE RESIDUES; GLYCOSYLATION; NUCLEAR; BRAIN; LOCALIZATION; SERUM; GLYCOPROTEINS	Glycosylation of nuclear and cytoplasmic proteins by O-linked N-acetylglucosamine (O-GlcNAc) monosaccharides is an abundant, ubiquitous, and transient posttranslational modification. To characterize enzymes involved in removal of these sugars, a neutral and cytoplasmic N-acetyl-beta-D-glucosaminidase (O-GlcNAcase) with strong selectivity for O-GlcNAc-synthetic glycopeptides has been purified over 22,000-fold from rat spleen homogenate. The purified O-GlcNAcase has two major polypeptides of apparent M(r) = 54,000 (alpha subunit) and M(r) = 51,000 (beta subunit). Enzyme activity sediments at M(r) = 106,000 on sucrose gradients, indicating that the native O-GlcNAcase is an alpha beta heterodimer. The O-GlcNAcase also shows substantially stronger relative activity against O-GlcNAc-synthetic glycopeptides than other hexosaminidases. Unlike acidic lysosomal hexosaminidases, O-GlcNAcase is not inhibited by GalNAc or its analogs, has no other detectable glycosidase activities, and does not cross-react with antibodies against acidic hexosaminidases. Subcellular fractionation and latency studies demonstrate the cytoplasmic and nucleoplasmic localization of the enzyme and its ubiquitous presence in tissues. These studies suggest that O-GlcNAcase is involved in the regulated removal of O-GlcNAc from O-GlcNAc-bearing glycoproteins in the nucleoplasmic and cytoplasmic compartments of cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NICHD NIH HHS [R01 HD13563] Funding Source: Medline; NIGMS NIH HHS [5T3-GM07445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alberts B., 1989, MOL BIOL CELL; BESLEY GTN, 1976, BIOCHEM J, V155, P205, DOI 10.1042/bj1550205; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRAIDMAN I, 1974, FEBS LETT, V41, P181, DOI 10.1016/0014-5793(74)81206-8; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Chou Teh-Ying, 1993, Glycobiology, V3, P523; DEWJI NN, 1986, BIOCHEM J, V234, P157, DOI 10.1042/bj2340157; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; EMILIANI C, 1990, BIOCHEM J, V267, P111, DOI 10.1042/bj2670111; FROHWEIN YZ, 1966, BIOCHIM BIOPHYS ACTA, V128, P216, DOI 10.1016/0926-6593(66)90167-6; FROHWEIN YZ, 1973, CLIN CHIM ACTA, V43, P439; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GREBNER EE, 1973, BIOCHIM BIOPHYS ACTA, V321, P228, DOI 10.1016/0005-2744(73)90077-6; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, C MOSBACH, V44, P91; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HOOGHWINKEL GJM, 1972, Z PHYSIOL CHEM, V353, P839; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; IKONNE JU, 1975, AM J HUM GENET, V27, P639; IZUMI T, 1983, J BIOL CHEM, V258, P6991; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JIANG MS, 1994, J CELL BIOCH B, V18, P344; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; KINOSHITA K, 1988, J BIOCHEM-TOKYO, V104, P827, DOI 10.1093/oxfordjournals.jbchem.a122557; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEUFELD EF, 1989, J BIOL CHEM, V264, P10927; OVERDIJK B, 1981, BIOCHIM BIOPHYS ACTA, V659, P255, DOI 10.1016/0005-2744(81)90052-8; OVERDIJK B, 1975, BIOCHEM J, V151, P257, DOI 10.1042/bj1510257; POENARU L, 1973, BIOMED EXPRESS, V19, P538; PRICE RG, 1972, BIOCHIM BIOPHYS ACTA, V271, P145, DOI 10.1016/0005-2795(72)90142-0; PROIA RL, 1984, J BIOL CHEM, V259, P3350; REASON AJ, 1992, J BIOL CHEM, V267, P16911; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SANDHOFF K, 1969, FEBS LETT, V4, P351, DOI 10.1016/0014-5793(69)80274-7; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STIRLING JL, 1972, BIOCHIM BIOPHYS ACTA, V271, P154, DOI 10.1016/0005-2795(72)90143-2; TORRES CR, 1984, J BIOL CHEM, V259, P3308; UENO R, 1991, BIOCHIM BIOPHYS ACTA, V1074, P79, DOI 10.1016/0304-4165(91)90043-G	53	393	425	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19321	19330						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034696				2022-12-27	WOS:A1994NY33200021
J	MONTIJN, RC; VANRINSUM, J; VANSCHAGEN, FA; KLIS, FM				MONTIJN, RC; VANRINSUM, J; VANSCHAGEN, FA; KLIS, FM			GLUCOMANNOPROTEINS IN THE CELL-WALL OF SACCHAROMYCES-CEREVISIAE CONTAIN A NOVEL TYPE OF CARBOHYDRATE SIDE-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; PROTEIN; YEAST; GLYCOSYLATION; MANNOPROTEIN; GROWTH; MNN9	Mannoproteins in the walls of mnn9 cells of Saccharomyces cerevisiae were released by laminarinase, and purified by concanavalin A affinity chromatography and ion-exchange chromatography. Carbohydrate analysis revealed that they contained N-acetylglucosamine, mannose, and glucose. An antiserum raised against beta(1-6)-glucan reacted with four proteins with molecular masses of 66, 100, 155, and 220 kDa, respectively. Recognition by the antiserum was competitively inhibited by beta(1-6)-glucan, but not by beta(1-3)-glucan, mannan, or dextran (an alpha(1-6)-glucan). Mild periodate treatment of the wall proteins completely abolished recognition by the antiserum. Glucose-containing side chains were isolated and compared with N- and O-carbohydrate side chains. The glucose containing side chains consisted of about equal amounts of glucose and mannose and some N-acetylglucosamine, and were larger than N-chains. They were, however, not extended N-chains, because after acetolysis, which preferentially cleaves (1-6)-linkages, their elution profiles differed strongly. A model is presented of how glucose-containing side chains might anchor mannoproteins into the glucan layer of the cell wall.			MONTIJN, RC (corresponding author), UNIV AMSTERDAM, BIOCENTRUM AMSTERDAM, INST MOLEC CELL BIOL, KRUISLAAN 318, 1098 SM AMSTERDAM, NETHERLANDS.		Klis, Frans M/B-9085-2008	Klis, Frans M/0000-0003-0079-9492				BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; DENOBEL JG, 1989, J GEN MICROBIOL, V135, P2077; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Fleet G.H., 1991, YEASTS, VVol. 4, P199, DOI [10.1002/jobm.19720120411, DOI 10.1002/JOBM.19720120411]; HARD K, 1989, FEBS LETT, V248, P111, DOI 10.1016/0014-5793(89)80442-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MEIKLE PJ, 1991, PLANTA, V185, P1, DOI 10.1007/BF00194507; MULLER G, 1992, J BIOL CHEM, V267, P25337; ROY R, 1984, CAN J BIOCHEM CELL B, V62, P270, DOI 10.1139/o84-037; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TSAI PK, 1984, J BIOL CHEM, V259, P3805; VALENTIN E, 1984, J GEN MICROBIOL, V130, P1419; VANRINSUM J, 1991, YEAST, V7, P717, DOI 10.1002/yea.320070707; ZUECO J, 1986, BIOCHIM BIOPHYS ACTA, V884, P93, DOI 10.1016/0304-4165(86)90231-X	19	127	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19338	19342						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034698				2022-12-27	WOS:A1994NY33200023
J	BAJPAI, A; BRAHMI, Z				BAJPAI, A; BRAHMI, Z			TARGET CELL-INDUCED INACTIVATION OF CYTOLYTIC LYMPHOCYTES - ROLE AND REGULATION OF CD45 AND CALYCULIN A-INHIBITED PHOSPHATASE IN RESPONSE TO INTERLEUKIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHATASE; NATURAL-KILLER-CELLS; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; KINASE-C; T-CELLS; SENSITIVE TARGETS; NK INACTIVATION; OKADAIC ACID; ACTIVATION	Cytolytic T lymphocyte (CTL) and natural killer cells (NK) lose their lytic potential after interaction with sensitive target cells that can be restored upon incubation with interleukin-2. In this study we observed that preincubation with Ser/Thr phosphatase inhibitor calyculin A inhibited both CTL and NK cell-mediated cytotoxicity (CMC) in a dose-dependent manner. In contrast, okadaic acid inhibited only CTL-CMC without significantly affecting NK-CMC. Incubation of CTL and NK cells with their sensitive TC inhibited both CTL-CMC by 74% and NK-CMC by >80%. This loss in lytic activity was accompanied by a loss of 60% and >80% in the cellular p-nitrophenyl phosphate phosphatase (pNPPase) activity in CTL and NK cells, respectively. When treated with 100 units/ml interleukin-2 for 16-18 h at 37 degrees C, inactivated CTL and NK cells recovered 70% and 100% of their lytic activity and approximately 60% and 100% of phosphatase activity, respectively. Analysis revealed that >80% of the pNPPase activity was associated with membrane-bound CD45, and it is this phosphatase activity that was reversibly affected by target cell-induced inactivation/reactivation of CTL and NK cells. These results suggest that Ser/Thr phosphatases and CD45 play a key role in modulating the lytic activity of effector cells exposed to sensitive target cells.	INDIANA UNIV,JAMES WHITCOMB RILEY HOSP CHILDREN,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ABRAMS SI, 1988, J IMMUNOL, V140, P2090; ABRAMS SI, 1987, FED PROC, V46, P1228; ALEXANDER D, 1992, IMMUNOL TODAY, V13, P477, DOI 10.1016/0167-5699(92)90021-X; BAJPAI A, 1991, IMMUNOLOGY, V74, P258; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAHMI Z, 1985, J IMMUNOL, V135, P4108; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GIBBONEY JJ, 1992, NAT IMMUN, V11, P57; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRANJA C, 1991, J BIOL CHEM, V266, P16277; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HOMMELBERREY GA, 1991, J IMMUNOL, V147, P3237; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; LANE PJL, 1991, J IMMUNOL, V146, P715; LEIBSON PJ, 1990, J IMMUNOL, V145, P1498; MITTLER RS, 1991, J IMMUNOL, V147, P3434; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; RICHARDS FM, 1992, IMMUNOLOGY, V76, P642; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHENOY AM, 1991, CELL IMMUNOL, V138, P24, DOI 10.1016/0008-8749(91)90129-Y; STEELE TA, 1988, J IMMUNOL, V141, P3164; TADA Y, 1992, IMMUNOPHARMACOLOGY, V24, P17, DOI 10.1016/0162-3109(92)90065-K; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18864	18869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034641				2022-12-27	WOS:A1994NX32700028
J	MOROSOV, A; PHELPS, WC; RAYCHAUDHURI, P				MOROSOV, A; PHELPS, WC; RAYCHAUDHURI, P			ACTIVATION OF THE C-FOS GENE BY THE HPV16 ONCOPROTEINS DEPENDS UPON THE CAMP-RESPONSE ELEMENT AT -60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; PROTO-ONCOGENE FOS; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; E7 ONCOPROTEIN; GROWTH-FACTOR; E6 PROTEIN; PROMOTER	The E6 and the E7 genes of the high-risk types of human papillomavirus (types 16 and 18) are associated with the induction or maintenance of malignant growth. The molecular mechanism by which these oncogenes contribute to the malignant phenotype is not clear. To study the effects of E7 on cellular processes, we constructed a stable cell line that inducibly expressed the E7 gene of HPV16. By using this cell line, we provide evidence that expression of E7 of HPV16 stimulates c-fos gene expression. Also, by doing transient transfection experiments, we show that the expression of either E6 or E7 induces transcription from the c-fos promoter. Analysis of a series of c-fos promoter mutants indicates that the activation by both E6 and E7 is dependent on the cyclic AMP response element. To further investigate the mechanism(s) of the activation of the c-fos gene and their relation to the oncogenic properties of E6 and E7, several mutants of the E6 and E7 genes were analyzed. The results of these studies indicate that the CR1 and CR2 regions in the E7 protein, and sequences distinct from the p53-binding region in the E6 protein, are critical for activation of the c-fos promoter.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612; BURROUGHS WELLCOME CO,DIV VIROL,RES TRIANGLE PK,NC 27709	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Burroughs Wellcome Fund					NATIONAL CANCER INSTITUTE [R01CA055279] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LECHNER MS, 1992, EMBO J, V11, P3034; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MUNGER K, 1989, J VIROL, V63, P4417; NEVINS JR, 1992, SCIENCE, V258, P424; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P405; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; SIVARAMAN L, 1986, P NATL ACAD SCI USA, V83, P5914, DOI 10.1073/pnas.83.16.5914; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	54	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18434	18440						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034592				2022-12-27	WOS:A1994NW79800034
J	HAMABATA, T; OKIMURA, H; YOKOYAMA, N; TAKAHASHI, T; TAKAHASHI, K				HAMABATA, T; OKIMURA, H; YOKOYAMA, N; TAKAHASHI, T; TAKAHASHI, K			PURIFICATION, CHARACTERIZATION, AND LOCALIZATION OF FOLLIPSIN, A NOVEL SERINE PROTEINASE FROM THE FLUID OF PORCINE OVARIAN FOLLICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4 TANDEM REPEATS; PLASMINOGEN-ACTIVATOR; PLASMA PREKALLIKREIN; POLYACRYLAMIDE GELS; AMINO-ACID; RAT OVARY; FACTOR-XA; OVULATION; MEMBRANES; SEQUENCE	Follipsin, an enzyme that accumulates in the follicular fluid of porcine ovaries during follicular maturation, was purified to apparent homogeneity. The purified enzyme consists of two different polypeptide chains having M(r) = 45,000 and 32,000 each, associated covalently. The enzyme activity was strongly inhibited by diisopropyl fluorophosphate, benzamidine, leupeptin, and antipain, indicating that follipsin is a serine proteinase. Using synthetic peptide substrates containing 4-methylcoumaryl-7-amide, follipsin was shown to preferentially hydrolyze Arg X bonds but not Lys-X bonds. The NH2-terminal amino acid sequences of the 45- and 32-kDa polypeptides were highly homologous with those of the heavy and light chains, respectively, of human plasma kallikrein and human factor XI(a). Immunological analyses and substrate specificity studies, together with other existing evidence, indicated that follipsin is distinct from kallikrein and factor XI(a), thus being a novel type of serine proteinase. Follipsin is immunohistochemically localized in follicular fluid as well as in stroma cells of porcine ovaries. The results strongly suggest that follipsin originates from interstitial cells of the ovarian stroma.	HOKKAIDO UNIV,GRAD SCH SCI,DIV BIOL SCI,SAPPORO 060,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Hokkaido University; University of Tokyo				Hamabata, Takashi/0000-0003-0429-6550				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; BARRETT AJ, 1980, MAMMALIAN PROTEASES, V1, P65; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BEERS WH, 1975, CELL, V6, P379, DOI 10.1016/0092-8674(75)90187-7; BORGERS M, 1973, J HISTOCHEM CYTOCHEM, V21, P812, DOI 10.1177/21.9.812; CANIPARI R, 1985, J BIOL CHEM, V260, P5121; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; ESPEY LL, 1976, BIOL REPROD, V14, P233, DOI 10.1095/biolreprod14.3.233; ESPEY LL, 1975, PROTEASES BIOL CONTR, P767; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KURACHI K, 1981, METHOD ENZYMOL, V80, P211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YX, 1991, EUR J BIOCHEM, V195, P549, DOI 10.1111/j.1432-1033.1991.tb15736.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McNatty K.P., 1978, P215; MCRAE BJ, 1981, BIOCHEMISTRY-US, V20, P7196, DOI 10.1021/bi00528a022; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; PETERS H, 1980, OVARY, P29; Schochet SS, 1916, ANAT REC, V10, P447, DOI 10.1002/ar.1090100605; SHOTTON D M, 1970, Nature (London), V225, P802, DOI 10.1038/225802a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; TAKAHASHI T, 1992, ZOOL SCI, V9, P343; TAMANOUE Y, 1993, J BIOCHEM-TOKYO, V113, P229, DOI 10.1093/oxfordjournals.jbchem.a124031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHINO T, 1993, J BIOL CHEM, V268, P527; WALSH KA, 1964, P NATL ACAD SCI USA, V52, P884, DOI 10.1073/pnas.52.4.884	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17899	17904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027045				2022-12-27	WOS:A1994NV42200025
J	MEHUL, B; BAWUMIA, S; MARTIN, SR; HUGHES, RC				MEHUL, B; BAWUMIA, S; MARTIN, SR; HUGHES, RC			STRUCTURE OF BABY HAMSTER-KIDNEY CARBOHYDRATE-BINDING PROTEIN CBP30, AN S-TYPE ANIMAL LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; ENDOGENOUS LECTIN; EXPRESSION; SEQUENCE; CELLS; SECRETION; LACTOSE; L-29; IDENTIFICATION	A galactose-binding protein of M(r) = 30,000 previously described in baby hamster kidney cells (Foddy, L., Stamatoglou, S. C., and Hughes, R. C. (1990) J. Cell Sci. 97, 139-148) has been analyzed by the cloning and sequencing of cDNA clones encoding the complete sequence and an amino-terminal fragment. The intact lectin CBP30 contains 245 amino acid residues, including the initiating methionine residue, and is closely homologous to mammalian S-type lectins of similar size characterized in human, rat, and mouse species. The carboxyl-terminal domain contains the carbohydrate binding activity and the amino-terminal domain, which is extremely sensitive to bacterial collagenase, contains a repetitive sequence rich in glycine, tyrosine, and proline. There are 8 repeats in hamster CBP30, as in the human homologue, compared with about 10 in rat and mouse and >10 in dog homologues. This repeat sequence is also sensitive to the tissue metalloproteinases, gelatinase B and matrilysin, but, unlike the bacterial collagenase, the mammalian enzymes also cause extensive degradation of the carbohydrate binding carboxyl domain. Physical measurements using CD and tryptophan fluorescence spectroscopy indicate that the two domains of CBP30 are structurally, as well as functionally, distinct and independent. Cross-linking studies indicate that the amino-terminal lectin fragment can efficiently self-assemble into oligomeric species, and less efficient but significant aggregation of the intact lectin is also shown. Domain-specific antibodies to hamster CBP30 have been prepared and used to show that only the full-length, undegraded form of CBP30 is present in whole cell lysates.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								AGRWAL N, 1993, J BIOL CHEM, V268, P14932; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DENG TL, 1990, GENE, V93, P229, DOI 10.1016/0378-1119(90)90229-K; FODDY L, 1990, J CELL SCI, V97, P139; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; JIA S, 1987, GENE, V60, P197, DOI 10.1016/0378-1119(87)90228-9; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LIU FT, 1990, CRIT REV IMMUNOL, V10, P289; LIU FT, 1985, P NATL ACAD SCI USA, V82, P4100, DOI 10.1073/pnas.82.12.4100; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; ODA Y, 1991, GENE, V99, P279; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1994, EUR J IMMUNOL, V24, P216, DOI 10.1002/eji.1830240134; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J	40	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18250	18258						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027086				2022-12-27	WOS:A1994NV42200072
J	OLAH, ME; JACOBSON, KA; STILES, GL				OLAH, ME; JACOBSON, KA; STILES, GL			IDENTIFICATION OF AN ADENOSINE RECEPTOR DOMAIN SPECIFICALLY INVOLVED IN BINDING OF 5'-SUBSTITUTED ADENOSINE AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; A1; ANTAGONISTS; EXPRESSION; AFFINITY; SITE	The bovine A(1) adenosine receptor (A(1)AR) and rat A(3) adenosine receptor (A(3)AR) display distinct agonist and antagonist binding properties. To identify regions involved in ligand recognition, A(1)AR/A(3)AR chimeric receptors were created, expressed in COS-7 cells, and analyzed by radioligand binding. A chimeric receptor in which the third intracellular loop of the A(1)AR was replaced with that of the A(3)AR bound agonists and the antagonist, [H-3]xanthine amine congener, with affinities identical to wild-type A(1)AR. A chimeric receptor with the fifth transmembrane domain (TM5) and third intracellular loop of the A(1)AR replaced with that of the A(3)AR displayed antagonist affinity similar to wild-type A(1)AR. However, relative to the A(1)AR, this chimeric demonstrated much greater affinity for 5'-substituted analogs, whereas affinity for N-6-substituted compounds was unaffected. Substitution of a 6-amino acid cassette of the exofacial half of TM5 of the A(3)AR into the A(1)AR produced enhanced binding of exclusively a 5'-substituted analog, indicating involvement of this specific region in ligand recognition. These findings suggest that the 5'- and N-6-substituents of adenosine agonists bind to distinct regions of ARs and that TM5 of the A(3)AR interacts more favorably with 5'-substituted compounds than does that of the A(1)AR.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; NIDDK,MOLEC RECOGNIT SECT,BIOORGAN CHEM LAB,BETHESDA,MD 20892	Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL017670] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [P50HL17670, R01HL35134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FONG TM, 1993, NATURE, V362, P350; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; IJzerman A P, 1992, Drug Des Discov, V9, P49; JACOBSON KA, 1990, COMPREHENSIVE MED CH, P601; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; LINDEN J, 1993, MOL PHARMACOL, V44, P524; OLAH ME, 1989, FEBS LETT, V257, P292, DOI 10.1016/0014-5793(89)81555-8; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLSSON RA, 1986, J MED CHEM, V29, P1683, DOI 10.1021/jm00159a020; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SCHWABE U, 1985, N-S ARCH PHARMACOL, V330, P212, DOI 10.1007/BF00572436; STILES GL, 1985, J BIOL CHEM, V260, P806; SURYANARAYANA S, 1993, MOL PHARMACOL, V44, P111; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VANGALEN PJM, 1994, IN PRESS MOL PHARM; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	28	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18016	18020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027060				2022-12-27	WOS:A1994NV42200042
J	HOVRING, PI; BOSTAD, A; ORDING, E; MYRSET, AH; GABRIELSEN, OS				HOVRING, PI; BOSTAD, A; ORDING, E; MYRSET, AH; GABRIELSEN, OS			DNA-BINDING DOMAIN AND RECOGNITION SEQUENCE OF THE YEAST BAS1 PROTEIN, A DIVERGENT MEMBER OF THE MYB FAMILY OF TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-RELATED MOTIF; C-MYB; HIS4 TRANSCRIPTION; CRYSTAL-STRUCTURE; RNA-POLYMERASE; ONCOPROTEIN; OLIGONUCLEOTIDES; BIOSYNTHESIS; HOMEODOMAIN; EXPRESSION	The yeast BAS1 protein is a transcriptional activator with an amino-terminal domain homologous to the DNA-binding domain of the oncoprotein Myb containing three imperfect tryptophan-rich repeats. In contrast to Myb-related transcription factors from higher eukaryotes, where the second and third repeat constitutes a minimal independent DNA-binding domain, all three repeats of BAS1 were found to be necessary for sequence-specific DNA binding. Moreover an active DNA-binding subdomain was obtained only if the first repeat was enlarged in the amino-terminal direction to include 3 tryptophans and a 23-amino acid insertion and if 55 amino acids carboxyl-terminal to the third repeat were included. The BAS1 DNA-binding site was analyzed in detail and found to cover 8-9 base pairs with no similarity to the Myb recognition element. The binding site included a conserved hexameric TGACTC motif, the methylation of which abolished BAS1 binding, as well as a 3-base pair extension that seemed to have a modulatory effect on BAS1 affinity and where binding was less affected by methylation.	UNIV OSLO, DEPT BIOCHEM, N-0316 OSLO 3, NORWAY	University of Oslo								ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; HINNEBUSCH AG, 1990, PROG NUCLEIC ACID RE, V38, P195; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Maxam A M, 1980, Methods Enzymol, V65, P499; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; 1991, PROGRAM MANUAL GCG P	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17663	17669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021277				2022-12-27	WOS:A1994NU12800051
J	KETTLE, AJ; WINTERBOURN, CC				KETTLE, AJ; WINTERBOURN, CC			SUPEROXIDE-DEPENDENT HYDROXYLATION BY MYELOPEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; HYPOCHLOROUS ACID; HUMAN-NEUTROPHILS; RADICAL PRODUCTION; PULSE-RADIOLYSIS; NORMAL BLOOD; GENERATION; OXIDATION; LEUKOCYTE; SYSTEM	When stimulated, neutrophils undergo a respiratory burst converting oxygen to superoxide. Although superoxide is critical for microbial killing by phagocytic cells, the precise role it plays has yet to be established. It has been proposed to optimize their production of hypochlorous acid and to be required for the generation of hydroxyl radicals. Superoxide is also involved in the hydroxylation of salicylate by neutrophils. However, the mechanism of this reaction is unknown. We found that neutrophils stimulated with opsonized zymosan hydroxylated salicylate to produce mainly 2,5-dihydroxybenzoate. Its formation was dependent on superoxide and a heme protein but was independent of hydrogen peroxide and hydroxyl radicals. Production of 2,5-dihydroxybenzoate was enhanced by methionine, which scavenges hypochlorous acid. Neutrophils from an individual with myeloperoxidase deficiency hydroxylated salicylate at only 13% of the level of control cells. Purified human myeloperoxidase and xanthine oxidase plus hypoxanthine hydroxylated salicylate to produce 2,5-dihydroxybenzoate. As with neutrophils, the reaction required superoxide but not hydrogen peroxide and was unaffected by hydroxyl radical scavengers. Thus, myeloperoxidase catalyzes superoxide dependent hydroxylation. This newly recognized reaction may be relevant to the in vivo functions of superoxide and myeloperoxidase.			KETTLE, AJ (corresponding author), CHRISTCHURCH SCH MED,DEPT PATHOL,FREE RAD RES UNIT,POB 4345,CHRISTCHURCH,NEW ZEALAND.		Kettle, Anthony J/A-8520-2008	Kettle, Anthony J/0000-0002-8218-7766				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BRITIGAN BE, 1989, BIOCHEM J, V264, P447, DOI 10.1042/bj2640447; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; COHEN MS, 1988, FREE RADICAL BIO MED, V5, P81, DOI 10.1016/0891-5849(88)90033-0; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DAVIS WB, 1989, BIOCHEM PHARMACOL, V38, P4013; DORDICK JS, 1986, BIOCHEMISTRY-US, V25, P2946, DOI 10.1021/bi00358a032; Dunford H B, 1990, PEROXIDASES CHEM BIO, V2, P1; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; FUJIMOTO S, 1993, BIOL PHARM BULL, V16, P525; FUJIMOTO S, 1991, CHEM PHARM BULL, V39, P1598; GROOTVELD M, 1986, BIOCHEM J, V237, P499, DOI 10.1042/bj2370499; HALLIWELL B, 1977, BIOCHEM J, V163, P441, DOI 10.1042/bj1630441; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAYNES DR, 1993, AGENTS ACTIONS, V39, P49, DOI 10.1007/BF01975714; KETTLE AJ, 1992, J BIOL CHEM, V267, P8319; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; KOBAYASHI K, 1981, J BIOL CHEM, V256, P2350; KOBAYASHI K, 1989, J BIOL CHEM, V264, P15280; MASON HS, 1957, BIOCHIM BIOPHYS ACTA, V24, P225, DOI 10.1016/0006-3002(57)90183-X; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; ODAJIMA T, 1972, BIOCHIM BIOPHYS ACTA, V284, P355, DOI 10.1016/0005-2744(72)90130-1; PATEL RP, 1971, BIOCHEM J, V124, P439, DOI 10.1042/bj1240439; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; SAGONE AL, 1987, J IMMUNOL, V138, P2177; SAMUNI A, 1988, J BIOL CHEM, V263, P13797; SAWADA Y, 1975, BIOCHEMISTRY-US, V14, P3761, DOI 10.1021/bi00688a007; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1988, EUR J CLIN INVEST, V18, P433, DOI 10.1111/j.1365-2362.1988.tb01037.x; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; STROBEL HW, 1971, J BIOL CHEM, V246, P7826; SUBRAHMANYAM VV, 1991, FREE RADICAL RES COM, V15, P285, DOI 10.3109/10715769109105224; TAUBER AI, 1985, ADV FREE RADICAL BIO, V1, P265; THOMAS EL, 1988, J BIOL CHEM, V263, P2178; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1978, J EXP MED, V147, P316, DOI 10.1084/jem.147.2.316; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Winterbourn C.C., 1990, OXYGEN RADICALS SYST, P31; WINTERBOURN CC, 1986, J CLIN INVEST, V78, P545, DOI 10.1172/JCI112607; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583	46	65	66	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17146	17151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006021				2022-12-27	WOS:A1994NT84600028
J	PITTMAN, DD; TOMKINSON, KN; KAUFMAN, RJ				PITTMAN, DD; TOMKINSON, KN; KAUFMAN, RJ			POSTTRANSLATIONAL REQUIREMENTS FOR FUNCTIONAL FACTOR-V AND FACTOR-VIII SECRETION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEINS; VON WILLEBRAND FACTOR; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; SUBUNIT STRUCTURE; COMPLETE CDNA; CALCIUM; ASSOCIATION	Coagulation factors V and VIII are homologous glycosylated plasma proteins that provide essential functions for hemostasis. Factor V is secreted as a single chain polypeptide, whereas factor VIII is processed intracellularly to yield a metal-ion-associated heterodimer that is stabilized through interaction with von Willebrand factor. In transfected mammalian cells, factor V is more efficiently secreted than factor VIII. To provide insight into the different secretion efficiencies, we compared the post-translational processing requirements for factor V and factor VIII expressed in mammalian cells. In contrast to factor VIII, factor V was not detected in association with the immunoglobulin-binding protein (BiP), a chaperonin protein of the endoplasmic reticulum (ER). Depletion of intracellular ATP levels by treatment of cells with low concentrations of carbonyl cyanide 3-chlorophenylhydrazone (CCCP), protonophore that uncouples oxidative phosphorylation, inhibited secretion of factor VIII but had no effect on the secretion of factor V. Inhibition of N-linked oligosaccharide addition by treatment with tunicamycin prevented secretion of both factor V and factor VIII, whereas treatment with an inhibitor of complex oligosaccharide addition, deoxymannojirimycin, did not affect secretion, although the specific activities of both factor V and factor VIII were slightly increased. Thus, complex oligosaccharide addition was not required for secretion or functional activity of either factor V or factor VIII. Depletion of intralumenal calcium with the ionophore A23187 did not affect secretion of either factor V or factor VIII. In the presence of A23187, the secreted factor V was fully functional, whereas the factor VIII heavy and light chains were not associated and the secreted molecule was inactive. In addition, A23187 treatment inhibited addition of serine/threonine (O)-linked oligosaccharides to factor V and factor VIII. The differences between factor V and factor VIII were further evaluated by characterization of a single chain mutant factor VIII. The single chain factor VIII was secreted with an efficiency similar to wild-type factor VIII and also required von Willebrand factor for stabilization. In addition, the activity of single chain factor VIII was also inhibited by A23187 treatment, suggesting a unique metal-ion requirement within the secretory pathway for functional factor VIII folding. The differences identified in BiP association, ATP requirements, and metal-ion dependence for effective functional secretion of these two molecules may underlie mechanisms accounting for their different secretion efficiencies.	UNIV MICHIGAN, HOWARD HUGHES MED INST, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan								BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIN T, 1987, EUR J BIOCHEM, V170, P305, DOI 10.1111/j.1432-1033.1987.tb13700.x; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; CERVENY TJ, 1984, BLOOD, V63, P1467; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ELDER B, 1993, GENOMICS, V16, P374, DOI 10.1006/geno.1993.1200; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; GANZ PR, 1988, EUR J BIOCHEM, V170, P521, DOI 10.1111/j.1432-1033.1988.tb13731.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GEWIRTZ AM, 1986, BLOOD, V67, P1639; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HELLSTERN P, 1986, THROMB HAEMOSTASIS, V56, P353; HELNIUS A, 1994, MOL BIOL CELL, V5, P1; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OSTERUD B, 1981, FEBS LETT, V127, P154, DOI 10.1016/0014-5793(81)80363-8; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1982, BLOOD, V60, P59; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WASLEY LC, 1991, BLOOD, V77, P2624; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WILSON DB, 1984, J CLIN INVEST, V73, P654, DOI 10.1172/JCI111256; WISE RJ, 1991, J BIOL CHEM, V266, P21948; ZANNI EE, 1989, J BIOL CHEM, V264, P9137	80	84	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17329	17337						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006042				2022-12-27	WOS:A1994NT84600053
J	SCHROEDER, TJ; JANKOWSKI, JA; SENYSHYN, J; HOLZ, RW; WIGHTMAN, RM				SCHROEDER, TJ; JANKOWSKI, JA; SENYSHYN, J; HOLZ, RW; WIGHTMAN, RM			ZONES OF EXOCYTOTIC RELEASE ON BOVINE ADRENAL-MEDULLARY CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CHROMAFFIN CELLS; CATECHOLAMINE SECRETION; QUANTAL SECRETION; BIOLOGICAL CELLS; ELECTRODES	Secretion of catecholamines from individual bovine adrenal medullary cells in culture was examined by amperometry with 1-mu m radius carbon-fiber electrodes, Vesicular secretion is observed as a series of current spikes upon exposure to a secretagogue. The small size of the electrodes was exploited to map exocytotic release sites on the surface of bovine adrenal medullary cells. These studies reveal for the first time that release sites are spatially localized on endocrine cells in culture for a time scale of at least 15 min. Fluorescent monitoring by confocal microscopy of deposition of dopamine-beta-hydroxylase from the vesicular membrane into the plasma membrane during exocytosis confirms the existence of zones of exocytotic inactivity on the surface of the cell. Measurement of coincident spikes with two adjacent electrodes (2.5-mu m radius) has allowed the spatial resolution for measurement of exocytosis to be defined as 2 pm from the projected circumference of the electrode on the surface of the cell. In this small domain, point-source release and diffusional broadening would result in narrow spikes (Schroeder, T. J., Jankowski, J. A., Kawagoe, K. T., Wightman, R. M., Lefrou, C., and Amatore, C. (1992) Anal. Chem. 64, 3077-3083), a feature not seen in the data. Thus, for adrenal medullary cells, release following vesicular fusion is not instantaneous, but is a prolonged event occurring over several milliseconds.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan			Senyshyn, Anatoliy/C-8267-2014	Senyshyn, Anatoliy/0000-0002-1473-8992	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1989, SECRETION ITS CONTRO, P203; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; GERHARDT G, 1982, ANAL CHEM, V54, P2618, DOI 10.1021/ac00251a054; HESKETH JE, 1981, CELL TISSUE RES, V218, P331; Heuser JE, 1977, HDB PHYSL, VI, P261; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; KAWAGOE KT, 1991, ANAL CHEM, V63, P1589, DOI 10.1021/ac00015a017; KELLY RS, 1986, ANAL CHIM ACTA, V187, P79, DOI 10.1016/S0003-2670(00)82900-1; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; PHILLIPS JH, 1983, J CELL BIOL, V97, P1906, DOI 10.1083/jcb.97.6.1906; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; STREIN TG, 1992, ANAL CHEM, V64, P1368, DOI 10.1021/ac00037a012; WALROND JP, 1985, J NEUROSCI, V5, P1118; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	18	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17215	17220						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006030				2022-12-27	WOS:A1994NT84600037
J	LAGRUTTA, A; SHEN, KZ; NORTH, RA; ADELMAN, JP				LAGRUTTA, A; SHEN, KZ; NORTH, RA; ADELMAN, JP			FUNCTIONAL DIFFERENCES AMONG ALTERNATIVELY SPLICED VARIANTS OF SLOWPOKE, A DROSOPHILA CALCIUM-ACTIVATED POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER LOCUS; K+ CHANNELS; GENE-EXPRESSION; XENOPUS OOCYTES; BINDING-SITE; TETRAETHYLAMMONIUM; INACTIVATION; CDNA; CONTRIBUTE; AMINO	The Slowpoke locus of Drosophila melanogaster encodes a family of alternatively spliced mRNAs which encode large conductance calcium-activated potassium channels. Variability resides in blocks of amino acids designated boxes A, C, E, G, and I. Oocytes were injected with cRNAs that had been chosen for direct functional comparison of single box differences. Single channel records from inside-out patches of oocyte membranes expressing A1 or A3 forms, E1 or E2 forms, and G2-G5 forms were analyzed and compared. The main functional difference between A1 and A3 was in unitary conductance, whereas the main difference in properties between E1 and E2 was in calcium sensitivity. Activation kinetics were different between G3 and G5, but not consistently in different A and E box backgrounds. The results indicate that alternative splicing of a common RNA precursor contributes to the functional diversity of the expressed channel. Our findings suggest that the variable region of the Slowpoke channel subunit comprises modular, yet interactive functional domains which influence the essential features of unit conductance, calcium sensitivity, and gating.			LAGRUTTA, A (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022		NINDS NIH HHS [NS28504] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; HAYLETT DG, 1990, POTASSIUM CHANNELS S, P70; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IVERSON LE, 1990, J NEUROSCI, V10, P2903; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLARO CR, 1994, BIOPHYS J, V66, pA23; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; SUTCLIFFE JG, 1988, TRENDS GENET, V4, P297, DOI 10.1016/0168-9525(88)90105-9; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	156	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20347	20351						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051129				2022-12-27	WOS:A1994PB31700024
J	MICHNICK, DA; PITTMAN, DD; WISE, RJ; KAUFMAN, RJ				MICHNICK, DA; PITTMAN, DD; WISE, RJ; KAUFMAN, RJ			IDENTIFICATION OF INDIVIDUAL TYROSINE SULFATION SITES WITHIN FACTOR-VIII REQUIRED FOR OPTIMAL ACTIVITY AND EFFICIENT THROMBIN CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; COAGULATION FACTOR-VIII; SEVERE HEMOPHILIA-A; HUMAN FACTOR-V; VONWILLEBRAND-FACTOR; MAMMALIAN-CELLS; PROCOAGULANT ACTIVITY; RECOMBINANT HIRUDIN; SUBUNIT STRUCTURE; LIGHT CHAIN	Factor VIII functions as an essential cofactor in the blood coagulation cascade for the factor IXa-mediated activation of factor X. Factor VIII contains 6 tyrosine residues at positions 346, 718, 719, 723, 1664, and 1680 that are modified by post-translational sulfation. This modification is required for full factor VIII procoagulant activity. We have employed site-directed mutagenesis to identify the individual sulfated tyrosines within factor VIII that influence activity. The molecules were expressed in COS-1 monkey cells by transient transfection, and the resultant proteins were characterized. Metabolic incorporation of [S-35]sulfate demonstrated that all 6 tyrosine residues are sulfated in factor VIII. Sulfation at residues 346 and 1664 was required for full activity in a factor VIII clotting assay but did not affect factor VIII activity monitored by a factor Xa generation assay. The Tyr(346) --> Phe and Tyr(1664) --> Phe mutants displayed played delayed thrombin activation that correlated with delayed cleavage at residues 372 and 1689, respectively. In contrast, these mutants were efficiently activated by factor Xa. A triple Tyr to Phe mutant at residues 718, 719, and 723 displayed both reduced factor VIII clotting activity and factor Xa generation activity. Finally, a Tyr(1680) --> Phe mutant factor VIII displayed a 5-fold reduced affinity for von Willebrand factor. The results demonstrate that 1) sulfation at tyrosine residues 346 and 1664 increases factor VIII activity by increasing the rate of thrombin activation and cleavage; 2) sulfation at tyrosine residues 718, 719, and 723 increases the intrinsic activity of factor VIIIa; and 3) sulfation at tyrosine residue 1680 increases the affinity for vWF. In addition, the results implicate that thrombin interacts with three distinct sites within factor VIII, two of which are required for proteolytic activation. The results demonstrate that the six sites of tyrosine sulfation modulate factor VIII activity through different mechanisms.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; GENET INST INC,DEPT MOLEC & CELLULAR GENET,CAMBRIDGE,MA 02140; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School								ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; HELLSTERN P, 1986, THROMB HAEMOSTASIS, V56, P353; HIGUCHI M, 1990, GENOMICS, V6, P65, DOI 10.1016/0888-7543(90)90448-4; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V151, P417, DOI 10.1016/0006-291X(88)90609-2; HORTIN GL, 1990, BLOOD, V76, P946; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KAUFMAN RJ, 1990, METHOD ENZYMOL, V107, P200; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LIU JW, 1993, BIOCHEM J, V294, P407, DOI 10.1042/bj2940407; LIU SL, 1989, THROMB HAEMOSTASIS, V62, pA638; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; OBRIEN DP, 1989, BLOOD, V73, P2117; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	42	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20095	20102						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051097				2022-12-27	WOS:A1994PA12600066
J	VIGNE, P; FARRE, AL; FRELIN, C				VIGNE, P; FARRE, AL; FRELIN, C			NA+-K+-CL- COTRANSPORTER OF BRAIN CAPILLARY ENDOTHELIAL-CELLS - PROPERTIES AND REGULATION BY ENDOTHELINS, HYPEROSMOLAR SOLUTIONS, CALYCULIN-A, AND INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL NATRIURETIC PEPTIDE; NA-K-2CL COTRANSPORT; VOLUME REGULATION; SODIUM-TRANSPORT; BLOOD; BARRIER; RECEPTOR; PHOSPHATASE; AMILORIDE; MICROVESSELS	Cultured rat brain capillary endothelial cells expressed a large Rb-86(+) uptake component that was de pendent on external Na+ and Cl- and that was inhibited by loop diuretics with unusual pharmacological properties: benzmetanide (IC50 = 1-5 mu M) = bumetanide (IC50 = 1-5 mu M) > piretanide (IC50 = 3-16 mu M) = furosemide (IC50 = 7-11 mu M) It was activated a fold by endothelin-1 (EC(50) = 1 nM) and endothelin-3 (EC(50) = 9 nM). The actions of endothelins were prevented by BQ-123 (cyclo-(D-Trp-D-AspPro-D-Val-Leu)) in a competitive manner and with a high affinity, thus indicating the involvement of an atypical BQ-123-sensitive, ET(A)-like receptor that had a high affinity for endothelin-3. Neither protein kinase C nor Ca2+-dependent protein kinases mediated the actions of endothelins. Cotransport activity was increased 4-fold by hyperosmotic cell shrinkage. Basal Na+-K+-Cl- cotransport activity was partially inhibited by isoproterenol and was unaffected by agents that promoted cGMP formation. Calyculin A, an inhibitor of protein phosphatases, stimulated cotransport activity and potentiated the action of endothelin-1, but not that of cell shrinkage. Basal and stimulated cotransport activities were inhibited by genistein, a protein kinase inhibitor with similar potencies, and by staurosporine, which has different potencies. Finally, endothelin-1-stimulated ac tivity was partially and specifically inhibited by interleukin-1. It is concluded that rat brain capillary endothelial cells express a Na+-K+-Cl- cotransporter that has unique properties and that is regulated by multiple protein kinase/phosphatase systems. It is a target for low concentrations of endothelins and may play a role in brain-to-blood movements of K+.	UNIV NICE SOPHIS ANTIPOLIS, CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				LOPEZ FARRE, ANTONIO/0000-0003-0301-067X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BATTISTINI B, 1993, LAB INVEST, V68, P600; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BETZ AL, 1983, J NEUROCHEM, V41, P1158, DOI 10.1111/j.1471-4159.1983.tb09066.x; BETZ AL, 1983, J NEUROCHEM, V41, P1150, DOI 10.1111/j.1471-4159.1983.tb09065.x; BLATTEIS CM, 1990, YALE J BIOL MED, V63, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW H, 1986, NATURE, V324, P466, DOI 10.1038/324466a0; BROCK TA, 1986, AM J PHYSIOL, V250, pC888, DOI 10.1152/ajpcell.1986.250.6.C888; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHASSANDE O, 1988, EUR J BIOCHEM, V171, P425, DOI 10.1111/j.1432-1033.1988.tb13807.x; CORNFORD EM, 1985, MOL PHYSIOL, V7, P219; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; DICKSON DW, 1991, LAB INVEST, V64, P135; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; EGLEZOS A, 1993, BRIT J PHARMACOL, V109, P736, DOI 10.1111/j.1476-5381.1993.tb13635.x; FRELIN C, 1986, BIOCHEM BIOPH RES CO, V134, P326, DOI 10.1016/0006-291X(86)90566-8; Frelin Christian, 1993, P249; FUJITA T, 1989, BIOCHEM BIOPH RES CO, V159, P734, DOI 10.1016/0006-291X(89)90056-9; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARIK SI, 1986, P NATL ACAD SCI USA, V83, P4067, DOI 10.1073/pnas.83.11.4067; IBARAGI M, 1989, J NEUROCHEM, V53, P1802, DOI 10.1111/j.1471-4159.1989.tb09246.x; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLEIN JD, 1990, J BIOL CHEM, V265, P22238; LADOUX A, 1991, BIOCHEM BIOPH RES CO, V180, P169, DOI 10.1016/S0006-291X(05)81271-9; MARSAULT R, 1991, AM J PHYSIOL, V261, pC986, DOI 10.1152/ajpcell.1991.261.6.C986; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; NEWMAN EA, 1986, SCIENCE, V233, P453, DOI 10.1126/science.3726539; ODONNELL ME, 1993, AM J PHYSIOL, V264, pC1316, DOI 10.1152/ajpcell.1993.264.5.C1316; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; ONEILL WC, 1992, AM J PHYSIOL, V262, pC436, DOI 10.1152/ajpcell.1992.262.2.C436; OWEN NE, 1985, J BIOL CHEM, V260, P1445; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V164, P587, DOI 10.1016/0006-291X(89)91760-9; STANIMIROVIC DB, 1994, J NEUROCHEM, V62, P592; VIGNE P, 1993, EUR J PHARM-MOLEC PH, V245, P229, DOI 10.1016/0922-4106(93)90101-E; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; VIGNE P, 1991, J BIOL CHEM, V266, P5925; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; VIGNE P, 1994, J NEUROCHEM, V62, P2269; YUAN YA, 1993, AM J PHYSIOL, V264, pH1734, DOI 10.1152/ajpheart.1993.264.5.H1734	46	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19925	19930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051075				2022-12-27	WOS:A1994PA12600042
J	COX, AD; GARCIA, AM; WESTWICK, JK; KOWALCZYK, JJ; LEWIS, MD; BRENNER, DA; DER, CJ				COX, AD; GARCIA, AM; WESTWICK, JK; KOWALCZYK, JJ; LEWIS, MD; BRENNER, DA; DER, CJ			THE CAAX PEPTIDOMIMETIC COMPOUND B581 SPECIFICALLY BLOCKS FARNESYLATED, BUT NOT GERANYLGERANYLATED OR MYRISTYLATED, ONCOGENIC RAS SIGNALING AND TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE; PROTEIN; FARNESYLTRANSFERASE; INHIBITION; GROWTH; ACTIVATION; PRODUCT; CELLS	Recently developed CAAX peptidomimetic compounds have been shown to be potent and specific inhibitors of farnesyl protein transferase activity and to block the growth of Ras-transformed eels. However whether this growth inhibitory action is specifically a consequence of blocking oncogenic Ras signaling has not been determined. To address this question, we have utilized mutants of the normally farnesylated oncogenic Ras protein (Ras-F) that are modified by alternative lipids, a geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras), to determine the specificity of the CAAX peptidomimetic compound, B581. Like Ras-F, both Ras-GG and Myr-Ras are membrane-associated and transforming. Unexpectedly, MH 3T3 cells transformed by each of the three Ras mutants underwent morphological alteration to a less transformed, but not normal, morphology. However, B581 inhibited the ability of only Ras-F-transformed cells, but not Ras-GG- or Myr-Ras(or Raf-) transformed cells, to grow in soft agar. Furthermore, although all three lipid-modified versions of Ras stimulated mitogen-activated protein kinase activation, and both Jun and Elk-1 transcriptional activity, B581 inhibited only farnesylated Ras activation of these three downstream components of Ras signaling. Therefore, B581 prevents the growth of Ras-transformed cells by specifically antagonizing Ras-mediated signaling.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT BIOCHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT BIOPHYS,CHAPEL HILL,NC 27599; EISAI RES INST,ANDOVER,MA 01810; UNIV CALIF SAN DIEGO,PROGRAM MOLEC PATHOL,SAN DIEGO,CA 92109	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Eisai Co Ltd; University of California System; University of California San Diego	COX, AD (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Brenner, David/0000-0003-2573-525X; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R29CA061951, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER; NCI NIH HHS [CA50528, CA61951] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DECLUE JE, 1991, CANCER RES, V51, P712; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P1; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL PM, 1988, ONCOGENE, V2, P533; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NIGAM M, 1993, J BIOL CHEM, V268, P20695; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SETH A, 1992, J BIOL CHEM, V267, P24796; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	22	116	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19203	19206						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034681				2022-12-27	WOS:A1994NY33200004
J	CHIN, LS; LI, L; GREENGARD, P				CHIN, LS; LI, L; GREENGARD, P			NEURON-SPECIFIC EXPRESSION OF THE SYNAPSIN-II GENE IS DIRECTED BY A SPECIFIC CORE PROMOTER AND UPSTREAM REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PHOSPHOPROTEINS; TISSUE-SPECIFIC TRANSCRIPTION; SODIUM-CHANNEL GENE; SQUID GIANT SYNAPSE; NERVE GROWTH-FACTOR; PROTEIN-KINASE-II; DNA-BINDING SITE; SILENCER ELEMENT; RECEPTOR GENE; RAT	Synapsin II is an abundant peripheral membrane protein of synaptic vesicles that is expressed exclusively in neuronal cells. Here we report the isolation and characterization of the 5'-terminal region of the murine synapsin II gene. Primer extension and S1 nuclease protection analysis show that synapsin II gene transcription is initiated from a unique site. The synapsin II gene promoter contains no canonical TATA or CAAT boxes but has putative binding sites for the transcription factors Sp1, AP2, and NGFIA. This promoter is embedded in a large G+C-rich domain with characteristics of a CpG island. Transfection experiments using synapsin II-luciferase fusion genes demonstrate that the 5'-flanking sequence functions as a strong promoter in neuronal but not in nonneuronal cells. Deletion analysis reveals the presence of a neuron-specific core promoter (-79 to 153) and, upstream, two positive and one negative regulatory elements. The 5'-terminal region of the murine synapsin I gene was also cloned and sequenced. Although there is no extensive sequence homology between the 5'-flanking regions of the synapsin I and II genes, comparison analysis has identified two regions of homologous sequences, which may be involved in determining neuron specificity of the core promoters of these two genes.			CHIN, LS (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.			Li, Lian/0000-0003-4700-1134; Chin, Lih-Shen/0000-0002-0817-0368	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039327, R37MH039327] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39327] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BARGOU RCEF, 1991, GENE, V99, P197, DOI 10.1016/0378-1119(91)90127-W; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAAS CA, 1988, J CELL BIOL, V106, P195, DOI 10.1083/jcb.106.1.195; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HAMES BD, 1993, GENE TRANSCRIPTION P, P51; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MANDELL JW, 1992, J NEUROSCI, V12, P736; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEDIVI E, 1992, J NEUROSCI, V12, P691; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8388; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THIEL G, 1990, J BIOL CHEM, V265, P16527; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VIBERT M, 1989, EUR J BIOCHEM, V161, P33; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WORLEY PF, 1991, P NATL ACAD SCI USA, V88, P5106, DOI 10.1073/pnas.88.12.5106; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	61	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18507	18513						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034599				2022-12-27	WOS:A1994NW79800045
J	ROE, MW; PHILIPSON, LH; FRANGAKIS, CJ; KUZNETSOV, A; MERTZ, RJ; LANCASTER, ME; SPENCER, B; WORLEY, JF; DUKES, ID				ROE, MW; PHILIPSON, LH; FRANGAKIS, CJ; KUZNETSOV, A; MERTZ, RJ; LANCASTER, ME; SPENCER, B; WORLEY, JF; DUKES, ID			DEFECTIVE GLUCOSE-DEPENDENT ENDOPLASMIC-RETICULUM CA2+ SEQUESTRATION IN DIABETIC MOUSE ISLETS OF LANGERHANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-CELLS; INSULIN-SECRETION; PLASMA-MEMBRANE; CA-2+; ATPASE; ELECTROPHYSIOLOGY; THAPSIGARGIN; HOMEOSTASIS; EXPRESSION; RELEASE	Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic disease associated with abnormal insulin secretion, the underlying mechanisms of which are unknown. Glucose-dependent signal transduction pathways were investigated in pancreatic islets derived from the db/db mouse, an animal model of NIDDM. After stimulation with glucose (4-12 mM), the changes in intracellular Ca2+ concentration ([Ca2+](i)) were different; unlike control islets, db/db islets lacked an initial reduction of [Ca2+](i) and the subsequent [Ca2+](i) oscillations following stimulation with 12 mM glucose. The severity of these defects in Ca2+ signaling correlated with the age-dependent development of hyperglycemia. Similarly defective glucose-induced Ca2+ signaling were reproduced in control islets by pre-exposure to thapsigargin, a selective inhibitor of endoplasmic reticulum (ER) Ca2+-ATPase. Estimation of ATPase activities from rates of ATP hydrolysis and by immunoblot hybridization with an antiserum directed against the sarco/endoplasmic reticulum Ca2+-ATPase both demonstrated that the ER Ca2+-ATPase was almost entirely absent from db/db islets. The effects of inhibition of ER Ca2+-ATPase on insulin secretion were also examined; a 4-day exposure of control islets to 1 mu M thapsigargin resulted in basal and glucose-stimulated insulin secretion levels similar to those found in db/db islets. These results suggest that aberrant ER Ca2+ sequestration underlies the impaired glucose responses in the db/db mouse and may play a role in defective insulin secretion associated with NIDDM.	GLAXO INC,RES INST,DEP CELL PHYSIOL,RES TRIANGLE PK,NC 27709; UNIV CHICAGO,DEPT MED MC-1027,ENDOCRINE SECT,CHICAGO,IL 60637	GlaxoSmithKline; University of Chicago								ALLEN BG, 1987, BIOCHEM J, V244, P617, DOI 10.1042/bj2440617; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; COLCA JR, 1983, BIOCHIM BIOPHYS ACTA, V729, P176, DOI 10.1016/0005-2736(83)90483-2; COLEMAN DL, 1982, DIABETES, V31, P1; COOK DL, 1990, DIABETES MELLITUS TH, P89; DUKES ID, 1994, J BIOL CHEM, V269, P10979; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KOTAGAL N, 1985, ARCH BIOCHEM BIOPHYS, V238, P161, DOI 10.1016/0003-9861(85)90152-3; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; MUALLEM S, 1990, INTRACELLULAR CALCIU, P349; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROSSI JP, 1988, BIOCHIM BIOPHYS ACTA, V943, P175, DOI 10.1016/0005-2736(88)90549-4; ROW MW, 1994, AM J PHYSIOL, V266, pE852; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLLHEIM CB, 1984, J BIOL CHEM, V259, P2262; WORLEY JF, 1994, J BIOL CHEM, V269, P14359	26	131	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18279	18282						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034570				2022-12-27	WOS:A1994NW79800006
J	WANG, HX; YAO, ZM; FISHER, EA				WANG, HX; YAO, ZM; FISHER, EA			THE EFFECTS OF N-3 FATTY-ACIDS ON THE SECRETION OF CARBOXYL-TERMINALLY TRUNCATED FORMS OF HUMAN APOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; ENDOPLASMIC-RETICULUM MEMBRANE; TRIGLYCERIDE TRANSFER PROTEIN; APOLIPOPROTEIN-B; RAT-LIVER; INTRACELLULAR DEGRADATION; EICOSAPENTAENOIC ACID; PLASMA-LIPOPROTEINS; CHOLESTERYL ESTER	We have previously reported that in primary rat hepatocytes, n-3 fatty acid (either eicosapentaenoic or docosahexaenoic) stimulates intracellular degradation of apoprotein B100 (apoB100) and apoB48 (Wang, H., Chen, X., and Fisher, E. A. (1993) J. Clin. Invest. 91, 1380-1389). There was a greater effect on apoB100 than on apoB48. Rat hepatoma (McArdle RH-7777) cell lines expressing carboxyl-truncated human apoB species apoB42, apoB28, and apoB18 were used to explore the relationship between the effects of n-3 fatty acids and apoB lipidation. After density gradient separation of conditioned media, apoB42 was found at d < 1.21 (lipid-rich), apoB18 at d > 1.21 (lipid-poor), and apoB28 in both fractions. After incubation with albumin complexed with eicosapentaenoic or docosahexaenoic acids, relative to oleic acid, the secretion of newly synthesized apoB was 35% (apoB42), 54% (apoB28), and 96% (apoB18). Further analysis of the apoB28 data showed decreased secretion of only lipid-rich (d < 1.21) apoB28. Pulse-chase studies indicated that with n-3 fatty acid there was increased intracellular degradation of apoB42 concomitant with its decreased secretion. We conclude that the ability of the n-3 fatty acids to promote apoB degradation correlated with the degree of lipidation of the secreted apoB, consistent with specialized intracellular pathways for the degradation of apoB and the assembly of buoyant, apoB-containing lipoproteins.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	Drexel University; University of Alberta; University of Alberta				Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARBEENY CM, 1992, J LIPID RES, V33, P843; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BASS J, 1991, J CLIN INVEST, V87, P470, DOI 10.1172/JCI115019; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN XL, 1993, J BIOL CHEM, V268, P21007; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELOVSON J, 1992, CIRCULATION S1, V86, P693; FOX JC, 1992, BIOCHEM J, V286, P305, DOI 10.1042/bj2860305; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HOEG JM, 1988, J LIPID RES, V29, P1215; HOMAN R, 1991, J LIPID RES, V32, P231; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P90; KHAN B, 1989, BIOCHEM J, V259, P807; LANG CA, 1990, J LIPID RES, V31, P2079; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE GF, 1989, J LIPID RES, V30, P757; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAN AC, 1988, J BIOL CHEM, V263, P8126; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SATO R, 1990, J BIOL CHEM, V265, P11880; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SMIT MJ, 1991, J CLIN INVEST, V88, P943, DOI 10.1172/JCI115397; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1988, J CLIN INVEST, V82, P37, DOI 10.1172/JCI113597; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WETTERAU JR, 1992, SCIENCE, V258, P999; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WONG L, 1987, EUR J BIOCHEM, V164, P357, DOI 10.1111/j.1432-1033.1987.tb11066.x; WONG SH, 1989, ARTERIOSCLEROSIS, V9, P836, DOI 10.1161/01.ATV.9.6.836; WU XJ, 1993, CIRCULATION, V88, P176; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300	53	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18514	18520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034600				2022-12-27	WOS:A1994NW79800046
J	JIMENEZCERVANTES, C; SOLANO, F; KOBAYASHI, T; URABE, K; HEARING, VJ; LOZANO, JA; GARCIABORRON, JC				JIMENEZCERVANTES, C; SOLANO, F; KOBAYASHI, T; URABE, K; HEARING, VJ; LOZANO, JA; GARCIABORRON, JC			A NEW ENZYMATIC FUNCTION IN THE MELANOGENIC PATHWAY - THE 5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID OXIDASE ACTIVITY OF TYROSINASE-RELATED PROTEIN-1 (TRP1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MELANOMA-CELLS; PERFORMANCE LIQUID-CHROMATOGRAPHY; DOPACHROME TAUTOMERASE; MAMMALIAN TYROSINASE; METAL-IONS; EUMELANIN; GENE; CDNA; MELANOCYTES; CONVERSION	Since the characterization of 5,6 dihydroxyindole-2-carboxylic acid (DHICA) as a major melanogenic intermediate, the fate of this compound and the mechanisms of its incorporation into the melanin polymer have become major issues in the study of melanogenesis. DHICA is a stable dihydroxyindole with a low rate of spontaneous oxidation, suggesting that enzymatic mechanism(s) might contribute to its evolution. The most obvious candidates are the melanosomal tyrosinases. We have recently shown that mouse melanosomes contain two electrophoretically distinct tyrosinase isoenzymes, termed low electrophoretic mobility tyrosinase (LEMT) and high electrophoretic mobility tyrosinase (HEMT), that can be resolved and purified. In this study, we report immunological evidence indicating that LEMT corresponds to the protein encoded by the brown locus (termed tyrosinase-related protein-1, TRP1), while HEMT corresponds to the tyrosinase encoded by the albino locus. We have compared the ability of both isoenzymes to catalyze DHICA evolution as determined by high performance liquid chromatography; although LEMT is a relatively poor tyrosine hydroxylase and DOPA oxidase as compared to HEMT, it was readily able to accelerate DHICA consumption concomitant with the production of a brownish product. However, the DHICA conversion activity of HEMT was barely detectable. The ability of purified LEMT to catalyze DHICA conversion could be almost completely abolished by treatment with heat or trypsin, and was inhibited in a concentration dependent way by the tyrosinase inhibitor 2-phenylthiourea and by L-tyrosine, Moreover, in the presence of low concentration of ascorbate, the DHICA conversion activity of LEMT displayed a lag period which was progressively longer at higher ascorbate concentrations. Based on the relationship between ascorbate added, enzyme activity, and lag period, it is very likely that the DHICA converting activity is indeed a DHICA oxidase activity. This was further proven by the demonstration that the product reacts rapidly and efficiently with the quinone trapping reagent 3-methyl-2-benzothiazolinone hydrazone, yielding a colored adduct similar to the one obtained with DOPAquinone. The DHICA oxidase activity of LEMT displayed a K-m for DHICA of about 0.8 mM, as compared to 1.9 mM for L-DOPA and 0.23 mM for L tyrosine. These results suggest that TRP1, the product of the brown locus, is indeed a tyrosinase with DHICA oxidase activity. However, as opposed to the tyrosinase encoded by the albino locus, TRP1's role in melanogenesis could be more directly related to DHICA metabolism than to the first steps of the pathway.	UNIV MURCIA, FAC MED, DEPT BIOCHEM & MOLEC BIOL, MURCIA, SPAIN; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of Murcia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Solano, Francisco/G-5001-2013; Jimenez-Cervantes, Celia/H-1953-2015; Garcia-Borron, Jose Carlos/H-2247-2015	Solano, Francisco/0000-0001-9612-761X; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Kobayashi, Takeshi/0000-0002-4372-5285				AROCA P, 1993, J BIOL CHEM, V268, P25650; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; AROCA P, 1992, EUR J BIOCHEM, V208, P155, DOI 10.1111/j.1432-1033.1992.tb17169.x; BENNETT DC, 1990, DEVELOPMENT, V110, P471; DELMARMOL V, 1993, FEBS LETT, V327, P307, DOI 10.1016/0014-5793(93)81010-W; DISCHIA M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P423, DOI 10.1016/0304-4165(91)90152-7; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HALABAN R, 1977, EXP CELL RES, V108, P111, DOI 10.1016/S0014-4827(77)80016-5; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; ITO S, 1993, J INVEST DERMATOL, V100, pS166, DOI 10.1111/1523-1747.ep12465109; ITO S, 1986, BIOCHIM BIOPHYS ACTA, V883, P155, DOI 10.1016/0304-4165(86)90146-7; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JARA JR, 1988, PIGM CELL RES, V1, P332, DOI 10.1111/j.1600-0749.1988.tb00128.x; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JIMENEZCERVANTES C, 1993, EUR J BIOCHEM, V217, P549, DOI 10.1111/j.1432-1033.1993.tb18276.x; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; MARTINEZLIARTE JH, 1992, J INVEST DERMATOL, V99, P435, DOI 10.1111/1523-1747.ep12616139; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; ORLOW SJ, 1992, PIGM CELL RES, V5, P113, DOI 10.1111/j.1600-0749.1992.tb00007.x; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PALUMBO A, 1991, BIOCHIM BIOPHYS ACTA, V1115, P1, DOI 10.1016/0304-4165(91)90003-Y; PALUMBO P, 1987, TETRAHEDRON LETT, V28, P467, DOI 10.1016/S0040-4039(00)95758-7; PALUMBO P, 1987, TETRAHEDRON, V43, P4203, DOI 10.1016/S0040-4020(01)83461-X; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; PEINADO P, 1992, CANCER J - FRANCE, V5, P348; PIFFERI PG, 1973, ANAL BIOCHEM, V52, P325, DOI 10.1016/0003-2697(73)90033-X; POMERANTZ SH, 1964, BIOCHEM BIOPH RES CO, V16, P188, DOI 10.1016/0006-291X(64)90359-6; Prota G., 1992, MELANINS MELANOGENES, P1; PROTA G, 1992, PIGMENT CELL RES S2, V5, P25; SALINAS C, 1994, BBA-PROTEIN STRUCT M, V1204, P53, DOI 10.1016/0167-4838(94)90032-9; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBATA T, 1993, J INVEST DERMATOL, V100, pS274, DOI 10.1038/jid.1993.49; SMIT NPM, 1990, ANAL BIOCHEM, V190, P286, DOI 10.1016/0003-2697(90)90195-F; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TSUKAMOTO K, 1992, PIGM CELL RES, P84; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; VALVERDE P, 1992, FEBS LETT, V304, P114, DOI 10.1016/0014-5793(92)80600-L; WAKAMATSU K, 1988, ANAL BIOCHEM, V170, P335, DOI 10.1016/0003-2697(88)90639-2; WESTERHOF W, 1987, J INVEST DERMATOL, V89, P78, DOI 10.1111/1523-1747.ep12580422; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; YAMAMOTO H, 1987, JPN J GENET, V62, P271, DOI 10.1266/jjg.62.271	50	232	243	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17993	18000						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027058				2022-12-27	WOS:A1994NV42200039
J	LECONTE, I; CARPENTIER, JL; CLAUSER, E				LECONTE, I; CARPENTIER, JL; CLAUSER, E			THE FUNCTIONS OF THE HUMAN INSULIN-RECEPTOR ARE AFFECTED IN DIFFERENT WAYS BY MUTATION OF EACH OF THE 4 N-GLYCOSYLATION SITES IN THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; TRANSMEMBRANE DOMAIN; LINKED OLIGOSACCHARIDES; SIGNAL TRANSDUCTION; BASIC POLYCATIONS; PROTEIN-KINASE; CELLS; INTERNALIZATION; AUTOPHOSPHORYLATION; ACTIVATION	The functional role of the oligosaccharide chains linked to the insulin receptor (IR) beta subunit was investigated by site directed mutagenesis of each of the 4 acceptor asparagines (N1 to N4 from the amino to the carboxyl terminus) and stable expression of the receptors in CHO cells. All mutant receptors are expressed normally at the cell surface, bind insulin with similar affinity, but have a beta subunit of smaller molecular mass, and a defect in ligand-induced internalization as compared to wild type receptor. In terms of receptor activation and signal transduction, the N1 and N2 mutants function normally, whereas the N4 mutant exhibits major alterations in in vitro tyrosine kinase activity and autophosphorylation and is unable to transduce the signal for either glycogen or DNA synthesis. By contrast, in vivo autophosphorylation and IRS-1 phosphorylation appear quantitatively normal, and only partial alterations of phosphatidylinositol 3-kinase and mitogen-activated protein kinase activation are observed. Mutation of the N3 site results in partial defect of IR activation. These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling.	COLL FRANCE, INSERM, U36, CHAIRE MED EXPTL, F-75005 PARIS, FRANCE; UNIV GENEVA, DEPT MORPHOL, GENEVA, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; University of Geneva								BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; BIENER Y, 1990, EUR J BIOCHEM, V194, P243, DOI 10.1111/j.1432-1033.1990.tb19449.x; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURONIO V, 1986, J BIOL CHEM, V261, P970; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HAYES GR, 1991, BIOCHEM BIOPH RES CO, V174, P735, DOI 10.1016/0006-291X(91)91479-V; HEFFETZ D, 1986, J BIOL CHEM, V261, P889; HERZBERG VL, 1985, BIOCHEM BIOPH RES CO, V129, P789, DOI 10.1016/0006-291X(85)91961-8; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHANSKI RA, 1989, J BIOL CHEM, V264, P20984; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LONGO N, 1992, J BIOL CHEM, V267, P12416; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; PODSKALNY J, 1984, BIOCHEM BIOPH RES CO, V125, P70, DOI 10.1016/S0006-291X(84)80335-6; PONZIO G, 1990, CELL SIGNAL, V2, P377, DOI 10.1016/0898-6568(90)90068-L; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; PONZIO G, 1987, EMBO J, V6, P333, DOI 10.1002/j.1460-2075.1987.tb04759.x; Rasmussen JR., 1992, CURR OPIN STRUC BIOL, V2, P682; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROTH RA, 1983, BIOCHEM BIOPH RES CO, V115, P245, DOI 10.1016/0006-291X(83)90996-8; ROUILLER DG, 1986, ENDOCRINOLOGY, V118, P1159, DOI 10.1210/endo-118-3-1159; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; STADSTED J, 1990, CELL, V62, P297; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859	56	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18062	18071						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027066				2022-12-27	WOS:A1994NV42200048
J	ADACHI, S; UCHIDA, S; ITO, H; HATA, M; HIROE, M; MARUMO, F; SASAKI, S				ADACHI, S; UCHIDA, S; ITO, H; HATA, M; HIROE, M; MARUMO, F; SASAKI, S			2 ISOFORMS OF A CHLORIDE CHANNEL PREDOMINANTLY EXPRESSED IN THICK ASCENDING LIMB OF HENLE LOOP AND COLLECTING DUCTS OF RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE; XENOPUS OOCYTES; MOLECULAR-CLONING; CL CHANNELS; TRANSPORT; PROTEIN; TUBULE	Complementary DNAs encoding rat kidney chloride channels (ClC-K2L and ClC-K2S) were isolated by a polymerase chain reaction cloning strategy. Degenerate primers were designed based on the significant amino acid identity of the previously cloned chloride channels (ClC-0, -1, -2, and -K1). The 687-amino acid protein encoded by ClC-K2L is about 80% identical to rat ClC-K1 and about 40% identical to ClC-0, -1, and -2. ClC-K2S encodes a 632-amino acid protein in which 55 amino acids containing the putative second membrane-spanning domain of ClC-K2L are deleted. Chloride currents induced by both clones were very similar in terms of inhibitor sensitivity and anion selectivity (Br- > I- > Cl- >> cyclamate(-)). Northern blot with total ClC-K2L as a probe under high stringency revealed its message predominantly in kidney, especially in the outer and inner medulla. Reverse transcription polymerase chain reaction technique using microdissected nephron segments revealed that the main site of expression of both clones in kidney was the thick ascending limb of Henle's loop and collecting ducts, where the existence of a variety of chloride channels and their importance for maintaining body fluid homeostasis have been demonstrated. These results suggest that ClC-K2L and -K2S are chloride channels in the thick ascending limb and collecting ducts and may be important routes for transcellular chloride transport like ClC-K1.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)			Uchida, Shinichi/D-1111-2013					GILL DR, 1992, NATURE, V355, P830; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HANLEY MJ, 1978, J CLIN INVEST, V62, P39, DOI 10.1172/JCI109111; Higuchi R., 1989, PCR TECHNOLOGY, P61; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; MORIYAMA T, 1990, AM J PHYSIOL, V258, pF1470, DOI 10.1152/ajprenal.1990.258.5.F1470; PAULAIS M, 1990, J MEMBRANE BIOL, V113, P253, DOI 10.1007/BF01870076; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES WB, 1992, ANNU REV PHYSIOL, V54, P29, DOI 10.1146/annurev.physiol.54.1.29; SANSOM SC, 1990, AM J PHYSIOL, V259, pF46, DOI 10.1152/ajprenal.1990.259.1.F46; SANSOM SC, 1984, AM J PHYSIOL, V247, pF291, DOI 10.1152/ajprenal.1984.247.2.F291; SCHLATTER E, 1991, EUR J PHYSL, V418, pR75; SCHNERMANN J, 1976, PFLUG ARCH EUR J PHY, V362, P229, DOI 10.1007/BF00581175; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH, P1975; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STONER LC, 1974, AM J PHYSIOL, V227, P453; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1991, J BIOL CHEM, V266, P9605; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; Uchida Shinichi, 1993, Journal of the American Society of Nephrology, V4, P882; WANGEMANN P, 1986, EUR J PHYSL S2, V407, pS128; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YOSHITOMI K, 1987, PFLUG ARCH EUR J PHY, V408, P600, DOI 10.1007/BF00581162; ZIMNIAK L, 1992, AM J PHYSIOL, V263, pF979, DOI 10.1152/ajprenal.1992.263.5.F979	30	149	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17677	17683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021279				2022-12-27	WOS:A1994NU12800053
J	AHMED, S; LEE, J; WEN, LP; ZHAO, ZS; HO, J; BEST, A; KOZMA, R; LIM, L				AHMED, S; LEE, J; WEN, LP; ZHAO, ZS; HO, J; BEST, A; KOZMA, R; LIM, L			BREAKPOINT CLUSTER REGION GENE PRODUCT-RELATED DOMAIN OF N-CHIMAERIN - DISCRIMINATION BETWEEN RAC-BINDING AND GTPASE-ACTIVATING RESIDUES BY MUTATIONAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; GAP; ENCODES; RHO; EXPRESSION; HOMOLOGY; 3-KINASE; CLONING; P21RAC	The breakpoint cluster region gene product (Bcr) is a GTPase-activating protein (GAP) for members of the Rho family, Cdc42Hs, and Rac1, as is the brain protein n-chimaerin. At least 15 proteins have sequence identity to the GAP domain (150 amino acid residues) of Bcr. The widespread occurrence of proteins that possess sequence identity to the Bcr-related GAP domain makes it especially important to understand its structure/ function relationships. Amino acid sequence alignment of these proteins reveals three blocks of conservation in the GAP domain. Here, we present a mutational analysis of this domain using n-chimaerin sequences. Ten mutations were constructed (at least two in each of the blocks of conservation), expressed as glutathione S-transferase fusion proteins in Escherichia coli, and purified. Seven of the mutants, including deletions, still possessed GAP activity for Rac1. Three of the mutants had no Rac1-GAP activity but were still able to bind Rac1. IC50 values obtained from competition experiments suggest that n-chimaerin and the mutants with no GAP activity bound Rac1 with similar apparent binding constants. Thus, this mutant analysis allows discrimination between Rac1 binding and Rac1 GTPase- activating residues.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	AHMED, S (corresponding author), INST NEUROL,DEPT NEUROCHEM,1 WAKEFIELD ST,LONDON WC1N 1PJ,ENGLAND.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768; Wen, Longping/0000-0003-0384-4578				AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BALDWIN GS, 1993, TRENDS BIOCHEM SCI, V18, P378, DOI 10.1016/0968-0004(93)90093-3; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOIGNON F, 1993, YEAST, V9, P189, DOI 10.1002/yea.320090210; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GUTMANN DH, 1993, ONCOGENE, V8, P761; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	32	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17642	17648						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021274				2022-12-27	WOS:A1994NU12800048
J	SILVA, AM; ROSARIO, LM; SANTOS, RM				SILVA, AM; ROSARIO, LM; SANTOS, RM			BACKGROUND CA2+ INFLUX MEDIATED BY A DIHYDROPYRIDINE-INSENSITIVE AND VOLTAGE-INSENSITIVE CHANNEL IN PANCREATIC BETA-CELLS - MODULATION BY NI2+, DIPHENYLAMINE-2-CARBOXYLATE, AND GLUCOSE-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; BURSTING ELECTRICAL-ACTIVITY; RAT EXOCRINE PANCREAS; INSULIN RELEASE; CALCIUM INFLUX; CYTOPLASMIC CALCIUM; ENDOTHELIAL-CELLS; DIVALENT-CATIONS; ACINAR-CELLS; B-CELLS	A stepwise increase in extracellular Ca2+ concentration ([Ca2+](o)) can evoke insulin release from pancreatic islets in the absence of secretagogues. We have investigated the ionic mechanism underlying this secretory response by recording intracellular free Ca2+ concentration ([Ca2+](i)) from single mouse islets of Langerhans using ratiometric fura-2 microfluorometry. In the presence of 11 mM glucose, the [Ca2+](i) undergoes fast oscillations associated with bursting electrical activity. Nifedipine (10 mu M) suppressed these oscillations and markedly lowered the [Ca2+](i). Raising the [Ca2+](o) from 2.56 to 12.8 mM in the continued presence of 11 mM glucose and nifedipine evoked pronounced [Ca2+](i) rises of variable amplitude and time course. This effect was dose-dependent (EC(50) = 3.6 mM) and remained essentially unchanged in the absence of glucose or in the presence of 3 mM glucose and nifedipine, conditions where beta-cells are hyperpolarized by approximately -25 mV. Depleting the acetylcholine-mobilizable internal Ca2+ pools by repetitively challenging the islets with acetylcholine in the absence of Ca2+ actually potentiated the standard high Ca2+ responses. The latter were strongly reduced by millimolar concentrations of Ni2+ (70% reduction at 3 mM) and by diphenylamine-2-carboxylate (DPC; IC50 = 145 mu M), a blocker of nonselective cation channels. The standard high Ca2+ responses were relatively insensitive to the glycolytic inhibitor mannoheptulose. It is proposed that the high Ca2+-evoked [Ca2+](i) responses are primarily accounted for by Ca2+ influx through dihydropyridine- and voltage-insensitive, nonselective cation channels. These channels do not appear to be under the control of glucose metabolism. Although their function is unknown, they may be essential to supplying the beta cells with Ca2+ in the absence of stimulatory levels of fuel secretagogues.	UNIV COIMBRA,FAC SCI & TECHNOL,DEPT BIOCHEM,P-3049 COIMBRA,PORTUGAL; UNIV COIMBRA,CTR NEUROSCI,P-3049 COIMBRA,PORTUGAL	Universidade de Coimbra; Universidade de Coimbra			Silva, Amélia M/J-7128-2013	Silva, Amélia M/0000-0002-7524-9914; Santos, Rosa/0000-0002-1577-1663; Rosario, Luis/0000-0001-8329-2333				ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ASHCROFT FM, 1988, J PHYSIOL-LONDON, V400, P501, DOI 10.1113/jphysiol.1988.sp017134; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; AVDONIN PV, 1991, EUR J BIOCHEM, V198, P267, DOI 10.1111/j.1432-1033.1991.tb16011.x; BAX CMR, 1992, BIOCHEM BIOPH RES CO, V183, P619, DOI 10.1016/0006-291X(92)90527-R; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BYRON KL, 1992, J BIOL CHEM, V267, P108; CASTRO E, 1994, IN PRESS PFLUEGERS A; CENA V, 1991, J MEMBRANE BIOL, V122, P23, DOI 10.1007/BF01872736; COOK DI, 1990, J MEMBRANE BIOL, V114, P37, DOI 10.1007/BF01869383; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DEVIS G, 1975, BIOCHEM BIOPH RES CO, V67, P525, DOI 10.1016/0006-291X(75)90843-8; DEVIS G, 1977, DIABETOLOGIA, V13, P531, DOI 10.1007/BF01234509; DICKENSON JM, 1992, BIOCHEM J, V284, P425, DOI 10.1042/bj2840425; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; FRANKEL BJ, 1978, J CLIN INVEST, V18, P525; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V150, P419, DOI 10.1016/0006-291X(88)90537-2; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GREGER R, 1987, PFLUG ARCH EUR J PHY, V409, P114, DOI 10.1007/BF00584757; GYLFE E, 1988, J BIOL CHEM, V263, P5044; GYLFE E, 1990, HORMONES CELL REGULA, V210, P5; HAYSLETT JP, 1987, PFLUG ARCH EUR J PHY, V410, P487, DOI 10.1007/BF00586530; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMAN B, 1984, Q J EXP PHYSIOL CMS, V69, P867, DOI 10.1113/expphysiol.1984.sp002874; HELLMAN B, 1976, FEBS LETT, V63, P125, DOI 10.1016/0014-5793(76)80208-6; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HERCHUELZ A, 1980, AM J PHYSIOL, V238, pE96, DOI 10.1152/ajpendo.1980.238.2.E96; IKEDA M, 1992, J PHYSIOL-LONDON, V447, P711, DOI 10.1113/jphysiol.1992.sp019025; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JUNG F, 1992, AM J PHYSIOL, V262, pC1464, DOI 10.1152/ajpcell.1992.262.6.C1464; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KIKUCHI M, 1978, ENDOCRINOLOGY, V102, P1339, DOI 10.1210/endo-102-5-1339; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEBRUN P, 1982, AM J PHYSIOL, V242, pE59, DOI 10.1152/ajpendo.1982.242.1.E59; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MURRAY RK, 1991, J PHYSIOL-LONDON, V435, P123, DOI 10.1113/jphysiol.1991.sp018501; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; NILSSON T, 1987, BIOCHEM BIOPH RES CO, V149, P152, DOI 10.1016/0006-291X(87)91617-2; PARTRIDGE LD, 1988, TRENDS NEUROSCI, V11, P69, DOI 10.1016/0166-2236(88)90167-1; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; POPP R, 1992, BIOCHIM BIOPHYS ACTA, V1108, P59, DOI 10.1016/0005-2736(92)90114-2; PORONNIK P, 1991, CELL CALCIUM, V12, P441, DOI 10.1016/0143-4160(91)90070-U; PORONNIK P, 1992, FEBS LETT, V296, P245, DOI 10.1016/0014-5793(92)80296-S; RACKE FK, 1993, FEBS LETT, V333, P132, DOI 10.1016/0014-5793(93)80390-G; ROJAS E, 1990, FEBS LETT, V261, P265, DOI 10.1016/0014-5793(90)80568-4; RORSMAN P, 1988, PFLUG ARCH EUR J PHY, V412, P597, DOI 10.1007/BF00583760; RORSMAN P, 1989, P NATL ACAD SCI USA, V86, P4505, DOI 10.1073/pnas.86.12.4505; RORSMAN P, 1984, FEBS LETT, V170, P196, DOI 10.1016/0014-5793(84)81398-8; ROSARIO LM, 1993, PFLUG ARCH EUR J PHY, V424, P439, DOI 10.1007/BF00374906; SANTOS RM, 1992, BIOCHEM BIOPH RES CO, V187, P872, DOI 10.1016/0006-291X(92)91278-X; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SANTOS RM, 1994, IN PRESS FRONTIERS P; SCHWARZ G, 1992, J PHYSIOL-LONDON, V458, P527, DOI 10.1113/jphysiol.1992.sp019432; SIEMER C, 1992, PFLUG ARCH EUR J PHY, V420, P319, DOI 10.1007/BF00374465; STURGESS NC, 1986, FEBS LETT, V208, P397, DOI 10.1016/0014-5793(86)81056-0; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V410, P169, DOI 10.1007/BF00581911; STUTTS MJ, 1990, PFLUG ARCH EUR J PHY, V415, P611, DOI 10.1007/BF02583514; SUN YD, 1989, NEUROCHEM RES, V14, P1061, DOI 10.1007/BF00965611; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VASSEUR M, 1987, FUNDAM CLIN PHARM, V1, P95, DOI 10.1111/j.1472-8206.1987.tb00549.x; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; WOLLHEIM CB, 1990, BIOCHEM SOC T, V18, P111, DOI 10.1042/bst0180111; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P188	72	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17095	17103						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006014				2022-12-27	WOS:A1994NT84600020
J	WANG, XM; XU, LW; ZHENG, L				WANG, XM; XU, LW; ZHENG, L			CLONING AND EXPRESSION OF PHOSPHATIDYLCHOLINE-HYDROLYZING PHOSPHOLIPASE-D FROM RICINUS-COMMUNIS L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; MEMBRANES; SEQUENCE; PROTEIN; CABBAGE; ENZYME	Phosphatidylcholine-hydrolyzing phospholipase D (PLD; EC 3.1.4.4) has been proposed to play an important role in the signal transduction pathways in animals and in various cellular processes in plants. To unravel the structure of PLD and further the investigation of its modes of regulation and cellular function, we have isolated a PLD cDNA from castor bean (Ricinus communis L. var. Hale) by using oligonucleotide probes based on the N-terminal amino acid sequence of purified PLD protein. The nucleotide sequence of the castor bean PLD cDNA clone contains an open reading frame of 2424 bases encoding an 808-amino acid protein of 92,400 daltons. Expression of this PLD cDNA clone in Escherichia coli resulted in the accumulation of a functional PLD able to catalyze hydrolysis and transphosphatidylation reactions, demonstrating that the introduction of this single gene product was sufficient to confer PLD activity and that both the hydrolysis and transphosphatidylation reactions are catalyzed the single PLD protein. Comparison of the deduced protein sequence of the clone to the N-terminal amino acid sequence of purified PLD revealed that the mature PLD protein is preceded by a 30-amino acid leader peptide. Removal of this leader peptide resulted in accumulation of non-functional PLD and also increased PLD degradation in E. coli, suggesting that this leader peptide may be involved in proper folding of PLD. The primary structure of the castor bean PLD exhibits no significant similarities with sequences of other cloned lipolytic enzymes.			WANG, XM (corresponding author), KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,WILLARD HALL,MANHATTAN,KS 66506, USA.		Wang, Xuemin/M-2853-2013	wang, xuemin/0000-0002-6251-6745				ABOUSALHAM A, 1993, BIOCHIM BIOPHYS ACTA, V1158, P1, DOI 10.1016/0304-4165(93)90088-P; ACHARYA MK, 1991, PHYTOCHEMISTRY, V30, P2895, DOI 10.1016/S0031-9422(00)98220-7; AITKEN A, 1990, IDENTIFICATION PROTE, P152; ALLGYER TT, 1979, BIOCHEMISTRY-US, V18, P5348, DOI 10.1021/bi00591a014; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOROCHOV A, 1982, PLANT PHYSIOL, V69, P296, DOI 10.1104/pp.69.2.296; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN JH, 1990, PHYTOCHEMISTRY, V30, P2537; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DYER JH, 1994, PLANT PHYSIOL, V105, P715, DOI 10.1104/pp.105.2.715; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HELLER M, 1974, BIOCHIM BIOPHYS ACTA, V369, P397, DOI 10.1016/0005-2760(74)90153-2; Heller M, 1978, Adv Lipid Res, V16, P267; HERMAN EM, 1980, PLANT PHYSIOL, V66, P1001, DOI 10.1104/pp.66.5.1001; HODGSON ALM, 1990, J BACTERIOL, V172, P1256, DOI 10.1128/jb.172.3.1256-1261.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE M H, 1989, Plant Science (Shannon), V59, P35, DOI 10.1016/0168-9452(89)90005-8; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAITO M, 1974, ARCH BIOCHEM BIOPHYS, V164, P420, DOI 10.1016/0003-9861(74)90051-4; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; TOUCHSTONE J C, 1981, Journal of High Resolution Chromatography and Chromatography Communications, V4, P423, DOI 10.1002/jhrc.1240040816; VOISINE R, 1993, PLANT PHYSIOL, V102, P213, DOI 10.1104/pp.102.1.213; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANG P, 1991, J BIOL CHEM, V266, P14877; WANG X, 1993, ARCH BIOCHEM BIOPHYS, V306, P466; WANG X, 1993, LIPID METABOLISM PLA, P499; WANG XM, 1988, PHYSIOL PLANTARUM, V72, P127, DOI 10.1111/j.1399-3054.1988.tb06633.x; WILLEMOT C, 1983, PHYTOCHEMISTRY, V22, P861, DOI 10.1016/0031-9422(83)85012-2	30	174	206	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20312	20317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051126				2022-12-27	WOS:A1994PB31700019
J	SANKARAN, K; WU, HC				SANKARAN, K; WU, HC			LIPID MODIFICATION OF BACTERIAL PROLIPOPROTEIN - TRANSFER OF DIACYLGLYCERYL MOIETY FROM PHOSPHATIDYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI OUTER-MEMBRANE; APOLIPOPROTEIN N-ACYLTRANSFERASE; TEMPERATURE-SENSITIVE MUTANT; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUREIN-LIPOPROTEIN; SIGNAL PEPTIDASE; NUCLEOTIDE-SEQUENCE; PRO-LIPOPROTEIN; STRUCTURAL GENE	The peptide, MKATKLVLGAVILGSTLLAGCSSN, corresponding to the N-terminal 24 amino acids of Braun's prolipoprotein, was used to study the lipid modification of prolipoprotein in Escherichia coli by measuring the rate of incorporation of either [2-H-3]glycerol or [9,10-H-3]palmitate from the corresponding labeled phosphatidylglycerol into the peptide. Using E. coli strains containing varying levels of prolipoprotein diacylglyceryl modification activities due to mutations in or overexpression of the gene involved in diacylglyceryl modification (lgt), we have shown that the activities based on the peptide assay correlated well with the prolipoprotein-based assay. Further, we have followed the fate of the lipid substrate, phosphatidylglycerol, during the modification reaction and found that lipid modification of prolipoprotein involves the transfer of diacylglyceryl moiety from phosphatidylglycerol to the sulfhydryl group of the cysteine residue with the concomitant formation of sn-glycerol 1-phosphate. This mechanism is contrary to the previously proposed two-step mechanism of an initial glyceryl transferase followed by O-acyl transfer (Chattopadhyay, P. K., and Wu, H. C. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5318-5322). Accordingly, the enzyme that catalyzes this activity has been named phosphatidylglycerol-prolipoprotein diacylglyceryl transferase. The revised pathway for the lipoprotein biogenesis in bacteria consists of three successive reactions catalyzed by prolipoprotein diacylglyceryl transferase, signal peptidase II, and apolipoprotein N-acyltransferase.	UNIFORMED SERV UNIV HLTH SCI,DEPT IMMUNOL & MICROBIOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA								ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN V, 1993, BACTERIAL CELL WALL, V27, P319; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; CHATTOPADHYAY PK, 1979, J BACTERIOL, V137, P309, DOI 10.1128/JB.137.1.309-312.1979; DEV IK, 1984, J BIOL CHEM, V259, P1114; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; GAN K, 1993, J BIOL CHEM, V268, P16544; Gonzalez-Cerezo H, 1975, Methods Enzymol, V41, P259; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HAYASHI S, 1992, LIPID MODIFICATION P, P261; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; HUSSAIN M, 1982, J BIOL CHEM, V257, P5177; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; INOUYE S, 1977, P NATL ACAD SCI USA, V74, P1004, DOI 10.1073/pnas.74.3.1004; INOUYE S, 1977, J BACTERIOL, V132, P308, DOI 10.1128/JB.132.1.308-313.1977; LAI JS, 1983, J BIOL CHEM, V255, P5384; OUDEGA B, 1993, FEMS MICROBIOL LETT, V108, P353, DOI 10.1016/0378-1097(93)90567-L; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; ROTERING H, 1977, FEBS LETT, V83, P41, DOI 10.1016/0014-5793(77)80637-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULMAN H, 1977, J BIOL CHEM, V252, P4250; SHIBUYA I, 1992, METHOD ENZYMOL, V209, P321; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; TOKUNAGA M, 1984, J BIOL CHEM, V259, P3825; WILLIAMS MG, 1989, J BACTERIOL, V171, P565, DOI 10.1128/jb.171.1.565-568.1989; YANG SF, 1967, J BIOL CHEM, V242, P477; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1; ZHANG WY, 1992, FEBS LETT, V311, P311, DOI 10.1016/0014-5793(92)81127-8	35	304	320	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19701	19706						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051048				2022-12-27	WOS:A1994PA12600011
J	TAIRIS, N; GABRIEL, JL; GYDA, M; SOPRANO, KJ; SOPRANO, DR				TAIRIS, N; GABRIEL, JL; GYDA, M; SOPRANO, KJ; SOPRANO, DR			ARG(269) AND LYS(220) OF RETINOIC ACID RECEPTOR-BETA ARE IMPORTANT FOR THE BINDING OF RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL PATTERN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; THYROID-HORMONE; X-RECEPTORS; IDENTIFICATION; PROTEIN; MOUSE; GAMMA; DOMAIN	Retinoic acid receptors, RARs, are retinoic acid (RA)inducible transcriptional regulatory proteins which transduce the RA signal at the level of gene expression via a retinoic acid response element. Three subtypes of RARs have been described termed RAR-alpha, RAR-beta, and RAR-gamma. RARs, like other members of the steroid/thyroid hormone receptor family, are composed of six structur ally distinct domains, one of which is responsible for binding RA. No structural information is available concerning the nature of the amino acids which are responsible for binding of RA within the ligand binding domain of any RAR. In this report, the role of 2 positively charged amino acids of RAR-beta for binding of RA, Arg(269) and Lys(220), was examined using site-directed mutagenesis. When compared with wild type RAR-beta, mutation of either Arg(269) or Lys(220) singly to the small neutral amino acid Ala had only a small effect on both the EC(50) value in all-trans-RA and 9-cis-RA transactivation assays and the apparent K-d for all-trans-RA. However, mutation of both of these positively charged amino acids simultaneously to Ala caused a 500- and 100-fold elevation in the EC for all-trans-RA and 9-cis-RA, respectively, compared with that of wild type RAR-beta. Similarly the apparent K-d for all-trans-RA was increased 580-fold when that of the double mutant was compared with that of the wild type RAR-beta. Furthermore, this double mutant RAR-beta acted as a dominant negative mutant when transfected with wild type RAR-alpha, -beta, or -gamma in a RA concentration-dependent fashion. Taken together these data demonstrate the importance of both Arg(269) and Lys(220) Of RAR-beta for the binding of RA, possibly by interacting with the negatively charged carboxyl group of RA.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19104	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Tairis, Nikolaos/W-9326-2019		NCI NIH HHS [CA56309] Funding Source: Medline; NIDDK NIH HHS [DK44517, DK41089] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517, R29DK041089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI M, 1992, BIOCHEM BIOPH RES CO, V182, P1032, DOI 10.1016/0006-291X(92)91835-E; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BENBROOK D, 1988, NATURE, V333, P444; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARTER R, 1991, ONCOGENE, V6, P229; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FUKASAWA H, 1993, BIOL PHARM BULL, V16, P343; GIGUERE V, 1990, METHOD ENZYMOL, V189, P223; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GUDAS L, 1993, RETINOIDS, P443; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KNEGTEL RMA, 1993, BIOCHEM BIOPH RES CO, V192, P492, DOI 10.1006/bbrc.1993.1442; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1993, RETINOIDS, P319; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; PENA A, 1993, J BIOL CHEM, V268, P27277; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANI BP, ARCH BIOCHEM BIOPHYS, V283, P107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHIMAZAWA R, 1991, BIOCHEM BIOPH RES CO, V180, P249, DOI 10.1016/S0006-291X(05)81284-7; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SOPRANO DR, 1994, MECH DEVELOP, V45, P243, DOI 10.1016/0925-4773(94)90011-6; SOPRANO DR, 1993, TOXICOL APPL PHARM, V122, P159, DOI 10.1006/taap.1993.1183; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THOLE HH, 1993, FEBS LETT, V320, P92, DOI 10.1016/0014-5793(93)80069-7; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	64	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19516	19522						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034721				2022-12-27	WOS:A1994NY33200050
J	ZHANG, J; WANG, L; SCHWARTZ, J; BOND, RW; BISHOP, WR				ZHANG, J; WANG, L; SCHWARTZ, J; BOND, RW; BISHOP, WR			PHOSPHORYLATION OF THR(642) IS AN EARLY EVENT IN THE PROCESSING OF NEWLY SYNTHESIZED PROTEIN-KINASE C-BETA(1) AND IS ESSENTIAL FOR ITS ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PRIMARY SEQUENCE; RAT-BRAIN; C-ALPHA; AUTOPHOSPHORYLATION; CELLS; MEMBER; FAMILY; SITE	Earlier studies of a site-specific mutant of protein kinase C beta(1) (PKC beta(1)) altered at Thr(635) and Thr(642) indicated that these phosphorylation sites are critical for enzymatic function (Zhang, J., Wang, L., Petrin, J., Bishop, W R., and Bond, R. W (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 6130-6134). To determine the contribution of the individual threonines, we report here on two site-specific mutants in which either Thr(635) or Thr(642) was changed to alanine. When transiently overexpressed in Cos cells wild-type PKC beta(1) exists in two farms: a Triton-insoluble form with high electrophoretic mobility and a slower migrating Triton-soluble form. Mutation at Thr(642) (but not Thr(635)) results in production of only the fast-migrating form. [S-35]Methionine pulse chase labeling indicates that wild-type PKC beta(1) is synthesized as the fast-migrating form and is subsequently converted to the slow-migrating form. P-32 labeling shows that only the slow-migrating form is a phosphoprotein. Mutation of Thr(642) abolishes this phosphorylation. Finally, the Thr(642) mutant PKC beta(1) lacks enzymatic activity and, when expressed in NIH 3T3 cells, reduces phorbol ester-induced c-fos promoter activity. These results indicate that Thr(642) phosphorylation is an early event in the processing of newly synthesized PKC beta(1) and is required for enzymatic function. These results support a role for a PKC kinase in PKC processing and activation.	SCHERING PLOUGH CORP,RES INST,MOLEC PHARMACOL SECT,KENILWORTH,NJ 07003	Merck & Company; Schering Plough Corporation								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAIER G, 1993, J BIOL CHEM, V268, P4997; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, J BIOL CHEM, V261, P2134; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; MCFADDEN PN, 1989, J BIOL CHEM, V264, P12765; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLINA CA, 1991, CANCER RES, V51, P4624; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1990, J BIOL CHEM, V265, P6296; ONO Y, 1988, J BIOL CHEM, V263, P6927; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; SEED B, 1988, GENE AMST, V676, P771; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	32	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19578	19584						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034726				2022-12-27	WOS:A1994NY33200059
J	BAYKOUSHEVA, SP; LUTHRIA, DL; SPRECHER, H				BAYKOUSHEVA, SP; LUTHRIA, DL; SPRECHER, H			ARACHIDONIC-ACID FORMED BY PEROXISOMAL BETA-OXIDATION OF 7,10,13,16-DOCOSATETRAENOIC ACID IS ESTERIFIED INTO 1-ACYL-SN-GLYCERO-3-PHOSPHOCHOLINE BY MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-LIVER MICROSOMES; METABOLISM; CARNITINE; REDUCTASE; CELLS	Peroxisomal beta-oxidation of linoleic acid and arachidonic acid was depressed when 1-palmitoyl-sn-glycero-3-phosphocholine and microsomes were included in incubations. This reduction was due to the esterification of the substrate into the acceptor by microsomal 1-acyl-sn-glycero-3-phosphocholine acyltransferase. The first cycle of the beta-oxidation of 7,10,13,16-docosatetraenoic acid was independent of 1-acyl-sn-glycero-3-phosphocholine and microsomes. However, when arachidonate was produced it was esterified rather than serving as a substrate for continued beta-oxidation. When arachidonate and linoleate were incubated with peroxisomes alone, 2-trans-4,7,10-hexadecatetraenoic acid and 2-trans-4-decadienoic acid were the respective end products of beta-oxidation. 2-Oxo-8,11-heptadecadienone, a catabolite produced from linoleate, was most likely a nonenzymatic decarboxylation product of 3-oxo-9,12-octadecadienoic acid. In addition to the termination of beta-oxidation by microsomal-peroxisomal communication, our results with linoleate and arachidonate suggest that the reaction catalyzed by 2-trans-4-cis-dienoyl-CoA reductase is the control step in double bond removal. In addition, the beta-ketothiolase step may play a regulatory role in the peroxisomal beta-oxidation of linoleate but not arachidonate or 7,10,13,16-docosatetraenoic acid.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University			Baykoucheva, Svetla P/H-1969-2011	Baykoucheva, Svetla P/0000-0001-7066-058X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT K, 1990, BIOCHEM J, V270, P175, DOI 10.1042/bj2700175; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; CHRISTENSEN E, 1993, SCAND J CLIN LAB INV, V53, P61, DOI 10.3109/00365519309090698; COOK L, 1992, BIOCHEM J, V287, P91, DOI 10.1042/bj2870091; DAS AK, 1992, J BIOL CHEM, V267, P9724; FOLCH J, 1957, J BIOL CHEM, V226, P497; HADJIAGAPIOU C, 1987, ARCH BIOCHEM BIOPHYS, V253, P1, DOI 10.1016/0003-9861(87)90631-X; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LUTHRIA DL, 1993, LIPIDS, V28, P853, DOI 10.1007/BF02536242; MARTINEZ M, 1989, LIPIDS, V24, P261, DOI 10.1007/BF02535160; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RAMSAY RR, 1993, ARCH BIOCHEM BIOPHYS, V302, P307, DOI 10.1006/abbi.1993.1216; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPRECHER H, 1965, LIPIDS, V3, P14; Sprecher H., 1979, GEOMETRICAL POSITION, P303; SPRECHER H, 1967, BIOCHIM BIOPHYS ACTA, V144, P96; SPRECHER H, 1971, LIPIDS, V6, P884; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1545, DOI 10.1515/bchm2.1970.351.2.1545; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; VERDINO B, 1964, J NUTR, V83, P234, DOI 10.1093/jn/83.3.234; VOSS A, 1991, J BIOL CHEM, V266, P19995; VOSS A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P33, DOI 10.1016/0005-2760(92)90198-5; WIGREN J, 1993, J LIPID RES, V34, P625	28	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18390	18394						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034586				2022-12-27	WOS:A1994NW79800027
J	HARDY, MM; FLICKINGER, AG; RILEY, DP; WEISS, RH; RYAN, US				HARDY, MM; FLICKINGER, AG; RILEY, DP; WEISS, RH; RYAN, US			SUPEROXIDE-DISMUTASE MIMETICS INHIBIT NEUTROPHIL-MEDIATED HUMAN AORTIC ENDOTHELIAL-CELL INJURY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL REPERFUSION INJURY; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; FREE-RADICALS; FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; SUSTAINED LIMITATION; INFARCT SIZE; ISCHEMIA	In this study, we evaluated the ability of low molecular weight manganese-based superoxide dismutase mimetics to attenuate neutrophil mediated oxygen radical damage to human aortic endothelial cells in vitro. Human neutrophils, when exposed to tumor necrosis factor-alpha and the complement component C5a, induced endothelial damage assessed by the release of Cr-51 into the medium. This damage correlated with the amount of superoxide generated by neutrophils. Three superoxide dismutase mimetics, with catalytic rate constants for superoxide dismutation ranging from 4 to 9 x 10(7) M(-1) s(-1), inhibited neutrophil- or xanthine oxidase-mediated endothelial cell injury in a concentration-dependent manner. A similar manganese-based compound with no detectable superoxide dismutase activity was ineffective in inhibiting injury. Fluorescent studies of the neutrophil respiratory burst showed that the superoxide dismutase mimetics were protective without interfering with the generation of superoxide by activated neutrophils. Catalase, elastase inhibitors, and desferrioxamine mesylate (an iron chelator and hydroxyl radical scavenger) were not protective against cell injury. This investigation demonstrates that neutrophil-mediated human aortic endothelial cell injury in vitro is mediated by the superoxide anion and that low molecular weight manganese-based superoxide dismutase mimetics are effective in abrogating this damage.	MONSANTO CO,DEPT CHEM SCI,ST LOUIS,MO 63167	Monsanto	HARDY, MM (corresponding author), MONSANTO CO,DEPT HLTH SCI,MAIL ZONE T2K,800 N LINDBERGH BLVD,ST LOUIS,MO 63167, USA.							ALEXANDER MD, 1970, INORG NUCL CHEM LETT, V6, P445; ATKINSON YH, 1988, J CLIN INVEST, V81, P759, DOI 10.1172/JCI113381; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERKOW RL, 1987, J IMMUNOL, V139, P3783; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; BRIGHAM KL, 1987, PULMONARY ENDOTHELIU, P207; CHAPMANKIRKLAND ES, 1991, J IMMUNOL METHODS, V142, P95; CROUCH S, 1991, BRIT J HAEMATOL, V77, P158, DOI 10.1111/j.1365-2141.1991.tb07971.x; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; ENGLER R, 1989, CIRCULATION, V79, P1137, DOI 10.1161/01.CIR.79.5.1137; ENGLER RL, 1986, AM J PHYSIOL, V251, pH314, DOI 10.1152/ajpheart.1986.251.2.H314; ENTMAN ML, 1992, J CLIN INVEST, V90, P1335, DOI 10.1172/JCI115999; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; GHEZZI P, 1989, CYTOKINE, V1, P122; GINSBURG I, 1989, FREE RADICAL BIO MED, V7, P369, DOI 10.1016/0891-5849(89)90123-8; HALLLIWELL B, HAEMOSTASIS, V2318, P93; INAUEN W, 1990, AM J PHYSIOL, V259, pH925, DOI 10.1152/ajpheart.1990.259.3.H925; JOHANSSON MH, 1990, CARDIOVASC RES, V24, P500, DOI 10.1093/cvr/24.6.500; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LUCCHESI BR, 1990, ANNU REV PHYSIOL, V52, P561, DOI 10.1146/annurev.ph.52.030190.003021; MA XL, 1991, CIRC RES, V69, P95, DOI 10.1161/01.RES.69.1.95; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; MAROKO PR, 1978, J CLIN INVEST, V13, P1491; MAURY CPJ, 1987, J EXP MED, V166, P1132, DOI 10.1084/jem.166.4.1132; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MEHTA JL, 1989, CIRC RES, V65, P1283, DOI 10.1161/01.RES.65.5.1283; MULLANE KM, 1984, J PHARMACOL EXP THER, V228, P510; NEJIMA J, 1989, CIRCULATION, V79, P143, DOI 10.1161/01.CIR.79.1.143; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; OMAR BA, 1991, J MOL CELL CARDIOL, V23, P149, DOI 10.1016/0022-2828(91)90102-R; RICEEVANS CA, 1993, FREE RADICAL BIO MED, V15, P77, DOI 10.1016/0891-5849(93)90127-G; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RYAN US, 1986, J TISSUE CULT METHOD, V10, P15; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; Shibata T, 1993, Nihon Kyobu Geka Gakkai Zasshi, V41, P427; SIMPSON PJ, 1987, AM HEART J, V113, P129, DOI 10.1016/0002-8703(87)90020-2; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; Takemura T, 1993, Nihon Kyobu Geka Gakkai Zasshi, V41, P247; TURRENS JF, 1991, XENOBIOTICA, V21, P1033, DOI 10.3109/00498259109039543; VANHAECKE J, 1991, J AM COLL CARDIOL, V18, P224, DOI 10.1016/S0735-1097(10)80243-8; VARANI J, 1992, LAB INVEST, V66, P708; VARANI J, 1985, LAB INVEST, V53, P656; VONASMUTH EJU, 1991, SCAND J IMMUNOL, V34, P197; WARD PA, 1990, J LEUKOCYTE BIOL, V48, P97, DOI 10.1002/jlb.48.1.97; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WERNS SW, 1988, J CARDIOVASC PHARM, V11, P36, DOI 10.1097/00005344-198801000-00006; WINN RK, 1992, ENDOTHELIAL CELL DYS, P141	56	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18535	18540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034601				2022-12-27	WOS:A1994NW79800049
J	NAKAMURA, T; ABE, A; BALAZOVICH, KJ; WU, D; SUCHARD, SJ; BOXER, LA; SHAYMAN, JA				NAKAMURA, T; ABE, A; BALAZOVICH, KJ; WU, D; SUCHARD, SJ; BOXER, LA; SHAYMAN, JA			CERAMIDE REGULATES OXIDANT RELEASE IN ADHERENT HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; STIMULATED HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; RESPIRATORY BURST; PHOSPHATIDATE PHOSPHOHYDROLASE; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; MEMBRANE-FUSION; SPHINGOSINE	We investigated the role of sphingolipids in regulating oxidant release in adherent human neutrophils. Stimulation of adherent neutrophils with formyl-Met-Leu-Phe (fMLP) resulted in the accumulation of ceramide at a time when H2O2 release is terminated. H2O2 release in fMLP-stimulated neutrophils was suppressed in a concentration-dependent manner by the exogenous addition of several free sphingoid amines and short chain ceramides. Sphingosine, dihydrosphingosine, phytosphingosine, N-acetylsphingosine, and N-acetylphytosphingosine, but not N-acetyldihydrosphingosine, inhibited formyl peptide-stimulated oxidant release. The half-maximal inhibitory concentrations of N-acetylsphingosine and N-acetylphytosphingosine were 0.51 and 0.38 mu M, respectively. Sphingosine, dihydrosphingosine, and phytosphingosine were less potent inhibitors with half-maximal inhibitory concentrations of 1.78, 15.4, and 1.48 mu M respectively. The 4 beta-phorbol 12 beta-myristate 13 alpha-acetate-induced respiratory burst was inhibited by 5 mu M of sphingosine but not by 5 mu M of N-acetylsphingosine. The effects of N-acetyl-conjugated sphingols (C-2 ceramides) on phosphatidylcholine-specific phospholipase D and phosphatidic acid phosphohydrolase were markedly different from the effects of the related sphingoid bases. Both C-2 ceramides and sphingoid bases partially inhibited the diradylglycerol formation by the phosphatidylcholine-specific phospholipase D pathway. Under the same conditions, however, N-acetyldihydrosphingosine and dihydrosphingosine failed to suppress H2O2 release in fMLP-stimulated neutrophils. These findings demonstrate that C-2 ceramides inhibit H2O2 generation in fMLP stimulated neutrophils via protein kinase C- or sphingoid base-independent mechanisms. The effect of ceramide in inhibiting the respiratory burst is structurally specific, because either a 4,5-trans double bond or l-hydroxyl group is required for the inhibition. Therefore, ceramides may regulate oxidant release in adherent neutrophils.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAID NIH HHS [AI26863, AI20065] Funding Source: Medline; NIDDK NIH HHS [DK41487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065, R29AI026863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BABIOR BM, 1981, METHODS HEMATOLOGY L, P1; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CURNUTTE JT, 1979, J CLIN INVEST, V63, P637, DOI 10.1172/JCI109346; DING JB, 1992, J BIOL CHEM, V267, P6442; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P1653; KISS Z, 1990, J BIOL CHEM, V265, P7345; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MULLMANN TJ, 1993, J LEUKOCYTE BIOL, V53, P630, DOI 10.1002/jlb.53.6.630; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHKI K, 1982, BIOCHIM BIOPHYS ACTA, V693, P341, DOI 10.1016/0005-2736(82)90441-2; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; SUCHARD SJ, 1991, J IMMUNOL, V146, P3945; SUCHARD SJ, 1994, J BIOL CHEM, V269, P8063; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WILLSON E, 1986, J BIOL CHEM, V261, P12616; Wilschut J, 1991, MEMBRANE FUSION, P89; WU WI, 1993, J BIOL CHEM, V268, P13830	36	74	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18384	18389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034585				2022-12-27	WOS:A1994NW79800026
J	PARVIN, JD; SHYKIND, BM; MEYERS, RE; KIM, JS; SHARP, PA				PARVIN, JD; SHYKIND, BM; MEYERS, RE; KIM, JS; SHARP, PA			MULTIPLE SETS OF BASAL FACTORS INITIATE TRANSCRIPTION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; ACCURATE INITIATION; LESS PROMOTER; MINIMAL SET; IDENTIFICATION; DNA; GENE; PURIFICATION; COMPONENT	The minimal requirements for transcription initiation from supercoiled templates were determined for the two major forms of TATA-binding factors found in cell extracts, the 300-kDa B-TFIID and the 1000-kDa D-TFIID complexes. As had been observed for the TATA-binding protein (TBP) subunit (Parvin and Sharp, 1993), transcription from the IgH promoter minimally requires TFIID activity plus TFIIB and RNA polymerase II. This minimal reaction is only active on negatively supercoiled template DNA. In contrast, the supercoiled templates encoding the adenovirus major late promoter (MLP), or several other promoters, require the addition of TFIIF to the minimal reaction. Further addition of TFIIE and TFIIH boosts the level of transcription from these latter promoters but is not required. In contrast to the complete reaction on linear template, transcription from supercoiled IgH or MLP templates does not require the hydrolysis of the beta-gamma bond of ATP. Fourteen different core promoters were compared in complete and minimal basal transcription reactions reconstituted with one of the three TATA activities: TBP, B-TFIID, and D-TFIID. Of these 14 promoters, only the IgH was active in the absence of TFIIF, and the other promoters demonstrated different levels of transcription depending on which basal factors were present in reaction. It is proposed that a significant level of basal transcription only requires a minimal set of factors, and stimulation by upstream activators may in part be mediated by the inclusion of additional basal factors into the initiation reaction.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIRD WC, 1994, J BIOL CHEM, V269, P883; Ausubel FM, 1988, MOL REPROD DEV; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	40	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18414	18421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034589				2022-12-27	WOS:A1994NW79800031
J	SAGLIOCCO, FA; ZHU, DL; LASO, MRV; MCCARTHY, JEG; TUITE, MF; BROWN, AJP				SAGLIOCCO, FA; ZHU, DL; LASO, MRV; MCCARTHY, JEG; TUITE, MF; BROWN, AJP			RAPID MESSENGER-RNA DEGRADATION IN YEAST CAN PROCEED INDEPENDENTLY OF TRANSLATIONAL ELONGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; CELL-FREE-EXTRACT; SACCHAROMYCES-CEREVISIAE; CODING REGION; NONSENSE MUTATIONS; POLY(A) TAIL; BETA-TUBULIN; DECAY; GENE	We have exploited a modular cat reporter system (Vega Laso, M. R., Zhu, D., Sagliocco, F A., Brown, A. J. P., Tuite, M. F., and McCarthy, J. E. G. (1993) J. Biol. Chem. 268, 6453-6462) to investigate the relationship between mRNA structure, translation, and stability in the yeast Saccharomyces cerevisiae. The stability of the cat mRNA was not influenced by changes in the length and nucleotide sequence of the 5'-leader, but was affected by the formation of stable 5'-secondary structures (>-15 kcal.mol(-1)). Cat mRNA stability changed only slightly when the CYC1 3'-trailer was replaced with PGK1 sequences, and was influenced by some secondary structures in the 3'-trailer. Secondary structures formed by interactions between the 5'-leader and 3'-trailer increased the stability of the cat mRNA. However, all of the cat mRNAs studied were intrinsically unstable, having half-lives between 4 and 14 min. The translatability of the cat mRNAs did not correlate with their half-life, and their decay was not blocked by cycloheximide. Therefore, the rapid degradation of the cat mRNA does not seem to depend on translational elongation and is not related in any obvious way to the rate of translational initiation. Furthermore, sequences in the 3'-trailer do not program the rapid decay of the cat mRNA. We discuss the implications of these data in the light of current models of mRNA degradation pathways.	UNIV ABERDEEN, MARISCHAL COLL, ABERDEEN AB9 1AS, SCOTLAND; UNIV KENT, BIOL LAB, CANTERBURY CT2 7NJ, KENT, ENGLAND; GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY	University of Aberdeen; University of Kent; Gesellschaft fur Biotechnologische Forschung mbH			Tuite, Mick/ABC-7909-2020; Brown, Alistair J.P./B-6627-2014	Tuite, Mick/0000-0002-5214-540X; 				BRAWERMAN G, 1993, CONTROL MRNA STABILI; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BROWN AJP, 1989, YEAST, V5, P239, DOI 10.1002/yea.320050405; Brown Alistair J. P., 1993, Trends in Cell Biology, V3, P180, DOI 10.1016/0962-8924(93)90206-G; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HARTWELL LH, 1970, MOL GEN GENET, V106, P347, DOI 10.1007/BF00324052; HEATON B, 1992, NUCLEIC ACIDS RES, V20, P5365, DOI 10.1093/nar/20.20.5365; HERRICK D, 1992, GENE, V114, P35, DOI 10.1016/0378-1119(92)90704-S; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LEEDS P, 1991, GENE DEV, V5, P2302; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOSSON R, 1983, EMBO J, V12, P2179; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; PARKER R, 1991, METHOD ENZYMOL, V194, P415; PELSY F, 1984, CURR GENET, V8, P277, DOI 10.1007/BF00419725; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; PELTZ SW, 1993, NATO ASI SERIES H, V71, P1; PURVIS IJ, 1987, NUCLEIC ACIDS RES, V15, P7951, DOI 10.1093/nar/15.19.7951; PURVIS IJ, 1987, NUCLEIC ACIDS RES, V15, P7963, DOI 10.1093/nar/15.19.7963; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SANTIAGO TC, 1987, NUCLEIC ACIDS RES, V15, P2417, DOI 10.1093/nar/15.6.2417; SANTIAGO TC, 1986, NUCLEIC ACIDS RES, V14, P8347, DOI 10.1093/nar/14.21.8347; STEVENS A, 1980, J BIOL CHEM, V255, P3080; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDENHEUVEL JJ, 1990, YEAST, V6, P473, DOI 10.1002/yea.320060604; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; VREKEN P, 1991, BIOCHIMIE, V73, P729, DOI 10.1016/0300-9084(91)90053-4; VREKEN P, 1992, NUCLEIC ACIDS RES, V20, P2503, DOI 10.1093/nar/20.10.2503; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; ZARET KS, 1984, J MOL BIOL, V177, P107, DOI 10.1016/0022-2836(84)90060-3; ZITOMER RS, 1979, P NATL ACAD SCI USA, V76, P3627, DOI 10.1073/pnas.76.8.3627; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18630	18637						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034611				2022-12-27	WOS:A1994NW79800063
J	BARTHOLOMEW, B; BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP				BARTHOLOMEW, B; BRAUN, BR; KASSAVETIS, GA; GEIDUSCHEK, EP			PROBING CLOSE DNA CONTACTS OF RNA-POLYMERASE-III TRANSCRIPTION COMPLEXES WITH THE PHOTOACTIVE NUCLEOSIDE 4-THIODEOXYTHYMIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID COMPLEXES; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; PHOTO-CROSS-LINKING; ENZYME-BOUND P-32; ESCHERICHIA-COLI; NASCENT RNA; 5-AZIDO-2'-DEOXYURIDINE 5'-TRIPHOSPHATE; INTRINSIC PHOTOLABEL; BINDING DOMAIN; 3' END	Photoactive 4-thiodeoxythymidine 5'-triphosphate (4-S-dTTP) has been synthesized and used to enzymatically incorporate the corresponding nucleotide, 4-thiodeoxythymidine 5'-phosphate (4-S-dTMP), at specific positions of the Saccharomyces cerevisiae 5 S rRNA and SUP4 tRNA(Tyr) genes. RNA polymerase III transcription complexes have been assembled on this DNA and analyzed by photocrosslinking for proteins making close contact with DNA. Comparison DNA probes with a long-tether photoactive nucleotide 5-[N-(p-azidobenzoyl)-3-aminoallyl]-dUMP (N(3)RdUMP)(1) incorporated at the same positions have also been analyzed, in order to compare the properties of these two crosslinking reagents. At least 10 of the 16 different S. cerevisiae polymerase III subunits make direct contact with DNA. The 120-kDa subunit of transcription factor (TF)IIIC, which is thought to play the key role in positioning TFIIIB upstream of the transcriptional start site, also contacts DNA near the transcriptional start site in TFIII(C+B) complexes with a SUP4 tRNA(Tyr) gene. The photocrosslinking patterns generated by 4-S-dTMP and N(3)RdUMP are distinctive, implying that these two reagents can yield complementary information about the structures of complex protein assemblies on DNA. Surprisingly, some subunits of the S. cerevisiae RNA polymerase III are crosslinked by 4-S-dTMP but not by N(3)RdUMP.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BEZERRA R, 1990, BIOCHEM BIOPH RES CO, V166, P29, DOI 10.1016/0006-291X(90)91907-A; BOWSER CA, 1991, J MOL BIOL, V220, P227, DOI 10.1016/0022-2836(91)90009-U; BRADLEY DH, 1992, TETRAHEDRON LETT, V33, P6223, DOI 10.1016/S0040-4039(00)60938-3; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DERIEMER LH, 1981, BIOCHEMISTRY-US, V20, P1606, DOI 10.1021/bi00509a030; DERIEMER LH, 1981, BIOCHEMISTRY-US, V20, P1612, DOI 10.1021/bi00509a031; DOSSANTOS DV, 1993, NUCLEIC ACIDS RES, V21, P201; DUBREUIL YL, 1991, NUCLEIC ACIDS RES, V19, P3653; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FAVRE A, 1974, BIOCHEM BIOPH RES CO, V58, P507, DOI 10.1016/0006-291X(74)90394-5; FOURREY JL, 1989, J CHEM SOC CHEM COMM, P1334, DOI 10.1039/c39890001334; FOX JJ, 1959, J AM CHEM SOC, V81, P178, DOI 10.1021/ja01510a042; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P6455, DOI 10.1093/nar/15.16.6455; GRACHEV MA, 1981, FEBS LETT, V130, P23, DOI 10.1016/0014-5793(81)80657-6; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; HANNA MM, 1993, NUCLEIC ACIDS RES, V21, P2073, DOI 10.1093/nar/21.9.2073; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; Hutchinson F., 1980, PROG MOL SUBCELL BIO, V7, P1; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KELLY S, 1990, J BIOL CHEM, V265, P7787; LEE DK, 1991, J BIOL CHEM, V266, P16478; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; NIKIFOROV TT, 1992, NUCLEIC ACIDS RES, V20, P1209, DOI 10.1093/nar/20.6.1209; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; Rahn R.O., 1976, PHOTOCHEM PHOTOBIOL, V2, P97; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; RUSH J, 1990, J BIOL CHEM, V265, P4821; SAFER B, 1988, MOL CELL BIOL, V8, P105, DOI 10.1128/MCB.8.1.105; SCHEIT KH, 1978, NUCLEIC ACID CHEM, P793; SENTENAC A, 1995, TRANSCRIPTIONAL REGU, V1, P27; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P2248, DOI 10.1021/bi00060a017; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P4938, DOI 10.1021/bi00069a031; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; WANG SY, 1976, PHOTOCHEM PHOTOBIOL, V1, P296; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WOODY AYM, 1988, BIOCHEM BIOPH RES CO, V150, P917, DOI 10.1016/0006-291X(88)90716-4; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; [No title captured]	64	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18090	18095						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027070				2022-12-27	WOS:A1994NV42200052
J	PALMER, CNA; HSU, MH; MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF				PALMER, CNA; HSU, MH; MUERHOFF, AS; GRIFFIN, KJ; JOHNSON, EF			INTERACTION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA WITH THE RETINOID-X RECEPTOR-ALPHA UNMASKS A CRYPTIC PEROXISOME PROLIFERATOR RESPONSE ELEMENT THAT OVERLAPS AN ARP-1-BINDING SITE IN THE CYP4A6 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HYDRATASE-DEHYDROGENASE; ACID OMEGA-HYDROXYLASE; FATTY-ACIDS; GENE; HORMONE; SUPERFAMILY; HETERODIMER; UPSTREAM; TRANSCRIPTION; EXPRESSION	P450 4A6 is highly induced by peroxisome proliferators in vivo. Gene transfer experiments indicate that this induction can be mediated by the mouse peroxisome proliferator-activated receptor alpha (PPAR alpha) and that it is dependent on upstream enhancer elements in the CYP4A6 gene. However, as has been seen for other peroxisome proliferator response elements (PPREs), PPAR alpha does not bind directly to a previously characterized PPRE of the CYP4A6 gene in the absence of additional proteins such as the retinoid X receptor alpha (RXR alpha). When PPAR alpha and RXR alpha are coexpressed, the overall transcription of the CYP4A6 reporter is increased, and a synergistic response to both retinoids and peroxisome proliferators is evident that is dependent on the presence of both receptors. In addition, a cryptic response element is unmasked in constructs lacking the upstream enhancers. DNase I protection assays indicate that when present together, but not singly, PPAR alpha and RXR alpha bind to a site located within 29 base pairs upstream of the CYP4A6 transcription start site. This region contains a sequence similar to that found in the apolipoprotein CIII gene that has been shown to bind RXR alpha and the orphan nuclear receptor, ARP-1. The corresponding sequence in the CYP4A6 gene also binds ARP-1. A similar sequence found in the promoter region of the rat CYP4A1 gene does not, however, bind either PPAR alpha/ RXR alpha or ARP-1. Transfection of increasing amounts of the ARP-1 expression vector blocks the PPAR alpha/RXR alpha-mediated induction of transcription from the CYP4A6 promoter. Mutations that prevent the binding of either PPAR alpha/RXR alpha or ARP-1 to a double-stranded oligonucleotide corresponding to the proximal enhancer eliminate the peroxisome proliferator-induced transcriptional response observed for the promoter construct in the presence of PPAR alpha/RXR alpha, but these mutations do not eliminate the response seen when the upstream enhancers are present. These results indicate that the PPREs of the CYP4A6 gene are recognized by multiple members of the nuclear receptor family that are likely to contribute to the regulation of CYP4A6 expression in both an agonistic (RXR alpha) and an antagonistic (ARP-1) manner.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute			Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; ING NH, 1992, J BIOL CHEM, V267, P17617; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MOODY DE, 1991, FUND APPL TOXICOL, V16, P233, DOI 10.1016/0272-0590(91)90108-G; MUERHOFF AS, 1992, ARCH BIOCHEM BIOPHYS, V296, P66, DOI 10.1016/0003-9861(92)90545-8; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1993, ARCH BIOCHEM BIOPHYS, V300, P670, DOI 10.1006/abbi.1993.1093; RAO MS, 1987, CARCINOGENESIS, V8, P631; Sambrook J, 1989, MOL CLONING LABORATO; THOMSON AA, 1990, J BIOL CHEM, V265, P16709; ZHANG BW, 1993, J BIOL CHEM, V268, P12939	27	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18083	18089						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027069				2022-12-27	WOS:A1994NV42200051
J	ADACHI, K; KONITZER, P; PAULRAJ, CG; SURREY, S				ADACHI, K; KONITZER, P; PAULRAJ, CG; SURREY, S			ROLE OF LEU-BETA-88 IN THE HYDROPHOBIC ACCEPTOR POCKET FOR VAL-BETA-6 DURING HEMOGLOBIN-S POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HEMOGLOBINS; AMINO-ACIDS; SOLUBILITY; STABILITY; DEOXYHEMOGLOBIN	X-ray crystallographic studies indicate that the hydrophobic acceptor pocket made by E and F helices involving Leu-beta 88 and Phe-beta 85 is critical for the formation of stable hydrophobic interactions with Val-beta 6 on an adjacent deoxy-hemoglobin (Hb) S tetramer. Ala and Phe substitutions at the beta 88 position in Hb S were made using a yeast expression system in an effort to clarify the role of Leu-beta 88 in creating a suitable acceptor site for Val-beta 6 during polymerization of Hb S. Both Ala- and Phe-beta 88 substitutions in Hb S inhibited polymerization compared with Hb S. Critical concentrations for polymerization of alpha(2) beta(2)(Val-6,Ala-88) and alpha(2) beta(2)(Val-6,Phe-88) were 6- and 10-fold higher, respectively, than that of Hb S (alpha(2) beta(2)(Val-6,Leu-88)). De- oxy-Hb S containing Phe-beta 88 polymerized without a delay time like Trp-beta 6- and Phe-beta 6-substituted hemoglobins (Adachi, K., Konitzer, P., Kim, J., Welch, N., and Surrey, S, (1993) J. Biol. Chem. 268, 21650-21656). In contrast, oversaturated deoxy-Hb S containing Ala-beta 88 also polymerized without a delay time; however, with decreasing hemoglobin concentrations, the kinetics of polymerization were biphasic. At lower hemoglobin concentrations, closer to the critical concentration for polymerization, deoxy-Hb S containing Ala-beta 88 polymerized after a distinct delay time. These results suggest that bulky beta 88 hydrophobic replacements like Phe may sterically inhibit insertion of Val-beta 6 into the acceptor pocket. In contrast, smaller sized, less hydrophobic amino acids like Ala compared with Leu-beta 88 may allow insertion of Val-beta 6 into the acceptor pocket but may not promote stable protein-protein interactions with an adjacent Hb molecule. Stereospecificity and hydrophobicity of the Val-beta 6 hydrophobic acceptor pocket as well as the beta 6 amino acid are, therefore, critical for polymerization of deoxy-Hb S.			ADACHI, K (corresponding author), UNIV PENN,CHILDRENS HOSP,SCH MED,DIV HEMATOL,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL32908, HL38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL032908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, HEMOGLOBIN, V17, P329, DOI 10.3109/03630269308997486; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1980, HEMOGLOBIN, V4, P1, DOI 10.3109/03630268009042370; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1994, J BIOL CHEM, V269, P9562; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; CUO D, 1986, J CHROMATOGR, V359, P499; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1980, BIOPHYS J, V32, P361, DOI 10.1016/S0006-3495(80)84962-9; HOLLENDER A, 1969, NATURE, V222, P953, DOI 10.1038/222953a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OOSAWA F, 1975, MOL BIOL THERMODYNAM; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; TANAKA Y, 1985, HEMOGLOBIN, V9, P157, DOI 10.3109/03630268508996997; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WITKOWSKA HE, 1991, NEW ENGL J MED, V325, P1150, DOI 10.1056/NEJM199110173251607	24	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17477	17480						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021253				2022-12-27	WOS:A1994NU12800024
J	SOYOMBO, AA; DICORLETO, PE				SOYOMBO, AA; DICORLETO, PE			STABLE EXPRESSION OF HUMAN PLATELET-DERIVED GROWTH-FACTOR-B CHAIN BY BOVINE AORTIC ENDOTHELIAL-CELLS - MATRIX ASSOCIATION AND SELECTIVE PROTEOLYTIC CLEAVAGE BY THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; FACTOR-LIKE PROTEIN; HUMAN-TUMOR CELLS; SIS GENE; PDGF-BB; V-SIS; CULTURED-CELLS; MESSENGER-RNA; FACTOR-ALPHA	The localization of platelet-derived growth factor (PDGF) B chain and the regulation of its release by thrombin were investigated in bovine aortic endothelial cells stably transfected with the cDNA for human PDGF B chain (c-sis). Northern blot analysis of c-sis transfected cells revealed increased expression of PDGF B mRNA and constitutive release of 5-10 fold greater amounts of PDGF than in control cells. Incubation with bovine cy-thrombin further induced PDGF release into the conditioned medium. Metabolic labeling of bovine aortic endothelial cells overexpressing c-sis revealed an inefficient rate of constitutive PDGF release, with the majority of newly synthesized PDGF remaining extracellular matrix-associated. Thrombin treatment, however, led to a dramatic increase in the amount of PDGF released into the medium due to selective proteolytic cleavage of matrix-associated precursors. Incubation with a synthetic peptide representing residues 212-230 of precursor PDGF B chain, previously shown to induce the release of PDGF from cell- or matrix-associated heparan sulfate proteoglycans, led to the release of slightly larger species of PDGF which were susceptible to proteolytic cleavage by thrombin in vitro. In addition, PDGF precursors immunoprecipitated from cells were also cleaved by thrombin in vitro. We have demonstrated, using normal diploid endothelial cells overexpressing c-sis, that PDGF B chain is stably expressed as a matrix-associated protein which is either inefficiently released into the medium or cleaved by paracrine proteases such as thrombin. Modulation of PDGF release by selective cleavage of preformed, matrix-bound precursors may represent a significant mechanism for acute regulation of release of this growth factor independent of changes in the rate of synthesis.	CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NHLBI NIH HHS [HL-29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1990, J BIOL CHEM, V265, P5219; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GELEHRTER TD, 1986, J CLIN INVEST, V77, P15; GOSPODAROWICZ D, 1983, J CELL PHYSIOL, V114, P191, DOI 10.1002/jcp.1041140208; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; IGARASHI H, 1987, ONCOGENE, V1, P79; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEVINE JD, 1982, BLOOD, V60, P531; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V1, P173; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SMITS A, 1992, AM J PATHOL, V140, P639; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; STEIN J, 1991, ONCOGENE, V6, P601; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671	59	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17734	17740						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021286				2022-12-27	WOS:A1994NU12800061
J	GOMISRUTH, FX; GRAMS, F; YIALLOUROS, I; NAR, H; KUSTHARDT, U; ZWILLING, R; BODE, W; STOCKER, W				GOMISRUTH, FX; GRAMS, F; YIALLOUROS, I; NAR, H; KUSTHARDT, U; ZWILLING, R; BODE, W; STOCKER, W			CRYSTAL-STRUCTURES, SPECTROSCOPIC FEATURES, AND CATALYTIC PROPERTIES OF COBALT(II), COPPER(II), NICKEL(II), AND MERCURY(II) DERIVATIVES OF THE ZINC ENDOPEPTIDASE ASTACIN - A CORRELATION OF STRUCTURE AND PROTEOLYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-A; 3-DIMENSIONAL STRUCTURE; PSEUDOMONAS-AERUGINOSA; SNAKE-VENOM; PROTEASE; THERMOLYSIN; FAMILY; METAL; AMINOPEPTIDASE; COLLAGENASES	The catalytic zinc ion of astacin, a prototypical metalloproteinase from crayfish, has been substituted by Co(II), Cu(II), Hg(II), and Ni(II) in order to probe the role of the metal for both catalysis and structure. Compared to Zn(II)-astacin, Co(II)- and Cu(II)-astacin display enzymatic activities of about 140 and 37%, respectively, while Ni(II)- and Hg(II)-astacin are almost inactive. The electron paramagnetic resonance spectrum of Cu(II)-astacin is typical of 5-fold coordinated copper(II), and its intense absorption maxima at 445 and 325 nm are probably due to ligand-metal charge-transfer transitions involving Tyr-149. This residue had been identified previously by x-ray crystallography of the zinc enzyme as a zinc ligand, in addition to three imidazoles and a glutamic acid-bound water molecule. We present now the refined high-resolution x-ray crystal structures of Cu(II)-, Co(II), and Ni(II)-astacin, which exhibit a virtually identical protein framework to the previously analyzed structures of Zn(II)-, apo-, and Hg(II)-astacin. In Co(II)- and Cu(II)-astacin, the metal is penta-coordinated similarly to the native zinc enzyme. In the Ni(II) derivative, however, an additional solvent molecule expands the metal coordination sphere to a distorted octahedral ligand geometry, while in Hg(II)-astacin, no ordered solvent molecule at all is observed in the inner coordination sphere of the metal. This indicates a close correlation between catalytic properties and groundstate metal coordination of astacin.	UNIV HEIDELBERG,INST ZOOL,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; TECH UNIV MUNICH,INST ANORGAN CHEM,D-85748 GARCHING,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society; Technical University of Munich			Stöcker, Walter/AAB-9704-2019	Stöcker, Walter/0000-0002-1515-6994; Nar, Herbert/0000-0002-3878-6964; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				AASA R, 1963, BIOCHIM BIOPHYS ACTA, V75, P203, DOI 10.1016/0006-3002(63)90599-7; AISEN P, 1967, J BIOL CHEM, V242, P2484; AULD DS, 1974, BIOCHEMISTRY-US, V13, P4355, DOI 10.1021/bi00718a018; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; AULD DS, 1987, ENZYME MECHANISMS, P240; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bertini I., 1981, MET IONS BIOL SYST, V12, P31; BJARNASON JB, 1983, BIOCHEMISTRY-US, V22, P3770, DOI 10.1021/bi00285a009; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; COLEMAN JE, 1961, J BIOL CHEM, V236, P2244; DUA RD, 1984, BIOCHEM INT, V9, P379; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EIGEN M, 1963, PURE APPL CHEM, V6, P105; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEINBERG H, 1993, J CHEM INF COMP SCI, V33, P501, DOI 10.1021/ci00013a030; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; HARDMAN KD, 1984, J AM CHEM SOC, V106, P463, DOI 10.1021/ja00314a057; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; HOLMQUIST B, 1974, J BIOL CHEM, V249, P4601; Jameson R. F, 1981, MET IONS BIOL SYST, V12, P1; JONES TA, 1978, J APPL CRYSTALLOGR, V15, P23; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LARSEN KS, 1991, BIOCHEMISTRY-US, V30, P2613, DOI 10.1021/bi00224a007; LATT SA, 1971, BIOCHEMISTRY-US, V10, P4263, DOI 10.1021/bi00799a017; Lipscomb W N, 1968, Brookhaven Symp Biol, V21, P24; MARET W, 1993, METHOD ENZYMOL, V226, P52; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MESSERSCHMIDT A, 1990, J APPL CRYSTALLOGR, V23, P436, DOI 10.1107/S0021889890005301; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MORIHARA K, 1975, AGR BIOL CHEM TOKYO, V39, P1123, DOI 10.1080/00021369.1975.10861729; MORIHARA K, 1974, AGR BIOL CHEM TOKYO, V38, P621, DOI 10.1080/00021369.1974.10861191; REES DC, 1986, ZINC ENZYMES, P155; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P2092, DOI 10.1021/ja00841a016; SCHAFFER A, 1986, BIOCHEMISTRY-US, V25, P2476, DOI 10.1021/bi00357a028; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; STOCKER W, 1991, BIOL CHEM H-S, V372, P385, DOI 10.1515/bchm3.1991.372.1.385; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005; VALLEE BL, 1968, CHEM BRIT, V4, P397; VALLEE BL, 1970, PROTEINS, V5, P95; VALLEE BL, 1984, ADV ENZYMOL RELAT AR, V56, P238; WARNER RC, 1953, J AM CHEM SOC, V75, P5094, DOI 10.1021/ja01116a056; WILKES SH, 1987, J BIOL CHEM, V262, P8621; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILLIAMS RPJ, 1994, BIOL CHEM ELEMENTS, P299; WOLZ RL, 1990, ARCH BIOCHEM BIOPHYS, V281, P275, DOI 10.1016/0003-9861(90)90444-4; ZWILLING R, 1981, METHOD ENZYMOL, V80, P633; 1974, HDB CHEM PHYSICS, pF198	59	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17111	17117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006015				2022-12-27	WOS:A1994NT84600022
J	BOQUE, L; COLL, MG; VILANOVA, M; CUCHILLO, CM; FITA, I				BOQUE, L; COLL, MG; VILANOVA, M; CUCHILLO, CM; FITA, I			STRUCTURE OF RIBONUCLEASE-A DERIVATIVE-II AT 2.1-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; MAGNETIC-RESONANCE SPECTROSCOPY; CYTIDYLIC ACID 2'-CMP; X-RAY REFINEMENT; ACTIVE-SITE; CRYSTAL-STRUCTURE; RNASE-A; BINDING; EXISTENCE; COMPLEX	The crystal structure of bovine pancreatic ribonuclease A derivative II, a covalent derivative obtained by reaction of 6-chloropurine 9-beta-D-ribofuranosyl 5'-monophosphate with the Lambda-amino group of Lys-1, has been determined and refined at 2.1-Angstrom resolution with an agreement factor R = 0.166 for 6254 reflections in the resolution shell 8.0 to 2.1 Angstrom. Crystals are orthorhombic and belong to space group C222(1) with unit cell parameters a = 75.73 Angstrom, b = 57.85 Angstrom, and c = 53.26 Angstrom. This crystal packing had never been reported before for pancreatic ribonuclease nor its complexes. The structure found is in accordance with the location of p(2), B-3, and R(3) subsites at the N-terminal region of the protein and provides an explanation of the catalytic behavior observed for this derivative. In particular, differences in kinetic parameters and in the pK(a) value of His-119 between derivative II and native ribonuclease A can be interpreted on the basis of the position of the phosphate moiety within the derivative structure. Some uncertainty remains on the nucleotide sugar conformation determined.	UNIV POLITECN CATALUNYA, DEPT ENGN QUIM, E-08028 BARCELONA, SPAIN; UNIV GIRONA, FAC CIENCIAS EXPTL SALUT, DEPT BIOL, UNITAT BIOQUIM & BIOL MOLEC, E-17071 GIRONA, SPAIN; UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN	Universitat Politecnica de Catalunya; Universitat de Girona; Autonomous University of Barcelona			Vilanova, Maria/ABG-5767-2020; Vilanova, Maria/D-9525-2011	Vilanova, Maria/0000-0003-0523-815X; Vilanova, Maria/0000-0003-0523-815X				AGUILAR CF, 1992, J MOL BIOL, V224, P265, DOI 10.1016/0022-2836(92)90589-C; ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ALONSO J, 1989, INT J PEPT PROT RES, V34, P66; ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARUS C, 1981, BIOCHIM BIOPHYS ACTA, V660, P117, DOI 10.1016/0005-2744(81)90116-9; ARUS C, 1982, BIOCHEMISTRY-US, V21, P4290, DOI 10.1021/bi00261a018; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; Blackburn P, 1982, ENZYMES, VXV, P317; BOIX E, 1994, J BIOL CHEM, V269, P2529; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; BROOKS C, 1986, ANN NY ACAD SCI, V471, P295, DOI 10.1111/j.1749-6632.1986.tb48046.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; DEMEL VSJ, 1992, J BIOL CHEM, V267, P247; Eftink M. R., 1987, HYDROLYTIC ENZYMES, P333; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HAYDOCK K, 1990, J AM CHEM SOC, V112, P3826, DOI 10.1021/ja00166a016; HOWLIN B, 1987, J MOL BIOL, V196, P159, DOI 10.1016/0022-2836(87)90518-3; IRIE M, 1986, J BIOCHEM-TOKYO, V100, P1057, DOI 10.1093/oxfordjournals.jbchem.a121785; IRIE M, 1984, J BIOCHEM-TOKYO, V95, P751, DOI 10.1093/oxfordjournals.jbchem.a134666; IWAHASHI K, 1981, J BIOCHEM-TOKYO, V90, P1685, DOI 10.1093/oxfordjournals.jbchem.a133644; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATTMAN EE, 1970, ACTA CRYSTALL B-STRU, VB 26, P1854, DOI 10.1107/S0567740870004995; LISGARTEN JN, 1993, ACTA CRYSTALLOGR D, V49, P541, DOI 10.1107/S090744499300719X; MARCHIORI F, 1974, INT J PEPT PROT RES, V6, P419; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MITSUI Y, 1978, BIOCHIM BIOPHYS ACTA, V535, P299, DOI 10.1016/0005-2795(78)90096-X; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; PALMER RA, 1984, BIOCHIM BIOPHYS ACTA, V785, P81, DOI 10.1016/0167-4838(84)90237-1; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; PARES X, 1980, INT J PEPT PROT RES, V7, P379; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; RAINES RT, 1991, STRUCTURE, MECHANISM AND FUNCTION OF RIBONUCLEASES, P139; RICHARDS FM, 1973, ATLAS MOL STRUCTURES, V1; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; SAWADA F, 1969, J BIOCHEM-TOKYO, V66, P415, DOI 10.1093/oxfordjournals.jbchem.a129162; TRAUTWEIN K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P53; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WLODAWER A, 1982, J BIOL CHEM, V257, P1325; WODAK SY, 1977, J MOL BIOL, V116, P855, DOI 10.1016/0022-2836(77)90275-3	54	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19707	19712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051049				2022-12-27	WOS:A1994PA12600012
J	HARA, S; MIYATA, A; YOKOYAMA, C; INOUE, H; BRUGGER, R; LOTTSPEICH, F; ULLRICH, V; TANABE, T				HARA, S; MIYATA, A; YOKOYAMA, C; INOUE, H; BRUGGER, R; LOTTSPEICH, F; ULLRICH, V; TANABE, T			ISOLATION AND MOLECULAR-CLONING OF PROSTACYCLIN SYNTHASE FROM BOVINE ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THROMBOXANE SYNTHASE; OXIDE SYNTHASE; CDNA SEQUENCE; EXPRESSION; SITE; BIOSYNTHESIS; PURIFICATION; METABOLISM; PLATELETS; MECHANISM	Prostacyclin synthase catalyzes the conversion of prostaglandin H-2 to prostacyclin, which is a powerful vasodilator and the most potent natural occurring in hibitor of platelet aggregation. In the present study, we determined the amino acid sequence of bovine prostacyclin synthase by combined protein chemical and molecular cloning techniques. The enzyme was purified and characterized from bovine aorta microsomes, and the partial amino acid sequences were determined with the native enzyme and endoproteinase Lys-C-cleaved peptides. Using primers synthesized according to the amino acid sequences, cDNA coding for prostacyclin synthase was amplified by polymerase chain reaction with bovine endothelial cell poly(A)(+) RNA and cloned into pBluescript II. Nucleotide sequence analyses of the cloned cDNA inserts revealed that cDNA for this enzyme contained a 1500-base pair open reading frame coding for a 500-amino acid polypeptide with a M(r) of 56,628. COS-7 cells transfected with an expression plasmid harboring this cDNA clone expressed prostacyclin synthase activity. The primary structure of the enzyme showed structural characteristics of cytochrome P450 and exhibited a 32% identity to that of human cholesterol 7 alpha-hydroxylase. However, the identity between the amino acid sequences of bovine prostacyclin synthase and human thromboxane synthase was only 16%, and no P450 showed an identity higher than 40%, suggesting that prostacyclin synthase represents a new family in the P450 superfamily. RNA blot analysis indicated that the mRNA for prostacyclin synthase from bovine endothe lial cells showed a size of approximately 2.7 kilobases and that the mRNA level increased about 3-fold by treat ment of tumor necrosis factor-alpha.	NATL CARDIOVASC CTR, RES INST, DEPT PHARMACOL, SUITA, OSAKA 565, JAPAN; UNIV KONSTANZ, DEPT BIOL, D-78434 CONSTANCE, GERMANY; MAX PLANCK INST BIOCHEM, GENZENTRUM, D-82152 MARTINSRIED, GERMANY	National Cerebral & Cardiovascular Center - Japan; University of Konstanz; Max Planck Society								BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GOTOH O, 1989, BASIS MECHANISMS REG, P195; GRAF H, 1982, CYTOCHROME P450 BIOC, P103; GRANSTROM E, 1982, METHOD ENZYMOL, V86, P493; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1988, BIOCHEM PHARMACOL, V37, P3363, DOI 10.1016/0006-2952(88)90652-1; HECKER M, 1989, J BIOL CHEM, V264, P141; HECKER M, 1986, EUR J BIOCHEM, V157, P217, DOI 10.1111/j.1432-1033.1986.tb09659.x; Inoue M, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P29; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAWAKAMI M, 1986, BIOCHEM BIOPH RES CO, V141, P482, DOI 10.1016/S0006-291X(86)80198-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; NUSING R, 1990, ARCH BIOCHEM BIOPHYS, V280, P325, DOI 10.1016/0003-9861(90)90337-X; OHASHI K, 1992, J BIOL CHEM, V267, P789; PEREIRA B, 1993, BIOCHEM BIOPH RES CO, V197, P1041, DOI 10.1006/bbrc.1993.2583; SALMON JA, 1982, METHOD ENZYMOL, V86, P91; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TONE Y, 1994, FEBS LETT, V340, P241, DOI 10.1016/0014-5793(94)80146-0; ULLRICH V, 1981, BIOCHEM PHARMACOL, V30, P2033, DOI 10.1016/0006-2952(81)90218-5; ULLRICH V, 1990, ADV PROSTAG THROMB L, V20, P95; ULLRICH V, 1984, TRENDS PHARMACOL SCI, V5, P352, DOI 10.1016/0165-6147(84)90467-X; XIA Z, 1993, BIOCHEM J, V295, P457, DOI 10.1042/bj2950457; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; YOKOYAMA C, 1993, FEBS LETT, V318, P91, DOI 10.1016/0014-5793(93)81335-W; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884	43	115	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19897	19903						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051072				2022-12-27	WOS:A1994PA12600038
J	LEE, KS; PATTON, JL; FIDO, M; HINES, LK; KOHLWEIN, SD; PALTAUF, F; HENRY, SA; LEVIN, DE				LEE, KS; PATTON, JL; FIDO, M; HINES, LK; KOHLWEIN, SD; PALTAUF, F; HENRY, SA; LEVIN, DE			THE SACCHAROMYCES-CEREVISIAE PLB1 GENE ENCODES A PROTEIN REQUIRED FOR LYSOPHOSPHOLIPASE AND PHOSPHOLIPASE-B ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIUM-NOTATUM; PLASMA-MEMBRANES; ESCHERICHIA-COLI; YEAST; PHOSPHATIDYLINOSITOL; PURIFICATION; SEQUENCE; GLYCEROPHOSPHORYLINOSITOL; TRANSFORMATION; TRANSCRIPTION	Several enzymes with lysophospholipase/phospholipase B activity have been described from the budding yeast saccharomyces cerevisiae. In vitro, these enzymes are capable of hydrolyzing all phospholipids that can be extracted from yeast cells. Two forms of the enzyme have been isolated from plasma membranes and a third from culture supernatants and the periplasmic space, but their biological roles have not been determined. These highly glycosylated enzymes were reported to have very similar catalytic properties but differed with respect to apparent molecular weight. We isolated a gene from S. cerevisiae, encoding a protein predicted to share 45% amino acid sequence identity with phospholipase B from penicillium notatum. This yeast gene, designated PLB1, ws mapped to the left arm of chromosome VIII. No residual lysophospholipase/phospholipase B activity was detected upon assay of extracts or culture supernatants of a plb1 Delta mutant. Thus, either the PBL1 gene encodes all of the previously detected isoforms of phospholipase B or its gene product is required for their expression or activation. Deletion of PLB1 did not result in any apparent phenotypic defect, suggesting either that we failed to identify the growth conditions that would betray such a defect or that Plb1p is functionally redundant with another protein, whose activity has gone undetected. A plb1 Delta mutant released wild-type levels of the soluble phosphatidylinositol metabolite glycerophosphoinositol into the growth medium but released greatly reduced levels of the corresponding phosphatidylcholine and phosphatidylethanolamine metabolites. These results indicate that PLB1 is principally responsible for the production of the deacylation products of phosphatidylcholine and phosphatidylethanolamine but not phosphatidylinositol.	JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; GRAZ TECH UNIV, DEPT BIOCHEM, A-8010 GRAZ, AUSTRIA	Johns Hopkins University; Carnegie Mellon University; Graz University of Technology			Henry, Susan/K-5464-2014	Levin, David/0000-0003-0696-2860; Kohlwein, Sepp Dieter/0000-0002-1030-0598	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629, R01GM048533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48533, GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ANGUS WW, 1975, J BIOL CHEM, V250, P22; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; DAUM G, 1982, J BIOL CHEM, V257, P3028; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; KUWABARA Y, 1988, J BIOCHEM, V104, P236, DOI 10.1093/oxfordjournals.jbchem.a122449; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Maniatis T., 1982, MOL CLONING; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; OKUMURA T, 1981, ARCH BIOCHEM BIOPHYS, V211, P419, DOI 10.1016/0003-9861(81)90473-2; PAULTAUF F, 1992, MOL CELLULAR BIOL YE, P415; REARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAITO K, 1991, METHOD ENZYMOL, V197, P446; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Sherman F., 1986, METHODS YEAST GENETI; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; VORBECK ML, 1965, BIOCHEMISTRY-US, V4, P296, DOI 10.1021/bi00878a018; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WITT W, 1982, BIOCHIM BIOPHYS ACTA, V711, P403, DOI 10.1016/0005-2760(82)90054-6; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P108, DOI 10.1016/0005-2760(84)90110-3; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	37	118	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19725	19730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051052				2022-12-27	WOS:A1994PA12600015
J	AUDENAERT, AM; KNOCKAERT, I; COLLEN, D; DECLERCK, PJ				AUDENAERT, AM; KNOCKAERT, I; COLLEN, D; DECLERCK, PJ			CONVERSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 FROM INHIBITOR TO SUBSTRATE BY POINT MUTATIONS IN THE REACTIVE-SITE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ACTING INHIBITOR; ENDOTHELIAL-CELLS; HUMAN-PLASMA; TYPE-1; PROTEIN; SERPINS; GENE; PURIFICATION; MUTAGENESIS; CLONING	Plasminogen activator inhibitor-1 (PAI-1), the main physiological inhibitor of tissue-type plasminogen activator (t-PA), may occur in three interconvertible conformations: active, latent, and substrate. To delineate specific domains in the PAI-1 molecule responsible for its conformational flexibility and associated functional diversity, four mutants of PAI-1 (with the amino acids at positions P-12, P-10, P-8, and P-6, respectively, substituted with proline) were expressed in Escherichia coli, purified, and characterized. Wild-type PAI-1 (wtPAI-1) had a specific activity of 21 +/- 10% (mean +/- S.D., n = 3) of the theoretical maximum value. PAI-1-P-12 (Ala --> Pro at P-12), PAI-1-P-10 (Ser --> Pro at P-10), and PAI-1-P-8 (Thr --> Pro at P-8) had specific activities of 0.06 +/- 0.03% (n = 3), 2.6 +/- 1.0% (n = 4), and 2.7 +/- 1.1% (n = 3), respectively (p < 0.03 versus wtPAI-1). PAI-1-P-6 (Val --> Pro at P-6) had a specific activity of 12 +/- 3.3% (n = 3) of the theoretical maximum value (p = not significant versus wtPAI-1). SDS-polyacrylamide gel electrophoresis of mixtures of wtPAI-1 or PAI-1-P-6 with a 2-fold molar excess of t-PA yielded a mixture of a covalent 110-kDa t-PA PAI-1 complex (15-25%), nonreactive 45 kDa material (44-67%), and a 41-kDa band (18-31%) representing cleaved PAI-1. PAI-1-P-12, PAI-1-P-10, and PAI-1-P-8 behaved as substrates, yielding predominantly the 41-kDa cleavage product (85-91%) and a small amount (9-15%) of nonreactive material. NH2-terminal amino acid sequencing revealed that cleavage occurred at the P-1-P-1' bond (Arg(346)-Met(347)). Incubation of PAI-1-P-12, PAI-1-P-10, or PAI-1-P-8 with a 2-fold molar excess of urokinase-type plas minogen activator, plasmin, or thrombin also primarily generated a 41-kDa cleavage product (62-89%). Incubation of wtPAI-1 and PAI-1-P-6 at 37 degrees C resulted in a loss of inhibitory activity, whereas the substrate behavior of PAI-1-P-12, PAI-1-P-10, and PAI-1-P-8 remained unaltered. Treatment of the three substrate-like mutants with guanidinium Cl did not induce inhibitory activity. In conclusion, point mutations at positions P-12, P-10, and P-8 yield PAI-1 variants with stable substrate properties, which may facilitate more detailed structure/function studies.	KATHOLIEKE UNIV LEUVEN, PHARMACEUT BIOL & PHYTOPHARMACOL LAB, B-3000 LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM	KU Leuven; KU Leuven			Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DECLERCK P J, 1988, Fibrinolysis, V2, P77; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KRUITHOF E K O, 1988, Fibrinolysis, V2, P59; KRUITHOF EKO, 1984, BLOOD, V64, P907; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PERRY DJ, 1989, MOL BIOL MED, V6, P239; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; SPRANG SR, 1992, TRENDS BIOCHEM SCI, V17, P49, DOI 10.1016/0968-0004(92)90495-U; SPRENGERS ED, 1987, BLOOD, V69, P381; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; YORK JD, 1991, J BIOL CHEM, V266, P8495	38	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19559	19564						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034724				2022-12-27	WOS:A1994NY33200056
J	ZUCKER, SD; GOESSLING, W; ZEIDEL, ML; GOLLAN, JL				ZUCKER, SD; GOESSLING, W; ZEIDEL, ML; GOLLAN, JL			MEMBRANE LIPID-COMPOSITION AND VESICLE SIZE MODULATE BILIRUBIN INTERMEMBRANE TRANSFER - EVIDENCE FOR MEMBRANE-DIRECTED TRAFFICKING OF BILIRUBIN IN THE HEPATOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC-MICROSOMAL GLUCURONIDATION; GLUTATHIONE-S-TRANSFERASES; LARGE UNILAMELLAR VESICLES; ACYL CHAIN ORDER; PLASMA-MEMBRANE; RAT-LIVER; PHOSPHATIDYLCHOLINE VESICLES; FATTY-ACIDS; UNCONJUGATED BILIRUBIN; TRANSMEMBRANE MOVEMENT	To characterize the mechanisms underlying intracellular bilirubin transport, stopped-flow fluorometry was utilized to study the effects of membrane vesicle size and lipid composition on the kinetics of unconjugated bilirubin movement between model and native hepatocyte membranes. Bilirubin transfer rates declined asymptotically with increasing donor vesicle diameter, due primarily to a 1.4 kcal.mol(-1) decrease in the entropy of activation for the larger vesicles. The incorporation of phosphatidylethanolamine and phosphatidylserine significantly enhanced the dissociation of bilirubin from phosphatidylcholine vesicles. Cholesterol induced a biphasic effect on the transfer rate constant; an initial decrease in rate from 248 to 217 s(-1) associated with cholesterol:phospholipid ratios up to 20% was followed by a dramatic rise to 312 s(-1) as the cholesterol concentration was increased to 70 mol %. The bilirubin dissociation rate from isolated rat liver endoplasmic reticulum (9.1 s(-1)) was significantly slower than for both basolateral and canalicular plasma membranes, which exhibited rate constants of 11.7 and 25.8 s(-1), respectively. Collectively, these data suggest that the cholesterol:phospholipid ratio is the principal determinant of bilirubin dissociation from membranes. We postulate that the inherent cellular membrane cholesterol gradient in the hepatocyte creates a directed flux of bilirubin from the plasma membrane to the endoplasmic reticulum and represents a potential driving force for intracellular bilirubin transport.	HARVARD UNIV, CTR DIGEST DIS, BOSTON, MA 02115 USA; UNIV PITTSBURGH, PRESBYTERIAN HOSP, SCH MED, DIV RENAL ELECTROLYTE, PITTSBURGH, PA 15213 USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	ZUCKER, SD (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV GASTROENTEROL, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Zucker, Stephen/AAJ-3359-2020	Goessling, Wolfram/0000-0001-9972-1569	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002047, R01DK036887, R01DK043955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36887, DK-43955, DK-02047] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ALMEIDA PFF, 1993, BIOPHYS J, V64, P399, DOI 10.1016/S0006-3495(93)81381-X; ARION WJ, 1989, METHOD ENZYMOL, V174, P58; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bevington P. R, 1969, DATA REDUCTION ERROR; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BLANCKAERT N, 1979, P NATL ACAD SCI USA, V76, P2037, DOI 10.1073/pnas.76.4.2037; BOGGS JM, 1973, CAN J BIOCHEM CELL B, V51, P1451, DOI 10.1139/o73-192; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; BROUILLETTE CG, 1982, BIOCHEMISTRY-US, V21, P4569, DOI 10.1021/bi00262a009; CLARKE RJ, 1989, BIOPHYS CHEM, V34, P225, DOI 10.1016/0301-4622(89)80061-4; COHEN DE, 1989, AM J PHYSIOL, V257, pG1, DOI 10.1152/ajpgi.1989.257.1.G1; DAVIES MA, 1990, BIOCHEMISTRY-US, V29, P4368, DOI 10.1021/bi00470a016; DEMEL RA, 1976, BIOCHIM BIOPHYS ACTA, V457, P109, DOI 10.1016/0304-4157(76)90008-3; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; DEPIERRE JW, 1988, LIVER BIOL PATHOBIOL, P165; DEYOUNG LR, 1988, BIOCHEMISTRY-US, V27, P5281, DOI 10.1021/bi00414a050; DILL KA, 1988, BIOCHEMISTRY-US, V27, P3446, DOI 10.1021/bi00409a048; DOD BJ, 1968, BIOCHIM BIOPHYS ACTA, V150, P397, DOI 10.1016/0005-2736(68)90138-7; Emmelot P, 1974, Methods Enzymol, V31, P75; ENGELMAN DM, 1972, J BIOL CHEM, V247, P3694; ESTEP TN, 1978, BIOCHEMISTRY-US, V17, P1984, DOI 10.1021/bi00603a029; FENSKE DB, 1990, BIOCHEMISTRY-US, V29, P11222, DOI 10.1021/bi00503a010; FRICKER G, 1989, J CLIN INVEST, V84, P876, DOI 10.1172/JCI114248; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; HAAVE NC, 1991, BIOCHIM BIOPHYS ACTA, V1085, P35, DOI 10.1016/0005-2760(91)90229-B; HAHM JS, 1992, J LIPID RES, V33, P1123; HOMMA H, 1986, BIOCHEM J, V235, P763, DOI 10.1042/bj2350763; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLEINFELD AM, 1993, BIOCHEMISTRY-US, V32, P2053, DOI 10.1021/bi00059a024; KORTEN K, 1980, BIOCHIM BIOPHYS ACTA, V599, P271, DOI 10.1016/0005-2736(80)90073-5; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KREMMER T, 1976, BIOCHIM BIOPHYS ACTA, V455, P655, DOI 10.1016/0005-2736(76)90039-0; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J LIPID RES, V32, P329; LENTZ BR, 1981, BIOCHEMISTRY-US, V20, P6803, DOI 10.1021/bi00527a010; LENTZ BR, 1980, BIOCHEMISTRY-US, V19, P1943, DOI 10.1021/bi00550a034; LIGHT WR, 1990, J BIOL CHEM, V265, P15632; LIGHT WR, 1990, J BIOL CHEM, V265, P15623; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; LIVINGSTONE CJ, 1980, BIOCHEMISTRY-US, V19, P4823, DOI 10.1021/bi00562a017; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; MCMULLEN TPW, 1993, BIOCHEMISTRY-US, V32, P516, DOI 10.1021/bi00053a016; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; NAGAOKA S, 1978, J BIOL CHEM, V253, P2005; NEEDHAM D, 1988, BIOCHEMISTRY-US, V27, P4668, DOI 10.1021/bi00413a013; NEIL K, 1980, AM J PHYSIOL, V239, pG439, DOI 10.1152/ajpgi.1980.239.6.G439; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; PASENKIEWICZGIERULA M, 1990, BIOCHEMISTRY-US, V29, P4059, DOI 10.1021/bi00469a006; PIETRANGELO A, 1990, BIOCHEM PHARMACOL, V39, P123, DOI 10.1016/0006-2952(90)90655-5; PRESTI FT, 1982, BIOCHEMISTRY-US, V21, P3831, DOI 10.1021/bi00259a017; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; REINL H, 1992, BIOPHYS J, V61, P1025, DOI 10.1016/S0006-3495(92)81910-0; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10676, DOI 10.1021/bi00499a015; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHUH JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P219, DOI 10.1016/0005-2736(82)90549-1; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; THOMAS PD, 1988, BIOCHEM J, V254, P155, DOI 10.1042/bj2540155; TIPPING E, 1981, BIOCHEM J, V195, P441, DOI 10.1042/bj1950441; TIPPING E, 1976, EUR J BIOCHEM, V67, P583, DOI 10.1111/j.1432-1033.1976.tb10724.x; VILLALAIN J, 1988, BIOCHIM BIOPHYS ACTA, V941, P55, DOI 10.1016/0005-2736(88)90213-1; WHITMER DI, 1984, J BIOL CHEM, V259, P1969; WHITMER DI, 1986, J BIOL CHEM, V261, P7170; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020; ZUCKER SD, 1993, GASTROENTEROLOGY, V104, pA1025	74	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19262	19270						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034688				2022-12-27	WOS:A1994NY33200013
J	GOWDA, LR; SAVITHRI, HS; RAO, DR				GOWDA, LR; SAVITHRI, HS; RAO, DR			THE COMPLETE PRIMARY STRUCTURE OF A UNIQUE MANNOSE/GLUCOSE-SPECIFIC LECTIN FROM FIELD BEAN (DOLICHOS LAB LAB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CONCANAVALIN-A; 3-DIMENSIONAL STRUCTURE; LEGUME LECTINS; VICIA-CRACCA; PROTEINS; CHAIN; BIOSYNTHESIS; MOLECULES; COVALENT	The complete amino acid sequence of two non identical subunits of the glucose/mannose-specific lectin from Dolichos lab lab (field bean) has been determined by sequential Edman analyses of the intact subunits and peptides derived by enzymatic and chemical cleavage. Peptides were purified by reverse phase high performance liquid chromatography and ion pair chromatography. The D. lab lab lectin is a glycoprotein having two polypeptide chains of 132 and 105 amino acid residues. The amino acid sequence of the D. Lab lab lectin is compared with the various lectins of the family Leguminosae. The D. lab lab lectin is the only species of the tribe Phaseoleae that contains two nonidentical subunits of almost equal size and that shows a specificity to glucose/ mannose. The lectin shows a greater homology to the glucose/mannose specific lectins, especially concanavalin A. The unique subunit architecture of the D. lab lab lectin indicates the presence of new post translational cleavage sites.	CENT FOOD TECHNOL RES INST, DEPT BIOCHEM & NUTR, MYSORE 570013, KARNATAKA, INDIA; INDIAN INST SCI, DEPT BIOCHEM, BANGALORE 560012, KARNATAKA, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI); Indian Institute of Science (IISC) - Bangalore			Gowda, Lalitha/C-7644-2009					AITKEN A, 1989, PROTEIN SEQUENCING P, P43; AMBLER R, 1965, METHOD ENZYMOL, V10, P143; BAUMANN C, 1979, FEBS LETT, V102, P216, DOI 10.1016/0014-5793(79)80003-4; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CHANG JY, 1979, BIOCHIM BIOPHYS ACTA, V578, P175, DOI 10.1016/0005-2795(79)90125-9; CUNNINGHAM BA, 1975, J BIOL CHEM, V250, P1503; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; ENFIELD DL, 1980, BIOCHEMISTRY-US, V19, P659, DOI 10.1021/bi00545a009; FORIERS A, 1981, J BIOL CHEM, V256, P5550; HEMPERLY JJ, 1983, TRENDS BIOCHEM SCI, V8, P100, DOI 10.1016/0968-0004(83)90260-8; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HIRANO H, 1992, J BIOCHEM-TOKYO, V111, P754, DOI 10.1093/oxfordjournals.jbchem.a123831; HOPP TP, 1982, J BIOL CHEM, V257, P4473; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; Liener I.E., 1986, LECTINS PROPERTIES F; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; MO H, 1990, LECTINS BIOL BIOCH C, V7, P35; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NUTE PE, 1979, BIOCHEMISTRY-US, V18, P467, DOI 10.1021/bi00570a014; QUINN JM, 1989, PLANT PHYSIOL, V91, P613; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; RUDIGER H, 1977, EUR J BIOCHEM, V72, P317, DOI 10.1111/j.1432-1033.1977.tb11255.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL DJ, 1988, J BIOL CHEM, V263, P14648; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIVAKUMAR N, 1986, J BIOSCIENCE, V10, P95; TROWBRIDGE IS, 1974, J BIOL CHEM, V249, P6004; YANG CY, 1981, H-S Z PHYSIOL CHEM, V362, P1131, DOI 10.1515/bchm2.1981.362.2.1131	32	27	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18789	18793						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034631				2022-12-27	WOS:A1994NX32700018
J	WAKASUGI, K; ISHIMORI, K; IMAI, K; WADA, Y; MORISHIMA, I				WAKASUGI, K; ISHIMORI, K; IMAI, K; WADA, Y; MORISHIMA, I			MODULE SUBSTITUTION IN HEMOGLOBIN SUBUNITS - PREPARATION AND CHARACTERIZATION OF A CHIMERA BETA-ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; QUATERNARY STRUCTURES; CARBON-MONOXIDE; HYBRID HEMOGLOBINS; BINDING-PROPERTIES; ESCHERICHIA-COLI; LASER PHOTOLYSIS; FUNCTIONAL-ROLE; MINI-MYOGLOBIN; LIGAND-BINDING	In the genes of alpha- and beta-subunits of hemoglobin, Go showed that modules F1, F2 + F3, and F4 correspond to exons 1, 2, and 3, respectively (Go, M. (1981) Nature 291, 90). The analysis of the correlation of function with its exon pattern showed that the residues associated with the defined function are concentrated in the specific exons encoding the ''module'' (Eaten, W.A. (1980) Nature 284, 183). To investigate the functional and structural significance of the ''modular structure,'' we engineered a ''chimera'' subunit, in which module F4 of the beta-subunit was replaced by that of the alpha-subunit by use of mutagenesis. The NMR and resonance Raman spectra of the isolated ''chimera beta alpha-subunit'' have revealed that it has a beta-subunit-like heme environmental structure. However, the gel chromatography and NMR spectra of mixtures of the chimera and native subunits clearly showed that the chimera beta alpha-subunit binds specifically to the beta-subunit to form a heterotetramer, not to the alpha-subunit. These results led us to conclude that the predominant role of the module F4 is the subunit association and suggest that the modules are structural and functional units that have advantages in producing stable functional proteins.	KYOTO UNIV,GRAD SCH ENGN,DIV MOLEC ENGN,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSICOCHEM PHYSIOL,OSAKA 565,JAPAN; OSAKA MED CTR,OSAKA 59002,JAPAN; RES INST MATERNAL & CHILD HLTH,OSAKA 59002,JAPAN	Kyoto University; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases			Ishimori, Koichiro/AAQ-4434-2021; Ishimori, Koichiro/S-1247-2016; Wakasugi, Keisuke/AAQ-1642-2020	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Wakasugi, Keisuke/0000-0002-8408-5616				ANTONINI E, 1970, HEMOGLOBIN MYOGLOBIN; CRAIK CS, 1980, P NATL ACAD SCI-BIOL, V77, P1384, DOI 10.1073/pnas.77.3.1384; CRAIK CS, 1981, NATURE, V291, P87, DOI 10.1038/291087a0; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; DESANCTIS G, 1986, J MOL BIOL, V188, P73, DOI 10.1016/0022-2836(86)90481-X; DESANCTIS G, 1991, J MOL BIOL, V222, P637, DOI 10.1016/0022-2836(91)90501-V; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DIIORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025, DOI 10.1073/pnas.90.5.2025; EATON WA, 1980, NATURE, V284, P183, DOI 10.1038/284183a0; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; GERACI G, 1969, J BIOL CHEM, V244, P4664; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HORI H, 1980, J AM CHEM SOC, V102, P3608, DOI 10.1021/ja00530a049; IMAI K, 1994, METHOD ENZYMOL, V232, P559; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1991, J MOL BIOL, V218, P769, DOI 10.1016/0022-2836(91)90265-8; Imai K, 1981, Methods Enzymol, V76, P438; Imai K., 1982, ALLOSTERIC EFFECTS H; ISHIMORI K, 1986, BIOCHEMISTRY-US, V25, P4892, DOI 10.1021/bi00365a025; ISHIMORI K, 1988, BIOCHEMISTRY-US, V27, P4060, DOI 10.1021/bi00411a023; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; KILMARTIN JV, 1973, J BIOL CHEM, V248, P7039; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KONKEL DA, 1978, CELL, V15, P1125, DOI 10.1016/0092-8674(78)90040-5; LAMAR GN, 1973, NMR PARAMAGNETIC MOL, pCH3; LEDER A, 1978, P NATL ACAD SCI USA, V75, P6187, DOI 10.1073/pnas.75.12.6187; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LINDSTROM TR, 1972, BIOCHEMISTRY-US, V11, P1677, DOI 10.1021/bi00759a023; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MIMS MP, 1983, J BIOL CHEM, V258, P4219; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NISHIOKA Y, 1979, CELL, V18, P875, DOI 10.1016/0092-8674(79)90139-9; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PHILO JS, 1988, J BIOL CHEM, V263, P682; REISBERG PI, 1980, J BIOL CHEM, V255, P4151; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; VALDES R, 1977, J BIOL CHEM, V252, P74; WADA Y, 1989, MASS SPECTROM REV, V8, P379, DOI 10.1002/mas.1280080504; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493	50	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18750	18756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034628				2022-12-27	WOS:A1994NX32700013
J	BARONDELAGE, S; CAPEAU, J; BARBU, V; CHASTRE, E; LEVY, P; GESPACH, C; CHERQUI, G				BARONDELAGE, S; CAPEAU, J; BARBU, V; CHASTRE, E; LEVY, P; GESPACH, C; CHERQUI, G			REDUCED INSULIN-RECEPTOR EXPRESSION AND FUNCTION IN HUMAN COLONIC CACO-2 CELLS BY RAS AND POLYOMA MIDDLE-T ONCOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; MEDIATED SIGNAL-TRANSDUCTION; PHORBOL ESTERS; GLUCOSE-TRANSPORT; TYROSINE KINASE; MESSENGER-RNA; EPITHELIAL-CELLS; GENE-EXPRESSION; HEPATOMA-CELLS	Taking advantage of the potent mitogenic effect exerted by insulin in human colonic cells, we used Caco-2 cells transfected with an activated (Val-12) human Ha-ras gene or the polyoma middle T (PyMT) oncogene, a constitutive activator of pp60(c-src)tyrosine kinase activity, to investigate the effect of oncogenic p21(ras) and PyMT/ pp60(c-src) on insulin mitogenic signaling. As compared to vector control Caco-2 cells, both oncogene-transfected cells exhibited: 1) a loss of response to insulin's stimulatory effect on mitogen-activated protein (MAP) kinase activity and cell proliferation, both of which were constitutively increased; 2) a decrease in insulin receptor (IR) affinity and insulin-stimulated exogenous tyrosine kinase activity, which resulted from increased protein kinase C (PKC) activity (Delage, S., Chastre, E., Empereur, S., Wicek, D., Veissiere, D., Capeau, J., Gespach, C., and Cherqui, G. (1993) Cancer Res. 53, 2762-2770), since IR alterations were corrected by PKC down-regulation; and 3) a decrease in both IR mRNA level and IR number, which was independent of PKC since it persisted after PKC down-regulation. In conclusion, this is the first evidence that oncogenic p21(ras) and PyMT/ pp60(c-src) abolish insulin mitogenic signaling in human colonic cells through mechanisms involving (i) constitutive activation of MAP kinase and (ii) marked decreases in both IR function and expression which are mediated by PKC-dependent and PKC-independent pathways, respectively.	UNIV PARIS 06,INSERM,U402,BIOL CELLULAIRE LAB,F-75571 PARIS 12,FRANCE; INSERM,U55,EQUIPE CANCEROGENESE & DIFFERENCIAT EPITHELIUM GA,F-75571 PARIS 12,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)			CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHN JC, 1993, J BIOL CHEM, V268, P7571; ANDERSON CM, 1991, J BIOL CHEM, V266, P21760; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBU V, 1993, EXP CLIN ENDOCRINOL, V101, P84; BINOUX M, 1986, J CLIN ENDOCR METAB, V63, P1151, DOI 10.1210/jcem-63-5-1151; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAPEAU J, 1982, ENDOCRINOLOGY, V111, P993, DOI 10.1210/endo-111-3-993; CARON M, 1994, IN PRESS METABOLISM; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CEZARD JP, 1981, CANCER RES, V41, P1148; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; COGHLAN MP, 1993, BIOCHEM BIOPH RES CO, V193, P371, DOI 10.1006/bbrc.1993.1633; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELAGE S, 1993, CANCER RES, V53, P2762; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P153; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; HARING H, 1986, J BIOL CHEM, V261, P3869; JELINEK MA, 1992, ONCOGENE, V7, P1687; KIRSCH D, 1985, BIOCHEM BIOPH RES CO, V128, P824, DOI 10.1016/0006-291X(85)90121-4; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KULL FC, 1983, J BIOL CHEM, V258, P6561; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEVY JR, 1992, J BIOL CHEM, V267, P25289; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOUNTJOY KG, 1990, BIOCHEM BIOPH RES CO, V169, P978, DOI 10.1016/0006-291X(90)91990-A; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PILLION DJ, 1985, J BIOL CHEM, V260, P5244; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAPP UR, 1991, ONCOGENE, V6, P495; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SETH A, 1992, J BIOL CHEM, V267, P24796; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; THOMASKA L, 1993, BIOCHEM J, V293, P215; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696	60	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18686	18693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034618				2022-12-27	WOS:A1994NW79800072
J	SUN, JY; KALE, SP; CHILDRESS, AM; PINSWASDI, C; JAZWINSKI, SM				SUN, JY; KALE, SP; CHILDRESS, AM; PINSWASDI, C; JAZWINSKI, SM			DIVERGENT ROLES OF RAS1 AND RAS2 IN YEAST LONGEVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN-DIPLOID FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; GENETIC-ANALYSIS; LIFE-SPAN; SENESCENCE; CELLS	Individual cells of the yeast Saccharomyces cerevisiae have a limited replicative life-span. The role of the genes RAS1 and RAS2 in yeast longevity was examined. Overexpression of RAS2 led to a 30% increase in the life-span on average and postponed the senescence related increase in generation time seen during yeast aging. No life-span extension was obtained by overexpression of RAS1. However, deletion of RAS1 prolonged the life-span. These results suggest that RAS1 and RAs2 play reciprocal roles in determining yeast longevity. RAS1 and RAS2 mRNA and protein levels declined with replicative age, suggesting a diminishing impact on yeast longevity. The major known pathway through which Ras proteins function in yeast involves stimulation of adenylate cyclase. No evidence for a life-span-extending effect of elevated intracellular cAMP was found. Indeed, high intracellular cAMP was associated with curtailed lifespan. A similar decrease in life-span was found on disruption of BCY1, which codes for the regulatory subunit of protein kinase A, the downstream target of cAMP. Importantly overexpression of an effector domain mutant of RAS2, defective in stimulation of adenylate cyclase, prolonged life-span to the same extent as the wild-type gene, suggesting that the cAMP pathway is neither sufficient nor necessary for increased longevity.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,CTR AGING,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System								BOWEN HJ, 1993, FOCUS, V15, P32; BREVIARIO D, 1986, P NATL ACAD SCI USA, V83, P4152, DOI 10.1073/pnas.83.12.4152; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHEN JB, 1909, MOL MICROBIOL, V4, P2081; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; EGILMEZ NK, 1989, J BIOL CHEM, V264, P14312; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, GENETICS, V118, P75; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HAWKINS PT, 1993, J BIOL CHEM, V268, P3374; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAZWINSKI SM, 1990, MOL MICROBIOL, V4, P337, DOI 10.1111/j.1365-2958.1990.tb00601.x; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; LEVIN DE, 1993, J NIH RES, V5, P49; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MATSUMOTO K, 1983, EXP CELL RES, V146, P151, DOI 10.1016/0014-4827(83)90333-6; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MOTIZUKI M, 1992, BIOCHEM BIOPH RES CO, V183, P1191, DOI 10.1016/S0006-291X(05)80316-X; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; Parent S A, 1985, Yeast, V1, P83, DOI 10.1002/yea.320010202; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Sambrook J, 1989, MOL CLONING LABORATO; SIKORSKI RS, 1989, GENETICS, V122, P19; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	47	146	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18638	18645						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034612				2022-12-27	WOS:A1994NW79800064
J	CHANG, ZF; LIU, CJ				CHANG, ZF; LIU, CJ			HUMAN THYMIDINE KINASE CCAAT-BINDING PROTEIN IS NF-Y, WHOSE A-SUBUNIT EXPRESSION IS SERUM-DEPENDENT IN HUMAN IMR-90 DIPLOID FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CLASS-II; GENE; PROMOTER; IDENTIFICATION; BOX; ELEMENT; NUCLEI; SITE	The nuclear protein interacting with the distal CCAAT box of human thymidine kinase (TK) gene promoter has been suggested to be a specific TK-CCAAT-binding protein, which is responsible for the serum dependence of TK transactivation in normal human IMR-90 fibroblasts. By biochemical characterization, TK-CCAAT-binding protein was found to be distinct from other known CCAAT-binding proteins (Pang, J. H., and Chen, K. Y. (1993) J. Biol. Chem. 268, 2909-2916). In this study, we identify NF-Y, which is composed of Ya and Yb subunits, to be responsible for the TK-CCAAT binding activity in the crude nuclear extract from HL-60 cells. The interaction of NF-Y with the distal CCAAT box of the TK promoter in the crude extract appeared to be more heat-sensitive than that in the DNA affinity chromatography purified fraction. We have further established that the serum dependence of TK-CCAAT binding activity in normal IMR-90 fibroblasts is due to the decrement of NF-Ya, but not NF-Yb expression following serum-deprivation, and that such serum dependence is absent in HL-60 cells.			CHANG, ZF (corresponding author), CHANG GUNG COLL MED & TECHNOL,DEPT BIOCHEM,259 WEN HWA 1 RD,TAYUAN,TAIWAN.							CHANG ZF, 1993, CANCER RES, V53, P3253; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIM YK, 1992, J BIOL CHEM, V267, P2723; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PANG JH, 1993, J BIOL CHEM, V268, P2909; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203	24	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17893	17898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027044				2022-12-27	WOS:A1994NV42200024
J	NODA, M; KATOH, T; TAKUWA, N; KUMADA, M; KUROKAWA, K; TAKUWA, Y				NODA, M; KATOH, T; TAKUWA, N; KUMADA, M; KUROKAWA, K; TAKUWA, Y			SYNERGISTIC STIMULATION OF PARATHYROID HORMONE-RELATED PEPTIDE GENE-EXPRESSION BY MECHANICAL STRETCH AND ANGIOTENSIN-II IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMORAL HYPERCALCEMIA; CARDIAC MYOCYTES; POTASSIUM CHANNELS; SYNTHETIC PEPTIDE; HUMAN-TUMOR; RECEPTOR; MALIGNANCY; INVITRO; PHOSPHORYLATION	Repetitive cyclic stretch (60 cycles/min) of rat aortic smooth muscle cells dramatically enhances the effect of angiotensin II (AII) on mRNA expression of the vasorelaxant, parathyroid hormone-related peptide (PTHrP). Thus, combined stimulation of rat aortic smooth muscle cells by cyclic stretch and low concentrations of AII, but not either alone, induces a synergistic, marked increase in the PTHrP mRNA level, in a manner dependent on the strength of stretch, This response is accompanied by a synergistic increase in secretion of PTHrP from smooth muscle cells. Removal of extracellular Ca2+ or addition of Ca2+ channel blockers, including Gd3+ and nitrendipine, does not considerably reduce the combined effects of stretch and AII, indicating that this response is not dependent on stretch-induced Ca2+ influx across the plasma membrane. The combined effect of stretch and AII on PTHrP mRNA expression is strongly attenuated by the protein kinase C (PKC) inhibitor staurosporine or by down-regulation of PKC, suggesting that PKC plays an important role in the synergistic response. However, stretch neither elicits activation of phospholipase C or PKC by itself, nor does it enhance AII-induced activation of these enzymes. These results indicate that in vascular smooth muscle cells mechanical stretch acts together with the vasoconstrictor AII to regulate the expression of the vasodilator PTHrP and suggest the role of PTHrP as a local modulator of myogenic tone.	UNIV TOKYO,SCH MED,DEPT CARDIOVASC BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,SCH MED,DEPT INTERNAL MED,TOKYO 113,JAPAN; UNIV TOKYO,SCH MED,DEPT PHYSIOL,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo				TAKUWA, Noriko/0000-0002-4278-2704				ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BAYLISS WM, 1903, J PHYSIOL-LONDON, V28, P330; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; EXTON JH, 1990, J BIOL CHEM, V265, P1; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1993, J BIOL CHEM, V268, P1174; JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KARAPLIS AC, 1990, MOL ENDOCRINOL, V4, P441, DOI 10.1210/mend-4-3-441; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1929; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MUSSO MJ, 1989, EUR J PHARMACOL, V174, P139, DOI 10.1016/0014-2999(89)90306-3; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1993, TRENDS CARDIOVAS MED, V3, P54, DOI 10.1016/1050-1738(93)90037-7; NICHOLS GA, 1990, ENDOCRINOLOGY, V126, P721; NICKOLS GA, 1989, ENDOCRINOLOGY, V125, P834, DOI 10.1210/endo-125-2-834; NODA M, 1993, BIOCHEM PHARMACOL, V46, P311; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; PIROLA CJ, 1993, J BIOL CHEM, V268, P1987; ROCACUSACHS A, 1991, J PHARMACOL EXP THER, V256, P110; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; THIEDE MA, 1990, P NATL ACAD SCI USA, V87, P6969, DOI 10.1073/pnas.87.18.6969; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; TRIZNA W, 1991, PHARMACOLOGY, V42, P91, DOI 10.1159/000138778; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WINQUIST RJ, 1987, BIOCHEM BIOPH RES CO, V149, P227, DOI 10.1016/0006-291X(87)91628-7; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406; ZHOU W, 1993, J BIOL CHEM, V268, P23041	45	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17911	17917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027047				2022-12-27	WOS:A1994NV42200027
J	MALANGA, M; ALTHAUS, FR				MALANGA, M; ALTHAUS, FR			POLY(ADP-RIBOSE) MOLECULES FORMED DURING DNA-REPAIR IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY ADP-RIBOSYLATION; STRAND BREAKS; EXCISION REPAIR; MAMMALIAN-CELLS; RIBOSE POLYMERS; RECOGNITION; CHROMATIN; PROTEINS; HISTONES; INVITRO	We have found that human cells respond to treatment with an alkylating carcinogen by producing a specific, highly conserved array of poly(ADP-ribose) molecules. Using in situ radiolabeling and boronate affinity chromatography, we have been able to isolate ADP-ribose polymers from living cells and to quantify individual molecular size classes on high resolution polyacrylamide gels. Despite carcinogen-induced changes in poly(ADP-ribose) turnover, the relative frequency of linear polymers was strictly conserved. However, the abundance of branched polymers with high affinity for histones increased 2.6-fold. These polymers mere degraded more slowly than linear polymers. Our results indicate that the poly(ADP-ribose) molecules involved in the shuttling of histones on DNA in vitro also play a role in the repair of DNA damage in vivo.	UNIV ZURICH, TIERSPITAL, INST PHARMACOL & TOXICOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich								ABOULELA N, 1988, ANAL BIOCHEM, V174, P239, DOI 10.1016/0003-2697(88)90541-6; ALTHAUS FR, 1992, J CELL SCI, V102, P663; ALTHAUS FR, 1982, J BIOL CHEM, V257, P5528; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; ALVAREZGONZALEZ R, 1986, ANAL BIOCHEM, V156, P473, DOI 10.1016/0003-2697(86)90281-2; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BORENFREUND E, 1990, IN VITRO CELL DEV B, V26, P1030; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRADBURY EM, 1975, EUR J BIOCHEM, V57, P521, DOI 10.1111/j.1432-1033.1975.tb02327.x; Burton K., 1968, METHODS ENZYMOLOGY B, V12B, P163; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JACOBSON MK, 1984, METHOD ENZYMOL, V106, P483; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KIEHLBAUCH CC, 1993, ANAL BIOCHEM, V208, P26, DOI 10.1006/abio.1993.1004; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MATHIS G, 1987, BIOCHEM BIOPH RES CO, V143, P1049, DOI 10.1016/0006-291X(87)90358-5; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; REALINI CA, 1992, J BIOL CHEM, V267, P18858; SCOVASSI AI, 1993, EXP CELL RES, V206, P177, DOI 10.1006/excr.1993.1135; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; THIERRY D, 1985, RADIAT RES, V102, P347, DOI 10.2307/3576710; THOMA F, 1983, J MOL BIOL, V167, P619, DOI 10.1016/S0022-2836(83)80102-8; WIELCKENS K, 1981, EUR J BIOCHEM, V117, P69; ZHANG J, 1989, ADP RIBOSE TRANSFER, P145	35	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17691	17696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021281				2022-12-27	WOS:A1994NU12800055
J	PALOKANGAS, H; METSIKKO, K; VAANANEN, K				PALOKANGAS, H; METSIKKO, K; VAANANEN, K			ACTIVE VACUOLAR H(+)ATPASE IS REQUIRED FOR BOTH ENDOCYTIC AND EXOCYTIC PROCESSES DURING VIRAL-INFECTION OF BHK-21-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI FOREST VIRUS; ADP-RIBOSYLATION FACTOR; VESICULAR STOMATITIS-VIRUS; CANINE KIDNEY-CELLS; GOLGI-COMPLEX; H+-ATPASE; MEMBRANE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; DIPHTHERIA-TOXIN; G PROTEIN	Bafilomycin A(1) (Baf), a specific inhibitor of the vacuolar-type proton pump, inhibited the entry of Semliki Forest virus and vesicular stomatitis virus into BHK-21 cells. The inhibition occurred at concentrations that dissipated intracellular acidic compartments. Viral infection was totally inhibited by 30 nM Baf while endocytosis of the virus or fluorescein isothiocyanate dextran was not affected. Thus, a vacuolar-type proton pump was responsible for acidification of the endosomes needed for virus entry. When the cells were exposed to 100 nM Eaf after virus entry, viral glycoprotein synthesis continued normally. The viral glycoproteins acquired resistance to endoglycosidase H, indicating arrival in the medial Golgi apparatus. However, maturation processes occurring in the trans-Golgi compartment were inhibited, and the amounts of viral glycoproteins appearing at the cell. surface were reduced. Double immunofluorescence studies showed that in the presence of Baf the viral glycoproteins were found in and around mannosidase II-positive Golgi structures. To analyze whether Baf blocked transport from the trans-Golgi compartment to the cell surface, the viral glycoproteins were allowed to accumulate in the trans-Golgi network by utilizing a 20 degrees C block. Subsequent incubation at 37 degrees C in the presence of Baf did not inhibit the terminal maturation processes or transport to the cell surface, suggesting that the block was before the trans-Golgi network. These results indicate that an active vacuolar-type proton pump in the Golgi apparatus is essential for protein transport in BHK-21 cells.			PALOKANGAS, H (corresponding author), UNIV OULU, DEPT ANAT, KAJAANINTIE 52A, SF-90220 OULU, FINLAND.							ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BALCH WE, 1986, J BIOL CHEM, V261, P4690; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARON MD, 1990, J BIOL CHEM, V265, P19928; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; HARE JF, 1989, BIOCHEMISTRY-US, V28, P574, DOI 10.1021/bi00428a024; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; KAARIAINEN L, 1982, GLYCOCONJUGATES, V4, P191; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; METSIKKO K, 1990, J VIROL, V64, P4678; METSIKKO K, 1992, J CELL BIOL, V117, P987, DOI 10.1083/jcb.117.5.987; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PESONEN M, 1984, J CELL BIOL, V99, P803, DOI 10.1083/jcb.99.3.803; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; UMATA T, 1990, J BIOL CHEM, V265, P21940; WAHLBERG JM, 1989, J VIROL, V63, P4991, DOI 10.1128/JVI.63.12.4991-4997.1989; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	38	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17577	17585						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021266				2022-12-27	WOS:A1994NU12800039
J	WATANABE, T; INUI, M; CHEN, BY; IGA, M; SOBUE, K				WATANABE, T; INUI, M; CHEN, BY; IGA, M; SOBUE, K			ANNEXIN-VI-BINDING PROTEINS IN BRAIN - INTERACTION OF ANNEXIN VI WITH A MEMBRANE SKELETAL PROTEIN, CALSPECTIN (BRAIN SPECTRIN OR FODRIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; NON-ERYTHROID SPECTRIN; BETA-SPECTRIN; ACTIN-BINDING; CALCIUM-BINDING; ALPHA-FODRIN; F-ACTIN; CELLULAR-DISTRIBUTION; PLASMA-MEMBRANE; SECRETORY-CELLS	Identification of annexin VI-binding proteins is essential to elucidate the physiological functions of annexin VI. Here, we developed the methods to identify an annexin VI-binding protein and characterized the binding. Annexin VI bound to about 14 species of proteins in the whole homogenate of rat forebrain, when examined with I-125-annexin VI using blots of SDS-polyacrylamide gels. The binding was Ca2+-dependent and specific for phosphatidylserine (PS) and phosphatidic acid. A line of evidence indicates that the binding of annexin VI to its target proteins is a protein-protein interaction. One of annexin VI-binding proteins with M(r) 240,000 was enriched in the cytoskeletal fraction and was identified as calspectin (brain spectrin or fodrin). When the binding was examined with purified calspectin in the native state, the Ca2+ affinity (K-Ca) was 7.6 mu M, and the affinity for annexin VI (K-d) was 68 nM. Annexin VI bound to beta subunit of calspectin, but not to alpha subunit. The binding site was localized to the NH2-terminal domain of beta subunit, which contains an actin-binding site and exhibits striking homology with the NH2-terminal regions of dystrophin and alpha-actinin. When the effect of annexin VI on the interaction between F-actin and calspectin was examined by low shear viscometry, annexin VI inhibited the F-actin cross-linking activity of calspectin in a Ca2+/PS dependent manner. Cosedimentation assay showed that annexin VI dissociates calspectin from F-actin in the presence of Ca2+ and PS. These results suggest that annexin VI can dissociate and redistribute calspectin in a Ca2+/phospholipid-dependent manner under the plasma membrane and that annexin VI may be involved in the regulation of the membrane skeleton of neuronal cells in response to Ca2+.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT NEUROCHEM & NEUROPHARMACOL, SUITA, OSAKA 565, JAPAN	Osaka University								ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; AUNIS D, 1988, J EXP BIOL, V139, P253; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRENNER SL, 1979, J BIOL CHEM, V254, P8620; BURRIDGE K, 1982, J CELL BIOL, V95, P478, DOI 10.1083/jcb.95.2.478; CALVERT R, 1980, EUR J BIOCHEM, V107, P355; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHENEY RE, 1989, J BIOL CHEM, V264, P18068; COLEMAN TR, 1987, J CELL BIOL, V104, P519, DOI 10.1083/jcb.104.3.519; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P248, DOI 10.1002/cm.970120406; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GEISOW M, 1984, EMBO J, V3, P2969, DOI 10.1002/j.1460-2075.1984.tb02242.x; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HAYASHI H, 1989, J BIOL CHEM, V264, P17222; HOSOYA H, 1992, CELL MOTIL CYTOSKEL, V22, P200, DOI 10.1002/cm.970220307; HU RJ, 1992, J BIOL CHEM, V267, P18715; KAKIUCHI S, 1981, FEBS LETT, V132, P144, DOI 10.1016/0014-5793(81)80449-8; KAKIUCHI S, 1982, BIOCHEM INT, V5, P755; KANDA K, 1986, BIOCHEM BIOPH RES CO, V140, P1051, DOI 10.1016/0006-291X(86)90741-2; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1989, ANNU REV CELL BIOL, V5, P427; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; LEHTO VP, 1983, EMBO J, V2, P1701, DOI 10.1002/j.1460-2075.1983.tb01645.x; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG S, 1992, BIOCHEMISTRY-US, V31, P5665, DOI 10.1021/bi00139a034; MANGEAT PH, 1988, BIOL CELL, V64, P261, DOI 10.1016/0248-4900(88)90001-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; NELSON WJ, 1983, P NATL ACAD SCI-BIOL, V80, P363, DOI 10.1073/pnas.80.2.363; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; REPASKY EA, 1982, CELL, V29, P821, DOI 10.1016/0092-8674(82)90444-5; RHOADS AR, 1985, BIOCHEM J, V229, P587, DOI 10.1042/bj2290587; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SOBUE K, 1990, NEUROSCI RES, pS80, DOI 10.1016/0921-8696(90)90035-2; SOBUE K, 1982, FEBS LETT, V148, P221, DOI 10.1016/0014-5793(82)80811-9; SOBUE K, 1988, P NATL ACAD SCI USA, V85, P482, DOI 10.1073/pnas.85.2.482; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOLL G, 1988, NEUROSCI LETT, V86, P27, DOI 10.1016/0304-3940(88)90177-2; SUDHOF TC, 1984, BIOCHEMISTRY-US, V23, P1103; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TSUKITA S, 1983, J CELL BIOL, V97, P574, DOI 10.1083/jcb.97.2.574; TYLER JM, 1980, J BIOL CHEM, V255, P7034; WALLIS CJ, 1992, J BIOL CHEM, V267, P4333; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WOOLGAR JA, 1990, J NEUROCHEM, V54, P62, DOI 10.1111/j.1471-4159.1990.tb13283.x	77	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17656	17662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021276				2022-12-27	WOS:A1994NU12800050
J	BRUNETTI, CR; BURKE, RL; KORNFELD, S; GREGORY, W; MASIARZ, FR; DINGWELL, KS; JOHNSON, DC				BRUNETTI, CR; BURKE, RL; KORNFELD, S; GREGORY, W; MASIARZ, FR; DINGWELL, KS; JOHNSON, DC			HERPES-SIMPLEX VIRUS GLYCOPROTEIN-D ACQUIRES MANNOSE B-PHOSPHATE RESIDUES AND BINDS TO MANNOSE 6-PHOSPHATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; ACANTHAMOEBA-CASTELLANII; LINKED OLIGOSACCHARIDES; HEPARAN-SULFATE; SHEEP SERUM; AIDS VIRUS; TYPE-1; PROTEIN; ENTRY; EXPRESSION	Herpes simplex viruses (HSV) use multiple and sequential receptors to enter host cells. HSV glycoprotein D (gD) has been implicated in binding to cellular receptors that facilitate virus penetration into cells. We used soluble forms of gD that were expressed in Chinese hamster ovary cells to characterize and identify a putative cellular receptor for HSV as the 275-kDa mannose 6-phosphate/insulin-like growth factor II receptor. Soluble gD also bound to the 46-kDa cation-dependent mannose 6-phosphate (Man-6-P) receptor and was extensively modified with Man-6-P residues on its Asn-linked oligosaccharides. Additionally, soluble gD was a high affinity substrate for N-acetylglucosamine-1-phosphotransferase, the first enzyme in the biosynthetic pathway for the addition of Man-6-P residues to lysosomal enzymes. The membrane form of gD immunoprecipitated from HSV-infected cells also bound to the 275-kDa mannose 6-phosphate/insulin-like growth factor II receptor, albeit poorly, and only a small fraction of the membrane gD was modified with Man-6-P. Notwithstanding this low level of mannose phosphorylation, the interaction between gD and Man-6-P receptors may play a role in some aspect of virus entry or egress.	MCMASTER UNIV, DEPT PATHOL, MOLEC VIROL & IMMUNOL PROGRAM, HAMILTON L8N 3Z5, ON, CANADA; CHIRON CORP, EMERYVILLE, CA 94608 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	McMaster University; Novartis; Washington University (WUSTL)					NCI NIH HHS [CA 08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1984, VIROLOGY, V50, P207; BAINES JD, 1991, J VIROL, V65, P938, DOI 10.1128/JVI.65.2.938-944.1991; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAI WH, 1987, J VIROL, V61, P714, DOI 10.1128/JVI.61.3.714-721.1987; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CLAIRMONT KB, 1991, J BIOL CHEM, V266, P12131; COHEN GH, 1983, J VIROL, V46, P679, DOI 10.1128/JVI.46.3.679-689.1983; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; FAN DP, 1978, CELL, V15, P985, DOI 10.1016/0092-8674(78)90282-9; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; GABEL CA, 1989, J VIROL, V63, P4264, DOI 10.1128/JVI.63.10.4264-4276.1989; GELATO MC, 1989, ENDOCRINOLOGY, V124, P2935, DOI 10.1210/endo-124-6-2935; HAYWOOD AM, 1994, J VIROL, V68, P1; HEY AW, 1987, ENDOCRINOLOGY, V121, P1975, DOI 10.1210/endo-121-6-1975; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HONESS RW, 1975, J VIROL, V16, P1308, DOI 10.1128/JVI.16.5.1308-1326.1975; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; JEFFREY AM, 1975, BIOCHEM BIOPH RES CO, V62, P608, DOI 10.1016/0006-291X(75)90442-8; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; JOHNSON DC, 1982, J VIROL, V43, P1102, DOI 10.1128/JVI.43.3.1102-1112.1982; JOHNSON DC, 1988, VIROLOGY, V164, P1, DOI 10.1016/0042-6822(88)90613-7; JOHNSON RM, 1989, J VIROL, V63, P819, DOI 10.1128/JVI.63.2.819-827.1989; JONES F, 1988, J VIROL, V62, P2701, DOI 10.1128/JVI.62.8.2701-2711.1988; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KETCHAM CM, 1992, J BIOL CHEM, V267, P11654; KIELIAN M, 1990, MOL BIOL MED, V7, P17; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LASKEY LA, 1987, BIOTECHNOLOGY, V2, P527; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; LI M, 1989, METHOD ENZYMOL, V179, P304; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; ROOP C, 1993, J VIROL, V67, P2285, DOI 10.1128/JVI.67.4.2285-2297.1993; SANCHEZPESCADOR L, 1988, J IMMUNOL, V141, P1720; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SLODKI ME, 1973, BIOCHIM BIOPHYS ACTA, V304, P449, DOI 10.1016/0304-4165(73)90264-X; SODORA DL, 1991, J VIROL, V65, P4432, DOI 10.1128/JVI.65.8.4432-4441.1991; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; SPEAR PG, 1993, IN PRESS VIRAL FUSIO, P201; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STUVE LL, 1987, J VIROL, V61, P326, DOI 10.1128/JVI.61.2.326-335.1987; WEISS RA, 1989, BIOCHEM SOC T, V17, P644, DOI 10.1042/bst0170644; WHEALY ME, 1991, J VIROL, V65, P1066, DOI 10.1128/JVI.65.3.1066-1081.1991; WHITE RM, 1982, J CLIN INVEST, V69, P1239, DOI 10.1172/JCI110563; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989	59	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17067	17074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006011				2022-12-27	WOS:A1994NT84600016
J	DZIARSKI, R				DZIARSKI, R			CELL-BOUND ALBUMIN IS THE 70-KDA PEPTIDOGLYCAN, LIPOPOLYSACCHARIDE, AND LIPOTEICHOIC ACID BINDING-PROTEIN ON LYMPHOCYTES AND MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SPLENOCYTES; MONOCLONAL-ANTIBODIES; LYMPHOID-CELLS; RECEPTOR; SPECIFICITY; SITES; ENDOTOXIN; MICE	The 70-kDa protein that is present on the surface of lymphocytes and macrophages and that binds peptidoglycan, lipopolysaccharide, lipoteichoic acid, heparin, and sulfated heparinoids was identified as cell-bound albumin. It originated from the tissue culture medium or from the serum in vivo and was not produced by the cells. The fallowing results supported this conclusion: (a) mouse and human cell lines grown in serum-free and albumin free medium did not have this 70-kDa protein and did not bind peptidoglycan and lipopolysaccharide in photoaffinity cross-linking assay; (b) the appearance of the 70-kDa protein in these cells and the ligand binding were restored by 30-min incubation with serum or purified albumin; (c) soluble albumin bound peptidoglycan and lipopolysaccharide, and this binding was inhibited by the same competitive inhibitors that inhibited the binding to the 70-kDa cellular protein; (d) albumin co-migrated with the 70-kDa cellular protein in two-dimensional polyacrylamide gel electrophoresis; (e) peptide maps of albumin and the 70-kDa cellular protein digested with four proteases were identical; (f) the only protein recognized by anti-albumin monoclonal and polyclonal antibodies on Western immunoblots was the 70-kDa protein that exactly matched with the cellular peptidoglycan/lipopolysaccharide-binding protein; (g) anti-albumin monoclonal antibodies immunoprecipitated the 70-kDa cellular protein; and (h) species-specific anti-bovine, anti-human, and anti-mouse albumin antibodies recognized the 70-kDa protein on mouse and human cells according to the species of albumin that was present in the culture medium or in the serum in vivo, but not according to the species of the cells. The cell-bound albumin was not required for cell activation, because macrophage cell lines that were grown in albumin-free medium and did not have the cell-bound albumin (the 70-kDa protein) fully responded to the stimulation by peptidoglycan and lipopolysaccharide with production of tumor necrosis factor-alpha.			DZIARSKI, R (corresponding author), INDIANA UNIV, SCH MED, NW CTR MED EDUC, GARY, IN 46408 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRIGHT SW, 1990, J IMMUNOL, V145, P1; CHEN TY, 1990, J IMMUNOL, V145, P8; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; Dziarski R, 1992, J Immunol, V148, P1590; DZIARSKI R, 1993, INT CONGR SER, V1020, P151; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GREEN SJ, 1992, J IMMUNOL, V149, P2069; HALLING JL, 1992, INFECT IMMUN, V60, P845, DOI 10.1128/IAI.60.3.845-852.1992; JETT M, 1977, J BIOL CHEM, V252, P2134; LEBLANC PA, 1994, J LEUKOCYTE BIOL, V55, P262, DOI 10.1002/jlb.55.2.262; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LEI MG, 1991, J IMMUNOL, V147, P1925; LEI MG, 1993, INFECT IMMUN, V61, P1359, DOI 10.1128/IAI.61.4.1359-1364.1993; MORRISON DC, 1990, J INFECT DIS, V162, P1063, DOI 10.1093/infdis/162.5.1063; PERERA PY, 1992, J LEUKOCYTE BIOL, V51, P501, DOI 10.1002/jlb.51.5.501; RABIN RL, 1993, J INFECT DIS, V168, P135, DOI 10.1093/infdis/168.1.135; ROEDER DJ, 1989, INFECT IMMUN, V57, P1054, DOI 10.1128/IAI.57.4.1054-1058.1989; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068	21	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20431	20436						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051139				2022-12-27	WOS:A1994PB31700036
J	SELIGMAN, L; MANOIL, C				SELIGMAN, L; MANOIL, C			AN AMPHIPATHIC SEQUENCE DETERMINANT OF MEMBRANE-PROTEIN TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE FUSIONS; POSITIVELY CHARGED RESIDUES; DISULFIDE CROSS-LINKING; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; SENSORY RECEPTOR; SIGNAL SEQUENCE; GENE FUSIONS; CHEMORECEPTOR	We developed a screen involving alkaline phosphatase gene fusions to identify mutations altering the membrane topology of a bacterial chemoreceptor (Escherichia coli Tsr). We identified three informative classes of mutations causing increased export of the protein's normally cytoplasmic carboxyl-terminal domain. The first class consisted of deletions eliminating all or most of the membrane-spanning sequence (TM2) immediately amino-terminal to the cytoplasmic domain. The second class consisted of mutations altering a highly amphipathic sequence at the beginning of the domain. The third class of mutation was a deletion of an upstream spanning sequence (TM1). The amphipathic sequence appears to be a novel determinant of membrane topology whose function is not due to its positive residue density. The amphipathic character of the sequence is relatively well-conserved in chemoreceptors and their relatives. Although deletions removing the amphipathic sequence or TM1 alone caused only partial carboxyl-terminal domain export, a double mutation removing both caused efficient export. This result suggests that the two sequences function independently to promote normal membrane insertion. The independent functioning of the two sequences may help ensure that Tsr insertion is normally a high fidelity process.			SELIGMAN, L (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046493] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46493] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; Creighton TE, 1983, PROTEINS STRUCTURES; DAHL MK, 1989, J BACTERIOL, V171, P2361, DOI 10.1128/jb.171.5.2361-2371.1989; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HENNING U, 1978, EUR J BIOCHEM, V92, P491, DOI 10.1111/j.1432-1033.1978.tb12771.x; HUANG HH, 1988, IMPROVED SUPPRESSOR, P269; JACKSON ME, 1987, MOL MICROBIOL, V1, P23, DOI 10.1111/j.1365-2958.1987.tb00522.x; JEFFERY CJ, 1993, PROTEIN SCI, V2, P559; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MADDOCK JR, 1993, SCIENCE, V259, P1717; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MICHAELIS S, 1983, J BACTERIOL, V154, P356, DOI 10.1128/JB.154.1.356-365.1983; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PRENTKI P, 1981, GENE, V14, P289, DOI 10.1016/0378-1119(81)90161-X; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROISE D, 1988, J BIOL CHEM, V263, P4509; SARTHY A, 1981, J BACTERIOL, V145, P288, DOI 10.1128/JB.145.1.288-292.1981; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SELIGMAN L, 1994, SEQUENCE DETERMINANT; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890; YAMAMOTO K, 1993, P NATL ACAD SCI USA, V90, P217, DOI 10.1073/pnas.90.1.217; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	56	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19888	19896						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051071				2022-12-27	WOS:A1994PA12600037
J	PITTMAN, RH; CLAY, CM; FARMERIE, TA; NILSON, JH				PITTMAN, RH; CLAY, CM; FARMERIE, TA; NILSON, JH			FUNCTIONAL-ANALYSIS OF THE PLACENTA-SPECIFIC ENHANCER OF THE HUMAN GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE - EMERGENCE OF A NEW ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; PROTEIN-BINDING DOMAINS; CAMP RESPONSE ELEMENTS; RNA POLYMERASE-II; CYCLIC-AMP; NUCLEAR-PROTEIN; TRANSCRIPTION; DNA; PROMOTER	Placental expression of the alpha subunit gene of the human glycoprotein hormones requires a multicomponent enhancer composed of tandem cAMP-response elements and an adjacent upstream regulatory element. Based on recent studies indicating that the upstream regulatory element includes binding sites for more than one protein, we investigated how functional activity correlated with these binding sites. Through extensive replacement mutagenesis of the native promoter regulatory region, we provide the first functional map of the upstream regulatory element. Within this region, we find that distinct proteins interact with three overlapping binding sites. While each site is functionally significant, no single site is essential or displays clear dominance. This is surprising since one of the sites binds a placenta-specific protein that heretofore has been regarded as essential for activity of the human a subunit placenta-specific enhancer. Consequently, our refined functional map of the upstream regulatory element reveals a complex combinatorial code that directs expression of the human alpha subunit gene to placenta.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK08612, DK28559, DK43039] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, R01DK043039, F32DK008612] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRADBURY JT, 1950, RECENT PROG HORM RES, V5, P151; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Cole HH, 1930, AM J PHYSIOL, V93, P57, DOI 10.1152/ajplegacy.1930.93.1.57; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PATTILLO RA, 1968, CANCER RES, V28, P1231; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	31	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19360	19368						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034701				2022-12-27	WOS:A1994NY33200027
J	WACHTFOGEL, YT; DELACADENA, RA; KUNAPULI, SP; RICK, L; MILLER, M; SCHULTZE, RL; ALTIERI, DC; EDGINGTON, TS; COLMAN, RW				WACHTFOGEL, YT; DELACADENA, RA; KUNAPULI, SP; RICK, L; MILLER, M; SCHULTZE, RL; ALTIERI, DC; EDGINGTON, TS; COLMAN, RW			HIGH MOLECULAR-WEIGHT KININOGEN BINDS TO MAC-1 ON NEUTROPHILS BY ITS HEAVY-CHAIN (DOMAIN-3) AND ITS LIGHT-CHAIN (DOMAIN-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEIN ENDOTHELIAL-CELLS; BLOOD-COAGULATION; INTEGRIN MAC-1; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; COMPLEMENT RECEPTOR; RECOGNITION SITE; ANIONIC SURFACE; FACTOR-XI; PLATELETS	High molecular weight kininogen (HK) binds specifically, saturably, and reversibly to neutrophils and also reciprocally inhibits the binding of fibrinogen to neutrophils. Since fibrinogen binds to the leukocyte integrin CD11b/18 (Mac-1, alpha(M) beta(2)), we investigated whether HK bound to Mac-1 and whether the binding site was similar to that for factor X. We also examined whether one or both chains of cleaved HK (HKa) were involved. Two monoclonal antibodies, 2B5 (0.29 mu M) to HK heavy chain domains 2 (D2) and 3 (D3), and C11C1 (0.26 mu M) to HK light chain domain 5 (D5), inhibited by 99 and 93% the binding, respectively, of I-125-HK (8.3 nM) to neutrophils. To minimize steric hindrance, we further demonstrated that the Fab' fragments of 2B5 and C11C1 were able to inhibit the binding of this ligand to virtually the same extent as the intact antibody, indicating that, as in binding of HK to platelets and endothelial cells, both chains are involved. To directly demonstrate the involvement of each chain, we showed that the reduced alkylated light chain derived from HK and low molecular weight kininogen, which contains the same heavy chain as HX, each markedly inhibited the binding of HK to neutrophils. We localized the domain responsible for the binding in each chain by showing that recombinant D3 and D5 decreased the binding of HK to neutrophils. To define the receptor for HK, we employed three monoclonal antibodies to Mac-1: OKM1 and OKM10 to epitopes on the alpha(M) subunit and IB4 to an epitope on the beta(2) chain. OKM1, which can inhibit fibrinogen binding to neutrophils, inhibited HK binding by 79%, whereas the other antibodies inhibited HK binding less than 25%. Coagulation factor X also binds to Mac-1 on monocytes at a similar site to C3bi. Synthetic peptides which define noncontiguous surface loops in factor X that interact with Mac-1, failed to inhibit I-125-HK binding to neutrophils. We conclude that HK binds, via domains on its heavy chain, D3, and light chain, D5, to Mac-1 on the neutrophil surface, and HK occupies a site overlapping with fibrinogen and different from factor X.	TEMPLE UNIV, SCH MED, SOL SHERRY THROMBOSIS RES CTR, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19140 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Scripps Research Institute					NHLBI NIH HHS [HL45486, HL02681, HL19055] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002681, P50HL045486, R01HL019055] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DELACADENA RA, 1988, BLOOD, V72, P1748; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JIANG YP, 1992, THROMB HAEMOSTASIS, V68, P143; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; PURI RN, 1991, BLOOD, V77, P500; REDDIGARI SR, 1993, BLOOD, V81, P1306; REGOLI D, 1990, J CARDIOVASC PHARM, V15, pS30; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TODA N, 1992, AM J PHYSIOL, V262, pH995; TREZZINI C, 1988, BIOCHEM BIOPH RES CO, V156, P477, DOI 10.1016/S0006-291X(88)80866-0; TREZZINI C, 1991, BRIT J HAEMATOL, V77, P16, DOI 10.1111/j.1365-2141.1991.tb07942.x; TROWBRIDGE IS, 1981, J EXP MED, V154, P1517, DOI 10.1084/jem.154.5.1517; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VILLANUEVA GB, 1989, BIOCHEM BIOPH RES CO, V158, P72, DOI 10.1016/S0006-291X(89)80178-0; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	49	100	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19307	19312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034694				2022-12-27	WOS:A1994NY33200019
J	EFIOK, BJS; CHIORINI, JA; SAFER, B				EFIOK, BJS; CHIORINI, JA; SAFER, B			A KEY TRANSCRIPTION FACTOR FOR EUKARYOTIC INITIATION FACTOR-2-ALPHA IS STRONGLY HOMOLOGOUS TO DEVELOPMENTAL TRANSCRIPTION FACTORS AND MAY LINK METABOLIC GENES TO CELLULAR GROWTH AND DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SEA-URCHIN EMBRYO; LEUCINE ZIPPER; REGULATORY FACTORS; SERUM DEPLETION; ACTIVATION; EXPRESSION; SEQUENCE; DOMAINS; TRANSLATION	In response to growth, metabolic, and other signals, eukaryotic cells regulate protein biosynthesis through post-translational mechanisms which target the alpha subunit of eukaryotic initiation factor-2 (eIF-2 alpha). Previous efforts to study transcriptional mechanisms underlying this regulation identified a novel transcription factor (alpha-Pal) for the eIF-2 alpha gene. To gain insights into the overall biological function of alpha-Pal, we cloned its cDNA. Sequence analysis of the encoded protein reveals that alpha-Pal is a putative bZIP transcription factor. Surprisingly, both the protein sequence and the DNA-recognition site (TGCGCATGCGCA) of this human protein are strongly homologous to those of two evolutionarily distant developmental transcription factors, P3A2 and ewg. Since P3A2 directs territory-specific transcription of muscle genes in sea urchin embryos, and ewg apparently directs transcription of flight muscle and neuronal genes in Drosophila embryos, it is likely that alpha-Pal directs similar gene transcription during human embryo-genesis. In other studies, we also identified genes containing alpha-Pal-binding sequences as those involved in cellular proliferation, or the growth-responsive metabolic pathways, energy transduction, translation, and DNA replication/repair. Such data suggest that alpha-Pal also functions to modulate the transcription of metabolic genes required for cellular growth.	NHLBI,MOLEC HEMATOL LAB,PROT & RNA BIOSYNTH SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALBERTS D, 1989, MOL BIOL CELL, P388; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHIORINI JA, 1993, J BIOL CHEM, V268, P13748; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FLINT KJ, 1991, ONCOGENE, V6, P2091; HASSELBACH W, 1983, ANNU REV PHYSIOL, V45, P325, DOI 10.1146/annurev.ph.45.030183.001545; HOOG C, 1991, DEVELOPMENT, V112, P351; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JACOB WF, 1989, J BIOL CHEM, V264, P20374; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; JAGUS R, 1982, CURR TOP CELL REGUL, V21, P35; KATZE MG, 1986, MOL CELL BIOL, V6, P1741, DOI 10.1128/MCB.6.5.1741; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE KAW, 1992, J CELL SCI, V103, P9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MIKAELIAN I, 1993, J VIROL, V67, P734; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; ONEAL KT, 1990, SCIENCE, V249, P774; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SAFER B, 1981, BIOCHIMIE, V63, P709, DOI 10.1016/S0300-9084(81)80219-2; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; ZAR JH, 1984, BIOSTAT ANAL, P52	50	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18921	18930						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034649				2022-12-27	WOS:A1994NX32700036
J	LOGUIDICE, JM; WIERUSZESKI, JM; LEMOINE, J; VERBERT, A; ROUSSEL, P; LAMBLIN, G				LOGUIDICE, JM; WIERUSZESKI, JM; LEMOINE, J; VERBERT, A; ROUSSEL, P; LAMBLIN, G			SIALYLATION AND SULFATION OF THE CARBOHYDRATE CHAINS IN RESPIRATORY MUCINS FROM A PATIENT WITH CYSTIC-FIBROSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL-MUCUS GLYCOPROTEINS; 500-MHZ H-1-NMR SPECTROSCOPY; TRACHEOBRONCHIAL MUCOUS GLYCOPROTEINS; QUANTITATIVE SUGAR ANALYSIS; EPITHELIAL ION-TRANSPORT; LINKED OLIGOSACCHARIDES; MYCOPLASMA-PNEUMONIAE; STRUCTURAL-ANALYSIS; SALIVARY MUCINS; HEN OVOMUCIN	Mucin glycopeptides were prepared from the sputum of a patient suffering from cystic fibrosis. The carbohydrate chains were released by alkaline borohydride treatment. Sialylated and sulfated oligosaccharide-alditols were purified by ion-exchange chromatography, gel filtration, and high performance anion-exchange chromatography. The structures of the oligosaccharide alditols were determined by high resolution H-1 NMR spectroscopy in combination with fast atom bombardment-mass spectrometry. Twenty-four oligosaccharides were characterized and illustrate the diversity of the carbohydrate chains of cystic fibrosis respiratory mucins. Among these 24 oligosaccharide-alditols, 15 are novel structures. Sialylation may occur on the C-6 of the N-acetylgalactosamine involved in the carbohydrate-peptide linkage or on a terminal galactose residue, either on C-3 or on C-6. Sulfation may occur either on the C-3 of a terminal galactose residue or on the C-6 of a N-acetylglucosamine residue. The most complex structures contain sulfated derivatives of the H, X, or Y determinants or a sialylated and sulfated derivative of the X determinant (Structure A).	INSERM,U377,F-59045 LILLE,FRANCE; UNIV SCI & TECHNOL LILLE,CHIM BIOL LAB,F-59650 VILLENEUVE DASCQ,FRANCE; UNIV SCI & TECHNOL LILLE,CNRS,UMR 111,F-59650 VILLENEUVE DASCQ,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			lemoine, jerome/C-4272-2014; GUIDICE, Jean-Marc LO/O-3177-2017	lemoine, jerome/0000-0002-5497-6880; GUIDICE, Jean-Marc LO/0000-0003-3486-6809				AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Boat T F, 1976, Mod Probl Paediatr, V19, P141; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CARNOY C, 1993, AM J RESP CELL MOL, V9, P323, DOI 10.1165/ajrcmb/9.3.323; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CONTRERAS RR, 1988, CARBOHYD RES, V179, P411; DALTON JP, 1991, EUR J BIOCHEM, V195, P789, DOI 10.1111/j.1432-1033.1991.tb15767.x; Demaille J, 1965, Bull Soc Chim Fr, V12, P3506; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANDA A, 1991, BIOCHEM BIOPH RES CO, V175, P1, DOI 10.1016/S0006-291X(05)81191-X; HARD K, 1992, EUR J BIOCHEM, V205, P785; HOIBY N, 1988, CHEST, V94, pS97, DOI 10.1378/chest.94.2_Supplement.97S; KERCKAERT JP, 1978, ANAL BIOCHEM, V84, P354, DOI 10.1016/0003-2697(78)90052-0; KLEIN A, 1992, BIOCHEMISTRY-US, V31, P6152, DOI 10.1021/bi00141a028; KLEIN A, 1988, EUR J BIOCHEM, V171, P631, DOI 10.1111/j.1432-1033.1988.tb13834.x; KNOWLES MR, 1986, CLIN CHEST MED, V7, P285; KORVEL AMS, 1984, EUR J BIOCHEM, V140, P571; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamblin G, 1976, Mod Probl Paediatr, V19, P153; LAMBLIN G, 1984, J BIOL CHEM, V259, P9051; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; LAMBLIN G, 1977, CLIN CHIM ACTA, V36, P329; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MARIANNE T, 1986, CARBOHYD RES, V151, P7, DOI 10.1016/S0008-6215(00)90325-2; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; MAWHINNEY TP, 1992, CARBOHYD RES, V235, P179, DOI 10.1016/0008-6215(92)80087-H; MAWHINNEY TP, 1992, CARBOHYD RES, V223, P187, DOI 10.1016/0008-6215(92)80016-T; QUINTON PM, 1989, CLIN CHEM, V35, P726; RAHMOUNE H, 1991, AM J RESP CELL MOL, V5, P315, DOI 10.1165/ajrcmb/5.4.315; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROUSSEL P, 1975, J BIOL CHEM, V250, P2114; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; SLAYTER HS, 1984, EUR J BIOCHEM, V142, P209, DOI 10.1111/j.1432-1033.1984.tb08273.x; SPENCER B, 1960, BIOCHEM J, V75, P435, DOI 10.1042/bj0750435; STRECKER G, 1989, CARBOHYD RES, V185, P1, DOI 10.1016/0008-6215(89)84016-9; STRECKER G, 1987, GLYCOCONJUGATE J, V4, P329, DOI 10.1007/BF01048366; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANARKEL C, 1963, J CHROMATOGR, V11, P421, DOI 10.1016/S0021-9673(01)80940-7; VANHALBEEK H, 1984, BIOCHEM SOC T, V12, P601, DOI 10.1042/bst0120601; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P7; VANHALBEEK H, 1988, EUR J BIOCHEM, V177, P443; VANHALBEEK H, 1980, BIOCHIM BIOPHYS ACTA, V623, P295, DOI 10.1016/0005-2795(80)90257-3; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	58	123	127	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18794	18813						20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034632				2022-12-27	WOS:A1994NX32700019
J	MONTAGUE, JW; GAIDO, ML; FRYE, C; CIDLOWSKI, JA				MONTAGUE, JW; GAIDO, ML; FRYE, C; CIDLOWSKI, JA			A CALCIUM-DEPENDENT NUCLEASE FROM APOPTOTIC RAT THYMOCYTES IS HOMOLOGOUS WITH CYCLOPHILIN - RECOMBINANT CYCLOPHILIN-A, CYCLOPHILIN-B, AND CYCLCLOPHILIN-C HAVE NUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; BINDING-PROTEIN CYCLOPHILIN; PROGRAMMED CELL-DEATH; CYCLOSPORINE-A; DNA FRAGMENTATION; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; ENDONUCLEASE; CLEAVAGE; GLUCOCORTICOIDS	Apoptosis is an important physiological process that involves the deletion of specific cells in a controlled and timely manner. A biochemical hallmark typifying apoptosis in normal lymphocytes is DNA cleavage caused by a calcium-dependent nuclease. We have previously identified and purified an 18-kDa nuclease (NUC18) from glucocorticoid treated rat thymocytes whose activity is associated with this apoptotic DNA fragmentation. Partial protein sequencing of pure NUC18 has generated two peptide sequences that have a remarkable similarity to rat cyclophilin A and other members of the cyclophilin family We report here that recombinant cyclophilins A, B, and C have a calcium/magnesium-dependent nuclease activity with biochemical and pharmacological properties similar to those of NUC18. Our results raise the intriguing possibility that cyclophilin or a cyclophilin-related protein may play a role in lymphocyte apoptosis.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK 32078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; CARONI P, 1991, J BIOL CHEM, V266, P10739; CARONLESLIE LAM, 1994, ENDOCRINE, V2, P47; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; COHEN JJ, 1993, CHEST, V103, pS99; COHEN JJ, 1984, J IMMUNOL, V132, P38; COMPTON MM, 1992, TRENDS ENDOCRIN MET, V3, P17, DOI 10.1016/1043-2760(92)90087-H; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; NIKONOVA LV, 1993, EUR J BIOCHEM, V215, P893, DOI 10.1111/j.1432-1033.1993.tb18107.x; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; SCHWARTZMAN RA, 1993, ENDOCRINOLOGY, V133, P591, DOI 10.1210/en.133.2.591; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/rstb.1976.0084; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	40	137	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18877	18880						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034643				2022-12-27	WOS:A1994NX32700030
J	NG, SB; TAN, YH; GUY, GR				NG, SB; TAN, YH; GUY, GR			DIFFERENTIAL INDUCTION OF THE INTERLEUKIN-6 GENE BY TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SIGNAL TRANSDUCTION; HUMAN-FIBROBLASTS; FACTOR-ALPHA; MESSENGER-RNA; REGULATED KINASES; PROTEIN-KINASES; GROWTH-FACTORS; PHOSPHORYLATION; EXPRESSION; ACTIVATION	Although tumor necrosis factor (TNF) and interleukin-1 (IL) induce the expression of the IL-8, TNF-stimulated gene 6, and plasminogen activation inhibitor-2 genes and the activation of NF-kappa B with nearly identical kinetics, the two cytokines differ significantly in the induction of the IL-6 gene in all primary fibroblasts tested. IL-1 induces IL-6 gene expression after 30 min of IL-1 treatment, reaching a maximum level by 7 h, and is sustained for up to 14 h. TNF also induces the IL-6 gene expression at 30 min but the induction was low. A similar difference in the amount of IL-6 secreted was observed in the IL-1/TNF-treated cells. Measurement of IL-6 gene transcription by nuclear run-on transcription assays indicated a 4-fold higher rate of IL-6 gene transcription in IL-1-treated than in TNF-treated cells. The IL-1-induced IL-6 mRNA has a significantly longer half-life (>6 h) compared to 30 min for TNF-treated cells. These results suggest that the induction of the IL-6 gene expression in primary human fibroblasts by TNF and IL-1 is differentially regulated at the transcriptional as well as at the post-transcriptional level.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BERESINI MH, 1988, J IMMUNOL, V140, P485; BIRD TA, 1991, J BIOL CHEM, V266, P22661; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAPLIN DD, 1992, TUMOR NECROSIS FACTO, P197; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; ELIAS JA, 1990, J IMMUNOL, V145, P161; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1994, ELECTROPHORESIS, V15, P417, DOI 10.1002/elps.1150150160; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; JELINEK DF, 1987, J IMMUNOL, V139, P2970; KATZ Y, 1989, J IMMUNOL, V142, P3862; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MOORE MAS, 1987, P NATL ACAD SCI USA, V84, P7134, DOI 10.1073/pnas.84.20.7134; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TAN YH, 1970, P NATL ACAD SCI USA, V67, P464, DOI 10.1073/pnas.67.1.464; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZUCALI JR, 1988, J IMMUNOL, V140, P840	32	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19021	19027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034659				2022-12-27	WOS:A1994NX32700049
J	SHIMADA, K; TAKAHASHI, M; TANZAWA, K				SHIMADA, K; TAKAHASHI, M; TANZAWA, K			CLONING AND FUNCTIONAL EXPRESSION OF ENDOTHELIN-CONVERTING ENZYME FROM RAT ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUTRAL ENDOPEPTIDASE 24.11; AMINO-ACID SEQUENCE; BIG ENDOTHELIN-1; MOLECULAR-CLONING; MESSENGER-RNA; ENKEPHALINASE; CONVERSION; MEMBRANE; KIDNEY; CDNA	Endothelin (ET) is a 21-residue potent vasoconstrictive peptide produced by vascular endothelial cells and formed from its precursor, big endothelin (big ET), by endothelin-converting enzyme (ECE). Here we report the cloning and functional expression of a complementary DNA encoding a rat ECE from endothelial cells. Rat ECE is a highly glycosylated protein consisting of 10 possible N-linked glycosylation sites, a zinc binding domain, and a single membrane-spanning region. It has structural and sequence homology to neutral endopeptidase and Kell blood group protein, a putative neutral endopeptidase. Monoclonal antibody risen against purified rat lung ECE recognized broad glycosylated bands in membrane fractions prepared from both rat lung and COS cells transfected with a rat ECE expression vector. Expressed ECE was inhibited by phosphoramidon, but not by thiorphan. It also cleaved big ET-1 efficiently but not big ET-2 or big ET-3. Northern blot analysis revealed that ECE messenger RNA is widely expressed in many tissues.	SANKYO CO LTD,BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	Daiichi Sankyo Company Limited								BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BENCHETRIT T, 1988, BIOCHEMISTRY-US, V27, P592, DOI 10.1021/bi00402a014; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DORLEANSJUSTE P, 1990, BIOCHEM PHARMACOL, V29, P821; GEE NS, 1985, BIOCHEM J, V230, P753, DOI 10.1042/bj2300753; HEXUM TD, 1990, BIOCHEM BIOPH RES CO, V167, P294, DOI 10.1016/0006-291X(90)91764-J; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; ICHIMORI Y, 1985, J IMMUNOL METHODS, V80, P55, DOI 10.1016/0022-1759(85)90164-4; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KIMURA S, 1989, J CARDIOVASC PHARM, V13, pS5, DOI 10.1097/00005344-198900135-00003; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LEE S, 1991, P NATL ACAD SCI USA, V88, P633; MACMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUMURA Y, 1990, FEBS LETT, V272, P166, DOI 10.1016/0014-5793(90)80475-X; MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S; MCKERROW JH, 1987, J BIOL CHEM, V262, P5943; NUNEZ DJR, 1990, J CLIN INVEST, V85, P1537, DOI 10.1172/JCI114601; OHNAKA K, 1991, BIOCHEM INT, V23, P499; OHNAKA K, 1959, J BIOL CHEM, V268, P267; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	29	285	293	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18275	18278						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034569				2022-12-27	WOS:A1994NW79800005
J	JOHNSON, DR; KNOLL, LJ; ROWLEY, N; GORDON, JI				JOHNSON, DR; KNOLL, LJ; ROWLEY, N; GORDON, JI			GENETIC-ANALYSIS OF THE ROLE OF SACCHAROMYCES-CEREVISIAE ACYL-COA SYNTHETASE GENES IN REGULATING PROTEIN N-MYRISTOYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; MYRISTIC ACID AUXOTROPHY; COENZYME-A CARBOXYLASE; MAMMALIAN G-PROTEIN; FATTY-ACIDS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; BINDING PROTEIN; YEAST HOMOLOG	NMT1 is an essential Saccharomyces cerevisiae gene which encodes myristoyl-CoA:protein N-myristoyltransferase (Nmt1p). Nmt1p transfers myristate (C14:0), from myristoyl-CoA to the amino terminal Gly residue of several essential cellular proteins. Little information is available about how myristoyl-CoA metabolism is regulated in eukaryotic cells. We have isolated and characterized three unlinked Fatty Acid Activation genes from S. cerevisiae, FAA1, FAA2, and FAA3. In vitro biochemical assays reveal that the myristoyl-CoA synthetase activity of purified Faa2p is approximately equal to that of Faa1p, and two orders of magnitude greater than that of Faa3p. Analysis of NMT1 strains containing faa1, faa2, and/or faa3 null alleles indicates that Faa1p, Faa2p, and Faa3p are not essential for vegetative growth when de novo acyl-CoA synthesis by fatty acid synthetase (Fas) is active. S. cerevisiae strains containing nmt1-181 exhibit temperature-sensitive growth arrest and myristic acid auxotrophy due to the reduced affinity of its mutant protein product (nmt(Gly451-->Asp)) for myristoyl-CoA. Comparison of the growth characteristics of isogenic NMT1 and nmt1-181 strains with all possible combinations of faa1, faa2, and faa3 null alleles, in the presence or absence of an active Fas complex, indicates that (i) Faa1p is responsible for activation of imported fatty acids to their CoA derivatives; (ii) Faa2p and Faa3p are able to access endogenous but not imported fatty acid substrates; (iii) nmt181p requires myristoyl-CoA production from both Fas and Faas for cells to remain viable at nonpermissive temperatures; (iv) Faa2p is unique among the three Faas in its ability, when overproduced, to partially rescue growth of a nmt1-181 strain at nonpermissive temperatures on yeast/peptone/dextrose (YPD) media without C14:0 supplementation; (v) acyl-CoAs produced by Faa1p, Faa2p, or Faa3p are not specifically targeted for beta-oxidation; and (vi) the ability of NMT1, faa1 Delta, faa2 Delta, faa3 Delta strains to remain viable in the absence of an active Fas complex on YPD plus C 14:0, or on media that contains fatty acids as the sole carbon source, suggests that S. cerevisiae contains other acyl-CoA synthetases which can activate imported fatty acids.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; MRC, MOLEC BIOL LAB, DIV PROT & NUCLE ACID CHEM, CAMBRIDGE CB2 2QH, ENGLAND	Washington University (WUSTL); MRC Laboratory Molecular Biology					NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BLACK PN, 1992, J BIOL CHEM, V267, P25513; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DEVADAS B, 1993, BIOORG MED CHEM LETT, V31, P779; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DOHLMAN HG, 1994, IN PRESS P NATL ACAD; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KOHLWEIN SD, 1983, BIOCHIM BIOPHYS ACTA, V792, P310; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LU TB, 1994, J BIOL CHEM, V269, P5346; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MISHINA M, 1978, EUR J BIOCHEM, V89, P321, DOI 10.1111/j.1432-1033.1978.tb12533.x; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NUNN WD, 1986, J BIOL CHEM, V261, P167; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RILES L, 1993, GENETICS, V134, P81; ROSE TM, 1992, P NATL ACAD SCI USA, V89, P11287, DOI 10.1073/pnas.89.23.11287; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TUNG BS, 1991, J LIPID RES, V32, P1025; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WITT W, 1982, BIOCHIM BIOPHYS ACTA, V711, P403, DOI 10.1016/0005-2760(82)90054-6; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5	88	43	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18037	18046						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027063				2022-12-27	WOS:A1994NV42200045
J	SCHWANSTECHER, M; LOSER, S; CHUDZIAK, F; PANTEN, U				SCHWANSTECHER, M; LOSER, S; CHUDZIAK, F; PANTEN, U			IDENTIFICATION OF A 38-KDA HIGH-AFFINITY SULFONYLUREA-BINDING PEPTIDE IN INSULIN-SECRETING CELLS AND CEREBRAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENSITIVE K+-CHANNELS; H-3 GLIBENCLAMIDE; GLYBURIDE ANALOG; ATP; RECEPTOR; RAT; NEURONS; BRAIN; PURIFICATION; DIAZOXIDE	Previous studies have described specific photoincorporation of radiolabeled sulfonylureas into a peptide with high molecular mass (140-175 kDa), which thus has been suggested to represent the sulfonylurea receptor. In the present study, a I-125-labeled 4-azidosalicyloyl analog of glibenclamide, I-125-N-3-GA (N-[4-(2-(4-azido-2-hydroxy-5- I-125-iodobenzamido)ethyl)benzenesulfonyl]-N'-cyclohexylurea), was used for photoaffinity labeling. This novel probe was specifically photoincorporated into a peptide with an apparent molecular mass of 160-175 kDa when samples from insulin-secreting HIT cells or cerebral cortex were boiled in a SDS-buffer prior to separation with SDS-polyacrylamide gel electrophoresis, However, omitting the heating step revealed specific labeling of an additional peptide with an apparent molecular mass of 38 kDa. The amount of radioactivity specifically photoincorporated into this peptide was 3-4-fold higher than that incorporated into the 160-175-kDa peptide. Both peptides displayed similar dissociation constants for binding of the sulfonylureas IN3-GA (N-[4-(2- (4-azido-2-hydroxy-5-iodobenzamido)ethyl)benzenesulfonyl]-N'-cyclohexylurea), glibenclamide, glipizide, and tolbutamide. Analysis of photoaffinity labeling of solubilized fractions indicated an almost exclusive specific linkage to the 38-kDa peptide. The data support the view that the sulfonylurea receptor in insulin-secreting cells and cerebral cortex consists of a peptide with an apparent molecular mass of 38 kDa, which seems to be tightly coupled to a 160-175 kDa peptide.			SCHWANSTECHER, M (corresponding author), UNIV GOTTINGEN,INST PHARMACOL & TOXICOL,ROBERT KOCH STR 40,D-37075 GOTTINGEN,GERMANY.							AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERNARDI H, 1993, P NATL ACAD SCI USA, V90, P1340, DOI 10.1073/pnas.90.4.1340; BERNARDI H, 1992, BIOCHEMISTRY-US, V31, P6328, DOI 10.1021/bi00142a023; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUDZIAK F, 1994, IN PRESS J LABELLED; DUNN MJ, 1987, ADV ELECTROPHORESIS, P1; GOPALAKRISHNAN M, 1993, DRUG DEVELOP RES, V28, P95, DOI 10.1002/ddr.430280202; GOPALAKRISHNAN M, 1991, J PHARMACOL EXP THER, V257, P1162; HODGES SC, 1984, CLIN CHEM, V30, P2003; KAUBISCH N, 1982, BIOCHEM PHARMACOL, V31, P1171, DOI 10.1016/0006-2952(82)90363-X; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; NELSON DA, 1992, J BIOL CHEM, V267, P14928; OHNOSHOSAKU T, 1992, PFLUG ARCH EUR J PHY, V422, P260, DOI 10.1007/BF00376211; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; POLITI DMT, 1991, MOL PHARMACOL, V40, P308; SCHWANSTECHER C, 1993, N-S ARCH PHARMACOL, V348, P113, DOI 10.1007/BF00168546; SCHWANSTECHER M, 1992, J NEUROCHEM, V59, P1325, DOI 10.1111/j.1471-4159.1992.tb08444.x; SCHWANSTECHER M, 1992, BRIT J PHARMACOL, V106, P295, DOI 10.1111/j.1476-5381.1992.tb14331.x; SCHWANSTECHER M, 1994, IN PRESS J NEUROCHEM	21	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17768	17771						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027029				2022-12-27	WOS:A1994NV42200004
J	KURACHI, T; MORITA, I; OKI, T; UEKI, T; SAKAGUCHI, K; ENOMOTO, S; MUROTA, S				KURACHI, T; MORITA, I; OKI, T; UEKI, T; SAKAGUCHI, K; ENOMOTO, S; MUROTA, S			EXPRESSION ON OUTER MEMBRANES OF MANNOSE RESIDUES, WHICH ARE INVOLVED IN OSTEOCLAST FORMATION VIA CELLULAR FUSION EVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SPERM-EGG FUSION; ANTIFUNGAL ANTIBIOTICS; PRADIMICIN-A; BINDING; PROTEIN; RECEPTOR; INTEGRIN; INVITRO; SURFACE	Osteoclast, the bone-resorbing cell, is formed from hematopoietic precursors via cell cell fusion. To evaluate the possibility that under certain specific conditions mannose residues may be expressed on the mammalian cell surface, we examined the action of pradimicin derivatives, which bind specific sugars such as the mannose residue, on the formation of osteoclast induced in the coculture of mouse spleen cells with mouse stromal cells, a process in which cell cell fusion is involved. Osteoclast formation was inhibited by treatment of this coculture system with pradimicin at the later stage (day 4-7), and this inhibition was specifically abrogated by mannose-rich yeast mannan. During the 8-day cocultivation, osteoclast formation was blocked by the pradimicin on days 6 and 7, when mononuclear preosteoclasts fused into multinucleated osteoclasts. With an interactive laser cytometer ACAS570, fluorescein isothiocyanate-labeled pradimicin was observed to bind osteoclast progenitors at the fusion stage and to have no binding affinity for osteoclast progenitors at the early stage (day 0-3) or for osteoclasts, which were formed after performing fusion between mononuclear preosteoclasts. These results suggest that mannose residues were expressed on outer membranes of monocytes under pathophysiological conditions and that they were involved in the osteoclast formation via cellular membrane fusion events.	TOKYO MED & DENT UNIV,GRAD SCH,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN; TOYAMA PREFECTURAL UNIV,BIOTECHNOL RES CTR,TOYAMA 99303,JAPAN; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,WALLINGFORD,CT 06492	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Toyama Prefectural University; Bristol-Myers Squibb			郑, 丽丽/HGE-2239-2022					ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; BATTAILLE R, 1991, J CLIN INVEST, V88, P62; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BURSTONE MS, 1958, J NATL CANCER I, V21, P523; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; JAMIESON JC, 1992, BIOCHEM CELL BIOL, V70, P408, DOI 10.1139/o92-063; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAUFMAN SJ, 1985, J CELL BIOL, V100, P1977, DOI 10.1083/jcb.100.6.1977; KLEIN B, 1991, BLOOD, V78, P1198; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KURACHI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P259, DOI 10.1016/0167-4889(93)90202-Z; LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; OKI T, 1988, J ANTIBIOT, V41, P1701, DOI 10.7164/antibiotics.41.1701; OKI T, 1990, J ANTIBIOT, V43, P763, DOI 10.7164/antibiotics.43.763; OKI T, 1991, RECENT PROGR ANTIFUN, P381; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756-3282(09)80003-3; ROODMAN GD, 1992, J CLIN INVEST, V89, P883; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSENBERG J, 1985, P NATL ACAD SCI USA, V82, P8409, DOI 10.1073/pnas.82.24.8409; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TANABETOCHIKURA A, 1990, VIROLOGY, V176, P467, DOI 10.1016/0042-6822(90)90016-K; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TOMITA K, 1990, J ANTIBIOT, V43, P755, DOI 10.7164/antibiotics.43.755; TSUNAKAWA M, 1989, J ORG CHEM, V54, P2532, DOI 10.1021/jo00272a013; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; UEKI T, 1993, J ANTIBIOT, V46, P149, DOI 10.7164/antibiotics.46.149; UEKI T, 1993, J ANTIBIOT, V46, P465, DOI 10.7164/antibiotics.46.465; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331	35	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17572	17576						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021265				2022-12-27	WOS:A1994NU12800038
J	SMIT, L; DEVRIESSMITS, AMM; BOS, JL; BORST, J				SMIT, L; DEVRIESSMITS, AMM; BOS, JL; BORST, J			B-CELL ANTIGEN RECEPTOR STIMULATION INDUCES FORMATION OF A SHC-GRB2 COMPLEX CONTAINING MULTIPLE TYROSINE-PHOSPHORYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE IMMUNOGLOBULIN; SH3 DOMAINS; KINASE LYN; ACTIVATION; ASSOCIATION; GRB2	Activation of growth factor receptor tyrosine kinases, such as the epidermal growth factor and insulin receptors, induces tyrosine phosphorylation of Shc proteins and their association with the SH2 domain-containing adaptor protein Grb2. The Shc-Grb2 complex has been implicated in coupling these receptors to p21(ras). The B cell. antigen receptor plays a key role in directing B cell proliferation and differentiation. Although the B cell receptor lacks intrinsic tyrosine kinase activity, its mode of action parallels that of receptor tyrosine kinases in many aspects. B cell receptor stimulation activates src-related tyrosine kinases and the tyrosine kinase syk, which leads to phosphorylation of various cytoplasmic proteins and initiates multiple signaling events, including p21(ras) activation, Therefore, we have, investigated whether Shc proteins are targets for the activated B cell receptor. It was found that the 52- and 46-kDa forms of Shc are expressed in mature human Il cells and become rapidly phosphorylated on tyrosine upon B cell receptor stimulation. Also, Shc is induced to associate with the Grb2 molecule and an undefined 130-kDa protein. In a specific response to B cell activation, the Shc-Grb2 complex associates with several tyrosine-phosphorylated proteins, including two prominent phosphoproteins with molecular masses of 130 and 110 kDa. These observations strongly suggest that the Shc and Grb2 adaptor proteins are involved in coupling the B cell antigen receptor to one or multiple signal transduction pathways.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3508 TA UTRECHT,NETHERLANDS	Netherlands Cancer Institute; Utrecht University				Borst, Jannie/0000-0002-8043-5009; Smit, Linda/0000-0003-0025-269X				BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	30	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20209	20212						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051109				2022-12-27	WOS:A1994PB31700001
J	BALLATORI, N; DUTCZAK, WJ				BALLATORI, N; DUTCZAK, WJ			IDENTIFICATION AND CHARACTERIZATION OF HIGH AND LOW-AFFINITY TRANSPORT-SYSTEMS FOR REDUCED GLUTATHIONE IN LIVER-CELL CANALICULAR MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT TRANSPORT; RAT-LIVER; BILIARY TRANSPORT; HEPATIC GLUTATHIONE; PLASMA-MEMBRANES; PERFUSED RAT; S-CONJUGATE; VESICLES; BILE; METHYLMERCURY	Driving forces and substrate specificity for transport of reduced glutathione (GSH) across rat liver cell canalicular membrane were examined in vesicles isolated from this plasma membrane domain. In contrast to previous studies indicating a single saturable component of canalicular GSH transport, the present results demonstrate the presence of both high and low affinity components with apparent K-m values of 0.24 +/- 0.04 and 17.4 +/- 2.1 mM and V-max values of 0.09 +/- 0.01 and 2.3 +/- 0.3 nmol.mg(-1).20 s(-1), respectively. The K-m values in two previously published reports are discordant, 0.33 versus 16 mM, but are comparable with the two transport components identified in the present study. To further characterize these GSH transport mechanisms, [H-3]GSH uptake by canalicular vesicles was measured at concentrations of 50 mu M, where transport is expected to occur largely on the high affinity component, and at 5 mM, where the low affinity system should predominate. Neither component of GSH transport was affected by ATP or a Na+ gradient, but both were stimulated by a valinomycin-induced membrane potential, indicating electrogenic transport pathways. The high affinity component was cis-inhibited by glutathione S-conjugates (1 mM), other gamma-glutamyl compounds (5 mM), and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (0.1 mM), whereas these agents had no effect on the low affinity component at similar inhibitor concentrations. Sulfobromophthalein (BSP, 0.1 mM) inhibited both GSH transport components. However, neither component was affected by taurocholate (0.5 mM) or L-glutamate (10 mM). The inhibition by S-butylglutathione, the GSH analogue ophthalmic acid, and by BSP was competitive in nature, although BSP also produced a slight decrease in V-max, suggesting a mixed type of inhibition. Ophthalmic acid and some glutathione S-conjugates were also able to trans stimulate high affinity GSH uptake. These results indicate the presence of at least two ATP-independent, electrogenic glutathione transport mechanisms on the canalicular membrane; the high affinity component may function to deliver some glutathione S-conjugates, gamma-glutamyl compounds, and other anions into bile, whereas the low affinity system probably functions as a high capacity transporter capable of delivering large amounts of GSH into bile.			BALLATORI, N (corresponding author), UNIV ROCHESTER,SCH MED,DEPT ENVIRONM MED,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P30ES001247] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39165] Funding Source: Medline; NIEHS NIH HHS [NIEHS ES-01247, ES-06484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKERBOOM T, 1984, EUR J BIOCHEM, V141, P211, DOI 10.1111/j.1432-1033.1984.tb08177.x; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BALLATORI N, 1989, AM J PHYSIOL, V256, pG482, DOI 10.1152/ajpgi.1989.256.3.G482; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BALLATORI N, 1989, AM J PHYSIOL, V256, pG22, DOI 10.1152/ajpgi.1989.256.1.G22; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BALLATORI N, 1983, AM J PHYSIOL, V244, pG435, DOI 10.1152/ajpgi.1983.244.4.G435; BALLATORI N, 1982, SCIENCE, V216, P61, DOI 10.1126/science.7063871; DUTCZAK WJ, 1994, J BIOL CHEM, V269, P9746; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1993, J BIOL CHEM, V268, P10836; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; Gibaldi M., 1975, PHARMACOKINETICS DRU; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; INOUE M, 1984, J BIOL CHEM, V259, P4998; INOUE M, 1983, EUR J BIOCHEM, V134, P467, DOI 10.1111/j.1432-1033.1983.tb07590.x; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KOBAYASHI K, 1991, BIOCHEM BIOPH RES CO, V176, P622, DOI 10.1016/S0006-291X(05)80229-3; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOSELEY RH, 1988, AM J PHYSIOL, V255, pG253, DOI 10.1152/ajpgi.1988.255.2.G253; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P676; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SIMMONS TW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P462, DOI 10.1016/0005-2736(90)90140-J; SIMMONS TW, 1992, J PHARMACOL EXP THER, V262, P1182; WHELAN FJ, 1963, TOXICOL APPL PHARM, V5, P457, DOI 10.1016/0041-008X(63)90017-6; WHELAN G, 1970, J LAB CLIN MED, V75, P542	40	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19731	19737						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051053				2022-12-27	WOS:A1994PA12600016
J	DAVIS, RE; SINGH, H; BOTKA, C; HARDWICK, C; ELMEANAWY, MA; VILLANUEVA, J				DAVIS, RE; SINGH, H; BOTKA, C; HARDWICK, C; ELMEANAWY, MA; VILLANUEVA, J			RNA TRANSSPLICING IN FASCIOLA-HEPATICA - IDENTIFICATION OF A SPLICED LEADER (SL) RNA AND SL SEQUENCES ON MESSENGER-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHISTOSOMA-MANSONI; MESSENGER-RNAS; DNA; PLATYHELMINTHES; PHYLOGENY	We have identified a new spliced leader (SL) in Fasciola hepatica by characterizing the 5'-terminal sequences of its enolase mRNA, an mRNA also trans-spliced in the flatworm Schistosoma mansoni (Rajkovic, A., Davis, R. E., Simonsen, J. N., and Rottman, F. M, (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8879-8883). This 37-nucleotide spliced leader is at the 5' ends of multiple Fasciola mRNAs and is likely to be derived from the 5' terminus of a nonpolyadenylated, 108-nucleotide RNA with a trimethylguanosine cap. The SL RNA gene is present in similar to 100 copies within a 1.1-kilobase genomic tandem repeat. Secondary structure predictions indicate that the Fasciola SL RNA contains three stem loops in contrast to two previously observed in S. mansoni. Fasciola and S. mansoni SLs are likely to be evolutionarily related although their sequence identity is only 65%. In contrast with nematodes, absolute conservation of SL sequences and secondary structure does not occur in trematodes. A spliced leader in Fasciola indicates that trans-splicing is likely to be a common feature in other trematodes and perhaps other flatworms.	METROHLTH MED CTR,DEPT MED,CLEVELAND,OH 44109	MetroHealth System	DAVIS, RE (corresponding author), SAN FRANCISCO STATE UNIV,DEPT BIOL,1600 HALLOWAY AVE,SAN FRANCISCO,CA 94132, USA.				NIAID NIH HHS [AI 32709] Funding Source: Medline; NIGMS NIH HHS [GM48972] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI032709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM048972] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIR D, 1993, INT J PARASITOL, V23, P169, DOI 10.1016/0020-7519(93)90138-O; BOOTHROYD JC, 1982, GENE, V20, P279; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RE, 1988, MOL CELL BIOL, V8, P4745, DOI 10.1128/MCB.8.11.4745; DOSREIS MG, 1993, MOL BIOCHEM PARASIT, V59, P235, DOI 10.1016/0166-6851(93)90221-I; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MASLOV DA, 1993, MOL BIOCHEM PARASIT, V61, P127, DOI 10.1016/0166-6851(93)90165-T; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P385; Nisson P E, 1991, PCR Methods Appl, V1, P120; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; ROHDE K, 1990, INT J PARASITOL, V20, P979, DOI 10.1016/0020-7519(90)90041-K; ROHDE K, 1993, INT J PARASITOL, V23, P705, DOI 10.1016/0020-7519(93)90067-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591; Willmer P., 1990, INVERTEBRATE RELATIO; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	24	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20026	20030						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051087				2022-12-27	WOS:A1994PA12600056
J	MOREL, P; STASIAK, A; EHRLICH, SD; CASSUTO, E				MOREL, P; STASIAK, A; EHRLICH, SD; CASSUTO, E			EFFECT OF LENGTH AND LOCATION OF HETEROLOGOUS SEQUENCES ON RECA-MEDIATED STRAND EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLEX DNA-MOLECULES; ESCHERICHIA-COLI; BRANCH MIGRATION; 3-STRANDED DNA; PROTEIN; RECOMBINATION; INSERTIONS; DELETIONS; BREAKS; GENE	We systematically investigated the effect of heterology on RecA-mediated strand exchange between double-stranded linear and single-stranded circular DNA. Strand exchange took place through heterologies of up to 150-200 base pairs when the insertion was at the proximal (initiating) end of the duplex DNA but was completely blocked by an insert of only 22 base pairs placed at the distal end of the duplex. In the case of medial heterology created by insertion either in the duplex or the single-stranded DNA, the ability of RecA to exchange strands decreased as the heterology was shifted toward the distal end of the duplex. These results suggest that two different strand exchange mechanisms operate in the proximal and distal portions of the duplex substrate.	INRA,F-78352 JOUY EN JOSAS,FRANCE; UNIV LAUSANNE,ANAL STRUCT LAB,CH-1015 LAUSANNE,SWITZERLAND	INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Lausanne			Stasiak, Andrzej/E-5551-2010; Ehrlich, S./Y-2423-2019	Stasiak, Andrzej/0000-0002-0398-1989; Ehrlich, S./0000-0002-7563-4046; morel, patrice/0000-0003-1690-8032				ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BIANCHI M, 1985, EMBO J, V4, P3025, DOI 10.1002/j.1460-2075.1985.tb04039.x; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804	30	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19830	19835						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051065				2022-12-27	WOS:A1994PA12600029
J	ALBERT, AC; ROMAN, AM; BOUCHE, G; LENG, M; RAHMOUNI, AR				ALBERT, AC; ROMAN, AM; BOUCHE, G; LENG, M; RAHMOUNI, AR			GRADUAL AND ORIENTED B-Z TRANSITION IN 5'-UNTRANSCRIBED REGION OF MOUSE RIBOSOMAL DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; NEGATIVELY SUPERCOILED PLASMIDS; RAT PROLACTIN GENE; PHYSIOLOGICAL CONDITIONS; TOPOISOMERASE MUTANTS; FORMING SEQUENCES; HUMAN GENOME; Z-JUNCTIONS; TRANSCRIPTION; INVIVO	The structural transition of an alternating purine-pyrimidine sequence ((CG)(5)(TG)(28)) from the 5'-untranscribed region of the mouse ribosomal DNA was analyzed by two-dimensional gel electrophoresis and chemical probes. The repeat undergoes a supercoil dependent gradual and oriented B-Z transition. At a threshold level of negative supercoiling, a limited region of the repeat encompassing the (CG)(5) motif converts cooperatively into Z-DNA. As the superhelical stress increases, the Z-structure propagates along the remaining part of the repeat by successive transitions until the full-length sequence is converted. By in situ OsO4 probing experiments, we show also that this (TG)(n)-containing repeat adopts the Z-structure in Escherichia coli.	CNRS,CTR BIOPHYS MOLEC,F-45071 ORLEANS 2,FRANCE; CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)								BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; FIGUEROA N, 1988, P NATL ACAD SCI USA, V85, P9416, DOI 10.1073/pnas.85.24.9416; GALAZKA G, 1986, J BIOL CHEM, V261, P7093; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1991, J BIOL CHEM, V266, P2576; JIMENEZRUIZ A, 1991, P NATL ACAD SCI USA, V88, P31, DOI 10.1073/pnas.88.1.31; JOHNSTON BH, 1988, J BIOL CHEM, V263, P4512; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; JOHNSTON BH, 1991, BIOCHEMISTRY-US, V30, P5257, DOI 10.1021/bi00235a020; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.pc.38.100187.002513; KLADDE MP, 1993, J MOL BIOL, V229, P344, DOI 10.1006/jmbi.1993.1039; KOHWISHIGEMATSU T, 1987, P NATL ACAD SCI USA, V84, P2223, DOI 10.1073/pnas.84.8.2223; KUHN A, 1987, EMBO J, V6, P3487, DOI 10.1002/j.1460-2075.1987.tb02673.x; LENG M, 1985, BIOCHIM BIOPHYS ACTA, V825, P339, DOI 10.1016/0167-4781(85)90059-4; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MCLEAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V950, P243, DOI 10.1016/0167-4781(88)90120-0; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; REEDER RH, 1984, CELL, V38, P349, DOI 10.1016/0092-8674(84)90489-6; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Sambrook J, 1989, MOL CLONING LABORATO; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; VOGT N, 1988, J MOL BIOL, V201, P773, DOI 10.1016/0022-2836(88)90474-3; VOLOGODSKII AV, 1984, J BIOMOL STRUCT DYN, V1, P1325, DOI 10.1080/07391102.1984.10507523; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	37	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19238	19244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034685				2022-12-27	WOS:A1994NY33200009
J	GUNDERSEN, CB; MASTROGIACOMO, A; FAULL, K; UMBACH, JA				GUNDERSEN, CB; MASTROGIACOMO, A; FAULL, K; UMBACH, JA			EXTENSIVE LIPIDATION OF A TORPEDO CYSTEINE STRING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FATTY ACYLATION; ACID; PALMITOYLATION; SUBUNIT; CHANNEL; CNS	Cysteine string proteins are relatively low mass components of synaptic vesicle membranes. Structurally, their primary sequence is distinguished by a remarkable, cysteine-rich motif. Investigations revealed an unprecedented degree of lipidation of these cysteine residues. At least 11 of the 13 cysteines of the Torpedo protein were modified, principally by palmitoyl moieties. This fatty acylation creates a prominent hydrophobic domain flanked by polar amino and carboxyl termini. An amphipathic structure of this type is uniquely suited to mediate events at membrane interfaces. Thus, cysteine string proteins are candidates to participate in exocytotic membrane fusion.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	GUNDERSEN, CB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC PHARMACOL,LOS ANGELES,CA 90024, USA.							BISHROMARY M, 1981, J BIOL CHEM, V256, P4715; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; FOLCH J, 1951, J BIOL CHEM, V191, P807; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUTNIKOV G, 1991, J CHROMATOGR, V587, P292, DOI 10.1016/0021-9673(91)85170-K; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HESS DT, 1992, J NEUROSCI, V12, P4634; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WEIMBS T, 1992, BIOCHEMISTRY-US, V31, P12289, DOI 10.1021/bi00164a002; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	24	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19197	19199						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034679				2022-12-27	WOS:A1994NY33200002
J	ZHOU, JH; HOFFMAN, EP				ZHOU, JH; HOFFMAN, EP			PATHOPHYSIOLOGY OF SODIUM CHANNELOPATHIES - STUDIES OF SODIUM-CHANNEL EXPRESSION BY QUANTITATIVE MULTIPLEX FLUORESCEMCE POLYMERASE CHAIN-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERKALEMIC PERIODIC PARALYSIS; BECKER MUSCULAR-DYSTROPHY; CELLS DEVELOPING INVITRO; ALPHA-SUBUNIT GENE; SKELETAL-MUSCLE; MESSENGER-RNA; PARAMYOTONIA-CONGENITA; FUNCTIONAL EXPRESSION; CARRIER DETECTION; RIBONUCLEIC-ACID	The inherited diseases hyperkalemic periodic paralysis and paramyotonia congenita are caused by mutations in the adult skeletal muscle sodium channel gene. To determine if differences in the expression patterns of the adult and cardiac/fetal sodium channel genes could explain some clinical features of these disorders, we developed a novel mRNA quantitation strategy called quantitative multiplex fluorescent polymerase chain reaction (QMF-PCR). This assay tests the relative levels of multiple mRNA species simultaneously using automated sequenators. We show validation of this method by competitive-PCR and RNase protection. Developmental studies of sodium channel mRNAs in humans and mice by QMF-PCR showed that the adult sodium channel mRNA quickly increased, while the cardiac/fetal sodium channel mRNA slowly decreased similarly in both limb and diaphragm muscle. We find that the adult sodium channel gene expression is predominant in fetal and neonatal muscle of both humans and mice: adult isoform mRNA concentration in fetal muscle was 8.4 x 10(-6) mu g/mu g of total RNA; cardiac/fetal isoform mRNA was 2.0 x 10(-6) mu g/mu g; and actin mRNA was 3.4 x 10(-3) mu g/mu g. Our results suggest that differential sodium channel gene expression correlates with age of onset of disease, but not with diaphragm involvement, in patients with hyperkalemic periodic paralysis.	UNIV PITTSBURGH,SCH MED,DEPT HUMAN GENET,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ZHOU, JH (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261, USA.			Hoffman, Eric/0000-0001-6470-5139	NIAMS NIH HHS [AR41025] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041025] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CANNON SC, 1993, J PHYSIOL-LONDON, V466, P501; CANNON SC, 1993, BIOPHYS J, V65, P270, DOI 10.1016/S0006-3495(93)81045-2; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; FEENER CA, 1991, AM J HUM GENET, V48, P621; FEERO WG, 1993, NEUROLOGY, V43, P668, DOI 10.1212/WNL.43.4.668; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FRELIN C, 1983, J BIOL CHEM, V258, P7256; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GONOI T, 1985, J NEUROSCI, V5, P2559; HARADA N, 1992, ENDOCRINOLOGY, V131, P2306, DOI 10.1210/en.131.5.2306; HARRIS J B, 1973, Nature New Biology, V243, P191; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOFFMAN EP, 1993, ARCH NEUROL-CHICAGO, V50, P1227, DOI 10.1001/archneur.1993.00540110101010; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; LAWRENCE JC, 1981, J BIOL CHEM, V256, P6213; LEHMANNHORN F, 1991, PFLUG ARCH EUR J PHY, V418, P297, DOI 10.1007/BF00370530; LIU P, 1989, SCIENCE, V246, P813, DOI 10.1126/science.2479099; LUPA MT, 1993, J NEUROSCI, V13, P1326; MCCARREY JR, 1992, GENET ANAL-BIOMOL E, V9, P117, DOI 10.1016/1050-3862(92)90051-6; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OUDET C, 1990, HUM GENET, V84, P283; PEGORARO E, 1994, AM J HUM GENET, V54, P989; PORCHER C, 1992, BIOTECHNIQUES, V13, P106; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUDOLPH JA, 1992, NAT GENET, V2, P144, DOI 10.1038/ng1092-144; Sambrook J, 1989, MOL CLONING LABORATO; SASTRE A, 1976, P NATL ACAD SCI USA, V73, P1355, DOI 10.1073/pnas.73.4.1355; SCHWARTZ LS, 1992, AM J HUM GENET, V51, P721; SHERMAN SJ, 1983, J BIOL CHEM, V258, P2488; SHERMAN SJ, 1982, J GEN PHYSIOL, V80, P1106; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WANG J, 1993, AM J HUM GENET, V52, P1074; WANG JZ, 1992, BIOCHEM BIOPH RES CO, V182, P794, DOI 10.1016/0006-291X(92)91802-W	42	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18563	18571						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034605				2022-12-27	WOS:A1994NW79800053
J	LEE, WY; BUTLER, AP; LOCNISKAR, MF; FISCHER, SM				LEE, WY; BUTLER, AP; LOCNISKAR, MF; FISCHER, SM			SIGNAL-TRANSDUCTION PATHWAY(S) INVOLVED IN PHORBOL ESTER AND AUTOCRINE INDUCTION OF INTERLEUKIN-1-ALPHA MESSENGER-RNA IN MURINE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; MYELIN BASIC-PROTEIN; NF-KAPPA-B; MESSENGER-RNA; HUMAN-FIBROBLASTS; MAP KINASE; RAPID PHOSPHORYLATION; REGULATED KINASES	We investigated the signal transduction pathways leading to the 12-O-tetradecanoylphorbol-13-acetate (TPA) and interleukin-1 alpha (IL-1)-induced IL-1 alpha mRNA in mouse keratinocytes. Induction of IL-1 alpha mRNA by TPA or IL-1 alpha was followed by increases in cell-associated IL-1 alpha protein measured by enzyme linked immunosorbent assay. Although protein kinase C (PKC) was involved in TPA-induced IL-1 alpha mRNA, down-regulation of PKC did not block the induction of this gene by TPA. The autocrine induction of IL-1 alpha was not mediated through PKC or cAMP. IL-1 alpha did activate mitogen activated protein kinase. Genistein, a tyrosine kinase inhibitor, blocked both IL-1 alpha induced mitogen-activated protein kinase activation as well as IL-1 alpha mRNA expression. Genistein, at an unsaturating dose, plus a serine/threonine kinase inhibitor, H7, completely blocked the autocrine induction of IL-1 alpha suggesting that expression of this gene is regulated by tyrosine kinase(s) in combination or independently with serine/threonine kinase(s). In addition, both TPA and IL-1 alpha caused increases not only in the phosphorylation of c-Jun and c-Fos protein but also in the transactivating activity of AP-1 nuclear transcription factor. Neither TPA nor IL-1 alpha induced NF-kappa B binding activity, as assessed by electrophoretic mobility shift analysis. This study suggests that the activation of AP-1 may be a common event through which TPA and IL-1 alpha induce IL-1 alpha mRNA.	UNIV TEXAS, COLL PHARM, DEPT PHARMACOL TOXICOL, AUSTIN, TX 78712 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; UNIV TEXAS, DIV NUTR SCI, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin					NCI NIH HHS [CA 34443, CA 52468] Funding Source: Medline; PHS HHS [42211] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1988, P NATL ACAD SCI USA, V85, P1408, DOI 10.1073/pnas.85.5.1408; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANSEL JC, 1988, J IMMUNOL, V140, P2274; ARNER EC, 1991, ARTHRITIS RHEUM, V34, P1006, DOI 10.1002/art.1780340810; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; ASHENDEL CL, 1983, CANCER RES, V43, P4327; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BELURY MA, 1993, NUTR CANCER, V19, P307, DOI 10.1080/01635589309514261; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CHANG J, 1986, J IMMUNOL, V136, P1283; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, BLOOD, V77, P1627; DLUGOSZ AA, 1991, CANCER RES, V51, P4677; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1991, CANCER RES, V51, P850; GALLIS B, 1989, J IMMUNOL, V143, P3235; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; GUY GR, 1991, J BIOL CHEM, V266, P14343; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE SW, 1991, J INVEST DERMATOL, V97, P106, DOI 10.1111/1523-1747.ep12478503; LEE WY, 1993, MOL CARCINOGEN, V7, P26, DOI 10.1002/mc.2940070106; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCGUIRE J, 1988, ANN NY ACAD SCI, V548, P283, DOI 10.1111/j.1749-6632.1988.tb18816.x; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUNOZ E, 1990, J IMMUNOL, V144, P964; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PRENS EP, 1990, J INVEST DERMATOL, V95, pS121, DOI 10.1111/1523-1747.ep12874991; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SAUDER DN, 1990, LYMPHOKINE RES, V9, P465; SCHMIDT J, 1990, HDB EXP PHARM, V95, P473; SCHMITT A, 1986, LYMPHOKINE RES, V5, P105; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TURNER M, 1989, J IMMUNOL, V143, P3556; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WANG XJ, 1993, J CANCER RES CLIN, V119, P279, DOI 10.1007/BF01212726; YAMATO K, 1989, J CELL PHYSIOL, V139, P610, DOI 10.1002/jcp.1041390322; ZU Y, 1990, BIOCHEMISTRY-US, V29, P1055, DOI 10.1021/bi00456a030	59	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17971	17980						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027056				2022-12-27	WOS:A1994NV42200036
J	PRASAD, R; BEARD, WA; WILSON, SH				PRASAD, R; BEARD, WA; WILSON, SH			STUDIES OF GAPPED DNA SUBSTRATE-BINDING BY MAMMALIAN DNA-POLYMERASE-BETA - DEPENDENCE ON 5'-PHOSPHATE GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; CROSS-LINKING; REPAIR; ALPHA; IDENTIFICATION; DOMAIN; FIBROBLASTS; INITIATION; INHIBITORS	Purified mammalian DNA polymerase beta (beta-pol) fills short gaps of up to 6 nucleotides by a processive mechanism, and this gap-filling activity requires a PO4 group on the 5'-side of the gap (Singhal, R. K., and Wilson, S. H. (1993) J. Biol. Chem. 268, 15906-15911). To assess details of bimolecular binding between beta-pol and a 5-nucleotide (nt) gapped radiolabeled heteropolymeric DNA substrate, beta-pol.DNA complexes were formed, photochemically cross-linked using UV light, and analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. A 39-nt template was annealed with two 17-mer oligonucleotides, generating a 5-nt gap. The results indicate that beta-pol binds to both the template and primer strands, and binding is strongly enhanced by a 5'-PO4 on the downstream oligonucleotide, even though little cross-linking is observed to this oligonucleotide, The results suggest that beta-pol recognizes the 5'-side of a long single stranded gap in DNA, provided it contains a 5'-PO4. Additional beta-pol.DNA binding measurements were performed using a competition assay to assess the ability of heteropolymeric DNA to inhibit synthesis on a homopolymeric template-primer system. The results indicate that in addition to the 5'-PO4, the length of the single-stranded template nucleic acid adjacent to the 5'-PO4 is also important for tight binding. Proteolysis of the cross-linked beta-pol.DNA complex with trypsin resulted in a single radiolabeled tryptic product corresponding to nucleic acid cross-linked to the 8-kDa domain. The results demonstrate that the role of the 8-kDa domain is to direct beta-pol binding to the phosphorylated 5'-position in gapped DNA substrates.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; CHANG LMS, 1973, J BIOL CHEM, V248, P6983; DETERA SD, 1981, J BIOL CHEM, V256, P6933; FRY M, 1986, ANIMAL CELL DNA POLY; FRY M, 1983, ENZYMES NUCLEIC ACID, P39; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; KEYSE SM, 1985, MUTAT RES, V146, P109, DOI 10.1016/0167-8817(85)90061-6; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; MATSUKAGE A, 1979, J BIOCHEM-TOKYO, V85, P1551, DOI 10.1093/oxfordjournals.jbchem.a132487; MATSUKAGE A, 1983, NEW APPROACHES EUKAR, P81; MOSBAUGH DW, 1984, J BIOL CHEM, V259, P247; PRASAD R, 1993, J BIOL CHEM, V268, P22746; Sambrook J, 1989, MOL CLONING LABORATO; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMADA K, 1985, J BIOL CHEM, V260, P412	26	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18096	18101						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027071				2022-12-27	WOS:A1994NV42200053
J	SLATER, SJ; KELLY, MB; TADDEO, FJ; RUBIN, E; STUBBS, CD				SLATER, SJ; KELLY, MB; TADDEO, FJ; RUBIN, E; STUBBS, CD			EVIDENCE FOR DISCRETE DIACYLGLYCEROL AND PHORBOL ESTER ACTIVATOR SITES ON PROTEIN-KINASE-C - DIFFERENCES IN EFFECTS OF 1-ALKANOL INHIBITION, ACTIVATION BY PHOSPHATIDYLETHANOLAMINE AND CALCIUM CHELATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BILAYER MEMBRANES; HEXAGONAL PHASE-TRANSITION; RECEPTOR PROTEIN; BINDING; VESICLES; PHOSPHATIDYLSERINE; COOPERATIVITY; MECHANISM; CONTAINS; BEHAVIOR	Stimulation of protein kinase C (PKC) activity is achieved in vivo by diacylglycerol but can also be obtained with tumor-promoting phorbol esters. Evidence is presented indicating that these two classes of activator may interact at different regions of the enzyme. The activity of a calcium-dependent PKC isoform (PKC-I) preparation was determined using 1,2-dioleoylglycerol (DOG) together with the phorbol ester 4 beta-12-O-tetradecanoylphorbol-13-acetate (TPA). The resulting PKC activity was in excess of that attained with either activator alone, each being at a maximum concentration for activation. A similar result was obtained with purified PKC-alpha and -epsilon isoforms, indicating that the additive effect was not due to sites being on distinct enzyme molecules. Support for two dissimilar activator sites came from the observation that the inactive phorbol ester 4 alpha-TPA competed for TPA but not for DOG in PKC activation. Other differences were observed between TPA and DOG-activated PKC. It was found that 1-butanol inhibited DOG-activated PEG-I, while being without effect on stimulation by TPA. Also, the inclusion of phosphatidylethanolamine in the lipid vesicles led to a potentiation of PKC-I activity which was greater when activation was achieved by DOG compared to TPA. Further, the calcium- and DOG dependent active conformational change of PKC was fully reversible upon calcium chelation, while that stimulated by TPA was only partially reversible. These experiments taken together suggest that diacylglycerols and phorbol esters bind with different affinities and at different sites on PKC, and induce distinct activated conformational forms of the enzyme.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University					NIAAA NIH HHS [AA08022, AA07215, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008022, P50AA007186, R29AA008022] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1988, BIOCHEM BIOPH RES CO, V152, P336, DOI 10.1016/S0006-291X(88)80719-8; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BONI LT, 1985, J BIOL CHEM, V260, P819; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CUNNINGHAM BA, 1989, BIOCHEMISTRY-US, V28, P32, DOI 10.1021/bi00427a006; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAS S, 1984, BIOCHEM BIOPH RES CO, V124, P491, DOI 10.1016/0006-291X(84)91580-8; EPAND RM, 1992, BIOCHEMISTRY-US, V31, P1550, DOI 10.1021/bi00120a036; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V944, P144, DOI 10.1016/0005-2736(88)90427-0; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; KISS Z, 1986, FEBS LETT, V198, P203, DOI 10.1016/0014-5793(86)80405-7; Kitano T, 1986, Methods Enzymol, V124, P349; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; ORR N, 1990, ANAL BIOCHEM, V191, P80, DOI 10.1016/0003-2697(90)90391-L; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SNOEK GT, 1988, BIOCHEM J, V255, P629; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; WOLF M, 1985, J BIOL CHEM, V260, P5718	50	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17160	17165						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006023				2022-12-27	WOS:A1994NT84600030
J	ODERMATT, A; SUTER, H; KRAPF, R; SOLIOZ, M				ODERMATT, A; SUTER, H; KRAPF, R; SOLIOZ, M			PRIMARY STRUCTURE OF 2 P-TYPE ATPASES INVOLVED IN COPPER HOMEOSTASIS IN ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION MOTIVE ATPASES; ESCHERICHIA-COLI; RESISTANCE GENES; NUCLEOTIDE-SEQUENCE; DNA; CLONING; METALLOTHIONEIN; PROTEINS; MERCURY; TOMATO	We cloned an operon, copAB, from Enterococcus hirae encoding two P-type ATPases of 727 and 745 amino acids, respectively. Both enzymes display heavy metal ion binding motifs in their polar N-terminal region. With an antibody against CopB, we showed on Western blots that expression of the operon is induced by either low or high ambient copper concentrations. Disruption of the copA gene renders the cells dependent, whereas copper disruption of copB results in a copper-sensitive phenotype. CopA exhibits 35% sequence similarity to CopB and 43% similarity to the ATPase encoded by the recently cloned human Mc1 gene, a gene responsible for the Menkes inborn error of copper metabolism. Our results imply that CopA and CopB are heavy metal ion ATPases that regulate the cytoplasmic copper activity, with CopA serving in the uptake and CopB in the extrusion of copper.	UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND; CANTONAL HOSP ST GALLEN,CH-9007 ST GALLEN,SWITZERLAND	University of Bern; Kantonsspital St. Gallen			Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Odermatt, Alex/0000-0002-6820-2712				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENDER CL, 1987, J BACTERIOL, V169, P470, DOI 10.1128/jb.169.2.470-474.1987; BROWN NL, 1991, J CELL BIOCHEM, V46, P106; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERARDI FX, 1987, APPL ENVIRON MICROB, V53, P1951, DOI 10.1128/AEM.53.8.1951-1954.1987; GARDE S, 1991, APPL ENVIRON MICROB, V57, P2435, DOI 10.1128/AEM.57.8.2435-2439.1991; GRAY MR, 1987, METHOD ENZYMOL, V154, P129; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HUMPHREYS GO, 1975, BIOCHIM BIOPHYS ACTA, V383, P457, DOI 10.1016/0005-2787(75)90318-4; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; INOUE C, 1989, GENE, V84, P47, DOI 10.1016/0378-1119(89)90138-8; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MACRINA FL, 1982, GENE, V19, P345, DOI 10.1016/0378-1119(82)90025-7; Maniatis T., 1982, MOL CLONING; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; NUCIFORA G, 1989, J BACTERIOL, V171, P4241, DOI 10.1128/JB.171.8.4241-4247.1989; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TETAZ TJ, 1983, J BACTERIOL, V154, P1263, DOI 10.1128/JB.154.3.1263-1268.1983; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WASER M, 1990, BIOCHIMIE, V72, P279; WINGE DR, 1985, J BIOL CHEM, V260, P4464	38	315	327	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12775	12779						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8048974				2022-12-27	WOS:A1993LG65800081
J	BOORER, KJ; LOO, DDF; WRIGHT, EM				BOORER, KJ; LOO, DDF; WRIGHT, EM			STEADY-STATE AND PRESTEADY-STATE KINETICS OF THE H+/HEXOSE COTRANSPORTER (STP1) FROM ARABIDOPSIS-THALIANA EXPRESSED IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; FUNCTIONAL EXPRESSION; VOLTAGE-CLAMP; NA+/GLUCOSE COTRANSPORTER; HETEROLOGOUS EXPRESSION; PLASMA-MEMBRANE; CELL-MEMBRANE; TRANSPORTER; CHLORELLA	We have investigated the steady-state and presteady-state kinetics of the cloned H+/hexose cotransporter from Arabidopsis thaliana (STP1) expressed in Xenopus oocytes using the two electrode voltage-clamp method. Steady-state sugar-dependent currents were measured between -150 and +50 mV as a function of external [3-O-methyl-D- glucose] (3OMG) and [H+]. At pH 6.5 (316 nM H+) the maximal current for sugar, i(max)(3OMG), was voltage-dependent, increasing from 40 nA at -30 mV to 95 nA at -150 mV,The apparent affinity of sugar, K-0.5(3OMG), at pH 6.5 decreased from 30 mu M at -30 mV to 11 mu M at -70 mV and was then voltage-independent between -70 and -150 mV, Increasing the extracellular [H+] to 3160 nM (pH 5.5) increased i(max)(3OMG) to 65 nA at -30 mV and 212 nA at -150 mV. K-0.5(3OMG) at pH 5.5 also increased and was voltage-dependent: 15 mu M at -50 mV rising to 25 mu M at -150 mV. At pH 6.5 and 5.5, the Hill coefficient n for 3OMG was voltage independent and averaged 1.2 and 1.4, respectively. At saturating [3OMG] i(max)(H) was voltage-dependent and K-0.5(H) was voltage-independent, averaging 370 nM (pH 6.4). The Hill coefficient n for H+ was voltage-independent and averaged 1. The sugar specificity of STP1 was D-mannose greater than or equal to 2-deoxyglucose > D-galactose greater than or equal to 3OMG > D-xylose > D-glucose > D-fucose > D-fructose > L-glucose > L-arabinose > D-arabinose, demonstrating that STP1 has a low substrate specificity. Transient currents recorded after rapid steps in membrane potential relaxed with time constants tau, between 3 and 14 ms. The charge movement Q (the integral of the current transients) fitted to a Boltzmann relation with maximal charge Q(max) of 3.4 nanocoulombs and an apparent valence z approximate to 1 corresponding to a transporter density of 2 x 10(10)/oocyte. Potential for 50% Q(max) (V-0.5) was -28 mV. At saturating 3OMG and at low external [H+] (pH 7.5), the transient STP1 currents were eliminated. The presteady-state data indicate that STP1 can bind H+ in the absence of sugar, and the steady-state data suggest that H+/hexose cotransport occurs via a sequential mechanism.			BOORER, KJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.				NIDDK NIH HHS [DK44602, DK19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567, R01DK044602] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOSHIMA H, 1993, J PLANT PHYSIOL, V141, P293, DOI 10.1016/S0176-1617(11)81737-2; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BENZANILLA F, 1991, SCIENCE, V254, P679; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; BOORER KJ, 1992, FEBS LETT, V302, P166, DOI 10.1016/0014-5793(92)80431-F; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P78, DOI 10.1007/BF00378644; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GRANDIN N, 1989, BIOL CELL, V67, P321, DOI 10.1016/0248-4900(89)90070-1; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HAZAMA A, 1993, FASEB J, V7, pA575; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KOMOR E, 1974, J GEN PHYSIOL, V64, P568, DOI 10.1085/jgp.64.5.568; LEFEVRE PG, 1961, PHARMACOL REV, V13, P39; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RAUSCH T, 1991, PHYSIOL PLANTARUM, V82, P134; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SAUER N, 1989, FEBS LETT, V259, P43, DOI 10.1016/0014-5793(89)81489-9; SAUER N, 1990, P NATL ACAD SCI USA, V87, P7949, DOI 10.1073/pnas.87.20.7949; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0	30	81	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20417	20424						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051137				2022-12-27	WOS:A1994PB31700034
J	TOYODA, N; HARNEY, JW; BERRY, MJ; LARSEN, PR				TOYODA, N; HARNEY, JW; BERRY, MJ; LARSEN, PR			IDENTIFICATION OF CRITICAL AMINO-ACIDS FOR 3,5,3'-TRIIODOTHYRONINE DEIODINATION BY HUMAN TYPE-1 DEIODINASE BASED ON COMPARATIVE FUNCTIONAL-STRUCTURAL ANALYSES OF THE HUMAN, DOG, AND RAT ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; THYROID-HORMONE; MESSENGER-RNA; LIVER; SELENOCYSTEINE; TRIIODOTHYRONINE; PROPYLTHIOURACIL; METABOLISM; THYROXINE; BINDING	The selenoenzyme, type 1 iodothyronine deiodinase (type 1 DI), catalyzes the activation of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) but 3,3',5'-triiodothyronine (rT3) is the preferred substrate for the human enzyme. Since the dog type 1 DI has a significantly lower affinity for rT3, we cloned the dog type 1 DI to identify amino acids critical for rT3 binding. The K-m of the transiently expressed dog enzyme for rT3 5'-deiodination is 25-fold higher than that of the human enzyme. However, the K-i of T4 for rT3 deiodination by dog type 1 DI is only 3-fold higher than that for the human, suggesting that the differences between the two proteins affect binding of rT3 more than that of T4. Comparative competition studies in which rT3 or T4 is used to block covalent bromoacetyl T3 binding to the two proteins support this. Mutational studies showed that the critical differences between the dog (D) and human (H) enzymes are Asn (D) 45 Gly (H), Gly (D) 46 Glu (H), and Leu (D) 60:Phe (H) 65. Substitution of the human residues for those of the dog at these positions causes Che predicted changes in the K-m (rT3) and vice versa. A Phe(65) to Leu mutation alone in the human enzyme increases the K-m (rT3) 10-fold. We speculate that phe(65) is especially important for rT3 binding due to an interaction between the tyrosyl ring of rT3 and the aromatic ring of Phe(65).	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV THYROID,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36256] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUID J, 1974, J CLIN INVEST, V54, P201, DOI 10.1172/JCI107744; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; BRENT GA, 1989, J BIOL CHEM, V264, P178; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; CHOPRA IJ, 1976, J CLIN INVEST, V58, P32, DOI 10.1172/JCI108456; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; DEBRUIJNE JJ, 1981, METABOLISM, V30, P190, DOI 10.1016/0026-0495(81)90171-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEFFNER DL, 1975, J CLIN INVEST, V55, P224, DOI 10.1172/JCI107925; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KAPLAN MM, 1978, J CLIN INVEST, V61, P459, DOI 10.1172/JCI108957; KAPTEIN EM, 1990, ENDOCRINOLOGY, V126, P2003, DOI 10.1210/endo-126-4-2003; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LAURBERG P, 1982, ENDOCRINOLOGY, V110, P2124, DOI 10.1210/endo-110-6-2124; LAURBERG P, 1984, METABOLISM, V33, P323, DOI 10.1016/0026-0495(84)90191-4; Leonard JL, 1986, THYROID HORMONE META, P189; LOPRESTI JS, 1989, J CLIN INVEST, V84, P1650, DOI 10.1172/JCI114343; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MOL JA, 1984, BIOCHEM BIOPH RES CO, V124, P475, DOI 10.1016/0006-291X(84)91578-X; MORENO M, 1994, FEBS LETT, V344, P143, DOI 10.1016/0014-5793(94)00365-3; SABERI M, 1975, J CLIN INVEST, V55, P218, DOI 10.1172/JCI107924; SAFRAN M, 1990, ENDOCRINOLOGY, V126, P826, DOI 10.1210/endo-126-2-826; SCHONMAKERS CHH, 1992, BIOCHIM BIOPHYS ACTA, V1121, P160, DOI 10.1016/0167-4838(92)90349-I; VISSER TJ, 1988, J CLIN ENDOCR METAB, V67, P17, DOI 10.1210/jcem-67-1-17; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	33	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20329	20334						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051127				2022-12-27	WOS:A1994PB31700021
J	KIMURA, F; SUZU, S; NAKAMURA, Y; WAKIMOTO, N; KANATANI, Y; YANAI, N; NAGATA, N; MOTOYOSHI, K				KIMURA, F; SUZU, S; NAKAMURA, Y; WAKIMOTO, N; KANATANI, Y; YANAI, N; NAGATA, N; MOTOYOSHI, K			STRUCTURAL-ANALYSIS OF PROTEOGLYCAN MACROPHAGE-COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BIOLOGICAL-ACTIVITY; MOLECULAR-CLONING; FACTOR-I; IDENTIFICATION; EXPRESSION; CELLS; PROHORMONE; PROTEINS; DECORIN	Proteoglycan macrophage colony-stimulating factor (PG-M-CSF) was recently reported as a high molecular type of macrophage colony stimulating factor (M-CSF). We analyzed its structure by determining the expression of mutant M-CSF cDNA in Chinese hamster ovary cells. PG-M-CSF contained two types of molecules, a homodimeric 150-200-kDa subunit and a heterodimeric form of a 43-kDa subunit and the 150-200-kDa subunit. The 150-200-kDa subunit carries a chondroitin sulfate chain, and its amino terminal amino acid sequence was identical to that of the 43-kDa subunit, which is known to form the conventional M-CSF molecule (85-kDa M-CSF). The results obtained with the carboxyl-terminal deleted mutants showed that the PG-M-CSF-specific 150-200-kDa subunit had a large part of the precursor sequence at its carboxyl terminus removed in the 43-kDa subunit by proteolytic processing. The expression of mutagenized cDNA, in which Arg(220) was replaced by an alanine residue, resulted in the disappearance of the 43-kDa subunit but not that of the 150-200-kDa subunit, indicating that Arg(220)-Pro-Pro-Arg is essential to process PG M-CSF to 85-kDa M-CSF. Truncated mutation analysis showed that the carboxyl terminus of the 150-200-kDa subunit lay downstream of Arg(412). We also showed that the chondroitin sulfate binding site in the 150-200-kDa subunit was Ser(277), since conversion of Ser(277) to the alanine residue resulted in complete loss of the chondroitin sulfate substitution.	NATL DEF MED COLL,DEPT INTERNAL MED 3,TOKOROZAWA,SAITAMA 359,JAPAN; MORINAGA MILK IND CO LTD,BIOCHEM RES LAB,ZAMA,KANAGAWA 228,JAPAN	National Defense Medical College - Japan; Morinaga Milk Industry Company, Ltd			Suzu, Shinya/F-5786-2013; Kanatani, Yasuhiro/AAE-5551-2019	Kanatani, Yasuhiro/0000-0001-5790-4084; Suzu, Shinya/0000-0003-2531-4770				ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAMURA T, 1988, BLOOD, V72, P886; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; ISHIYAMA M, 1994, CHEM PHARM BULL, V41, P1118; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN DM, 1990, J BIOL CHEM, V265, P5317; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MOTOYOSHI K, 1982, BLOOD, V60, P1378; MOTOYOSHI K, 1978, BLOOD, V52, P1012; NAKOINZ I, 1990, J IMMUNOL, V145, P860; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SUZU S, 1994, BLOOD, V83, P3113, DOI 10.1182/blood.V83.11.3113.bloodjournal83113113; SUZU S, 1991, BLOOD, V77, P2160; SUZU S, 1992, J BIOL CHEM, V267, P4345; SUZU S, 1992, J BIOL CHEM, V267, P16812; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V161, P892, DOI 10.1016/0006-291X(89)92683-1; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	34	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19751	19756						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051056				2022-12-27	WOS:A1994PA12600019
J	BINGHAM, BR; MONK, PN; HELM, BA				BINGHAM, BR; MONK, PN; HELM, BA			DEFECTIVE PROTEIN-PHOSPHORYLATION AND CA2+ MOBILIZATION IN A LOW SECRETING VARIANT OF THE RAT BASOPHILIC LEUKEMIA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; KINASE-C; RBL-2H3 CELLS; ACTIVATION; DEPHOSPHORYLATION; ENGAGEMENT; RESPONSES	High and low secreting variants of the rat basophilic leukemia cell line represent powerful tools to study the molecular basis of stimulus/secretion coupling via the high affinity receptor (Fc epsilon R1) complex for immunoglobulin E since an identification of the differences between these subclones may produce important information concerning the signaling pathways involved. A comparison between a variant supporting high mediator secretion (>50%) and one with a 10-fold reduced response to antigen shows that the latter is associated with a defect in threonine and tyrosine phosphorylation of the subunits of the Fc epsilon R1 complex. The delayed onset and reduced mediator release in the low secretor facilitated a slow motion study of the early events following receptor activation. It showed that tyrosine phosphorylation of a 72-kDa protein is an early event preceding threonine and subsequent tyrosine phosphorylation of the gamma-chain. This points to the activation of both protein-tyrosine kinases and protein kinase(s) C as early events in signal transduction. The retarded onset and low intensity of phosphorylation in the low secreting variant is associated with reduced levels of inositol phosphate production, and this and the lack of the Ca2+ mobilization from intracellular stores indicate a defect upstream of the activation of phospholipase C.	UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,ENGLAND	University of Sheffield			Monk, Peter/C-6155-2008	Monk, Peter/0000-0003-4637-3059				ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Bingham B.R., 1994, THESIS U SHEFFIELD; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MONK PN, 1993, RECEPTOR, V3, P77; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; WOULDEMUSSIE E, 1987, J IMMUNOL, V139, P2431; YAMADA K, 1992, J IMMUNOL, V149, P1031	22	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19300	19306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034693				2022-12-27	WOS:A1994NY33200018
J	ZHOU, DJ; CAM, LL; LAUGHTON, CA; KORZEKWA, KR; CHEN, S				ZHOU, DJ; CAM, LL; LAUGHTON, CA; KORZEKWA, KR; CHEN, S			MUTAGENESIS STUDY AT A POSTULATED HYDROPHOBIC REGION NEAR THE ACTIVE-SITE OF AROMATASE CYTOCHROME-P450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; INTRATUMORAL AROMATASE; CRYSTAL-STRUCTURE; BREAST; INHIBITORS; SYSTEM; EXPRESSION; ESTROGEN; POTENT	Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. On the basis of a recent computer modeling of the active site of aromatase, a hydrophobic pocket, thought to be important for the binding of some aromatase inhibitors, was predicted to extend roughly in the plane of the steroid substrate, from the position that would be occupied by its C4 and C7 atoms. Four mutants, G121A, I125N, F235N, and I474F, were generated to test this model. Although the mutagenesis results have shown that the current model for the active site of aromatase almost certainly contains a number of errors, the results are in general very satisfactory in that they suggest how the model should be altered by local realignments of the aromatase sequence with that of cytochrome P450(cam). Among the mutants, I474F is the most interesting one. Its K-m value for androstenedione was found to be lower than the wild type enzyme, and the kinetic analysis exhibited a substrate inhibition-like kinetic profile through an ''in-cell'' assay. In addition, this mutation reduces the binding affinity of an aromatase inhibitor, 4-hydroxyandrostenedione, and increases the binding affinity of two aromatase inhibitors, aminoglutethimide and CGS 16949. This study demonstrates a useful approach, by a combination of computer modeling, site-directed mutagenesis, and inhibitor binding studies, to examine the structure of the active site of aromatase and the binding nature of various aromatase inhibitors.	BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010; INST CANC RES,CRC,BIOMOLEC STRUCT UNIT,SUTTON SM2 5NG,SURREY,ENGLAND; NIH,BETHESDA,MD 20892	City of Hope; Beckman Research Institute of City of Hope; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA			Laughton, Charles A/E-5667-2010	Laughton, Charles A/0000-0003-4090-3960	NCI NIH HHS [CA33572, CA44735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA044735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARNEH B, 1993, MOL ENDOCRINOL, V7, P1617, DOI 10.1210/me.7.12.1617; Banting L, 1988, J Enzyme Inhib, V2, P215, DOI 10.3109/14756368809040728; BROWNE LJ, 1991, J MED CHEM, V34, P725, DOI 10.1021/jm00106a038; BRUEGGEMEIER RW, 1978, J MED CHEM, V21, P1008; CHEN S, 1992, J BIOL CHEM, V267, P22587; CHEN SU, 1993, J STEROID BIOCHEM, V44, P347, DOI 10.1016/0960-0760(93)90238-R; ESTEBAN JM, 1992, AM J PATHOL, V140, P337; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FURET P, 1993, J MED CHEM, V36, P1393, DOI 10.1021/jm00062a012; GRAHAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; GROGAN J, 1993, BIOCHEMISTRY-US, V32, P12007, DOI 10.1021/bi00096a010; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KADOHAMA N, 1992, J STEROID BIOCHEM, V43, P693, DOI 10.1016/0960-0760(92)90295-T; KADOHAMA N, 1993, BIOCHIM BIOPHYS ACTA, V1163, P195, DOI 10.1016/0167-4838(93)90181-P; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAUGHTON CA, 1993, J STEROID BIOCHEM, V44, P399, DOI 10.1016/0960-0760(93)90243-P; MACLUSKY N J, 1987, Steroids, V50, P459, DOI 10.1016/0039-128X(87)90032-8; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; PEET NP, 1993, J STEROID BIOCHEM, V44, P409, DOI 10.1016/0960-0760(93)90244-Q; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; SILVA MC, 1989, CANCER RES, V49, P2588; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZHOU D, 1990, CANCER RES, V50, P6949; ZHOU D, 1992, J BIOL CHEM, V267, P762; ZHOU DJ, 1991, P NATL ACAD SCI USA, V88, P410, DOI 10.1073/pnas.88.2.410	28	50	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19501	19508						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034720				2022-12-27	WOS:A1994NY33200048
J	HIGASHI, S; NISHIMURA, H; AITA, K; IWANAGA, S				HIGASHI, S; NISHIMURA, H; AITA, K; IWANAGA, S			IDENTIFICATION OF REGIONS OF BOVINE FACTOR-VII ESSENTIAL FOR BINDING TO TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; CRYSTAL-STRUCTURE; ACTIVATION; PURIFICATION; COAGULATION; PATHWAY; COMPLEX; DOMAIN; EXPRESSION; COFACTOR	Initiation of the extrinsic blood coagulation pathway is mediated by a complex formed between plasma-derived factor VII/VIIa and cell-derived tissue factor (TF). To identify the site(s) of interaction, zymogen VII and VIIa were enzymatically and chemically modified, and their affinities for TF were estimated by measuring their inhibitory effects on the amidolytic activity enhanced after formation of the VIIa-TF complex. We found that the VIIa-light chain (K-i = 3.5 x 10(-7) M) and its fragment consisting of the gamma-carboxyglutamic acid (Gla)-domain and the first epidermal growth factor (EGF)-like domain (Gla-EGF1 peptide; K-i = 1.0 x 10(-6) M) have an affinity for TF. Therefore, one of the binding sites of VII with TF is probably located in the Gla-EGF1 region. On the other hand, a dansyl-Glu-Gly-Arg chloromethyl ketone-treated Gla-domainless VIIa (K-i = 0.7 x 10(-7) M) showed a high affinity for TF: whereas the corresponding Gla-domainless VII similarly treated showed no binding potential, thereby indicating that binding site(s) other than in the Gla-EGF1 region are present in VIIa but not in VII. Acetylation or carbamylation of the alpha-amino group of the NH2-terminal Ile-153 of VIIa resulted in the loss of binding affinity for TF; such modifications convert VIIa into a zymogen-like inactive form by destroying the salt bridge between Ile-153 and Asp-343 in VIIa. The rate of carbamylation of VIIa was reduced in the presence of TF. Protection of the alpha-amino group of Ile-153 from carbamylation after complex formation was consistent with salt bridge formation between Ile-153 and Asp-343 in the VIIa-TF complex. Therefore, binding of TF with the heavy chain of VIIa may induce a conformational change that brings the alpha-amino group of Ile-153 close to the beta-carboxyl group of Asp-343 to make a stable salt bridge.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT HYG CHEM,SAPPORO 060,JAPAN	Kyushu University; Kyushu University; Hokkaido University								BACH R, 1981, J BIOL CHEM, V256, P8324; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; BROZE GJ, 1985, J BIOL CHEM, V260, P917; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; HIGASHI S, 1990, THROMB HAEMOSTASIS, V65, P1866; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MORITA T, 1986, J BIOL CHEM, V261, P4015; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; OPPENHEIMER HL, 1966, J BIOL CHEM, V241, P2720; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I. H., 1975, ENZYME KINETICS, P320; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	29	87	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18891	18898						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034645				2022-12-27	WOS:A1994NX32700032
J	TAOKA, S; TU, CK; KISTLER, KA; SILVERMAN, DN				TAOKA, S; TU, CK; KISTLER, KA; SILVERMAN, DN			COMPARISON OF INTRAMOLECULAR AND INTERMOLECULAR PROTON-TRANSFER IN HUMAN CARBONIC-ANHYDRASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIDE HYDRATION ACTIVITY; SITE-DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; HISTIDINE-64; CO2; EXPRESSION; ISOENZYME; KINETICS; MUTANT; ENZYME	The catalysis of the hydration of CO2 by human carbonic anhydrase II (HCA II) includes the transfer of a proton from zinc-bound water to histidine 64 utilizing a network of intervening hydrogen-bonded water molecules, then the proton is transferred to buffer in solution. We used stopped-flow spectrophotometry and O-18 exchange between CO2 and water measured by mass spectrometry to compare catalytic constants dependent on proton transfer in HCA II and in the mutant H64A HCA II containing the replacement His(64) --> Ala. Maximal velocities and oxygen-18 exchange catalyzed by H64A HCA II showed that nearly all of the proton transfer with this mutant proceeded through the imidazole buffer. The following parameters were very similar or identical in catalysis by H64A HCA II compared with catalysis by wild-type HCA II both in the presence of large concentrations of imidazole (100 mM): the maximal rate of initial velocity and of exchange of O-18 between CO2 and water, solvent hydrogen isotope effects on the maximal velocity, and the dependence of these isotope effects on the atom fraction of deuterium in solvent water. These results indicate that the proton transfer involving the zinc-bound water in catalysis is not significantly affected by the difference between the mobility of the free imidazole buffer and the side chain of His 64. Moreover, data for both the wild-type and mutant enzymes are consistent with proton transfer through intervening hydrogen-bonded water bridges in the active site. These features of the proton transfer are discussed in terms of a model in which the first proton transfer from the zinc-bound water to an adjacent water is rate limiting.	UNIV FLORIDA,CTR HLTH,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FORSMAN C, 1988, FEBS LETT, V229, P360, DOI 10.1016/0014-5793(88)81156-6; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; KASSEBAUM JW, 1989, J AM CHEM SOC, V111, P2691, DOI 10.1021/ja00189a052; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KREBS JF, 1991, BIOCHEMISTRY-US, V30, P9153, DOI 10.1021/bi00102a005; KRESGE AJ, 1977, J AM CHEM SOC, V99, P7228, DOI 10.1021/ja00464a023; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LIANG JY, 1988, BIOCHEMISTRY-US, V27, P8676, DOI 10.1021/bi00423a025; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; NYMAN PO, 1964, BIOCHIM BIOPHYS ACTA, V85, P141, DOI 10.1016/0926-6569(64)90174-9; POCKER Y, 1977, BIOCHEMISTRY-US, V16, P5698, DOI 10.1021/bi00645a008; POCKER Y, 1986, ZINC ENZYMES, P341; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STEINER H, 1976, FEBS LETT, V62, P16, DOI 10.1016/0014-5793(76)80006-3; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TU CK, 1989, J BIOL CHEM, V264, P12389; TU CK, 1981, J BIOL CHEM, V256, P9466; VENKATASUBBAN KS, 1980, BIOCHEMISTRY-US, V19, P4984, DOI 10.1021/bi00563a008	29	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17988	17992						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027057				2022-12-27	WOS:A1994NV42200038
J	ALEXSON, SEH; FINLAY, TH; HELLMAN, U; SVENSSON, LT; DICZFALUSY, U; EGGERTSEN, G				ALEXSON, SEH; FINLAY, TH; HELLMAN, U; SVENSSON, LT; DICZFALUSY, U; EGGERTSEN, G			MOLECULAR-CLONING AND IDENTIFICATION OF A RAT SERUM CARBOXYLESTERASE EXPRESSED IN THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYL-COA HYDROLASE; ENDOPLASMIC-RETICULUM; CDNA CLONING; MICROSOMAL CARBOXYLESTERASES; MONOACYLGLYCEROL LIPASE; DIFFERENT LABORATORIES; GLYCOPROTEIN ESTERASE; NUCLEOTIDE-SEQUENCE; MULTIGENE FAMILY; PLASMA ESTERASE	We have cloned and sequenced a carboxylesterase from rat liver and purified the corresponding protein from rat blood. The cDNA encodes the entire mature serum esterase protein. It is apparently identical to cDNAs cloned from rat liver by several groups (Long, R. M., Satoh, H., Martin, B. M., Kimura, S., Gonzales, F. J., and Pohl, L. R. (1988) Biochem. Biophys. Res. Commun. 156, 866-873; Takagi, Y., Morohashi, K.-i., Kawabata, S.-i., Go, M., and Omura, T. (1988) J. Biochem. (Tokyo) 104, 801-806; and Robbi, M., and Beaufay, H. (1992) Biochem. Biophys. Res. Commun. 183, 836-841). However, the identification of the protein encoded by this cDNA has not been previously reported. The COOH-terminal -TEHT sequence found in the rat serum carboxylesterase does not possess retention properties and is therefore responsible for its secretion and presence in the circulation. The rat serum carboxylesterase was purified to apparent homogeneity by affinity chromatography on immobilized antibody to rat liver microsomal acyl-CoA thioesterase followed by ion exchange chromatography. The purified protein, with a M(r) of approximately 70,000, was cleaved in situ in a polyacrylamide gel with trypsin, and two peptides were isolated and sequenced. Sequence analysis showed that both peptides were identical only to the corresponding deduced amino acid sequence of the cloned cDNA Antibodies raised to the COOH-terminal amino acid sequence deduced from the cDNA cross-reacted with the purified rat serum carboxylesterase. Changes in serum esterase activity levels followed changes in protein mass in rat serum and changes in liver mRNA levels in response to various nutritional conditions while total liver esterase activity was essentially unchanged. The above experiments confirm the identity of the protein isolated from rat sera with the cDNA cloned from rat liver and suggest a function for the serum esterase in lipid metabolism.	NYU,MED CTR,DEPT OBSTET & GYNECOL,NEW YORK,NY 10016; LUDWIG INST CANC RES,UPPSALA BRANCH,S-75127 UPPSALA,SWEDEN; UNIV STOCKHOLM,WENNER GREN INST,DEPT METAB RES,S-10691 STOCKHOLM,SWEDEN	New York University; Ludwig Institute for Cancer Research; Stockholm University	ALEXSON, SEH (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN.		Diczfalusy, Ulf/A-5336-2008					ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ARNDT R, 1978, H-S Z PHYSIOL CHEM, V359, P641; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GASSER DL, 1973, BIOCHEM GENET, V10, P207, DOI 10.1007/BF00485699; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GENETTA TL, 1988, BIOCHEM BIOPH RES CO, V151, P1364, DOI 10.1016/S0006-291X(88)80513-8; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HATTORI K, 1981, BIOCHEM PHARMACOL, V30, P2051, DOI 10.1016/0006-2952(81)90222-7; HEIDRICH HJ, 1987, BIOCH GENET, V25, P79; HEIDRICH HJ, 1987, J HERED, V78, P92; HEYMANN E, 1980, ENZYMATIC BASIS DETO, V2, P291; HIROSE T, 1990, EUR J BIOCHEM, V189, P431, DOI 10.1111/j.1432-1033.1990.tb15506.x; HOSOKAWA M, 1990, ARCH BIOCHEM BIOPHYS, V277, P219, DOI 10.1016/0003-9861(90)90572-G; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KADNER SS, 1984, ENDOCRINOLOGY, V115, P2406, DOI 10.1210/endo-115-6-2406; KDNER SS, 1992, ARCH BIOCHEM BIOPHYS, V296, P435; KORZA G, 1988, J BIOL CHEM, V263, P3486; LEINWEBER FJ, 1987, DRUG METAB REV, V18, P379, DOI 10.3109/03602538708994129; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LONG RM, 1991, LIFE SCI, V48, P43; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MEDDA S, 1992, EUR J BIOCHEM, V206, P801, DOI 10.1111/j.1432-1033.1992.tb16987.x; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1984, BIOCHEM PHARMACOL, V33, P1243, DOI 10.1016/0006-2952(84)90176-X; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MENTLEIN R, 1985, ARCH BIOCHEM BIOPHYS, V240, P801, DOI 10.1016/0003-9861(85)90089-X; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V234, P612, DOI 10.1016/0003-9861(84)90311-4; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; MURAKAMI K, 1993, J BIOCHEM-TOKYO, V113, P61, DOI 10.1093/oxfordjournals.jbchem.a124004; OTTO J, 1981, EUR J BIOCHEM, V116, P285, DOI 10.1111/j.1432-1033.1981.tb05331.x; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OZOLS J, 1987, J BIOL CHEM, V262, P15316; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; RIDDLES PW, 1991, GENE, V108, P289, DOI 10.1016/0378-1119(91)90448-K; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROBBI M, 1993, ESTERASES LIPASES PH; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J, 1989, MOL CLONING LABORATO; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TSUJITA T, 1988, J BIOCHEM, V103, P327, DOI 10.1093/oxfordjournals.jbchem.a122269; VANLITH HA, 1989, LIPIDS, V24, P86, DOI 10.1007/BF02535271; VANLITH HA, 1993, ARCH BIOCHEM BIOPHYS, V301, P265, DOI 10.1006/abbi.1993.1143; VANLITH HA, 1992, EUR J BIOCHEM, V206, P527; VANZUTPHEN LFM, 1984, J HERED, V75, P313, DOI 10.1093/oxfordjournals.jhered.a109942; ZSCHUNKE F, 1991, BLOOD, V78, P506	56	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17118	17124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006016				2022-12-27	WOS:A1994NT84600023
J	BRANDT, R; NORMANNO, N; GULLICK, WJ; LIN, JH; HARKINS, R; SCHNEIDER, D; JONES, BW; CIARDIELLO, F; PERSICO, MG; ARMENANTE, F; KIM, N; SALOMON, DS				BRANDT, R; NORMANNO, N; GULLICK, WJ; LIN, JH; HARKINS, R; SCHNEIDER, D; JONES, BW; CIARDIELLO, F; PERSICO, MG; ARMENANTE, F; KIM, N; SALOMON, DS			IDENTIFICATION AND BIOLOGICAL CHARACTERIZATION OF AN EPIDERMAL GROWTH FACTOR-RELATED PROTEIN - CRIPTO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MAMMARY EPITHELIAL-CELLS; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; INVITRO TRANSFORMATION; COLORECTAL TUMORS; FACTOR GENE; EXPRESSION; AMPHIREGULIN; EGF	The human and mouse cripto-1 (CR-1) genes can code for proteins related in structure to epidermal growth factor (EGF). A specific 36-kDa immunoreactive protein was detected by Western blot analysis in human cell lines that express CR-1 mRNA but not in cell lines that fail to express this transcript. Immunoprecipitation of GEO colon carcinoma or mouse embryonal carcinoma cells detected 27-29-kDa and 24-kDa proteins, respectively. Cell lysates and conditioned medium that were prepared from several CHO clones and were expressing either a recombinant human or mouse CR-1 cDNA contained immunospecific 27-29-kDa and 24 kDa proteins, respectively. Monensin or tunicamycin treatment resulted in a shift of the 27-29-kDa human CR-1 protein to 24 kDa and 20 kDa, respectively. The 20-kDa protein was also observed after digestion of the 27-29-kDa human CR-1 protein with N-glycosidase F. Using two CR-1 synthetic refolded peptides that correspond to the EGF-like domain of the human CR-1 sequence or conditioned medium obtained from human CR-1 expressing CHO cells, growth stimulatory activity could be detected on nontransformed human mammary epithelial cells and on two human breast cancer cell lines. EGF receptor-blocking antibody did not inhibit the growth stimulatory action of the CR-1 protein. Likewise, the CR-1 refolded peptides or conditioned medium from the human CR-1-expressing CHO cells failed to inhibit the binding of I-125-EGF in an EGF-radioreceptor assay. These data demonstrate that the CR-1 is a glycoprotein that can function as a growth factor through an EGF receptor-independent pathway.	NCI, TUMOR IMMUNOL & BIOL LAB, TUMOR GROWTH FACTOR SECT, BETHESDA, MD 20892 USA; HAMMERSMITH HOSP, IMPERIAL CANC RES FUND, MOLEC ONCOL UNIT, LONDON W12 0NN, ENGLAND; BERLEX BIOSCI INC, RICHMOND, CA 94804 USA; UNIV NAPLES FEDERICO II, FAC MED & CHIRURG, CATTEDRA ONCOL MED, I-80131 NAPLES, ITALY; INT INST GENET & BIOPHYS, CNR, I-80125 NAPLES, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; Imperial College London; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Normanno, Nicola/AAT-1107-2021	Normanno, Nicola/0000-0002-7158-2605; Ciardiello, Fortunato/0000-0002-3369-4841				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; AVIVI A, 1991, ONCOGENE, V6, P673; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DONO R, 1991, AM J HUM GENET, V49, P555; DONO R, 1993, DEVELOPMENT, V118, P1157; GOUSTIN AS, 1986, CANCER RES, V46, P1015; Gullick W J, 1988, Methods Mol Biol, V3, P341, DOI 10.1385/0-89603-126-8:341; HAND PH, 1992, INT J BIOL MARKER, V7, P1; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; NORMANNO N, 1993, INT J ONCOL, V2, P903; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QI C, 1994, IN PRESS BR J CANCER; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SALOMON DS, 1992, CURRENT PERSPECTIVES, P211; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1991, METHOD ENZYMOL, V198, P213; SPEAR KL, 1991, TECHNIQUES IN PROTEIN CHEMISTRY II, P233; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; Todaro G J, 1990, Semin Cancer Biol, V1, P257; VUSSIN H, 1986, EMBO J, V6, P3431	51	94	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17320	17328						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006041				2022-12-27	WOS:A1994NT84600052
J	GOLDBERGER, A; MIDDLETON, KA; OLIVER, JA; PADDOCK, C; YAN, HC; DELISSER, HM; ALBELDA, SM; NEWMAN, PJ				GOLDBERGER, A; MIDDLETON, KA; OLIVER, JA; PADDOCK, C; YAN, HC; DELISSER, HM; ALBELDA, SM; NEWMAN, PJ			BIOSYNTHESIS AND PROCESSING OF THE CELL-ADHESION MOLECULE PECAM-1 INCLUDES PRODUCTION OF A SOLUBLE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; TRITON X-114; CD31; DIFFERENTIATION; PURIFICATION; EXPRESSION; ACTIVATION; ANTIGEN	PECAM-1 (CD31) is a 130-kDa glycoprotein found on platelets, endothelial cells, granulocytes, and monocytes, as well as on certain myelomonocytic cell lines. Recent studies have shown that PECAM-1 may be involved in activation of leukocyte integrins and may also be involved in adhesive interactions of circulating leukocytes and the vessel wall. In spite of the important functional role that PECAM-1 plays in these processes, little is known about the biosynthesis, processing, and turnover of PECAM-1 on the cell surface. We have studied the biosynthesis of PECAM-1 in the promonocytic cell line U937, and in endothelial cells, by pulse-chase labeling and immunoprecipitation. PECAM-1 was synthesized as a 110-kDa precursor form, which was processed into the 130-kDa mature form within 1-3 h, during which time it began to move to the cell surface. The protein disappeared from the cell surface in both cell types about 48 h after labeling. A soluble form of PECAM-1, which is 5-10 kDa smaller than cell-associated PECAM-1 and contains the cytoplasmic tail, was observed in the culture media of HUVECs and phorbol ester-treated U937 cells. This form of soluble PECAM-1 is encoded by an alternatively spliced mRNA from which the exon containing the transmembrane domain has been removed. Soluble PECAM-1 was also detected in normal human plasma at levels of 10-25 ng/ml. Two isoforms of plasma PECAM-1, which differed in the presence of the cytoplasmic tail, were observed by Western blot analysis. In parallel with soluble forms of other cell adhesion molecules, soluble PECAM-1 may play a role in modulating the inflammatory response.	UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; MED COLL WISCONSIN,DEPT CELLULAR BIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53226	University of Pennsylvania; The Wistar Institute; Medical College of Wisconsin; Medical College of Wisconsin	GOLDBERGER, A (corresponding author), BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI, USA.		DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-07902, HL-43611, HL-40926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043611, R01HL040926, T32HL007902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; ASHMAN LK, 1991, TISSUE ANTIGENS, V38, P199, DOI 10.1111/j.1399-0039.1991.tb01898.x; BECKER JC, 1991, J IMMUNOL, V147, P4398; BOGEN SA, 1992, AM J PATHOL, V141, P843; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CABANAS C, 1989, EUR J IMMUNOL, V19, P1373, DOI 10.1002/eji.1830190804; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GOLDBERGER A, 1991, BLOOD, V78, P681; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GOYERT SM, 1986, J IMMUNOL, V137, P3909; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LYONS AB, 1988, PATHOLOGY, V20, P137, DOI 10.3109/00313028809066624; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1982, THROMB RES, V27, P221, DOI 10.1016/0049-3848(82)90202-X; NEWMAN PJ, 1986, J CELL BIOL, V103, P81, DOI 10.1083/jcb.103.1.81; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NEWMAN PJ, 1994, IN PRESS ANN NY ACAD; OHTO H, 1985, BLOOD, V66, P873; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKEUCHI A, 1988, CLIN IMMUNOL IMMUNOP, V49, P439, DOI 10.1016/0090-1229(88)90131-6; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	39	108	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17183	17191						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006026				2022-12-27	WOS:A1994NT84600033
J	SATO, R; YANG, JX; WANG, XD; EVANS, MJ; HO, YK; GOLDSTEIN, JL; BROWN, MS				SATO, R; YANG, JX; WANG, XD; EVANS, MJ; HO, YK; GOLDSTEIN, JL; BROWN, MS			ASSIGNMENT OF THE MEMBRANE ATTACHMENT, DNA FINDING, AND TRANSCRIPTIONAL ACTIVATION DOMAINS OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 (SREBP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MUTANT HAMSTER-CELLS; RECEPTOR PROMOTER; NUCLEAR-PROTEIN; CULTURED-CELLS; IDENTIFICATION; ENDOCYTOSIS; MEVALONATE; GENES	Transcription of the low density lipoprotein receptor gene and other sterol-regulated genes is stimulated by sterol regulatory element-binding protein-1 (SREBP-1), a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) transcription factor. Human SREBP-1 is synthesized as an 1147-amino acid precursor that is attached intrinsically to membranes of the nuclear envelope and endoplasmic reticulum. In sterol-depleted cells the precursor is cleaved to generate an NH2-terminal fragment that enters the nucleus and activates transcription by binding to sterol regulatory element-1 (SRE-1). Sterols prevent transcriptional activation by blocking the proteolytic cleavage. In the current studies, performed with hamster SREBP-1, we used mutational analysis to localize the transcriptional activation domain to an acidic NH2-terminal sequence. Deletion of this sequence converted SREBP-1 from an activator to an inhibitor of transcription. DNA binding was assigned to the basic region of the bHLH-ZIP domain. Binding was abolished by substitution of 3 amino acids that were previously implicated in DNA binding by Max, another bHLH-ZIP protein. The membrane attachment domain was localized to two hydrophobic regions at residues 477-497 and 536-556. Truncation of SREBP-1 prior to these regions gave rise to an NH2-terminal fragment that was soluble and entered the nucleus. This fragment was more than 30-fold more active than full-length SREBP-1 in stimulating transcription of an SRE-1 containing reporter gene in transfected cells. Deletion of the hydrophobic sequences (Delta 476-556) yielded a protein that appeared cytosolic by immunofluorescence microscopy but failed to enter the nucleus readily, apparently because of inhibition by sequences in the remaining COOH-terminal domain. This study provides a picture of the domain structure of SREBP-1 and further elucidates the mechanism by which it adjusts gene transcription to maintain cholesterol homeostasis in animal cells.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					FOGARTY INTERNATIONAL CENTER [F05TW004571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; FIC NIH HHS [F05TW04571] Funding Source: Medline; NHLBI NIH HHS [HL20948] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HERZ J, 1990, J BIOL CHEM, V265, P21355; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIM CM, 1992, J BIOL CHEM, V267, P23113; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; PTASHNE M, 1992, GNEETIC SWITCH, P133; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Sambrook J, 1989, MOL CLONING LABORATO; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	19	187	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17267	17273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006035				2022-12-27	WOS:A1994NT84600045
J	BOFFI, A; TAKAHASHI, S; SPAGNUOLO, C; ROUSSEAU, DL; CHIANCONE, E				BOFFI, A; TAKAHASHI, S; SPAGNUOLO, C; ROUSSEAU, DL; CHIANCONE, E			STRUCTURAL CHARACTERIZATION OF OXIDIZED DIMERIC SCAPHARCA-INAEQUIVALVIS HEMOGLOBIN BY RESONANCE RAMAN-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-HEME INTERACTIONS; TETRAMERIC HEMOGLOBINS; SPECTRA; DERIVATIVES; OXIDATION; COMPLEXES; BINDING	Resonance Raman spectra of the ferric homodimeric hemoglobin from Scapharca inaequivalvis have been measured over the pH range 5.8-8.3 in buffers of ionic strengths 0.01 and 0.1 M to determine the spin and coordination state of the iron atom. Three species contribute to the spectra: a low spin hexacoordinate, a high spin pentacoordinate, and a high spin hexacoordinate component. Optical absorption and EPR spectra measured under the same conditions allowed the identification of the ligands in the sixth coordination position, namely the distal histidine in the low spin derivative and a water molecule in the high spin one. The relative concentrations of these three species depend on pH in an unusual way. Thus, the aquomet derivative is present over the whole pH range, albeit in small amounts as most of the hemoglobin converts to the low spin hemichrome at acid pH values and to the pentacoordinate derivative at neutral and slightly alkaline ones. The formation of a pentacoordinate heme as the pH is increased has not been reported previously for other myoglobins and hemoglobins. Low ionic strength and high protein concentration favor the formation of the high spin pentacoordinate species, while at high ionic strength and low protein concentration the low spin hexacoordinate species prevails. Ionization of the iron-bound water molecule occurs at pH greater than or equal to 9.3; accordingly, signals from the hydroxyl derivative were not observed in the Raman spectra over the pH range studied.	AT&T BELL LABS,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs	BOFFI, A (corresponding author), UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY.							ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CHIANCONE E, 1990, BIOPHYS CHEM, V37, P287, DOI 10.1016/0301-4622(90)88028-Q; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; GURD FRN, 1967, J BIOL CHEM, V242, P5724; HENRY ER, 1985, BIOCHEMISTRY-US, V24, P5907, DOI 10.1021/bi00342a033; MALTEMPO MM, 1974, BIOCHIM BIOPHYS ACTA, V342, P290, DOI 10.1016/0005-2795(74)90084-1; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; ROUSSEAU DL, 1981, J RAMAN SPECTROSC, V10, P94, DOI 10.1002/jrs.1250100116; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; SCHOLLER DL, 1978, J AM CHEM SOC, V101, P1655; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SPAGNUOLO C, 1994, J BIOL CHEM, V269, P20441; SPAGNUOLO C, 1991, BIOCHIM BIOPHYS ACTA, V1074, P270, DOI 10.1016/0304-4165(91)90163-B; SPAGNUOLO C, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P147; SPAULDING LD, 1975, J AM CHEM SOC, V97, P4526; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SPIRO TG, 1974, J AM CHEM SOC, V96, P338, DOI 10.1021/ja00809a004; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320	23	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20437	20440						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051140				2022-12-27	WOS:A1994PB31700037
J	ANUKANTH, A; KHORANA, HG				ANUKANTH, A; KHORANA, HG			STRUCTURE AND FUNCTION IN RHODOPSIN .8. REQUIREMENTS OF A SPECIFIC STRUCTURE FOR THE INTRADISCAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; GENE; SEQUENCE; EXPRESSION; PROTEINS; CELLS	We concluded previously from mutagenesis in the intradiscal domain of bovine rhodopsin that the formation of a tertiary structure comprising the N-terminal tail and the three polypeptide loops is essential to the in vivo assembly of the functional rhodopsin. We now report on more comprehensive mutagenic studies in the intradiscal domain to determine more precisely the requirement for the formation of the above proposed tertiary structure. Three large deletions, two consisting of groups of 10 amino acids each, and the third of 34 amino acids, were carried out in the N-terminal loop. All the three mutant opsins only poorly formed the rhodopsin chromophore. In the BC loop, we carried out five 2 amino acid deletions, 2 single amino acid deletions, and three mutations in which short sequences in the loop were reversed. All the resulting mutant opsins had lost the ability to bind 11-cis-retinal. In the DE loop, where extensive mutagenesis had previously been carried out, we carried out 3 amino acid replacements (Asn, Thr, Tyr) at Cys(187). None of these mutants bound 11-cis-retinal. In loop FG, we carried out four 2 amino acid deletions, 1 single amino acid deletion, 3 amino acid replacements, and one mutation in which the sequence of the 7 amino acids was reversed. Ah the mutants in FG loop partially formed the rhodopsin chromophore. All the mutants now described appeared to be retained in the endoplasmic reticulum: several that were examined in detail were complexed with non-opsin proteins, the chaperonins. Treatment with ATP-MgCl2 released the latter from the mutant rhodopsins, Our overall conclusion is that the formation of the specific structure in the intradiscal domain has highly stringent spatial requirements.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MADURAI KAMARAJ UNIV,SCH BIOL SCI,DEPT BIOPHYS,MADURAI 625021,TAMIL NADU,INDIA	Massachusetts Institute of Technology (MIT); Madurai Kamaraj University	ANUKANTH, A (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FISHMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P646, DOI 10.1001/archopht.1992.01080170068026; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KHORANA HG, 1992, J BIOL CHEM, V267, P1; NAKAYAMA TA, 1990, J ORG CHEM, V55, P4953, DOI 10.1021/jo00303a038; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; YOKOYAMA R, 1990, VISION RES, V30, P807, DOI 10.1016/0042-6989(90)90049-Q	25	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19738	19744						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051054				2022-12-27	WOS:A1994PA12600017
J	MASUDA, T; TANAKA, K; NONAKA, H; YAMOCHI, W; MAEDA, A; TAKAI, Y				MASUDA, T; TANAKA, K; NONAKA, H; YAMOCHI, W; MAEDA, A; TAKAI, Y			MOLECULAR-CLONING AND CHARACTERIZATION OF YEAST-RHO GDP DISSOCIATION INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; GDP/GTP EXCHANGE PROTEINS; BOVINE BRAIN CYTOSOL; ADP-RIBOSYLATION; POSTTRANSLATIONAL MODIFICATIONS; SACCHAROMYCES-CEREVISIAE; CLOSTRIDIUM-BOTULINUM; ACTIVATING PROTEIN; GENE-PRODUCT; SMG P21S	We have previously isolated rho GDP dissociation inhibitor (rho GDI) from bovine brain and characterized it. Bovine rho GDI is a protein of a M(r) of 23,421 with 204 amino acids, rho GDI inhibits the GDP/GTP exchange reaction of post translationally lipid-modified small GTP-binding proteins (G proteins) of the rho family, including the rho, rac, and cdc42 subfamilies, and keeps them in the GDP-bound inactive form. In the present study, we first purified rho GDI from the cytosol fraction of the yeast Saccharomyces cerevisiae and isolated its gene. Yeast rho GDI gene had an open reading frame without introns encoding a protein of a M(r) of 23,138 with 202 amino acids. Yeast rho GDI protein was 36% identical with bovine rho GDI. Yeast rho GDI expressed in Escherichia coli was active not only on yeast rho1 but also on mammalian rho family members which were post-translationally modified. Disruption of rho GDI did not induce apparent phenotypes, whereas overexpression of yeast or bovine rho GDI resulted in the inhibition of cell growth. These results indicate that rho GDI exists and regulates the function of the rho family members in yeast.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LANG P, 1992, J BIOL CHEM, V267, P11677; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sherman F., 1986, METHODS YEAST GENETI; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	45	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19713	19718						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051050				2022-12-27	WOS:A1994PA12600013
J	SHITARA, K; YAMADA, H; WATANABE, K; SHIMONAKA, M; YAMAGUCHI, Y				SHITARA, K; YAMADA, H; WATANABE, K; SHIMONAKA, M; YAMAGUCHI, Y			BRAIN-SPECIFIC RECEPTOR-TYPE PROTEIN-TYROSINE-PHOSPHATASE RPTP-BETA IS A CHONDROITIN SULFATE PROTEOGLYCAN IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; BINDING; TISSUES; DOMAIN; REGION	By using polyclonal antiserum, which recognizes multiple proteoglycan core proteins, we isolated a cDNA species for an unknown chondroitin sulfate proteoglycan in bovine brain. Unexpectedly, DNA sequencing re- vealed that the cDNA encodes an open reading frame highly homologous to the human receptor-type protein-tyrosine phosphatase, RPTP beta. To prove that RPTP beta is a proteoglycan, we raised three polyclonal antibodies against extracellular and cytoplasmic domains of human RPTP beta. These antibodies have been shown to react with a smear band ranging from 350 to 500 kDa in human brain extracts. Digestion with chondroitinase ABC eliminated this smear and gave rise to a 310/300-kDa doublet band that was not detected without digestion, indicating that almost all of the RPTP beta molecules in the brain contain chondroitin sulfate chains. In the cerebellum, immunofluorescence staining of chondroitinase-treated sections revealed pericellular localization of RPTP beta in the external and internal granular layers. These data establish that RPTP beta is expressed constitutively as a chondroitin sulfate proteoglycan in the brain, and suggest that chondroitin sulfates may be an essential component for the physiological function of RPTP beta in vivo.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915	NATIONAL CANCER INSTITUTE [R01CA057366] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHARBONNEAU H, 1992, ANN REV CELL BIOL, V8, P493; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; FISHER EH, 1991, SCIENCE, V253, P401; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SAP J, 1994, MOL CELL BIOL, V14, P1; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; YAMADA H, 1994, J BIOL CHEM, V269, P10119	24	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20189	20193						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051107				2022-12-27	WOS:A1994PA12600078
J	TRAINER, VL; BADEN, DG; CATTERALL, WA				TRAINER, VL; BADEN, DG; CATTERALL, WA			IDENTIFICATION OF PEPTIDE COMPONENTS OF THE BREVETOXIN RECEPTOR-SITE OF RAT-BRAIN SODIUM-CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTOXIN BINDING; ALPHA-1 SUBUNIT; SCORPION TOXIN; ALLOSTERIC MODULATION; CA2+ CHANNELS; ELECTROPHORESIS; TETRODOTOXIN; SYNAPTOSOMES; GYMNODINIUM; DERIVATIVES	To identify the binding domain for brevetoxins, a family of lipid-soluble neurotoxins acting at Na+ channel receptor site 5, purified and reconstituted rat brain Na+ channels were photolabeled with p-azidobenzoyl tritium labeled brevetoxin, and the labeled peptides were identified. A radiolabeled band with an apparent molecular mass of 250 kDa corresponding to the Na+ channel alpha-subunit was revealed using both gel slicing and fluorography techniques. Regions of the alpha-subunit specifically photolabeled by this ligand were then identified by antibody mapping of proteolytic fragments. Even after extensive proteolysis, anti-peptide antibodies recognizing amino acid sequences within or adjacent to Na+ channel transmembrane segments IS6 and IVS5 were each able to immunoprecipitate up to 40% of the labeled peptides. A more extensive tryptic digest was obtained with a preparation in which the brevetoxin photolabel was incorporated into the alpha-subunit of purified Na+ channel in detergent solution. The identification of a specifically immunoprecipitated 6-kDa peptide containing transmembrane segment S6 from domain I restricted the labeled peptide fragment to residues Thr-400 to Lys-443 if tryptic digestion was complete or Ala-396 to Lys-455 if tryptic cleavage was incomplete. Similarly, the identification of a specifically immunoprecipitated 6-kDa peptide from domain IV restricted the labeled peptide to residues Glu-1738 to Lys-1785 or Glu-1738 to Lys-1793 on the extracellular side of transmembrane segment S5. These results provide direct evidence for close association of transmembrane segments IS6 and IVS5 in the native conformation of the Na+ channel alpha-subunit and implicate their region of interaction as an important component of the brevetoxin receptor site.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,MIAMI,FL 33149	University of Washington; University of Washington Seattle; University of Miami			Trainer, Vera/AAE-9306-2022		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006411, F32ES005586] Funding Source: NIH RePORTER; NIEHS NIH HHS [NIEHS F32 ES 05586, NIEHS P30 ES 06411] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CATTERALL WA, 1981, MOL PHARMACOL, V19, P345; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HUANG JMC, 1984, J PHARMACOL EXP THER, V229, P615; LIN YY, 1981, J AM CHEM SOC, V103, P6773, DOI 10.1021/ja00412a053; LOMBET A, 1987, FEBS LETT, V219, P355, DOI 10.1016/0014-5793(87)80252-1; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Orth DN, 1979, METHOD HORM RADIOIMM, P245; POLI MA, 1986, MOL PHARMACOL, V30, P129; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WU CH, 1988, ANNU REV PHARMACOL, V28, P141	31	136	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19904	19909						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051073				2022-12-27	WOS:A1994PA12600039
J	DELVECCHIO, RL; TONKS, NK				DELVECCHIO, RL; TONKS, NK			CHARACTERIZATION OF 2 STRUCTURALLY RELATED XENOPUS-LAEVIS PROTEIN-TYROSINE PHOSPHATASES WITH HOMOLOGY TO LIPID-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE HOMOLOGY; EXPRESSION; CLONING; GENE; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; KINASES; SITE	We have chosen Xenopus laevis as a model system to study how protein tyrosine phosphatases (PTPases) function in growth and development. As an initial step, we have previously isolated in a polymerase chain reaction (PCR)-based protocol cDNA fragments which correspond to sequences within the catalytic domains of PTPases (Yang, and., and Tonks, N. K. (1993) Adv. Protein Phosphatases 7, 359-372). Two of these PCR products, designated X1 and X10, have now been used to screen a X. laevis ovary cDNA library to obtain complete coding sequences for two distinct PTPases. The X1 cDNA encodes a protein (PTPX1) of 693 amino acids (approximate to 79 kDa); the X10 cDNA encodes a protein of 597 amino acids (approximate to 69 kDa). Both PTPX1 and PTPX10 lack potential membrane spanning sequences and therefore can be classified as non-transmembrane/cytoplasmic PTPases. While the overall structure of these PTPases are similar, sharing segments of 95% amino acid identity, they differ in that PTPX1 contains a unique 97-amino acid insert between the N-terminal segment and C-terminal catalytic domain. The absence of complete identity between PTPX1 and PTPX10 suggests that these two sequences are the products of separate genes and not the result of alternative splicing. This conclusion is confirmed by PCR analysis of Xenopus genomic DNA. Both PTPases share sequence identities in their N-terminal segments with two lipid-binding proteins, cellular retinaldehyde-binding protein and SEC14p, a phospholipid transferase. In addition, the unique insert sequence of PTPX1 shares identity with PSSA, a protein involved in phosphatidylserine biosynthesis. Sequence comparison suggests that PTPX10 is the Xenopus homolog of the human PTPase Meg-02, while PTPX1 is a structurally related yet distinct PTPase, Intrinsic PTPase activity of PTPX1 and PTPX10 was demonstrated in lysates of Sf9 cells infected with recombinant baculoviruses encoding either enzyme. PTPX1 can be recovered in both soluble and membrane fractions from Xenopus oocytes with the membrane form exhibiting approximate to 4-fold higher activity than the soluble form.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CRABB JW, 1988, J BIOL CHEM, V263, P18688; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE O, 1991, J BIOL CHEM, V266, P24184; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WARY KK, 1993, CANCER RES, V53, P1498; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG Q, 1993, ADV PROTEIN PHOSPHAT, V7, P359; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	25	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19639	19645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034733				2022-12-27	WOS:A1994NY33200068
J	LLOYD, JA; CASE, SS; PONCE, E; LINGREL, JB				LLOYD, JA; CASE, SS; PONCE, E; LINGREL, JB			POSITIVE TRANSCRIPTIONAL REGULATION OF THE HUMAN GAMMA-GLOBIN GENE - GAMMA-PE IS A NOVEL NUCLEAR FACTOR WITH MULTIPLE BINDING-SITES NEAR THE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; BETA-GLOBIN; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; FACTOR NF-E2; EXPRESSION; DNA; ENHANCER; PROMOTER; SEQUENCES	A novel nuclear factor involved in human gamma-globin gene regulation has been identified. Co migrating and cross-competing complexes were formed with five individual fragments from the 5'- and 3'-flanking regions of the gene in DNA-protein binding assays. This indicates that a nuclear factor, termed gamma PE, has multiple binding sites near the gamma-globin gene. This characteristic is shared by other important factors in globin gene regulation, such as GATA-1. The five gamma PE binding sites can be placed in two categories based on DNA-protein binding affinity and DNA sequence composition. The consensus sequence for the two higher affinity binding sites is ATTANNNGGAANNCT(N)TNNNTAATGG and for the three lower affinity sites is AAAAN(A/T)A(A/T)TT. Both the ATTA and the TAAT motifs of a high affinity binding site are required for efficient DNA-protein binding. The tissue distribution of gamma PE binding activity is broad, including both erythroid and non-erythroid cell types. Transcription of either a gamma-globin or heterologous promoter is increased in the presence of nearby gamma PE binding sites. Therefore, gamma PE may be involved in activating the gamma-globin gene in fetal erythroid cells. UV cross-linking analysis indicates that the major protein interacting with a high affinity gamma PE binding site has a molecular mass of 108 kDa.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati	LLOYD, JA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,POB 980033,RICHMOND,VA 23298, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039585, R01DK039585] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060080] Funding Source: Medline; NIDDK NIH HHS [DK 39585] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BRASIER AR, 1990, CURRENT PROTOCOLS MO; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; JANE S, 1993, MOL CELL BIOL, V13, P32732; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LIBERATOR PA, 1984, J BIOL CHEM, V259, P5497; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONCE E, 1991, BIOCHEMISTRY-US, V30, P2961, DOI 10.1021/bi00225a033; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SENGUPTA PK, 1994, BLOOD, V83, P1420; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	43	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19385	19393						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034705				2022-12-27	WOS:A1994NY33200031
J	YAMAGUCHI, Y; ZHANG, DE; SUN, Z; ALBEE, EA; NAGATA, S; TENEN, DG; ACKERMAN, SJ				YAMAGUCHI, Y; ZHANG, DE; SUN, Z; ALBEE, EA; NAGATA, S; TENEN, DG; ACKERMAN, SJ			FUNCTIONAL-CHARACTERIZATION OF THE PROMOTER FOR THE GENE ENCODING HUMAN EOSINOPHIL PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; PROMYELOCYTIC LEUKEMIA-CELLS; LUCIFERASE REPORTER GENE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CATIONIC PROTEIN; HUMAN MYELOPEROXIDASE; GRANULE PROTEINS; MYELOID DIFFERENTIATION; CHROMOSOMAL GENE	The molecular basis for commitment of progenitors to the eosinophil lineage and mechanisms by which eosinophil- specific genes are expressed and regulated during differentiation is unknown. Expression of eosinophil peroxidase (EPO) is restricted to the eosinophil lineage. To understand the mechanisms involved in transcriptional regulation of EPO gene expression, we cloned the region of the EPO gene upstream of the transcriptional start site and analyzed the cis-acting elements required for EPO promoter activity in an eosinophil-inducible leukemic cell line, HL-60-C15. The 5'-flanking region of the EPO gene containing 1.5 kilobases of sequence upstream of the transcriptional start site was subcloned into the promoterless pXP2-luciferase vector. The EPO-pXPS construct and 5' deletion mutants were electroporated into HL-60-C15 cells and luciferase reporter activity assessed. The -1.5-kilobase EPO-PXP2 promoter construct reproducibly expressed >120-fold more luciferase activity than did promoterless pXP2, and a 12-fold (90%) decrease in promoter activity was obtained when sequences between -122 and -45 base pairs (bp) were deleted. The specificity of the EPO promoter for the eosinophil lineage was analyzed by transfecting the EPO-pXP2 constructs and deletion mutants into HL-60-C15 cells and the parental HL-60 line; EPO promoter activity was 8-10-fold less in the HL 60 parental line, suggesting lineage specific elements in the -122 to -45 bp region. To further characterize regulatory sequences important for promoter activity, we performed linker-scanning analysis on the -122 to -45 bp region and identified a number of positively and negatively acting elements in the promoter. DNase I footprinting was performed with HL-60-C15, HL-60, and HeLa nuclear extracts to identify nuclear proteins that may bind to the functional elements; these experiments identified three protected regions of the EPO promoter which correspond to the functional segments defined by linker-scanning analysis and which contain consensus, potential binding sites for Egr-1, H4TF-1, PuF, CTCF: UBP-1, and GaEII transcription factors. Further study of EPO promoter regulation should elucidate unique transcriptional features of eosinophil gene regulation in granulocyte development.	BETH ISRAEL HOSP, DEPT MED, DIV INFECT DIS, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; OSAKA BIOSCI INST, OSAKA, JAPAN	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R29CA059589, R01CA041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033043] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59589, CA 41456] Funding Source: Medline; NIAID NIH HHS [AI33043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; Ackerman Steven J., 1993, P33; AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; BARKER RL, 1990, GENE, V86, P285, DOI 10.1016/0378-1119(90)90292-Y; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARKER RL, 1989, J IMMUNOL, V143, P952; BURN TC, 1992, BLOOD, V80, P3051; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; CLUTTERBUCK EJ, 1988, BLOOD, V71, P646; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FISCHKOFF SA, 1986, BLOOD, V68, P185; FISCHKOFF SA, 1990, LEUKEMIA RES, V14, P979, DOI 10.1016/0145-2126(90)90111-L; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GOMOLIN HI, 1993, BLOOD, V82, P1868; GRUART V, 1992, BLOOD, V79, P2592; HAMANN KJ, 1991, INT ARCH ALLER A IMM, V94, P202, DOI 10.1159/000235362; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; KLEBANOFF SJ, 1989, J IMMUNOL, V143, P239; KLEHR D, 1992, BIOCHEMISTRY-US, V31, P3222, DOI 10.1021/bi00127a025; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYON I, 1994, IN PRESS MOL CELL BI, V14; OLSSON I, 1985, BLOOD, V66, P1143; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROSMARIN AG, 1989, BLOOD, V73, P131; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERTHWAITE AB, 1990, BLOOD, V75, P2299; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SPRY CJF, 1983, Q J MED, V52, P1; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAI PC, 1987, LANCET, V1, P643; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; WEIL SC, 1987, P NATL ACAD SCI USA, V84, P2057, DOI 10.1073/pnas.84.7.2057; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YAMADA M, 1993, J BIOL CHEM, V268, P13479; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZON LI, 1993, BLOOD, V81, P3234	79	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19410	19419						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034708				2022-12-27	WOS:A1994NY33200035
J	RUPPEL, KM; UYEDA, TQP; SPUDICH, JA				RUPPEL, KM; UYEDA, TQP; SPUDICH, JA			ROLE OF HIGHLY CONSERVED LYSINE-130 OF MYOSIN MOTOR DOMAIN - IN-VIVO AND IN-VITRO CHARACTERIZATION OF SITE-SPECIFICALLY MUTATED MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; HEAVY-CHAIN GENE; DICTYOSTELIUM-DISCOIDEUM; ADENOSINE-TRIPHOSPHATASE; ACTIN FILAMENT; NULL MUTANTS; STEP SIZE; ATP; SUBFRAGMENT-1; MEROMYOSIN	We have created a mutant Dictyostelium myosin II heavy chain gene in which a highly conserved lysine residue (Lys-130) is changed to leucine. Lys-130 is a residue that is known to be trimethylated in skeletal muscle myosin and had been thought to play an integral role in the interaction of myosin with ATP during the actomyosin chemomechanical cycle. We report here the first in vivo and in vitro characterization of an engineered missense mutation in the motor domain of myosin. Expression of the K130L myosin in a Dictyostelium strain that lacks the myosin II heavy chain gene is sufficient to restore the ability of that cell line to undergo cytokinesis and multicellular development, processes that require functional myosin. The K130L myosin purified from these cells displays maximal actin-activated ATPase activities and promotes maximal sliding velocities of actin filaments in an in vitro motility assay that are comparable with those of wild type myosin. These results demonstrate that this lysine residue is not required for the enzymatic or motile activities of myosin. However, the mutant protein exhibits a 4-fold increase in K-m for ATP over wild-type myosin, indicating that this residue participates in the interaction of myosin with its nucleotide substrate.	STANFORD UNIV, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University					NIGMS NIH HHS [GM40509, GM07365, GM33289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289, T32GM007365, R01GM040509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COOKE R, 1979, BIOPHYS J, V28, P241, DOI 10.1016/S0006-3495(79)85174-7; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MOCKRIN SC, 1976, P NATL ACAD SCI USA, V73, P2321, DOI 10.1073/pnas.73.7.2321; MOOS C, 1973, COLD SPRING HARB SYM, V37, P137, DOI 10.1101/SQB.1973.037.01.021; MORITA F, 1967, J BIOL CHEM, V242, P4501; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; OOSAWA F, 1977, BIORHEOLOGY, V14, P11; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PATE E, 1993, P NATL ACAD SCI USA, V90, P2451, DOI 10.1073/pnas.90.6.2451; PATE E, 1991, J MUSCLE RES CELL M, V12, P376, DOI 10.1007/BF01738593; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; RUPPEL KM, 1990, ANN NY ACAD SCI, V582, P147; Sambrook J, 1989, MOL CLONING LABORATO; SHEETZ MP, 1984, J CELL BIOL, V99, P1867, DOI 10.1083/jcb.99.5.1867; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1987, BIOCHEMISTRY-US, V26, P7648, DOI 10.1021/bi00398a018; SZILAGYI L, 1979, BIOCHEM BIOPH RES CO, V87, P936, DOI 10.1016/0006-291X(79)92047-3; TAN JL, 1991, J BIOL CHEM, V266, P16044; TONG SW, 1983, J BIOL CHEM, V258, P3100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	135	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18773	18780						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034630				2022-12-27	WOS:A1994NX32700016
J	CHENG, L; NORRIS, AW; TATE, BF; ROSENBERGER, M; GRIPPO, JF; LI, E				CHENG, L; NORRIS, AW; TATE, BF; ROSENBERGER, M; GRIPPO, JF; LI, E			CHARACTERIZATION OF THE LIGAND-BINDING DOMAIN OF HUMAN RETINOID-X RECEPTOR-ALPHA EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; THYROID-HORMONE; ACID RECEPTORS; NUCLEAR RECEPTOR; DNA-BINDING; RXR-ALPHA; VITAMIN-D; PROTEIN; GENES; PURIFICATION	In order to study the structural details of ligand protein interactions of the human retinoid X receptor alpha (hRXR alpha), the DEF and EF domains of the receptor were expressed as glutathione S-transferase (GST) fusion proteins in Escherichia coli. The fusion proteins were expressed at high levels and were affinity-purified by chromatography over glutathione-agarose. The DEF and EF domains were cleaved from the fusion proteins by digestion with thrombin. Retinoic acid binding was quantitated using two different methods. The apparent dissociation constant (K-d) and the stoichiometry of 9-cis-retinoic acid binding were performed by monitoring quenching of protein fluorescence. To directly compare the binding affinity of the E. coli-derived truncated hRXR alpha with full-length hRXR alpha expressed in transiently transfected COS cells, Scatchard analyses of [H-3]9-cis-retinoic acid binding assays were performed. Both methods of analysis indicate that while the cleaved DEF peptide bound 9-cis-retinoic acid tightly, the cleaved EF peptide exhibited variable binding activity between preparations. By fluorimetric analysis, the K-d of the cleaved DEF peptide was estimated to be 3 +/- 0.5 nM with a stoichiometry of 1:1.1 +/- 0.1. By Scatchard analysis, the K-d values for [H-3]9-cis-retinoic acid to the GST-hRXR alpha(DEF) peptide and the cleaved DEF peptide were estimated to be 1.8 nM and 5.6 nM, respectively. The estimated molecular mass from high speed sedimentation equilibrium experiments was 36 +/- 2 kDa for the apo-DEF peptide alone and 38 +/- 3 kDa for the holo-DEF peptide complexed with 9-cis-retinoic acid. This suggests that the recombinant ligand binding domain was predominantly in the monomer form. However, dimers of the cleaved DEF peptides were detected in chemical crosslinking experiments both in the presence and absence of 9-cis-retinoic acid. Since the purified E. coli-derived truncated hRXR alpha DEF peptide appears to fully retain its ligand binding activity, it should provide a useful model system for further structural analysis of ligand-protein interactions.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT ONCOL,NUTLEY,NJ 07110	Washington University (WUSTL); Roche Holding; Roche Holding	CHENG, L (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.		Norris, Andrew/O-5499-2018	Norris, Andrew/0000-0001-8396-9543	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK002072, R29DK040172, R01DK040172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40172, DK02072] Funding Source: Medline; NIGMS NIH HHS [5-T32GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DALLERY N, 1993, BIOCHEMISTRY-US, V32, P12428, DOI 10.1021/bi00097a022; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1987, J BIOL CHEM, V262, P13773; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P424; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; REDFERN CPF, 1993, FEBS LETT, V321, P163, DOI 10.1016/0014-5793(93)80100-9; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SABLONNIERE B, 1994, ANAL BIOCHEM, V217, P110, DOI 10.1006/abio.1994.1090; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18662	18667						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034615				2022-12-27	WOS:A1994NW79800068
J	LIU, F; BATEMAN, E				LIU, F; BATEMAN, E			PURIFICATION AND CHARACTERIZATION OF TATA-BINDING PROTEIN PROMOTER-BINDING FACTOR - A REGULATORY TRANSCRIPTION FACTOR OF THE TBP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ACANTHAMOEBA-CASTELLANII; DNA-BINDING; EUKARYOTIC TRANSCRIPTION; ACTIVATION DOMAIN; CRYSTAL-STRUCTURE; LESS PROMOTER; MINOR GROOVE; COMPLEX; RECOGNITION	Transcription of the Acanthamoeba tbp gene is stimulated by a cis acting promoter element that is bound by an activator protein, TATA-binding protein promoter binding factor (TPBF). Here, we report the complete purification of TPBF and describe its transcription activating and DNA-binding properties. TPBF contains two polypeptides with molecular weights of 51,000 and 50,000, whereas the native molecular weight of TPBF suggests it is dimeric or trimeric in solution. Phosphatase treatment of TPBF converts the 51,000 molecular weight species to the 50,000 molecular weight form, demonstrating that TPBF is phosphorylated. Phosphorylation reduces DNA binding by TPBF, as assessed by electrophoretic mobility shift assays after phosphatase treatment. TPBF makes numerous contacts with the bases and phosphate backbone of its DNA recognition element, and the pattern of these contacts suggests that it is a novel type of DNA-binding protein. TPBF can bind to additional, low affinity sites within the TBP gene promoter, suggesting that, in addition to positive activation of tbp gene expression, TPBF could also inhibit transcription by competing for binding sites for other proteins within the TBP promoter.	UNIV VERMONT, MARKEY CTR MOLEC GENET, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA	University of Vermont					NEI NIH HHS [EY 08706] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008706, R01EY008706] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Byers T.J., 1979, International Review of Cytology, V61, P283; BYERS TJ, 1986, INT REV CYTOL, V99, P311; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DREW HR, 1988, ANNU REV CELL BIOL, V4, P1; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEONARD NJ, 1971, BIOCHEMISTRY-US, V10, P3335, DOI 10.1021/bi00794a003; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1993, NUCLEIC ACIDS RES, V21, P4321, DOI 10.1093/nar/21.18.4321; LIU F, 1992, GENE, V120, P143, DOI 10.1016/0378-1119(92)90087-6; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Ptashne M., 1986, A GENETIC SWITCH; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISBROD S, 1982, NATURE, V297, P289, DOI 10.1038/297289a0; WOLBERGER C, 1993, CURR OPIN STRUC BIOL, V3, P3, DOI 10.1016/0959-440X(93)90194-P; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18541	18548						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034602				2022-12-27	WOS:A1994NW79800050
J	SOBEL, RE; COOK, RG; ALLIS, CD				SOBEL, RE; COOK, RG; ALLIS, CD			NONRANDOM ACETYLATION OF HISTONE H4 BY A CYTOPLASMIC HISTONE ACETYLTRANSFERASE AS DETERMINED BY NOVEL METHODOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA-THERMOPHILA; MICRONUCLEI; H-4; MACRONUCLEI	During periods of active DNA replication and chromatin assembly, newly synthesized histone H4 is deposited in a diacetylated form. In Tetrahymena, a specific pair of residues, lysines 4 and 11, has been shown to undergo this modification in vivo (Chicoine, L. G., Schulman, I. G., Richman, R., Cook, R. G., and Allis, C. D. (1986) J. Biol. Chem. 261, 1071-1076). Presumably, this reaction is catalyzed, at least in part, by histone acetyltransferases (HAT) of the B type, cytoplasmic enzymes displaying strong preference for free, non-chromatin-bound H4. To investigate which lysines are preferred acetylation sites in H4 from other organisms, a cytoplasmic HAT B activity was prepared from Drosophila embryos and used to acetylate H4 from several species. When H4 or synthetic, NH2-terminal peptides from Tetrahymena were used as unblocked substrates, direct microsequence analyses showed that [H-3]acetate was preferentially incorporated at lysine 11 with little, if any, incorporation at other conserved, acetylatable lysines. Drosophila H4 was chemically deblocked following its acetylation in vitro using conditions that do not deacetylate internal lysines. Direct sequence analysis verified the correct NH2-terminal sequence of Drosophila H4 and demonstrated that [H-3]acetate incorporation occurred preferentially on lysine 12, the residue analogous to lysine 11 in Tetrahymena. These data show remarkable preference for lysine 11/12 by the Drosophila HAT B activity in vitro and provide support for the assertion that this activity functions to acetylate new H4, at least in part, for deposition and chromatin assembly in vivo. Since most H4s, like Drosophila, are blocked at their amino termini by an acetylthreonine or acetylserine, our results demonstrate that this deblocking and microsequencing strategy can be used to study acetylation site utilization in H4 and presumably other core histones NH2 terminally blocked with these residues.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	Syracuse University; Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016259] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16259] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLIS CD, 1980, CELL, V20, P609, DOI 10.1016/0092-8674(80)90307-4; ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; CHAMBERS SAM, 1984, J BIOL CHEM, V259, P3458; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; GIANCOTTI V, 1984, BIOCHEM J, V218, P321, DOI 10.1042/bj2180321; GLOVER CVC, 1979, P NATL ACAD SCI USA, V76, P585, DOI 10.1073/pnas.76.2.585; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HARISANOVA NT, 1986, CELL DIFFER DEV, V19, P115, DOI 10.1016/0045-6039(86)90068-0; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; MINGARRO I, 1993, J BIOL CHEM, V268, P13248; PFEFFER U, 1991, INT J BIOCHEM, V23, P277, DOI 10.1016/0020-711X(91)90107-X; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde K. E., 1989, CHROMATIN, P1; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; WANG TT, 1993, MOL CELL BIOL, V13, P163, DOI 10.1128/MCB.13.1.163; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WIEGAND RC, 1981, J BIOL CHEM, V256, P4578; WOLFFE A, 1992, CHROMATIN STRUCTURE, P1; WOODLAND HR, 1979, DEV BIOL, V68, P360, DOI 10.1016/0012-1606(79)90210-0	29	92	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18576	18582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034606				2022-12-27	WOS:A1994NW79800055
J	YUAN, JG; CLINE, K				YUAN, JG; CLINE, K			PLASTOCYANIN AND THE 33-KDA SUBUNIT OF THE OXYGEN-EVOLVING COMPLEX ARE TRANSPORTED INTO THYLAKOIDS WITH SIMILAR REQUIREMENTS AS PREDICTED FROM PATHWAY SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; INVITRO TRANSLOCATION; ENERGY-REQUIREMENTS; ESCHERICHIA-COLI; ATP; IMPORT; CHLOROPLASTS; MEMBRANES; PRECURSOR; SECA	Plastocyanin and the 33-kDa subunit of the oxygen-evolving complex (OE33) are two of several thylakoid lumen-located proteins that are made in the cytosol, imported into chloroplasts, and subsequently transported into thylakoids. Recently, competition studies showed that there are two pathways for protein transport into the thylakoid lumen and that plastocyanin and OE33 are on the same pathway (Cline, K., Henry, R., Li, C., and Yuan, J. (1993) EMBO J. 12, 4105-4114). Our expectation is that transport requirements reflect the steps of the process and that proteins on the same pathway share similar requirements. Unfortunately, the transport requirements for plastocyanin and OE33 are not well established. Here, we investigated transport in a reconstituted system with isolated thylakoids. Efficient transport of OE33 and plastocyanin was only obtained when stromal extract was included in the assay. Heat or protease treatment of stromal extract eliminated its ability to stimulate transport. Transport was abolished by treatments designed to deplete ATP or to prevent its formation and was greatly reduced in the presence of ionophores that dissipate the trans thylakoidal proton gradient. These results show that transport of OE33 and plastocyanin requires ATP and is stimulated by stromal protein(s) and the trans-thylakoidal proton gradient. Taken together, these and previous results suggest that there are two mechanistically distinct pathways for protein transport into the thylakoid lumen.	UNIV FLORIDA,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [1 R01 GM46951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K., 1992, RES PHOTOSYNTHESIS, VIII, P149; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HENRY R, 1994, J BIOL CHEM, V269, P10189; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; THEG SM, 1989, J BIOL CHEM, V264, P6730; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552	32	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18463	18467						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034593				2022-12-27	WOS:A1994NW79800038
J	BOER, H; TENHOEVEDUURKENS, RH; SCHUURMANWOLTERS, GK; DIJKSTRA, A; ROBILLARD, GT				BOER, H; TENHOEVEDUURKENS, RH; SCHUURMANWOLTERS, GK; DIJKSTRA, A; ROBILLARD, GT			EXPRESSION, PURIFICATION, AND KINETIC CHARACTERIZATION OF THE MANNITOL TRANSPORT DOMAIN OF THE PHOSPHOENOLPYRUVATE-DEPENDENT MANNITOL PHOSPHOTRANSFERASE SYSTEM OF ESCHERICHIA-COLI - KINETIC EVIDENCE THAT THE ESCHERICHIA-COLI MANNITOL TRANSPORT PROTEIN IS A FUNCTIONAL DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; C-TERMINAL DOMAIN; ENZYME-II; PHENOTYPIC SELECTION; NMR-SPECTROSCOPY; A-DOMAIN; PERMEASE; PHOSPHORYLATION; BINDING; ENZYME-II(MTL)	The overexpression of the membrane-bound C domain of the mannitol transport protein EII(Mtl) of Escherichia coli has been achieved. This protein, IICMtl, consisting of the first 346 amino acids, was purified from membrane vesicles and still bound mannitol with a high affinity. Gel filtration experiments showed that purified IICMtl was a dimer, confirming that the interaction within the EII(Mtl) dimer occurs between the membrane bound portions of the protein. IICMtl in combination with a chimeric protein consisting of the membrane-bound EII(Glc) C domain and the cytoplasmic EII(Mtl) BA domain could restore both phosphoenolpyruvate-dependent phosphorylation and mannitol/mannitol-P exchange activity. The interaction in this complex was comparable to that of IICMtl with soluble IIBA(Mtl) in as much as there appeared to be no specific interaction between IICMtl and the membrane-bound EII(Glc) C domain; the K-m of IICMtl for the chimer was so low that saturation could not be achieved. In contrast, a very high affinity with a K-m of 2 nM was measured between purified IICMtl and purified EII(Mtl). This interaction was manifested in a IICMtl-dependent stimulation of the EII(Mtl) catalyzed phosphoenolpyruvate dependent mannitol phosphorylation reaction and the mannitol/mannitol-P exchange reaction. The high affinity of IICMtl for the wild type enzyme can be explained by the formation of heterodimers consisting of a IICMtl monomer and an EII(Mtl) monomer which interact at the level of the membrane-bound domains. The 2-fold increase in mannitol phosphorylation activity of the hetero versus homodimer is an indication that the individual subunits in the homodimer are functionally coupled and work at only half their maximum rate. It is known that the EII(Mtl) dimer, but not the monomer, catalyzes the mannitol/mannitol-P exchange reaction. Since the heterodimer also catalyzes this reaction, it appears that only one functional B domain per dimer.	UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,9747 AG GRONINGEN,NETHERLANDS	University of Groningen				Boer, Harry/0000-0002-1685-2270				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; ERNI B, 1986, J BIOL CHEM, V261, P6398; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; Helenius A, 1979, Methods Enzymol, V56, P734; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; KROON GJA, 1993, PROTEIN SCI, V2, P1331, DOI 10.1002/pro.5560020816; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS LA, 1992, J MOL BIOL, V228, P310, DOI 10.1016/0022-2836(92)90511-H; LEE CA, 1983, J BIOL CHEM, V258, P761; LEONARD JE, 1983, J BIOL CHEM, V258, P757; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17850; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17844; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P4934, DOI 10.1021/bi00316a017; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEPHAN MM, 1989, BIOCHEMISTRY-US, V28, P7941, DOI 10.1021/bi00445a058; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANWEEGHEL RP, 1990, P NATL ACAD SCI USA, V87, P2613, DOI 10.1073/pnas.87.7.2613; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WENG QP, 1992, J BIOL CHEM, V267, P19529; WENG QP, 1993, BIOCHEMISTRY-US, V32, P11211, DOI 10.1021/bi00092a034; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17863	17871						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027040				2022-12-27	WOS:A1994NV42200020
J	OHMORI, H; DOHRMAN, AF; GALLUP, M; TSUDA, T; KAI, H; GUM, JR; KIM, YS; BASBAUM, CB				OHMORI, H; DOHRMAN, AF; GALLUP, M; TSUDA, T; KAI, H; GUM, JR; KIM, YS; BASBAUM, CB			MOLECULAR-CLONING OF THE AMINO-TERMINAL REGION OF A RAT MUC-2 MUCIN GENE HOMOLOG - EVIDENCE FOR EXPRESSION IN BOTH INTESTINE AND AIRWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA; SEQUENCE; POLYMORPHISM; CONSERVATION; CONTAINS; PROTEIN; DOMAINS; RICH	To obtain cDNAs for analysis of mucin gene transcription in rat models of human disease, we screened a rat intestinal cDNA library in lambda ZAPII using an upstream non-tandem repeat cDNA fragment of the human MUC 2 gene (Gum, J., Hicks, J., Toribara, N., Rothe, E., Lagace, R., and Y., K. (1992) J. Biol. Chem. 267, 21375-21383). Three cDNAs, 1-1, 8-1, and 21-1, were isolated. A translation start site was found in cDNA 21-1. Combined nucleotide sequence for the three cDNAs contained an open reading frame spanning 4546 base pairs. This amino-terminal sequence contains a non-tandem repeat domain enriched in cysteine (1391 residues) followed by an irregular tandem repeat domain (122 residues). Identity with the human gene is about 80% in the non-tandem repeat domain and about 38% in the irregular tandem repeat domain. Primer extension and S1 nuclease protection analysis indicate a transcription start site at 28 base pairs upstream of translation initiation. Northern analysis showed expression of cognate RNA in the intestine and airway but not heart and spleen. The cDNAs have been used to isolate the gene promoter, the structure of which should yield clues to the regulation of mucin expression in rat models of human disease.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL043762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047766] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1HL43762, P0-1HL24136] Funding Source: Medline; NIDDK NIH HHS [1P30DK47766] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BHASKAR KR, 1985, EXP LUNG RES, V9, P289, DOI 10.3109/01902148509057529; CHANG SK, 1994, IN PRESS GASTROENTER; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOHRMAN A, 1994, IN PRESS EXP LUNG RE; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARKEMA JR, 1989, TOXICOL PATHOL, V17, P525, DOI 10.1177/019262338901700307; HARKEMA JR, 1991, EXP LUNG RES, V17, P748; JANY B, 1991, BIOCHEM BIOPH RES CO, V181, P1, DOI 10.1016/S0006-291X(05)81373-7; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; KHATRI IA, 1993, BIOCHEM J, V294, P391, DOI 10.1042/bj2940391; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOPEZVIDRIERO MT, 1977, MOD PROBL PAEDIAT, V19, P120; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; OMORI H, 1993, AM REV RESPIR DIS, V147, pA438; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPICER AP, 1991, J BIOL CHEM, V266, P15099; STEIGER DJ, 1993, AM REV RESPIR DIS, V147, pA437; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TSUDA T, 1993, BIOCHEM BIOPH RES CO, V195, P363, DOI 10.1006/bbrc.1993.2052; WESLEY A, 1983, PEDIATR RES, V17, P65, DOI 10.1203/00006450-198301000-00013; XU GQ, 1992, J BIOL CHEM, V267, P5401	34	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17833	17840						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027037				2022-12-27	WOS:A1994NV42200015
J	MADUENO, F; BRADSHAW, SA; GRAY, JC				MADUENO, F; BRADSHAW, SA; GRAY, JC			THE THYLAKOID-TARGETING DOMAIN OF THE CHLOROPLAST RIESKE IRON-SULFUR PROTEIN IS LOCATED IN THE N-TERMINAL HYDROPHOBIC REGION OF THE MATURE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; FERREDOXIN-NADP+ REDUCTASE; CHLOROPHYLL A/B PROTEIN; TRANSIT PEPTIDE; PRECURSOR PROTEIN; CDNA CLONES; SPINACH-CHLOROPLASTS; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEIN; PEA-CHLOROPLASTS	The thylakoid-targeting domain of the Rieske FeS protein has been located in the N-terminal 55 amino acids of the mature protein by importing chimeric and truncated precursor proteins into isolated pea chloroplasts. A chimeric protein consisting of the presequence of ribulose-bisphosphate carboxylase/oxygenase (Rubisco) small subunit fused to the mature Rieske protein sequence was imported by chloroplasts, processed in the stroma, and translocated into the thylakoids, indicating that the thylakoid targeting information was located within the mature Rieske protein. A truncated Rieske protein precursor consisting of the presequence and the N-terminal 55 amino acids of the mature protein was imported by chloroplasts and routed to the thylakoids, indicating that the thylakoid-targeting domain of the Rieske protein is located within the predominantly hydrophobic N-terminal region of the mature protein. Chimeric proteins consisting of this truncated Rieske protein precursor fused to the mature Rubisco small subunit and to plastocyanin were efficiently imported by chloroplasts and translocated across the thylakoid membrane. A proton-motive force was necessary for thylakoid translocation of the mature Rieske protein, the truncated Rieske protein, and the fusion protein consisting of the truncated Rieske protein and the mature Rubisco small subunit. In contrast, plastocyanin and the fusion of the truncated Rieske protein with plastocyanin were translocated across the thylakoid membrane in the presence of nigericin and valinomycin, indicating that the energy requirement for thylakoid translocation was conferred by the passenger protein and not by the thylakoid-targeting sequence.	UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 3EA,CAMBS,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 3EA,CAMBS,ENGLAND	University of Cambridge; University of Cambridge			Madueño, Francisco/L-5167-2014	Madueño, Francisco/0000-0001-7598-3003				ALT J, 1983, EMBO J, V2, P979, DOI 10.1002/j.1460-2075.1983.tb01531.x; ANDERSON S, 1986, BIOCHEM J, V240, P709, DOI 10.1042/bj2400709; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BAUERLE C, 1991, J BIOL CHEM, V266, P5884; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HURT E, 1981, FEBS LETT, V134, P1, DOI 10.1016/0014-5793(81)80537-6; HURT E, 1981, EUR J BIOCHEM, V117, P591; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KALLAS T, 1988, P NATL ACAD SCI USA, V85, P5794, DOI 10.1073/pnas.85.16.5794; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LAUTNER A, 1988, J BIOL CHEM, V263, P10077; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MADUENO F, 1992, PLANT MOL BIOL, V20, P289, DOI 10.1007/BF00014496; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; ROBINSON C, 1993, FEBS LETT, V325, P67, DOI 10.1016/0014-5793(93)81415-V; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALTER AH, 1992, PLANT MOL BIOL, V20, P569, DOI 10.1007/BF00040617; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; THEG SM, 1989, J BIOL CHEM, V264, P6730; THEG SM, 1993, TRENDS CELL BIOL, V3, P185; TITTGEN J, 1986, MOL GEN GENET, V204, P258, DOI 10.1007/BF00425507; TSUGEKI R, 1993, FEBS LETT, V320, P198, DOI 10.1016/0014-5793(93)80585-I; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEBBER AN, 1989, FEBS LETT, V242, P435, DOI 10.1016/0014-5793(89)80517-4; WIDGER WR, 1991, PHOTOSYNTH RES, V30, P71, DOI 10.1007/BF00042005; WILLEY DL, 1988, PHOTOSYNTH RES, V17, P125, DOI 10.1007/BF00047685	57	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17458	17463						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021250				2022-12-27	WOS:A1994NU12800021
J	PATTERSON, WR; POULOS, TL				PATTERSON, WR; POULOS, TL			CHARACTERIZATION AND CRYSTALLIZATION OF RECOMBINANT PEA CYTOSOLIC ASCORBATE PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; RADICAL SITE	An Escherichia coli expression system has been developed for pea cytosolic ascorbate peroxidase (APX). The enzyme was expressed as a fusion product with the E. coli maltose-binding protein for rapid, affinity chromatography purification. Recombinant ascorbate peroxidase (rAPX) was purified by tryptic digestion to separate the maltose-binding protein from rAPX followed by three chromatographic steps. The purified rAPX protein demonstrated identical electrophoretic, enzymatic, and spectral properties when compared to native APX isolated from pea shoots. Upon addition of an equal molar amount of H2O2, rAPX exhibits an initial decrease in the Soret maximum, which slowly converts to a stable, redshifted Soret peak similar to that observed for cytochrome c peroxidase Compound I, indicating that rAPX Compound I consists of an oxyferryl (Fe4+-O) center. rAPX has been crystallized in a form suitable for crystal structure determination, and a preliminary set of native data to 2.6 Angstrom have been collected.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07311, GM42614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bollag D.M., 1991, PROTEIN METHODS; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; McPherson A, 1982, PREPARATION ANAL PRO; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; MITTLER R, 1991, FEBS LETT, V289, P257, DOI 10.1016/0014-5793(91)81083-K; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; PONLOS TL, 1993, J BIOL CHEM, V268, P4429; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; 1992, PROTEIN FUSION PURFI	16	55	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17020	17024						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006006				2022-12-27	WOS:A1994NT84600008
J	ZHANG, BX; TORTORICI, G; XU, X; MUALLEM, S				ZHANG, BX; TORTORICI, G; XU, X; MUALLEM, S			ANTAGONISTS INACTIVATE THE INOSITOL 1,4,5-TRISPHOSPHATE (INS-1,4,5-P-3)-DEPENDENT CA2+ CHANNEL INDEPENDENT OF INS-1,4,5-P(3)P METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; SENSITIVE CALCIUM POOL; SMOOTH-MUSCLE CELLS; INTRACELLULAR CA-2+; AR42J CELLS; AGONIST STIMULATION; ADENINE-NUCLEOTIDES; FEEDBACK INHIBITION; AMYLASE RELEASE; TRISPHOSPHATE	Streptolysin O-permeable pancreatic acini, which retain intact signaling systems, were used to study the regulation of the inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3)-activated Ca2+ channel during agonist stimulation and antagonist inhibition. Stimulation of permeable cells with carbachol induced rapid Ca2+ release from internal stores. Addition of heparin prior to or after agonist stimulation inhibited the release, indicating the activation of the Ins-1,4,5-P-3-dependent Ca2+ channels by the agonist. Termination of cell stimulation with the specific antagonist atropine rapidly inactivated the release channels. Channel inactivation by the antagonist was independent of Ins-1,4,5-P-3 levels since (a) addition of atropine to carbachol-stimulated cells resulted in a slow hydrolysis of Ins-1,4,5-P-3, (b) addition of 10-fold excess Ins-1,4,5-P-3 together with the agonist did not prevent channel inactivation by the antagonist, and (c) the antagonist inactivated Ca2+ release in the presence of saturating concentration of the nonhydrolyzable Ins-2,4,5-P-3. Hence, the antagonist appears to stabilize the Ins 1,4,5-P-3-activated Ca2+ channel in a state refractory to Ins-1,4,5-P-3. These findings are the first direct evidence that the channel can exist in such a refractory state.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; Ferris Christopher D., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P95; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JENA BP, 1991, J BIOL CHEM, V266, P17744; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MERRITT JE, 1987, J BIOL CHEM, V262, P4958; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1990, INTRACELLULAR CALCIU, P349; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; ORON Y, 1985, NATURE, V313, P141, DOI 10.1038/313141a0; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PUTNEY JW, 1992, ADV SEC MESS PHOSPH, V26, P140; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; WAGNER ACC, 1992, AM J PHYSIOL, V263, pC1172, DOI 10.1152/ajpcell.1992.263.6.C1172; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZHAO H, 1990, J BIOL CHEM, V265, P20856	46	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17132	17135						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006018				2022-12-27	WOS:A1994NT84600025
J	WEBER, J; WILKEMOUNTS, S; SENIOR, AE				WEBER, J; WILKEMOUNTS, S; SENIOR, AE			COOPERATIVITY AND STOICHIOMETRY OF SUBSTRATE-BINDING TO THE CATALYTIC SITES OF ESCHERICHIA-COLI F1-ATPASE EFFECTS OF MAGNESIUM, INHIBITORS, AND MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTON-ATPASE; ISOLATED BETA-SUBUNIT; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESSENTIAL TYROSINE RESIDUE; NUCLEOTIDE-BINDING; ALPHA-SUBUNIT; UNCA MUTANTS; H+-ATPASE; BEEF-HEART; F1-ATPASE	The fluorescence of residue Trp(beta 331) in beta Y331W mutant Escherichia coli F-1-ATPase was used as reporter probe to investigate the effects of magnesium ions, inhibitors, and mutation on substrate (ATP) binding stoichiometry and cooperativity. It was found that Mg2+ is required for catalytic site binding cooperativity. In the absence of magnesium, ATP bound to three independent catalytic sites, each with K-d = 76 mu M. In contrast, MgATP bound to three catalytic sites with K-d1 < 50 nM, K-d2 = 0.5 mu M, and K-d3 = 25 mu M. There was no significant ATPase activity in the absence of Mg2+. Catalysis is therefore correlated with substrate binding cooperativity and the formation of the high-affinity catalytic site 1. Catalytic site 3 had properties similar to those of the isolated beta-subunit nucleotide-binding site. The inhibitors dicyclohexylcarbodiimide and N-ethylmaleimide (in alpha S373C/beta Y331W mutant F-1) gave potent inhibition of multisite ATPase activity without significantly affecting MgATP binding stoichiometry or cooperativity. Therefore each seems to selectively attenuate positive catalytic cooperativity. The same conclusions held for the alpha S373F mutation (in alpha S373F/beta Y331W mutant F-1). 7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole, however, reduced the catalytic site MgATP binding stoichiometry from three to two, and appears to inhibit catalysis by sterically blocking catalytic site 3.			WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; ANDREWS WW, 1984, J BIOL CHEM, V259, P8219; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1987, J BIOL CHEM, V262, P11675; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; HIRANO M, 1984, BIOCHEMISTRY-US, V23, P1652, DOI 10.1021/bi00303a011; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; KANAZAWA H, 1984, ARCH BIOCHEM BIOPHYS, V228, P258, DOI 10.1016/0003-9861(84)90066-3; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; NOUMI T, 1988, J BIOL CHEM, V263, P8765; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1979, J BIOL CHEM, V254, P1319; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; SMITH RA, 1985, BIOCHEMISTRY-US, V24, P4490, DOI 10.1021/bi00337a034; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; SUTTON R, 1985, EUR J BIOCHEM, V148, P551, DOI 10.1111/j.1432-1033.1985.tb08875.x; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; TURINA P, 1993, J BIOL CHEM, V268, P6978; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; WISE JG, 1981, J BIOL CHEM, V256, P383; YOSHIDA M, 1982, J BIOL CHEM, V257, P33; [No title captured]	49	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20462	20467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051144				2022-12-27	WOS:A1994PB31700041
J	LINGREL, JB; KUNTZWEILER, T				LINGREL, JB; KUNTZWEILER, T			NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SITE-DIRECTED MUTAGENESIS; ACTIVATED ADENOSINE-TRIPHOSPHATASE; NA,K-ATPASE ALPHA-SUBUNIT; OUABAIN-RESISTANT ENZYME; BETA-SUBUNIT; EXTRACELLULAR DOMAIN; NA+/K+-ATPASE; AMINO-ACIDS; SARCOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY				LINGREL, JB (corresponding author), UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA.							ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DEWEER P, 1985, KIDNEY PHYSL PATHOPH, P31; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; HANSEN O, 1984, PHARMACOL REV, V36, P143; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; LANE LK, 1993, J BIOL CHEM, V268, P17930; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Maunsbach A B, 1988, Prog Clin Biol Res, V268A, P39; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MODYANOV N, 1991, SOC GEN PHY, V46, P99; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SWEADNER KJ, 1994, ANN NY ACAD SCI, P217; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; VASILETS LA, 1993, J BIOL CHEM, V374, P593; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; WANG K, 1992, J BIOL CHEM, V267, P3577	61	636	652	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19659	19662						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051040				2022-12-27	WOS:A1994PA12600001
J	MORRICE, NA; GABRIELLI, B; KEMP, BE; WETTENHALL, REH				MORRICE, NA; GABRIELLI, B; KEMP, BE; WETTENHALL, REH			A CARDIOLIPIN-ACTIVATED PROTEIN-KINASE FROM RAT-LIVER STRUCTURALLY DISTINCT FROM THE PROTEIN-KINASES-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 PHOSPHORYLATION SITES; RIBOSOMAL PROTEIN-S6; MULTISITE PHOSPHORYLATION; HUMAN PLACENTA; PURIFICATION; INSULIN; EXPRESSION; EPSILON; BRAIN; IDENTIFICATION	A cardiolipin- and protease-activated protein kinase (PAK) has been isolated from cytoplasmic extracts of rat liver. The enzyme (PAK-1) phosphorylates the ribosomal protein S6-(229-239) peptide analogue and can be activated by limited proteolysis. Partial amino acid sequences of tryptic peptides derived from both the purified 116-kDa PAK-1 holoenzyme and its active catalytic fragment reveal that the catalytic domain is most related (50-58% identity) to the protein kinase C family. PAK-1 has protein and peptide substrate specificities distinct from those of known protein kinase C isoforms and is insensitive to inhibition by the protein kinase C-alpha-(19-31) pseudosubstrate peptide. Phosphatidylserine, diacylglycerol, and phorbol ester do not activate PAK-1 toward the S6 peptide substrate. However, other acidic phospholipids, the most effective being cardiolipin, activate PAK-1 to a similar extent as trypsin. The PAK-1 catalytic activities generated through activation by cardiolipin or limited proteolysis were kinetically similar, with K-m values of 3.6 and 3.4 mu M, respectively, for the S6-(229-239) peptide substrate. However, differences were observed in the catalytic activities with protamine sulfate and the glycogen synthase-(1-12) peptide analogue as substrates. It was concluded that PAK-1 is a phospholipid regulated protein kinase with a primary structure, substrate specificity, and mechanism of regulation in vitro distinct from those of any known member of the protein kinase C superfamily.	UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA; ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA	University of Melbourne; St. Vincent's Institute of Medical Research			Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Gabrielli, Brian G/B-3655-2011	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Gabrielli, Brian G/0000-0003-3933-1651				AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDON SD, 1991, J BIOL CHEM, V266, P380; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHENG HC, 1986, J BIOL CHEM, V261, P989; COHEN P, 1983, METHOD ENZYMOL, V99, P243; DENNIS PB, 1990, BIOCHEM BIOPH RES CO, V173, P673, DOI 10.1016/S0006-291X(05)80088-9; DENNIS PB, 1993, J BIOL CHEM, V268, P19833; DONAHUE MJ, 1984, J BIOL CHEM, V259, P435; GABRIELLI B, 1984, FEBS LETT, V175, P219, DOI 10.1016/0014-5793(84)80740-1; GONZATTIHACES MI, 1986, J BIOL CHEM, V261, P5266; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTICK SM, 1981, J BIOL CHEM, V256, P583; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MERRIL CR, 1980, ANAL BIOCHEM, V105, P361; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERISIC O, 1983, J BIOL CHEM, V258, P9589; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TRAUGH JA, 1986, PROG NUCLEIC ACID RE, V33, P195; WETTENHALL R E H, 1991, Peptide Research, V4, P158; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WETTENHALL REH, 1982, FEBS LETT, V148, P207, DOI 10.1016/0014-5793(82)80809-0; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	47	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20040	20046						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051089				2022-12-27	WOS:A1994PA12600058
J	MUSCH, MW; DAVIS, EM; GOLDSTEIN, L				MUSCH, MW; DAVIS, EM; GOLDSTEIN, L			OLIGOMERIC FORMS OF SKATE ERYTHROCYTE BAND-3 - EFFECT OF VOLUME EXPANSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPORT FUNCTION; TAURINE EFFLUX; MEMBRANE; PROTEIN	Volume expansion of little skate (Raja erinacea) erythrocytes leads to the formation of oligomeric forms of the band 3 protein. The oligomers are formed following incubation in hypotonic media or inclusion of a permeant solute such as ethylene glycol. Oligomers were detected by specifically labeling the skate erythrocyte band 3 homolog with the radiolabeled stilbene [H-3]4,4'-diisothiocyano-1,2 diphenylethane-2,2'-disulfonic acid and cross-linking membrane proteins with the homobifunctional agent bis(sulfosuccinimidyl) suberate, Under isoosmotic conditions, the distribution of band 3 in the monomer, dimer, and tetramer forms was 38, 54, and 8%. Medium of 0.5 osmolarity caused the distribution to change to 22% monomer, 31% dimer, and 47% tetramer. Upon return to isoosmotic conditions, cell volume, as well as the distribution of band 3 in the monomer, dimer, and tetrameric forms, returned to control values. Return of hypotonically swollen cells to isoosmotic conditions also returned taurine efflux back to control values. Hyperosmolarity caused a 20% shrinkage of cell volume but did not have any effect on either taurine efflux or the distribution of band 3 in the oligomeric forms. Pyridoxal 5'-phosphate and dinitrostilbene disulfonate, two agents that interact with and cause the formation of the tetrameric form of human band 3, also caused a shift toward to tetrameric peak in skate band 3. To determine whether the cross-linked oligomers had proteins that closely associate with band 3 in the intact cell, Western blots were performed to detect ankyrin and band 4.1. Neither protein appeared with the dimeric or tetrameric forms of band 3, suggesting that the mobility shift was in fact due to association of band 3 monomers. This is the first demonstration that oligomerization of band 3 occurs during a physiologic effect that may be mediated by the band 3 protein.	BROWN UNIV, DEPT PHYSIOL, PROVIDENCE, RI 02912 USA; UNIV CHICAGO, DEPT MED, CTR INFLAMMATORY BOWEL DIS, CHICAGO, IL 60637 USA; MT DESERT ISL BIOL LAB, SALSBURY COVE, ME 04672 USA	Brown University; University of Chicago; Mount Desert Island Biological Laboratory					NIDDK NIH HHS [DK-42086, DK-38510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R01DK038510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1982, BIOCHIM BIOPHYS ACTA, V689, P475, DOI 10.1016/0005-2736(82)90305-4; BOYD TA, 1977, J EXP ZOOL, V199, P435, DOI 10.1002/jez.1401990318; BRILL SR, 1992, J EXP ZOOL, V264, P19, DOI 10.1002/jez.1402640104; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DICKMAN KG, 1990, AM J PHYSIOL, V258, pR1217; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MULZER K, 1990, COLLOID POLYM SCI, V268, P60, DOI 10.1007/BF01410424; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; SALHANY JM, 1989, BIOCHEM BIOPH RES CO, V159, P1337, DOI 10.1016/0006-291X(89)92257-2; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; YOON SC, 1984, BIOCHIM BIOPHYS ACTA, V778, P385, DOI 10.1016/0005-2736(84)90383-3	16	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19683	19686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051044				2022-12-27	WOS:A1994PA12600007
J	YANG, YQ; MAYO, KH; DALY, TJ; BARRY, JK; LAROSA, GJ				YANG, YQ; MAYO, KH; DALY, TJ; BARRY, JK; LAROSA, GJ			SUBUNIT ASSOCIATION AND STRUCTURAL-ANALYSIS OF PLATELET BASIC-PROTEIN AND RELATED PROTEINS INVESTIGATED BY H-1-NMR SPECTROSCOPY AND CIRCULAR-DICHROISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; BETA-THROMBOGLOBULIN; HUMAN BASOPHILS; ALPHA-CHYMOTRYPSIN; CHEMOTACTIC FACTOR; HISTAMINE; ACID; CYTOKINES; AFFINITY; INTERLEUKIN-8	Platelet basic protein (PBP) (94 residues) is naturally processed via N-terminal cleavage to yield connective tissue activating peptide-III (85 residues), beta-thrombo globulin (81 residues), and neutrophil activating peptide-2 (70 residues). Chemical cross-linking and gel filtration data indicate that each homolog can form dimers and tetramers. Subunit association equilibria for dimer (K-D) and tetramer (K-T) formation have been derived for each species from H-1 NMR (600 MHz) spectral analysis of slowly exchanging (NMR time scale) monomer- dimer-tetramer aggregation state populations. In general, raising the pH from about pH 3.5 to pH 6 increases K-D by two to three orders in magnitude and decreases K-T by some 50-fold. Ionic strength effects also suggest that intersubunit electrostatic interactions are critical to subunit association. Subunit stabilization can be ranked proportional to N-terminal chain length: platelet basic protein > connective tissue activating peptide-III > beta-thromboglobulin > neutrophil activating peptide-2. Under more physiologic conditions, PBP family monomers are favored at normal cytokine protein concentrations and may form the biologically active state. CD and NMR data indicate conservation of alpha-helix and anti-parallel beta-sheet structure among PBP-related species and support the idea that the extended N terminus folds over and masks the neutrophil activation domain and is part of the intersubunit binding domain.	REPLIGEN CORP,CAMBRIDGE,MA 02139		YANG, YQ (corresponding author), UNIV MINNESOTA,HLTH SCI CTR,CTR BIOMED ENGN,DEPT BIOCHEM,420 DELAWARE ST, SE,MINNEAPOLIS,MN 55455, USA.							ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1609; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1617; BAEZA ML, 1990, J CLIN INVEST, V85, P1516, DOI 10.1172/JCI114598; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BISCHOFF SC, 1991, BIOCHEM BIOPH RES CO, V179, P628, DOI 10.1016/0006-291X(91)91418-C; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; CAR BD, 1991, BIOCHEM J, V275, P581, DOI 10.1042/bj2750581; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CHEN MJ, 1991, BIOCHEMISTRY-US, V30, P6402, DOI 10.1021/bi00240a009; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; COHEN AB, 1992, AM J PHYSIOL, V263, P249; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; GOODMAN RB, 1992, BIOCHEMISTRY-US, V31, P10483, DOI 10.1021/bi00158a011; HOLT JC, 1992, P SOC EXP BIOL MED, V199, P171; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAPLAN AP, 1991, INT ARCH ALLER A IMM, V94, P148, DOI 10.1159/000235348; KRIEGER M, 1992, J IMMUNOL, V149, P2662; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYO KH, 1992, BIOCHEMISTRY-US, V31, P12255, DOI 10.1021/bi00163a040; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MORRISSON T, 1952, J CHEM SOC, V3, P3814; MOSER B, 1991, J BIOL CHEM, V266, P10666; Myers J A, 1991, Protein Expr Purif, V2, P136, DOI 10.1016/1046-5928(91)90062-N; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REDDIGARI SR, 1992, J ALLERGY CLIN IMMUN, V89, P666, DOI 10.1016/0091-6749(92)90372-9; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STRIETER RM, 1992, IMMUNOL INVEST, V21, P589, DOI 10.3109/08820139209069393; TAI PKK, 1992, J BIOL CHEM, V267, P19579; VANOSSELAER N, 1991, AM J PATHOL, V138, P23; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYMAN J, 1964, ADVANCES PROTEIN CHE, V19, P224; YANG YQ, 1993, J BIOL CHEM, V268, P9223; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	48	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20110	20118						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051099				2022-12-27	WOS:A1994PA12600068
J	CHICCO, AG; ADIBI, SA; LIU, WQ; MORRIS, SM; PAUL, HS				CHICCO, AG; ADIBI, SA; LIU, WQ; MORRIS, SM; PAUL, HS			REGULATION OF GENE-EXPRESSION OF BRANCHED-CHAIN KETO ACID DEHYDROGENASE COMPLEX IN PRIMARY CULTURED-HEPATOCYTES BY DEXAMETHASONE AND A CAMP ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP URINE DISEASE; RAT-LIVER; ACTIVITY STATE; MESSENGER-RNA; PROTEIN-SYNTHESIS; DIETARY-PROTEIN; HEPATOMA-CELLS; BOVINE KIDNEY; PURIFICATION; MUSCLE	The present study demonstrates that dexamethasone and 8-(4-chlorophenylthio)adenosine 3',5'-monophosphate (CPT-cAMP), a cAMP analog, increase the substrate flux through branched chain keto acid dehydrogenase (BCKDH) in primary rat hepatocytes cultured in defined medium. Maximum response (2.7-fold increase in flux) was observed when hepatocytes were cultured with 1 mu M dexamethasone plus 50 mu M CPT-cAMP for 24 h. This increase in the flux rate was accompanied by significant increases in both the basal and total activities of BCKDH (2.2- and 2.0-fold, respectively), without any significant change in the activity state of this enzyme. The increase in BCKDH activity was the result of in- creased protein mass of E(1) alpha (3.2-fold), E(1) beta (2.9-fold), and E(2) (1.6-fold) subunits of BCKDH, indicating that E(2) is the limiting subunit for the expression of BCKDH. The relative abundance of mRNAs encoding the E(1) alpha, E(1) beta, and E(2) subunits of BCKDH increased by 7.4-, 21.7-, and 4.8-fold, respectively. We conclude that increased flux through BCKDH in hepatocytes cultured with dexamethasone and CPT-cAMP is due to increased expression of BCKDH subunit genes. However, nonstoichiometric expression of individual subunits and the corresponding mRNAs suggests regulation of BCKDH also at translational and post-translational steps.	UNIV PITTSBURGH, SCH MED, DEPT MED, CLIN NUTR RES UNIT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Morris, Sidney M/I-3440-2015		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM015855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-15855] Funding Source: Medline; NIDDK NIH HHS [DK-33144] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMANN H, 1983, J BIOL CHEM, V258, P563; BEALE EG, 1991, MOL ENDOCRINOL, V5, P661, DOI 10.1210/mend-5-5-661; BEGGS M, 1989, BIOCHEM J, V257, P271, DOI 10.1042/bj2570271; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLOCK KP, 1987, AM J PHYSIOL, V252, pE396, DOI 10.1152/ajpendo.1987.252.3.E396; BONNEY RJ, 1974, IN VITRO CELL DEV B, V9, P399; BRANDT H, 1975, J BIOL CHEM, V250, P8038; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; CHINSKY JM, 1994, FASEB J, V8, P114, DOI 10.1096/fasebj.8.1.7507870; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX RP, 1993, MOL GENETIC BASIS NE, P189; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; EISENSTEIN AB, 1979, AM J PHYSIOL, V236, pE20, DOI 10.1152/ajpendo.1979.236.1.E20; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILLIM SE, 1983, BIOCHEM BIOPH RES CO, V111, P74, DOI 10.1016/S0006-291X(83)80119-3; GOODWIN GW, 1988, METHOD ENZYMOL, V166, P189; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARRIS RA, 1990, ADV ENZYME REGUL, V30, P245; HARRIS RA, 1986, BIOCHEM J, V234, P285, DOI 10.1042/bj2340285; HARRIS RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P542, DOI 10.1016/0003-9861(85)90531-4; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LITWER S, 1989, J BIOL CHEM, V264, P14597; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER RH, 1988, J BIOL CHEM, V263, P3454; NAWA K, 1986, J BIOL CHEM, V261, P6883; NEBES VL, 1987, BIOCHEM J, V246, P237, DOI 10.1042/bj2460237; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; PAUL HS, 1992, J BIOL CHEM, V267, P11208; PAUL HS, 1983, J BIOL CHEM, V258, P1471; PAUL HS, 1982, J BIOL CHEM, V257, P4875; PAUL HS, 1984, BRANCHED CHAIN AMINO, P182; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; POPOV KM, 1992, J BIOL CHEM, V267, P13127; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SHIMOMURA Y, 1987, ANAL BIOCHEM, V163, P74, DOI 10.1016/0003-2697(87)90094-7; SNEDECOR GW, 1955, STATISTICAL METHODS, P54; SOETIJOSO S, 1989, J NUTR, V119, P1203; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHAO Y, 1992, BIOCHEM J, V285, P167, DOI 10.1042/bj2850167; ZHAO Y, 1993, FASEB J, V7, pA1278	47	29	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19427	19434						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034710				2022-12-27	WOS:A1994NY33200037
J	LOZANO, J; BERRA, E; MUNICIO, MM; DIAZMECO, MT; DOMINGUEZ, I; SANZ, L; MOSCAT, J				LOZANO, J; BERRA, E; MUNICIO, MM; DIAZMECO, MT; DOMINGUEZ, I; SANZ, L; MOSCAT, J			PROTEIN-KINASE-C-ZETA ISOFORM IS CRITICAL FOR KAPPA-B-DEPENDENT PROMOTER ACTIVATION BY SPHINGOMYELINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							XENOPUS-LAEVIS OOCYTES; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE HYDROLYSIS; SUBSPECIES BLOCKS; LYMPHOCYTES; MATURATION; EXPRESSION; MECHANISM; ALPHA	Recent evidence demonstrates that the protein kinase C zeta (zeta PKC) isoform is required for the activation of nuclear factor kappa B (NF-kappa B) and mitogenic signaling in Xenopus oocytes and mammalian cells. The mechanism whereby zeta PKC regulates NF-kappa B most probably involves the activation of a putative I kappa B kinase of molecular mass similar to 50 kDa, which phosphorylates and inactivates I kappa B. Tumor necrosis factor alpha (TNF alpha) and interleukin-1 besides activating the phospholipase C-mediated breakdown of phosphatidylcholine, also generate ceramide, which is produced by stimulation of sphingomyelin hydrolysis. We show here that exogenous addition of sphingomyelinase (SMase) to NIH-3T3 fibroblasts transactivates a kappa B-dependent chloramphenicol acetyltransferase reporter plasmid, to an extent similar to that produced by TNF alpha or phosphatidylcholine/phospholipase C. More importantly, the ability of SMase to stimulate this parameter is severely impaired by transfection of a zeta PKC kinase defective dominant negative mutant, which suggests a critical role of zeta PKC in SMase signaling. In keeping with this notion, we also demonstrate here that zeta PKC is acti vated in vitro by ceramide and in vivo by treatment of NIH-3T3 fibroblasts with SMase.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Moscat, Jorge/A-7011-2009; Lozano, José/C-2760-2014; Berra, Edurne/F-9692-2011	Lozano, José/0000-0002-8187-2833; Berra, Edurne/0000-0002-3820-5744; /0000-0001-9617-4141; Diaz-Meco, Maria/0000-0003-0147-0998				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, IN PRESS EMBO J, V15; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU J, 1994, J BIOL CHEM, V269, P3047; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YANG ZH, 1993, J BIOL CHEM, V268, P20520	21	447	454	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19200	19202						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034680				2022-12-27	WOS:A1994NY33200003
J	PETE, MJ; ROSS, AH; EXTON, JH				PETE, MJ; ROSS, AH; EXTON, JH			PURIFICATION AND PROPERTIES OF PHOSPHOLIPASE-A(1) FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-TISSUE; PROTEIN-KINASE-C; ARACHIDONIC-ACID METABOLISM; PHOSPHATIDYLCHOLINE BREAKDOWN; SUBSTRATE SPECIFICITIES; PHASE-TRANSITION; HUMAN-PLATELETS; PHOSPHATIDYLETHANOLAMINES; HYDROLYSIS; LIPASE	Phospholipase A(1) (PLA(1)) was isolated from a soluble fraction of bovine brain. The purification included sequential DEAE-Sephacel, phenyl-Sepharose FF, and heparin-Sepharose CL-6B column chromatography. Mono Q, Sephacryl S-300, and Mono S high resolution column chromatography in the presence of the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (10 mM) and glycerol (10%, v/v) was required to further separate the enzyme from contaminating material. The purified PLA(1) eluted from the Sephacryl S-300HR column in a volume corresponding to a molecular mass of 365 kDa and migrated as two bands (M(r) = 112,000 and 95,000) when separated by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. Chromatofocusing, hydroxylapatite, and lectin affinity column chromatography and nondenaturing polyacrylamide gel electrophoresis were unsuccessful in separating the two electrophoretic bands, implying a close association or similarity. The purified enzyme was stable in solutions containing detergent and glycerol and was insensitive to metal chelators, dithiothreitol, phenylmethylsulfonyl fluoride, and diisopropyl fluorophosphate, but was inactivated by heat (60 degrees C) and ZnCl2. At pH 7.5, the purified enzyme showed highest specific activity, 23.8 mu mol/min-mg, when 1-pahnitoyl-2-[1-C-14]arachidonoyl-phosphatidylethanolamine was the substrate. The rate of catalysis was optimal at a pH of 9.0 and could be enhanced S-fold by Ca2+, Mg2+, and Sr2+, but not Mn2+. The enzyme catalyzed the specific hydrolysis of acyl groups from the sn-1 position of a broad range of phospholipid substrates, including lysophospholipids, and accounts for most of the soluble phospholipase A(1) activity of bovine brain.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								ARTHUR G, 1989, BIOCHEM J, V261, P581, DOI 10.1042/bj2610581; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CHAU LY, 1981, BIOCHEM BIOPH RES CO, V100, P1688, DOI 10.1016/0006-291X(81)90713-0; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DAWSON RMC, 1983, BIOCHEM J, V209, P865, DOI 10.1042/bj2090865; DAWSON RMC, 1982, NEUROCHEM RES, V7, P1149, DOI 10.1007/BF00964892; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DIEZ E, 1992, J BIOL CHEM, V267, P18342; EXTON JH, 1990, J BIOL CHEM, V265, P1; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HABERLAND ME, 1975, J BIOL CHEM, V250, P6636; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARDMAN PD, 1982, EUR J BIOCHEM, V124, P95, DOI 10.1111/j.1432-1033.1982.tb05910.x; HARLOS K, 1981, BIOCHEMISTRY-US, V20, P2888, DOI 10.1021/bi00513a027; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HIRASAWA K, 1981, EUR J BIOCHEM, V120, P53, DOI 10.1111/j.1432-1033.1981.tb05669.x; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; HOSTETLER KY, 1982, J BIOL CHEM, V257, P13367; INOUE M, 1984, J BIOL CHEM, V259, P5083; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; KUUSI T, 1979, FEBS LETT, V98, P314, DOI 10.1016/0014-5793(79)80207-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MADDEN TD, 1982, BIOCHIM BIOPHYS ACTA, V684, P149, DOI 10.1016/0005-2736(82)90061-X; MANTSCH HH, 1981, BIOCHEMISTRY-US, V20, P3138, DOI 10.1021/bi00514a024; MARTIN TW, 1987, J BIOL CHEM, V262, P13086; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; NALBONE G, 1985, J LIPID RES, V26, P104; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARKIN SM, 1982, BIOCHEM J, V207, P485, DOI 10.1042/bj2070485; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBINSON M, 1983, J BIOL CHEM, V258, P4371; RODA A, 1983, J BIOL CHEM, V258, P6362; ROOKE JA, 1976, J NEUROCHEM, V27, P613, DOI 10.1111/j.1471-4159.1976.tb12291.x; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; UEDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1272, DOI 10.1006/bbrc.1993.2181; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; Waite M, 1981, Methods Enzymol, V71 Pt C, P674; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	54	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19494	19500						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034719				2022-12-27	WOS:A1994NY33200047
J	BROWN, NF; ANDERSON, RC; CAPLAN, SL; FOSTER, DW; MCGARRY, JD				BROWN, NF; ANDERSON, RC; CAPLAN, SL; FOSTER, DW; MCGARRY, JD			CATALYTICALLY IMPORTANT DOMAINS OF RAT CARNITINE PALMITOYLTRANSFERASE-II AS DETERMINED BY SITE-DIRECTED MUTAGENESIS AND CHEMICAL MODIFICATION - EVIDENCE FOR A CRITICAL HISTIDINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; CHOLINE-ACETYLTRANSFERASE; MALONYL-COA; CITRATE SYNTHASE; HUMAN ISOFORMS; TRIAD FORMS; LIVER; CDNA; EXPRESSION; CLONING	Rat carnitine palmitoyltransferase (CPT) II was expressed in Saccharomyces cerevisiae. Mitochondrial fractions prepared from the cells displayed high CPT activity and reacted with an antibody to the rat protein on immunoblots, whereas no activity or immunoreactive protein was observed in control cells. The recombinant enzyme was largely membrane associated. Treatment of the expressed protein with diethyl pyrocarbonate, a reagent that modifies histidine residues, abolished CPT activity, but this was completely restored by reversal of the modification with hydroxylamine. It is inferred that a histidine residue plays a critical role in CPT function. Expression and analysis of site-directed mutants of CPT II showed that histidine 372, as well as aspartates 376 and 464 (all conserved throughout the carnitine/ choline acyltransferase family), are essential for catalytic activity. The data suggest that the mechanism by which CPT II effects transesterification between palmitoyl-CoA and carnitine possibly involves histidine 372 and one of these aspartate residues, interacting with the carnitine hydroxyl group, in a reaction analogous to that carried out by a histidine/aspartate/serine catalytic triad in certain other enzyme systems. Mutagenic analysis of a region of CPT II that is highly conserved among the carnitine and choline acyltransferases, and which is homologous to the ''adenine binding loop'' of citrate synthase, implies that it has no similar function in CPT II.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; SANDOZ PHARMACEUT CORP,RES INST,PRECLIN RES,DEPT DIABET,E HANOVER,NJ 07936; SANDOZ PHARMACEUT CORP,RES INST,PRECLIN RES,DEPT ATHEROSCLEROSIS & VASC BIOL,E HANOVER,NJ 07936	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Novartis; Sandoz; Novartis; Sandoz					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018573, R01DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRARD S, 1989, BRAIN RES BULL, V22, P147, DOI 10.1016/0361-9230(89)90139-1; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; BROWN NF, 1991, J BIOL CHEM, V266, P15446; BROWN NF, 1993, BIOCHEM J, V294, P79, DOI 10.1042/bj2940079; CHASE JFA, 1970, BIOCHEM J, V116, P713, DOI 10.1042/bj1160713; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; DAVID F, 1993, J BIOL CHEM, V268, P17247; DUGI KA, 1992, J BIOL CHEM, V267, P25086; ESSER V, 1993, J BIOL CHEM, V268, P5817; EVANS CT, 1988, BIOCHEMISTRY-US, V27, P4680, DOI 10.1021/bi00413a015; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; JONES ME, 1992, BIOCHEM J, V288, P533, DOI 10.1042/bj2880533; KISPAL G, 1993, J BIOL CHEM, V268, P1824; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; Miles E W, 1977, Methods Enzymol, V47, P431; MILES EW, 1974, J BIOL CHEM, V249, P2843; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; NICABHAIRD N, 1993, BIOCHEM J, V294, P654; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SAEED A, 1993, ARCH BIOCHEM BIOPHYS, V305, P307, DOI 10.1006/abbi.1993.1427; Sambrook J, 1989, MOL CLONING LABORATO; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; SCHRAG JD, 1992, J BIOL CHEM, V267, P4300; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720	43	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19157	19162						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034673				2022-12-27	WOS:A1994NX32700069
J	SAARINEN, J; KALKKINEN, N; WELGUS, HG; KOVANEN, PT				SAARINEN, J; KALKKINEN, N; WELGUS, HG; KOVANEN, PT			ACTIVATION OF HUMAN INTERSTITIAL PROCOLLAGENASE THROUGH DIRECT CLEAVAGE OF THE LEU(83)-THR(84) BOND BY MAST-CELL CHYMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; SKIN FIBROBLAST PROCOLLAGENASE; RHEUMATOID SYNOVIAL-CELLS; PROTEINASE CHYMASE; COLLAGENASE; MECHANISMS; GRANULES; DEGRADATION; HISTAMINE; SEQUENCE	In inflamed tissue sites characterized by on-going matrix degradation, the matrix metalloproteinases are secreted as latent precursors which are capable of proteolysis only after extracellular activation. Such areas often contain locally increased numbers of mast cells capable of releasing complexes between heparin proteoglycans and fully active endopeptidases with either tryptic (tryptase) or both tryptic and chymotryptic (chymase) activity. We have examined the ability of purified human skin chymase to activate human interstitial procollagenase (matrix metalloproteinase-1) in the absence and presence of heparin, the physiologic associate of chymase. Our studies indicate that chymase activates procollagenase in a time- and concentration-dependent manner. Heparin was found to increase markedly the rate at which chymase activates procollagenase both by accelerating the cleavage of procollagenase and also by preventing its further degradation. Moreover, we found that chymase activates procollagenase directly by cleaving the Leu(83)-Thr(84) bond, without formation of any intermediate species. This is a novel mechanism for procollagenase activation, which contrasts sharply with the activation mechanisms of other activators studied so far. The ability of chymase to activate procollagenase suggests that chymase plays an active role in matrix degradation at tissue sites where mast cells coexist with extracellular procollagenase.	WIHURI RES INST,SF-00140 HELSINKI,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,SF-00380 HELSINKI,FINLAND; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	Wihuri Research Institute; University of Helsinki; Barnes-Jewish Hospital; Washington University (WUSTL)			Kalkkinen, Nisse EJ/B-3923-2010					ATKINS FM, 1985, INT ARCH ALLER A IMM, V7, P96; BROMLEY M, 1984, ANN RHEUM DIS, V43, P76, DOI 10.1136/ard.43.1.76; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DABBOUS MK, 1986, BRIT J CANCER, V54, P459, DOI 10.1038/bjc.1986.198; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; EISENBERG M, 1984, BIOCHEM BIOPH RES CO, V125, P279, DOI 10.1016/S0006-291X(84)80365-4; EKLUND KK, 1993, INNOVATIONS PROTEASE, P241; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; FREEMONT AJ, 1985, ANN RHEUM DIS, V44, P312, DOI 10.1136/ard.44.5.312; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GRUBER BL, 1988, J IMMUNOL, V140, P3936; GRYMES RA, 1993, CONNECTIVE TISSUE DI, P69; HE G, 1989, P NATL ACAD SCI USA, V86, P2632; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JOHNSON LA, 1986, ANAL BIOCHEM, V15, P358; KAARTINEN M, 1994, IN PRESS ARTERIOSCLE; KALKKINEN N, 1988, J PROTEIN CHEM, V7, P242; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; KOVANEN PT, 1993, EUR HEART J, V14, P105; KREJCI NC, 1992, J INVEST DERMATOL, V98, P748, DOI 10.1111/1523-1747.ep12499942; LINDAHL U, 1979, BIOCHEM J, V182, P189, DOI 10.1042/bj1820189; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU MC, 1986, J IMMUNOL, V136, P2588; MALONE DG, 1987, ARTHRITIS RHEUM, V30, P130, DOI 10.1002/art.1780300202; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; NAGAI Y, 1990, ANN NY ACAD SCI, V598, P71, DOI 10.1111/j.1749-6632.1990.tb42278.x; NAGASE H, 1991, BIOMED BIOCHIM ACTA, V50, P749; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALI A, 1993, J BIOL CHEM, V268, P9023; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER NM, 1983, J BIOL CHEM, V258, P2973; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; SUOMALAINEN K, 1991, ORAL MICROBIOL IMMUN, V6, P24, DOI 10.1111/j.1399-302X.1991.tb00447.x; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VINE N, 1991, CLIN SCI, V81, P233, DOI 10.1042/cs0810233; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WIZE J, 1986, AGENTS ACTIONS, V18, P262, DOI 10.1007/BF01988037; YOFFE JR, 1984, BIOCHEM BIOPH RES CO, V122, P270, DOI 10.1016/0006-291X(84)90470-4	54	275	284	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18134	18140						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027075				2022-12-27	WOS:A1994NV42200058
J	OSTROWSKI, J; VANSEUNINGEN, I; SEGER, R; RAUCH, CT; SLEATH, PR; MCMULLEN, BA; BOMSZTYK, K				OSTROWSKI, J; VANSEUNINGEN, I; SEGER, R; RAUCH, CT; SLEATH, PR; MCMULLEN, BA; BOMSZTYK, K			PURIFICATION, CLONING, AND EXPRESSION OF A MURINE PHOSPHOPROTEIN THAT BINDS THE KAPPA-B MOTIF IN-VITRO IDENTIFIES IT AS THE HOMOLOG OF THE HUMAN HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K-PROTEIN - DESCRIPTION OF A NOVEL DNA-DEPENDENT PHOSPHORYLATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION; T-CELLS; SUBUNIT; REL; KINASE; SEQUENCE; RECEPTOR; AFFINITY; COMPLEX	The kappa B enhancer element regulates expression of many genes involved in immune responses and other processes. kappa B motif binds a number of proteins, some but not all, are related to the NF-kappa B family of transcription factors. We have previously identified a 65-kDa phosphoprotein that is specifically recognized by the kappa B motif (Ostrowski, J., Sims, J. E., Sibley, C. H., Valentine, M. A., Dower, S. K., Meier, K. E., and Bomsztyk, K. (1991) J. Biol. Chem. 266, 12722-12733). This protein is closely associated with a serine/threonine kinase that is responsive to treatment of cells with interleukin-1 and other agents. We report here purification, cloning, and expression of this kappa B motif-binding phosphoprotein. The primary structure deduced from the isolated murine cDNA, identifies the protein as the homolog of the human heterogeneous nuclear ribonucleoprotein K protein. Antipeptide antibodies and expression of the cloned cDNA in Escherichia coli, demonstrated that the K protein is the authentic phosphoprotein that binds the kappa B motif in vitro. We also demonstrate that the in vitro phosphorylation of the natural and the recombinant K proteins by the associated kinase is stimulated by the kappa B motif.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; MED CTR POSTGRAD EDUC,DEPT GASTROENTEROL & METAB,PL-02606 WARSAW,POLAND	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre of Postgraduate Medical Education - Poland			VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Ostrowski, Jerzy/0000-0003-1363-3766	NHLBI NIH HHS [R01 HL16919] Funding Source: Medline; NIGMS NIH HHS [R01 GM45134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ADAMS BS, 1991, NEW BIOL, V3, P1063; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEINTEMA JJ, 1985, EUR J BIOCHEM, V153, P305, DOI 10.1111/j.1432-1033.1985.tb09301.x; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Maxam A M, 1980, Methods Enzymol, V65, P499; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; OSTROWSKI J, 1993, NUCLEIC ACIDS RES, V21, P1045, DOI 10.1093/nar/21.4.1045; RACHIE NA, 1993, J BIOL CHEM, V268, P22143; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; Sanbrook J, 1989, MOL CLONING LABORATO; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249	39	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17626	17634						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021272				2022-12-27	WOS:A1994NU12800046
J	VANHEERDEN, A; BROWNING, KS				VANHEERDEN, A; BROWNING, KS			EXPRESSION IN ESCHERICHIA-COLI OF THE 2 SUBUNITS OF THE ISOZYME FORM OF WHEAT-GERM PROTEIN-SYNTHESIS INITIATION-FACTOR-4F - PURIFICATION OF THE SUBUNITS AND FORMATION OF AN ENZYMATICALLY ACTIVE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; ELONGATION-FACTORS; MESSENGER-RNA; SEQUENCE; IDENTIFICATION	The subunits (p28 and p86) of the isoenzyme form of eukaryotic initiation factor 4F (eIF-(iso)4F) from wheat were expressed separately in Escherichia coli. The sub units were purified by affinity chromatography (p28) and ion exchange chromatography (p86). The purified subunits alone did not support polypeptide synthesis in an eIF-(iso)4F and eIF-4F-deficient translation system from wheat germ. However, when the two subunits were mixed together, activity equal to that of the native form of eIF-(iso)4F was obtained. These results show that subunits expressed separately are able to associate and form an enzymatically active complex.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; JOSHI B, 1994, J BIOL CHEM, V269, P2048; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SAMBROOK J, 1989, MOL CLONING LABORATO, pA5; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TIMMER RT, 1993, J BIOL CHEM, V268, P24863; YAN RQ, 1992, J BIOL CHEM, V267, P23226	19	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17454	17457						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021249				2022-12-27	WOS:A1994NU12800020
J	ZHANG, SH; BROOME, MA; LAWTON, MA; HUNTER, T; LAMB, CJ				ZHANG, SH; BROOME, MA; LAWTON, MA; HUNTER, T; LAMB, CJ			ATPK1, A NOVEL RIBOSOMAL-PROTEIN KINASE GENE FROM ARABIDOPSIS .2. FUNCTIONAL AND BIOCHEMICAL-ANALYSIS OF THE ENCODED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAINS; RECEPTOR KINASE; PHOSPHORYLATION; BINDING; FAMILY; ACTIVATION; THREONINE; THALIANA; CALCIUM; INVITRO	The Arabidopsis Atpk1 protein expressed in insect cells and plant cells exhibited multiple sizes consisting mainly of two doublets: p70 (68 and 70 kDa) and p85 (82 and 85 kDa). Extraction of p85 from cells required the presence of SDS, suggesting that p85 is associated with less soluble subcellular components. p70 was extracted by nonionic detergent without SDS, indicating that this form is cytoplasmic. p70 expressed in either Arabidopsis or insect cells underwent serine-specific autophosphorylation, indicating that Atpk1 is a protein-serine kinase. A point mutation (lysine 163 to arginine) in the ATP-binding site of the catalytic domain substantially diminished activity when expressed in insect cells. A 14-kDa protein (p14) was co-immunoprecipitated with p70 from insect cells expressing wild-type Atpk1 and was phosphorylated in immune complex kinase assays with Atpk1, suggesting it is a homolog of a natural substrate of Atpk1. Two plant ribosomal proteins (14 and 16 kDa) can be phosphorylated by the Atpk1 protein kinase, and we propose that Atpk1 is a novel ribosomal protein kinase. A 60-kDa form of Atpk1 derived from the insect cell-expressed p70 was more highly phosphorylated than p70 in in vitro kinase assays, suggesting a negative regulatory domain can be removed by proteolysis.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM CHEM, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute					NCI NIH HHS [CA 37980] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEYSERRES J, 1990, PLANT PHYSIOL, V94, P1237, DOI 10.1104/pp.94.3.1237; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BUDDE RJA, 1990, PLANT BIOL, V9, P351; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DEVRIES S, 1988, PLANT MOL BIOL MAN B, V6, P1; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JF, 1993, BIOCHEMISTRY-US, V32, P3282, DOI 10.1021/bi00064a010; HASLER P, 1991, J BIOL CHEM, V266, P13815; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MIZOGUCHI T, 1993, PLANT MOL BIOL, V21, P279, DOI 10.1007/BF00019944; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; PILECKI M, 1992, EUR J BIOCHEM, V206, P259, DOI 10.1111/j.1432-1033.1992.tb16924.x; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEIN JC, 1993, PLANT PHYSIOL, V101, P1103, DOI 10.1104/pp.101.3.1103; Summers MD, 1987, MANUAL METHODS BACUL; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG SH, 1994, J BIOL CHEM, V269, P17586	36	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17593	17599						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021267				2022-12-27	WOS:A1994NU12800041
J	DONOVAN, FM; VAUGHAN, PJ; CUNNINGHAM, DD				DONOVAN, FM; VAUGHAN, PJ; CUNNINGHAM, DD			REGULATION OF PROTEASE NEXIN-1 TARGET PROTEASE SPECIFICITY BY COLLAGEN TYPE-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; NEURITE OUTGROWTH ACTIVITY; GLIA-DERIVED NEXIN; BASEMENT-MEMBRANE; SERINE PROTEASES; MONOCLONAL-ANTIBODIES; THROMBIN INHIBITION; HEPARIN COFACTOR; PROMOTING FACTOR; BINDING	Recent studies have shown that serine protease inhibitors can be regulated in their activity, specificity, and location by glycoprotein or extracellular matrix (ECM) co-factors. Protease nexin-1 (PN-1) is a member of the serpin superfamily of serine protease inhibitors which can rapidly inhibit thrombin, urokinase, and plasmin. PN-1 binds tightly to and is regulated by the ECM. This interaction accelerates the inhibition of thrombin by PN-1 and blocks urokinase and plasmin inhibition by PN-1. Previous work showed that heparan sulfate proteoglycan is largely responsible for the acceleration of thrombin inhibition by PN-1. Our current studies were directed at identifying ECM component(s) that decreased the ability of PN-1 to inhibit urokinase and plasmin. These studies showed that collagen type TV decreased the formation of SDS stable complexes between urokinase or plasmin and PN-1 without affecting formation of complexes between thrombin and PN-1. The second order rate constant for inhibition of urokinase by PN-1 was markedly decreased with increasing collagen type IV, whereas the second order rate constant for inhibition of thrombin by PN-1 was unaffected by addition of collagen type IV. Other ECM components (collagen type I, vitronectin, fibronectin, and heat-denatured collagen type IV) did not affect complex formation or the rate of inhibition of proteases by PN-1, indicating that these effects were specific to collagen type IV. Binding of PN-1 to immobilized collagen type IV was demonstrated using an enzyme-linked immunosorbent assay; the concentration of PN-1 necessary to obtain 50% saturation of the immobilized collagen type IV binding sites was approximately 15 nM. Collagen type IV was also co-purified with PN-1 from fibroblast-conditioned medium. These results demonstrate a novel regulation of serpin specificity in which an ECM co-factor decreased the inhibition of certain proteases by the serpin without affecting the inhibition of its target protease.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine			Galgiani, John/GLT-7012-2022		NIA NIH HHS [AG10598] Funding Source: Medline; NIGMS NIH HHS [GM07311] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010598] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHOI BH, 1990, AM J PATHOL, V137, P741; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FARRELL DH, 1986, BIOCHEM J, V237, P907, DOI 10.1042/bj2370907; FARRELL DH, 1987, BIOCHEM J, V245, P543, DOI 10.1042/bj2450543; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GLOOR S, 1986, CELL, V47, P687; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HANCOCK WW, 1984, PATHOLOGY, V16, P197, DOI 10.3109/00313028409059105; HOFFMANN MC, 1992, NEUROSCIENCE, V49, P397, DOI 10.1016/0306-4522(92)90105-B; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIOTTA LA, 1981, CANCER RES, V41, P4629; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MACKAY AR, 1990, CANCER RES, V50, P5997; MARTIN GR, 1987, ANN REV CELL BIOL, V3, P47; MARTINEZHERNANDEZ A, 1983, LAB INVEST, V48, P656; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MURAKAMI A, 1989, J BIOCHEM-TOKYO, V106, P490, DOI 10.1093/oxfordjournals.jbchem.a122879; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENBLATT DE, 1987, BRAIN RES, V415, P40, DOI 10.1016/0006-8993(87)90267-8; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; WAGNER SL, 1988, BIOCHEMISTRY-US, V27, P2173, DOI 10.1021/bi00406a053; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553	48	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17199	17205						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006028				2022-12-27	WOS:A1994NT84600035
J	CHRISTIANO, AM; GREENSPAN, DS; LEE, S; UITTO, J				CHRISTIANO, AM; GREENSPAN, DS; LEE, S; UITTO, J			CLONING OF HUMAN TYPE-VII COLLAGEN - COMPLETE PRIMARY SEQUENCE OF THE ALPHA-1(VII) CHAIN AND IDENTIFICATION OF INTRAGENIC POLYMORPHISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; ANCHORING FIBRILS; GENETIC-LINKAGE; SKIN DISEASES; CDNA CLONING; COL7A1; PERSPECTIVES; ORGANIZATION; DIAGNOSIS; PROTEINS	Type VII collagen is the major, if not the exclusive, component of the anchoring fibrils, attachment structures at the dermal-epidermal basement membrane zone. In this study, we have isolated overlapping cDNA clones which correspond to full-length human type VII collagen mRNA of similar to 9.2 kilobases. The full-length cDNA sequence contains an 8,833 nucleotide open reading frame encoding 2,944 amino acids. The deduced amino acid sequence revealed the presence of a central collagenous domain flanked by a large NH2-terminal non-collagenous (NC-1) domain which consists of submodules with homology to known adhesive proteins, including nine fibronectin type III-like segments (FNIII), and a smaller COOH-terminal non-collagenous (NC-2) domain. In addition, we report six intragenic polymorphisms in the type VII collagen gene (COL7A1) which can be detected by restriction enzyme digestion of polymerase chain reaction-amplified segments. The complete cDNA sequence and polymorphisms in COL7A1 will facilitate mutational analysis and prenatal diagnosis for patients with the dystrophic forms of epidermolysis bullosa, in which mutations in COL7A1 have been demonstrated.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706	Jefferson University; Jefferson University; Jefferson University; Jefferson University; University of Wisconsin System; University of Wisconsin Madison			Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline; NIGMS NIH HHS [R01-GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046846] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG B, 1990, EXTRACELLULAR MATRIX, P115; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; CHRISTIANO AM, 1994, P NATL ACAD SCI USA, V91, P3549, DOI 10.1073/pnas.91.9.3549; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; CHRISTIANO AM, 1993, ARCH DERMATOL, V129, P1455, DOI 10.1001/archderm.129.11.1455; CHRISTIANO AM, 1992, HUM MOL GENET, V1, P475, DOI 10.1093/hmg/1.7.475; CHRISTIANO AM, 1992, GENOMICS, V14, P827, DOI 10.1016/S0888-7543(05)80204-6; CHRISTIANO AM, 1994, CHRON DERMATOL, V4, P1; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; GAMMON WR, 1992, J INVEST DERMATOL, V99, P691, DOI 10.1111/1523-1747.ep12614080; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; HART GW, 1979, J BIOL CHEM, V254, P9747; HILAL L, 1993, NAT GENET, V5, P287, DOI 10.1038/ng1193-287; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LI K, 1993, GENOMICS, V16, P733, DOI 10.1006/geno.1993.1255; Lin AN, 1992, EPIDERMOLYSIS BULLOS; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MCGRATH JA, 1993, J INVEST DERMATOL, V100, P366, DOI 10.1111/1523-1747.ep12471830; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYYNANEN M, 1991, AM J HUM GENET, V49, P797; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; UITTO J, 1993, SEMIN DERMATOL, V12, P191; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105	33	173	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20256	20262						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051117				2022-12-27	WOS:A1994PB31700010
J	BALVAY, L; PRET, AM; LIBRI, D; HELFMAN, DM; FISZMAN, MY				BALVAY, L; PRET, AM; LIBRI, D; HELFMAN, DM; FISZMAN, MY			SPLICING OF THE ALTERNATIVE EXONS OF THE CHICKEN, RAT, AND XENOPUS BETA-TROPOMYOSIN TRANSCRIPTS REQUIRES CLASS-SPECIFIC ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRE-MESSENGER-RNA; PREMESSENGER RNA; GENE-EXPRESSION; SR PROTEINS; MUSCLE TROPOMYOSIN; NONMUSCLE CELLS; TRANSGENIC MICE; SINGLE GENE; SKELETAL; SITE	The diversity of protein isoforms is often generated from single genes by alternative splicing of the primary transcript. Using transfection of beta tropomyosin minigene constructs into homologous and heterologous cell systems, we show that there are differences, among higher vertebrates, in the components of the splicing machinery which control the conserved regulated splicing pattern of two mutually exclusive exons (6A and 6B) present in this gene. These experiments demonstrate that genes which give rise to alternative transcripts may require an appropriate combination of splicing factors which are species-specific, or at least restricted to the same taxonomic subgroup (class). An important practical implication is that the splicing of these genes may be deregulated in heterologous systems in vitro and in vivo, i.e. in transgenic animals.	INST PASTEUR,DEPT BIOL MOLEC,F-75724 PARIS 15,FRANCE; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Brandeis University; Cold Spring Harbor Laboratory			Helfman, David M./C-2058-2011					BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GRABOWSKI PJ, 1991, MOL CELL BIOL, V11, P5919, DOI 10.1128/MCB.11.12.5919; GRAHAM IR, 1992, MOL CELL BIOL, V12, P3872, DOI 10.1128/MCB.12.9.3872; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1993, NUCLEIC ACIDS RES, V21, P4762, DOI 10.1093/nar/21.20.4762; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HARDY S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P239, DOI 10.1016/0167-4781(92)90087-G; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1992, MOL CELL BIOL, V12, P3204, DOI 10.1128/MCB.12.7.3204; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NORTON PA, 1994, J CELL SCI, V107, P1; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; ROESSER JR, 1993, J BIOL CHEM, V268, P8366; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIBLEY CG, 1988, AUK, V105, P409, DOI 10.1093/auk/105.3.409; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WIJNHOLDS J, 1993, NUCLEIC ACIDS RES, V21, P1629, DOI 10.1093/nar/21.7.1629; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zorn A. M., 1991, BioTechniques, V11, P181	39	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19675	19678						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051042				2022-12-27	WOS:A1994PA12600005
J	FOSTER, BA; THOMAS, SM; MAHR, JA; RENOSTO, F; PATEL, HC; SEGEL, IH				FOSTER, BA; THOMAS, SM; MAHR, JA; RENOSTO, F; PATEL, HC; SEGEL, IH			CLONING AND SEQUENCING OF ATP SULFURYLASE FROM PENICILLIUM-CHRYSOGENUM - IDENTIFICATION OF A LIKELY ALLOSTERIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE KINASE; SULFATE-ACTIVATING ENZYMES; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; FILAMENTOUS FUNGI; ADENOSINE-5'-PHOSPHOSULFATE KINASE; KINETIC CHARACTERIZATION; PRODUCT INHIBITION; SULFHYDRYL-GROUP; GENE-EXPRESSION	Fungal (Penicillium chrysogenum) and yeast (Saccharomyces cerevisiae) ATP sulfurylases were shown to have very similar kinetic and chemical properties except that the fungal enzyme (a) contains a highly reactive Cys residue (SH-1) whose modification results in sigmoidal velocity curves (Renosto, F, Martin, R. L., and Segel, I. H. (1987) J. Biol. Chem. 262, 16279-16288) and (b) is allosterically inhibited by 3'-phosphoadenosine 5'phosphosulfate (PAPS), while the yeast enzyme displays neither of these properties. The fungal enzyme subunit (64.3 kDa, 572 amino acids) is also larger than the yeast enzyme subunit (59.3 kDa, 521 amino acids). To correlate the unique allosteric properties of the fungal enzyme with specific structural features, we cloned and sequenced the ATP sulfurylase gene taps) from P. chrysogenum. The yeast and fungal enzymes are homologous over the first 400 amino acids and contain two regions high in basic residues which are conserved in sulfurylases from Arabidopsis and the Riftia pachyptila (hydrothermal vent tube worm) chemolithotrophic symbiont, These regions may participate in forming the binding sites for MgATP(2-) and SO42-. The fungal enzyme has no significant sequence homology to the yeast enzyme in the C-terminal 172 amino acids. This C-terminal region contains SH-1 (Cys-508) and has homology to MET14 (S. cerevisiae), CYSC (E. coli), and NODQ (Rhizobium meliloti), i.e. adenosine 5'-phosphosulfate (APS) kinase. The cumulative results suggest that (a) the allosteric PAPS binding site of P. chrysogenum ATP sulfurylase is located in the C-terminal domain of the protein and (b) that this domain may have evolved from APS kinase. In spite of the homology, this C-terminal region does not account for the APS kinase activity of P. chrysogenum, Fungal ATP sulfurylase has no significant homology to (or regulatory properties in common with) CYSD or CYSN, proteins reported to comprise E. coli ATP sulfurylase (Leyh, T., Vogt, T. F, and Sue, Y. (1992) J. Biol. Chem. 267, 10405-10410).	UNIV CALIF DAVIS, DIV BIOL SCI, MOLEC & CELLULAR BIOL SECT, DAVIS, CA 95616 USA	University of California System; University of California Davis								Ausubel FM, 1991, CURRENT PROTOCOLS MO; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; CHEREST H, 1985, GENE, V34, P269; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER BP, 1985, ARCH MICROBIOL, V141, P384, DOI 10.1007/BF00428854; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; DEVITO PC, 1964, J BACTERIOL, V88, P1341, DOI 10.1128/JB.88.5.1341-1348.1964; DILWORTH GL, 1977, BIOCHEM J, V163, P521, DOI 10.1042/bj1630521; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GURANOWSKI A, 1988, BIOCHEMISTRY-US, V27, P2959, DOI 10.1021/bi00408a044; Gurr S. J., 1987, SPECIAL PUBLICATIONS, P93; HAAS H, 1993, GENE, V126, P237, DOI 10.1016/0378-1119(93)90372-A; HAAS H, 1992, GENE, V113, P129, DOI 10.1016/0378-1119(92)90680-N; HARADA T, 1960, J GEN MICROBIOL, V22, P520, DOI 10.1099/00221287-22-2-520; HAWES CS, 1973, BIOCHEM J, V133, P541, DOI 10.1042/bj1330541; ITAHASHI M, 1961, J BIOCHEM, V50, P52, DOI 10.1093/oxfordjournals.jbchem.a127408; KANNO N, 1988, NIPPON SUISAN GAKK, V54, P1635; KETTER JS, 1991, BIOCHEMISTRY-US, V30, P1780, DOI 10.1021/bi00221a008; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE BE, 1994, IN PRESS J BACTERIOL, V176; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH T, 1990, FASEB J, V4, pA1988; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P542; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LI JY, 1991, BIOCHIM BIOPHYS ACTA, V1078, P68, DOI 10.1016/0167-4838(91)90094-G; Maniatis T., 1982, MOL CLONING; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; NARA F, 1993, CURR GENET, V23, P134, DOI 10.1007/BF00352012; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; OSSLUND T, 1982, PLANT PHYSIOL, V70, P39, DOI 10.1104/pp.70.1.39; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; RENOSTO F, 1985, J BIOL CHEM, V260, P1535; RENOSTO F, 1987, J BIOL CHEM, V262, P16279; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RENOSTO F, 1985, J BACTERIOL, V164, P674, DOI 10.1128/JB.164.2.674-683.1985; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V284, P30, DOI 10.1016/0003-9861(91)90258-K; RENOSTO F, 1985, J BIOL CHEM, V260, P1903; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHMIDT ND, 1983, J THEOR BIOL, V100, P597, DOI 10.1016/0022-5193(83)90325-9; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SCHWEDOCK JS, 1992, GENETICS, V132, P899; Segel I.H., 1975, ENZYME KINETICS; SEGEL IH, 1987, METHOD ENZYMOL, V143, P334; SEUBERT PA, 1983, ARCH BIOCHEM BIOPHYS, V225, P679, DOI 10.1016/0003-9861(83)90079-6; Takebe I, 1960, J GEN APPL MICROBIOL, V6, P83; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9; 1989, PIERCE HDB GENERAL C, P210	59	83	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19777	19786						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051058				2022-12-27	WOS:A1994PA12600022
J	FRANKE, S; SCHOLZ, G; SCHEIDEREIT, C				FRANKE, S; SCHOLZ, G; SCHEIDEREIT, C			IDENTIFICATION OF NOVEL UBIQUITOUS AND CELL-TYPE-SPECIFIC FACTORS THAT SPECIFICALLY RECOGNIZE IMMUNOGLOBULIN HEAVY-CHAIN AND KAPPA-LIGHT-CHAIN PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR OTF-1; ENHANCER-BINDING-PROTEIN; OCTAMER MOTIF; STIMULATES TRANSCRIPTION; SEQUENCE ELEMENTS; GENE-EXPRESSION; B-CELLS; OCT-2; PURIFICATION; ACTIVATION	In a search for novel factors that interact with the octamer element, immunoglobulin kappa light chain (V-kappa) and heavy chain (V-H) gene promoters were compared for binding to nuclear proteins from lymphoid cells. Both promoters showed a similar pattern of bound factors, which was entirely different from that seen with the human immunodeficiency virus, type I promoter. Besides OTF-1 (Oct-1) and OTF-2 (Oct-2), at least three additional complexes were observed. Two of these were functionally analyzed: C1, a slowly migrating complex, which was much more abundant in B cells than in non-lymphoid cells, and C4, which appeared to have ubiquitous distribution. As determined by several methods, the protein(s) forming the C1 complex bound on the V-kappa gene to a site that partially covers the octamer element, whereas, surprisingly, in the V-H gene a region spanning the TATA box up to the transcriptional initiation site was recognized. The ubiquitous C4 complex was analyzed for the light chain promoter. The protein specifically bound to a site immediately 5' to the octamer. By in vitro transcription analysis, we found that C4 augments the octamer-dependent transcription of the V-kappa gene. The activation required binding of OTF-1/OTF-2, and C4 could not stimulate transcription by itself, implying a synergistic interaction. Due to the overlapping binding sites, the effect of C1 by itself could not be clearly separated from the C4 effect. However, the specific interaction of C1 with crucial control elements of light chain and heavy chain promoters strongly suggests a functional role in immunoglobulin gene transcription control.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-14195 BERLIN,GERMANY	Max Planck Society								ALTENBURGER W, 1980, NATURE, V287, P603, DOI 10.1038/287603a0; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COOPER C, 1992, J IMMUNOL, V149, P3225; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JENSEN EO, 1988, EMBO J, V7, P1265, DOI 10.1002/j.1460-2075.1988.tb02940.x; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MAY G, 1991, J BIOL CHEM, V266, P3052; MITZUSHIMASUGAN.J, 1986, P NATL ACAD SCI USA, V83, P8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WEITZ J, 1991, NUCLEIC ACIDS RES, V19, P5725, DOI 10.1093/nar/19.20.5725; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YOZA BK, 1990, MOL CELL BIOL, V10, P2145, DOI 10.1128/MCB.10.5.2145	43	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20075	20082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051094				2022-12-27	WOS:A1994PA12600063
J	WRIGHT, BE; FIELD, RJ				WRIGHT, BE; FIELD, RJ			THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM - 2 METHODS OF ANALYSIS USING THE SAME DATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMS-ANALYSIS; MODEL; METABOLISM	The results of using metabolic control theory versus biochemical systems theory to analyze a model of the tricarboxylic acid cycle in Dictyostelium are described. The two types of analysis give essentially the same results, except that smaller responses to perturbations are observed for the model analyzed by metabolic control theory. The basis for this difference is discussed.	UNIV MONTANA,DEPT CHEM,MISSOULA,MT 59812	University of Montana System; University of Montana	WRIGHT, BE (corresponding author), UNIV MONTANA,DIV BIOL SCI,MISSOULA,MT 59812, USA.							ALBE KR, 1992, J BIOL CHEM, V267, P3106; ALBE KR, 1994, IN PRESS J THEOR BIO; Pippard A. B., 1985, RESPONSE STABILITY; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1993, J BIOL CHEM, V268, P16917; SHIRAISHI F, J BIOL CHEM, V267, P22919; SHIRAISHI F, J BIOL CHEM, V267, P22926; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; TURANYI T, 1990, J MATH CHEM A, V45, P135; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1981, CURR TOP CELL REGUL, V19, P103; WRIGHT BE, 1968, J CELL PHYSIOL, V72, P145, DOI 10.1002/jcp.1040720411; WRIGHT BE, 1975, J BIOL CHEM, V250, P2219; WRIGHT BE, 1977, EUR J BIOCHEM, V74, P217, DOI 10.1111/j.1432-1033.1977.tb11384.x; WRIGHT BE, 1994, IN PRESS J THEOR BIO	16	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19931	19932						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051076				2022-12-27	WOS:A1994PA12600043
J	LEONG, SR; KABAKOFF, RC; HEBERT, CA				LEONG, SR; KABAKOFF, RC; HEBERT, CA			COMPLETE MUTAGENESIS OF THE EXTRACELLULAR DOMAIN OF INTERLEUKIN-8 (IL-8) TYPE-A RECEPTOR IDENTIFIES CHARGED RESIDUES MEDIATING IL-8 BINDING AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; CYTOSKELETAL REORGANIZATION; CRYSTAL-STRUCTURE; AMINO TERMINUS; LIGAND; PROTEINS; ACID	We systematically converted each of the amino acids in the extracellular domain of the interleukin-8 (IL-8) type A receptor to alanine for the purpose of identifying amino acids contributing to a IL-8 binding and IL-8-mediated signal transduction. We identified 20 mutations which cause a decrease in receptor affinity from a K, of 2 nM to a K-d greater than or equal to 25 nM. We then analyzed these receptor mutants for their ability to mobilize intracellular calcium upon stimulation with 10 nM IL-8. The majority of the mutants were able to produce calcium fluxes at levels approximating that of wild-type IL-8 receptor A, with the exception of six mutants (R199A, R203A C30A, C110A, C187A, and C277A) which showed no significant response. In addition, we performed calcium mobilization experiments to further characterize a series of previously constructed mutants which had only been characterized by their binding affinities in our previous report and found that mutant D265A showed no response upon stimulation with 10 nM IL-8. Our study shows that, besides the extracellular domain cysteines which may be critical for the overall folding of the receptor, three residues, Arg-199, Arg-203, and Asp-265, are important for IL-8 binding and IL-8-mediated signal transduction.			LEONG, SR (corresponding author), GENENTECH INC,DEPT IMMUNOL,460 POINT SAN BRUNO BLVD,SAN FRANCISCO,CA 94080, USA.							BROADDUS VC, 1994, J IMMUNOL, V152, P2960; CACALANO G, 1994, IN PRESS SCIENCE; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEE J, 1992, J IMMUNOL, V148, P1261; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NACCACHE PH, 1989, J IMMUNOL, V142, P2438; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PACAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WESTLIN WF, 1991, FASEB J, V5, pA1624	30	134	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19343	19348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034699				2022-12-27	WOS:A1994NY33200024
J	WONG, SKF; ROSS, EM				WONG, SKF; ROSS, EM			CHIMERIC MUSCARINIC CHOLINERGIC - BETA-ADRENERGIC RECEPTORS THAT ARE FUNCTIONALLY PROMISCUOUS AMONG G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; TURKEY ERYTHROCYTE-MEMBRANES; ACETYLCHOLINE-RECEPTOR; PHOSPHOLIPASE-C; AMINO-ACID; BINDING PROTEINS; GAMMA-SUBUNITS; ALPHA-SUBUNITS; INSECT CELLS; ACTIVATION	We evaluated the G protein selectivity of chimeric M1 and M2 muscarinic cholinergic receptors in which either the third intracellular (I3) loop or the N-terminal portion of this loop (the I3N peptide) was replaced by the corresponding sequence from the beta(1)-adrenergic receptor. The chimeras retained agonist-dependent G protein regulatory activity, but were completely promiscuous among potential G protein targets. When expressed in transfected cells, the chimeric receptors activated adenylyl cyclase, the major target of the beta-adrenergic receptor, and activated phospholipase C via a pertussis toxin-insensitive G protein, presumably a G(q). G(s) is not a target of either muscarinic receptor, and G(q) is not a cellular target of either the M2 muscarinic or beta-adrenergic receptor. When co-reconstituted into phospholipid vesicles with purified G proteins, the chimeric receptors were completely nonselective among all G proteins tested. They activated G(i), G(o), G(z), G(q), and G(s) with similar efficiencies. This promiscuity was largely suppressed, both in transfected cells and in reconstituted vesicles, by the additional replacement of the second intracellular (I2) loop of the beta-adrenergic receptor. Such double substitutions created receptors specific for G(s), the target of the beta-adrenergic receptor. These findings suggest that G protein specificity depends on the proper combination of multiple regions on a receptor's cytoplasmic surface. In addition, the promiscuous receptors described here may be useful for regulating novel G proteins whose natural regulators are not yet known.	UNIV TEXAS,SW MED CTR,SW GRAD SCH BIOMED SCI,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [R37GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA K, 1983, J BIOL CHEM, V258, P3575; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KATADA T, 1986, J BIOL CHEM, V261, P8182; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MORO O, 1993, J BIOL CHEM, V268, P22273; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18968	18976						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034654				2022-12-27	WOS:A1994NX32700042
J	YU, JX; CHAO, L; CHAO, J				YU, JX; CHAO, L; CHAO, J			PROSTASIN IS A NOVEL HUMAN SERINE PROTEINASE FROM SEMINAL FLUID - PURIFICATION, TISSUE DISTRIBUTION, AND LOCALIZATION IN PROSTATE-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; 4 TANDEM REPEATS; URINARY KALLIKREIN; MOLECULAR-CLONING; SPERM PROACROSIN; T-KININOGENASE; ANTIGEN; PROTEASE; SEQUENCE; BINDING	A novel serine proteinase, designated as prostasin, has been purified from human seminal fluid to apparent homogeneity by DEAE-Sepharose CL-6B and aprotinin-affinity chromatography. The purified protein migrates as two close bands with an apparent molecular mass of 40 kDa on SDS-polyacrylamide gel electrophoresis under reducing conditions. It can be labeled with [C-14]diisopropyl fluorophosphate and has a pI ranging from 4.5 to 4.8. Sequence analysis reveals that the two protein bands have an identical NH2-terminal amino acid sequence which is different from any known protein sequence in the SwissPro or GenBank data base. The NH2-terminal 20-amino acid sequence shares 50-55% identity with human alpha-tryptase, elastase 2A and 2B, chymotrypsin, acrosin, and the catalytic chains of hepsin, plasma kallikrein, and coagulation factor XI. Prostasin has trypsin like activity with a pH optimum of 9.0, hydrolyzing peptidyl fluorogenic substrates: D Pro-Phe-Arg-MCA, D-Phe-Phe-Arg-MCA, D-Val-Leu-Arg-MCA, and Z-Gly-Pro-Arg-AFC, It is inhibited by aprotinin, antipain,leupeptin, and benzamidine. The tissue distribution of prostasin was determined by a newly developed radioimmunoassay. Linear displacement curves for immunoreactive prostasin in body fluids and tissues were parallel with the standard curve of purified prostasin, indicating their immune logical identity. Immunoreactive prostasin levels were 8.61 +/- 0.42 mu g/ml in the seminal fluid and 0.201 +/- 0.029 mu g/ml in urine. Prostasin is present at high levels in the prostate gland (143.7 +/- 15.9 ng/mg protein), moderate levels (2-6 ng/mg protein) in colon, lung, kidney, pancreas, salivary gland, liver, and bronchi, but it is not detected in the brain, muscle, testis, ventricle, atrium, and aorta. Immunohistochemical localization reveals that prostasin is present in epithelial cells and ducts of the prostate gland. These studies indicate that prostasin purified from seminal fluid is a novel serine proteinase and originates from the prostate gland.	MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL, CHARLESTON, SC 29425 USA	Medical University of South Carolina					NHLBI NIH HHS [HL 29397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADHAM IM, 1990, HUM GENET, V84, P125; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BALERNA M, 1982, ARCH ANDROLOGY, V8, P97, DOI 10.3109/01485018208987025; CHAO J, 1988, METHOD ENZYMOL, V163, P128; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO S, 1989, BIOCHIM BIOPHYS ACTA, V991, P477, DOI 10.1016/0304-4165(89)90076-7; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DUNBAR BS, 1985, BIOL REPROD, V32, P619, DOI 10.1095/biolreprod32.3.619; FINK E, 1985, BIOL CHEM H-S, V366, P917, DOI 10.1515/bchm3.1985.366.2.917; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GUINAN P, 1987, J UROLOGY, V137, P686, DOI 10.1016/S0022-5347(17)44175-9; GUNTHER C, 1991, J IMMUNOL, V146, P3025; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; JONES R, 1988, DEVELOPMENT, V102, P781; KAWASHIMA I, 1987, DNA-J MOLEC CELL BIO, V6, P163, DOI 10.1089/dna.1987.6.163; KOBAYASHI T, 1992, ARCH ANDROLOGY, V28, P165, DOI 10.3109/01485019208987694; Kumamoto Y, 1989, Adv Exp Med Biol, V247A, P567; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miska W, 1989, Adv Exp Med Biol, V247A, P299; MORRIS BJ, 1989, CLIN EXP PHARMACOL P, V16, P345, DOI 10.1111/j.1440-1681.1989.tb01570.x; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SENSABAUGH GF, 1990, J UROLOGY, V144, P1523, DOI 10.1016/S0022-5347(17)39790-2; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; SIEGEL MS, 1986, BIOCHIM BIOPHYS ACTA, V883, P567, DOI 10.1016/0304-4165(86)90298-9; SKIDGEL RA, 1988, ARCH BIOCHEM BIOPHYS, V267, P660, DOI 10.1016/0003-9861(88)90074-4; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; TOPFERPETERSEN E, 1987, FEBS LETT, V226, P38, DOI 10.1016/0014-5793(87)80546-X; TSAI YC, 1984, CLIN CHEM, V30, P2026; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VANLERSEL J, 1985, ANAL BIOCHEM, V151, P196; WANG MC, 1979, INVEST UROL, V17, P159; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; XIONG W, 1990, J BIOL CHEM, V265, P2822; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	40	139	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18843	18848						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034638				2022-12-27	WOS:A1994NX32700025
J	EKER, P; HOLM, PK; VANDEURS, B; SANDVIG, K				EKER, P; HOLM, PK; VANDEURS, B; SANDVIG, K			SELECTIVE REGULATION OF APICAL ENDOCYTOSIS IN POLARIZED MADIN-DARBY CANINE KIDNEY-CELLS BY MASTOPARAN AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; HETEROTRIMERIC G-PROTEIN; EPIDERMAL GROWTH-FACTOR; TRANS-GOLGI NETWORK; EPITHELIAL-CELLS; CHOLERA-TOXIN; BREFELDIN-A; COATED PITS; CYCLIC-AMP; POTASSIUM-DEPLETION	We here demonstrate that mastoparan, fluoride, forskolin, cholera toxin, and 8-bromoadenosine-3'-5'-cyclic monophosphate all selectively stimulate apical endocytosis of the protein toxin ricin without increasing the uptake at the basolateral side of polarized Madin-Darby canine kidney cells. Activation of adenylyl cyclase and an increased level of cAMP seem to increase ricin endocytosis by a clathrin-independent mechanism since stimulation of endocytosis by cholera toxin and 8-bromoadenosine-3'-5'-cyclic monophosphate occurred even when the clathrin-dependent pathway was blocked by low cytosolic pH. The data suggest that mastoparan stimulates apical endocytosis by interacting with heterotrimeric Gr proteins, and also this stimulation of endocytosis appears to be clathrin independent since the uptake of transferrin at the apical side was strongly inhibited by mastoparan after brefeldin A-induced missorting of the transferrin receptor to this pole of the cell. In addition, mastoparan stimulated apical endocytosis when clathrin-mediated endocytosis was blocked by acidification of the cytosol. Furthermore, we provide evidence for the existence of clathrin-independent endocytosis on both the apical and the basolateral surface of control Madin-Darby canine kidney cells. Our results suggest that endocytosis at the apical pole of epithelial cells can be regulated selectively by a physiological signal.	NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO, NORWAY; UNIV COPENHAGEN, PANUM INST, DEPT MED ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN N, DENMARK	University of Oslo; University of Copenhagen								AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ANTONNY B, 1993, J BIOL CHEM, V268, P2393; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BRIGNONI M, 1993, EXP CELL RES, V205, P171, DOI 10.1006/excr.1993.1072; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FIELD M, 1974, P NATL ACAD SCI USA, V71, P3299, DOI 10.1073/pnas.71.8.3299; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILL DM, 1975, J BIOL CHEM, V250, P6424; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HALL MO, 1993, INVEST OPHTH VIS SCI, V34, P2392; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOLM PK, 1993, EUR J CELL BIOL, V62, P362; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KSISTAKIS NT, 1992, NATURE, V356, P344; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEVEY GS, 1970, BIOCHEM BIOPH RES CO, V38, P86, DOI 10.1016/0006-291X(70)91087-9; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MADSHUS IH, 1987, J CELL PHYSIOL, V131, P14, DOI 10.1002/jcp.1041310104; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SANDVIG K, 1991, CELL BIOL INT REP, V15, P3, DOI 10.1016/0309-1651(91)90077-V; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANDVIG K, 1988, J CELL BIOCHEM, V36, P73, DOI 10.1002/jcb.240360108; SANDVIG K, 1989, METHOD CELL BIOL, V32, P365; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1990, EUR J CELL BIOL, V51, P96; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VERREY F, 1993, J MEMBRANE BIOL, V133, P213; WAN JS, 1992, J BIOL CHEM, V267, P13446; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WIRTH JJ, 1982, J IMMUNOL, V129, P2759	55	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18607	18615						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034609				2022-12-27	WOS:A1994NW79800060
J	MENG, JJ; KHAN, S; IP, W				MENG, JJ; KHAN, S; IP, W			CHARGE INTERACTIONS IN THE ROD DOMAIN DRIVE FORMATION OF TETRAMERS DURING INTERMEDIATE FILAMENT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL MOLECULES; CROSS-LINKING; PROTEINS; VIMENTIN; KERATIN; DESMIN; CELLS; PHOSPHORYLATION; PROTOFILAMENT; MECHANISM	The purpose of this study was to test a long standing hypothesis regarding the forces that drive the assembly of intermediate filaments (IFs). The initial step of IF assembly is the formation of dimeric, alpha-helical coiled coils. On the outside of the coiled coils, charged amino acids are distributed periodically such that positively and negatively charged residues are arranged in alternating zones, 9.5/2 residues wide (Parry et al., 1977; McLachlan and Stewart, 1982). This structural feature has given rise to the hypothesis that, if neighboring coiled coils were staggered axially by an odd multiple of a charged zone, electrostatic interactions between them could provide the driving force for the assembly of higher order oligomers or filaments (Fraser et al., 1986; Parry and Steinert, 1992). Using the IF protein vimentin as a model system, we carried out deletion mutagenesis experiments to test this hypothesis. We generated mutant vimentin proteins lacking 14, 21, and 28 residues in Helix 1B of the rod domain, and analyzed their assembly properties by DNA transfection into IF null cells, in vitro assembly and chemical cross-linking. Results from these experiments are consistent with, and support, the hypothesis that charge complementation plays a key role in the assembly and stabilization of intermediate filaments.	UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA	University of Cincinnati				Khan, Sohaib/0000-0002-0792-9109	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035973] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35973] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; ATKINSON SJ, 1992, J MOL BIOL, V226, P7, DOI 10.1016/0022-2836(92)90118-4; BLOSE SH, 1976, J CELL BIOL, V70, P459, DOI 10.1083/jcb.70.2.459; CHOU RGR, 1990, BIOCHEM J, V272, P139, DOI 10.1042/bj2720139; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; CREWTHER WG, 1983, INT J BIOL MACROMOL, V5, P267, DOI 10.1016/0141-8130(83)90040-5; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; GRUEN LC, 1983, BIOCHEM J, V209, P587, DOI 10.1042/bj2090587; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; IP W, 1990, ANAL BIOCHEM, V185, P10, DOI 10.1016/0003-2697(90)90247-7; IP W, 1985, ANN NY ACAD SCI, V455, P185, DOI 10.1111/j.1749-6632.1985.tb50412.x; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MAKAROVA I, 1994, IN PRESS CELL MOTIL; MCLACHLAN AD, 1982, J MOL BIOL, V162, P693, DOI 10.1016/0022-2836(82)90396-5; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; POTSCHKA M, 1986, BIOPHYS J, V49, P129, DOI 10.1016/S0006-3495(86)83621-9; QUINLAN RA, 1982, P NATL ACAD SCI-BIOL, V79, P3452, DOI 10.1073/pnas.79.11.3452; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SAEED T, 1989, BIOCHEM BIOPH RES CO, V165, P1059, DOI 10.1016/0006-291X(89)92709-5; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; Stewart M, 1990, CURR OPIN CELL BIOL, V2, P91, DOI 10.1016/S0955-0674(05)80037-7; TOKUYASU KT, 1984, J CELL BIOL, V98, P1961, DOI 10.1083/jcb.98.6.1961; TRAUB P, 1992, J CELL SCI, V101, P363; TURNER PC, 1992, BIOTECHNIQUES, V13, P764; WEBER K, 1969, J BIOL CHEM, V244, P4406	52	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18679	18685						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034617				2022-12-27	WOS:A1994NW79800071
J	BAUDE, EJ; DIGNAM, SS; REIMANN, EM; UHLER, MD				BAUDE, EJ; DIGNAM, SS; REIMANN, EM; UHLER, MD			EVIDENCE FOR THE IMPORTANCE OF HYDROPHOBIC RESIDUES IN THE INTERACTIONS BETWEEN THE CAMP-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT AND THE PROTEIN-KINASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; II REGULATORY SUBUNIT; PEPTIDE INHIBITOR; MOLECULAR-CLONING; MUTATIONS; ISOFORMS; RECOGNITION; EXPRESSION; BINDING; SITES	The protein kinase inhibitors (PKIs) are potent inhibitors of the catalytic (C) subunit of cAMP-dependent protein kinase. In this study, the interaction between Phe(10) of PKI and the C subunit residues Tyr(235) and Phe(239) was investigated using site-directed mutagenesis. Previous peptide studies as well as the crystal structure suggested that these residues may play a key role in C-PKI binding. The C subunit codons for Tyr(235) and Phe(239) were changed singly and in combination to serine codons. The mutated C alpha proteins were overexpressed in Escherichia coli. The purified C alpha Y235S, C alpha F239S, and C alpha Y235S/F239S proteins did not exhibit any differences in their K-m(app) for the peptide substrate Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) or V-max(app), with respect to wild-type C alpha. All of the C subunit mutants displayed less than 2-fold changes in their K-m(app) for ATP. The PKI alpha isoform displayed increased IC50 values for C alpha Y235S (71-fold), C alpha F239S (150-fold), and C alpha Y235S/F239S (1800-fold). Similarly, the PKI beta 1 protein showed increased IC50 values against the C alpha Y235S, C alpha F239S, and C alpha Y235S/F239S proteins, 9.4-, 11-, and 44-fold, respectively. In addition, the PKI alpha F10 codon was altered to an alanine codon, and this mutation decreased its ability to inhibit C alpha kinase activity, but did not affect its ability to inhibit C alpha Y235S/F239S. The mutation of Tyr(235) and Phe(239) to serines, however, did not alter the ability of the type II R subunit to inhibit phosphotransferase activity. These results suggest that C alpha Y235 and C alpha F239 are important for specific inhibition by both PKI alpha and PKI beta but not the type II R subunit and that mutations at these residues would be useful for in vivo analysis of C-PKI interactions.	UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; MED COLL OHIO, DEPT BIOCHEM, TOLEDO, OH 43699 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIGMS NIH HHS [GM38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038788, R01GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CHENG HC, 1986, J BIOL CHEM, V261, P989; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HOFFMAN F, 1980, J BIOL CHEM, V255, P1559; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEBER W, 1979, BIOCHEM BIOPH RES CO, V90, P1073, DOI 10.1016/0006-291X(79)91935-1; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142	40	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18128	18133						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027074				2022-12-27	WOS:A1994NV42200057
J	CHAN, MT; CHAO, YC; YU, SM				CHAN, MT; CHAO, YC; YU, SM			NOVEL GENE-EXPRESSION SYSTEM FOR PLANT-CELLS BASED ON INDUCTION OF ALPHA-AMYLASE PROMOTER BY CARBOHYDRATE STARVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BETA-GLUCURONIDASE; ESCHERICHIA-COLI; CULTURED-CELLS; FUSION MARKER; RICE; GLYCOSYLATION; SUGAR	The 5' regulatory region and putative signal sequence of a rice alpha-amylase gene, alpha Amy8, was fused to a bacterial gene encoding beta-glucuronidase (GUS) and introduced into rice, tobacco, and potato via Agrobacterium-mediated transformation systems. Expression of this chimeric gene in suspension cells of transgenic plants was suppressed by the presence of sucrose in the medium and induced by its absence. Induction or suppression of GUS expression in transgenic rice could be reversed by the deprivation or replenishment, respectively, of sucrose in the medium. The expressed GUS fusion protein was translocated to the endoplasmic reticulum, modified by glycosylation, and secreted into the culture medium of transgenic cells. In the presence of a glycosylation inhibitor, tunicamycin, the enzymatically active form of GUS was assembled in the endoplasmic reticulum. The yield of GUS secreted by transgenic cells was estimated to be as high as 40% of total secreted proteins. The reversible induction of the alpha-amylase promoter in culture cells by sugar level in the medium provides an excellent inducible expression system for basic research in plant science. Combination of the alpha-amylase prometer and signal sequence also offers a novel approach for large scale production of low cost, easily purified, secreted recombinant proteins.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Chan, Ming-Tsair/L-2465-2015; Yu, Su-May/ABB-6950-2021	Yu, Su-May/0000-0001-8744-9246				BELANGER FC, 1986, P NATL ACAD SCI USA, V83, P1354, DOI 10.1073/pnas.83.5.1354; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; CHAN MT, 1993, PLANT MOL BIOL, V22, P491, DOI 10.1007/BF00015978; D.P.S, PLANT MOL BIOL MANUA, P1, DOI 10.1007/978-94-009-0951-9; DOES MP, 1991, PLANT MOL BIOL, V17, P151, DOI 10.1007/BF00036819; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; ITURRIAGA G, 1989, PLANT CELL, V1, P381, DOI 10.1105/tpc.1.3.381; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JEFFERSON RA, 1988, PLANT GENETIC TRANSF, P263; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KARRER EE, 1992, PLANT J, V2, P517; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PAN SZ, 1992, GENE, V112, P229; SCHUSTER JR, 1989, YEAST GENETIC ENG, P83; SHEU JJ, 1994, PLANT J, V5, P655, DOI 10.1111/j.1365-313X.1994.00655.x; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG PJ, 1982, AM POTATO J, V59, P33, DOI 10.1007/BF02854881; YU SM, 1992, GENE, V122, P247, DOI 10.1016/0378-1119(92)90212-8; YU SM, 1991, J BIOL CHEM, V266, P21131	25	51	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17635	17641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021273				2022-12-27	WOS:A1994NU12800047
J	HENDERSON, BR; MENOTTI, E; BONNARD, C; KUHN, LC				HENDERSON, BR; MENOTTI, E; BONNARD, C; KUHN, LC			OPTIMAL SEQUENCE AND STRUCTURE OF IRON-RESPONSIVE ELEMENTS - SELECTION OF RNA STEM-LOOPS WITH HIGH-AFFINITY FOR IRON REGULATORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSFERRIN RECEPTOR EXPRESSION; FE-S CLUSTER; BINDING-PROTEIN; UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; DEPENDENT REGULATION; MOLECULAR-CLONING; CYTOSOLIC PROTEIN	Iron regulatory factor (IRF) is a cytoplasmic mRNA binding protein with specificity for iron-responsive element (IRE) RNA stem-loops. IRF post-transcriptionally regulates intracellular iron levels via binding to IREs in the untranslated regions of ferritin, transferrin receptor, and erythroid 5-aminolevulinic-acid synthase mRNAs. Specific IRE nucleotides are phylogenetically conserved: those of the 6-base loop (5'-CAGUGN-3') and an unpaired ''bulge'' cytosine. We prepared a pool of 16,384 IRE molecules randomized at these seven nucleotide positions and employed in vitro selection to identify RNAs that bind human IRF. Two major classes of high affinity RNA ligands were selected; the optimal loop sequences of each are 5'-CAGUGN-3' (wild type) and 5'-UAGUAN-3'. This novel finding predicts base pairing within the PRE loop between positions 1 and 5, thus facilitating the formation of a specific loop structure in which nucleotides at positions 2-4 are made accessible for protein interaction, Nucleotide substitution at these loop positions, or at the position of the bulge cytosine, decreased binding by 36-99%. In addition, we demonstrate a preferred IRE bulge structure and report a striking difference in the RNA binding specificity of rat IRF compared with that of the related IRE-binding protein, IRF(B).	SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research								AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CHERN YJ, 1992, BIOCHEM BIOPH RES CO, V185, P304, DOI 10.1016/S0006-291X(05)90000-4; COLVIN RA, 1992, J VIROL, V66, P930, DOI 10.1128/JVI.66.2.930-935.1992; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GUTELL RR, 1993, CURR OPIN STRUC BIOL, V3, P313, DOI 10.1016/S0959-440X(05)80101-0; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P32; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VISVADER J, 1991, ONCOGENE, V6, P187; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; ZHENG L, 1992, ARCH BIOCHEM BIOPHYS, V2, P356; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	60	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17481	17489						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021254				2022-12-27	WOS:A1994NU12800025
J	LEROMANCER, M; REYLDESMARS, F; CHERIFI, Y; PIGEON, C; BOTTARI, S; MEYER, O; LEWIN, MJM				LEROMANCER, M; REYLDESMARS, F; CHERIFI, Y; PIGEON, C; BOTTARI, S; MEYER, O; LEWIN, MJM			THE 86-KDA SUBUNIT OF AUTOANTIGEN KU IS A SOMATOSTATIN RECEPTOR REGULATING PROTEIN PHOSPHATASE-2A ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE HGT-1; PHOSPHOPROTEIN PHOSPHATASES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; PANCREATIC-CANCER; EXPRESSION; KINASE; DEPHOSPHORYLATION; PHOSPHORYLATION; BRAIN	We previously reported the immunopurification of a somatostatin receptor from the human tumoral gastric cell HGT1 using the monoclonal antibody 30F3 (Reyl-Desmars, F., Le Roux, S., Linard, C., Benkouka, F., and Lewin, M. J. M. (1989) J. Biol. Chem. 264, 18789-18795). Screening of a lambda gt11 HGT1-cDNA library with 30F3 led us to isolate a cDNA encoding an 86-kDa polypeptide displaying 100% structural identity with the 86-kDa subunit (p86-Ku) of the Ku autoantigen. Recombinant p86 expressed in Escherichia coli cross-reacted with 30F3 and specifically bound [I-125-Tyr(11)]somatostatin-14. Binding was totally displaced by somatostatin-14, somatostatin-28, and SMS 201-995, with IC50 values of 0.7, 1.0, and 1.2 nM, respectively. In a search for a biological effect associated with binding, we purified a 36-kDa, okadaic acid-sensitive phosphatase (protein phosphatase-2A (PP2A)) from rat gastric cytosol. PP2A catalyzed P-32 release from p34(cdc2)-phosphorylated histone H1. However, PP2A-induced P-32 release was concentration dependently inhibited by recombinant p86-Ku, with a decrease in maximal velocity without a change in K-m. Steric exclusion high pressure chromatography indicated that the inhibition resulted from direct interaction of the enzyme with p86-Ku. Furthermore, it was antagonized by increased concentrations of somatostatin-14 and prevented by preincubating p86-Ku with 30F3. Given the key role played by PP2A in cell cycle regulation, the current findings suggest that p86-Ku could be a physiological target of somatostatin antiproliferative action.	HOP BICHAT,INSERM,U10,UNITE RECH GASTROENTEROL,F-75877 PARIS 18,FRANCE; GRP HOSP BICHAT CLAUDE BERNARD,SERV RHUMATOL,F-75877 PARIS 18,FRANCE; CEN,INSERM,U244,UNITE RECH,F-38041 GRENOBLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Bottari, Serge/ABF-3990-2021	Bottari, Serge P./0000-0002-4172-2400; Le Romancer, Muriel/0000-0002-8491-4015				BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DALZIEL RG, 1992, AUTOIMMUNITY, V13, P265, DOI 10.3109/08916939209112334; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROMANCER M, 1993, CR ACAD SCI III-VIE, V316, P1286; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; LI XJ, 1992, J BIOL CHEM, V267, P21307; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LINARD C, 1992, REGUL PEPTIDES, V41, P219, DOI 10.1016/0167-0115(92)90115-B; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; MEYERHOF W, 1991, DNA CELL BIOL, V10, P689, DOI 10.1089/dna.1991.10.689; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; QIN YF, 1992, CANCER RES, V52, P6025; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P361; REYL F, 1981, BIOCHIM BIOPHYS ACTA, V675, P297, DOI 10.1016/0304-4165(81)90241-5; REYL FJ, 1982, P NATL ACAD SCI-BIOL, V79, P978, DOI 10.1073/pnas.79.4.978; REYLDESMARS F, 1982, BIOCHEM BIOPH RES CO, V109, P1324, DOI 10.1016/0006-291X(82)91922-2; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; REYLDESMARS F, 1986, REGUL PEPTIDES, V16, P207, DOI 10.1016/0167-0115(86)90020-0; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; RUSZNIEWSKI P, 1993, REGUL PEPTIDES, V43, P141, DOI 10.1016/0167-0115(93)90148-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YAMADA Y, 1993, BIOCHEM BIOPH RES CO, V195, P844, DOI 10.1006/bbrc.1993.2122; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1989, J BIOL CHEM, V264, P13407; YANG SD, 1988, J BIOL CHEM, V263, P8856; YASUDA K, 1992, J BIOL CHEM, V267, P20422	46	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17464	17468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021251				2022-12-27	WOS:A1994NU12800022
J	LIN, RT; MUSTAFA, A; NGUYEN, H; GEWERT, D; HISCOTT, J				LIN, RT; MUSTAFA, A; NGUYEN, H; GEWERT, D; HISCOTT, J			MUTATIONAL ANALYSIS OF INTERFERON (IFN) REGULATORY FACTOR-1 AND FACTOR-2 - EFFECTS ON THE INDUCTION OF IFN-BETA GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VIRUS-INDUCIBLE ENHANCER; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; FACTOR-II; IRF-1; ELEMENTS; PROTEIN; BINDING; SEQUENCES	Interferon (IFN) regulatory factor 1 (IRF-1) and IRF-2 are structurally similar but functionally distinct transcription factors that bind to the positive regulatory domains I and III (PRDI/III) within the human IFN-beta promoter. To begin structure-function analysis of IRF-1 and IRF-8, the regulatory potential of carboxyl-terminal deletion mutants was analyzed by co-transfection studies in human cells and was correlated with DNA binding capacity. Transcriptional repression by IRF-2 was contained within the first 125 amino-terminal amino acids and correlated directly with IRF-2 DNA binding; deletion to a protein of 100 amino acids resulted in loss of repression and IRF-2 DNA binding. Thus, the carboxyl terminus appears dispensible for trans-repression. Hybrid constructs which fuse the DNA binding domain of HRF-1 and IRF-2 to the trans-activation domain of NF-kappa B p65 were also generated; both IRF-1/p65 and IRF-2/p65 chimeras were strong transcriptional activators. IRF-2-mediated repression was also dominant over trans-activation by these fusion proteins. The trans-activation region of IRF-1 resides in the carboxyl terminus, primarily carboxyl-terminal to amino acid 250. Mutation of three potential casein kinase II phosphorylation sites within the IRF carboxyl terminus failed to identify an essential site that contributes to IRF-1 trans-activation potential.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,ABE STERN CANC RES LAB,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT IMMUNOL & MICROBIOL,MONTREAL H3T 1E2,PQ,CANADA; WELLCOME FDN LTD,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	Lady Davis Institute; McGill University; McGill University; GlaxoSmithKline			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1992, P NATL ACAD SCI USA, V89, P1250; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, IN PRESS J VIROL, V68; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEISZ A, 1991, Journal of Interferon Research, V11, pS136; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	43	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17542	17549						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021262				2022-12-27	WOS:A1994NU12800034
J	SEINO, A; FURUKAWA, K; MIURA, T; YAGINUMA, T; MOMOSE, K; OHIZUMI, Y				SEINO, A; FURUKAWA, K; MIURA, T; YAGINUMA, T; MOMOSE, K; OHIZUMI, Y			3',3'',5',5''-TETRAIODOPHENOLSULFONEPHTHALEIN IS A SELECTIVE INHIBITOR OF CA2+-PUMPING ATPASE IN INTRACELLULAR CA2+ STORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CA-2+,MG-2+-ADENOSINE TRIPHOSPHATASE; CONFORMATIONAL TRANSITIONS; CALCIUM RELEASE; THAPSIGARGIN; CA-2+-ATPASE; MUSCLE; MEMBRANE; ACID; RAT	3',3'',5',5''-Tetraiodophenolsulfonephthalein (I4PSP) stimulated both Ca2+ transient levels and aggregation in response to thrombin in platelets. Ca2+ uptake into skeletal sarcoplasmic reticulum (SR) was inhibited by I4PSP (IC50, 1.8 mu M) whereas that of red blood cell ghosts was not affected by it. Furthermore, I4PSP inhibited the SR Ca2+-ATPase activity (IC50, 1.1 mu M). Kinetic analysis of the inhibitory effects of I4PSP reveals that I4PSP shows an inhibition of noncompetitive and competitive type with respect to low and high concentrations of ATP, respectively. The mode of inhibition by I4PSP is an uncompetitive type with respect to Ca2+. I4PSP decreased the decomposition rate of the phosphorylated enzyme intermediate (EP). The change in the tryptophan fluorescence of SR Ca2+-ATPase induced by ATP was reduced by I4PSP indicating inhibition of the EP transition from Ca(2)E(1)P to E(2)P. The concentration-inhibitory response curves for I4PSP in Ca2+-ATPase activities and fluorescence changes were closely correlated. These results suggest that I4PSP slows down the structure transition from Ca(2)E(1)P to E(2)P, resulting in inhibition of the Ca2+-ATPase activity. On the basis of these results, it is suggested that the stimulation of Ca2+ transient levels in platelets and their aggregation in response to thrombin are due to the inhibition of Ca2+ pump in intracellular Ca2+ stores by I4PSP.	TOHOKU UNIV, INST PHARMACEUT, DEPT PHARMACEUT MOLEC BIOL, SENDAI, MIYAGI 980, JAPAN; MITSUBISHI KASEI IND, RES CTR, YOKOHAMA 227, KANAGAWA, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, DEPT PHARMACOL, TOKYO 142, JAPAN	Tohoku University; Showa University								BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRUNE B, 1991, FEBS LETT, V284, P1, DOI 10.1016/0014-5793(91)80747-Q; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1981, SARCOPLASMIC RETICUL; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FANG YI, 1993, J BIOL CHEM, V268, P18622; HUGGINS JP, 1985, MOL MECHANISMS TRANS, P57; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KIM DH, 1983, J BIOL CHEM, V258, P9662; KOBAYASHI M, 1984, J BIOL CHEM, V259, P5007; KOBAYASHI M, 1988, J PHARMACOL EXP THER, V246, P667; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MARTONOSI A, 1987, ELECTRON MICROS, V6, P255; MARTONOSI AN, 1983, HDB PHYSL 10, V10, P417; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; NAKAMURA Y, 1984, J BIOL CHEM, V259, P8183; NAKAMURA Y, 1986, J BIOL CHEM, V261, P4139; NAKAO T, 1973, J BIOCHEM-TOKYO, P609; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PAPP B, 1991, J BIOL CHEM, V266, P14593; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; SCOTT TL, 1988, MOL CELL BIOCHEM, V82, P51; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SEINO A, 1991, J PHARMACOL EXP THER, V256, P861; SOKOLOVE PM, 1986, FEBS LETT, V203, P121, DOI 10.1016/0014-5793(86)80726-8; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAYLOR KA, 1988, METHOD ENZYMOL, V157, P271; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; WATANABE A, 1993, BRIT J PHARMACOL, V109, P29, DOI 10.1111/j.1476-5381.1993.tb13527.x; YASUOKAYABE K, 1983, J BIOCHEM-TOKYO, V94, P665, DOI 10.1093/oxfordjournals.jbchem.a134406; YASUOKAYABE K, 1983, J BIOCHEM-TOKYO, V94, P677, DOI 10.1093/oxfordjournals.jbchem.a134407	36	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17550	17555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021263				2022-12-27	WOS:A1994NU12800035
J	CROUCH, E; PERSSON, A; CHANG, D; HEUSER, J				CROUCH, E; PERSSON, A; CHANG, D; HEUSER, J			MOLECULAR-STRUCTURE OF PULMONARY SURFACTANT PROTEIN-D (SP-D)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CONGLUTININ; BASEMENT-MEMBRANE; BINDING-PROTEIN; COLLAGEN; PHOSPHATIDYLINOSITOL; ACCUMULATION; SIMILARITY; FREEZE; MICA; CDNA	Previous studies have shown that pulmonary surfactant protein D (SP-D) is composed of a 43-kDa polypeptide with a short NH2-terminal domain, a collagen sequence, and a COOH-terminal C-type lectin domain. In the present studies, ultrastructural and biochemical techniques were used to examine the quaternary structure of native rat SP-D (rSP-D). Electron microscopy of freeze-dried preparations demonstrated a highly homogeneous population of molecules with four identical rod-like arms (46 nm in length), each with an an 8-9-nm diameter globular terminal expansion. The arms, which are similar in diameter to the type I collagen helix (approximate to 4 nm), emanate from the central ''hub'' in two pairs that closely parallel each other for their first 10 nm. This structure is consistent with hydrodynamic studies that predict an highly asymmetric and extended molecule (f/f(0) = 3.26) with a large Stokes radius (R(s) = 18 nm). Pepsin digestion gave glycosylated, trimeric collagenous fragments (43 +/- 4 nm, 17 kDa/chain). Trimeric subunits containing intact triple helical domains were also liberated from SP-D dodecamers by sulfhydryl reduction under non denaturing conditions. Digestion of rSP-D with bacterial collagenase generated a COOH terminal carbohydrate binding fragment and a smaller peptide (approximate to 12 kDa, unreduced) that contains interchain disulfide bonds. Electron microscopy also demonstrated higher orders of multimerization, with as many as 8 molecules associated at the hub. These studies demonstrate that SP-D is assembled as homopolymers of four identical trimeric subunits, that interactions between the amino-terminal domains of the trimers are stabilized by interchain disulfide bonds, and that SP-D molecules can associate to form complex multimolecular assemblies.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44015] Funding Source: Medline; NIGMS NIH HHS [GM-29647] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROUCH E, 1991, AM J PATHOL, V139, P765; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, PROG R RES, V27, P132; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; ELGSAETER A, 1978, BIOCHIM BIOPHYS ACTA, V536, P235, DOI 10.1016/0005-2795(78)90069-7; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUAN SF, 1992, FASEB J, V6, pA1270; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Schachman H.K., 1959, ULTRACENTRIFUGATION; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; STRANG CJ, 1986, BIOCHEM J, V234, P381, DOI 10.1042/bj2340381; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VEIS A, 1982, METHOD ENZYMOL, V82, P186; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109	35	195	200	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17311	17319						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006040				2022-12-27	WOS:A1994NT84600051
J	SOTTILE, J; WILEY, S				SOTTILE, J; WILEY, S			ASSEMBLY OF AMINO-TERMINAL FIBRONECTIN DIMERS INTO THE EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; PLASMA FIBRONECTIN; POLYACRYLAMIDE GELS; CELL-LAYERS; I MODULES; RECEPTOR; FIBROBLASTS; PROTEINS; BINDING; DOMAIN	Fibronectin is a dimeric adhesion molecule that consists of three types of repeating modules. Adherent cells bind soluble fibronectin and incorporate it into insoluble fibrils in the extracellular matrix. The aminoterminal 70-kDa portion of fibronectin mediates binding to the cell surface, but amino terminal fragments do not accumulate in the extracellular matrix. The ninth type I and first type III modules, the cell adhesion region, and the cysteines that form the interchain disulfide bonds have also been implicated in matrix assembly. To further define which regions of fibronectin are essential for matrix assembly, we generated a dimeric protein (d70 kDa) in which the 70-kDa amino terminus is directly linked to the last 51 amino acids of fibronectin, which contain the cysteines involved in interchain disulfide bonding. d70 kDa bound to cells and accumulated in the extracellular matrix. Incorporation of d70 kDa into the extracellular matrix was dependent upon protein synthesis; in cycloheximide-treated cultures that lacked a pre-existing matrix, d70 kDa accumulated in the extracellular matrix only in the presence of intact fibronectin. Monomeric 70-kDa protein was not incorporated into the matrix in the presence or absence of cycloheximide. These data indicate that fibronectin molecules containing only the amino-terminal 70-kDa region and the carboxyl-terminal 51 amino acids can become assembled into the extracellular matrix.			SOTTILE, J (corresponding author), ALBANY MED COLL,ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208, USA.				NCRR NIH HHS [SO7RR05394-31] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005394] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BALIAN G, 1979, J BIOL CHEM, V254, P1429; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Engvall E, 1980, Methods Enzymol, V70, P419; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; ICHIHARATANAKA K, 1992, FEBS LETT, V299, P155, DOI 10.1016/0014-5793(92)80236-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH RA, 1993, NUCLEIC ACIDS RES, V21, P1753, DOI 10.1093/nar/21.8.1753; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGOPJ, 1989, FIBRINECTIN, P163; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; Mosher, 1989, FIBRONECTIN, P1; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; SOO SA, 1992, BIOCHEMISTRY-US, V31, P9927; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; Sottile J, 1990, Protein Expr Purif, V1, P104, DOI 10.1016/1046-5928(90)90002-G; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU CY, 1993, J BIOL CHEM, V268, P21883; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	38	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17192	17198						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006027				2022-12-27	WOS:A1994NT84600034
J	NANOFF, C; BOEHM, S; HOHENEGGER, M; SCHUTZ, W; FREISSMUTH, M				NANOFF, C; BOEHM, S; HOHENEGGER, M; SCHUTZ, W; FREISSMUTH, M			2',3'-DIALDEHYDE GTP AS AN IRREVERSIBLE G-PROTEIN ANTAGONIST - DISRUPTION AND RECONSTITUTION OF G-PROTEIN-MEDIATED SIGNAL-TRANSDUCTION IN CELLS AND CELL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK SYMPATHETIC NEURONS; BETA-GAMMA-SUBUNITS; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; BOVINE BRAIN; ESCHERICHIA-COLI; SYNTHETIC PEPTIDES; PLATELET MEMBRANES; ADENOSINE RECEPTOR; CALCIUM CURRENTS	The 2',3'-dialdehyde analogue of GTP, oGTP, was devised as an irreversible antagonist of regulatory GTP-binding proteins (G proteins), Here, we show that oGTP uncouples transmembrane signaling mediated by a set of distinct G proteins both in isolated membranes and in whole cells, In human platelet membranes, pretreatment with oGTP suppressed receptor- and G protein-controlled regulation of adenylyl cyclase activity, In chick neuronal cells, inhibition of the voltage-sensitive Ca2+-current by various membrane receptors (alpha(2)-adrenergic, somatostatin, GABA(B)) was eliminated when oGTP was applied intracellularly in the whole cell patch-clamp configuration, Disruption of endogenous signaling pathways by oGTP occurred through specific blockage of the GTP-binding site of G protein alpha-subunits by the following criteria: (i) pretreatment of membranes with oGTP blocked direct G protein activation by guanine nucleotides as well as labeling of G(s alpha) and G(i alpha), with the photoaffinity probe [(alpha-P-32]GTP azidoanilide, (ii) The effect of oGTP was antagonized by the simultaneous introduction of guanosine 5'-(3-O-thio)triphosphate into the patch-clamped cell, (iii) The time to onset of action was similar for oGTP and guanosine 5'-O-thio)diphosphate, (iv) Inactivation of G protein-dependent signaling was overcome by substituting G protein alpha-subunits. Addition of both the short and long form of recombinant G(s alpha)(rG(s alpha-s) and rG(s alpha-L)) restored guanine nucleotide-dependent adenylyl cyclase activity to oGTP-treated platelet membranes with rG(s alpha-L) being similar to 3-10-fold more potent than rG(s alpha-s). This apparent preference was due to the intrinsically different activation rates of rG(s alpha-L) and rG(s alpha-s). When reconstituted with exogenous rG(s alpha), the A(2) adenosine receptor did not discriminate among the two forms of rG(s alpha).Thus, G(s alpha-L) is the primary determinant of basal cARIP formation in platelets, In contrast, neither the addition of various recombinant subtypes of G(i/o) nor purified bovine brain py-dimers reconstituted adenylyl cyclase inhibition in oGTP-treated membranes, All subtypes of G(i alpha) stimulated adenylyl cyclase, In the presence of rG(s alpha), a conditional. stimulation by beta gamma-dimers was observed, This pattern of stimulation shows that platelet adenylyl cyclase is a type II-Iike isoform, Either a differently modified G protein or an ancillary GTP-binding component is required for adenylyl cyclase inhibition in platelets, oGTP can be considered a useful tool for disruption and reconstitution of transmembrane signaling mediated by presumably all classes of heterotrimeric G proteins.	UNIV VIENNA, INST PHARMACOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, INST NEUROPHARMACOL, A-1090 VIENNA, AUSTRIA	University of Vienna; University of Vienna			Hohenegger, Martin/AAF-6479-2020	Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470; Hohenegger, Martin/0000-0001-6537-9574				BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOEHM S, 1992, N-S ARCH PHARMACOL, V345, P606; BOEHM S, 1994, J NEUROCHEM, V63, P146; BOEHM S, 1991, N-S ARCH PHARMACOL, V344, P382; Boehm S., 1993, Society for Neuroscience Abstracts, V19, P1263; BRAUN S, 1979, BIOCHEMISTRY-US, V18, P2134, DOI 10.1021/bi00577a045; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; ELMSLIE KS, 1993, PFLUG ARCH EUR J PHY, V423, P472, DOI 10.1007/BF00374943; FREISSMUTH M, 1991, BIOCHEM J, V275, P651, DOI 10.1042/bj2750651; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLARD A, 1993, J NEUROSCI, V13, P3884; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOHENEGGER M, 1994, J BIOL CHEM, V269, P32008; HUTTEMANN E, 1984, N-S ARCH PHARMACOL, V325, P226, DOI 10.1007/BF00495948; JAKOBS KH, 1989, EUR J BIOCHEM, V183, P115, DOI 10.1111/j.1432-1033.1989.tb14903.x; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P32; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; MUKAI H, 1992, J BIOL CHEM, V267, P16237; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1993, J RECEPTOR RES, V13, P961, DOI 10.3109/10799899309073703; NANOFF C, 1991, MOL PHARMACOL, V39, P130; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OPPI C, 1992, P NATL ACAD SCI USA, V89, P8268, DOI 10.1073/pnas.89.17.8268; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PFEUFFER E, 1985, P NATL ACAD SCI USA, V82, P3086, DOI 10.1073/pnas.82.10.3086; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOSS T, 1993, J BIOL CHEM, V268, P4637; WIELAND T, 1992, J BIOL CHEM, V267, P20791	54	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31999	32007						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989376				2022-12-27	WOS:A1994PX30300101
J	WEISSBACH, L; SETTLEMAN, J; KALADY, MF; SNIJDERS, AJ; MURTHY, AE; YAN, YX; BERNARDS, A				WEISSBACH, L; SETTLEMAN, J; KALADY, MF; SNIJDERS, AJ; MURTHY, AE; YAN, YX; BERNARDS, A			IDENTIFICATION OF A HUMAN RASGAP-RELATED PROTEIN CONTAINING CALMODULIN-BINDING MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SCHIZOSACCHAROMYCES-POMBE; TYROSINE KINASE; GENE; GAP; MYOSIN; ASSOCIATION; RECEPTOR; ENCODES; CANCER	Conversion of active GTP-bound has to its inactive GDP-bound form is catalyzed by GTPase-activating proteins (GAPs). Two mammalian Ras-specific GAPs, p120GAP and neurofibromin, the product of the NF1 tumor suppressor gene, have been previously described. We report here the identification of a new human cDNA clone, IQGAP1, which predicts a 1657-amino acid protein that displays extensive sequence similarity to the catalytic domain of all previously reported RasGAPs. IQGAP1 is most closely related to the Schizosaccharomyces pombe RasGAP-like protein, Sar1. Sequence similarity to IQGAP1 is seen throughout the entire Sar1 protein. The N-terminal half of IQGAP1, which does not overlap with Sar1, contains six copies of a unique amino acid motif, as well as four so-called IQ motifs. The latter motifs are found in several proteins, including conventional and unconventional myosins, and mediate the interaction with calmodulin and calmodulin-related proteins. Thus, IQGAP1 appears to represent a novel RasGAP-like protein that may link Ras signaling to some calmodulin-mediated process.	MASSACHUSETTS GEN HOSP E,CTR CANC,BOSTON,MA 02129		WEISSBACH, L (corresponding author), MASSACHUSETTS GEN HOSP,ORTHOPAED RES LABS,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031747, R01NS022224] Funding Source: NIH RePORTER; NIAMS NIH HHS [R1AR16265-19] Funding Source: Medline; NINDS NIH HHS [NS 22224, NS 31747] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GEISSLER EN, 1991, SOMAT CELL MOLEC GEN, V17, P207, DOI 10.1007/BF01232978; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PELLETIER J, 1991, GENOMICS, V10, P1079, DOI 10.1016/0888-7543(91)90203-Q; PRESTI JC, 1991, CANCER RES, V51, P1544; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WEISSBACH L, 1992, BIOCHEM BIOPH RES CO, V186, P1108, DOI 10.1016/0006-291X(92)90861-E; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHOU JY, 1993, CANCER GENET CYTOGEN, V69, P1, DOI 10.1016/0165-4608(93)90102-R	34	200	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20517	20521						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051149				2022-12-27	WOS:A1994PB31700049
J	YAMADA, H; MIYATA, S; IGAKI, N; YATABE, H; MIYAUCHI, Y; OHARA, T; SAKAI, M; SHODA, H; OIMOMI, M; KASUGA, M				YAMADA, H; MIYATA, S; IGAKI, N; YATABE, H; MIYAUCHI, Y; OHARA, T; SAKAI, M; SHODA, H; OIMOMI, M; KASUGA, M			INCREASE IN 3-DEOXYGLUCOSONE LEVELS IN DIABETIC RAT PLASMA - SPECIFIC IN-VIVO DETERMINATION OF INTERMEDIATE IN ADVANCED MAILLARD REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; PHYSIOLOGICAL CONDITIONS; ALDEHYDE REDUCTASE; REACTION INVIVO; CROSS-LINKING; HUMAN URINE; PROTEINS; AMINOGUANIDINE; GLUCOSE; COLLAGEN	A specific assay of 3-deoxyglucosone (3-DG) was developed in our laboratory to help elucidate the relationship between advanced Maillard reaction and diabetic complications. 3-DG is known as a highly reactive intermediate of the reaction in vitro and a precursor of advanced glycosylation end products such as pyrraline and pentosidine, which have been previously detected in vivo. 3-DG was converted to a stable compound, 2-(2,3,4-trihydroxybutyl)-benzo[g]quinoxaline, by reacting with 2,3-diaminonaphthalene. Since the derivative had a characteristic UV spectrum, it was determined at 268 nm by high performance liquid chromatography. This method was sensitive enough to detect 10 ng/ml (61.7 nM) of 3-DG in vitro. A slight modification to this method allowed in vivo detection of small amounts of 3-DG. Plasma free 3-DG levels were significantly higher in streptozotocin-induced diabetic rats compared with controls (918 +/- 134 nM versus 379 +/- 69 nM, p < 0.001) and were suppressed with the administration of aminoguanidine, an inhibitor of Maillard reaction. Plasma pyrraline levels in diabetic rats also increased in parallel with elevated 3-DG levels but were only marginally suppressed by administration of aminoguanidine. Our results indicate that 3-DG is present in vivo under normal conditions and that its level increases in diabetic subjects. Determination of 3-DG represents a good tool to predict development and progression of diabetic complications and to assess the efficiency of inhibitors to Maillard reaction.	KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, INST DRUG DEV RES, CLIN PHARMACOL RES LABS, ITABASHI KU, TOKYO 174, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, INST DRUG DISCOVERY RES, ENDOCRINOL & METAB DIS RES LABS, TSUKUBA, IBARAKI 305, JAPAN	Kobe University; Astellas Pharmaceuticals; Astellas Pharmaceuticals								ANET EFLJ, 1960, J AM CHEM SOC, V82, P1502, DOI 10.1021/ja01491a055; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COHEN MP, 1986, DIABETES PROTEIN GLY; COHEN MP, 1987, POLYOL PARADIGM COMP; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1991, J BIOL CHEM, V266, P11654; EDELSTEIN D, 1992, DIABETES, V41, P26, DOI 10.2337/diabetes.41.1.26; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HAYASE F, 1989, J BIOL CHEM, V264, P3758; IGAKI N, 1990, CLIN CHEM, V36, P631; KANAZU T, 1991, BIOCHEM J, V279, P903, DOI 10.1042/bj2790903; KATO H, 1990, BIOCHIM BIOPHYS ACTA, V1035, P71, DOI 10.1016/0304-4165(90)90175-V; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P2009, DOI 10.1080/00021369.1987.10868313; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; KATO H, 1962, AGR BIOL CHEM TOKYO, V26, P187, DOI 10.1080/00021369.1962.10857953; KHADEM HE, 1971, CARBOHYD RES, V17, P182; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; KNECHT KJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P130, DOI 10.1016/0003-9861(92)90146-N; LIANG ZQ, 1991, EUR J BIOCHEM, V197, P373, DOI 10.1111/j.1432-1033.1991.tb15921.x; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/bi00406a016; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1989, MAILLARD REACTION AG; NAKAMURA K, 1992, J CHEM SOC CHEM COMM, P992, DOI 10.1039/c39920000992; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; OHMORI S, 1987, J CHROMATOGR-BIOMED, V414, P149, DOI 10.1016/0378-4347(87)80033-6; OIMOMI M, 1989, EXPERIENTIA, V45, P463, DOI 10.1007/BF01952031; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHIN DB, 1988, AGR BIOL CHEM TOKYO, V52, P1451; SZWERGOLD BS, 1990, SCIENCE, V247, P451, DOI 10.1126/science.2300805; TAKAHASHI M, 1993, GENE, V127, P249, DOI 10.1016/0378-1119(93)90728-L	35	104	105	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20275	20280						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051120				2022-12-27	WOS:A1994PB31700013
J	WADE, DP; LINDAHL, GE; LAWN, RM				WADE, DP; LINDAHL, GE; LAWN, RM			APOLIPOPROTEIN(A) GENE-TRANSCRIPTION IS REGULATED BY LIVER-ENRICHED TRANS-ACTING FACTOR HEPATOCYTE NUCLEAR FACTOR 1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APO(A) MESSENGER-RNA; SIZE HETEROGENEITY; LP(A) LIPOPROTEIN; EXPRESSION; PROMOTER; ENHANCER; ELEMENT; PROTEIN; MEMBER; FAMILY	Elevated levels of lipoprotein(a) (Lp(a)) in the plasma are a risk factor for coronary artery disease and stroke. Plasma Lp(a) concentrations are highly heritable and predominantly determined by the liver-specific apolipoprotein(a) (apo(a)) gene. In this report we show by deletion analysis that sequences from -98 to +130 of the apo(a) gene are sufficient to direct liver-specific transcription. DNase I protection analysis of this region using HepG2 nuclear extracts revealed six major protein-binding sites, designated A to F.A mutation within footprint C, situated in the 5'-untranslated region of the gene, resulted in a marked reduction of luciferase expression from a reporter construct to 12% of wild type. This was not due to a decrease in mRNA stability. Gel mobility shift assays demonstrated that site C binds hepatocyte nuclear factor 1 alpha (HNF-1 alpha), and overexpression of HNF-1 alpha in HepGS cells resulted in a significant stimulation of transcription from this promoter fragment. Mutation of footprint B resulted in a a-fold enhancement of transcription. These results show that positive regulation of transcription of the apo(a) gene is dependent on the binding of HNF-1 alpha to a regulatory element situated downstream of the mRNA start site, and suggest that an as yet unidentified protein may negatively regulate apo(a) transcription by binding to a discrete sequence within the 5' untranslated region.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA	Stanford University					NHLBI NIH HHS [HL 48638-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBERS JJ, 1977, J LIPID RES, V18, P331; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1991, CURRENT PROTOCOLS MO; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GONZALEZ FJ, 1991, ALCOHOL ALCOHOLISM, P97; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HERBST RS, 1989, P NATL ACAD SCI USA, V85, P9076; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAJIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V190, P767, DOI 10.1006/bbrc.1993.1115; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRAFT HG, 1992, HUM GENET, V90, P220; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENDEL DB, 1991, J BIOL CHEM, V266, P677; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROLLIER A, 1993, MOL BIOL CELL, V4, P59, DOI 10.1091/mbc.4.1.59; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; UTERMANN G, 1988, HUM GENET, V78, P47, DOI 10.1007/BF00291233; VANBIERVLIET JP, 1991, ATHEROSCLEROSIS, V86, P173, DOI 10.1016/0021-9150(91)90213-M; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; WHITE AL, 1994, J BIOL CHEM, V269, P9060; ZARET KS, 1988, P NATL ACAD SCI USA, V86, P1553; ZHANG DE, 1991, J BIOL CHEM, V266, P21179	47	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19757	19765						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051057				2022-12-27	WOS:A1994PA12600020
J	PAQUET, L; BERGERON, F; BOUDREAULT, A; SEIDAH, NG; CHRETIEN, M; MBIKAY, M; LAZURE, C				PAQUET, L; BERGERON, F; BOUDREAULT, A; SEIDAH, NG; CHRETIEN, M; MBIKAY, M; LAZURE, C			THE NEUROENDOCRINE PRECURSOR 7B2 IS A SULFATED PROTEIN PROTEOLYTICALLY PROCESSED BY A UBIQUITOUS FURIN-LIKE CONVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY POLYPEPTIDE 7B2; TOXIN PROTECTIVE ANTIGEN; NH2-TERMINAL SEQUENCE; PROPROTEIN CONVERTASE; TYROSINE SULFATION; ENDOCRINE PROTEIN; SECRETORY PATHWAY; FACTOR-RECEPTOR; CDNA SEQUENCE; CELL-SURFACE	The neuroendocrine granule-associated protein 7B2, unlike many other neuroendocrine precursor proteins stored in secretory granules, carries in its primary structure the Arg-Xaa-Arg/Lys-Arg processing site usually found in constitutively secreted precursor proteins and recognized by the ubiquitously expressed convertase, furin. pro7B2 (30 kDa), when expressed in endocrine (AtT-20, PC12, and GH(4)C(1)) or non-endocrine (Ltk(-)) cell lines using recombinant vaccinia viruses, was converted to a 23-kDa form. Mutation of the P4 Arg to Gly completely prevented this conversion. When excess pro7B2 was coexpressed with the pro-protein convertases PC1, PC2, or furin, only furin could induce complete processing. In addition, coexpression of pro7B2 in LoVo cells, which are devoid of endogenous furin activity, with each one of the three convertases, showed that only furin was able to induce processing of this precursor. pro7B2 processing in AtT-20 was completely abolished when protein transport into Gels compartments was blocked by cell incubation at either 15 or 37 degrees C in the presence of monensin or brefeldin A. Furthermore, pulse-chase experiments in the presence of Na-2[S-35]SO4 showed that pro7B2 is Tyr-sulfated in the trans-Golgi network before it is processed, These results demon strate that pro7B2 is first processed by a furin-like enzyme within the trans-Golgi network into a 23-kDa form that is then sequestered into secretory granules.	UNIV MONTREAL,CLIN RES INST MONTREAL,MOLEC NEUROENDOCRINOL LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,STRUCT & METAB NEUROPEPTIDES LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,BIOCHEM NEUROENDOCRINOL LAB,MONTREAL H2W 1R7,PQ,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013; MBIKAY, Majambu/ABF-8356-2020	Seidah, Nabil/0000-0001-6503-9342; MBIKAY, Majambu/0000-0003-4854-6507				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG JY, 1986, NEUROENDOCRINOLOGY, V44, P373, DOI 10.1159/000124671; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; IGUCHI H, 1987, PEPTIDES, V8, P593, DOI 10.1016/0196-9781(87)90030-1; JUNG LJ, 1993, RECENT PROG HORM RES, V48, P415; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAZURE C, 1991, INT J PEPT PROT RES, V38, P392; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; PAQUET L, 1991, FEBS LETT, V294, P23, DOI 10.1016/0014-5793(91)81334-5; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIGAFOOS J, 1993, CELL MOL NEUROBIOL, V13, P271, DOI 10.1007/BF00733755; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D F, 1980, Ann N Y Acad Sci, V343, P1, DOI 10.1111/j.1749-6632.1980.tb47238.x; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOMAS G, 1988, BIOCHIMIE, V70, P89, DOI 10.1016/0300-9084(88)90163-0; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIEAU D, 1991, J NEUROENDOCRINOL, V3, P229, DOI 10.1111/j.1365-2826.1991.tb00268.x; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WATENABE T, 1992, J BIOL CHEM, V267, P8270; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZHOU A, 1993, J BIOL CHEM, V268, P1763	50	82	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19279	19285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034690				2022-12-27	WOS:A1994NY33200015
J	TSU, CA; PERONA, JJ; SCHELLENBERGER, V; TURCK, CW; CRAIK, CS				TSU, CA; PERONA, JJ; SCHELLENBERGER, V; TURCK, CW; CRAIK, CS			THE SUBSTRATE-SPECIFICITY OF UCA PUGILATOR COLLAGENOLYTIC SERINE-PROTEASE-1 CORRELATES WITH THE BOVINE TYPE-I COLLAGEN CLEAVAGE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIDDLER CRAB; TRYPSIN; PURIFICATION; INHIBITOR; SEQUENCE; HEPATOPANCREAS; CHYMOTRYPSIN; PROTEINASE; ELASTASE; ECOTIN	Affinity-based purification and characterization of the collagenolytic serine protease 1 from Uca pugilator (fiddler crab) hepatopancreas shows that the enzyme cleaves the native bovine alpha 1(I) collagen chain carboxyl-terminal to Gln and Arg residues adjacent to the metallocollagenase site. Cleavage carboxyl-terminal to Leu residues is observed in the alpha 2(I) chain and at a secondary site in alpha 1(I). These sites correlate with the prefer ences observed toward p-nitroanilide substrates varying at the P1 position, for which the specificity (k(cat)/K-m) is Arg > Leu, Phe, Lys > Gin > Ala. Furthermore, collagen cleavage after Gln was found exclusively between two Gln-Arg bonds. The P'1-P'3 specificity of collagenase, as determined by nucleophile acyl transfer, indicated a strong preference for Arg in the P'1 position. Crab collagenase cleaves peptide bonds adjacent to Leu and Gln at the P1 position more efficiently than trypsin, chymotrypsin, or elastase. Moreover, the efficiency of collagenase toward P1-Arg substrates is equivalent to that of trypsin. Crystals of crab collagenase have been grown complexed with the protein inhibitor ecotin. These crystals diffract to better than 2.8 Angstrom resolution and belong to the space group P3(2)21 with unit cell dimensions of a = b = 89.0 Angstrom, c = 291.7 Angstrom.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NIGMS NIH HHS [NRSA GM13818-03, GM07175] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASGEIRSSON B, 1989, EUR J BIOCHEM, V180, P85; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; DELMAR EG, 1980, BIOCHEMISTRY-US, V19, P468, DOI 10.1021/bi00544a011; EISEN AZ, 1973, BIOCHEMISTRY-US, V12, P1814, DOI 10.1021/bi00733a024; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; GRANT GA, 1980, BIOCHEMISTRY-US, V19, P6089, DOI 10.1021/bi00567a022; GRANT GA, 1981, METHOD ENZYMOL, V80, P722; GRANT GA, 1980, BIOCHEMISTRY-US, V19, P4653, DOI 10.1021/bi00561a018; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; GROSS J, 1974, BIOCHEM BIOPH RES CO, V61, P605, DOI 10.1016/0006-291X(74)91000-6; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; HARPER JW, 1981, ANAL BIOCHEM, V118, P382, DOI 10.1016/0003-2697(81)90597-2; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECROISEY A, 1979, EUR J BIOCHEM, V101, P385, DOI 10.1111/j.1432-1033.1979.tb19730.x; MAINARDI CL, 1980, J BIOL CHEM, V255, P2006; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MCGRATH ME, 1991, J MOL BIOL, V222, P139, DOI 10.1016/0022-2836(91)90199-G; MILLER DON CURTIS, 1961, ZOOLOGICA [NEW YORK], V46, P89; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PERONA JJ, 1993, J MOL BIOL, V230, P934, DOI 10.1006/jmbi.1993.1211; Powers J C, 1977, Methods Enzymol, V46, P208; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4344, DOI 10.1021/bi00067a025; TURKIEWICZ M, 1991, COMP BIOCHEM PHYS B, V99, P359, DOI 10.1016/0305-0491(91)90056-J; VANWORMHOUDT A, 1992, COMP BIOCHEM PHYS B, V103, P675, DOI 10.1016/0305-0491(92)90389-9; WELGUS HG, 1982, BIOCHEMISTRY-US, V21, P5183, DOI 10.1021/bi00264a012; WELGUS HG, 1983, BIOCHEMISTRY-US, V22, P2228, DOI 10.1021/bi00278a026; YOSHINAKA R, 1986, J BIOCHEM-TOKYO, V99, P459, DOI 10.1093/oxfordjournals.jbchem.a135500	38	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19565	19572						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034725				2022-12-27	WOS:A1994NY33200057
J	MARAS, B; STOVER, P; VALIANTE, S; BARRA, D; SCHIRCH, V				MARAS, B; STOVER, P; VALIANTE, S; BARRA, D; SCHIRCH, V			PRIMARY STRUCTURE AND TETRAHYDROPTEROYLGLUTAMATE BINDING-SITE OF RABBIT LIVER CYTOSOLIC 5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE HYDROXYMETHYLTRANSFERASE; FOLINIC ACID; PURIFICATION; CELLS; 5-FORMYLTETRAHYDROFOLATE; TETRAHYDROFOLATE; 5-FLUOROURACIL; LEUCOVORIN; HYDROLYSIS	The primary sequence of 5,10-methenyltetrahydrofolate synthetase from rabbit liver was determined by amino acid sequencing of the purified enzyme. The enzyme contains 201 amino acid residues with a predicted mass of 22,779 Da. The enzyme is located in the cytosolic fraction of liver homogenates. Carbodiimide-activated 5-formyltetrahydropteroylmonoglutamate and the pentaglutamate form of the substrate both irreversibly inactivate the enzyme by forming a covalent bond to Lys-18. Non activated 5-formyltetrahydropteroylpentaglutamate protected against this inactivation. Substrate specificity studies showed that increasing the number of glutamate residues from zero to five on 5-formyltetrahydropteroate results in a 2 order of magnitude increase in the affinity of the substrate for the enzyme but only a 3-fold increase in the value of V-max.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; UNIV ROMA LA SAPIENZA, DIPARTIMENTO SCI BIOCHIM, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY	Virginia Commonwealth University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Barra, Donatella/D-1236-2011; Maras, Bruno/A-2020-2010		NIGMS NIH HHS [GM 28143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBERG GR, 1954, J AM CHEM SOC, V76, P1458, DOI 10.1021/ja01634a104; GREM JL, 1987, CANCER TREAT REP, V71, P1249; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; HSU LM, 1985, J BACTERIOL, V161, P1162, DOI 10.1128/JB.161.3.1162-1170.1985; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KEYOMARSI K, 1986, CANCER RES, V46, P5229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALEY F, 1981, FOLYL ANTIFOLYL POLY, P45; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MATTHEWS RG, 1990, CHEM REV, V90, P1275, DOI 10.1021/cr00105a010; MINI E, 1990, PHARMACOL THERAPEUT, V47, P1, DOI 10.1016/0163-7258(90)90042-Z; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; USHA R, 1992, J BIOL CHEM, V267, P9289; WAGNER C, 1984, ARCH BIOCHEM BIOPHYS, V233, P457, DOI 10.1016/0003-9861(84)90467-3	27	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18429	18433						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034591				2022-12-27	WOS:A1994NW79800033
J	ZHAO, Y; HAWES, J; POPOV, KM; JASKIEWICZ, J; SHIMOMURA, Y; CRABB, DW; HARRIS, RA				ZHAO, Y; HAWES, J; POPOV, KM; JASKIEWICZ, J; SHIMOMURA, Y; CRABB, DW; HARRIS, RA			SITE-DIRECTED MUTAGENESIS OF PHOSPHORYLATION SITES OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DEHYDROGENASE; MOLECULAR-CLONING; BOVINE KIDNEY; RAT-LIVER; ESCHERICHIA-COLI; SKELETAL-MUSCLE; PROTEIN-KINASES; ACTIVITY STATE; E1 COMPONENT; PURIFICATION	Regulation of the branched chain alpha-ketoacid dehydrogenase complex, the rate-limiting enzyme of branched chain amino acid catabolism, involves phosphorylation of 2 amino acid residues (site 1, serine 293; site 2, serine 303). To directly assess the roles played by these sites, site-directed mutagenesis was used to convert these serines to glutamates and/or alanines. Functional E1 heterotetramers were expressed in Escherichia coli carrying genes for E1 alpha and E1 beta under control of separate T7 promoters in a dicistronic vector. Mutation of phosphorylation site 1 serine to glutamate inactivated E1 activity, i.e. mimicked the effect of phosphorylation of site 1. Replacement of the site 1 serine with alanine greatly increased K-m for the alpha-ketoacid substrate but had no effect on maximum velocity. The site 1 serine to alanine mutant was phosphorylated at site 2, but phosphorylation had no effect upon enzyme activity. Mutation of site 2 serine to either glutamate or alanine also had no effect upon enzyme activity, but phosphorylation of these proteins at site 1 inhibited enzyme activity. E1 mutated to change both phosphorylation site serines to glutamates was without enzyme activity. The binding affinity of E1 to the E2 core was not affected by mutation of the phosphorylation sites to glutamates, suggesting no gross perturbation of the association of E1 with the E2 core. The results provide direct evidence that a negative charge at phosphorylation site 1 is responsible for kinase-mediated inactivation of E1. Site 2 is silent with respect to regulation of activity by phosphorylation.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NIDDK NIH HHS [DK19259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGGS M, 1988, BIOCHEM J, V256, P929, DOI 10.1042/bj2560929; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; COOK KG, 1984, EUR J BIOCHEM, V145, P587, DOI 10.1111/j.1432-1033.1984.tb08597.x; COOK KG, 1988, METHOD ENZYMOL, V166, P303; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; ESPINAL J, 1985, BIOCHEM J, V225, P509, DOI 10.1042/bj2250509; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOODWIN GW, 1988, METHOD ENZYMOL, V166, P189; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARRIS RA, 1992, ADV ENZYME REGUL, V32, P267; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HARRIS RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P542, DOI 10.1016/0003-9861(85)90531-4; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JONES SMA, 1987, BIOCHEM BIOPH RES CO, V144, P628, DOI 10.1016/S0006-291X(87)80012-8; LAU KS, 1983, FEBS LETT, V160, P149, DOI 10.1016/0014-5793(83)80955-7; MILLER RH, 1988, J BIOL CHEM, V263, P3454; PAXTON R, 1986, ARCH BIOCHEM BIOPHYS, V244, P187, DOI 10.1016/0003-9861(86)90108-6; POPOV KM, 1992, J BIOL CHEM, V267, P13127; RANDLE PJ, 1984, ENZYME REGULATION RE, P1; SHIMOMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P210, DOI 10.1016/0003-9861(88)90252-4; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; SHIMOMURA Y, 1993, BIOCHIM BIOPHYS ACTA, V1157, P290, DOI 10.1016/0304-4165(93)90112-L; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YEAMAN SJ, 1984, FEBS LETT, V172, P38, DOI 10.1016/0014-5793(84)80868-6; ZHANG B, 1987, J BIOL CHEM, V262, P15220; ZHAO Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P207, DOI 10.1016/0167-4781(92)90014-Q; ZHAO Y, 1992, BIOCHEM J, V285, P167, DOI 10.1042/bj2850167	31	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18583	18587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034607				2022-12-27	WOS:A1994NW79800056
J	GENET, R; DENOYELLE, C; MENEZ, A				GENET, R; DENOYELLE, C; MENEZ, A			PURIFICATION AND PARTIAL CHARACTERIZATION OF AN AMINO-ACID ALPHA,BETA-DEHYDROGENASE, L-TRYPTOPHAN 2',3'-OXIDASE FROM CHROMOBACTERIUM-VIOLACEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN OXIDASE; PEROXIDASE; BIOSYNTHESIS; METABOLISM	L-Tryptophan 2',3' oxidase is a novel enzyme that specifically catalyzes the alpha,beta-dehydrogenation of L-tryptophan derivatives. It was extracted from Chromobacterium violaceum and purified 108-fold to apparent homogeneity with a 34% overall recovery. The molecular weight of the native enzyme is approximately 680,000, and its isoelectric point is nearly equal to 4. SDS-polyacrylamide gel electrophoresis showed that the enzyme is composed of two components with molecular weight of approximately 74,000 and 14,000. It also contains a noncovalently bound heme prosthetic group, as judged from a typical spectrum showing maxima at 427, 530, and 560 nm. The catalyzed reaction is completed without side-product formation over a broad pH range comprised between 3 and 8. The enzyme is reoxidized at the expense of molecular oxygen by producing one molecule of H2O2. Kinetic parameters for modification of N-acetyl-L-tryptophanamide were determined (K-m = 19.5 mu M; k(cat) = 45.2 s(-1)). A Hill coefficient of about 1 suggests the absence of any cooperative effect. As inferred from both its kinetic and stability optimal conditions, L-tryptophan 2',3'-oxidase constitutes a promising tool for chemical modification of tryptophanyl side chain in peptides and proteins.	CEA SACLAY, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; DAVIS PJ, 1975, BIOCHIM BIOPHYS ACTA, V385, P133, DOI 10.1016/0304-4165(75)90081-1; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GROSS E, 1976, HDB BIOCH MOL BIOL, V1, P111; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOSHINO T, 1987, AGR BIOL CHEM TOKYO, V51, P965, DOI 10.1080/00021369.1987.10868084; HOSHINO T, 1987, AGR BIOL CHEM TOKYO, V51, P2733; HOSHINO T, 1993, BIOSCI BIOTECH BIOCH, V57, P1609, DOI 10.1271/bbb.57.1609; JOHNSON JK, 1992, BIOCHEMISTRY-US, V31, P10564, DOI 10.1021/bi00158a020; KIMMEL KE, 1969, CAN J MICROBIOL, V15, P111, DOI 10.1139/m69-017; Labeyrie F, 1978, Methods Enzymol, V53, P238; MAELICKE A, 1978, FEBS LETT, V85, P296, DOI 10.1016/0014-5793(78)80477-3; MAKINEN KK, 1982, ANAL BIOCHEM, V126, P100, DOI 10.1016/0003-2697(82)90114-2; Meienhofer J., 1983, PEPTIDES ANAL SYNTHE, P285; MITOMA C, 1956, ARCH BIOCHEM BIOPHYS, V63, P122, DOI 10.1016/0003-9861(56)90016-9; NEU HC, 1964, J BIOL CHEM, V239, P3893; NODA Y, 1977, J BIOL CHEM, V252, P4413; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PINTOALPHANDARY H, 1988, J LABELLED COMPD RAD, V25, P1273, DOI 10.1002/jlcr.2580251114; ROBERTS J, 1977, J BIOL CHEM, V252, P2640; SARAVIS CA, 1979, J IMMUNOL METHODS, V29, P91, DOI 10.1016/0022-1759(79)90130-3; Schmidt U, 1979, Fortschr Chem Org Naturst, V37, P251; Stammer CH, 1982, CHEM BIOCH AMINO ACI, V6, P33; TAKAI K, 1987, METHOD ENZYMOL, V142, P195; TAKAI K, 1977, J BIOL CHEM, V252, P2648; TAKAI K, 1984, PROGR TRYPTOPHAN SER, P765; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; USHIRO H, 1979, J BIOL CHEM, V254, P1794; VOORDOUW G, 1976, BIOCHEMISTRY-US, V15, P3716, DOI 10.1021/bi00662a012; ZAVALA F, 1983, J BIOL CHEM, V258, P344; 1984, ENZYME NOMENCLATURE, P474	32	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18177	18184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027079				2022-12-27	WOS:A1994NV42200063
J	RADU, A; BLOBEL, G; WOZNIAK, RW				RADU, A; BLOBEL, G; WOZNIAK, RW			NUP107 IS A NOVEL NUCLEAR-PORE COMPLEX PROTEIN THAT CONTAINS A LEUCINE-ZIPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; POLYVINYLIDENE DIFLUORIDE; MONOCLONAL-ANTIBODIES; SEQUENCE; GLYCOPROTEINS; MICROSCOPY; NUCLEOPORINS; FAMILY; NSP1; P62	We have previously described procedures for the isolation of potential nuclear pore complex proteins (nucleoporins or Nups) from rat liver nuclear envelopes and their subsequent subfractionation into those binding to wheat germ agglutinin (WGA) and those that do not. One of these non-WGA-reactive proteins, termed Nup155, was previously molecularly cloned and sequenced and by immunoelectron microscopy shown to be a bona fide nucleoporin. Here we have characterized a second protein of the non-WGA-reactive type and show that it is a Nup as well. Molecular cloning and sequencing revealed that the protein has a calculated molecular mass of 107.2 kDa. It is, therefore, termed Nup107 (for nucleoporin of 107 kDa). Like other Nups that have so far been analyzed, Nup107 contains an abundance of kinase consensus sites. However, the primary structure of Nup107 is unique and not similar to other proteins in the data banks. Its most striking feature is a leucine zipper in its carboxyl-terminal region.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	RADU, A (corresponding author), ROCKEFELLER UNIV,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; METRIONE RM, 1982, ANAL BIOCHEM, V120, P91, DOI 10.1016/0003-2697(82)90321-9; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MULLER GM, 1982, P NATL ACAD SCI-BIOL, V79, P569, DOI 10.1073/pnas.79.2.569; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RADU A, 1993, J CELL BIOL, V121, P1, DOI 10.1083/jcb.121.1.1; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RIS H, 1990, 12TH P INT C EL MICR, P18; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083	54	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17600	17605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021268				2022-12-27	WOS:A1994NU12800042
J	COSTELLO, JF; FUTSCHER, BW; TANO, K; GRAUNKE, DM; PIEPER, RO				COSTELLO, JF; FUTSCHER, BW; TANO, K; GRAUNKE, DM; PIEPER, RO			GRADED METHYLATION IN THE PROMOTER AND BODY OF THE O-6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) GENE CORRELATES WITH MGMT EXPRESSION IN HUMAN GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O6-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSCRIPTION FACTORS; BRAIN TUMORS; REPAIR; LINES; O-6-ALKYLGUANINE; PATTERNS; PROTEIN; CANCERS; TISSUE	Expression of the O-6-methylguanine DNA methyltransferase (MGMT) gene in human glioma cell lines is strongly associated with resistance to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea. To examine the possibility that methylation of the body and promoter regions of the MGMT gene is associated with MGMT expression in a graded, rather than a completely on/off fashion, the present study analyzed the methylation status of the MGMT gene in human glioma cell lines exhibiting a wide range of MGMT expression. Methylation in the body of the gene was uniform within each cell line and correlated directly with MGMT expression. The level of MGMT promoter methylation was also graded across the cell lines, at 21 of 25 CpGs tested, but correlated inversely with MGMT expression. Two sites in the MGMT promoter were also much more accessible to restriction enzyme digestion, and thus in a more open chromatin conformation, in nuclei from high MGMT expressors relative to nuclei from cells with little or no MGMT expression. We conclude that the level of methylation, in both the body and promoter of the MGMT gene, is associated with MGMT expression in a graded fashion and may be important in setting the transcriptional state of the MGMT promoter through changes in chromatin structure.	LOYOLA UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; LOYOLA UNIV,NEUROSCI PROGRAM,MAYWOOD,IL 60153; UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724; KYOTO UNIV,INST RES REACTOR,OSAKA 59004,JAPAN	Loyola University Chicago; Loyola University Chicago; Arizona Center Cancer Care; University of Arizona; Kyoto University					NATIONAL CANCER INSTITUTE [R29CA055064, R01CA055064, R01CA045628] Funding Source: NIH RePORTER; NCI NIH HHS [CA45628, CA55064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BAYLIN SB, 1986, CANCER RES, V46, P2917; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CAIRNSSMITH S, 1992, CANCER RES, V52, P5257; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRON M, 1991, CANCER RES, V51, P4131; DAY RS, 1983, P AM ASSOC CANC RES, V24, P335; DAY RS, 1990, DNA REPAIR MECHANISM, P83; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Futscher B W, 1989, Cancer Commun, V1, P65; HARRIS LC, 1992, CANCER RES, V52, P6404; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P1663; ISHIDA R, 1988, CARCINOGENESIS, V9, P1079, DOI 10.1093/carcin/9.6.1079; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JOST JP, 1993, DNA METHYLATION MOL, P109; KORNBLITH PL, 1981, CANCER, V47, P255, DOI 10.1002/1097-0142(19810115)47:2<255::AID-CNCR2820470209>3.0.CO;2-J; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; Maxam A M, 1980, Methods Enzymol, V65, P499; MITANI H, 1989, CARCINOGENESIS, V10, P1879, DOI 10.1093/carcin/10.10.1879; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; NELSON M, 1989, NUCLEIC ACIDS RES, V17, pR389, DOI 10.1093/nar/17.1.389; OHMORI H, 1978, NUCLEIC ACIDS RES, V5, P1479, DOI 10.1093/nar/5.5.1479; OSTROWSKI LE, 1991, CARCINOGENESIS, V12, P1739, DOI 10.1093/carcin/12.9.1739; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; SALUZ HP, 1987, LABORATORY GUIDE SEQ, P11; STEIN R, 1983, P NATL ACAD SCI-BIOL, V80, P2422, DOI 10.1073/pnas.80.9.2422; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; VERTINO PM, 1993, CANCER RES, V53, P1684; Von Wronski M. A., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P355; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; WANG Y, 1992, MUTAT RES, V273, P221, DOI 10.1016/0921-8777(92)90083-F; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILSON CB, 1970, CANCER CHEMOTH REP 1, V54, P273; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WU SW, 1987, CANCER RES, V47, P6229; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199	44	169	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17228	17237						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006031				2022-12-27	WOS:A1994NT84600039
J	GALLIE, DR; TANGUAY, R				GALLIE, DR; TANGUAY, R			POLY(A) BINDS TO INITIATION-FACTORS AND INCREASES CAP-DEPENDENT TRANSLATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; WHEAT-GERM; PROTEIN-SYNTHESIS; TAIL; EXPRESSION; SUBUNIT; INVITRO; EIF-4B; ALPHA	Both the 5' cap (m(7)GpppN) and the 3' poly(A) tail of eukaryotic mRNAs are important regulators of translation efficiency in vivo. Their function, however, is markedly reduced in in vitro translation systems derived from either rabbit reticulocytes or wheat germ. The impact of exogenous poly(A) on cap-dependent translation was examined in vitro. The translation of uncapped mRNA was preferentially repressed in the presence of exogenous poly(A). As a result, translation became in creasingly cap dependent with the increase in exogenous poly(A). Translation in wheat germ lysate was stimulated by the addition of purified eukaryotic initiation factor (eIF)-4B or eIF-4F; however, addition of poly(A) prevented this eIF-4B- or eIF-4F-mediated stimulation. Addition of eIF-4F or eIF-4B, alone, was not sufficient to restore translation in lysate to which poly(A) had been added. Restoration, however, was observed when eIF-4F, eIF-4B, and eLF-4A were added in combination. These data suggest that 1) exogenous poly(A) may bind to and sequester factors required for translation and 2) that capped messages compete with poly(A) more efficiently for these factors than do uncapped mRNAs. Gel shift analysis of purified initiation factors isolated from wheat germ confirmed that eIF-4B and eIF-4F do in fact form complexes with poly(A) in vitro.			GALLIE, DR (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							BABLANIAN R, 1991, J VIROL, V65, P4449, DOI 10.1128/JVI.65.8.4449-4460.1991; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; GALLIE DR, 1991, MOL GEN GENET, V228, P258, DOI 10.1007/BF00282474; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HELLERMAN JG, 1975, P NATL ACAD SCI USA, V72, P1021, DOI 10.1073/pnas.72.3.1021; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; LODISH HF, 1972, J BIOL CHEM, V247, P7822; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	21	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17166	17173						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006024				2022-12-27	WOS:A1994NT84600031
J	KNAUS, HG; FOLANDER, K; GARCIACALVO, M; GARCIA, ML; KACZOROWSKI, GJ; SMITH, M; SWANSON, R				KNAUS, HG; FOLANDER, K; GARCIACALVO, M; GARCIA, ML; KACZOROWSKI, GJ; SMITH, M; SWANSON, R			PRIMARY SEQUENCE AND IMMUNOLOGICAL CHARACTERIZATION OF BETA-SUBUNIT OF HIGH-CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL FROM SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; RAT-BRAIN; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; DENDROTOXIN ACCEPTOR; BINDING-PROPERTIES; ION CHANNELS; PROTEIN; CHARYBDOTOXIN; PURIFICATION	The charybdotoxin receptor, purified from bovine tracheal smooth muscle, consists of two subunits (alpha and beta) and, when reconstituted into planar lipid bilayers, forms functional high conductance Ca2+-activated K+ channels. Amino acid sequence, obtained from proteolytic fragments of the beta-subunit, was used to design oligonucleotide probes with which cDNAs encoding this protein were isolated. The cDNAs encode a protein of 191 amino acids that contains two hydrophobic (putative transmembrane) domains and bears little sequence homology to subunits of other known ion channels. Site-directed antisera, raised against putative extracellular epitopes of this protein, specifically immunoprecipitated I-125-labeled Bolton-Hunter beta-subunit as well as [I-125]charybdotoxin cross-linked beta-subunit. Under nondenaturing conditions, however, these anti-beta sera immunoprecipitated a complex consisting of both the alpha- and beta-subunits. The data demonstrate that, in vivo, the high conductance Ca2+-activated K+ channel exists as a multimer containing both alpha- and beta-subunits, and this cDNA represents the first beta-subunit of a potassium channel cloned to date. Furthermore, we demonstrate that the cloned protein is the subunit to which charybdotoxin is specifically and covalently incorporated when crosslinked to the channel.	MERCK SHARP & DOHME LTD,RES LABS,DEPT PHARMACOL,W POINT,PA 19486; MERCK SHARP & DOHME LTD,RES LABS,DEPT MEMBRANE BIOCHEM & BIOPHYS,W POINT,PA 19486	Merck & Company; Merck & Company			Smith, McHardy/E-9191-2010	Smith, McHardy/0000-0001-9682-5557				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL W, 1992, DIABETOLOGIA, V35, pS23, DOI 10.1007/BF00586276; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1993, SEMIN NEUROSCI, V5, P107; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; Gutman G.A., 1993, SEMIN NEUROSCI, P101; Hille B., 1992, IONIC CHANNELS EXCIT; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, IN PRESS BIOCHEMISTR; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; Pongs O., 1993, SEMIN NEUROSCI, V5, P93; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REINHART PH, 1991, J NEUROSCI, V11, P1627; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902	34	279	289	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17274	17278						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006036				2022-12-27	WOS:A1994NT84600046
J	TENDIJKE, P; YAMASHITA, H; SAMPATH, TK; REDDI, AH; ESTEVEZ, M; RIDDLE, DL; ICHIJO, H; HELDIN, CH; MIYAZONO, K				TENDIJKE, P; YAMASHITA, H; SAMPATH, TK; REDDI, AH; ESTEVEZ, M; RIDDLE, DL; ICHIJO, H; HELDIN, CH; MIYAZONO, K			IDENTIFICATION OF TYPE-I RECEPTORS FOR OSTEOGENIC PROTEIN-1 AND BONE MORPHOGENETIC PROTEIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SERINE THREONINE KINASE; GROWTH-FACTOR-BETA; DAUER LARVA DEVELOPMENT; TGF-BETA; ACTIVIN RECEPTOR; EXPRESSION CLONING; DIFFERENTIATION; ENCODES; BINDING; FAMILY	Bone morphogenetic proteins (BMPs) are multifunctional proteins, structurally related to transforming growth factor-beta (TGF-beta) and activin. TGF-beta and activin exert their effects by forming heteromeric complexes of type I and type II serine/threonine kinase receptors. We have previously identified a series of type I serine/threonine kinase receptors, termed activin receptor-like kinase (ALK)-1 to -6. ALK-5 is a TGF-beta type I receptor, whereas ALK-2 and ALK-4 are activin type I receptors. Here we investigated the binding of proteins in the BMP family to ALKs. In transfected COS cells, the binding of osteogenic protein (OP)-1 and BMP-4 to certain ALKs was observed in the absence of type II receptors, and their binding was increased after co-transfection of a BMP type II receptor from Caenorhabditis elegans, DAF-4. OP-1 bound to ALK-2 and ALK-6 efficiently, and to ALK-3 less efficiently, whereas BMP-4 bound to ALK-3 and ALK-6 efficiently, Similarly, OP-1 bound to ALK-2, ALK-3, and/or ALK-6 in various nontransfected cell lines, although the binding profiles were different between different cell types. BMP-4 bound to ALK-3 in MC3T3-E1 osteoblasts and human foreskin fibroblasts. These results suggest that ALK-3 and ALK-6 are type I receptors for OP-1 and BMP-4; in addition, ALK-2 is a type I receptor shared by activin and OP-1, but not by BMP-4.	BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; CREAT BIOMOLECULES INC,HOPKINTON,MA 01748; JOHNS HOPKINS UNIV,SCH MED,DEPT ORTHOPED SURG,BALTIMORE,MD 21205; UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; UNIV MISSOURI,PROGRAM MOLEC BIOL,COLUMBIA,MO 65211; TOKYO MED & DENT UNIV,DEPT ORAL PATHOL,BUNKYO KU,TOKYO 113,JAPAN	Ludwig Institute for Cancer Research; Johns Hopkins University; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Tokyo Medical & Dental University (TMDU)			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011239] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11239] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HAMMONDS RG, 1990, MOL ENDOCRINOL, V4, P149; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; NISTER M, 1988, CANCER RES, V48, P3910; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; THOMPSON S, 1984, J CELL SCI, V72, P37; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	41	647	672	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					16985	16988						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006002				2022-12-27	WOS:A1994NT84600001
J	LANGEDIJK, JPM; PUIJK, WC; VANHOORN, WP; MELOEN, RH				LANGEDIJK, JPM; PUIJK, WC; VANHOORN, WP; MELOEN, RH			LOCATION OF CD4 DIMERIZATION SITE EXPLAINS CRITICAL ROLE OF CDR3-LIKE REGION IN HIV-1 INFECTION AND T-CELL ACTIVATION AND IMPLIES A MODEL FOR COMPLEX OF CORECEPTOR-MHC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MHC; BINDING-SITE; LYMPHOCYTE-T; SYNCYTIUM FORMATION; GP120 BINDING; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE	CD4 cross-linking by antibodies or its natural ligands triggers a tyrosine kinase activity that is one of the necessary steps in the mechanism of human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and full T(h)-cell activation. In this study we mapped a part of the dimerization site of human CD4 to amino acids 87-98 using a bivalent CD4 immunoadhesin and a series of overlapping 12-mer peptides of the D1 domain. The dimerization site we found is part of the complementary determining region (CDR) 3-like region of CD4. Using the three-dimensional structure of other immunoglobulin dimers as a basis, a molecular modeling study was performed to dimerize the D1 domains of CD4. Both the peptide binding studies and molecular modeling studies independently led to the conclusion that the CDR3-like region is part of the CD4 dimerization site. The suggested dimerization of CD4 through its CDR3-like region explains the important role that has been ascribed to this region in T(h)-cell activation and HIV-1-mediated fusion. Based on this model of the CD4 dimer and published results of different mutational analysis studies, a model was proposed for the complex of the CD4 dimer with two MHC-II molecules. The CD4 dimer allows tight binding to a large surface of MHC-II and the complex of CD4 and MHC-II reconciles mutational analysis studies that were previously incompatible. Moreover, the complex suggests how CD4 can dimerize through ligand binding.	CENT VET INST,CDI DLO,POB 65,8200 AB LELYSTAD,NETHERLANDS	Wageningen University & Research								ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BRODER CC, 1993, J VIROL, V67, P913, DOI 10.1128/JVI.67.2.913-926.1993; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CORBEAU P, 1993, J IMMUNOL, V150, P290; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HWANG J, 1990, NATURE, V348, P411; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KUPFER A, 1988, P NATL ACAD SCI USA, V85, P8216, DOI 10.1073/pnas.85.21.8216; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; MACKAY HJ, 1989, PREDICTION PROTEIN S, P340; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PRESS WH, 1988, CONJUGATE GRADIENTS, P301; REPKE H, 1992, J IMMUNOL, V149, P1809; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TRAVERS P, 1990, NATURE, V348, P393, DOI 10.1038/348393a0; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WHITE RAH, 1978, J EXP MED, V148, P664, DOI 10.1084/jem.148.3.664; YOSHIDA H, 1992, INT IMMUNOL, V4, P233, DOI 10.1093/intimm/4.2.233	53	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16875	16878						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8043041				2022-12-27	WOS:A1993LQ98800002
J	MASULLO, M; DEVENDITTIS, E; BOCCHINI, V				MASULLO, M; DEVENDITTIS, E; BOCCHINI, V			ARCHAEBACTERIAL ELONGATION-FACTOR 1-ALPHA CARRIES THE CATALYTIC SITE FOR GTP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TU; SULFOLOBUS-SOLFATARICUS; STRUCTURAL-PROPERTIES; MONO-VALENT; FACTOR-II; RIBOSOMES; CATIONS; ABSENCE; DOMAIN	The elongation factor 1 alpha from the archaebacterium Sulfolobus solfataricus (aEF-1 alpha) possesses an intrinsic GTPase activity that is triggered by NaCl up to 5.2 M and requires the presence of at least 1 mM MgCl2 or MnCl2. Chloride salts of other monovalent cations are inefficient, whereas other sodium salts are much less efficient or not efficient at all as compared with NaCl. This aEF-1 alpha GTPase (GTPase(Na)) reaches a maximum in a broad pH range and is not affected by other nucleoside triphosphates but is competitively inhibited by GDP. The turnover of GTPase(Na) is rate limited by the breakdown of GTP. The K-m for GTP is in the range of 2.2-9.3 mu M, depending on the NaCl concentration and temperature. The highest catalytic efficiency is reached at 87 degrees C, which is the optimum temperature for growth of S. solfataricus. The energetic parameters of GTPase(Na) are similar to those reported in the literature for the GTPase of Escherichia coli elongation factor Tu (EF-Tu) triggered by 2 M KCl, thus suggesting that the GTPase activity supported by either EF-Tu or aEF-1 alpha undergoes a similar mechanism of activation by salt at high concentration. A molecular mechanism for this activation is proposed.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	University of Naples Federico II			Masullo, Mariorosario/H-4884-2016	Masullo, Mariorosario/0000-0003-4485-7383				ARCARI P, 1994, BBA-GENE STRUCT EXPR, V1217, P333, DOI 10.1016/0167-4781(94)90296-8; BEAUCLERK AAD, 1985, EUR J BIOCHEM, V151, P245, DOI 10.1111/j.1432-1033.1985.tb09095.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVENDITTIS E, 1986, J BIOL CHEM, V261, P4445; FASANO O, 1982, J BIOL CHEM, V257, P3145; IVELL R, 1981, BIOCHEMISTRY-US, V20, P6852, DOI 10.1021/bi00527a017; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; MASULLO M, 1991, EUR J BIOCHEM, V199, P529, DOI 10.1111/j.1432-1033.1991.tb16151.x; MASULLO M, 1989, BIOCHEM J, V261, P725, DOI 10.1042/bj2610725; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; RAIMO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P127, DOI 10.1016/0167-4781(92)90002-H; RAIMO G, 1993, ITAL J BIOCHEM, V42, P1; WOLF H, 1974, P NATL ACAD SCI USA, V71, P4910, DOI 10.1073/pnas.71.12.4910	15	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20376	20379						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	8051132				2022-12-27	WOS:A1994PB31700028
J	HASHIMOTO, K; HIGASHIYAMA, S; ASADA, H; HASHIMURA, E; KOBAYASHI, T; SUDO, K; NAKAGAWA, T; DAMM, D; YOSHIKAWA, K; TANIGUCHI, N				HASHIMOTO, K; HIGASHIYAMA, S; ASADA, H; HASHIMURA, E; KOBAYASHI, T; SUDO, K; NAKAGAWA, T; DAMM, D; YOSHIKAWA, K; TANIGUCHI, N			HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR IS AN AUTOCRINE GROWTH-FACTOR FOR HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SERUM-FREE MEDIUM; FACTOR-ALPHA; MESSENGER-RNA; PSORIATIC EPIDERMIS; INDUCTION; EGF; AMPHIREGULIN; EXPRESSION; RECEPTOR	Since heparin-binding epidermal growth factor (HB-EGF) is a member of the EGF family and binds to EGF receptor, we tested recombinant HB-EGF for its ability to stimulate human keratinocyte proliferation. The effect of HB-EGF on human Keratinocytes was dependent on the cell density. HB-EGF optimally increased the cell number by 1.8-fold at 1.0 ng/ml for a 4-day incubation period under subconfluent culture. In contrast, under confluent culture, 10 ng/ml HB-EGF optimally increased the DNA synthesis 2.1-fold. To examine the production of HB-EGF by human keratinocytes, the analysis of human keratinocyte-conditioned medium was undertaken by a combination of heparin affinity column chromatography, EGF receptor-stimulating; assay, immunoblotting, and neutralization. Heparin column chromatography fractionated three activities, peaks 1, 2, and 3, which contained immunoreactive 30- and 27-, 19-, and 14.5-kDa bands, respectively. The anti-HB-EGF-blocking antibody neutralized the activities of peaks 2 and 3 by 38 and 22%, respectively, but did not neutralize the activity of peak 1 at all. The antibody reduced the cell growth by 37% for a 4-day incubation period. Northern blot analysis detected a 2.5-kilobase transcript of HB-EGF. The addition of 1 ng/ml HB-EGF optimally increased the levels of HB-EGF mRNA 5.4-fold at 1 h and TGF-alpha mRNA 3.1-fold at 3 h. Interestingly, the addition of TGF-ar at 1 ng/ml to keratinocyte cultures enhanced the level of HB-EGF mRNA 10.2-fold at 6 h. 1 ng/ml EGF also increased HB-EGF mRNA levels 10.9-fold at 1 h. These results suggest that HB-EGF is an autocrine growth factor for human keratinocytes, and HB-EGF and TGF-alpha act not only by an autoinductive mechanism but also by mutual amplification.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT DERMATOL,SUITA,OSAKA 565,JAPAN; SCIOS NOVA INC,MT VIEW,CA 94043	Osaka University; Osaka University; Scios			Taniguchi, Naoyuki/I-4182-2014; Asada, Hideo/U-5710-2019; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Asada, Hideo/0000-0003-1971-9835; 				BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; COOK PW, 1992, CANCER RES, V52, P3224; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; DURING K, 1991, ANAL BIOCHEM, V196, P433, DOI 10.1016/0003-2697(91)90490-K; ELDER JT, 1992, ARCH DERMATOL RES, V284, P324, DOI 10.1007/BF00372034; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FENJVES ES, 1989, P NATL ACAD SCI USA, V86, P8803, DOI 10.1073/pnas.86.22.8803; FINZI E, 1991, J INVEST DERMATOL, V96, P328, DOI 10.1111/1523-1747.ep12465223; FINZI E, 1992, AM J PATHOL, V141, P643; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; HIGASHIYAMA M, 1991, Journal of Dermatology (Tokyo), V18, P117; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; LANZILLO JJ, 1991, ANAL BIOCHEM, V194, P45, DOI 10.1016/0003-2697(91)90149-N; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P767, DOI 10.1111/1523-1747.ep12560956; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Pittelkow M R, 1992, Adv Dermatol, V7, P55; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; Sambrook J, 1989, MOL CLONING LABORATO; SHIPLEY GD, 1987, ARCH DERMATOL, V123, P1541; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	34	211	220	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20060	20066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051092				2022-12-27	WOS:A1994PA12600061
J	SIDHU, SS; KALMAR, GB; WILLIS, LG; BORGFORD, TJ				SIDHU, SS; KALMAR, GB; WILLIS, LG; BORGFORD, TJ			STREPTOMYCES-GRISEUS PROTEASE-C - A NOVEL ENZYME OF THE CHYMOTRYPSIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; COMMERCIAL PREPARATION PRONASE; BACILLUS-CIRCULANS WL-12; PROTEOLYTIC-ENZYMES; SUBSTRATE-BINDING; ESCHERICHIA-COLI; RESOLUTION; INHIBITOR; GENE; PURIFICATION	In this report we describe a novel chymotrypsin-like serine protease produced by Streptomyces griseus. The enzyme has been tentatively named S. griseus protease C (SGPC). The gene encoding the enzyme (sprC) was identified and isolated on the basis of its homology to the previously characterized S. griseus protease B (SGPB), The sprC gene encodes a 457-amino acid prepro-mature protein of which only the 255 carboxyl-terminal amino acids are present in the mature enzyme. Mature SGPC contains two distinct domains connected by a 19-amino acid linker region rich in threonines and prolines. While the amino-terminal domain is homologous to S. griseus proteases A, B, and E and the alpha-lytic protease of Lysobacter enzymogenes, the carboxyl-terminal domain is not homologous with any known protease. However, the carboxyl-terminal domain shares extensive homology with chitin-binding domains of Bacillus circulans chitinases A1 and D, suggesting that the enzyme is specialized for the degradation of chitin-linked proteins. Recombinant expression and preliminary characterization of the catalytic properties of the enzyme are also reported. The primary specificity of SGPC is similar to that of SGPB; both enzymes preferentially cleave peptide bonds following large hydrophobic side chains.	SIMON FRASER UNIV,DEPT CHEM,BURNABY V5A 1S6,BC,CANADA; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	Simon Fraser University; Simon Fraser University								AWAD WM, 1972, J BIOL CHEM, V247, P4144; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P22; FUJISHIGE A, 1992, J CELL BIOL, V118, P33, DOI 10.1083/jcb.118.1.33; HENDERSON G, 1987, J BACTERIOL, V169, P3778, DOI 10.1128/jb.169.8.3778-3784.1987; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; KIM JC, 1991, BIOCHEM BIOPH RES CO, V181, P707, DOI 10.1016/0006-291X(91)91248-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; READ RJ, 1983, BIOCHEMISTRY-US, V22, P4420, DOI 10.1021/bi00288a012; Ruiz-Herrera J., 1991, FUNGAL CELL WALL STR, V1st, P5; SIDHU SS, 1993, BIOCHEM CELL BIOL, V71, P454, DOI 10.1139/o93-067; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; TAPANI R, 1992, PROTEINS, V14, P475; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; YOSHIDA N, 1988, J BIOCHEM, V104, P451, DOI 10.1093/oxfordjournals.jbchem.a122488	27	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20167	20171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051104				2022-12-27	WOS:A1994PA12600075
J	SOTEROPOULOS, P; ONG, AM; MCCARTY, RE				SOTEROPOULOS, P; ONG, AM; MCCARTY, RE			ALKYLATION OF CYSTEINE-89 OF THE GAMMA-SUBUNIT OF CHLOROPLAST COUPLING FACTOR 1 WITH N-ETHYLMALEIMIDE ALTERS NUCLEOTIDE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; EPSILON-SUBUNIT; SPINACH-CHLOROPLASTS; ATP SYNTHASE; ADENOSINE-TRIPHOSPHATASE; BINDING; PHOTOPHOSPHORYLATION; ACTIVATION; MECHANISM; STOICHIOMETRY	Alkylation of Cys-89 of the gamma subunit of the coupling factor portion (CF1) of the chloroplast ATP synthase by N-ethyhnaleimide was previously shown to inhibit ATP synthesis and hydrolysis. The gamma subunit interacts with the inhibitory epsilon subunit. Alkylation of gamma Cys-89 could cause changes that result in the strengthening of the interactions between the two subunits which would be inhibitory. We show that the inhibition of the ATPase activity of CF1 in solution persists after removal of the epsilon subunit. Additionally, epsilon rebinds to control and alkylated CF1 at very similar CF1 to epsilon concentration ratios. Although the bound nucleotide contents of control and alkylated CF1 were similar, the rate of exchange of nucleotide bound to one site with medium nucleotide was accelerated by more than two orders of magnitude by alkylation. We show that ATP-induced release of bound 2'(3')-O-trinitrophenyl adenosine 5'-diphosphate can be monitored conveniently by stopped-flow fluorescence. The effects of N-ethylmaleimide modification are likely to be felt over long distances. As determined by fluorescence resonance energy transfer, no nucleotide binding site so far mapped is closer than 5 nm to Cys-89. The bulky maleimide probably causes structural changes that perturb subunit and catalytic site interactions.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University								ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; ARANA JL, 1982, J BIOL CHEM, V257, P1125; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVITAL S, 1991, J BIOL CHEM, V266, P7067; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUHE RJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P70, DOI 10.1016/0005-2728(90)90180-C; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3829, DOI 10.1021/bi00821a024; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KOHLBRENNER WE, 1983, J BIOL CHEM, V258, P881; KOMATSUTAKAKI M, 1989, J BIOL CHEM, V264, P17750; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNUSSON RP, 1975, J BIOL CHEM, V250, P2593; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MCCARTY RE, 1967, J BIOL CHEM, V242, P3435; MCCARTY RE, 1972, J BIOL CHEM, V247, P3048; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MCCARTY RE, 1973, BIOCHEMISTRY-US, V12, P1503, DOI 10.1021/bi00732a006; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MOAL J, 1989, COMP BIOCHEM PHYS B, V93, P307, DOI 10.1016/0305-0491(89)90086-2; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1982, J BIOL CHEM, V257, P5910; MORONEY JV, 1981, PHOTOSYNTHESIS, V2, P849; NALIN CM, 1983, J BIOL CHEM, V258, P3376; NALIN CM, 1984, J BIOL CHEM, V259, P7275; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIMENOV AM, 1988, CHROMATOGRAM, V9, P6; QUICK WP, 1986, BIOCHIM BIOPHYS ACTA, V851, P166, DOI 10.1016/0005-2728(86)90122-2; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHHIN K, 1992, J BIOL CHEM, V267, P20835; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; SUSS KH, 1982, FEBS LETT, V144, P213, DOI 10.1016/0014-5793(82)80640-6; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WANG ZY, 1993, J BIOL CHEM, V258, P20785	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19810	19816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	8051062				2022-12-27	WOS:A1994PA12600026
J	ISAS, JM; BURGESS, BK				ISAS, JM; BURGESS, BK			PURIFICATION AND CHARACTERIZATION OF A NADP(+) NADPH-SPECIFIC FLAVOPROTEIN THAT IS OVEREXPRESSED IN FDI- STRAINS OF AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; FERREDOXIN-I; ESCHERICHIA-COLI; ENCODING FLAVODOXIN; ACTIVATION; REDUCTASE; MUTAGENESIS; NITROGENASE; PROTEINS; SYNTHASE	Earlier studies have established that mutant strains of Azotobacter vinelandii that do not synthesize ferredoxin I (AvFdI) overexpress another protein designated Protein X (Morgan, T. V., Lundell, P. J., and Burgess, B. K. (1988) J. Biol. Chem. 263, 1370-1375). This protein has now been purified using two-dimensional gel electrophoresis as an assay. The purified protein is a monomer with M(r) approximate to 29,000 which degrades slowly to a specific M(r) approximate to 22,000 form when stored in solution. The native protein is bright yellow and contains noncovalently attached FAD that is reduced by either dithionite or NADPH without formation of a stable semiquinone. Titration with NADP(+)/NADPH gives an E(0)' value of approximately -327 mV versus SHE. Because this E(0)' is so close to that of the NADP(+)/NADPH couple it is not clear if Protein X is an NADPH oxidase or an NADP(+) reductase in vivo. Comparison of the NH2-terminal sequence and other properties of Protein X with those of other proteins, suggests that it is likely to be related to the Escherichia coli ferredoxin NADP(+) reductase (the fpr gene product), and affinity chromatography shows that Protein X binds specifically to AvFdI.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM45209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P331; BENEMANN JR, 1971, BIOCHIM BIOPHYS ACTA, V226, P206; BENNETT LT, 1988, J BIOL CHEM, V263, P1364; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Edman P, 1975, PROTEIN SEQUENCE DET, P232; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HARDER J, 1992, J BIOL CHEM, V267, P25548; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; NAKAMURA S, 1971, J BIOL CHEM, V246, P6235; SHAH VK, 1983, J BIOL CHEM, V258, P2064; SHIN M, 1990, ARCH BIOCHEM BIOPHYS, V279, P97, DOI 10.1016/0003-9861(90)90467-D; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V87, P598; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; YOCH DC, 1972, BIOCHEM BIOPH RES CO, V49, P335, DOI 10.1016/0006-291X(72)90415-9; YOCH DC, 1972, J BIOL CHEM, V247, P4514	27	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19404	19409						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034707				2022-12-27	WOS:A1994NY33200034
J	REN, HY; KOMATSU, N; SHIMIZU, R; OKADA, K; MIURA, Y				REN, HY; KOMATSU, N; SHIMIZU, R; OKADA, K; MIURA, Y			ERYTHROPOIETIN INDUCES TYROSINE PHOSPHORYLATION AND ACTIVATION OF PHOSPHOLIPASE C-GAMMA-1 IN A HUMAN ERYTHROPOIETIN-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PDGF RECEPTOR; GROWTH; ASSOCIATION; INCREASES; SIGNAL; MYC	Erythropoietin (Epo) is the major regulator of the proliferation and differentiation of erythroid precursors through interaction with its receptor (Epo-R). Although Epo-R lacks a tyrosine kinase consensus sequence within its intracellular domain, the addition of its ligand to Epo-responsive cells, UT-7/Epo, induces the rapid and transient tyrosine phosphorylation of 145-, 130-, 80, and 40-kDa cellular proteins. Tyrosine phosphorylation of these proteins occurred dose- and time-dependently. We showed that the tyrosine phosphorylated 145- kDa protein is identical to phospholipase C-gamma 1 (PLC-gamma 1). Tyrosine phosphorylation of this protein is detectable within 30 s and almost reaches the maximum at 1 min. This can last up to 10 min and declines thereafter. Additionally, in Epo stimulated cells, PLC-gamma 1 become physically associated with 80- and 40-kDa proteins which have been tyrosine-phosphorylated in response to Epo. The activity of PLC-gamma 1 was also investigated using inositol 1,4,5-trisphosphate (Ins-P-3) as an indicator. We found that stimulation of UT-7/Epo cells with Epo induces a significant accumulation of Ins-P-3. This effect is dose-dependent and occurs very rapidly. The production of Ins-P-3 can explain the Epo-induced mobilization of calcium from intracellular stores in these cells. These results demonstrate that Epo induces tyrosine phosphorylation and activation of PLC-gamma 1 to produce Ins-P-3 and then it mobilizes calcium from intracellular stores. This signal transduction pathway may play a role in regulating the proliferation of erythroid cells.	JICHI MED SCH,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DEPT MED,DIV ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University; Jichi Medical University			Shimizu, Ritsuko/A-4877-2010	Shimizu, Ritsuko/0000-0001-6672-7606				BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HE TC, 1993, BLOOD, V82, P3530; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES SS, 1990, BLOOD, V76, P31; JUNE CH, 1990, J IMMUNOL, V144, P1591; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOMATSU N, 1992, BLOOD, V80, P53; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER BA, 1989, BLOOD, V73, P1188; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALMER S, 1989, BIOCHEM J, V260, P593, DOI 10.1042/bj2600593; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SAWADA T, 1991, INT J HEMATOL, V54, P109; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPANGLER R, 1992, BLOOD, V79, P52; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS AP, 1984, J BIOL CHEM, V259, P5574; TORTI M, 1992, J BIOL CHEM, V267, P8293; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	46	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19633	19638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034732				2022-12-27	WOS:A1994NY33200067
J	SCHORB, W; PEELER, TC; MADIGAN, NN; CONRAD, KM; BAKER, KM				SCHORB, W; PEELER, TC; MADIGAN, NN; CONRAD, KM; BAKER, KM			ANGIOTENSIN-II-INDUCED PROTEIN-TYROSINE PHOSPHORYLATION IN NEONATAL RAT CARDIAC FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; KINASE-C ISOENZYMES; CHICK HEART-CELLS; SIGNAL TRANSDUCTION; FOCAL ADHESIONS; HYPERTROPHY; STIMULATION; ACTIVATION; RECEPTOR; GROWTH	Angiotensin II has been demonstrated to act as a growth factor in rat cardiac fibroblasts. However, the signaling events that lead to fibroblast cell growth in response to angiotensin II remain to be elucidated. This study was designed to determine whether angiotensin II stimulated tyrosine phosphorylation of proteins in cardiac fibroblasts. Immunoblot analysis demonstrated rapid tyrosine phosphorylation of distinct substrates of 125, 95, 46-60, and 44 kDa in response to 10 nM angiotensin II. Tyrosine phosphorylation was maximal at 5 min and persisted for at least 180 min. Additional tyrosine-phosphorylated proteins of 185, 145, and 85 kDa were detected in response to 10 ng/ml platelet-derived growth factor BB. A cluster of 75-80-kDa proteins were phosphorylated in response to angiotensin II, phorbol ester, and platelet-derived growth factor. Angiotensin II-induced tyrosine phosphorylation was unaffected by phorbol ester-sensitive protein kinase C down-regulation and could be partially blocked by pertussis toxin pretreatment. Angiotensin II stimulation resulted in increased cytosolic tyrosine kinase activity which was recovered by immunoprecipitation. Immunoblot analysis demonstrated tyrosine phosphorylation of p44(MAPK), and, in addition, we demonstrated for the first time tyrosine phosphorylation of p125(FAK), p46(SHC), and p56(SHC) in response to angiotensin II. The finding that angiotensin II and platelet-derived growth factor stimulated tyrosine phosphorylation of p46(SHC) and p56(SHC) suggested that this protein may serve as a common tyrosine kinase substrate in the mitogenic signaling cascade induced by G-protein-coupled receptors and growth factors and is consistent with the hypothesis that angiotensin II-induced tyrosine phosphorylation is involved in mitogenic signaling pathways in neonatal rat cardiac fibroblasts.	SUSQUEHANNA UNIV,DEPT BIOL,SELINSGROVE,PA 17870	Susquehanna University	SCHORB, W (corresponding author), WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044379, R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44379, HL44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAKER KM, 1991, J VASC MED BIOL, V3, P30; BEINLICH CJ, 1991, AM J PHYSIOL, V261, P3, DOI 10.1152/ajplung.1991.261.4.L3; BOLEN JB, 1993, ONCOGENE, V8, P2024; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEMENS MJ, 1992, J CELL SCI, V103, P881; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; EGHBALI M, 1990, MOL CELL BIOCHEM, V96, P1; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FORCE T, 1991, J BIOL CHEM, V266, P6650; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JULIUS S, 1991, HYPERTENSION, V17, P1161, DOI 10.1161/01.HYP.17.6.1161; KAHAWARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAFTILAN AL, 1990, MOL CELL BIOL, V11, P5536; OWENS GK, 1991, ADV EXP MED BIOL, V308, P71; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOEZERI O, 1992, ONCOGENE, V7, P2259; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TSUDA T, 1990, J BIOL CHEM, V265, P1165; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; ULLRICH A, 1986, COLD SPRING HARB SYM, V51, P713, DOI 10.1101/SQB.1986.051.01.084; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANKRIMPEN C, 1991, J MOL CELL CARDIOL, V23, P1245, DOI 10.1016/0022-2828(91)90082-W; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; 1991, NEW ENGL J MED, V325, P293	57	106	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19626	19632						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	8034731				2022-12-27	WOS:A1994NY33200066
J	CLEARY, CM; DONNELLY, RJ; SOH, J; MARIANO, TM; PESTKA, S				CLEARY, CM; DONNELLY, RJ; SOH, J; MARIANO, TM; PESTKA, S			KNOCKOUT AND RECONSTITUTION OF A FUNCTIONAL HUMAN TYPE-I INTERFERON RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-LEUKOCYTE INTERFERONS; IFN-ALPHA RECEPTOR; ACCESSORY FACTOR; CELLS; BETA; RECOMBINANT; IDENTIFICATION; ANTIBODIES; EXPRESSION; CLONING	The functional subunits of the human Type I interferon (IFN) receptor complex have not been defined. Using site-specific recombination in a yeast artificial chromosome (YAC), we have produced a deletion within the human IFN-alpha receptor (Hu-IFN-alpha R1) gene which eliminates exon II of the gene. This deletion effectively eliminates the MHC Class I antigen induction and antiviral activity previously reported for this fully functional parentalYAC clone (Soh, J., Mariano, T.M., Lim, J.-K., Izotova, L., Mirochnitchenko, O., Schwartz, B., Langer, J., and Pestka, S. (1994c) J. Biol. Chem. 269, 18102-18110). We have successfully reconstituted this activity by expression of the cDNA encoding the Hu-IFN-alpha R1 component (Uze, G., Lutfalla, G., and Gresser, I, (1990) Cell 60, 225-234) in cells containing the YAC with this deletion. The Hu-IFN-alpha R1 subunit thus plays a critical role in the functional human Type I IFN receptor complex, whose components are encoded on this YAC. In addition, as binding of ligands is retained in the cells containing the YAC with the deletion, it is clear a second subunit encoded on the YAC is responsible for ligand binding activity. This system will now allow the identification of additional subunits involved in the response to the Type I IFNs and the functional significance of each.			CLEARY, CM (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.				NCI NIH HHS [R01 CA46465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOIT P, 1993, J IMMUNOL, V150, P707; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1994, GENE ANAL TECH APPLI, V10, P109; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Familletti P C, 1981, Methods Enzymol, V78, P387; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HU RQ, 1993, J BIOL CHEM, V268, P12591; JUNG V, 1986, METHOD ENZYMOL, V119, P597; JUNG V, 1991, THESIS RUTGERS U PIS; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MARIANO TM, 1992, INTERFERON PRINCIPLE, P129; MULLER U, 1994, IN PRESS SCIENCE; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1983, ARCH BIOCHEM BIOPHYS, V221, P1, DOI 10.1016/0003-9861(83)90118-2; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1984, BIOCH BIOPHYSICAL ST, P11; RAZIUDDIN A, 1985, 2 5A SYSTEM, P219; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, DNA CELL BIOL, V13, P301, DOI 10.1089/dna.1994.13.301; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z	29	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18747	18749						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034627				2022-12-27	WOS:A1994NX32700012
J	DOUVILLE, K; LEONARD, M; BRUNDAGE, L; NISHIYAMA, K; TOKUDA, H; MIZUSHIMA, S; WICKNER, W				DOUVILLE, K; LEONARD, M; BRUNDAGE, L; NISHIYAMA, K; TOKUDA, H; MIZUSHIMA, S; WICKNER, W			BAND 1 SUBUNIT OF ESCHERICHIA-COLI PREPROTEIN TRANSLOCASE AND INTEGRAL MEMBRANE EXPORT FACTOR-P12 ARE THE SAME PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECRETORY PROTEINS; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; ACIDIC PHOSPHOLIPIDS; SECA; RECONSTITUTION; COMPONENTS; RELEASE; BINDING; SECY/E	Escherichia coli preprotein translocase consists of the peripheral membrane protein SecA and the integral membrane domain SecY/E. SecY/E, whether isolated chromatographically or by immunoprecipitation, was found to be a complex of three polypeptides, SecY, SecE, and band 1. Band 1 did not correspond to a known sec gene product. The independent purification of the separate integral membrane polypeptides needed for reconstitution of translocation yielded SecY, SecE, and a protein that we termed P12. Eased on the sequence of P12, we have prepared antisera to a carboxyl-terminal peptide domain and shown that this antiserum specifically labels only P12 on immunoblots of inner membrane vesicles. We now report that affinity-purified anti-Pla antibodies specifically label the band 1 subunit of the SecY/E complex, whether the SecY/E was isolated chromatographically or by precipitation with antibodies to an epitope-tagged SecY subunit. In addition, the antiserum to P12 can specifically immunoprecipitate the full three-subunit SecY/E complex from detergent extracts. This finding completes the identification of the polypeptides that are essential for catalysis of preprotein translocation.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; TOKYO COLL PHARM,SCH LIFE SCI,HACHIOJI,TOKYO 19203,JAPAN	Dartmouth College; University of Tokyo; Tokyo University of Pharmacy & Life Sciences								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165	28	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18705	18707						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034620				2022-12-27	WOS:A1994NX32700001
J	PIMPLIKAR, SW; SIMONS, K				PIMPLIKAR, SW; SIMONS, K			ACTIVATORS OF PROTEIN-KINASE A STIMULATE APICAL BUT NOT BASOLATERAL TRANSPORT IN EPITHELIAL MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; VESICULAR STOMATITIS-VIRUS; GTP-BINDING PROTEINS; GOLGI-COMPLEX; MEMBRANE GLYCOPROTEIN; MDCK CELLS; SECRETION; RECEPTOR; SURFACE; PHOSPHORYLATION	In polarized Madin-Darby canine kidney cells the newly synthesized plasma membrane proteins, on the exocytic pathway, are sorted in the trans-Golgi network (TGN) and delivered directly to the apical or basolateral surface. Forskolin, isobutylmethylxanthine, and dibutyryl cAMP, all known to activate protein kinase A, stimulated transport of influenza hemagglutinin (HA) from the TGN to the apical surface. The same reagents, however, did not affect the transport of HA from the endoplasmic reticulum to the Golgi complex nor did they affect transport of vesicular stomatitis virus G protein from the TGN to the basolateral surface. The addition of staurosporin, a general protein kinase inhibitor, did not affect the transport of HA in nontreated cells but blocked the stimulation caused by the above reagents. Apical transport of HA was also stimulated by phorbol ester, an activator of protein kinase C. Activation of apical transport by phorbol ester as well as aluminum fluoride (Pimplikar, S. W., and Simons, K. (1993) Nature 362, 456-458) was also negated by staurosporin. These results show that in polarized Madin-Darby canine kidney cells, protein kinase A and protein kinase C selectively stimulate the apical transport.			PIMPLIKAR, SW (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAM,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.			Simons, Kai/0000-0002-9231-9996				BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHOI OH, 1994, J BIOL CHEM, V269, P536; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; Hansen S. H., 1993, Molecular Biology of the Cell, V4, p97A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Luini Alberto, 1993, Trends in Cell Biology, V3, P290, DOI 10.1016/0962-8924(93)90002-I; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1983, J CELL BIOL, V97, P1623, DOI 10.1083/jcb.97.5.1623; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	32	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19054	19059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034664				2022-12-27	WOS:A1994NX32700054
J	UTANI, A; NOMIZU, M; TIMPL, R; ROLLER, PP; YAMADA, Y				UTANI, A; NOMIZU, M; TIMPL, R; ROLLER, PP; YAMADA, Y			LAMININ CHAIN ASSEMBLY - SPECIFIC SEQUENCES AT THE C-TERMINUS OF THE LONG ARM ARE REQUIRED FOR THE FORMATION OF SPECIFIC DOUBLE- AND TRIPLE-STRANDED COILED-COIL STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; ALPHA-FIBROUS PROTEINS; MULTIDOMAIN PROTEIN; GLOBULAR DOMAIN; B2 CHAIN; A-CHAIN; CELLS; SUBUNITS; REPEATS; EXPRESSION	The assembly of laminin chains into double- and triple-stranded structures was studied with recombinant proteins derived from the C-terminal alpha-helical region of the long arm of laminin. Both affinity assays and structural studies demonstrated chain-specific assembly of the B1, B2, and A chains, while associations between homotypic and homologous chains could not be observed. These results suggest that chain selection is controlled by the C-terminal region. Deletion mapping in the B1e and B2e chains identified two sites important for dimer and trimer formation. These two sites were separated by 23 amino acids in the B1e chain, whereas they were adjacent in the B2e chain. The Ae and Am chains contained only one site for trimerization. Site-directed mutagenesis revealed that charged amino acid residues within these sites were essential for association. These results suggest that distinct sites within the C-terminal alpha-helical region of the laminin long arm are critical for the chain-specific assembly of these macromolecules.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; NCI, MED CHEM LAB, BETHESDA, MD 20892 USA	Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	UTANI, A (corresponding author), NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA.							BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Engel J., 1993, MOL CELLULAR ASPECTS, P147, DOI [10.1016/B978-0-12-593165-6.50014-0, DOI 10.1016/B978-0-12-593165-6.50014-0]; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER I, 1992, J BIOL CHEM, V267, P6006; HUNTER I, 1990, EUR J BIOCHEM, V188, P205, DOI 10.1111/j.1432-1033.1990.tb15391.x; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1993, MOL CELLULAR ASPECTS, P177; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PIKKARAINEN T, 1992, EUR J BIOCHEM, V209, P571, DOI 10.1111/j.1432-1033.1992.tb17322.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x	34	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19167	19175						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034675				2022-12-27	WOS:A1994NX32700071
J	YAN, MH; TEMPLETON, DJ				YAN, MH; TEMPLETON, DJ			IDENTIFICATION OF 2 SERINE RESIDUES OF MEK-1 THAT ARE DIFFERENTIALLY PHOSPHORYLATED DURING ACTIVATION BY RAF AND MEK KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; SCHIZOSACCHAROMYCES-POMBE; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; IN-VITRO; FAMILY; TRANSCRIPTION; CLONING; MEMBERS	The signal transduction kinase MEK (mitogen-activated protein (MAP) or extracellular signal-regulated (Erk) kinase)-1 is activated via phosphorylation by MEKK (MEK kinase) and rafkinases. We show here that these two kinases phosphorylate rat MEK-1 exclusively on two serine codons, Ser(318) and Ser(222). Phosphorylation of MEK-1 on serines 218 and 222 is both necessary and sufficient for MEK-1 to be activated and able to phosphorylate MAP kinase. A mutant form of MEK-1 that replaces these two codons with alanine cannot be activated, and one that substitutes glutamic acid residues in place of these 2 serines is active independent of activation by phosphorylation. These sites of activation occur in a region of MEK-1 that is similar to sites of activating phosphorylation in several other serine/threonine kinases, suggesting that this region may represent a conserved ''activating domain'' of many kinases. MEKK and raf display differences in site preference between these two codons, with MEKK showing preference for the amino acid at codon 218 and raf phosphorylating each residue approximately equally. This site preference might result in differences in the temporal or subsequent substrate patterns of MEK activation that result from these two activation pathways.			YAN, MH (corresponding author), CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA.		Templeton, Dennis J/F-7695-2011					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KREK W, 1992, NEW BIOL, V4, P323; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NADINDAVIS SA, 1990, MOL CELL BIOL, V10, P549, DOI 10.1128/MCB.10.2.549; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	36	156	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19067	19073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	8034665				2022-12-27	WOS:A1994NX32700056
J	SACHER, MG; ATHLAN, ES; MUSHYNSKI, WE				SACHER, MG; ATHLAN, ES; MUSHYNSKI, WE			INCREASED PHOSPHORYLATION OF THE AMINO-TERMINAL DOMAIN OF THE LOW-MOLECULAR-WEIGHT NEUROFILAMENT SUBUNIT IN OKADAIC ACID-TREATED NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE-ACTIVITY; BOVINE SPINAL-CORD; HEAD DOMAIN; INTERMEDIATE FILAMENTS; KINASE-C; CHROMAFFIN CELLS; CDC2-LIKE KINASE; TAIL DOMAIN; NF-M; SITES	Treatment of rat dorsal root ganglion cultures with 1 mu M okadaic acid leads to a fragmentation of neurofilaments and a reduction in the electrophoretic mobilities of the three subunits on SDS-polyacrylamide gels (Sacher, M. G., Athlan, E. S., and Mushynski, W. E. (1992) Biochem. Biophys. Res. Commun. 186, 524-530). Based on the observed response to varying concentrations of okadaic acid, fragmentation was inferred to be due to inhibition of protein phosphatase-2A activity and reduction in electrophoretic mobility to inhibition of protein phos- phatase-1. Okadaic acid treatment led to an increase in amino-terminal, relative to carboxyl terminal, domain phosphorylation in the low molecular weight (NF-L) subunit in the Triton X-100-soluble and -insoluble fractions. The purified catalytic subunit of protein phosphatase-2A dephosphorylated P-32-labeled NF-L and the middle molecular weight subunit from okadaic acid-treated cultures, whereas the catalytic subunit of protein phosphatase-1 had no effect. In the case of NF-L, phosphate moieties were preferentially removed from the amino terminal domain. These results show that the amino-terminal domain of NF-L can be phosphorylated in situ and implicate protein phosphatase-2A in the turnover of phosphate moieties in this domain.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA	McGill University								AGOSTINIS P, 1987, J BIOL CHEM, V262, P1060; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHOU CF, 1993, J CELL SCI, V105, P433; CHOU YH, 1991, J BIOL CHEM, V266, P7325; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEORGES E, 1989, J NEUROCHEM, V52, P1156, DOI 10.1111/j.1471-4159.1989.tb01861.x; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; GRANT NJ, 1990, EUR J CELL BIOL, V52, P36; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1993, J BIOCHEM-TOKYO, V113, P705, DOI 10.1093/oxfordjournals.jbchem.a124107; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, BIOCHIM BIOPHYS ACTA, V755, P25, DOI 10.1016/0304-4165(83)90268-4; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW J, 1992, J BIOL CHEM, V267, P25922; LINDENBAUM MH, 1987, J BIOL CHEM, V262, P605; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MAHBOUB S, 1986, ANAL BIOCHEM, V154, P171, DOI 10.1016/0003-2697(86)90511-7; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; SHEA TB, 1993, J NEUROSCI RES, V35, P507, DOI 10.1002/jnr.490350507; SHETTY KT, 1992, NEUROSCI LETT, V137, P83; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SIHAG RK, 1988, FEBS LETT, V233, P181, DOI 10.1016/0014-5793(88)81380-2; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; STEINERT PM, 1982, BIOCHEMISTRY-US, V21, P177, DOI 10.1021/bi00530a030; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SWANSTROM R, 1978, ANAL BIOCHEM, V86, P184, DOI 10.1016/0003-2697(78)90333-0; TORUDELBAUFFE D, 1983, FEBS LETT, V162, P230, DOI 10.1016/0014-5793(83)80761-3; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720	56	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18480	18484						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034596				2022-12-27	WOS:A1994NW79800041
J	SCHNEIDER, P; MCCONVILLE, MJ; FERGUSON, MAJ				SCHNEIDER, P; MCCONVILLE, MJ; FERGUSON, MAJ			CHARACTERIZATION OF GDP-ALPHA-D-ARABINOPYRANOSE, THE PRECURSOR OF D-ARA(P) IN LEISHMANIA-MAJOR LIPOPHOSPHOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL MODIFICATION; PROMASTIGOTES; STAGE; METACYCLOGENESIS; EXPRESSION; CRITHIDIA	Protozoan parasites of the genus Leishmania synthesize a complex lipophosphoglycan (LPG), which is the major cell surface macromolecule. The LPG from Leishmania major contains beta-D-Ara(p)-terminating side chains that are involved in regulating the attachment of the parasite to the midgut epithelium of its insect vector. An arabinose sugar nucleotide donor was identified in soluble extracts of L. major promastigotes. This sugar nucleotide was biosynthetically labeled with D-[2-H-3]Glc and with D-[5-H-3]Ara. The labeled sugar nucleotide generated [H-3]Ara and GDP after mild acid hydrolysis. The absolute configuration of the arabinose was determined after reduction and acylation with a pure enantiomer of Mosher's acid chloride. The pyranose ring configuration was inferred from the ability of GDP-Ara to form borate complexes, and the anomeric configuration was deduced from the results of mild base hydrolysis experiments. Taken together these data suggest that the sugar nucleotide has the structure GDP-alpha-D-Ara(p). This sugar nucleotide has not been previously described from natural sources and may be unique to trypanosomatid pro- tozoan parasites. Ara-1-PO4 and GDP-Ara were the only soluble metabolites labeled with [H-3]Ara, and pulse-chase experiment data are consistent with them being precursors of the arabinosyl residues of LPG.			SCHNEIDER, P (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Schneider, Pascal/0000-0003-0677-9409	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CARBER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309; CAWLEY TN, 1971, CARABOHYDR RES, V19, P372; Chaplin M.F., 1986, MASS SPECTROM, P1; FEINGOLD DS, 1990, METHODS PLANT BIOCH, P39; GORIN PAJ, 1979, J PROTOZOOL, V26, P473, DOI 10.1111/j.1550-7408.1979.tb04656.x; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MOLYNEUX DH, 1983, BIOL TRYPANOSOMA LEI, P1; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, 1992, SCIENCE, V256, P1612; PREVIATO JO, 1982, EXP PARASITOL, V53, P170, DOI 10.1016/0014-4894(82)90058-3; PREVIATO JO, 1993, GLYCOCONJUGATE J, V10, P340, DOI 10.1007/BF01210177; PUENTES SM, 1990, J IMMUNOL, V145, P4311; RIJCKEN WRP, 1990, BIOCHEM J, V266, P777, DOI 10.1042/bj2660777; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SCHNEIDER P, 1993, BIOCHEM J, V295, P555, DOI 10.1042/bj2950555; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; VOLK WA, 1960, BIOCHIM BIOPHYS ACTA, V37, P365, DOI 10.1016/0006-3002(60)90253-5	20	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18332	18337						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	8034578				2022-12-27	WOS:A1994NW79800018
J	AHNE, B; STRATLING, WH				AHNE, B; STRATLING, WH			CHARACTERIZATION OF A MYELOID-SPECIFIC ENHANCER OF THE CHICKEN LYSOZYME GENE - MAJOR ROLE FOR AN ETS TRANSCRIPTION FACTOR-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER; PU.1; ONCOGENE; PROTEIN; ACTIVATION; EXPRESSION; CHROMATIN; ELEMENT; INVITRO; DOMAIN	Expression of the lysozyme gene in chicken macro phages is regulated by an enhancer located 2.7 kilobases upstream of the transcription start site. The organization of this enhancer was analyzed by in vitro assays (DNase I footprinting, dimethyl sulfate methylation protection, and band shift assays) and in vivo footprinting experiments. The results show that the enhancer contains four regions (I-IV) of protein-DNA interactions. First, transient gene transfer experiments demonstrate that region II contributes most to the enhancer function. This region contains a recognition site for the macrophage- and B cell-specific transcription factor PU.1, a member of the Ets transcription factor family. This site plays a major role in the enhancer since a mutation of this site abolishes enhancer activity. Second, in competition band shift experiments, we show that the only myeloid-specific complexes in regions I and II with nuclear factors are formed on the PU.1 recognition site by a member of the Ets transcription factor family. Third in in vivo footprinting experiments, the only sign of a protein-DNA interaction is a dimethyl sulfate-hyperreactive guanine 3'-adjacent to the PU.1 recognition site.	UNIV HAMBURG,KRANKENHAUS EPPENDORF,INST PHYSIOL CHEM,D-20246 HAMBURG,GERMANY	University of Hamburg								ALTSCHMIED J, 1989, NUCLEIC ACIDS RES, V17, P4975, DOI 10.1093/nar/17.13.4975; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE A, 1990, GENE, V95, P187, DOI 10.1016/0378-1119(90)90361-T; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FRITTON HP, 1984, NATURE, V311, P163, DOI 10.1038/311163a0; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SIEBENLIST U, 1980, P NATL ACAD SCI USA, V73, P804; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; THEISEN M, 1992, EMBO J, V12, P2135; WASELYK C, 1991, EMBO J, V10, P1127; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628	35	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17794	17801						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	8027033				2022-12-27	WOS:A1994NV42200009
J	DIDONATO, A; CAFARO, V; DALESSIO, G				DIDONATO, A; CAFARO, V; DALESSIO, G			RIBONUCLEASE-A CAN BE TRANSFORMED INTO A DIMERIC RIBONUCLEASE WITH ANTITUMOR-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE SEMINAL RIBONUCLEASE; INVITRO; GROWTH; RNASE	A cDNA coding for bovine pancreatic RNase A was mutagenized to insert a proline, a leucine, and 2 cysteine residues, i.e. the residues present at corresponding positions in the subunit of seminal RNase, the only dimeric RNase of the pancreatic-type superfamily, The mutant, expressed in Escherichia coli, eventually aggregated into catalytically active dimers. Like naturally dimeric seminal RNase, at equilibrium the mutant dimeric RNase A adopted two quaternary structures (one with an exchange of the N-terminal segments between partner subunits, the other with no exchange) and displayed a selective toxicity for malignant cells, absent in the monomeric, parent protein.	UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY	University of Naples Federico II			Cafaro, Valeria/GLV-3363-2022	DI DONATO, Alberto/0000-0001-9129-9850				BARTHOLEYNS J, 1974, SCIENCE, V186, P444, DOI 10.1126/science.186.4162.444; BARTHOLEYNS J, 1976, P NATL ACAD SCI USA, V73, P573, DOI 10.1073/pnas.73.2.573; BLACKBURN P, 1982, ENZYMES, V15, P417; CAPASSO S, 1983, BIOPOLYMERS, V22, P327, DOI 10.1002/bip.360220142; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; CRESTFIELD AM, 1967, J BIOL CHEM, V242, P3279; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DENIGRIS M, 1993, BIOCHEM BIOPH RES CO, V193, P155, DOI 10.1006/bbrc.1993.1603; DIDONATO A, 1993, BIOCHEM BIOPH RES CO, V194, P1440, DOI 10.1006/bbrc.1993.1986; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACCETTI P, 1992, CANCER RES, V52, P4582; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; MIKULSKI SM, 1992, BRIT J CANCER, V66, P304, DOI 10.1038/bjc.1992.261; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; VESCIA S, 1980, CANCER RES, V40, P3740	16	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17394	17396						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021240				2022-12-27	WOS:A1994NU12800010
J	GAMBA, G; MIYANOSHITA, A; LOMBARDI, M; LYTTON, J; LEE, WS; HEDIGER, MA; HEBERT, SC				GAMBA, G; MIYANOSHITA, A; LOMBARDI, M; LYTTON, J; LEE, WS; HEDIGER, MA; HEBERT, SC			MOLECULAR-CLONING, PRIMARY STRUCTURE, AND CHARACTERIZATION OF 2 MEMBERS OF THE MAMMALIAN ELECTRONEUTRAL SODIUM-(POTASSIUM)-CHLORIDE COTRANSPORTER FAMILY EXPRESSED IN KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; K-CL COTRANSPORT; SHARK RECTAL GLAND; RAT-KIDNEY; NA+-K+-2CL COTRANSPORT; BUMETANIDE BINDING; APICAL MEMBRANE; NACL TRANSPORT; DISTAL TUBULE; MOUSE KIDNEY	Electrically silent Na+-(K+)-Cl- transporter systems are present in a wide variety of cells and serve diverse physiological functions. In chloride secretory and absorbing epithelia, these cotransporters provide the chloride entry mechanism crucial for transcellular chloride transport. We have isolated cDNAs encoding the two major electroneutral sodium-chloride transporters present in the mammalian kidney, the bumetanide-sensitive Na+-K+-Cl- symporter and thiazide-sensitive Na+-Cl- cotransporter, and have characterized their functional activity in Xenopus laevis oocytes. Despite their differing sensitivities to bumetanide and thiazides and their different requirements for potassium, these similar to 115-kDa proteins share significant sequence similarity (similar to 60%) and exhibit a topology featuring 12 potential membrane-spanning helices flanked by long non-hydrophobic domains at the NH2 and COOH termini. Northern blot analysis and in situ hybridization indicate that these transporters are expressed predominantly in kidney with an intrarenal distribution consistent with their recognized functional localization. These proteins establish a new family of Na+-(K+)-Cl- cotransporters.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, MOLEC PHYSIOL & BIOPHYS LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HARVARD CTR STUDY KIDNEY DIS, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			; Gamba, Gerardo/P-4873-2016	Hediger, Matthias/0000-0003-1946-027X; Lytton, Jonathan/0000-0003-4770-2512; Gamba, Gerardo/0000-0002-4378-9043				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALVO M, 1985, AM J PHYSIOL, V249, pF34, DOI 10.1152/ajprenal.1985.249.1.F34; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BEAUMONT K, 1989, J PHARMACOL EXP THER, V250, P414; BEAUMONT K, 1988, P NATL ACAD SCI USA, V85, P2311, DOI 10.1073/pnas.85.7.2311; BROWN CDA, 1985, J MEMBRANE BIOL, V87, P131, DOI 10.1007/BF01870659; BURG M, 1973, AM J PHYSIOL, V225, P119, DOI 10.1152/ajplegacy.1973.225.1.119; BURNHAM CE, 1990, AM J PHYSIOL, V259, pF383, DOI 10.1152/ajprenal.1990.259.2.F383; CABANTCHIK ZI, 1972, J MEMBRANE BIOL, V10, P311, DOI 10.1007/BF01867863; CALDER JA, 1992, EUR J PHARMACOL, V220, P19, DOI 10.1016/0014-2999(92)90006-P; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; COSTANZO LS, 1985, AM J PHYSIOL, V248, pF527, DOI 10.1152/ajprenal.1985.248.4.F527; CREMASCHI D, 1992, J MEMBRANE BIOL, V129, P221; DISTEFANO A, 1989, PFLUG ARCH EUR J PHY, V414, P640, DOI 10.1007/BF00582129; DISTEFANO A, 1990, PFLUG ARCH EUR J PHY, V417, P161, DOI 10.1007/BF00370694; DREWNOWSKA K, 1991, AM J PHYSIOL, V260, pC122, DOI 10.1152/ajpcell.1991.260.1.C122; ELALOUF JM, 1984, AM J PHYSIOL, V246, pF213, DOI 10.1152/ajprenal.1984.246.2.F213; ELLISON DH, 1993, AM J PHYSIOL, V264, pF141, DOI 10.1152/ajprenal.1993.264.1.F141; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; FEIT PW, 1988, J MEMBRANE BIOL, V103, P135, DOI 10.1007/BF01870944; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gamba Gerardo, 1993, Journal of the American Society of Nephrology, V4, P866; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GECK P, 1986, J MEMBRANE BIOL, V91, P97, DOI 10.1007/BF01925787; GOOD DW, 1988, AM J PHYSIOL, V255, pF78, DOI 10.1152/ajprenal.1988.255.1.F78; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; GREGER R, 1981, SCAND AUDIOL, P1; GREGER R, 1983, KLIN WOCHENSCHR, V61, P1019, DOI 10.1007/BF01537500; GRUPP C, 1989, KIDNEY INT, V36, P201, DOI 10.1038/ki.1989.180; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HAAS M, 1987, KIDNEY INT, V32, pS134; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HEBERT SC, 1981, AM J PHYSIOL, V241, pF412, DOI 10.1152/ajprenal.1981.241.4.F412; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; HEBERT SC, 1988, AM J PHYSIOL, V255, pF962, DOI 10.1152/ajprenal.1988.255.5.F962; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOMMA T, 1990, J BIOL CHEM, V265, P17613; JESSEN F, 1989, J MEMBRANE BIOL, V108, P139, DOI 10.1007/BF01871025; JORGENSEN PL, 1984, BIOCHIM BIOPHYS ACTA, V775, P105; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIKERI D, 1990, AM J PHYSIOL, V258, pF445, DOI 10.1152/ajprenal.1990.258.3.F445; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI JH, 1990, DIURETICS, V3, P107; LUO H, 1991, BIOCHEM PHARMACOL, V41, P1745, DOI 10.1016/0006-2952(91)90179-9; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MOLONY DA, 1987, AM J PHYSIOL, V252, pF177, DOI 10.1152/ajprenal.1987.252.1.F177; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Palfrey H. Clive, 1992, Cellular Physiology and Biochemistry, V2, P293; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; Rauchman Michael, 1993, Journal of the American Society of Nephrology, V4, P877; SAIER MH, 1984, MOL CELL BIOCHEM, V59, P11; SANDS JM, 1986, AM J PHYSIOL, V251, pF475, DOI 10.1152/ajprenal.1986.251.3.F475; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHETLAR R E, 1990, FASEB Journal, V4, pA563; SHETLAR RE, 1990, BIOCHIM BIOPHYS ACTA, V1023, P184, DOI 10.1016/0005-2736(90)90412-H; STOKES JB, 1989, KIDNEY INT, V36, P427, DOI 10.1038/ki.1989.212; STOKES JB, 1984, J CLIN INVEST, V74, P7, DOI 10.1172/JCI111420; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; SUVITAYAVAT W, 1994, AM J PHYSIOL, V266, pC284, DOI 10.1152/ajpcell.1994.266.1.C284; TRAN JM, 1990, AM J PHYSIOL, V258, pF908, DOI 10.1152/ajprenal.1990.258.4.F908; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; VELAZQUEZ H, 1984, AM J PHYSIOL, V247, pF904, DOI 10.1152/ajprenal.1984.247.6.F904; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	74	522	527	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17713	17722						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021284				2022-12-27	WOS:A1994NU12800058
J	WATANABE, T; NAKAO, A; EMERLING, D; HASHIMOTO, Y; TSUKAMOTO, K; HORIE, Y; KINOSHITA, M; KUROKAWA, K				WATANABE, T; NAKAO, A; EMERLING, D; HASHIMOTO, Y; TSUKAMOTO, K; HORIE, Y; KINOSHITA, M; KUROKAWA, K			PROSTAGLANDIN-F2-ALPHA ENHANCES TYROSINE PHOSPHORYLATION AND DNA-SYNTHESIS THROUGH PHOSPHOLIPASE-C COUPLED RECEPTOR VIA CA2+-DEPENDENT INTRACELLULAR PATHWAY IN NIH-3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GROWTH-FACTOR RECEPTOR; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; VASOPRESSIN; ENDOTHELIN; BOMBESIN; ASSOCIATION; NEUTROPHILS; STIMULATION	Previously, we characterized the prostaglandin (PG) F-2 alpha receptor linked to phospholipase C activation and DNA synthesis in NIH-3T3 cells (Nakao, A., Watanabe, T., Taniguchi, S., Nakamura, M., Honda, Z-I., Shimizu, T., and Kurokawa, K. (1993) J. Cell. Physiol. 155, 257-264). To elucidate intracellular events evoked via this receptor, we examined changes caused by PGF(2 alpha) stimulation in the phosphotyrosine composition of cellular proteins. The addition of PGF(2 alpha) to cells in quiescent culture rapidly increased the levels of phosphotyrosine in cellular proteins with M(r) values of 70,000 (pp70), 85,000 (pp85), 92,000 (pp92), 100,000 (pp100), and 125,000 (pp125); the latter was immunologically identified as p125 focal adhesion kinase. The PGF(2 alpha)-induced changes in the level of intracellular Ca2+ ([Ca2+](i)) elevation, formation of inositol phosphates, and [H-3]thymidine incorporation followed a similar dose dependence as PGF(2 alpha)-induced tyrosine phosphorylation. This tyrosine phosphorylation was independent of extracellular Ca2+, while a [Ca2+](i) chelator, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (50 mu M), completely inhibited the PGF(2 alpha)-induced elevation of [Ca2+](i), tyrosine phosphorylation, and [H-3]thymidine incorporation. Ionomycin (0.1 mu M), which induced [Ca2+](i) elevation without formation of inositol phosphates, mimicked the PGF(2 alpha)-induced tyrosine phosphorylation. 12-O-Tetradecanoylphorbol-13-acetate (TPA) also induced [H-3]thymidine incorporation in a dose-dependent manner but had no significant effect on tyrosine phosphorylation. The PGF(2 alpha)-induced tyrosine phosphorylation could be observed even in the cells pretreated with TPA (5 mu M, 24 h). PGF(2 alpha) exhibited an additive effect on TPA-induced [H-3]thymidine incorporation but had no effect on the P-32-phosphorylation of a known 80-kDa protein kinase (PK) C substrate. Both staurosporine and H-7 inhibited the PGF(2 alpha)-induced increase in [H-3]thymidine incorporation and tyrosine phosphorylation in a similar dose-dependent manner whether or not cells were pretreated with TPA (5 mu M, 24 h). However, W-7 and KN-62 had no effect on these cellular responses even at the concentration for the almost complete inhibition of Ca2+/calmodulin-dependent Pks (20 mu M). These results, taken together, indicate that PGF(2 alpha) receptor-mediated tyrosine phosphorylation is evoked by a [Ca2+](i)-dependent mechanism that is sensitive to staurosporine and H-7 but which is independent of PKC or Ca2+/calmodulin Pks. Finally, the data suggest that this PGF(2 alpha)-induced signaling pathway is linked to the proliferation of cells.			WATANABE, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,7-3-1 HONGO,TOKYO 113,JAPAN.							ARMATO U, 1983, LIFE SCI, V33, P1745, DOI 10.1016/0024-3205(83)90681-1; ASUDA J, 1981, P NATL ACAD SCI USA, V78, P1004; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRANOT Y, 1990, BIOCHEM BIOPH RES CO, V162, P1478; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KANAMORI M, 1981, J PHARMACOL EXP THER, V217, P494; LUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUARLES LD, 1993, ENDOCRINOLOGY, V132, P1505, DOI 10.1210/en.132.4.1505; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOM RE, 1989, FEBS LETT, V244, P181, DOI 10.1016/0014-5793(89)81188-3; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; WILLIAMS LT, 1989, CLIN RES, V37, P564; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	35	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17619	17625						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	8021271				2022-12-27	WOS:A1994NU12800045
J	BREWER, JW; RANDALL, TD; PARKHOUSE, RME; CORLEY, RB				BREWER, JW; RANDALL, TD; PARKHOUSE, RME; CORLEY, RB			MECHANISM AND SUBCELLULAR-LOCALIZATION OF SECRETORY IGM POLYMER ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; J-CHAIN; IMMUNOGLOBULIN-M; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; BREFELDIN-A; PRE-GOLGI; PROTEIN; BIOSYNTHESIS; SURFACE	The predominant functions of secreted IgM, complement fixation and transcytosis across epithelial barriers via the poly(Ig) receptor, are properties of IgM polymers; thus, the mechanisms that regulate oligomerization are critical to immune function. We have developed methods to assess the mechanism and subcellular location of IgM polymer formation. Using denaturing agarose/SDS-polyacrylamide gel electrophoresis and sucrose gradient fractionation, we demonstrate that IgM polymers are assembled in a stepwise fashion in which primary intermediates, including heavy chain-light chain complexes, are sequentially incorporated. Assembly intermediates include both covalent and non-covalent components, suggesting that IgM subunit interactions precede covalent assembly. IgM polymers are assembled from primary intermediates containing immature N-linked oligosaccharides. Polymerization is insensitive to brefeldin A and occurs at temperatures that inhibit protein transport along the secretory pathway. Together, these data demonstrate that IgM polymerization occurs early in the secretory pathway, most likely in the endoplasmic reticulum. These results are consistent with a model in which secretory IgM represents an oligomeric protein that is retained in the endoplasmic reticulum and does not mature along the secretory pathway until complete assembly is achieved.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; INST ANIM HLTH,PIRBRIGHT LAB,DIV IMMUNOL,PIRBRIGHT GU24 0NF,SURREY,ENGLAND	Duke University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute				Corley, Ronald/0000-0002-7498-0545; Parkhouse, Michael/0000-0001-5967-3291	NIAID NIH HHS [AI31209] Funding Source: Medline; NIGMS NIH HHS [GM07184, GM07754] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184, T32GM007754] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ANDERSON DR, 1985, ARCH BIOCHEM BIOPHYS, V243, P605, DOI 10.1016/0003-9861(85)90538-7; ANDERSSON J, 1973, P NATL ACAD SCI USA, V70, P416, DOI 10.1073/pnas.70.2.416; ASKONAS BA, 1971, BIOCHEM J, V123, P629, DOI 10.1042/bj1230629; BAUMAL R, 1973, TRANSPLANT REV, V14, P163; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BEVAN MJ, 1972, PROGR BIOPHYS MOL BI, V25, P131; BORSOS T, 1965, SCIENCE, V150, P505, DOI 10.1126/science.150.3695.505; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; CONGER JD, 1989, J IMMUNOL, V143, P4044; CREWER JW, 1994, IMMUNOL TODAY, V15, P165; DAVIS AC, 1989, J IMMUNOL, V143, P1352; DAVIS AC, 1989, MOL IMMUNOL, V26, P147, DOI 10.1016/0161-5890(89)90096-5; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DELLACOR.E, 1973, BIOCHEM J, V136, P597; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAJDU I, 1983, J EXP MED, V158, P1993, DOI 10.1084/jem.158.6.1993; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MEINKE GC, 1972, J IMMUNOL, V109, P903; MENG YG, 1988, J IMMUNOL, V141, P2684; MESTECKY J, 1971, SCIENCE, V171, P1163, DOI 10.1126/science.171.3976.1163; MOSMANN T, 1975, J IMMUNOL, V115, P955; MOSTOV KE, 1983, METHOD ENZYMOL, V98, P458; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; OVNIC M, 1987, J IMMUNOL, V138, P3075; PARKHOUSE RM, 1969, BIOCHEM J, V115, P163, DOI 10.1042/bj1150163; PARKHOUSE RM, 1971, BIOCHEM J, V123, P635, DOI 10.1042/bj1230635; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RANDALL TD, 1992, J BIOL CHEM, V267, P18002; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RANDALL TD, 1992, P NATL ACAD SCI USA, V89, P962, DOI 10.1073/pnas.89.3.962; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TOMANA M, 1972, IMMUNOCHEMISTRY, V9, P933, DOI 10.1016/0019-2791(72)90166-8; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x	55	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17338	17348						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006043				2022-12-27	WOS:A1994NT84600054
J	RHEE, KS; MA, TL; THOMPSON, EA				RHEE, KS; MA, TL; THOMPSON, EA			THE MACROMOLECULAR STATE OF THE TRANSCRIPTION FACTOR E2F AND GLUCOCORTICOID REGULATION OF C-MYC TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; THYMIDINE KINASE; TRANS-ACTIVATION; P1798 CELLS; PROTEIN; GENE; PROMOTER; BINDING; COMPLEXES; PROTOONCOGENE	Glucocorticoids inhibit transcription of the proto-oncogene c-myc in lymphoid cells of thymic origin. To determine if this effect is associated with changes in the properties of the transcription factor E2F, extracts were prepared from control and glucocorticoid-treated P1798 murine T lymphoma cells, and the macromolecular state of E2F was assessed by gel-mobility shift. Control extracts exhibit two predominant gel-mobility shift entities of which one corresponds to ''free'' E2F. A second entity, complex C, has properties similar to those described for the complex containing E2F, p107, cyclin A, and Cdk2. Complex C disappears after addition of dexamethasone and is replaced by complex D. The mobility of this complex and its sensitivity to SV40 T antigen suggest that complex D corresponds to an E2F.p105(Rb-1) complex. Extracts from control and glucocorticoid-treated cells yield identical DNase I protection patterns on the c-myc P2 promoter. Furthermore, such extracts transcribe the c-myc P2 promoter in vitro with equal activity. The relative abundance of the E2F complexes was measured after addition of dexamethasone. Complex C disappears as cells withdraw from S phase, and complex D appears at this time. The genes encoding thymidine kinase (Tk-1) and p34(cdc2) (cdc2) are regulated with kinetics similar to those observed for changes in the macromolecular state of E2F. However, regulation of c-myc expression occurs long before any change in E2F. The macromolecular state of E2F may regulate expression of genes at the G(1)/S boundary. However, the data are not consistent with the hypothesis that association of E2F with tumor suppressor gene products such as p107 or p105(Rb-1) is relevant to glucocorticoid regulation of c-myc transcription.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042788] Funding Source: NIH RePORTER; NCI NIH HHS [CA24347] Funding Source: Medline; NIDDK NIH HHS [DK42788] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BARBOUR KW, 1988, MOL ENDOCRINOL, V2, P78, DOI 10.1210/mend-2-1-78; BOURGEOIS S, 1985, BIOCH ACT HORM, V12, P312; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARMON JM, 1988, RESISTANCE ANTINEOPL, P385; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MARODER M, 1990, NUCLEIC ACIDS RES, V18, P1153, DOI 10.1093/nar/18.5.1153; MAT T, 1992, MOL ENDOCRINOL, V6, P960; MOBERG KH, 1992, ONCOGENE, V7, P411; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; PEIT A, 1992, ONCOGENE, V7, P1847; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SKIRODKAR S, 1992, CELL, V68, P157; STEVENS J, 1983, BIOCHEM ACTION HORM, V10, P383; STEVENS J, 1985, HORMONALLY RESPONSIV, P155; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON EA, 1980, MOL CELL ENDOCRINOL, V17, P95; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YU YS, 1989, J BIOL CHEM, V264, P10904	37	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17035	17042						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	8006008				2022-12-27	WOS:A1994NT84600011
